XXXIV AINI CONGRESS
ROMA, 4 – 5 MAGGIO 2026

RAZIONALE SCIENTIFICO

The annual congress of the Italian Neuroimmunology Society is an opportunity for updates on neuroimmunological and neuroinflammatory mechanisms in neurodegenerative, autoimmune and psychiatric disorders.
This year, for the XXXIV edition of the congress that will be held in Rome, we have selected topics covering different aspects and innovative approaches in the Neuroimmunology field, including control of innate immune responses in neuroinflammation, lymphocyte response dysregulation in Multiple Sclerosis and other autoimmune diseases, new insights in neurological and autoimmune disorders including modeling of CNS diseases and the role of complement in this context, as well emerging biomarkers and mechanisms of regenerative neuroimmunology in demyelinating CNS disorders.

PROGGRAMMA SCIENTIFICO

DAY 1 | Monday May 4th

12:00 – 12:15 **Congress Opening - Welcome Remarks**
Martina Severa, Antonella Conte, Marco Salvetti, Massimiliano Di Filippo, Diego Centonze & Gabriela Constantin

12:15 – 12:45 **Opening lecture**
Towards MS and related diseases 2030 Agenda, together with the stakeholders
Mario A. Battaglia, Siena, Italy | Gabriela Constantin, Verona, Italy

Session I | Neuroimmunology Insights
Chairs: Martina Severa, Rome, Italy | Claudio Procaccini, Naples, Italy

12:45 – 13:30 Metabolic control of Innate Immunity in Neuroinflammation
Luke O'Neill, Dublin, Ireland

13:30 – 15:30 *Lunch & Poster Session*
Chairs: Valerio Chiurchiù, Rome, Italy |Caterina Veroni Rome, Italy | Claudio Procaccini, Naples, Italy| Matteo Gastaldi, Pavia, Italy

Session II | Lymphocyte Response dysregulation in Autoimmune Diseases
Chairs: Rosella Mechelli, Rome, Italy | Giovanna Borsellino, Rome, Italy

15:30 – 16:00 T and B Cells Involvement in Autoimmune Diseases and EBV Response
Marvin van Luijn, Rotterdam, The Netherlands

16:00 – 17:30 **Round Table - Lymphocyte Response dysregulation in Autoimmune Diseases**
Chairs: Rosella Mechelli, Rome, Italy | Giovanna Borsellino, Rome, Italy

16:00 – 16:20 Effects of anti-CD20 therapy on T lymphocyte-dependent synaptic excitotoxity in MS
Giorgia Mandolesi (IRCCS San Raffaele Roma - Rome, Italy)

16:20 – 16:40 Serological quantitative, qualitative and functional profiling and neurofilaments as biomarkers in autoimmune encephalitis with LGI1 and CASPR2 antibodies
Pietro Businaro (University of Pavia - Pavia, Italy)

16:40 – 17:00 Extensive characterization of HSV1 antibody responses in herpes encephalitis reveals compartmentalization in CSF and predicts development of post-herpes autoimmune encephalitis
Marianna Spatola (University of Barcelona, Spain and Caixa Research Institute (CRI) - Barcelona, Spain)

17:00 – 17:30 Q&A

17:30 – 18:00 *Coffee break*

18:00 – 18:30 Autoreactive T Cells in Autoimmune Peripheral Neuropathies
Daniela Latorre, Milan, Italy

DAY 2 | Tuesday May 5th

Session III | Border Control in CNS Diseases
Chairs: Gabriela Constantin, Verona, Italy| Roberto Furlan, Milan, Italy

09:00 – 09:45 CNS immune privilege
Jonathan Kipnis, St. Louis, MO, USA

09:45 – 11:00 **Round Table - Border Control in CNS Diseases**
Chairs: Gabriela Constantin, Verona, Italy| Roberto Furlan, Milan, Italy

09:45 – 10:05 Analysis of EBNA2-regulated genes in MS: a study of blood and CNS tissue
Rosella Mechelli (IRCCS San Raffaele - Rome, Italy)

10:05 – 10:25 Tracking EBV-specific T-cell receptor sequences from published data in the CNS and periphery of Multiple Sclerosis patients
Roberta Amoriello (University of Florence - Florence, Italy)
10:25 – 11:00 Q&A

11:00 – 11:30 *Coffee Break*

Session IV | PART 1 - News & Views from Neurological Diseases
Chairs: Luca Battistini, Rome, Italy| Cinthia Farina, Milan, Italy

11:30 – 12:00 Modeling of CNS inflammation in MS
Martina Absinta, Rozzano, MI, Italy

12:00 – 13:00 **Round Table - News & Views from Neurological Diseases**
Chairs: Luca Battistini, Rome, Italy| Cinthia Farina, Milan, Italy

12:00 – 12:20 Tracking EBV-specific T-cell receptor sequences from published data in the CNS and periphery of Multiple Sclerosis patients
Roberta Amoriello (University of Florence - Florence, Italy)
12:20 – 13:00 Q&A

13:00 – 15:00 *Lunch & Poster Session*
Chairs: Valerio Chiurchiù, Rome, Italy | Caterina Veroni, Rome, Italy | Claudio Procaccini, Naples, Italy, Matteo Gastaldi, Pavia, Italy

Session IV | PART 2 - News & Views from Neurological Diseases
Chairs: Sara Mariotto, Verona, Italy | Diego Centonze, Rome, Italy

15:00 – 15:30 The role of complement in neurological diseases
Peter Späth, Bern, Switzerland

15:30 – 16:30 **Round Table - News & Views from Neurological Diseases**
Chairs: Sara Mariotto, Verona, Italy | Diego Centonze, Rome, Italy

15:30 – 15:50 Microbiota-derived metabolome: towards a non-invasive biomarker of multiple sclerosis
Davide Maioli (University of Genoa – Genoa, Italy)
15:50 – 16:30 Q&A

16:30 – 17:00 *Coffee Break*

Session V | Myasthenia Gravis and Other Autoimmune Disorders
Chairs: Raffaele Iorio, Rome, Italy | Diana Ferraro, Modena, Italy

17:00 – 17:30 Myasthenia Gravis Pathogenesis
Rozen Le Panse, Paris, France

17:30 – 18:15 **Round Table - Myasthenia Gravis and Other Autoimmune Disorders**
Chairs: Raffaele Iorio, Rome, Italy | Diana Ferraro, Modena, Italy

17:30 – 17:50 FcRn Inhibition by Efgartigimod in Myasthenia Gravis: evidence for immunoregulatory effects beyond IgG reduction
Maria Cristina Tarasco (Fondazione IRCCS Istituto Neurologico Carlo Besta - Milan, Italy/ University of Milano-Bicocca - Monza, Italy)

17:50 – 18:15 Q&A

Session VI | Neuroscience research in space
Discussant: Diego Centonze, Rome, Italy | Gabriela Constantin, Verona, Italy |
Chairs: Andrea Fuso, Rome, Italy | Martina Severa, Rome, Italy

18:15 – 18:45 **Italian Space Agency: the Experience of ASI in Neuroscience Research**
Sara Piccirillo, Rome, Italy

DAY 3 | Wednesday May 6th

Session VII | Regenerative Neuroimmunology
Chairs: Marco Salvetti, Rome, Italy | Clara Ballerini, Florence, Italy

09:30 – 10:00 Fuels and drivers of smouldering brain diseases
Stefano Pluchino, Cambridge, UK

10:00 – 11:00 **Round Table - Regenerative Neuroimmunology**
Chairs: Marco Salvetti, Rome, Italy | Clara Ballerini, Florence, Italy

10:00 – 10:20 Virtual Brain modelling in Brain diseases
Egidio D'Angelo (University of Pavia – Pavia, Italy)
10:20 – 11:00 Q&A

11:00 – 11:15 *Coffee Break*

Session VIII | Emerging Biomarkers in Demyelinating CNS Disorders
Chairs: Massimiliano di Filippo, Perugia, Italy | Giovanni Ristori, Rome, Italy

11:15 – 11:45 Novel biomarkers and therapeutic targets in CNS disorders
Anne-Katrin Pröbstel, Bonn, Germany
11:45 – 12:15 Markers of neuroglial damage in autoimmune neurology
Sara Mariotto, Verona, Italy

12:15 – 13:00 **Round Table - Emerging Biomarkers in Demyelinating CNS Disorders**
Chairs: Massimiliano di Filippo, Perugia, Italy | Giovanni Ristori, Rome, Italy

12:15 – 12:35 Antibody targets against glial surface proteins in demyelinating disorders
Matteo Gastaldi (IRCCS Mondino Foundation & University of Pavia - Pavia, Italy)
12:35 – 13:00 Q&A

13:00 – 14:00 *Lunch Break*

14:00 – 14:30 **EQAS** – External Quality Assessment Scheme
Matteo Gastaldi, Pavia, Italy
14:30 – 15:15 B cells in CNS autoimmunity
Thomas Korn, München, Germany

15:15 – 16:00 **Award Session & Closing Remarks**
Gabriela Constantin, Verona, Italy

CURRICULUM VITAE



April 7, 2026

(Signature) _____
(Typed Name) Martina Absinta

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

01/10/2024 Associate Professor of Neurology, Humanitas University, Milan
Head of the Experimental Neuropathology Lab, IRCSS Humanitas Research Hospital, Milan
2021-present Adjunct Professor of Neurology, Johns Hopkins University School of Medicine, Baltimore, US

Personal Data

Date of Birth: April 30, 1981
Citizenship: Italian
Tel +39-3388352062
E-mail: martina.absinta@hunimed.eu

Languages: Italian, English

Education and Previous Appointments

2000-2006 MD, Vita-Salute San Raffaele University, Milan, Italy (110/110 lode e menzione ad honorem)
2007-2012 Residency in Neurology, Vita-Salute San Raffaele University, Milan, Italy (70/70 lode)
2013-2016 PhD Molecular Medicine-Experimental Neurology, Vita-Salute San Raffaele University, Milan, Italy
2012-2016 Visiting research fellow, NINDS, NIH, Bethesda, US
2016-2019 Postdoctoral fellowship, NINDS, NIH, Bethesda, US
2019-2020 Assistant Professor of Neurology, Johns Hopkins University, Baltimore, US
2021-2022 Neuroimmunology researcher, Vita-Salute San Raffaele University, Milan, Italy
2023-2024 Group Leader, Translational Neuropathology Lab, IRCSS San Raffaele Research Hospital, Milan, Italy

Biosketch

Prof. Martina Absinta dedicated her work to ultra-high field 7T MRI– human neuropathological correlations in multiple sclerosis, and related identification of novel imaging biomarkers of chronic inflammation (with special focus on microglia-mediated and leptomeningeal inflammation). In the last few years, her work highlighted the clinical relevance of chronic inflammation and chronic active lesions in driving progression in multiple sclerosis and prompted for the planning of novel-designed MRI-based clinical trials aimed at treating such perilesional chronic inflammation. Her scientific work has been published in high impact scientific journals, including *Nature, Nature Reviews Neurology, Nature Communications, JCI, eLife*, and *JAMA Neurology*.

PUBLICATIONS

PubMed publications 114
Scopus H-index 47, citations 7,183
https://pubmed.ncbi.nlm.nih.gov/?term=absinta&sort=date

Top selected publications:

1. Fagiani F, Pedrini E, Taverna S, Brambilla, Murtaj V, Podini P, Ruffini F, Butti E, Braccia C, Andolfo A, Magliozzi R, Smirnova L, Kuhlmann T, Quattrini A, Calabresi PA, Reich DS, Martino G, Panina-Bordignon P, **Absinta M**. A glia-enriched stem-cell 3D model of the human brain mimics the glial-immune neurodegenerative phenotypes of multiple sclerosis. *Cell Rep Med*. 2024 Aug 20;5(8):101680. doi: 10.1016/j.xcrm.2024.101680. PMID: 39121861
2. Maggi P, Bulcke CV, Pedrini E, Bugli C, Sellimi A, Wynen M, Stölting A, Mullins WA, Kalaitzidis G, Lolli V, Perrotta G, El Sankari S, Duprez T, Li X, Calabresi PA, van Pesch V, Reich DS, **Absinta M**. B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. *Lancet eBioMedicine* 2023 Aug:94:104701. doi: 10.1016/j.ebiom.2023.104701. PMID 37437310.
3. **Absinta M**, Maric D, Gharagozloo M, Garton T, Smith MD, Jin J, Fitzgerald KC, Song A, Liu P, Lin JP, Wu T, Johnson KR, McGavern DB, Schafer DP, Calabresi PA, Reich DS. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. *Nature*. 2021 Sep 8. doi: 10.1038/s41586-021-03892-7. PMID 34497421
4. Maggi P, Kuhle J, Schädelin S, van der Meer F, Weigel M, Galbusera R, Mathias A, Lu PJ, Rahmanzadeh R, Benkert P, La Rosa F, Bach Cuadra M, Sati P, Théaudin M, Pot C, van Pesch V, Leppert D, Stadelmann C, Kappos L, Du Pasquier R, Reich DS, **Absinta M*,** Granziera C* (co-last authors). Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. *Neurology*. 2021 Aug 10;97(6):e543-e553. PMID 34088875
5. Maggi, P., P. Sati, G. Nair, I.C.M. Cortese, S. Jacobson, B.R. Smith, A. Nath, J. Ohayon, V. van Pesch, G. Perrotta, C. Pot, M. Theaudin, V. Martinelli, R. Scotti, T. Wu, R. Du Pasquier, P.A. Calabresi, M. Filippi, D.S. Reich, and **Absinta M**. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. *Annals of Neurology*, 2020. PMID 32799417
6. **Absinta**, M., P. Sati, F. Masuzzo, G. Nair, V. Sethi, H. Kolb, J. Ohayon, T. Wu, I.C.M. Cortese, and D.S. Reich, Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. *JAMA Neurology*, 2019. 76(12): p. 1474-1483. PMID 31403674
7. **Absinta M**, Nair G, Monaco MCG, Maric D, Lee NJ, Ha SK, Luciano NJ, Sati P, Jacobson S, Reich DS. The "central vein sign" in inflammatory demyelination: The role of fibrillar collagen type I. *Annals of Neurology. 2019* Jun;85(6):934-942. doi: 10.1002/ana.25461. PMID: 30847935
8. **Absinta,** M., S.K. Ha, G. Nair, P. Sati, N.J. Luciano, M. Palisoc, A. Louveau, K.A. Zaghloul, S. Pittaluga, J. Kipnis, and D.S. Reich, Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. *Elife*, 2017. 6. PMID 28971799
9. **Absinta**, M., P. Sati, M. Schindler, E.C. Leibovitch, J. Ohayon, T. Wu, A. Meani, M. Filippi, S. Jacobson, I.C. Cortese, and D.S. Reich, Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. *Journal of Clinical Investigation*, 2016. 126(7): p. 2597-609. PMID 27270171
10. **Absinta,** M., P. Sati, and D.S. Reich, Advanced MRI and staging of multiple sclerosis lesions. *Nature Review Neurology*, 2016. 12(6): p. 358-68. PMID 27125632
11. **Absinta,** M., L. Vuolo, A. Rao, G. Nair, P. Sati, I.C. Cortese, J. Ohayon, K. Fenton, M.I. Reyes-Mantilla, D. Maric, P.A. Calabresi, J.A. Butman, C.A. Pardo, and D.S. Reich, Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. *Neurology*, 2015. 85(1): p. 18-28. PMID 25888557
12. **Absinta,** M., P. Sati, M.I. Gaitan, P. Maggi, I.C. Cortese, M. Filippi, and D.S. Reich, Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. *Annals of Neurology*, 2013. 74(5): p. 66978. PMID 23813441

Additional Original Research (chronological order)

10. Agosta, F., M. **Absinta,** M.P. Sormani, A. Ghezzi, A. Bertolotto, E. Montanari, G. Comi, and M. Filippi, In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain, 2007. 130(Pt 8): p. 2211-9.
11. Rocca, M.A., E. Pagani, M. **Absinta,** P. Valsasina, A. Falini, G. Scotti, G. Comi, and M. Filippi, Altered functional and structural connectivities in patients with MS: a 3-T study. Neurology, 2007. 69(23): p. 2136-45.
12. Mesaros, S., M.A. Rocca, M. **Absinta**, A. Ghezzi, N. Milani, L. Moiola, P. Veggiotti, G. Comi, and M. Filippi, Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology, 2008. 70(13 Pt 2): p. 1107-12.
13. Agosta, F., P. Valsasina, M. **Absinta,** S. Sala, D. Caputo, and M. Filippi, Primary progressive multiple sclerosis: tactileassociated functional MR activity in the cervical spinal cord. Radiology, 2009. 253(1): p. 209-15.

14. Rocca, M.A., M. **Absinta**, A. Ghezzi, L. Moiola, G. Comi, and M. Filippi, Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients? Hum Brain Mapp, 2009. 30(9): p. 2844-51.
15. Rocca, M.A., P. Valsasina, A. Ceccarelli, M. **Absinta,** A. Ghezzi, G. Riccitelli, E. Pagani, A. Falini, G. Comi, G. Scotti, and M. Filippi, Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp, 2009. 30(1): p. 276-90.
16. **Absinta,** M., M.A. Rocca, L. Moiola, A. Ghezzi, N. Milani, P. Veggiotti, G. Comi, and M. Filippi, Brain macro- and microscopic damage in patients with paediatric MS. J Neurol Neurosurg Psychiatry, 2010. 81(12): p. 1357-62.
17. Agosta, F., M.A. Rocca, E. Pagani, M. **Absinta,** G. Magnani, A. Marcone, M. Falautano, G. Comi, M.L. GornoTempini, and M. Filippi, Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp, 2010. 31(4): p. 515-25.
18. Pievani, M., F. Agosta, E. Pagani, E. Canu, S. Sala, M. **Absinta,** C. Geroldi, R. Ganzola, G.B. Frisoni, and M. Filippi, Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp, 2010. 31(12): p. 1862-75.
19. Rocca, M.A., M. **Absinta**, L. Moiola, A. Ghezzi, B. Colombo, V. Martinelli, G. Comi, and M. Filippi, Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis. Radiology, 2010. 254(2): p. 541-50.
20. Rocca, M.A., P. Valsasina, M. **Absinta,** B. Colombo, V. Barcella, A. Falini, G. Comi, and M. Filippi, Central nervous system dysregulation extends beyond the pain-matrix network in cluster headache. Cephalalgia, 2010. 30(11): p. 138391.
21. Rocca, M.A., P. Valsasina, M. **Absinta,** G. Riccitelli, M.E. Rodegher, P. Misci, P. Rossi, A. Falini, G. Comi, and M. Filippi, Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology, 2010. 74(16): p. 1252-9.
22. Valsasina, P., F. Agosta, M. **Absinta,** S. Sala, D. Caputo, and M. Filippi, Cervical cord functional MRI changes in relapse-onset MS patients. J Neurol Neurosurg Psychiatry, 2010. 81(4): p. 405-8.
23. **Absinta,** M., M.A. Rocca, and M. Filippi, Dentate nucleus T1 hyperintensity in multiple sclerosis. AJNR Am J Neuroradiol, 2011. 32(6): p. E120-1.
24. **Absinta,** M., M.A. Rocca, L. Moiola, M. Copetti, N. Milani, A. Falini, G. Comi, and M. Filippi, Cortical lesions in children with multiple sclerosis. Neurology, 2011. 76(10): p. 910-3.
25. Agosta, F., P. Valsasina, M. **Absinta,** N. Riva, S. Sala, A. Prelle, M. Copetti, M. Comola, G. Comi, and M. Filippi, Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cereb Cortex, 2011. 21(10): p. 2291-8.
26. Benedetti, F., M. **Absinta,** M.A. Rocca, D. Radaelli, S. Poletti, A. Bernasconi, S. Dallaspezia, E. Pagani, A. Falini, M. Copetti, C. Colombo, G. Comi, E. Smeraldi, and M. Filippi, Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord, 2011. 13(4): p. 414-24.
27. Kacar, K., M.A. Rocca, M. Copetti, S. Sala, S. Mesaros, T. Stosic Opincal, D. Caputo, M. **Absinta**, J. Drulovic, V.S. Kostic, G. Comi, and M. Filippi, Overcoming the clinical-MR imaging paradox of multiple sclerosis: MR imaging data assessed with a random forest approach. AJNR Am J Neuroradiol, 2011. 32(11): p. 2098-102.
28. Preziosa, P., M.A. Rocca, S. Mesaros, E. Pagani, T. Stosic-Opincal, K. Kacar, M. **Absinta,** D. Caputo, J. Drulovic, G. Comi, and M. Filippi, Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology, 2011. 260(2): p. 541-50.
29. Valsasina, P., M.A. Rocca, M. **Absinta**, M.P. Sormani, L. Mancini, N. De Stefano, A. Rovira, A. Gass, C. Enzinger, F. Barkhof, C. Wegner, P.M. Matthews, and M. Filippi, A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. Eur J Neurosci, 2011. 33(7): p. 1256-63.
30. **Absinta,** M., M.A. Rocca, B. Colombo, M. Copetti, D. De Feo, A. Falini, G. Comi, and M. Filippi, Patients with migraine do not have MRI-visible cortical lesions. J Neurol, 2012. 259(12): p. 2695-8.
31. **Absinta,** M., M.A. Rocca, B. Colombo, A. Falini, G. Comi, and M. Filippi, Selective decreased grey matter volume of the pain-matrix network in cluster headache. Cephalalgia, 2012. 32(2): p. 109-15.
32. Rocca, M.A., M. **Absinta**, P. Valsasina, M. Copetti, D. Caputo, G. Comi, and M. Filippi, Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler, 2012. 18(11): p. 1552-9.
33. Valsasina, P., M.A. Horsfield, M.A. Rocca, M. **Absinta**, G. Comi, and M. Filippi, Spatial normalization and regional assessment of cord atrophy: voxel-based analysis of cervical cord 3D T1-weighted images. AJNR Am J Neuroradiol, 2012. 33(11): p. 2195-200.
34. Valsasina, P., M.A. Rocca, M. **Absinta,** F. Agosta, D. Caputo, G. Comi, and M. Filippi, Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis. Hum Brain Mapp, 2012. 33(9): p. 2072-80.

35. Nair, G., M. **Absinta**, and D.S. Reich, Optimized T1-MPRAGE sequence for better visualization of spinal cord multiple sclerosis lesions at 3T. AJNR Am J Neuroradiol, 2013. 34(11): p. 2215-22.
36. Rocca, M.A., A.C. Turconi, S. Strazzer, M. **Absinta,** P. Valsasina, E. Beretta, M. Copetti, M. Cazzagon, A. Falini, and M. Filippi, MRI predicts efficacy of constraint-induced movement therapy in children with brain injury. Neurotherapeutics, 2013. 10(3): p. 511-9.
37. Valsasina, P., M.A. Rocca, M.A. Horsfield, M. **Absinta,** R. Messina, D. Caputo, G. Comi, and M. Filippi, Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. Radiology, 2013. 266(3): p. 853-61.
38. Rocca, M.A., M. **Absinta**, M.P. Amato, L. Moiola, A. Ghezzi, P. Veggiotti, R. Capra, E. Portaccio, A. Fiorino, L. Pippolo, M.C. Pera, M.A. Horsfield, A. Falini, G. Comi, and M. Filippi, Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. Neurology, 2014. 82(15): p. 1314-21.
39. Rocca, M.A., P. Valsasina, M. **Absinta,** L. Moiola, A. Ghezzi, P. Veggiotti, M.P. Amato, M.A. Horsfield, A. Falini, G. Comi, and M. Filippi, Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. Hum Brain Mapp, 2014. 35(8): p. 4180-92.
40. **Absinta,** M., G. Nair, P. Sati, I.C. Cortese, M. Filippi, and D.S. Reich, Direct MRI detection of impending plaque development in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm, 2015. 2(5): p. e145.
41. George, I.C., P. Sati, M. **Absinta**, I.C. Cortese, E.M. Sweeney, C.D. Shea, and D.S. Reich, Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis. Mult Scler, 2016. 22(12): p. 1578-1586.
42. **Absinta,** M., I.C. Cortese, L. Vuolo, G. Nair, M.P. de Alwis, J. Ohayon, A. Meani, V. Martinelli, R. Scotti, A. Falini, B.R. Smith, A. Nath, S. Jacobson, M. Filippi, and D.S. Reich, Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology, 2017. 88(15): p. 1439-1444.
43. Petersen, M.A., J.K. Ryu, K.J. Chang, A. Etxeberria, S. Bardehle, A.S. Mendiola, W. Kamau-Devers, S.P.J. Fancy, A. Thor, E.A. Bushong, B. Baeza-Raja, C.A. Syme, M.D. Wu, P.E. Rios Coronado, A. Meyer-Franke, S. Yahn, L. Pous, J.K. Lee, C. Schachtrup, H. Lassmann, E.J. Huang, M.H. Han, M. **Absinta,** D.S. Reich, M.H. Ellisman, D.H. Rowitch, J.R. Chan, and K. Akassoglou, Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage. Neuron, 2017. 96(5): p. 1003-1012 e7.
44. Sethi, V., G. Nair, M. **Absinta**, P. Sati, A. Venkataraman, J. Ohayon, T. Wu, K. Yang, C. Shea, B.E. Dewey, I.C. Cortese, and D.S. Reich, Slowly eroding lesions in multiple sclerosis. Mult Scler, 2017. 23(3): p. 464-472.
45. **Absinta,** M., P. Sati, A. Fechner, M.K. Schindler, G. Nair, and D.S. Reich, Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI. AJNR Am J Neuroradiol, 2018. 39(7): p. 1233-1238.
46. Lee, N.J., S.K. Ha, P. Sati, M. **Absinta**, N.J. Luciano, J.A. Lefeuvre, M.K. Schindler, E.C. Leibovitch, J.K. Ryu, M.A. Petersen, A.C. Silva, S. Jacobson, K. Akassoglou, and D.S. Reich, Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. Brain, 2018. 141(6): p. 1637-1649.
47. Maggi, P., M. **Absinta,** M. Grammatico, L. Vuolo, G. Emmi, G. Carlucci, G. Spagni, A. Barilaro, A.M. Repice, L. Emmi, D. Prisco, V. Martinelli, R. Scotti, N. Sadeghi, G. Perrotta, P. Sati, B. Dachy, D.S. Reich, M. Filippi, and L. Massacesi, Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol, 2018. 83(2): p. 283-294.
48. Solomon, A.J., R. Watts, D. Ontaneda, M. **Absinta**, P. Sati, and D.S. Reich, Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. Mult Scler, 2018. 24(6): p. 750-757.
49. **Absinta,** M., G. Nair, M.C.G. Monaco, D. Maric, N.J. Lee, S.K. Ha, N.J. Luciano, P. Sati, S. Jacobson, and D.S. Reich, The "central vein sign" in inflammatory demyelination: The role of fibrillar collagen type I. Ann Neurol, 2019. 85(6): p. 934-942.
50. Lee, N.J., S.K. Ha, P. Sati, M. **Absinta**, G. Nair, N.J. Luciano, E.C. Leibovitch, C.C. Yen, T.A. Rouault, A.C. Silva, S. Jacobson, and D.S. Reich, Potential role of iron in repair of inflammatory demyelinating lesions. J Clin Invest, 2019. 129(10): p. 4365-4376.
51. Maggi, P., M. **Absinta,** P. Sati, G. Perrotta, L. Massacesi, B. Dachy, C. Pot, R. Meuli, D.S. Reich, M. Filippi, R.D. Pasquier, and M. Theaudin, The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study. Mult Scler, 2020. 26(4): p. 421-432.
52. Suthiphosuwan, S., P. Sati, M. Absinta, M. Guenette, D.S. Reich, A. Bharatha, and J. Oh, Paramagnetic Rim Sign in Radiologically Isolated Syndrome. JAMA Neurol, 2020. 77(5): p. 653-655.
53. Kolb H, **Absinta M**, Beck ES, Ha SK, Song Y, Norato G, Cortese I, Sati P, Nair G, Reich DS.7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions. Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.

54. Bhargava P, Kim S, Reyes AA, Grenningloh R, Boschert U, **Absinta M**, Pardo C, Van Zijl P, Zhang J, Calabresi PA.Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain. 2021 Jun 22;144(5):1396-1408. doi: 10.1093/brain/awab045.
55. Rahmanzadeh R, Lu PJ, Barakovic M, Weigel M, Maggi P, Nguyen TD, Schiavi S, Daducci A, La Rosa F, Schaedelin S, **Absinta M**, Reich DS, Sati P, Wang Y, Bach Cuadra M, Radue EW, Kuhle J, Kappos L, Granziera C. Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain. 2021 Jul 28;144(6):1684-1696.
56. Rahmanzadeh, R., R. Galbusera, P.J. Lu, E. Bahn, M. Weigel, M. Barakovic, J. Franz, T.D. Nguyen, P. Spincemaille, S. Schiavi, A. Daducci, F. La Rosa, **M. Absinta**, P. Sati, M. Bach Cuadra, E.W. Radue, D. Leppert, J. Kuhle, L. Kappos, W. Bruck, D.S. Reich, C. Stadelmann, Y. Wang, and C. Granziera, A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis. Ann Neurol, 2022. **92**(3): p. 486-502
57. Al-Louzi, O., S. Manukyan, M. Donadieu, **M. Absinta**, V. Letchuman, B. Calabresi, P. Desai, E.S. Beck, S. Roy, J. Ohayon, D.L. Pham, A. Thomas, S. Jacobson, I. Cortese, P.K. Auluck, G. Nair, P. Sati, and D.S. Reich, Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study. Mult Scler, 2022. 28(12): p. 1891-1902
58. Hamzaoui M, Garcia J, Boffa G, Lazzarotto A, **Absinta M,** Ricigliano VAG, Soulier T, Tonietto M, Gervais P, Bissery A, Louapre C, Bottlaender M, Bodini B, Stankoff B. Positron Emission Tomography with [18 F]-DPA-714 Unveils a Smoldering Component in Most Multiple Sclerosis Lesions which Drives Disease Progression. Ann Neurol. 2023 Aug;94(2):366-383. doi: 10.1002/ana.26657.
59. Okar SV, Dieckhaus H, Beck ES, Gaitán MI, Norato G, Pham DL, **Absinta M**, Cortese IC, Fletcher A, Jacobson S, Nair G, Reich DS. Highly Sensitive 3-Tesla Real Inversion Recovery MRI Detects Leptomeningeal Contrast Enhancement in Chronic Active Multiple Sclerosis. Invest Radiol. 2023 Jul 27. doi: 10.1097/RLI.0000000000001011.
60. Cagol, Benkert, Melie-Garcia, Schaedelin, Leber, Tsagkas, Barakovic, Galbusera, Lu, Weigel, Ruberte, Radue, Yaldizli, Oechtering, Lorscheider, D'Souza, Fischer-Barnicol, Müller, Achtnichts, Vehoff, Disanto, Findling, Chan, Salmen, Pot, Bridel, Zecca, Derfuss, Lieb, Remonda, Wagner, Vargas, Du Pasquier, Lalive, Pravata, Weber, Cattin, **Absinta M**, Gobbi, Leppert, Kappos, Kuhle, Granziera C. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. Neurology 2024
61. Martire MS, Moiola L, Maggi P, Borrelli S, Novati V, Martinelli V, Rocca MA, Vezzulli P, Falini A, Filippi M, **Absinta M**. Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple sclerosis patients. Mult Scler. 2025 Jul;31(8):955-963. doi: 10.1177/13524585251314358.
62. Garton T, Smith MD, Kesharwani A, Gharagozloo M, Oh S, Na CH, **Absinta M**, Reich DS, Zack DJ, Calabresi PA. Myeloid lineage C3 induces reactive gliosis and neuronal stress during CNS inflammation. Nat Commun. 2025 Apr 12;16(1):3481. doi: 10.1038/s41467-025-58708-3

Review Articles

1. **Absinta M**. Multiple sclerosis: a smoldering disease. Trends Mol Med. 2025 Jan;31(1):94-95. doi: 10.1016/j.molmed.2024.11.005. PMID: 39681498
2. Dal-Bianco A, Oh J, Sati P, **Absinta M**. Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Ther Adv Neurol Disord. 2024 Dec 19;17:17562864241306684. doi: 10.1177/17562864241306684.PMID: 39711984
3. Summers RA, Fagiani F, Rowitch DH, **Absinta M**, Reich DS. Novel human iPSC models of neuroinflammation in neurodegenerative disease and regenerative medicine. Trends Immunol. 2024 Oct;45(10):799-813. doi: 10.1016/j.it.2024.08.004. PMID: 39307583
4. Keegan BM, **Absinta M**, Cohen-Adad J, Flanagan EP, Henry RG, Klawiter EC, Kolind S, Krieger S, Laule C, Lincoln JA, Messina S, Oh J, Papinutto N, Smith SA, Traboulsee A. Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future. Brain Commun. 2024 Nov 6;6(6):fcae395. doi: 10.1093/braincomms/fcae395.
5. Graves JS, Krysko KM, Hua LH, **Absinta M**, Franklin RJM, Segal BM. Ageing and multiple sclerosis. Lancet Neurol. 2023 Jan;22(1):66-77. doi: 10.1016/S1474-4422(22)00184-3.
6. Martire MS, Moiola L, Rocca MA, Filippi M, **Absinta M**. What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis? Expert Rev Neurother 2022:1-9

7. Ineichen BV, Tsagkas C, **Absinta M**, Reich DS. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis. Neuroimage Clin. 2022 Jan 10;33:102939. doi: 10.1016/j.nicl.2022.102939
8. Kolb H, Al-Louzi O, Beck ES, Sati P, **Absinta M**, Reich DS. From pathology to MRI and back: Clinically relevant biomarkers of multiple sclerosis lesions. Neuroimage Clin 2022;36:103194
9. La Rosa, F., M. Wynen, O. Al-Louzi, E.S. Beck, T. Huelnhagen, P. Maggi, J.P. Thiran, T. Kober, R.T. Shinohara, P. Sati, D.S. Reich, C. Granziera, **M. Absinta**, and M. Bach Cuadra, Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues. Neuroimage Clin, 2022. 36: p. 103205
10. **Absinta**, M., H. Lassmann, and B.D. Trapp, Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol, 2020. 33(3): p. 277-285.
11. Ineichen, B.V., P. Sati, T. Granberg, M. **Absinta**, N.J. Lee, J.A. Lefeuvre, and D.S. Reich, Magnetic resonance imaging in multiple sclerosis animal models: A systematic review, meta-analysis, and white paper. Neuroimage Clin, 2020. 28: p. 102371.
12. **Absinta,** M., P. Sati, and D.S. Reich, Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol, 2016. 12(6): p. 358-68
13. **Absinta**, M., D.S. Reich, and M. Filippi, Spring cleaning: time to rethink imaging research lines in MS? J Neurol, 2016. 263(10): p. 1893-902.
14. Rocca, M.A., M. **Absinta**, and M. Filippi, The role of advanced magnetic resonance imaging techniques in primary. progressive MS. J Neurol, 2012. 259(4): p. 611-21.
15. Filippi, M., M. **Absinta**, and M.A. Rocca, Future MRI tools in multiple sclerosis. J Neurol Sci, 2013. 331(1-2): p. 14-8.

Books, Textbooks

1. Rocca MA, **Absinta** M**,** Filippi M, Nusbaum AO, Rapalino O, Fung K, Atlas SW (2016). White Matter Diseases and Inherited Metabolic Disorders. In: Magnetic Resonance Imaging of the Brain and Spine, 5th Edition. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilk.
2. **Absinta** M, Reich DS (2015). Multiple sclerosis: MRI and other imaging approaches in MS. Neurobiology of Disease 2nd Edition. OXFORD:Oxford University Press.
3. Filippi, M., A. Charil, M. Rovaris, M. **Absinta**, and M.A. Rocca, Insights from magnetic resonance imaging. Handb Clin Neurol, 2014. 122: p. 115-49.

International Consortia Research Articles and/or Consensus Statements

North American Imaging in Multiple Sclerosis Cooperative (NAIMS) - https://www.naimscooperative.org/

1. Oh, J., D. Ontaneda, C. Azevedo, E.C. Klawiter, M. **Absinta**, D.L. Arnold, R. Bakshi, P.A. Calabresi, C. Crainiceanu, B. Dewey, L. Freeman, S. Gauthier, R. Henry, M. Inglese, S. Kolind, D.K.B. Li, C. Mainero, R.S. Menon, G. Nair, S. Narayanan, F. Nelson, D. Pelletier, A. Rauscher, W. Rooney, P. Sati, D. Schwartz, R.T. Shinohara, I. Tagge, A. Traboulsee, Y. Wang, Y. Yoo, T. Yousry, Y. Zhang, N.L. Sicotte, D.S. Reich, on behalf of the North American Imaging in Multiple Sclerosis Cooperative. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS. Neurology, 2019. 92(11): p. 519-533.
2. Bagnato F, Sati P, Hemond CC, Elliott C, Gauthier SA, Harrison DM, Mainero M, Oh J, Pitt D, Shinohara RT, Smith SA, Trapp B, Azevedo CJ, Calabresi PA, Henry RG, Laule C, Ontaneda D, Rooney WD, Sicotte NL, Reich DS, and **Absinta M,** on behalf of the NAIMS Cooperative. Imaging Chronic Active Lesions in Multiple Sclerosis: A consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. BRAIN 2024 Sep 3;147(9):2913-2933.

Magnetic Resonance Imaging in Multiple Sclerosis Consortia (MAGNIMS) - https://www.magnims.eu/

3. Rocca, MA, M. **Absinta,** P. Valsasina, O. Ciccarelli, S. Marino, A. Rovira, A. Gass, C. Wegner, C. Enzinger, T. Korteweg, M.P. Sormani, L. Mancini, A.J. Thompson, N. De Stefano, X. Montalban, J. Hirsch, L. Kappos, S. Ropele, J. Palace, F. Barkhof, P.M. Matthews, and M. Filippi, Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp, 2009. 30(8): p. 2412-25.
4. Giorgio, A., M. Battaglini, M.A. Rocca, A. De Leucio, M. **Absinta**, R. van Schijndel, A. Rovira, M. Tintore, D. Chard,

O. Ciccarelli, C. Enzinger, C. Gasperini, J. Frederiksen, M. Filippi, F. Barkhof, N. De Stefano, and MAGNIMS Study Group. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013. 80(3): p. 234-41.

5. Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, **Absinta M**, Barkhof F, Calabrese M, Castellaro M, Ciccarelli O, Cocozza S, De Stefano N, Enzinger C, Filippi M, Jurynczyk M, Maggi P, Mahmoudi N, Messina S, Montalban X, Palace J, Pontillo G, Pröbstel AK, Rocca MA, Ropele S, Rovira À, Schoonheim MM, Sowa P, Strijbis E, Wattjes MP, Sormani MP, Kappos L, Granziera C, MAGNIMS Study Group. Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis. JAMA Neurol. 2023 Dec 11:e234737. doi: 10.1001/jamaneurol.2023.4737.

Editorials/Commentaries

1. **Absinta** M, Dal-Bianco A. Slowly expanding lesions are a marker of progressive MS - Yes. Mult Scler. 2021 Sep 3:13524585211013748. doi: 10.1177/13524585211013748
2. **Absinta,** M. and D. Ontaneda, Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis. Mult Scler, 2020. 26(2): p. 135-136
3. **Absinta,** M. and D.S. Reich, Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes. Mult Scler, 2019. 25(3): p. 330-331.
4. **Absinta**, M., Leptomeningeal enhancement of the spinal cord in sarcoidosis. Mult Scler, 2018: p. 1352458518771873.

Methods and Techniques, "How I Do It" articles

1. Horsfield, M.A., S. Sala, M. Neema, M. **Absinta,** A. Bakshi, M.P. Sormani, M.A. Rocca, R. Bakshi, and M. Filippi, Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage, 2010. 50(2): p. 446-55.
2. **Absinta,** M., G. Nair, M. Filippi, A. Ray-Chaudhury, M.I. Reyes-Mantilla, C.A. Pardo, and D.S. Reich, Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains. J Neuropathol Exp Neurol, 2014. 73(8): p. 780-8.
3. Luciano, N.J., P. Sati, G. Nair, J.R. Guy, S.K. Ha, M. **Absinta,** W.Y. Chiang, E.C. Leibovitch, S. Jacobson, A.C. Silva, and D.S. Reich, Utilizing 3D Printing Technology to Merge MRI with Histology: A Protocol for Brain Sectioning. J Vis Exp, 2016(118).
4. Ha, S.K., G. Nair, **M. Absinta**, N.J. Luciano, and D.S. Reich, Magnetic Resonance Imaging and Histopathological Visualization of Human Dural Lymphatic Vessels. Bio Protoc, 2018. 8(8).
5. Maggi, P., M.J. Fartaria, J. Jorge, F. La Rosa, M. **Absinta,** P. Sati, R. Meuli, R. Du Pasquier, D.S. Reich, M.B. Cuadra, C. Granziera, J. Richiardi, and T. Kober, CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis. NMR Biomed, 2020. 33(5): p. e4283.
6. Barquero, G., F. La Rosa, H. Kebiri, P.J. Lu, R. Rahmanzadeh, M. Weigel, M.J. Fartaria, T. Kober, M. Theaudin, R. Du Pasquier, P. Sati, D.S. Reich, M. **Absinta,** C. Granziera, P. Maggi, and M. Bach Cuadra, RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis. Neuroimage Clin, 2020. 28: p. 102412.
7. Lou C, Sati P, **Absinta M**, Clark K, Dworkin JD, Valcarcel AM, Schindler MK, Reich DS, Sweeney EM, Shinohara RT. Fully automated detection of paramagnetic rims in multiple sclerosis lesions on 3T susceptibility-based MR imaging. Neuroimage Clin. 2021;32:102796. doi: 10.1016/j.nicl.2021.102796.
8. Vanden Bulcke C, Wynen M, Detobel J, La Rosa F, **Absinta M**, Dricot L, Macq B, Bach Cuadra M, Maggi BMAT: An open-source BIDS managing and analysis tool. Neuroimage Clin. 2022;36:103252. doi: 10.1016/j.nicl.2022.103252.

RESEARCH ACTIVITIES

- Pathobiological understanding and radiological visualization of chronic inflammation in multiple sclerosis lesions and in the meningeal compartment.
- Single-cell RNA-seq and multi-omics approaches to study neuroinflammatory and neurodegenerative disorders and *in vitro* cellular modelling.
- Design of MRI-based clinical trials aimed at preventing or limiting chronic inflammation in multiple sclerosis.

- Lab website https://www.humanitas-research.com/groups/absinta-group/

FUNDING

2026-2030	ERC starting grant / "Dissecting microglia vulnerability to stress response in multiple sclerosis through human iPSC modelling"/ role: PI
2025-2026	Human Technopole GEDM 2024 ID 1989146 / "Unraveling the role of microglial C1q in neuroinflammation in multiple sclerosis using hiPSC-derived models" / role: PI
2024-2027	Italian MS Society #2023-R-Single-015 / "Glial-enriched stem-cell 3D model of smoldering inflammation in multiple sclerosis: towards a drug screening cellular platform" / role: PI
2023-2026	National MS Society (NMSS, US) #RFA-2203-39325 / "MRI-single cell transcriptomic investigation of chronic active inflammation of the spinal cord in patients with multiple sclerosis" /role: PI
2024-2026	Italian Ministry of Health Ricerca Finalizzata 2023 / "Hybrid recto proteins: new tools to regulate neuroinflammation" / role: PI Muzio/co-PI Absinta
2021-2024	International Progressive MS Alliance #PA-2107-38081/ "Multi-omics predictors of chronic inflammation in multiple sclerosis"/ role: PI Fitzgerald/co-PI Absinta
2021-2024	FRRB Early Career Award #1750327 / "Personalized brain organoid model of premature aging in multiple sclerosis" / role: PI
2020-2023	Cariplo Foundation #1677 / "Inflammation-induced accelerated brain aging in multiple sclerosis" / role: PI
2019-2023	Conrad N. Hilton Foundation #17313 / "Limiting chronic inflammation in MS lesions: from MRI to molecular pathways" / role: PI
2016-2019	National MS Society (NMSS, US) FG-2093-A-1 / "Chronic inflammation and remyelination failure in MS lesions: in vivo and postmortem investigation of chronic lesions with phase rims" / role: postdoctoral fellowship

CLINICAL ACTIVITIES

Clinical Focus Multiple sclerosis and neuroinflammatory disorders of the central nervous system (outpatient clinic).

Medical, other state/government licensure

03/2007 /Italy, identification # 006423

Boards, other specialty certification

09/2012 Neurology

EDUCATIONAL ACTIVITIES

Organization of workshops /seminars

2026-2029	Vice-co-chair / Neuroimmune communication in health and disease- Gordon conference https://www.grc.org/neuroimmune-communication-in-health-and-disease-conference/2025/
2022	NAIMS Consensus Agreement for the Definition of Chronic Active Lesions and Assessment of their Clinical Impact in Multiple Sclerosis (Feb 23, 2022, West Plam Beach, US) https://www.naimscooperative.org/2022-naims-workshop Organizers: Bagnato F, Absinta M, Harrison D, Reich DS, & Smith SA

2022-present	Weekly seminar "NeuroClub" of the Division of Neuroscience / ~100 participants / Vita-Salute San Raffaele University and IRCCS Raffaele Scientific Institute / Italy Organizers: Absinta M & Colasante G
2023-2024	Neuroscience Scientific Retreat of the Division of Neuroscience, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University / ~250 participants / Jan 18-19, 2024 / Italy Organizers: Absinta M, Colasante G, Perego J, Colnaghi L, Sessa A. & D'Adamo P.

Editorial Board

01/2022-present	Editorial Board member of Neurology Clinical Practice https://www.neurology.org/cpj/editorial-board
06/2021-06/2022	Guest Editor NeuroImage: Clinical / Special Issue "Mapping Multiple Sclerosis: new frontiers - old challenges" https://www.sciencedirect.com/journal/neuroimage-clinical/special-issue/101P9MKDPG1

Reviewing activities (grants/manuscripts)

2025	Grant reviewer for ERC panel LS5
2023	Fondazione Italiana Sclerosi Multipla (FISM) Biomedical Scientific Committee panel member / Italy
2022	Grant reviewer for the Germani-Israeli Foundation for Scientific Research & Development / Israel
2021 – 2023	Grant reviewer for the ARSEP Foundation - French MS Research Society / France
2012	Reviewer for the following peer-reviewed journals: Nature Neuroscience, Brain, Journal of Clinical Investigation, Annals of Neurology, Neurology, Multiple Sclerosis Journal, NeuroImage Clinical, Neurology: Neuroimmunology & Neuroinflammation, Neurology Clinical Practice.

Consulting activities and participation in Advisory Boards for Pharmaceutical companies

From 2023	Sanofi Global MS Franchise Strategic & International Advisory Board
From 2022	International Scientific Advisory Board - Biogen (virtual meetings) / US
From 2020	Consulting and/or speaker activity with honoraria for Sanofi, Roche, Biogen, Abata Therapeutics, GSK, Viatris, Celgene.

Membership

2021 – present Member, International Society of Neuroimmunology (ISNI)
2020 – present Member, International MS Analysis
2020 – present Member, Research Network "North American Imaging in MS Cooperative" (NAIMS)
2018 – present Member, American Neurological Association (ANA)
2012 – present Member, Italian Society of Neurology Italian Society of Neurology (SIN)

TEACHING ACTIVITIES

Teaching University Courses

2024- present	Associate Professor of Neurology / Neurology, School of Medicine/ Humanitas University, Milan, Italy
2024- present	Associate Professor of Neurology / Neurology, School of Medicine and Technology School / Humanitas University, Milan, Italy
2022-2024	Lecturer BIO13 (10h) – Applied Biology, School of Dentistry (Central Nervous System focus, I year)/ Vita-Salute San Raffaele University/ Italy
2022-2024	Lecturer BIO09 (52h) – Physiology (Physiology of the Nervous System), School of Medicine (II year) / Vita-Salute San Raffaele University/ Italy
2020-2023	Lecturer MED26 (8h) – Neurology Residency School / Vita-Salute San Raffaele University/ Italy

External member committee of PhD thesis defense

12/2023	PhD candidate in Molecular and Experimental Medicine / Humanitas University (Milan)
11/2024	PhD candidate in Neuroscience / University of Amsterdam (NL)

12/2024 PhD candidate in Biomedical Sciences / University of Leuven (Leuven, Belgium)
01/2026 PhD candidate in Neuroscience / University of Groningen (NL)

RECOGNITION

Awards

2009 Award for best poster - Italian Society of Neurology (SIN)
2016 Award for best paper with impact factor between 10 and 20 - Italian Society of Neurology (SIN)
2018 NIH Fellows Award for Research Excellence (FARE) competition, Bethesda, US
2021 Rita-Levi Montalcini Prize 2021 – Italian MS Society (FISM/AISM) https://aism.it/martina-absinta-premio-rita-levi-montalcini-2021
2022 Young Physician-Scientist Award - The American Society for Clinical Investigation (ASCI) https://the-asci.org/controllers/asci/ListingController.php?action=year&year=2022&category=ypsa

I dati personali saranno trattati in ottemperanza a quanto richiesto dal Dlgs 196/2003. Si attesta inoltre la consapevolezza del rispetto alle responsabilità connesse a dichiarazioni mendaci (DPR 445/2000 ar. 76)

April 7, 2026

Martina Absinta 

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "conflitto d'interessi E.C.M." è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA
l'assenza di interessi commerciali in ambito sanitario negli ultimi due anni dalla data di sottoscrizione del presente curriculum.

Milan, April 7, 2026 Martina Absinta

Biografia

Mario Alberto Battaglia

Mario Alberto Battaglia, medico e professore ordinario di Igiene e Sanità Pubblica all'Università di Siena, è da 50 anni volontario dell'Associazione Italiana Sclerosi Multipla (AISM), diventata realtà di riferimento per le persone con SM, i famigliari e tutti gli stakeholder. Dal 1986 al 2007 è Presidente Nazionale AISM e Presidente della Fondazione (FISM) dal 1998 ad oggi. AISM e FISM sono da sempre in prima linea in azioni di advocacy, progetti di ricerca scientifica e nella realizzazione di campagne di raccolta fondi innovative a sostegno del movimento nazionale e internazionale.

L'impegno per il movimento della sclerosi multipla lo porta a ricoprire da oltre 30 anni cariche internazionali e nell'ottobre 2024 viene eletto Presidente della Federazione Internazionale della Sclerosi Multipla (MSIF). Negli anni '90 fonda e presiede la Federazione Italiana Superamento Handicap (FISH) ed è tuttora attivo nell'associazionismo della disabilità. Si occupa di ricerca nei campi dell'epidemiologia e dell'organizzazione dei servizi sanitari, oltre che nel campo della sclerosi multipla ed è stato componente del Consiglio Superiore di Sanità da febbraio 2019 a febbraio 2022.

(www.aism.it)

*Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),*

DICHIARA
*l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.*

Il sottoscritto, consapevole che le dichiarazioni mendaci, la falsità negli atti e l'esibizione di atto falso o contenente dati non più rispondenti a verità sono puniti dal codice penale e delle leggi speciali in materia, dichiara la veridicità delle informazioni contenute nel presente curriculum.

Autorizza, altresì, il trattamento dei dati personali ai sensi del D.lgs196/03 e della normativa vigente in materia, anche ai fini degli adempimenti necessari per la corretta registrazione di eventi formativi validi ai fini del programma nazionale di Educazione Continua in Medicina

Genova, 12 marzo 2026

CURRICULUM VITAE

PERSONAL INFORMATION

Name	**MATTEO GASTALDI**
Address	**VIALE DELLA RIMEMBRANZA 109, NOVI LIGURE (AL), ITALY**
E-mail	**matteo.gastaldi@mondino.it**
Medical Licence (Italy)	8734 (Ordine dei medici di Pavia)
Nationality	Italian
Date of birth	29/07/1985

LATEST POSITION

• Date	**January 2021- present**
Department	Neuroimmunology laboratory/Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation
Address	Neuroimmunology laboratory, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia(PV), Italy
Position	Head of the Neuroimmunology Research Section
Occupation (laboratory)	Coordination of Neuroimmunology diagnostic and Research activity for the Mondino Neuroimmunology laboratory, a referral centre for second level diagnostic collecting samples from all Italian regions
Occupation (clinic)	Inpatient care; autoimmune neurology specialized outpatients care (myasthenia gravis, autoimmune encephalitis, paraneoplastic disorders, stiff person syndrome, neuromyelitis optica spectrum disorders, MOGAD and multiple sclerosis).

• Date	**December 2025-present**
University	University of Pavia
Role	Tenure Track researcher
Course	MED26, Medicine and Surgery

EDUCATION

• Date	**November 2015- November 2018**
University	University of Pavia, Pavia (PV), Italy
Department	Nervous system and behavioural sciences department
Position	PhD in Biomedical sciences
Tutor	Dr. Diego Franciotta (IRCCS C. Mondino, Pavia, Italy)
Co-Tutor	Prof. Angela Vincent (University of Oxford, Oxford, UK)
Thesis	Title:"Autoantibodies against neuroglial surface antigens: laboratory strategies for their detection and roles in acquired demyelinating syndromes, autoimmune encephalitis and acquired neuromyotonia"
Main topics	Diagnostic techniques in antibody mediated disorders of the nervous system; role of MOG antibodies in demyelinating disorders.

• Date	**July 2011- July 2016**
University	University of Pavia, specialization school in neurology, Pavia (PV), Italy

Title	Specialization in neurology (50/50 cum laude). Title: "*Antibody detection in anti-NMDAR encephalitis*"
• Date	**September 2003- July 2010**
University	University of Pavia, faculty of Medicine, Pavia (PV), Italy
Title	Medical degree (110/110 cum laude). Title: "Poliomavirus *DNA in patients with MS treated with natalizumab*"
• Date	**August 2007- February 2008**
University	University of Tampere, Tampere, Finland
Position	*Visiting Student* (Erasmus program)
• Date	**August 2007- February 2008**
School	High school (liceo classico) E. Amaldi, Novi Ligure (AL), Italy
Title	Diploma di maturita' (100/100)

PAST RESEARCH EXPERIENCE

• Date	**October 2017- December 2017**
University	University di Barcelona, Barcelona, Spain
Hospital	Hospital Clinic, Barcelona
Position	Visiting research fellow
Tutor	Prof. Francesc Graus/Prof. Josep Dalmau
Field	Diagnostic techniques in neuroimmunology
• Date	**January 2015- December 2015**
University	University of Oxford, Oxford (UK)
Hospital	John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences, Neuroimmunology Laboratory
Position	Visiting research fellow
Tutor	Prof. Angela Vincent
Field	Antibody mediated disorders of the central nervous system

MEDICAL EXPERIENCE

• Date	**From July 2016 to February 2019**
Hospital	IRCCS Mondino foundation, Pavia (PV), Italy
Department	Department of General neurology, Neuro-oncology and neuroinflammation unit
Position	Contract neurologist
Occupation	Outpatient clinic (clinical neuroimmunology, peripheral nervous system disorders, multiple sclerosis); neuroncology ward.
• Date	**January 2015- December 2015**
Hospital	John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences,
Department	Nuffield department of clinical neurosciences, Oxford (UK)
Position	Observer
Occupation	Outpatient clinic (Neuromyelitis Otpica, Myasthenia Gravis, Autoimmune Encephalitis)
• Date	**July 2011- July 2016**
University	University of Pavia, specialization school in Neurology, Pavia (PV), Italy
Position	Registrar
Hospital	Circolo Hospital / Macchi Foundation, Varese (VA), Italy, Neurology and Stroke Unit IRCCS Mondino Foundation, Pavia (PV), Italy, general neurology

Field	Neuroimmunology, Neuro-oncology, CNS infections, epilepsy, Multiple Sclerosis;
Technical skills	EEG, 24-hour EEG monitoring and video-EEG intepretation.
• Date	**August 2009- September 2009**
Hospital	Johannes Gutenberg University of Mainz, Department of neurology and neurosurgery
Position	Formulanterinn (Internship)
• Date	**June 2009- July 2009**
Hospital	Hospital St. Antonio e Arrigo, Alessandria (AL), Italy, Neurosurgery Unit
Position	Internship

TEACHING

• Date	**October 2013- December 2014**
University	AIMO (Italian academy of Ostheopathy), Saronno (VA), Italy
Position	Neurology course teaching
• Date	**September 2008- July 2010**
University	University of Pavia
Position	Tutor in “practical skills laboratory”
Role	Teaching basic practical skills to medicine students

CLINICAL TRIAL EXPERIENCE

In the past 5 years Principal Investigator for 6 trials in Myasthenia Gravis, 2 trials in MOGAD, 2 trials in NMOSD, 2 trials in Autoimmune Encephalitis

ROLE IN SCIENTIFIC SOCIETIES

• Date	**June 2019- Present**
Scientif Society	Italian Association of Neuroimmunology
Role	Member of the Board and Founder of the Italian group for the study of Autoimmune Neurology (NINA, www.nina.aini.it)
• Date	**December 2022- Present**
Scientif Society	Encephalitis society
Role	Member of the scientific advisory group
• Date	**April 2021- Present**
Scientif Society	Italian Association of Neuroimmunology
Role	Coordinator and Founder of the Italian Network for Autoimmune Neurology (NINA group)
• Date	**January 2020- Present**
Scientif Society	European Academy of Neurology
Role	Neuroimmunology Panel member (managing group)

FUNDING

• Date	**February 2025-Present**
Project	Clinical, prognostic and pathogenic relevance of conformational antibodies to proteolipid protein 1 in MOGAD, seronegative NMOSD, MS and other autoimmune demyelinating diseases of the central nervous system
Duration	2 years
Funding	Fondazione Italiana Sclerosi Multipla (FISM)

Topic	Characterization of the clinical relevance of PLP1 antibodies
Role	Principal Investigator,

• Date	**January 2025-Present**
Project	Natural history of chemotherapy related peripheral neuropathies
Duration	3 years
Funding	PNRR/PNC
Topic	Biomarkers in chemotherapy induced neuropathies
Role	Principal Investigator,

• Date	**December 2024-Present**
Project	iDOT study
Duration	2 years
Funding	Guthy Jackson Charitable Foundation (GJCF)
Topic	Worldwide validation of a novel iDOT test for AQP4 abs
Role	Principal Investigator,

• Date	**January 2022-Present**
Project	Conformational Antibodies and Neuromuscolar disorders: LABoratory diagnostics and novel targets (CANLAB)
Duration	3 years
Funding	Fondo Regionale per la Ricerca Biomedica (FRRB)
Topic	Standardization of antibody diagnostic in neuropathies, novel antibody targets, pathogenic mechanisms in nodo/paranodopathies
Role	Principal Investigator

• Date	**August 2024-Present**
Project	Autoantibodies against known and novel glial surface targets in demyelinating disorders: developing and validating high-thoughput in-vitro systems to assess effector functions (TARGET)
Duration	1 year
Funding	Bando a cascata per PNRR MNESYS
Topic	Functional characterization of autoantibodies in demyelinating disorders
Role	Co-Principal Investigator

• Date	**November 2024-Present**
Project	Implementation of a national network to promote diagnosis, care and research in autoimmune encephalitis and paraneoplastic neurological syndromes
Duration	2 years
Funding	Ministero della salute (PNRR)
Topic	Implementation of the italian registry for Autoimmune Encephalitis
Role	Co-Principal Investigator

• Date	**January 2022-Present**
Project	NINA-Flow project
Duration	2 years
Funding	Alexion/Astrazeneca farmaceutical
Topic	Implementation of a second level diagnostic system for AQP4, MOG, ACHR and MUSK abs
Role	Design and planning of the study; Hub laboratory

• Date	**June 2022-Present**
Project	Cognitive rehabilitation in patients with Autoimmune Encephalitis: the Core Aim Study”
Duration	2 years
Funding	Autoimmune Encephalitis Alliance SEED funding
Role	Principal Investigator

• Date	**January 2021-present**
Project	“antibody mediated disorders of the CNS and PNS”
Duration	3 years
Funding	IRCCS C. Mondino, Pavia- fondi ricerca corrente
Role	Principal Investigator

• Data	**January 2021-June 2025**

Project	Neuronal synaptic autoantibodies and PsycHosis: evaLuation of A systematic approach to increase autoiMmune Encephalitis diagnosis in acute adult and pediatric patients and relevance of the autoantibodies in chronic forms. The PHLAMES Study
Duration	3 years
Funding	Ministero della Salute, Progetti di ricerca finalizzata giovani ricercatori
Role	Principal Investigator

• Data	**March 2020-present**
Project	Conformational antibodies in patients with multiple sclerosis: re-evaluation of old targets
Duration	1 year
Funding	Fondazione Italiana Sclerosi Multipla (FISM), progetto pilota
Role	Principal Investigator

• Data	**January 2018-Jun 2020**
Project	Autoantibodies in psychosis
Funding	IRCCS C. Mondino, Pavia- fondi 5X1000
Role	Principal Investigator

SPECIAL AWARDS

2023 “Rita Levi Montalicini” prize for young researchers in the field of multiple sclerosis and associated disorders, Associazione Italiana Sclerosi Multipla (AISM)

Mondino best clinical paper of the year 2022 for “Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study”

AINI prize 2021 for relevant scientific contribution to the field. XXIX Italian Association of Neuroimmunology conference, Verona.

“Marco Vergelli” prize for the best scientifc contribution (title: *Thymoma-associated myasthenia gravis and neuromyotonia comorbidity: a clinical and serological study)*
XXVII Italian Association of Neuroimmunology Trieste, 7-10 Maggio 2018

Prize from Lions Club “Montù Beccaria Le Vigne”, for the best thesis on Musltiple Sclerosis of the year 2011

BIBLIOMETRIC SCORES

(Scopus) H-Index: 27; number of publications: 138; number of citations: 2569.

PUBLICATIONS (FIRST/LAST NAME)

In bold are highlighted the most relevant publications

Businaro, P., Masciocchi, S., Barnabei, R., Scaranzin, S., Morandi, C., Scucchi, M., Bernini, S., Bottiroli, S., Barone, P., Toriello, A., Arbasino, C., Padiglioni, C., Cenciarelli, S., Benedetti, L., Cerne, D., Risi, M., Paoletti, M., Pichiecchio, A., Diamanti, L., Bini, P., … Gastaldi, M. (2025). Serum Autoantibody Titers and Neurofilament Light Chain Levels in CASPR2/LGI1 Encephalitis: A Longitudinal Study. *Neurology(R) neuroimmunology & neuroinflammation,* 12(5), e200431. https://doi.org/10.1212/NXI.0000000000200431

Masciocchi, S., Businaro, P., Greco, G., Scaranzin, S., Malvaso, A., Morandi, C., Zardini, E., Risi, M., Vegezzi, E., Diamanti, L., Bini, P., Siquilini, S., Giannoccaro, M. P., Morelli, L., Liguori, R., Patti, F., De Giuli, V., Portaccio, E., Zanetta, C., Bergamoni, S., … Neuroimmunology

***(Houndmills, Basingstoke, England)*, *24*(13), 1743–1752. https://doi.org/10.1177/1352458517731911**

Gastaldi, M., Zardini, E., & Franciotta, D. (2017). An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. *Expert review of molecular diagnostics*, *17*(1), 31–46. https://doi.org/10.1080/14737159.2017.1262260

Gastaldi, M., Thouin, A., Franciotta, D., & Vincent, A. (2017). Pitfalls in the detection of N-methyl-d-aspartate-receptor (NMDA-R) antibodies. *Clinical biochemistry*, *50*(6), 354–355. https://doi.org/10.1016/j.clinbiochem.2016.11.023

Gastaldi, M., Thouin, A., & Vincent, A. (2016). Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, *13*(1), 147–162. https://doi.org/10.1007/s13311-015-0410-6

Gastaldi, M., Ferrario, A., Basilico, C., Merli, M., Mauri, M., Tibiletti, M. G., Passamonti, F., Franciotta, D., & Bono, G. (2014). Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy. *Journal of the neurological sciences*, *344*(1-2), 234–235. https://doi.org/10.1016/j.jns.2014.06.036

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Pavia, 8/4/2026

Firma: 

Nb : Si precisa che per "interessi commerciali" si intendono situazioni di possesso di quote azionarie di società che operano in ambito sanitario, rapporto di lavoro dipendente o comunque incarichi che lo collochino nell'organizzazione delle medesime società, oppure situazioni di percepimento di royalties o provvigioni commerciali dalle stesse società.

Personal Details:

Name: **Jonathan Kipnis**
Marital status: Married (Olga) + 3 (Noa, Michal and Ari)

Tel: 434.9646582
Email: kipnis@wustl.edu

Brief summary

Dr. Jonathan (Jony) Kipnis is BJC Investigator, Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology and Professor of Neurology, Neuroscience, and Neurosurgery at Washington University in St. Louis, School of Medicine. He is also the inaugural Director of Center for Brain immunology and Glia (BIG) at Washington University. Jony graduated from the Weizmann Institute of Science in Israel, where he was a Sir Charles Clore scholar and a recipient of distinguished prize for scientific achievements awarded by the Israeli Parliament, The Knesset.

Kipnis lab focuses on the complex interactions between the immune system and the central nervous system (CNS). The goal is to elucidate the cellular and molecular mechanisms underlying these interactions in neurodegenerative, neurodevelopmental, and mental disorders as well as in physiology (including healthy aging). The lab showed that the brain function is dependent, in part, on the function and integrity of the immune system and that immune molecules (cytokines) can play neuromodulatory roles. The fascination with immunity and its role in neurophysiology is what brought the lab to a breakthrough discovery of meningeal lymphatic vessels that drain the CNS into the peripheral lymph nodes and thus serve as a physical connection between the brain and the immune system. This finding challenged the prevailing mechanisms underlying CNS “immune privilege” and opened new avenues to mechanistically study the nature of neuroimmune interactions under physiological and pathological conditions. The implications of this work are broad and range from Autism to Alzheimer’s disease through neuroinflammatory conditions, such as Multiple Sclerosis. Recently Kipnis lab has also identified the skull and vertebrae bone marrow sites as local immune reservoirs for the brain and the spinal cord, whose role in neurological disorders is yet unknown.

Dr. Kipnis is a member of National Academy of Medicine and among other awards, he is a recipient NIH Director’s Pioneer award for 2018 to explore in more depth neuro-immune interactions in healthy and diseased brain.

Education

1995-1998	BSc	Tel Aviv University, Ramat Aviv, Israel Biology	Biology
1998-1999	MSc	Weizmann Institute of Science, Rehovot, Israel	Neurobiology
1999-2004	PhD	Weizmann Institute of Science, Rehovot, Israel	Neuroimmunology

Positions

2004-2005	Postdoctoral Research Associate, the Weizmann Institute of Science, Israel
2005-2007	Assistant Professor of Pharmacology and Ophthalmology, University of Nebraska Medical Center (UNMC), Omaha, NE (health professions, non-tenure track)
2007-2011	Assistant Professor of Neuroscience, Department of Neuroscience, University of Virginia Health System, Charlottesville, VA (tenure track)
2007-2020	Faculty, Neuroscience Graduate Program, University of Virginia
2007-2020	Faculty, Microbiology, Immunology, Infectious diseases graduate program, University of Virginia
2007-2020	Member, Carter Immunology Center, University of Virginia
2008-2020	Faculty, Medical Scientist Training Program, University of Virginia
2009-2020	Member, Center for Cell Clearance, University of Virginia
2011-2012	Associate Professor of Neuroscience, University of Virginia (tenured)
2011-2012	Associate Professor of Ophthalmology, University of Virginia
2012-2020	Director, Center for Brain Immunology and Glia (BIG), University of Virginia
2012-2020	Professor of Neuroscience and Ophthalmology, University of Virginia
2015-2020	Gutenberg Research College (GRC) Professor, Department of Neurology, Johannes Gutenberg University of Mainz, Germany
2016-2020	Harrison Distinguished Teaching Professor of Neuroscience
2016-2020	Chair, Department of Neuroscience, University of Virginia
2020-	BJC Investigator, Washington University in St. Louis, School of Medicine
2020 -	Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology, Washington University in St. Louis, School of Medicine
2020-	Professor of Neurology, Neuroscience and Neurosurgery, Washington University in St. Louis, School of Medicine
2020-	Director, Brain Immunology and Glia (BIG) Center, Washington University in St. Louis, School of Medicine

Honors and Awards

2002 Sir Charles Clore scholarship and award of excellence in doctoral studies

2002 Representative of Israeli Student Delegation for the International Summit of the American Academy of Achievement (Dublin, Ireland)

2003 Representative of Israeli Student Delegation, International Summit for Nobel Prize Laureates in Medicine (Lindau)

2004 Distinguished Prize for excellence in doctoral studies awarded by the Israeli Parliament (Knesset)

2004 Prize of excellence for doctoral studies awarded by the Feinberg Graduate School, Weizmann Institute of Science

2006 Vada Kinman Oldfield Alzheimer's Research Award, University of Nebraska Medical Center

2011 Robert Ader New Investigator Award for 2011, PsychoNeuroImmunology Research Society (PNIRS)
2012 Jordi Folch-Pi award, American Society for Neurochemistry
2014 Distinguished Research Career Development Award, University of Virginia
2015 Gutenberg Research College (GRC) fellowship, Johannes Gutenberg University of Mainz
2016 Harrison Foundation Distinguished Teaching Professorship in Neuroscience
2018 NIH Director's Pioneer Award
2020 NIH/NIA MERIT Award
2022 Elected member, National Academy of Medicine
2024 Comet-Wallerstein Prize, Bar Ilan University, Israel
2026 Elected member, Henry Kunkel Society

Publications

(10 most influential publications in chronological order)

1. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. (2015) Structural and functional features of central nervous system lymphatics. *Nature,* Jul 16;523(7560):337-41. doi: 10.1038/nature14432.

2. Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, Overall CC, Gadani SP, Turner SD, Weng Z, Peerzade SN, Chen H, Lee KS, Scott MM, Beenhakker MP, Litvak V, Kipnis J. (2016) Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour. *Nature*. Jul 21;535(7612):425-9.

3. Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE, Powell RD, Baker W, Dabhi N, Bai R, Cao R, Hu S, Rich SS, Munson JM, Lopes MB, Overall CC, Acton ST, Kipnis J. (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature*. Aug;560(7717):185-191. doi: 10.1038/s41586-018-0368-8. Epub 2018 Jul 25.

4. Rustenhoven J, Drieu A, Mamuladze T, de Lima KA, Dykstra T, Wall M, Papadopoulos Z, Kanamori M, Salvador AF, Baker W, Lemieux M, Da Mesquita S, Cugurra A, Fitzpatrick J, Sviben S, Kossina R, Bayguinov P, Townsend RR, Zhang Q, Erdmann-Gilmore P, Smirnov I, Lopes MB, Herz J, Kipnis J. (2021) Functional characterization of the dural sinuses as a neuroimmune interface. *Cell*. Feb 18;184(4):1000-1016.e27. doi: 10.1016/j.cell.2020.12.040. Epub 2021 Jan 27

5. Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, Louveau A, Goldman DH, Salvador AF, Onengut-Gumuscu S, Farber E, Dabhi N, Kennedy T, Milam MG, Baker W, Smirnov I, Rich SS; Dominantly Inherited Alzheimer Network, Benitez BA, Karch CM, Perrin RJ, Farlow M, Chhatwal JP, Holtzman DM, Cruchaga C, Harari O, Kipnis J. (2021) Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. *Nature*. Apr 28. doi: 10.1038/s41586-021-03489-0. Online ahead of print.

6. Cugurra A, Mamuladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg ZJ, Baker W, Papadopoulos Z, Drieu A, Blackburn S, Kanamori M, Brioschi S, Herz J, Schuettpelz LG,

Colonna M, Smirnov I, Kipnis J. (2021) Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. *Science*. Jun 3:eabf7844. doi: 10.1126/science.abf7844. Online ahead of print.

7. Drieu A, Du S, Storck SE, Rustenhoven J, Papadopoulos Z, Dykstra T, Zhong F, Kim K, Blackburn S, Mamuladze T, Harari O, Karch CM, Bateman RJ, Perrin R, Farlow M, Chhatwal J; Dominantly Inherited Alzheimer Network, Hu S, Randolph GJ, Smirnov I, Kipnis J. (2022) Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. *Nature* Nov 9. doi: 10.1038/s41586-022-05397-3. Online ahead of print. PMID: 36352225

8. Smyth LCD, Xu D, Okar SV, Dykstra T, Rustenhoven J, Papadopoulos Z, Bhasiin K, Kim MW, Drieu A, Mamuladze T, Blackburn S, Gu X, Gaitán MI, Nair G, Storck SE, Du S, White MA, Bayguinov P, Smirnov I, Dikranian K, Reich DS, Kipnis J. (2024) Identification of direct connections between the dura and the brain. *Nature*. Mar;627(8002):165-173. doi: 10.1038/s41586-023-06993-7. PMID: 38326613

9. Jiang-Xie LF, Drieu A, Bhasiin K, Quintero D, Smirnov I, Kipnis J (2024) Neuronal dynamics direct cerebrospinal fluid perfusion and brain clearance. *Nature*. Mar;627(8002):157-164. doi: 10.1038/s41586-024-07108-6. PMID: 38418877

10. Kim MW, Gao W, Lichti CF, Gu X, Dykstra T, Cao J, Smirnov I, Boskovic P, Kleverov D, Salvador AFM, Drieu A, Kim K, Blackburn S, Crewe C, Artyomov MN, Unanue ER, Kipnis J. (2025) Endogenous self-peptides guard immune privilege of the central nervous system. *Nature*. Jan;637(8044):176-183. doi: 10.1038/s41586-024-08279-y. Epub 2024 Oct 30. PMID: 39476864

All publications in chronological order

1. Blander G., Kipnis J., Leal J.F., Yu C.E., Schellenberg G.D., Oren M. (1999) Physical and functional interaction between p53 and the Werner's syndrome protein. *J. Biol. Chem*. 274(41), 29463-9.
2. **Kipnis J.,** Yoles E., Porat Z., Sela M., Cohen I.R., Schwartz M. (2000) Vaccination with copolymer-1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. *Proc. Natl. Acad. Sci. USA* **97**, 7446-7451.

3. Schwartz M. and **Kipnis J.** (2001) Protective autoimmunity: Genetic aspects and prospects for vaccination after brain and spinal cord injuries. *Trends in Mol. Med.* **7(6)**, 252-258.

4. **Kipnis J.,** Yoles E., Hauben E., Shaked I., Schwartz M. (2001) Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. *J Neuroscience* **21,** 4564-4571.

5. Schori H.,* **Kipnis J.,*** Yoles E. and Schwartz M. (2001) Vaccination for protection of neurons against glutamate cytotoxicity. *Proc. Natl. Acad. Sci. USA* **98**, 3398-3403. ***Equal contribution**.

6. **Kipnis J.** and Schwartz M. (2002) Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. *Trends Mol Med.* Jul;**8 (7)**:319-23.

7. Bakalash S., **Kipnis J.,** Yoles E. and Schwartz M. (2002) Neuronal survival in a rat model of chronically raised intraocular pressure is immune regulated. *IOVS*, **43(8):**2648-53.

8. Schwartz M and **Kipnis J**. (2002) Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: A paradigm shift. *The Neuroscientist*, **8,** 405-413.

9. **Kipnis J.,** Mizrahi T., Yoles E. and Schwartz M. (2002) Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. *J. Neuroimmunol,* **130(1-2)**:78.

10. Schwartz M. and **Kipnis J.,** (2002) Autoimmunity on Alert: Naturally Occurring Regulatory $CD4^+CD25^+$ T cells as Part of the Evolutionary Compromise Between a "Need" and a "Risk". *Trends Immunol.,* **23(11)**:530-4.

11. **Kipnis J.,** Hauben E., Mizrahi T., Shaked I., Shevach EM and Schwartz M. (2002) Neuroprotective autoimmunity: Naturally occurring CD4(+)CD25(+) regulatory T cells suppress the ability to withstand injury to the central nervous system. *Proc. Natl. Acad. Sci. USA,* **26;99(24)**:15620-5.

12. Nevo U, **Kipnis J**, Golding I, Shaked I, Neumann A, Akselrod S, Schwartz M. (2003) Autoimmunity as a special case of immunity: Removing threats from within. *Trends Mol Med.* **9(3):**88-93.

13. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, Yoles E, **Kipnis J**, Schori H, Reuter A, Ludolph A, Schwartz M. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. *Proc Natl Acad Sci U S A*. **15; 100(8)**:4790-5.

14. **Kipnis J.,** Nevo U., Panikashvili D., Yoles E., Akselrod S., Shohami E. and Schwartz M. (2003) Therapeutic Vaccination for Closed Head Injury. *J Neurotrauma,* **20(6)**; 559-69.

15. Monsonego A, Beserman ZP, **Kipnis J,** Yoles E, Weiner HL, Schwartz M. (2003) Beneficial effect of orally administered myelin basic protein in EAE-susceptible Lewis rats in a model of acute CNS degeneration. *J Autoimmun.* **21(2)**:131-8.

16. Shaked I, Porat Z, Gersner R, **Kipnis J***, Schwartz M*****. (2004) Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. *J Neuroimmunol*. **146(1-2)**:84-93. * ***equal contribution***

17. **Kipnis J.,** Avidan H., Markovich Y., Mizrahi T., Prigozhina T., Slavin S. and Schwartz M. (2004) Homeostasis-Driven Activation of Adaptive Immunity Induced by Low-Dose Irradiation: A Therapeutic Approach to Neurodegenerative Disorders. *Eur. J. Neuroscience,* **19**: 1-8.

18. **Kipnis J*.**, Cohen H., Cardon M., Ziv Y. and Schwartz M (2004) T cell deficiency leads to cognitive impairment: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. *Proc. Natl. Acad. Sci. USA,* **101**:8180-8185 (***corresponding author)**

19. **Kipnis J.,** Avidan H., Mordechay S., Lewitus G.M., Cardon M. and Schwartz M (2004) Dopamine, through the extracellular-regulated kinase pathway, downregulates $CD4^+CD25^+$ regulatory T cell activity: Implications for neurodegeneration. *J Neurosci, **24(27):**6133-43.*

20. **Kipnis J.,** Avidan H. and Schwartz M. (2004) Dual effect of $CD4^+CD25^+$ regulatory T cells in neurodegeneration: A dialogue with microglia. *Proc. Natl. Acad. Sci. USA, **101:** Aug 26 [epub ahead of print]*.

21. Schwartz M. and **Kipnis J.** (2004) Threatened tissues summon autoimmune aid controlled by naturally occurring regulatory T cells: a Darwinian interpretation of autoimmunity. *Cell Mol Life Sci.* **61(18)**:2285-9.

22. **Kipnis J.** and Schwartz M. (2004) A common vaccine for fighting neurodegenerative disorders: recharging immunity for homeostasis. *Trends Pharmacol Sci**, 25(8):**407-12.*

23. Avidan H, **Kipnis J**, Butovsky O, Caspi RR, Schwartz M. (2004) Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. *Eur J Immunol* Dec;34(12):3434-45.

24. Schwartz M. and **Kipnis J.** (2005) Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. *J Neurol Sci.* Jun 15;233(1-2):163-6.

25. Schwartz M. and **Kipnis J.** (2005) Therapeutic T Cell-Based Vaccination for Neurodegenerative Disorders: The Role of CD4+CD25+ Regulatory T Cells. *Ann N Y Acad Sci.* Jun;1051:701-8.

26. **Kipnis, J.** and Schwartz, M, (2005) Controlled autoimmunity in CNS maintenance and repair: naturally occurring CD4+CD25+ regulatory T-Cells at the crossroads of health and disease. *Neuromolecular Med*. 2005;7(3):197-206.

27. Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., **Kipnis, J***., Schwarz, M*., (2006) Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adults. *Nat. Neurosci.* Feb;9(2):268-75 (*corresponding authors).

28. Kadiu I, Glanzer JG, **Kipnis J**, Gendelman HE*, Thomas MP. (2005) Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. *Neurotox Res.* Oct;8(1-2):25-50.

29. **Kipnis, J*.,** Cardon, M., Strauss, R. and Schwartz, M. (2006) Loss of autoimmune T cells correlates with brain diseases: what are the implications for schizophrenia. *Trends in Mol Med,* Feb 7; [Epub ahead of print] (*corresponding author).

30. Cohen H., Ziv Y., Cardon M., Kaplan Z., Gidron Y., Schwartz M. and **Kipnis J.** (2006) Adaptation to mental stress is autoimmune T-cell dependent and is suppressed by regulatory T cells. *J Neurobiol,* 66(6):552-63.

31. Schwartz M., Butovsky O. and **J. Kipnis**. (2006) Does inflammation in an autoimmune disease differ from inflammation in neurodegenerative diseases? Possible implications for therapy. *Journal of Neuroimmune Pharmacology*, March;1(1):4-10.

32. Crutcher KA, Gendelman HE, **Kipnis J**, Perez-Polo JR, Perry VH, Popovich PG, Weaver LC. (2006) Debate: "is increasing neuroinflammation beneficial for neural repair?" *J Neuroimmune Pharmacol.* Sep;1(3):195-211. Epub 2006 May 23.

33. Lewitus GM, **Kipnis J**, Avidan H, Ben-Nun A, Schwartz M. (2006) Neuroprotection induced by mucosal tolerance is epitope-dependent: conflicting effects in different strains. *J Neuroimmunol. 2006 Jun;175(1-2):31-8. Epub 2006 Apr 19.*

34. Ziv Y, Finkelstein A, Geffen Y, **Kipnis J,** Smirnov I, Shpilman S, Vertkin I, Kimron M, Lange A, Hecht T, Reyman KG, Marder JB, Schwartz M, Yoles E. (2007) A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. *Stroke. 2007 Feb;38(2 Suppl):774-82.*

35. Johnson T.V., Camras C.B. and **Kipnis J.** (2007) Bacterial DNA Confers Neuroprotection Following Optic Nerve Injury By Suppressing CD4+CD25+ Regulatory T-cell Activity. *IOVS.* Aug;48(8):3441-9.

36. Oren-Benaroya R, Kipnis J, Eisenbach M. (2007) Phagocytosis of human post-capacitated spermatozoa by macrophages. *Hum Reprod.* Nov;22(11):2947-55. Epub 2007 Sep 1.

37. Lewitus G.M., Zhu J., Warren T., Xiong H., Hallworth R. and **Kipnis J.** (2007) Depletion of $CD4^{+}CD25^{+}$ Regulatory T Cells Results in Inhibition of Hippocampal Long-Term Potentiation by $CD4^{+}$ T Cells. *Eur. J. Neurosci.,* 26 (6), 1399–1406.

38. Liu J., Thomas J.V., Lin J., Bronich T.B., Caplan S., Persidsky Y., Gendelman H.E. and **Kipnis J.** (2007) T cell independent mechanism for Copolymer-1-induced neuroprotection. *Eur. J. Immunol.,* 37(11):3143-54.

39. Schwartz M. and **Kipnis J.** (2007) Model of acute injury to study neuroprotection. *Methods Mol Biol*. 399:41-53.

40. Zhang Y, Zhou Y, Schweizer U, Savaskan NE, Hua D, **Kipnis J,** Hatfield DL, Gladyshev VN. (2008) Comparative analysis of selenocysteine machinery and selenoproteome gene expression in mouse brain identifies neurons as key functional sites of selenium in mammals. *J Biol Chem.* Jan 25;283(4):2427-38.

41. Gorantla S, Liu J, Wang T, Holguin A, Sneller HM, Dou H, **Kipnis J**, Poluektova L, Gendelman HE. (2008) Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. *Glia*. Jan 15;56(2):223-32.

42. Brynskikh A., Warren T., Zhu J. and **Kipnis J.** (2008) Adaptive immunity affects learning behavior in mice. *Brain, Behavior, and Immunity.* Aug;22(6):861-9.

43. Garg S., Banerjee R. and **Kipnis J.** (2008) Neuroprotective Immunity: T cell-derived Glutamate Endows Astrocytes with a Neuroprotective Phenotype. *J Immunol.* Mar 15;180(6):3866-73.

44. Hanisch U-K., Johnson, T.V., and **Kipnis J.** (2008) Toll-like Receptors: Roles in neuroprotection? *Trends in Neurosci.* Apr;31(4):176-182.

45. Yamamoto M, Kiyota T, Walsh SM, Liu J, **Kipnis J**, Ikezu T. (2008) Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. *J Immunol*. Sep 15;181(6):3877-86.

46. **Kipnis J**, Derecki NC, Yang C, Scrable H. (2008) Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common? *Trends Immunol*. Oct;29(10):455-63.

47. Garg SK, **Kipnis J**, Banerjee R. (2009) IFN-gamma and IL-4 Differentially Shape Metabolic Responses and Neuroprotective Phenotype of Astrocytes. *J Neurochem*. Mar;108(5):1155-66.

48. Yan Z., Garg SK., **Kipnis J.,** Banerjee R. (2009) Modulation of Extracellular Redox Remodeling by Regulatory T Cells. *Nature Chem Biol* Oct;5(10):721-3.

49. Lu Z. and **Kipnis J.** (2010) Thrombospondin 1--a key astrocyte-derived neurogenic factor. *FASEB J.* Jun;24(6):1925-34.

50. Derecki N.C., Privman E. and **Kipnis J.** (2010) Rett syndrome and other autism spectrum disorders— brain diseases of immune malfunction? *Mol Psych* Apr;15(4):355-63.

51. Derecki N.C., Cardani A.N., Yang C.H., Quinnies K.M., Crihfield A., Lynch K.R., and **Kipnis J** (2010) Regulation of learning and memory by meningeal immunity: A key role for IL-4. *J Exp Med.* May 10;207(5):1067-80. Epub 2010 May 3.

52. Derecki N.C., Quinnies K.M. and **Kipnis J.** (2011) Alternatively activated myeloid (M2) cells enhance cognitive function in immune compromised mice. *Brain Behav Immun*. Mar;25(3):379-85.

53. Schwartz and **Kipnis J.** (2010) A conceptual revolution in the relationships between the brain and immunity. *Brain Behav Immun*. Jul;25(5):817-9.

54. Walsh J.T. and **Kipnis J.** (2011) Regulatory T cells in CNS injury: the simple, the complex, and the confused. *Trends Mol Med*. Oct;17(10):541-7.

55. Lu Z., Elliott M.R., Chen Y., Walsh J.T., Klibanov, A.I., Ravichandran K.S. and **Kipnis J.** (2011) Phagocytic activity of neuronal progenitors regulates adult neurogenesis. *Nat Cell Biol*. Jul 31;13(9):1076-83.

56. Derecki N.C., Cronk J.C., Lu Z., Xu E., Abbott S.B.G., Guyenet P.G. and **Kipnis J.** (2012) Wild type microglia arrest pathology in a mouse model of Rett syndrome. *Nature*. Mar 18;484(7392):105-9. doi: 10.1038/nature10907.

57. **Kipnis J**, Gadani S, Derecki NC. (2012) Pro-cognitive properties of T cells. *Nat Rev Immunol*. 2012 Aug 10;12(9):663-9. doi: 10.1038/nri3280.

58. Gadani SP, Cronk JC, Norris GT, **Kipnis J**. (2012) IL-4 in the brain: a cytokine to remember. *JImmunol*. 2012 Nov 1;189(9):4213-9.doi: 10.4049/jimmunol.1202246. Review.

99. Louveau A, **Kipnis J**. (2018) Sex, Gut, and Microglia. *Dev Cell*. Jan 22;44(2):137-138. doi: 10.1016/j.devcel.2018.01.003.

100. Mrdjen D, Pavlovic A, Hartmann FJ, Schreiner B, Utz SG, Leung BP, Lelios I, Heppner FL, **Kipnis J**, Merkler D, Greter M, Becher B. (2018) High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. *Immunity*. Feb 6. pii: S1074-7613(18)30032-3. doi: 10.1016/j.immuni.2018.01.011.

101. Vogelaar CF, Mandal S, Lerch S, Birkner K, Birkenstock J, Bühler U, Schnatz A, Raine CS, Bittner S, Vogt J, **Kipnis J**, Nitsch R, Zipp F. (2018) Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation. *Sci Transl Med*. Feb 28;10(430). pii: eaao2304.

102. Cronk JC, Filiano AJ, Louveau A, Marin I, Marsh R, Ji E, Goldman DH, Smirnov I, Geraci N, Acton S, Overall CC, **Kipnis J**. (2018) Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. *J Exp Med*. Apr 11. pii: jem.20180247.

103. Norris GT, Smirnov I, Filiano AJ, Shadowen HM, Cody KR, Thompson JA, Harris TH, Gaultier A, Overall CC, **Kipnis J**. (2018) Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury. *J Exp Med.* Jul 2;215(7):1789-1801. doi: 10.1084/jem.20172244. Epub 2018 Jun 25.

104. Louveau A, Filiano AJ, **Kipnis J**. (2018) Meningeal whole mount preparation and characterization of neural cells by flow cytometry. *Curr Protoc Immunol.* Apr;121(1). pii: e50. doi: 10.1002/cpim.50. Epub 2018 Apr 16.

105. **Kipnis J**. (2018) The Seventh Sense. Sci Am. Jul 17;319(2):28-35. doi: 10.1038/scientificamerican0818-28.

106. Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE, Powell RD, Baker W, Dabhi N, Bai R, Cao R, Hu S, Rich SS, Munson JM, Lopes MB, Overall CC, Acton ST, **Kipnis J**. (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature*. Aug;560(7717):185-191. doi: 10.1038/s41586-018-0368-8. Epub 2018 Jul 25.

107. Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, Herod SG, Knopp J, Setliff JC, Lupi AL, Da Mesquita S, Frost EL, Gaultier A, Harris TH, Cao R, Hu S, Lukens JR, Smirnov I, Overall CC, Oliver G, **Kipnis J**. (2018) CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. *Nat Neurosci.* Oct;21(10):1380-1391. doi: 10.1038/s41593-018-0227-9. Epub 2018 Sep 17.

108. Da Mesquita S, Fu Z, **Kipnis J**. (2018) The Meningeal Lymphatic System: A New Player in Neurophysiology. *Neuron*. Oct 24;100(2):375-388. doi:10.1016/j.neuron.2018.09.022. Review.

109. Norris GT, **Kipnis J**. (2019) Immune cells and CNS physiology: Microglia and beyond. *J Exp Med*. 2019 Jan 7;216(1):60-70. doi: 10.1084/jem.20180199. Review.

I, **Kipnis J.** (2022) Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid. Nature Nov 9. doi: 10.1038/s41586-022-05397-3. Online ahead of print. PMID: 36352225

136. Rustenhoven J, **Kipnis J.** (2022) Brain borders at the central stage of neuroimmunology. Nature. Dec;612(7940):417-429. doi: 10.1038/s41586-022-05474-7. Epub 2022 Dec 14.PMID: 36517712 Review
137. Chen X, Firulyova M, Manis M, Herz J, Smirnov I, Aladyeva E, Wang C, Bao X, Finn MB, Hu H, Shchukina I, Kim MW, Yuede CM, **Kipnis J**, Artyomov MN, Ulrich JD, Holtzman DM. (2023) Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. Mar 8. doi: 10.1038/s41586-023-05788-0.
138. Kim MW, **Kipnis J.** (2023) Picking a (neuroimmune) fight against fragile regulation of addiction. Cell. Feb 2;186(3):464-466. doi: 10.1016/j.cell.2023.01.003. Epub 2023 Jan 23.
139. Seo DO, O'Donnell D, Jain N, Ulrich JD, Herz J, Li Y, Lemieux M, Cheng J, Hu H, Serrano JR, Bao X, Franke E, Karlsson M, Meier M, Deng S, Desai C, Dodiya H, Lelwala-Guruge J, Handley SA, **Kipnis J**, Sisodia SS, Gordon JI, Holtzman DM. (2023) ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science. Jan 13;379(6628):eadd1236. doi: 10.1126/science.add1236. Epub 2023 Jan 13.
140. Brase L, You SF, D'Oliveira Albanus R, Del-Aguila JL, Dai Y, Novotny BC, Soriano-Tarraga C, Dykstra T, Fernandez MV, Budde JP, Bergmann K, Morris JC, Bateman RJ, Perrin RJ, McDade E, Xiong C, Goate AM, Farlow M; Dominantly Inherited Alzheimer Network (DIAN); Sutherland GT, **Kipnis J**, Karch CM, Benitez BA, Harari O. (2023) Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nat Commun. Apr 21;14(1):2314. doi: 10.1038/s41467-023-37437-5.PMID: 37085492
141. Salvador AFM, **Kipnis J.** (2023) Resilient brains run out of (c)GAS. Nat Immunol. May;24(5):741-742. doi: 10.1038/s41590-023-01485-2.PMID: 37095376 No abstract available.
142. Ozturk B, Koundal S, Al Bizri E, Chen X, Gursky Z, Dai F, Lim A, Heerdt P, **Kipnis J**, Tannenbaum A, Lee H, Benveniste H. (2023) Continuous positive airway pressure increases CSF flow and glymphatic transport. JCI Insight. Jun 22;8(12):e170270. doi: 10.1172/jci.insight.170270.PMID: 37159262
143. Rustenhoven J, Pavlou G, Storck SE, Dykstra T, Du S, Wan Z, Quintero D, Scallan JP, Smirnov I, Kamm RD, **Kipnis J.** (2023) Age-related alterations in meningeal immunity drive impaired CNS lymphatic drainage. J Exp Med. Jul 3;220(7):e20221929. doi: 10.1084/jem.20221929. Epub 2023 Apr 7.PMID: 37027179
144. Mamuladze T, **Kipnis J.** (2023) Type 2 immunity in the brain and brain borders. Cell Mol Immunol. Jul 10. doi: 10.1038/s41423-023-01043-8. Online ahead of print. PMID: 37429945 Review.
145. Salvador AFM, Dykstra T, Rustenhoven J, Gao W, Blackburn SM, Bhasiin K, Dong MQ, Guimarães RM, Gonuguntla S, Smirnov I, **Kipnis J**, Herz J. (2023) Age-dependent immune and lymphatic responses after spinal cord injury. Neuron. Jul 19;111(14):2155-2169.e9. doi: 10.1016/j.neuron.2023.04.011. Epub 2023 May 5.PMID: 37148871
146. Drieu A, Du S, Kipnis M, Bosch ME, Herz J, Lee C, Jiang H, Manis M, Ulrich JD, **Kipnis J**, Holtzman DM, Gratuze M. (2023) Parenchymal border macrophages regulate tau pathology and tau-mediated neurodegeneration. Life Sci Alliance. Aug 10;6(11):e202302087. doi: 10.26508/lsa.202302087. Print 2023 Nov. PMID: 37562846
147. Xu W, Rustenhoven J, Nelson CA, Dykstra T, Ferreiro A, Papadopoulos Z, Burnham CD, Dantas G, Fremont DH, **Kipnis J.** (2023) A novel immune modulator IM33 mediates a glia-gut-neuronal axis that controls lifespan. Neuron. Oct 18;111(20):3244-3254.e8. doi: 10.1016/j.neuron.2023.07.010. Epub 2023 Aug 14.PMID: 37582366
148. Sun C, Zheng S, Perry JSA, Norris GT, Cheng M, Kong F, Skyberg R, Cang J, Erisir A, **Kipnis J**, Hill DL. (2023) Maternal diet during early gestation influences postnatal taste

172. Plog BA, Smyth LCD, **Kipnis J.** (2025) The night shift: norepinephrine drives glymphatics. *Cell Res*. Mar 25. doi: 10.1038/s41422-025-01106-7. Online ahead of print. PMID: 40128608
173. Du S, **Kipnis J.** (2025) Beyond the brain: microglia-like cells regulate peripheral neuronal soma size. *Cell Mol Immunol*. May;22(5):466-467. doi: 10.1038/s41423-025-01276-9. Epub 2025 Apr 8. PMID: 40200088
174. Hitpass Romero K, Stevenson TJ, Smyth LCD, Watkin B, McCullough SJC, Vinnell L, Smith AM, Schweder P, Correia JA, **Kipnis J**, Dragunow M, Rustenhoven J. (2025) Age-related meningeal extracellular matrix remodeling compromises CNS lymphatic function. *J Neuroinflammation*. Apr 17;22(1):109. doi: 10.1186/s12974-025-03436-0. PMID: 40247257
175. Smyth LCD, **Kipnis J.** (2025) Redefining CNS immune privilege. *Nat Rev Immunol*. May 2. doi: 10.1038/s41577-025-01175-0. Online ahead of print. PMID: 40316862 Review.
176. Kim MW, **Kipnis J.** (2025) Glymphatics and meningeal lymphatics unlock the brain-immune code. *Immunity*. May 13;58(5):1040-1051. doi: 10.1016/j.immuni.2025.03.006. Epub 2025 May 4. PMID: 40324376
177. Geraghty AC, Acosta-Alvarez L, Rotiroti MC, Dutton S, O'Dea MR, Kim W, Trivedi V, Mancusi R, Shamardani K, Malacon K, Woo PJ, Martinez-Velez N, Pham T, Reche-Ley NN, Otubu G, Castenada EH, Nwangwu K, Xu H, Mulinyawe SB, Zamler DB, Ni L, Cross K, Rustenhoven J, **Kipnis J**, Liddelow SA, Mackall CL, Majzner RG, Monje M. (2025) Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. *Cell*. Jun 12;188(12):3238-3258.e25. doi: 10.1016/j.cell.2025.03.041. Epub 2025 May 12.PMID: 40359942
178. Plog BA, Kim K, Verhaege D, Kim MW, Papadopoulos Z, Dikranian K, Dykstra T, Cao J, Perrin RJ, Schwetye KE, **Kipnis J**, Drieu A. (2025) A route for cerebrospinal fluid flow through leptomeningeal arterial-venous overlaps enables macromolecule and fluid shunting. *Nat Neurosci.* Jul;28(7):1436-1445. doi: 10.1038/s41593-025-01977-4. Epub 2025 Jun 9. PMID: 40490598
179. Du S, Zhou Y, Li D, Lier J, Cella M, Tada M, Hamasaki H, Wu J, Cai Z, Orthmann-Murphy JL, Kakita A, **Kipnis J**, Bergner CG, Colonna M. (2025) Mutations in the human CSF1R gene impact microglia's maintenance of brain white matter integrity. *Nat Immunol*. Jul;26(7):1198-1211. doi: 10.1038/s41590-025-02195-7. Epub 2025 Jun 26. PMID: 40571738
180. Du S, **Kipnis J.** (2025) Replacing microglia to treat a brain disease. *Science*. Jul 10;389(6756):129-130. doi: 10.1126/science.adz0113. Epub 2025 Jul 10.PMID: 40638757
181. Gursky ZH, Khan ZN, Koundal S, Bhardwaj A, Caceres Melgarejo J, Xu K, Chen X, Lin HM, Gu X, Lee H, **Kipnis J**, Dori Y, Tannenbaum A, Santambrogio L, Benveniste H. (2025) Age-dependent brain responses to mechanical stress determine resilience in a chronic lymphatic drainage impairment model. *J Clin Invest*. Jul 15:e182555. doi: 10.1172/JCI182555. Online ahead of print.PMID: 40663395
182. Mamuladze T, Zaninelli TH, Smyth LCD, Wu Y, Abramishvili D, Silva R, Imbiakha B, Verhaege D, Du S, Papadopoulos Z, Gu X, Lee D, Storck S, Perrin RJ, Smirnov I, Dong X, Hu S, Diamond MS, Pinho-Ribeiro FA, **Kipnis J.** (2025) Mast cells regulate the brain-dura interface and CSF dynamics. *Cell*. Jul 16:S0092-8674(25)00748-2. doi: 10.1016/j.cell.2025.06.046. Online ahead of print. PMID: 40712577
183. Smyth LCD, Verhaege D, Standen-Bloom E, Wu Y, Gan Y, Storck SE, Boskovic P, Plog BA, Mamuladze T, Mazzitelli JA, Wang Z, Lee DD, Randolph GJ, Drieu A, Schwetye KE, Hu S, Reich DS, Kelley DH, Mehta RI, **Kipnis J.** (2026) Amyloidosis of bridging veins is a pathologic feature of Alzheimer's disease. *J Exp Med*. Feb 2;223(2):e20251860. doi: 10.1084/jem.20251860. Epub 2025 Dec 2.PMID: 41329157

184. Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, **Kipnis J**, Colonna M, Brioschi S. (2026) Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. *Nat Neurosci*. Jan 21. doi: 10.1038/s41593-025-02158-z. Online ahead of print.PMID: 41566006
185. Kim K, Title B, **Kipnis J**. (2026) Placebo effect influences vaccine responses. *Nat Med.* Jan 19. doi: 10.1038/s41591-025-04168-7. Online ahead of print.PMID: 41555036 No abstract available.
186. Herz J, **Kipnis J**. (2026) A head start: Bone channels shape meningeal immunity. *Immunity*. Jan 13;59(1):8-10. doi: 10.1016/j.immuni.2025.12.004.PMID: 41534514
187. Chen J, Du S, Cheng W, Amrute JM, Kim MW, Ohara RA, Han J, Jo S, Kim L, Wang Z, Song H, Postoak JL, Kim S, Randolph GJ, **Kipnis J**, Murphy TL, Murphy KM. (2026) Transcription factor Maf promotes expression of repressor Zeb2 to drive microglia development in primitive hematopoiesis. *Immunity*. Jan 13;59(1):48-59.e5. doi: 10.1016/j.immuni.2025.11.022. Epub 2025 Dec 26.PMID: 41455473
188. Kim MW, **Kipnis J**. (2025) Glymphatics and meningeal lymphatics unlock the brain-immune code. *Immunity*. Dec 9;58(12):3153. doi: 10.1016/j.immuni.2025.11.010. Epub 2025 Nov 13.PMID: 41237777 No abstract available.
189. **Kipnis J**, Benveniste H, Eichmann A, Thomas JL, Reich DS, Lewis LD, Tsai LH, Drieu A, Bakker ENTP, Kelley DH, Lundgaard I, Mestre H, Zott B, Eide PK, van Osch MJP, van Veluw SJ, Iliff J, Yang AC, Santambrogio L, Da Mesquita S, Daneman R, Rustenhoven J, Goldman SA, Nedergaard M. (2025) Resolving the mysteries of brain clearance and immune surveillance. *Neuron*. Dec 3;113(23):3908-3923. doi: 10.1016/j.neuron.2025.10.036. Epub 2025 Nov 24.PMID: 41289996 Review.

Selected Invited and Named Lectures and Seminars (showing only previous 5 years)

2025

- KEYNOTE lecture, Microenvironment of Brain Tumors, Paris, France
- Ariel University Symposium, Ariel, Israel
- Hebrew University of Jerusalem, Jerusalem Israel
- 32nd annual Adler symposium, San Diego, CA
- SMART symposium, Shenzhen, China
- CZI Neuroscience Meeting, San Jose, CA
- Scientific Deep Dive Workshop on “Augmenting Sleep to Slow Down Biological Ageing”, GESDA Forum, Singapore
- Norman Davidson Lectureship, Division of Biology and Biological Engineering, Caltech, Pasadena, CA
- CNIC seminar, Madrid, Spain
- NIH Director series lecture (WALS), Bethesda, MD
- Sheba Longevity Conference, Tel Aviv, Israel
- NOMIS Symposium at Salk, San Diego, CA
- Keynote Southeast Immunology, Charlottesville, VA
- Keystone Symposia on Neural-Immune Interactions, Whistler, Canada
- Fudan University, Shanghai, China
- AAI Advanced Course, Boston, MA

- Cell Symposia on Neuroimmunology, New York City, NY
- Symposium of the Aging Brain Initiative at MIT, Boston, MA
- ISNI2025 Chiba, Japan
- #ReThinkNeuroimmunology, Boston, MA
- 40th Annual tumor microenvironment, Boston MA
- Ernst Strüngmann Institute (ESI) Symposium, Berlin, Germany

2024

- Neuroscience department seminar, Johns Hopkins University, Baltimore, MD
- University lecture, UTSW, Dallas, TX
- CTSI/I3T Seminar, UCLA, Los Angeles, CA
- Neuroscience seminar, Weizmann Institute, Rehovot, Israel
- Lymphatic GRC, Ventura, CA
- Keynote Speaker Invitation: ASAP Collaborative Research Network Meeting, Rome, Italy
- Prestige Seminar, Toulouse, France
- EMBO Workshop on tissue-resident immune cells, Marseille, France
- O'Donnell Brain Institute Symposium, UTSW, Dallas, TX
- CRC Symposium Multiple sclerosis and related disorders, Munster, Germany
- Neuroimmunology session, AAI, Chicago, IL
- CureAlz RLG meeting, Boston, MA
- Scripps Neuroscience Seminar, San Diego, CA
- Dr. Tovi Comet -Walerstein lecture, Bar-Ilan University, Israel
- CZI Neuroscience 2024 Meeting, Monterey, CA
- Opening Keynote lecture, AAN Summer Conference, Atlanta, GA
- Seminar, McGovern/Peking University, Beijing, China
- Traynor Memorial Lecture, Duke University, Durham, NC
- NCI/IIG in Maryland, Translational Immunology Symposium, Bethesda, MA
- The Promise of Interleukin-2 (IL-2) Therapy, Paris, France
- Disease education forum seminar, Paris, France
- Carol & Gene Ludwig Family Foundation, Martha Vineyards, MA
- #ReThink Neuroimmunology symposium, St. Louis, MO
- 22nd Eibsee meeting, Munich, Germany
- CZI Symposium at UPENN, Philadelphia, PA
- Keynote lecture, ADRD Cedars Sinai, Los Angeles, CA
- Arc institute seminar, Los Angeles, CA
- Neuroscience seminar, Gladstone Institute, San Francisco, CA
- IMSYSU Symposium, Guangzhou, Guangdong, China
- Portuguese Neuroimmunology meeting, Porto, Portugal
- "Brainwashing" symposium, New York, NY

2023

- GRC Neuroimmune communication, Los Angeles, CA
- Adler Symposium, San Diego, CA
- Packard Center Keynote lecture, Baltimore, MD
- Yale Physiology Seminar, New Heaven, CT

*Title: Perivascular macrophages in ALS
Name of PD/PI: Kipnis, Jonathan; *Source of Support: Corsalex
Project/Proposal Start and End Date: 09/01/2023-08/31/2026

*Title: Skull bone marrow macrophages in AD
Name of PD/PI: Kipnis, Jonathan; *Source of Support: Eisai
Project/Proposal Start and End Date: 06/01/2024-05/31/2026

*Title: Entry & Exit Consortium: CNS barriers in Alzheimer's disease
Name of PD/PI: Kipnis, Jonathan; *Source of Support: Cure Alzheimer's Fund
Project/Proposal Start and End Date: 04/15/2022-04/14/2026

SELF-DECLARATION ON CONFLICT OF INTEREST – ECM

The undersigned, aware that an **E.C.M. conflict of interest** is any situation in which a secondary interest interferes or could interfere with the primary interest consisting of the objectivity, impartiality, and independence of professional education in the healthcare sector related to the **Continuing Medical Education (E.C.M.) Program**,

DECLARES

commercial interests in the healthcare sector in the last two years from the date of signing this curriculum:

Co-founder: Pranas Neuro and Rho Bio

Scientific advisory board member: Fibralign, Cognito Theraeutics

Advisor: MMI

Date and place of signature: __April 7, 2026, St. Louis, USA_____

Signature: _

Personal data

Prof. Thomas Korn (MD)
Technical University of Munich
Ismaninger Str. 22, 81675 München
Phone: (+49-89) 4140-5617
Fax: (+49-89) 4140-4675
E-mail: thomas.korn@tum.de
www.kornlab.med.tum.de
ORCID: 0000-0002-3633-0955

Professional appointments

Since 2019	Director of the Institute for Experimental Neuroimmunology at the Technical University of Munich School of Medicine and Health
2018	Offer of a position as full Professor and Chair, Center for Brain Research, MedUni Vienna, declined
Since 2017	Deputy Chairman of the Dept. of Neurology, Klinikum rechts der Isar
Since 2015	Full Professor of Neurology
2010 − 2015	Associate Professor of Neurology and Heisenberg Professor
2009 − 2010	Heisenberg Grant Awardee and Group leader at the Technical University of Munich
Since 2008	Senior Physician in Neurology, Klinikum rechts der Isar

Academic education

2009	Professoral thesis (Habilitation): "Differentiation and function of regulatory T cells and proinflammatory Th17 cells in organ-specific autoimmunity of the CNS"
2005 − 2008	Postdoctoral research fellow at Harvard Medical School, Boston, USA (Prof. Kuchroo)
2001 – 2005	Postdoctoral fellow in Neuroimmunology and junior group leader, Dept. of Neurology at the University of Homburg/Saar
2000	Doctoral thesis (MD) Summa cum laude (University of Würzburg)
1999 – 2005	Residency in Clinical Neurology (Universities of Würzburg and Homburg/Saar). Board approval as Fellow in Neurology (Facharzt)
1992 – 1999	Medical School at the Universities of Würzburg and London, UK (Julius-Maximilians-Universität and The Royal London School of Medicine)

Current institutional responsibilities

Since 2020	Chairman of the Executive Faculty Board of the Center for Preclinical Research at the Campus Klinikum rechts der Isar
Since 2020	Member of the Steering Committee - PhD program: Medical Life Science and Technology

Honours and awards

2025	ERC advanced grant
2023	Sobek Award for Multiple Sclerosis Research
2015 – 2021	ERC consolidator grant
2011	Hans-Jörg Weitbrecht Award for Clinical Neurosciences
2010	Heinrich-Pette-Award (German Society of Neurology)
2008	Heisenberg Award by the German Research Council
2008	Sobek Junior Award
2007	Helmut-Bauer-Award by the University of Göttingen
1992 – 1999	Bavarian State grant for outstanding students

Scholarly activities

Research consortia: DFG funded: TRR-128, TRR-274, TRR-355 (Co-speaker), CRC 1054, Synergy (Excellence cluster), Hertie Network of Excellence in Clinical Neuroscience

Teaching: Clinical Neurology, T cell immunology within the curricula of the PhD program "Medical Life Science and Technology" and in the Master program "Biomedical Neuroscience" at the Technical University of Munich

Reviewer for professional societies:

ERC-StG panel 2026, DFG, Israel Science Foundation, MRC (UK), Medical Research Scotland, ARSEP, Australian MS Society, Italian MS Society, Schweizerischer Nationalfonds, European Research Council

Reviewer for journals, including:

Nat Rev Immunol, Nature, Science, Cell, Nat Immunol, Immunity, Sci Immunol, J Exp Med, J Clin Invest, Trends in Immunol, Nat Communications, PNAS, Ann Neurol, Brain, Cell reports, Neurology, J Leuk Biol, J Immunol, Eur J Immunol

Memberships in professional societies:

	German Neurological Society (DGN), German Society for Clinical Neurophysiology and Functional Imaging (DGKN), NEUROWIND (founding member), American Association of Immunologists
Since 2017	National Committee for the Development of Clinical Guidelines for Multiple Sclerosis
Since 2016	Elected member of the Scientific Advisory Board of the International Society of Neuroimmunology (ISNI)
Since 2010	Scientific Advisory Board of the German Multiple Sclerosis Society (DMSG)

10 top publications

Chen HH, Tyystjärvi S, Ruiz Navarro D, Kant R, Groll T, Wagner I, Domínguez Moreno H, Bonafonte-Pardàs I, Öllinger R, Afzali AM, Heink S, Richter LC, Sie C, Lepennetier G, Seeholzer L, Steiger K, Merkler D, Rad R, Schotta G, Schubert B, Muschaweckh A, & **Korn T**. (2025) CD38 endows local antigen-specific Foxp3+ Treg cells with stress resilience for control of compartmentalized CNS inflammation. ***Nature Immunology***, 27(3): 516-529.

Afzali AM, Nirschl L, Sie C, Pfaller M, Ulianov O, Hassler T, Federle C, Petrozziello E, Kalluri SR, Chen HH, Tyystjärvi S, Muschaweckh A, Lammens K, Delbridge C, Büttner A, Steiger K, Seyhan G, Ottersen OP, Öllinger R, Rad R, Jarosch S, Straub A, Mühlbauer A, Grassmann S, Hemmer B, Böttcher JP, Wagner I, Kreutzfeldt M, Merkler D, Bonafonte Pardàs I, Schmidt-Supprian M, Buchholz VR, Heink S, Busch DH, Klein L & **Korn T**. (2024) B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4. ***Nature***, 627 (8003): 407-415.

Hiltensperger M, Beltrán E, Kant R, Tyystjärvi S, Lepennetier G, Domínguez Moreno H, Bauer IJ, Grassmann S, Jarosch S, Schober K, Buchholz VR, Kenet S, Gasperi C, Öllinger R, Rad R, Muschaweckh A, Sie C, Aly L, Knier B, Garg G, Afzali AM, Gerdes LA, Kümpfel T, Franzenburg S, Kawakami N, Hemmer B, Busch DH, Misgeld T, Dornmair K & **Korn T**. (2021) Skin and gut imprinted T helper cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. ***Nature Immunology***, 22 (7): 880-892.

Knier B, Hiltensperger M, Sie C, Aly L, Lepennetier G, Engleitner T, Garg G, Muschaweckh A, Mitsdörffer M, Koedel U, Höchst B, Knolle P, Gunzer M, Hemmer B, Rad R, Merkler D & **Korn T**. (2018) Myeloid-derived suppressor cells control B cells within the central nervous system during autoimmunity. ***Nature Immunology***, 19 (12): 1341-1351.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A & **Korn T**. (2017) Dendritic cells are non-redundant sources of IL-6 for the priming of pathogenic Th17 cells due to a novel mode of IL-6 signaling. ***Nature Immunology***, 18: 74-85.

Heinemann C, Heink S, Petermann F, Vasanthakumar A, Rothhammer V, Doorduijn E, Mitsdoerffer M, Sie C, Prazeres da Costa O, Buch T, Hemmer B, Oukka M, Kallies A & **Korn T**. (2014) IL-27 and IL-12 oppose pro-inflammatory IL-23 in $CD4^+$ T cells by inducing Blimp1. ***Nature Communications***, 5: 3770-3782.

Rothhammer V, Heink S, Petermann F, Srivastava R, Claussen MC, Hemmer B & **Korn T**. (2011) Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. ***Journal of Experimental Medicine***, 208: 2465-2476.

Petermann F, Rothhammer V, Claussen MC, Haas JD, Riol-Blanco L, Heink S, Prinz I, Hemmer B, Kuchroo VK, Oukka M & **Korn T**. (2010) γδ T cells enhance autoimmunity by restraining Treg responses via an IL-23 dependent mechanism. ***Immunity***, 33: 351-363.

Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M & Kuchroo VK. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T_H17 cells. ***Nature***, 448: 484-487.

Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M & Kuchroo VK. (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. ***Nature Medicine***, 13: 423-431.

Daniela Latorre

latorre.daniela@hsr.it + 39 02 2643 5071 Milan, Italy

Personal Information

latorre.danielaa@gmail.com

Born in Venosa (PZ), Italy on 02.12.1984

Italian

Education

PhD in Immunology
"Sapienza" University of Rome, Rome, Italy
November 2009 – January 2013
Date of PhD defense: 17.01.2013

Master's Degree in Medical, Molecular and Cellular Biotechnologies
"Sapienza" University of Rome, Rome, Italy
November 2006 – July 2009
Grade: 110/110 with honors

Bachelor's Degree in Biotechnologies
University of Rome "Tor Vergata", Rome, Italy
November 2003 – July 2006
Grade: 110/110 with honors

Work Experience

Current Position

- **Associate Professor of Applied Biology**
  Vita-Salute San Raffaele University, Milano, Italy
  December 2025- to date
- **Head of Neuro-Immune Interactions Unit**
  Division of Neuroscience, San Raffaele Hospital, Milan, Italy
  January 2025 – to date

Previous Positions

- **SNSF PRIMA Group Leader**
  Human Neuroimmunology Group, Institute of Microbiology, ETH Zurich, Switzerland
  January 2020 – December 2024
  Topic of research: Autoreactive T cell immunity in human neurological disorders
- **Senior Postdoctoral Fellow**
  Institute of Microbiology, ETH Zurich, Switzerland | Supervisor: Prof. Federica Sallusto
  January 2018 – December 2019
  Topics of research: Autoreactive T cell immunity in narcolepsy
- **Postdoctoral Fellow**
  Institute for Research in Biomedicine, Bellinzona, Switzerland | Supervisor: Prof. Federica Sallusto
  January 2013 – December 2017
  Topics of research: Autoreactive T cell immunity in narcolepsy & T cell response against microbial infections in healthy donors and patients affected by immunodeficiencies

Grants, Fellowships, and Awards

Research Grants

Research Grants as Principal Investigator

- **European Research Council - Consolidator Grant** | December 2025 – November 2030 (5 years) | Amount: €2,000,000
- **Fondo Italiano per la Scienza (FIS2) Consolidator Grant** | September 2025 – August 2028 (3 years) | Amount: €1,524,931
- **Armenise Harvard Career Development Award** | January 2025 – December 2027 (3 years) | Amount: $600,000
- **Spark Grant – Swiss National Science Foundation** | April 2025 – March 2026 (1 year) | Amount: CHF 100,000
- **2024 Discovery Research Grant – GBS|CIDP Foundation International** | July 2024 – July 2026 (2 years) | Amount: $100,000

- **Swiss Multiple Sclerosis Society Grant** | January 2024 – December 2025 (2 years) | Amount: CHF 200,000
- **Novartis Foundation for Medical-Biological Research** | January 2025 – December 2025 (1 year) | Amount: CHF 80,000
- **2024 Elevation Research Grant – GBS|CIDP Foundation International** | July 2023 – June 2024 (1 year) | Amount: $ 50,000
- **Young Investigator Grant – Helmut Horten Foundation** | January 2022 – December 2025 (4 years) | Amount: CHF 375,000
- **SNSF PRIMA Grant** | January 2020 – December 2024 (5 years) | Amount: CHF 1,500,000
- **ETH Research Grant** | January 2021 – December 2024 (3 years) | Amount: CHF 276,800
- **ETH Career Seed Grant** | August 2019 – October 2020 | Amount: CHF 30,000

Research Grants as Co-applicant

- **Horizon Europe Marie Skłodowska-Curie Actions (MSCA) Doctoral Network** | September 2025 – August 2028 (3 years) | Amount: €282,000
- **Dementia Research Switzerland – Synapsis Foundation** | September 2025 – August 2028 (3 years) | Amount: CHF 300,000
- **Swiss Cancer Research grant** | September 2025 – June 2028 (3 years) Amount: CHF 364,265
- **Betty and David Koetser Foundation Grant** | January 2023 – December 2024 (2 years) | Amount: CHF 30,000
- **Herzog-Egli Foundation Grant** | January 2023 – December 2023 (1 year) | Amount: CHF 10,000

Fellowships

- **FILAS Regione Lazio Scholarship** | "Sapienza" University of Rome, Italy | Host: Prof. Piera Valenti | January 2008 – June 2008
- **"Leonardo da Vinci" Scholarship** | Academy of Sciences of the Czech Republic, Prague | Host: Prof. Helena Tlaskalova-Hogenova | September 2007 – December 2007

Awards

Italian National Scientific Qualification for Associate Professor (II Fascia)

- **Molecular Biology** | Settore Concorsuale 05/E2, Bio/11 | May 2021
- **Applied Biology** | Settore Concorsuale 05/F1, Bio/13 | July 2024
- **Health Professions and Applied Medical Technologies** | Settore Concorsuale 06/N1, Med/46 | July 2024
- **General Pathology and Clinical Pathology**| Settore Concorsuale 06/A2, Med/04 | July 2024

Scientific awards

- **Career Development Award, Giovanni Armenise Harvard Foundation.** Awarded to foster the development of outstanding early-career scientists working abroad to establish their own lab at a host institute in Italy. 2024
- **Invited participant**, *6th World Laureates Forum*, Shanghai, China. Selected as an outstanding young researcher (one of 100 worldwide) in recognition of scientific achievements and influence. 2024
- **Invited participant**, *4th World Laureates Forum*, Shanghai, China (virtual). Chosen as one of the most promising young scientists at ETH Zurich. 2021
- **Paul Pettivano Fellowship**, *Association Monégasque contre les Myopathies*, for the best research grant proposal on muscle disorders. 2021
- **Pfizer Research Prize**, in the field of neurological sciences and diseases of the nervous system. Zurich, Switzerland. 2020
- **1st Prize, Best Scientific Work 2018/2019**, *Franco Regli Foundation*, Switzerland. Awarded for research in the field of neurodegenerative diseases. 2020
- **Best Publication in Basic Sleep Research**, *Swiss Society for Sleep Research, Sleep Medicine and Chronobiology (SSSSC)*, Switzerland. 2019
- **Young Scientist Award**, *European Narcolepsy Network (EU-NN)*, sponsored by the Klaus-Grawe Foundation, Switzerland. 2019
- **EFIS Travel Grant**, *European Federation of Immunological Societies*, supporting participation in the *5th Conference on Translational Medicine on Pathogenesis and Therapy of Immune-mediated Diseases*, Milan, Italy. 2019
- **Best International Young Researcher on Narcolepsy**, *Associazione Italiana Narcolettici e Ipersonni Onlus (AIN)*, Italy. 2018
- **SSAI Travel Grant**, *Swiss Society for Allergology and Immunology*, supporting participation in the *14th International Congress of Neuroimmunology*, Brisbane, Australia. 2018
- **Geneviève Spik Student Award**, *XI International Conference on Lactoferrin*, Rome, Italy. 2013

General Honors and Recognitions

- Recipient of the **Onorificenza Unione Province Italiane (UPI) – Basilicata**, awarded to 20 distinguished individuals from Basilicata recognized for their outstanding service to the community. Potenza, IT, 2025
- Recipient of the **Venosine per Esempio** Prize in occasion of the International Women's Day by my home-Town Council, Venosa (PZ), Italy. This prize acknowledges my achievements as a women researcher on the international scientific environment. Venosa (PZ), IT, 2021
- Recipient of the **Acknowledgment Prize** by Consiglio Regionale della Basilicata for the work performed on international scientific research. Potenza, IT, 2018

Contribution to Scientific Meetings

Organization

- Young European Federation of Immunological Societies (yEFIS) 1st Symposium: Shaping the Future of Immunology in Europe, Berlin, DE, Nov 2022
- Next generation immunologists Session, SSAI/ICHS Joint Meeting, Basel, CH, Sept 2022
- Workshop "Swiss Young Immunology Scientists, Novel mechanisms of immune response", World Immune Regulation Meeting XVI, Davos, CH, Jul 2022
- 1st Swiss Young Immunologists Society (SYIS) Annual symposium, Zurich, CH, May 2022
- Swiss Young Immunologists Symposium, SSAI Annual Congress 2021, Zurich, CH, Aug 2021

Invited talks (selection)

- 2026, VIB conference, Neuroimmunology, Antwerp, Belgium.
- 2026, XXXIV Italian Neuroimmunology Society (AINI) Congress, Rome, IT
- 2026, Helmholtz Munich Immunology Distinguished Speaker Seminar Series, Virtual
- 2026, Midwinter Conference, Seefeld, Austria
- 2025, Career Development Awardees/Italian Scholarship Advisory Committee Meeting, Rome, IT
- 2025, Immunology seminar series, University of Lausanne (UNIL), Lausanne, CH (Host: Prof. Margot Thome Miazza)
- 2025, NeuroImmunology Colloquium Berlin Buch Campus, Berlin, DE
- 2025, 17h ISNI International Congress, Japan
- 2025,15th Società Italiana di Immunologia, Immunologia Clinica e Allergologia (SIICA) Congress, IT (Plenary speaker)
- 2025, Annual Meeting, Peripheral Nerve Society, Edinburgh, UK (Plenary speaker- Arthur K. Asbury Lecture)
- 2025, San Raffaele Scientific Retreat, Baveno, IT
- 2025, XIX World Immune Regulation Meeting, Davos, CH (Plenary speaker)
- 2024, 40th Congress of ECTRIMS, Copenaghen, DK
- 2024, Annual meeting, Associazione Italiana Sistema Nervoso Periferico, Trento, IT (Keynote speaker)
- 2024, Final Symposium Collaborative Research Center CRC TR-128, Münster, DE (Plenary speaker)
- 2024, Seminar series, Institute Necker Enfants Malades (INEM), Université Paris Cité, Paris, FR (Host: Prof. van ENDERT)
- 2024, Seminar Series, Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, CH. (Host: Prof. Anna Oevermann)
- 2024, Immunomeeting Seminar Series, University of Basel, CH. (Host: Prof. Carolyn King)
- 2024, San Raffaele Immunology Division Retreat, Brescia, IT (Keynote speaker- Host: Prof. Matteo Iannacone)
- 2024, International PhD Program: Seminars in Biomedical Neurosciences, USI, Bellinzona, CH
- 2023, International Congress of Immunology, Cape Town, South Africa
- 2023, 6th World Laureates Forum, Shanghai, China
- 2023, SSAI Meeting, Bern, CH
- 2023, Bern Immunology Club, University of Bern, Bern, CH (Host: Prof. Martin Bachmann)
- 2022, Seminar series, Czech Immunological Society, Virtual
- 2022, Invited Seminar, University of Lausanne (UNIL) and Ludwig Institute for Cancer Research, Lausanne, CH (Host: Prof. Ping-Chih Ho)
- 2022, Invited seminar, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Inserm, Toulouse, FR. (Host: Dr. Nicolas Fazilleau)
- 2022, 1st Swiss Young Immunologists Annual Meeting, Zurich, CH (Keynote speaker)
- 2022, International PhD Program: Seminars in Biomedical Neurosciences, USI, Virtual, CH
- 2022, World Sleep Congress, Rome, IT
- 2022, Raising Stars, Norwegian Society of Immunology. Virtual (Host: Prof. Victor Greiff)
- 2022, 7th Swiss Narcolepsy Day, CH
- 2021, 4th World Laureates Forum, China, Virtual
- 2021, Foundation Franco Regli Price Award Ceremony. Virtual Event (Franco Regli Prize)
- 2020, 5th Swiss Narcolepsy Day, CH
- 2019, Narcolepsy and its borderland, European Narcolepsy Network Inselspital, Bern, CH (Young Scientist Award 2019)

Invited Chairperson and panelist

- 2025, Panelist in the Career Development Session, 15th SIICA Congress, IT
- 2025, Chair of the Innate lymphoid cells, NK cells and MAIT cells session, XIX World Immune Regulation Meeting (WIRM), CH
- 2024, Panelist in the yEFIS Women in Immunology 2024 Webinar
- 2022, Panelist in the Careers Workshop Shaping the Future of Immunology in Europe, yEFIS 1st Symposium, Berlin, DE
- 2022, Chair of the Experimental Immunology session and of the Next Generation Immunologist Session, SSAI/ICHS Joint Meeting, Basel, CH
- 2022, Chair of Swiss Young Immunology Scientists Workshop - Novel mechanisms of immune response, 16th World Immune Regulation Meeting (WIRM), Davos, CH
- 2022, Panelist in Career opportunities for life scientists in academia, MIM Career Event, Zurich, CH
- 2022, Chair of one scientific session during the 1st Annual Swiss Young Immunologists Symposium, Zurich, CH
- 2022, Chair of one scientific session during the MIM Introductory Course, Virtual Event, Jan 2022
- 2021, Chair of the Swiss Young Immunologists Symposium, SSAI Annual Congress 2021, Zurich, CH, Aug
- 2016, Chair of the Autoimmunity 2 Session at the ICI International Congress of Immunology, Melbourne, AUS.

Member of Abstract Selection and Poster Prize Committees

- Member of poster prize committee of San Raffaele Scientific Retreat, IT, March 2025
- Abstract selection for oral presentation and Member of oral and poster prize committees, yEFIS 1st Symposium: Shaping the Future of Immunology in Europe, Berlin, DE, Nov 2022
- Abstract selection for oral presentation and Member of oral and poster prize committees, 16th WIRM, Davos, CH, Jul 2022
- Abstract selection for poster presentation and Member of poster prize committee, 1st Annual Swiss Young Immunologists Symposium, Zurich, CH, May 2022
- Abstract selection for oral presentation, SYIS Symposium, SSAI Annual Congress 2021, Zurich, CH, Aug 2021
- Member of poster prize committee, 13th Swiss Meeting on Muscle Research, Magglingen, CH, Dec 2021

Institutional Responsibilities

- **PhD Committee Member** of 5 PhD students in CH (ETH Zurich, University of Zurich, Università della Svizzera Italiana) and IT (Humanitas University, University of Milan)
- **Principal Investigator**, Microbiology and Immunology (MIM) PhD program, Life Science Zurich Graduate School, CH
- **Member of the Experimental Immunology Committee**, Swiss Society for Allergology and Immunology (SSAI), CH
- **Teaching Activities**
  - 2025/2026, International MD program, Vita-Salute San Raffaele University
  - 2025/2026, Bachelor's Degree Course in Medical Radiology Techniques for Imaging and Radiotherapy, Vita-Salute San Raffaele University
  - 2025/2026, Bachelor's Degree Course in Osteopathy, Vita-Salute San Raffaele University
  - Block course on Immunology I. ETH Zurich. Co-organizer. 2023- 2024
  - Brain Disorders course, University of Zurich. Prof. Magdalini Polymenidou and Prof. Esther Stoeckli. 2022 - 2024
  - Autoimmune disorders in neurology. Università della Svizzera Italiana (USI), Lugano. Prof. Claudio Gobbi. 2021 - 2022
  - Food, Microbiota and Immunity. ETH Zurich. Prof. Emma Wetter Slack. 2019 - 2024
  - Block course on Human Immunology. ETH Zurich. Prof. Federica Sallusto. 2019-2022

Reviewing Activities

- **Reviewer**: Brain; Nature Immunology; Nature communications; Nature Microbiology; Nature Review Neurology; The Journal of Clinical Investigation; Cell; Cell Reports; Journal of Clinical Immunology; Annals of Neurology; Cell Reports; iScience; Plos Pathogen; Journal of Experimental Medicine, Frontiers in Immunology; Sleep; Scientific Report; European Journal of Immunology; Journal of Immunology Research; Journal of Autoimmunity; Immunity, Inflammation and Disease; Annals of Clinical and Translational Neurology
- **Review Editor**, T cell Biology, Frontiers in Immunology
- **Guest Associate Editor**: Special Issue on Neuroimmunology in Frontiers in in Front Immunol; Special Issue on "T cell Cross-reactivity – Implications in Physiology and Pathology" in Frontiers in Immunology; Special Issue: The crosstalk between hematopoietic and non-hematopoietic cells in European Journal of Immunology
- **Grant Reviewer**: Clinician Scientist Fellowship, Medical Research Council, UK; UK Research and Innovation (UKRI), Medical Research Council, UK
- **Travel grant Selection Committee**, SSAI, CH

Memberships of Scientific Societies

- **Co-founder** and **Past-President** of the Swiss Young Immunologists Society (SYIS)
- **Past Swiss representative** at the European Federation of Young Immunologist (yEFIS)

- **Co-founder** and **Past Board Member** of the AIRIcerca Swiss Chapter - International Association of Italian Researchers in the world
- **Member** International Society of Neuroimmunology (ISNI)
- **Member** Swiss Society for Allergology and Immunology (SSAI)
- **Member** Associazione Italiana Neuroimmunologia (AINI)
- **Member** Swiss Narcolepsy Network (SNaNe)

Mentorship to MD/PhD and master students

Academic Supervision:

- **PhD students**
  - Dafne Alberti (2025 – present)
  - Valentina Mirannalti (2025 – present)
  - Camilla Strano (2025 – present)
  - Lenka Súkeniková, (2020 – 2024; ETH Zurich, PhD degree obtained on April 11, 2024)
- **Postdoctoral fellows**:
  - Filippo Burattin (2025 – present)
  - Christophe Capelle (2023 – 2025)
  - Lenka Súkeniková (2024 – 2025)
  - Dr. Sam Edalat (2024)
  - Dr. Anna Mallone (2021 – 2023)
- **Undergraduates**
  - Ludovica Montani (2025 – present)
  - Pietro Piffaretti (2024 – 2025)
  - Häusle Lars (2023 – 2024; *ETH Medal recipient*)
  - Faherty Francesco (2023)
  - Kim Ji In (2021 – 2022)
  - Leon Claudio Schmidt (2021 – 2022)
  - Fabian Takacs (2020)
- **Visiting scientists**:
  - Lasse Frank Voss, Postdoc, Technical University of Denmark (2025)
  - Camilla Strano, MD-PhD student, San Raffaele Hospital, Milan (IT) (2024)
  - Ellen Edwards from Inselspital in Bern (CH) (2021 – 2022)
- **Research assistants**:
  - Maria Grazia Ceraolo (2025 – present)
  - Giuliana Bruccoleri (2024 – 2025)

Mentoring in specific mentoring programs

- Since 2024, SIICA Mentoring Program for Postdocs organized by the SIICA Career Development group
- Since 2024, SYIS Mentoring program for Postdocs organized by the SYIS

Spotlight Interviews and Articles

- ETH News 2024; Clarifying the cause of Guillain-Barré Syndrome
- Women in STEM becoming independent: Embracing every experience as part of the learning process. *J Exp Med* 4 September 2023; 220 (9): e20230980. https://doi.org/10.1084/jem.20230980
- ETH News 2021; What immune cells reveal about sleep disorders | ETH Zurich
- World Laureate Forum 2021; Interview
- Spotlight Research Interview: Narcolepsy, a Neurological Autoimmune Disorder; Perkin Elmer, 2021

2. **Latorre D*"**, Hausmann A*, Krishnarajah S, Weiden J, Näf P, Estrada Brull A (The SYIS board). *The Swiss Young Immunologists Society (SYIS): empowering the next generation of immunologists.* News Article. ***Eur. J. Immunol. 2023*** 53: 2350498. doi: 10.1002/eji.202350498 **(*) co-first author (") corresponding author**
3. **Latorre D**, Hawerkamp HC, Bechara R, Gkantaras A and Hahn AM. *2022 International Women's Day - yEFIS highlights outstanding women vaccine researchers.* Interview article. ***Eur. J. Immunol. 2022*** doi: 10.1002/eji.202270045
4. Arnoldini M, Lentsch V, **Latorre D**, Greter G, Slack E, Giorgetti A, Groppo A, Kha L. *How does the human microbiota influence our health - and how we can influence it?* ***Front. Young Minds. 2021*** 9:576428. doi: 10.3389/frym.2021.576428
5. Slack E, Arnoldini M, **Latorre D**, Aslani S, Biagioli V, Cruz T, Dünki N, Eichelberg A, Goldiger M, Howald N, Marastoni G, Marti T, Peterhans V, Selvakumar L and Winterberg A. *Why Is Measles Vaccination So Important?* ***Front. Young Minds. 2019*** 7:119. doi: 10.3389/frym.2019.00119

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Milano, 10.03.2026

Firma: 

Nb : Si precisa che per "interessi commerciali" si intendono situazioni di possesso di quote azionarie di società che operano in ambito sanitario, rapporto di lavoro dipendente o comunque incarichi che lo collochino nell'organizzazione delle medesime società, oppure situazioni di percepimento di royalties o provvigioni commerciali dalle stesse società.

CV Rozen LE PANSE

Last name, First name:	Date of birth:	ORCID iD:	Current position :
LE PANSE Rozen	**02/12/1968**	**000-0001-7522-5974**	**Research director**

EDUCATION

Institution and location	Degree	Completion date	Field of study
UPMC/Sorbonne University, Paris	**HDR** (Habilitation à diriger des recherches)	07/2014	Etiological mechanisms involved in autoimmune myasthenia gravis
UPMC/Sorbonne University, Paris	**PhD**	04/1995	Study of intracellular signalisation in skin cells

1- Summary of the scientific background

I am Director of Research (DR1) at CNRS (National Center for Scientific Research, France) and team leader at the Research of Center of Myology (Sorbonne University/INSERM) at La Pitié-Salpêtrière hospital in Paris.

I studied molecular and cellular biology at Pierre and Marie Curie University in Paris. During my different research experiences, a PhD (INSERM, France), a postdoctoral fellowship (King's College of London, UK) and a position in a private laboratory (Innothéra, France), I specialized in molecular and cellular signaling in different pathophysiological contexts. Since 2001, my research activities are focused on understanding the etiological and pathophysiological mechanisms involved in autoimmune myasthenia gravis. My research is also widely involved in the search for new therapeutic approaches using different experimental models. In collaboration with clinicians working on myasthenia gravis, my team is also looking for new cellular and molecular biomarkers for the follow up of the patients using new technological approaches.

2- Positions and scientific appointements

- Research Director - CNRS since 2017
- Team leader since 2014 in the center of Research in Myology – INSERM/Sorbonne Université - UMRS 974 - Paris, France. Team : Myasthenia Gravis : Etiology, Pathophysiology and Therapeutic Approaches

3- Major grants obtained over the last 5 years

- 2023-2026: HORIZON-MSCA-2022-DN-01 (MSCA Doctoral Networks) (230K€) - IgG4-mediated autoimmune diseases. (Partner)
- 2023-2026: ERAPerMed - Joint Transnational Call for Proposals - Prevention in Personalized Medicine: Personalising myasthenia gravis medicine: from “one-fits-all” to patient-specific immunosuppression (Partner).
- 2022-2026: ANR - MODCOM project - Modulation of trans-synaptic communication at the neuromuscular junction: from signaling to therapeutic strategies. (Partner)
- 2019-2021: Idex-Sorbonne Université - Exploring human thymic macrophages in physiological and pathophysiological conditions. (Principal investigator)
- 2019-2021: Industrial contract - Aheads Therapeutics - Investigation of the effects of PS-Liposomes loaded with a specific peptide on the experimental mouse model for myasthenia gravis. (Principal investigator)

4- Major invited conferences over the last 5 years

8th international congress - Myology (Paris 2024), Journée de Neurologie en Langue Française (Paris 2024), 14th MGFA international Conference on Myasthenia Gravis (2022, Miami, USA), International congress of Neuro-immunology (2021, Nice, France), 16th international congress on neuromuscular diseases (ICNMD 2021, Virtual).

5- Other activites (executive board, teaching, memberships in panels or individual scientific reviewing activities, …)

- Supervision of doctorate students and post-doctorates.
- Member of the Scientific Committee of the Cytometry Platform at Sorbonne University (CyPS)
- Reviewer and participation in thesis defense committees
- Occasional teaching and scientific dissemination
- Editorial activities (Involvement in the preparation of 2 special issues on myasthenia Gravis) and reviewer for various journals
- Reviewing for national and international calls for proposals

6- Publications

- 50 original articles, 20 reviews, and 7 peer-reviewed conference proceedings
- Citation number = 4409 and indice H = 39, extracted from google scholar (https://scholar.google.com/citations?hl=fr&user=zqAoZHEAAAAJ)
- **5 major publications in the last five years:**

1. M. Halliez, S. Cottin, A. You, C. Buon, A. Grondin, L. Lippens, M. Lemaitre, J. Ezan, C. Isch, Y. Ruffin, M. Montcouquiol, N. Sans, B. Fontaine, J. Messéant, **R. Le Panse** and L. Strochlic. MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis. Journal of Clinical Investigation, 2025. e173308. DOI 10.1172/JCI173308
2. J. Verdier, O-M Fayet, E. Hemery, F. Truffault, N. Pinzón, S. Demeret, A. Behin, E. Fadel, J. Guihaire, A. Corneau, C. Blanc, S. Berrih-Aknin, and **R. Le Panse**. Single-cell mass cytometry on peripheral cells in Myasthenia Gravis identifies dysregulation of innate immune cells. Frontiers in Immunology 2023. DOI: 10.3389/fimmu.2023.1083218
3. C. Payet, A. You, O-M Fayet, E. Hemery, F. Truffault, V. Bondet, D. Duffy, F. Michel, E. Fadel, J. Guihaire, S. Demeret, S. Berrih Aknin and **R. Le Panse**. Central role of macrophages and nucleic acid release in Myasthenia Gravis thymus. Annals of Neurology 93(4): 643, 2023. DOI: 10.1002/ana.26590
4. J.A. Villegas, J. Van Wassenhove, J. Merrheim, K. Matta, S. Hamadache, C. Flaugère, P. Pothin, F. Truffault, S. Hascoët, N. Santelmo, M. Alifano, S. Berrih-Aknin, **R. Le Panse** and N. Dragin. Targeting IL-23 ameliorates thymic and neuromuscular defects in Myasthenia Gravis. J. Neuroinflammation 20 (9): 1-16, 2023. DOI: 10.1186/s12974-023-02691-3
5. F. Truffault, D. Nazzal, J. Verdier, A. Gradolatto, E. Fadel, R. Roussin, B. Eymard, **R. Le Panse** and S. Berrih-Aknin. Comparative Analysis of Thymic and Blood Treg in Myasthenia Gravis: Thymic Epithelial Cells Contribute to Thymic Immunoregulatory Defects. Frontiers in Immunology 11, 782, 2020. DOI: 10.3389/fimmu.2020.00782

SELF-DECLARATION ON CONFLICT OF INTEREST – ECM

The undersigned, aware that an **E.C.M. conflict of interest** is any situation in which a secondary interest interferes or could interfere with the primary interest consisting of the objectivity, impartiality, and independence of professional education in the healthcare sector related to the **Continuing Medical Education (E.C.M.) Program**,

DECLARES

the absence of commercial interests in the healthcare sector in the last two years from the date of signing this curriculum.

Date and place of signature: 09/04/2026 – Paris
Signature:

Sara Mariotto, M.D. PhD

CURRICULUM VITAE ET STUDIORUM

Personal statement:

Sara Mariotto was born in Verona on 13-03-1985. She got her high school diploma at the "Scipione Maffei Institute" (classical studies) in 2004 with a score of 100/100 cum laude and graduated in Medicine and Surgery in July 2010 at the University of Verona, with a thesis entitled "Study of the Cingolate Anterior Cortex in Frontotemporal Dementia" obtaining a score of 110/110 cum laude. In July 2016 she specialised in Neurology with a thesis entitled "Diagnostic role of serum anti-myelin oligodendrocyte glycoprotein antibodies in patients with suspected neuromyelitis optica seronegative for anti-aquaporin-4 antibodies" obtaining a score of 70/70 cum laude. She then completed a 3-year PhD in the Graduate School of Life and Health Sciences, Doctoral program in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences at the Department of Neurosciences, Biomedicine, and Movement Sciences, University Hospital of Verona, Italy, defending her doctoral thesis entitled "Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs)" in May, 2020 with a positive result. She also obtained the certificate of Doctor Europaeus. During her 3-years PhD she performed clinical activity with night-shift as a neurologist at the Neurology Unit, University of Verona (5 *per* months). Her research areas include neuroimmunology, neuroinfectivology, neuropathology, and peripheral nerve diseases. Her principal field of interest is the study of autoimmune/inflammatory encephalitis, encephalomyelitis, and peripheral inflammatory neuropathies. In relation to these topics, she studied antibody-mediated disorders of the CNS under the supervision of Prof. Markus Reindl, learning anti-MOG antibodies detection/IgG subclass analysis with cell-based assay, peripheral blood mononuclear cells isolation, and the detection of cytokines in serum and CSF with ELISA during her fellowship at the Clinical Department of Neurology, Medical University of Innsbruck (March-October 2017). She also spent a period (October 2017) at the Institute of Neurology, Medical University of Vienna learning new techniques for the diagnosis of autoimmune encephalitis, under the supervision of Prof. Romana Höftberger. During her residency and PhD she actively participated to the clinical and research activities and study design on central and peripheral nervous system inflammatory and autoimmune conditions. In particular, she introduced novel diagnostic and prognostic assays in the diagnostic workup of the Laboratory of

Neuropathology, designed scientific collaborative studies, and she presented research results at national and international meetings on these topics. After her PhD she was awarded an 8-month scholarship (October-May 2020) on the study of diagnostic and prognostic test in antibody-mediated encephalitis and neuromyelitis optica. From December, 2020 to October 2021 she worked as a Junior Researcher at the Neurology Unit, University and AOUI of Verona, Italy. Since then, we works as a Neurologist at the AOUI Verona, Italy.
She obtained the National associated professor qualification (Neurology) on 28/01/2022.

H index: 33

Skills:

- Immunohistochemistry and immunofluorescence techniques, cell-based assay, ELISA, PBMC isolation
- Optic and fluorescence microscopy
- Nerve and skin biopsy
- Clinical neurology
- Neurophysiology and EEG

Publications:

1. Monaco S, **Mariotto S**, Ferrari S. Peripheral neuropathy and central nervous system involvement in Cryoglobulinemia. In F. Dammacco (ed.), HCV Infection and Cryoglobulinemia, Springer-Verlag; 2011.
2. Monaco S, Ferrari S, Gajofatto A, Zanusso G, **Mariotto S**. HCV-related nervous system disorders. Clin Dev Immunol. 2012: 236148; 2012.
3. **Mariotto S**, Bianchi MR, Ferrari S, Zanusso G, Ghimenton C, Testoni M, Faccioli F, Frisoni GB, Monaco S. Cauda equina syndrome caused by lumbosacral epidural lipomatosis. A case report. Clin Neurol Neurosurg. 115: 1549-51; 2013.
4. Stefani A, Riello M, Rossini F, **Mariotto S**, Fenzi F, Gambina A, Zanusso G, Monaco S. Neurosyphilis manifesting with rapidly progressive dementia: report of three cases. Neurol Sci. 34: 2027-30; 2013.
5. **Mariotto S**, Tamburin S, Salviati A, Ferrari S, Zoccarato M, Giometto B, Bertolasi L, Alessandrini F, Benedetti MD, Monaco S. Anti-N-methyl-d-aspartate receptor encephalitis

causing a prolonged depressive disorder evolving to inflammatory brain disease. Case Rep Neurol. 6: 38-43; 2014.

6. Baldan A, Ferronato S, Olivato S, Malerba G, Scuro A, Veraldi GF, Gelati M, Ferrari S, **Mariotto S**, Pignatti PF, Mazzucco S, Gomez-Lira M. Cyclooxygenase 2, toll-like receptor 4 and interleukin 1β mRNA expression in atherosclerotic plaques of type 2 diabetic patients. Inflamm Res. 63: 851-8; 2014.
7. Delbue S, Ferrante P, **Mariotto S**, Zanusso G, Pavone A, Chinaglia M, L'Erario R, Monaco S, Ferrari S. Review of West Nile virus epidemiology in Italy and report of a case of West Nile virus encephalitis. J Neurovirol. 20: 437-41; 2014.
8. **Mariotto S**, Ferrari S, Monaco S. HCV-related central and peripheral nervous system demyelinating disorders. Inflammation and Allergy-Drug targets. 13 (5): 299-304; 2014.
9. **Mariotto S**, Bonetti B, Donato F, Micheletti N, Zanoni T, Moretto G, Squintani G. Ophthalmoparesis mimicking myasthenia gravis as acute manifestation of Hashimoto's encephalopathy. J Mult Scler 2: 134; 2015.
10. **Mariotto S**, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Brentuximab vedotin: axonal microtubule's Apollyon. Blood Cancer J. 5: e343; 2015.
11. Iacono D, Ferrari S, Gelati M, Zanusso G, **Mariotto S**, Monaco S. Sporadic Creutzfeldt-Jakob Disease: Prion Pathology in Medulla Oblongata-Possible Routes of Infection and Host Susceptibility. Biomed Res Int. 2015: 396791; 2015.
12. Monaco S, **Mariotto S**, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, Sansonno D, Dammacco F. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. WJ Gastroenterol. 21: 11974-83; 2015.
13. Ferrari S, **Mariotto S**, Cavallaro T, Fabrizi GM, Monaco S. Infectious neuropathies in C. Angelini (ed.), Springer International Publishing Switzerland. Acquired Neuromuscular Disorders: Pathogenesis, Diagnosis and Treatment. DOI 10.1007/978-3-319-29514-5_19; 2016.
14. Erro R, Bozzetti S, Goffi F, **Mariotto S**, Tinazzi M. L-Dopa-induced off: functional overlay in Parkinson disease. J Neurol Sci. 365: 1-2; 2016.
15. Bartolo M, CHIò A, Ferrari S, Tassorelli C, Tamburin S, Avenali M, Azicnuda E, Calvo A, Caraceni AT, Defazio G, DE Icco R, Formisano R, Franzoni S, Greco E, Jedrychowska I, Magrinelli F, Manera U, Marchioni E, **Mariotto S**, Monaco S, Pace A, Saviola D, Springhetti I, Tinazzi M, DE Tanti A; Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN). Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in

Neurorehabilitation. Eur J Phys Rehabil Med. 52: 841-54; 2016.

16. Sandrini G, Tamburin S, Paolucci S, Boldrini P, Saraceni VM, Smania N; Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN). Additional authors: Agostini M, Alfonsi E, Aloisi AM, Alvisi E, Aprile I, Armando M, Avenali M, Azicnuda E, Barale F, Bartolo M, Bergamaschi R, Berlangieri M, Berlincioni V, Berliocchi L, Berra E, Berto G, Bonadiman S, Bonazza S, Bressi F, Brugnera A, Brunelli S, Buzzi MG, Cacciatori C, Calvo A, Cantarella C, Caraceni AT, Carone R, Carraro E, Casale R, Castellazzi P, Castelnuovo G, Castino A, Cella M, Cerbo R, Chiò A, Ciotti C, Cisari C, Coraci D, Dalla Toffola E, Defazio G, De Icco R, Del Carro U, Dell'Isola A, De Tanti A, D'Ippolito M, Fazzi E, Federico A, Ferrari A, Ferrari S, Ferraro F, Formaglio F, Formisano R, Franzoni S, Gajofatto F, Gandolfi M, Gardella B, Geppetti P, Giammò A, Gimigliano R, Giusti EM, Greco E, Ieraci V, Invernizzi M, Jacopetti M, Jedrychowska I, Lacerenza M, La Cesa S, Lobba D, Magrinelli F, Mandrini S, Manera U, Manzoni GM, Marchettini P, Marchioni E, **Mariotto S**, Martinuzzi A, Masciullo M, Mezzarobba S, Miotti D, Modenese A, Molinari M, Monaco S, Morone G, Nappi R, Negrini S, Pace A, Padua L, Pagliano E, Palmerini V, Paolucci S, Pazzaglia C, Pecchioli C, Pietrabissa G, Picelli A, Polli A, Porro CA, Porru D, Romano M, Roncari L, Rosa R, Saccavini M, Sacerdote P, Sandrini G, Saviola D, Schenone A, Schweiger V, Scivoletto G, Smania N, Solaro C, Spallone V, Springhetti I, Tamburin S, Tassorelli C, Tinazzi M, Togni R, Torre M, Torta R, Traballesi M, Trabucco E, Tramontano M, Truini A, Tugnoli V, Turolla A, Valeriani M, Vallies G, Verzini E, Vottero M, Mario P. Time for a consensus conference on pain in neurorehabilitation. Eur J Phys Rehabil Med. 52:714-6; 2016.
17. Castelnuovo G, Giusti EM, Manzoni GM, Saviola D, Gatti A, Gabrielli S, Lacerenza M, Pietrabissa G, Cattivelli R, Spatola CAM, Corti S, Novelli M, Villa V, Cottini A, Lai C, Pagnini F, Castelli L, Tavola M, Torta R, Arreghini M, Zanini L, Brunani A, Capodaglio P, D'Aniello GE, Scarpina F, Brioschi A, Priano L, Mauro A, Riva G, Repetto C, Regalia C, Molinari E, Notaro P, Paolucci S, Sandrini G, Simpson S, Wiederhold BK, Tamburin S. Additional authors: Agostini M, Alfonsi E, Aloisi AM, Alvisi E, Aprili I, Armando M, Avenali M, Azicnuda E, Barale F, Bartolo M, Bergamaschi R, Berlangieri M, Berlincioni V, Berliocchi L, Berra E, Berto G, Bonadiman S, Bonazza S, Bressi F, Brugnera A, Brunelli S, Buzzi MG, Cacciatori C, Calvo A, Cantarella C, Caraceni A, Carone R, Carraro E, Casale R, Castellazzi P, Castino A, Cerbo R, Chiò A, Ciotti C, Cisari C, Coraci D, Toffola ED, Defazio G, De Icco R, Del Carro U, Dell'Isola A, De Tanti A, D'Ippolito M, Fazzi E, Ferrari A, Ferrari S, Ferraro F, Formaglio F, Formisano R, Franzoni S, Gajofatto F, Gandolfi M, Gardella B, Geppetti P, Giammò A, Gimigliano R, Greco E, Ieraci V, Invernizzi M, Jacopetti M, La Cesa S, Lobba D, Magrinelli F,

Mandrini S, Manera U, Marchettini P, Marchioni E, **Mariotto S**, Martinuzzi A, Masciullo M, Mezzarobba S, Miotti D, Modenese A, Molinari M, Monaco S, Morone G, Nappi R, Negrini S, Pace A, Padua L, Pagliano E, Palmerini V, Pazzaglia C, Pecchioli C, Picelli A, Porro CA, Porru D, Romano M, Roncari L, Rosa R, Saccavini M, Sacerdote P, Schenone A, Schweiger V, Scivoletto G, Smania N, Solaro C, Spallone V, Springhetti I, Tassorelli C, Tinazzi M, Togni R, Torre M, Traballesi M, Tramontano M, Truini A, Tugnoli V, Turolla A, Vallies G, Verzini E, Vottero M, Zerbinati P. Psychological Treatments and Psychotherapies in the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Front Psychol. 7:115; 2016.

18. Castelnuovo G, Giusti EM, Manzoni GM, Saviola D, Gatti A, Gabrielli S, Lacerenza M, Pietrabissa G, Cattivelli R, Spatola CAM, Corti S, Novelli M, Villa V, Cottini A, Lai C, Pagnini F, Castelli L, Tavola M, Torta R, Arreghini M, Zanini L, Brunani A, Capodaglio P, D'Aniello GE, Scarpina F, Brioschi A, Priano L, Mauro A, Riva G, Repetto C, Regalia C, Molinari E, Notaro P, Paolucci S, Sandrini G, Simpson S, Wiederhold BK, Tamburin S. Additional authors: Agostini M, Alfonsi E, Aloisi AM, Alvisi E, Aprili I, Armando M, Avenali M, Azicnuda E, Barale F, Bartolo M, Bergamaschi R, Berlangieri M, Berlincioni V, Berliocchi L, Berra E, Berto G, Bonadiman S, Bonazza S, Bressi F, Brugnera A, Brunelli S, Buzzi MG, Cacciatori C, Calvo A, Cantarella C, Caraceni A, Carone R, Carraro E, Casale R, Castellazzi P, Castino A, Cerbo R, Chiò A, Ciotti C, Cisari C, Coraci D, Toffola ED, Defazio G, De Icco R, Del Carro U, Dell'Isola A, De Tanti A, D'Ippolito M, Fazzi E, Ferrari A, Ferrari S, Ferraro F, Formaglio F, Formisano R, Franzoni S, Gajofatto F, Gandolfi M, Gardella B, Geppetti P, Giammò A, Gimigliano R, Greco E, Ieraci V, Invernizzi M, Jacopetti M, La Cesa S, Lobba D, Magrinelli F, Mandrini S, Manera U, Marchettini P, Marchioni E, **Mariotto S**, Martinuzzi A, Masciullo M, Mezzarobba S, Miotti D, Modenese A, Molinari M, Monaco S, Morone G, Nappi R, Negrini S, Pace A, Padua L, Pagliano E, Palmerini V, Pazzaglia C, Pecchioli C, Picelli A, Porro CA, Porru D, Romano M, Roncari L, Rosa R, Saccavini M, Sacerdote P, Schenone A, Schweiger V, Scivoletto G, Smania N, Solaro C, Spallone V, Springhetti I, Tassorelli C, Tinazzi M, Togni R, Torre M, Traballesi M, Tramontano M, Truini A, Tugnoli V, Turolla A, Vallies G, Verzini E, Vottero M, Zerbinati P. Psychological Considerations in the Assessment and Treatment of Pain in Neurorehabilitation and Psychological Factors Predictive of Therapeutic Response: Evidence and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Front Psychol. 7:468; 2016.
19. Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, Immovilli P, Gajofatto A, Calabrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo

A, Frau J, **Mariotto S**, Gallina A, Gasperini C, Sola P; RIREMS group (Rising Italian Researchers in Multiple Sclerosis). A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. J Neurol. 264:973-8; 2017.

20. **Mariotto S**, Andreetta F, Farinazzo A, Monaco S, Ferrari S. Persistence of anti-NMDAR antibodies in CSF of after recovery from autoimmune encephalitis. Neurol Sci. 38:1523-4; 2017.
21. Cagnin A, **Mariotto S**, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, Buratti E, Zanusso G, Ferrari S, Monaco S. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy. J Alzheimers Dis. 59:13-20; 2017.
22. **Mariotto S**, Monaco S, Peschl P, Coledan I, Mazzi R, Höftberger, Reindl M, Ferrari S. MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome. BMC Neurol. 17: 190; 2017.
23. Gastaldi M, Zardini E, Leante R, Ruggieri M, Costa G, Cocco E, De Luca G, Cataldo I, Biagioli T, Ballerini C, Castellazzi M, Fainardi E, Pettini P, Zaffaroni M, Giunti D, Capello E, Bernardi G, Ciusani E, Giannotta C, Nobile-Orazio E, Bazzigaluppi E, Passerini G, Bedin R, Sola P, Brivio R, Cavaletti G, Sala A, Bertolotto A, Desina G, Leone MA, **Mariotto S**, Ferrari S, Paternoster A, Giavarina D, Lolli F, Franciotta D. Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurol Sci. 38(Suppl 2):217-24; 2017.
24. Zoccarato M, Gastaldi M, Zuliani L, Biagioli T, Brogi M, Bernardi G, Corsini E, Bazzigaluppi E, Fazio R, Giannotta C, Nobile-Orazio E, Costa G, Iorio R, Evoli A, **Mariotto S**, Ferrari S, Galloni E, De Riva V, Zardini E, Franciotta D, Giometto B. Diagnostics of paraneoplastic neurological syndromes. Neurol Sci. 38(Suppl 2):237-42; 2017.
25. Zuliani L, Zoccarato M, Gastaldi M, Iorio R, Evoli A, Biagioli T, Casagrande S, Bazzigaluppi E, Fazio R, Giannotta C, Nobile-Orazio E, Andreetta F, Simoncini O, Costa G, **Mariotto S**, Ferrari S, Galloni E, Marcon M, Franciotta D, Giometto B. Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens. Neurol Sci. 38(Suppl 2):225-9; 2017.
26. Franciotta D, Gastaldi M, Sala A, Andreetta F, Rinaldi E, Ruggieri M, Leante R, Costa G, Biagioli T, Massacesi L, Bazzigaluppi E, Fazio R, **Mariotto S**, Ferrari S, Galloni E, Perini F, Zardini E, Zuliani L, Zoccarato M, Giometto B, Bertolotto A. Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci. 38(Suppl 2):231-6; 2017.
27. Franciotta D, Gastaldi M, Benedetti L, Pesce G, Biagioli T, Lolli F, Costa G, Melis C, Andreetta F, Simoncini O, Giannotta C, Bazzigaluppi E, Fazio R, Bedin R, Ferraro D, **Mariotto S**, Ferrari S, Galloni E, De Riva V, Zardini E, Cortese A, Nobile-Orazio E. Diagnostics of

dysimmune peripheral neuropathies. Neurol Sci. 38(Suppl 2):243-7; 2017.

28. Franciotta D, Gastaldi M, Benedetti L, Garnero M, Biagioli T, Brogi M, Costa G, Fadda E, Andreetta F, Simoncini O, Giannotta C, Bazzigaluppi E, Fazio R, Bedin R, Ferraro D, **Mariotto S**, Ferrari S, Galloni E, De Riva V, Zardini E, Cortese A, Nobile-Orazio E. Diagnostics of anti-MAG antibody polyneuropathy. Neurol Sci. 38(Suppl 2):249-52; 2017.
29. **Mariotto S**, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol. 264: 2420-30; 2017.
30. Arru G, Sechi E, **Mariotto S**, Farinazzo A, Mancinelli C, Alberti D. Ferrari S, Gajofatto A, Capra R, Monaco S. Deiana G, Caggiu E, Mameli G, Sechi L, Sechi GP. Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler J Exp Transl Clin. 3: 2055217317742425; 2017.
31. **Mariotto S**, Farinazzo A, Monaco S. Gajofatto A, Zanusso G, Schanda K, Capra R, Mancinelli C, Bonora A, Bombardi R, Reindl M, Ferrari S. Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. Mult Scler J Exp Transl Clin 3: 2055217317743098; 2017.
32. **Mariotto S**, Bentivoglio M, Cotrufo T, Berzero A, Monaco S, Mazzarello P, Ferrari S. Clinical Neuropathology image 1-2018: Golgi silver staining, the black reaction. Clin Neuropathol. 37: 4-5; 2017.
33. Russi S, Sansonno D, Monaco S, **Mariotto S**, Ferrari S, Pavone F, Lauletta G, Dammacco F. HCV RNA genomic sequences and HCV-E2 glycoprotein in sural nerve biopsies from HCV-infected patients with peripheral neuropathy. Neuropathol Appl Neurobiol. 44: 427-38; 2018.
34. Sechi E, Addis A, Batzu L, **Mariotto S**, Ferrari S, Conti M, Sechi G. Late presentation of NMOSD as rapidly progressive leuokencephalopathy with atypical clinical and radiological findings. Mult Scler. 24: 685-8; 2018.
35. **Mariotto S**, Ferrari S, Monaco S. Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. Journal of Neuro-Oncology. 137: 665-6; 2018.
36. Bo M, Arru G, Sechi E, Niegowska M, **Mariotto S**, Mancinelli C, Farinazzo A, Alberti D, Gajofatto A, Ferrari S, Capra R, Monaco S, Sechi GP, Sechi LA. Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by

sera from patients with Neuromyelitis optica spectrum disorder. J Neuroimmunol. 318: 97-102; 2018.

37. Castelnuovo G, Giusti EM, Manzoni GM, Saviola D, Gabrielli S, Lacerenza M, Pietrabissa G, Cattivelli R, Spatola CAM, Rossi A, Varallo G, Novelli M, Villa V, Luzzati F, Cottini A, Lai C, Volpato E, Cavalera C, Pagnini F, Tesio V, Castelli L, Tavola M, Torta R, Arreghini M, Zanini L, Brunani A, Seitanidis I, Ventura G, Capodaglio P, D'Aniello GE, Scarpina F, Brioschi A, Bigoni M, Priano L, Mauro A, Riva G, Di Lernia D, Repetto C, Regalia C, Molinari E, Notaro P, Paolucci S, Sandrini G, Simpson S, Wiederhold BK, Gaudio S, Jackson JB, Tamburin S, Benedetti F. Additional authors: Agostini M, Alfonsi E, Aloisi AM, Alvisi E, Aprili I, Armando M, Avenali M, Azicnuda E, Barale F, Bartolo M, Bergamaschi R, Berlangieri M, Berlincioni V, Berliocchi L, Berra E, Berto G, Bonadiman S, Bonazza S, Bressi F, Brugnera A, Brunelli S, Buzzi MG, Cacciatori C, Calvo A, Cantarella C, Caraceni A, Carone R, Carraro E, Casale R, Castellazzi P, Castino A, Cerbo R, Chiò A, Ciotti C, Cisari C, Coraci D, Dalla Toffola E, Defazio G, De Icco R, Del Carro U, Dell'Isola A, De Tanti A, D'Ippolito M, Fazzi E, Federico A, Ferrari A, Ferrari S, Ferraro F, Formaglio F, Formisano R, Franzoni S, Gajofatto F, Gandolfi M, Gardella B, Geppetti P, Giammò A, Gimigliano R, Greco E, Ieraci V, Invernizzi M, Jacopetti M, La Cesa S, Lobba D, Magrinelli F, Mandrini S, Manera U, Manzoni GM, Marchettini P, Marchioni E, **Mariotto S**, Martinuzzi A, Masciullo M, Mezzarobba S, Miotti D, Modenese A, Molinari M, Monaco S, Morone G, Nappi R, Negrini S, Pace A, Padua L, Pagliano E, Palmerini V, Pazzaglia C, Pecchioli C, Picelli A, Porro CA, Porru D, Romano M, Roncari L, Rosa R, Saccavini M, Sacerdote P, Schenone A, Schweiger V, Scivoletto G, Smania N, Solaro C, Spallone V, Springhetti I, Tamburin S, Tassorelli C, Tinazzi M, Togni R, Torre M, Torta R, Traballesi M, Trabucco E, Tramontano M, Truini A, Tugnoli V, Turolla A, Vallies G, Verzini E, Vottero M, Zerbinati P. What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications From the Italian Consensus Conference on Pain in Neurorehabilitation. Front Neurol. 9: 310; 2018.
38. Arru G, Mameli G, Deiana GA, Rassu AL, Piredda R, Sechi E, Caggiu E, Bo M, Nako E, Urso D, **Mariotto S**, Ferrari S, Zanusso G, Monaco S, Sechi G, Sechi LA. Humoral immunity response to HERV-K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases. Eur J Neurol. 25: 1076-e84; 2018.
39. **Mariotto S**, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 23: 174-7; 2018.

40. **Mariotto S,** Zamò A, Franchini E, Bonetti B, Parisi A, Höftberger R, Gelpi E, Monaco S, Ferrari S. Lymphomatosis cerebri and anti-NMDAR antibodies: A unique constellation. J Neurol Sci. 398: 19-21; 2019.
41. Bentivoglio M, Cotrufo T, Ferrari S, Tesoriero C, **Mariotto S**, Bertini G, Berzero A, Mazzarello P. The original histological slides of Camillo Golgi and his discoveries on neuronal structure. Front Neuroanat. 13: 3; 2019.
42. **Mariotto S**, Gajofatto A, Zuliani L, Zoccarato M, Gastaldi M, Franciotta D, Cantalupo G, Piardi F, Polo A, Alberti D, Sartori S, Zanusso G, Agrò L, Demurtas R, Sechi GP, Sechi E, Monaco S, Ferrari S. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. J Neurol 266: 1643-8; 2019.
43. **Mariotto S**, Ferrari S, Gastaldi M, Franciotta D, Sechi E, Capra R, Mancinelli C, Schanda K, Alberti D, Orlandi R, Bombardi R, Zuliani L, Zoccarato M, Benedetti MD, Tanel R, Calabria F, Rossi F, Pavone A, Grazian L, Sechi G, Batzu L, Murdeu N, Janes F, Fetoni V, Fulitano D, Stenta G, Federle L, Cantalupo G, Reindl M, Monaco S, Gajofatto A. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J Neurol Neurosurg Psychiatry. 90: 1293-6; 2019.
44. Zoccarato M, Valeggia S, Zuliani L, Gastaldi M, **Mariotto S**, Franciotta D, Ferrari S, Lombardi G, Zagonel V, De Gaspari P, Ermani M, Signori A, Pichiecchio A, Giometto B, Manara R. Conventional brain MRI features distinguishing limbic encephalitis from mesial temporal glioma. Neuroradiology. 61: 853-60; 2019.
45. **Mariotto S**, Tecchio C, Sorio M, Bertolasi L, Turatti M, Tozzi MC, Benedetti F, Cavaletti G, Monaco S, Ferrari S. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma. 60: 2806-9; 2019.
46. Hofer L.S,* **Mariotto S**,*Wurth S, Ferrari S, Mancinelli CR, Delogu R, Monaco S, Gajofatto A, Schwaiger C, Rostasy K, Deisenhammer F, Hoftberger R, Berger T, Reindl M. Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Mult Scler J Exp Transl Clin. 5:2055217319848463; 2019.
47. Zuliani L, Nosadini M, Gastaldi M, Spatola M, Iorio R, Zoccarato M, **Mariotto** S, De Gaspari P, Perini F, Ferrari S, Evoli A, Sartori S, Franciotta D, Giometto B. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 40: 2017-30; 2019.
48. **Mariotto S**, Gajofatto A, Batzu L, Delogu R, Sechi G, Leoni S, Pirastru MI, Bonetti B, Zanoni M, Alberti D, Schanda K, Monaco S, Reindl M, Ferrari S. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. 93: e1867-72; 2019.

49. Arru G, Sechi E, **Mariotto S**, Zarbo IR, Ferrari S, Gajofatto A, Monaco S, Deiana GA, Bo M, Sechi LA, Sechi GP. Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. J Neuroimmunol. 338: 577110; 2019.
50. Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F, Luigetti M, Ferrari S, Clerici AM, Marfia GA, Rigamonti A, Carpo M, Fazio R, Corbo M, Mazzeo A, Giannini F, Cosentino G, Zardini E, Currò R, Gastaldi M, Vegezzi E, Alfonsi E, Berardinelli A, Kouton L, Manso C, Giannotta C, Doneddu P, Dacci P, Piccolo L, Ruiz M, Salvalaggio A, De Michelis C, Spina E, Topa A, Bisogni G, Romano A, **Mariotto S**, Mataluni G, Cerri F, Stancanelli C, Sabatelli M, Schenone A, Marchioni E, Lauria G, Nobile-Orazio E, Devaux J, Franciotta D. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 7:e639; 2019.
51. Gastaldi M, **Mariotto S**, Giannoccaro MP, Iorio R, Zoccarato M, Nosadini M, Benedetti L, Casagrande S, Di Filippo M, Valeriani M, Ricci S, Bova S, Arbasino C, Mauri M, Versino M, Vigevano F, Papetti L, Romoli M, Lapucci C, Massa F, Sartori S, Zuliani L, Barilaro A, De Gaspari P, Spagni G, Evoli A, Liguori R, Ferrari S, Marchioni E, Giometto B, Massacesi L, Franciotta D. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. Eur J Neurol. 27: 633-43; 2019.
52. Mattioli F, Bellomi F, Stampatori C, **Mariotto S**, Ferrari S, Monaco S, Mancinelli C, Capra R. Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients. J Neurol. 267: 2245-51; 2020.
53. Orlandi R, **Mariotto S**, Ferrari S, Gobbin F, Sechi E, Capra R, Mancinelli CR, Bombardi R, Zuliani L, Zoccarato M, Rossi F, Camera V, Ferraro D, Benedetti MD, Reindl M, Gajofatto A. Diagnostic features of initial demyelinating events associated with serum MOG-IgG. J Neuroimmunol. 344: 577260; 2020.
54. **Mariotto S**, Carta S, Bozzetti S, Zivelonghi C, Alberti D, Zanzoni S, Filosto M, Fusina S, Monaco S, Castellani F, Mantovani A, Cavallaro T, Briani C, Ferrari S. Sural Nerve Biopsy: current role and comparison with serum neurofilament light chain levels. J Neurol. 267: 2881-87; 2020.
55. **Mariotto S,** Sechi E, Ferrari S. Serum neurofilament light chain studies in neurological disorders, hints for interpretation. J Neurol Sci. 416: 116986; 2020.
56. **Mariotto S**, Savoldi A, Donadello K, Zanzoni S, Bozzetti S, Carta S, Zivelonghi C, Alberti A, Piraino F, Minuz P, Girelli D, Crisafulli E, Romano S, Marcon D, Marchi G, Gottin L, Polati E, Zanatta P, Monaco S, Tacconelli E, Ferrari S. Nervous system: subclinical target of SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry; 91: 1010-12; 2020.

57. Mangesius S, **Mariotto S**, Ferrari S, Pereverzyev Jr. S, Lerchner H, Haider L, Gizewski ER, Wenning G, Seppi K, Reindl M, Poewe W. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Park Relat Disord; 77: 57-63; 2020.
58. Maniscalco GT,* **Mariotto S,*** Höftberger R, Capra R, Servillo G, Manzo V, Napolitano M, Candelaresi P, Gerevini S, Ferrari S, Bozzetti S, Spatola M, Ciro F. $GABA_A$ receptor autoimmunity after Alemtuzumab treatment for multiple sclerosis. Neurology; 95: 399-401; 2020.
59. **Mariotto S**, Beatrice G, Carta S, Bozzetti S, Mantovani A. Gender Disparity In Editorial Boards of Journals in Neurology. Neurology; 95: 489-491; 2020.
60. Bozzetti S, Ferrari S, Gajofatto A, **Mariotto S**. Neurofilament light chain in demyelinating conditions of the central nervous system: a promising biomarker. Neuroimmunol Neuroinflammation; 2020. doi: 10.20517/2347-8659.2020.26.
61. Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, Zanette G, Zanoni T, Turatti M, Vitale G, Cadaldini M, Rossi F, Di Tizio L, Zuco C, Maniscalco GT, Soldani F, Monaco S, Trinka E, Hoeftberger R, and **Mariotto S**. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. J Neurol Neurosurg Psychiatry; 91:1145-53; 2020.
62. **Mariotto S**, Ferraro D, Soldani F, Alberti D, Bedin R, Sola P, Gastaldi M, Franciotta D, Ferrari S. Inter-center agreement in the interpretation of oligoclonal bands. Clin Chem Lab Med; 59:e91-94; 2020.
63. Pilotto A, Masciocchi S, Volonghi I, Crabbio M, Magni E, De Giuli V, Caprioli F, Rifino N, Sessa M, Gennuso M, Cotelli MS, Turla M, Balducci U, **Mariotto S**, Ferrari S, Ciccone A, Fiacco F, Imarisio A, Risi B, Benussi A, Premi E, Focà E, Caccuri F, Leonardi M, Gasparotti R, Castelli F, Zanusso G, Pezzini A, Padovani A; ENCOVID Study Group. Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study. J Infect Dis; 223:28-37; 2020.
64. Monaco S, **Mariotto S**, Bolzan A, Ferrari S, Alessandrini A. Superior diagnostic performance of reduced-FOV DWI versus conventional DWI MRI in anti-NMDAR encephalitis. Neurol Sci; 42:1567-1569; 2020.
65. Pilotto A, Benussi A, Libri I, Masciocchi S, Poli L, Premi E, Alberici A, Baldelli E, Bonacina S, Brambilla L, Benini M, Caratozzolo S, Cortinovis M, Costa A, Cotti Piccinelli S, Cottini E, Cristillo V, Delrio I, Filosto M, Gamba M, Gazzina S, Gilberti N, Gipponi S, Giunta M, Imarisio A, Liberini P, Locatelli M, Schiano F, Rao R, Risi B, Rozzini L, Scalvini A, Vergani

V, Volonghi I, Zoppi N, Borroni B, Magoni M, Leonardi M, Zanusso G, Ferrari S, **Mariotto S**, Pezzini A, Gasparotti R, Paolillo C, Padovani A. COVID-19 impact on consecutive neurological patients admitted to the emergency department. J Neurol Neurosurg Psychiatry; 92: 218-220; 2020.

66. Chinello M, Mauro M, Cantalupo G, Talenti G, **Mariotto S**, Balter R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Di Carlo D, Barzaghi F, Cesaro S. Acute Cervical Longitudinally Extensive Transverse Myelitis in a Child With Lipopolysaccharide-Responsive-Beige-Like-Anchor-Protein (LRBA) Deficiency: A New Complication of a Rare Disease. Front Pediatr. 8:580963; 2020.
67. Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC, **including Mariotto S**). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr. 2020;8:339.
68. Maniscalco GT, Allegorico L, Alfieri G, Napolitano M, Ranieri A, Renna R, Servillo G, Pezzella M, Capone E, Altomare L, Spiniello M, Ferrari S, Manzo V, **Mariotto S**. Anti-MOG-associated demyelinating disorders: two sides of the same coin. Neurol Sci. 42:1531-1534; 2021.
69. Tagliapietra M, Frasson E, Cardellini D, **Mariotto S**, Ferrari S, Zanusso G, Plebani M, Monaco S. Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature. J Alzheimers Dis. 79: 683-691; 2021.
70. McKeon A, Shelly S, Zivelonghi C, Basal E, Dubey D, Flanagan E, Madhavan AA, **Mariotto S**, Toledano M, Tracy JA, Zekeridou A, Pittock SJ. Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. Ann Clin Transl Neurol. 8: 425-439; 2021.
71. **Mariotto S** and Mantovani D. Scientific productivty in neurology: impact of the socio-economic status. Neurol Sci. 42: 1563-1566; 2021.
72. Pilotto A, Masciocchi S, Volonghi I, De Giuli V, Caprioli F, **Mariotto S**, Ferrari S, Bozzetti S, Imarisio A, Risi B, Premi E, Benussi A, Focà E, Castelli F, Zanusso G, Monaco S, Stefanelli P, Gasparotti R, Zekeridou A, McKeon A, Ashton NJ, Blennov K, Zetterberg H, Padovani A. SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021; doi: 10.1093/cid/ciaa1933.
73. Sechi E,* **Mariotto S**,* McKeon A, Krecke KN, Pittock SJ, Ferrari S, Monaco S, Flanagan EP, Zanzoni S, Rabinstein AA, Wingerchuk DM, Nasr DM, Zalewski NL. Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke. 52: 645-654; 2021.

74. Briani C, Ferrari S, Campagnolo M, Tagliapietra M, Castellani F, Salvalaggio A, **Mariotto S**, Visentin A, Cavallaro T. Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies. Brain Sci. 2021; 11:132.
75. Ranieri F, **Mariotto S**, Dubbioso R, Di Lazzaro V. Brain Stimulation as a Therapeutic Tool in Amyotrophic Lateral Sclerosis: Current Status and Interaction With Mechanisms of Altered Cortical Excitability. Front Neurol. 11:605335; 2021.
76. **Mariotto S**, Gastaldi M, Grazian L, Mancinelli C, Capra R, Marignier R, Alberti D, Zanzoni S, Schanda C, Franciotta D, Calabria F, Monaco S, Reindl M, Ferrari S, Gajofatto A. NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. Mult Scler Relat Disord. 2021; 50:102833.
77. Carta S, Höftberger R, Bolzan A, Bozzetti S, Bonetti B, Scarpelli M, Ottaviani S, Ghimenton C, Alberti D, Schanda K, Reindl M, Marignier R, Ferrari S, **Mariotto S**. Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol. 141:801-804; 2021.
78. Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C, Heim B, Serradell M, Sacchetto L, Garrido A, Capaldi S, Sánchez-Gómez A, Cecchini MP, **Mariotto S**, Ferrari S, Fiorini M, Schmutzhard J, Cocchiara P, Vilaseca I, Brozzetti L, Monaco S, Jose Marti M, Seppi K, Tolosa E, Santamaria J, Högl B, Poewe W, Zanusso G; SINBAR (Sleep Innsbruck Barcelona) group. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 144: 1118-26; 2021.
79. Maniscalco GT, Zekeridou A, Allegorico L, Ranieri A, Napolitano M, Pezzella M, Gatta LD, Manzo V, Ferrari S, **Mariotto S**. GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation. Neurol Sci. 2021 doi: 10.1007/s10072-021-05312-0. Epub ahead of print. PMID: 33977307.
80. Schanda K, Peschl P, Lerch M, Seebacher B, Mindorf S, Ritter N, Probst M, Hegen H, Di Pauli F, Wendel EM, Lechner C, Baumann M, **Mariotto S**, Ferrari S, Saiz A, Farrell M, Leite MIS, Irani SR, Palace J, Lutterotti A, Kümpfel T, Vukusic S, Marignier R, Waters P, Rostasy K, Berger T, Probst C, Höftberger R, Reindl M. Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurol Neuroimmunol Neuroinflamm ; 8:e1027; 2021.
81. Magrinelli F, **Mariotto S**, Nadali G, Todeschini G, Lanzafame M, Cavallaro T, Monaco S, Ferrari S. A 58-year-old man with B-cell chronic lymphocytic leukemia and multiple strokes. Brain Pathol. 2021 doi: 10.1111/bpa.13004. Epub ahead of print. PMID: 34327765.

82. Mantovani E, **Mariotto S**, Gabbiani D, Dorelli G, Bozzetti S, Federico A, Zanzoni S, Girelli D, Crisafulli E, Ferrari S, Tamburin S. Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors? J Neurovirol. 2021 doi: 10.1007/s13365-021-01002-x. Epub ahead of print. PMID: 34341960.
83. Bozzetti S, Ferrari S, Zanzoni S, Alberti D, Braggio M, Carta S, Piraino F, Gabbiani D, Girelli D, Nocini R, Monaco S, Crisafulli E, **Mariotto S**. Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? Immunol Res. 2021 doi: 10.1007/s12026-021-09220-5. Epub ahead of print. PMID: 34363587.
84. Maniscalco GT, Manzo V, Napolitano M, Ranieri A, Renna R, Servillo G, Alfieri G, Candelaresi P, Iorio WD, Rippa M, Bozzetti S, Zeccolini F, Gatta LD, Viola A, Santangelo C, Peluso R, Ferrari S, **Mariotto S**. Autoimmune encephalitis: A retrospective monocentric experience. Mult Scler Relat Disord. 2021 doi: 10.1016/j.msard.2021.103191. Epub ahead of print. PMID: 34388533.
85. Abboud H, Salazar-Camelo A, George N, Planchon SM, Matiello M, Mealy MA, Goodman A; On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium (including **S. Mariotto**). Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. J Neurol. 2021 doi: 10.1007/s00415-021-10783-4. Epub ahead of print. PMID: 34482456.
86. Argyriou AA, Karteri S, Bruna J, **Mariotto S**, Simo M, Velissaris D, Kalofonou F, Cavaletti G, Ferrari S, Kalofonos HP. Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. Support Care Cancer. 2021 doi: 10.1007/s00520-021-06509-x. Epub ahead of print. PMID: 34599664.
87. Magrinelli F, **Mariotto S**, Nadali G, Todeschini G, Lanzafame M, Cavallaro T, Monaco S, Ferrari S. A 58-year-old man with B-cell chronic lymphocytic leukemia and multiple strokes. Brain Pathol. 31:e13004; 2021.
88. Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, Koster M, **Mariotto S**, Pittock SJ, Chen JJ, Cauli A, Solla P, Sechi E. Exposure to TNF inhibitors is rare at MOGAD presentation. J Neurol Sci. 2021. doi: 10.1016/j.jns.2021.120044. Epub ahead of print. PMID: 34728073.
89. Sotirchos ES, Vasileiou ES, Salky R, Huda S, **Mariotto S**, Chen JJ, Levy M. Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin. Mult Scler Relat Disord. 2021;57:103462.
90. Dinoto A, Sechi E, Ferrari S, Gajofatto A, Orlandi R, Solla P, Maccabeo A, Maniscalco GT, Andreone V, Sartori A, Manganotti P, Rasia S, Capra R, Mancinelli CR, **Mariotto S**. Risk of

disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Mult Scler Relat Disord. 2022;58:103424.

91. **Mariotto S**, Carta S, Dinoto A, Lippi G, Salvagno GL, Masin L, Alberti D, Marignier R, Ferrari S. Is there a correlation between MOGAD and SARS-CoV-2 infection? Eur J Neurol; 2022 doi: 10.1111/ene.15304. Epub ahead of print. PMID: 35224824.
92. Trentinaglia M, Lippi G, Salvagno GL, Rispoli MG, De Angelis MV, Castellani F, Alberti D, Maniscalco GT, Rossi F, Turri M, Rossi P, Del Zotto E, Fusina S, Cardellini D, Zivelonghi C, Volonghi I, Monaco S, Briani C, Ferrari S, **Mariotto S**. Peripheral neuropathies during the COVID-19 pandemic: is there a relation? Immunol Res. 2020; doi: 10.1007/s12026-022-09272-1. Epub ahead of print. PMID: 35237933; PMCID: PMC8890815.
93. Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, **Mariotto S**, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2022 doi: 10.1001/jamaneurol.2022.0489. Epub ahead of print. PMID: 35377395.
94. Karteri S, Bruna J, Argyriou AA, **Mariotto S**, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP. Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients. J Peripher Nerv Syst. 2022 doi: 10.1111/jns.12493. Epub ahead of print. PMID: 35384143.
95. Dinoto A, Sechi E, Flanagan EP, Ferrari S, Solla P, **Mariotto S**, Chen JJ. Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Front Neurol. 2022;13:866824.
96. Dinoto A, Gastaldi M, Iorio R, Marini S, Damato V, Farina A, Zoccarato M, Sechi E, Pinna F, Maniscalco GT, Barnabei R, Zuliani L, Ferrari S, **Mariotto S**. Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. Mult Scler Relat Disord. 63:103827; 2022.
97. Wieczorek M, **Mariotto S**, Ferrari S, Mosna F, Micò MC, Borghero C, Dubbini MV, Malagola M, Skert C, Andreini A, De Marco B, Polo D, Tfaily A, Krampera M, Grassi A, Candoni A, Ranzato F, Volonghi I, Quatrale R, Benedetti F, Tecchio C. Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term

follow-up in a multicenter series. Bone Marrow Transplant. 2022; doi: 10.1038/s41409-022-01690-x. Epub ahead of print. PMID: 35513485.

98. Dinoto A, McKeon A, Vattemi G, Carta S, Ferrari S, **Mariotto S**. Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma. J Neuroimmunol. 368:577882; 2022.
99. Dalle Carbonare L, Valenti MT, Bisoffi Z, Piubelli C, Pizzato M, Accordini S, **Mariotto S**, Ferrari S, Minoia A, Bertacco J, Li Vigni V, Dorelli G, Crisafulli E, Alberti D, Masin L, Tiberti N, Longoni SS, Lopalco L, Beretta A, Zipeto D. Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve. Commun Med (Lond). 1:38; 2021.
100. Singh B, Lant S, Cividini S, Cattrall JWS, Goodwin LC, Benjamin L, Michael BD, Khawaja A, Matos AMB, Alkeridy W, Pilotto A, Lahiri D, Rawlinson R, Mhlanga S, Lopez EC, Sargent BF, Somasundaran A, Tamborska A, Webb G, Younas K, Al Sami Y, Babu H, Banks T, Cavallieri F, Cohen M, Davies E, Dhar S, Fajardo Modol A, Farooq H, Harte J, Hey S, Joseph A, Karthikappallil D, Kassahun D, Lipunga G, Mason R, Minton T, Mond G, Poxon J, Rabas S, Soothill G, Zedde M, Yenkoyan K, Brew B, Contini E, Cysique L, Zhang X, Maggi P, van Pesch V, Lechien J, Saussez S, Heyse A, Brito Ferreira ML, Soares CN, Elicer I, Eugenín-von Bernhardi L, Ñancupil Reyes W, Yin R, Azab MA, Abd-Allah F, Elkady A, Escalard S, Corvol JC, Delorme C, Tattevin P, Bigaut K, Lorenz N, Hornuss D, Hosp J, Rieg S, Wagner D, Knier B, Lingor P, Winkler AS, Sharifi-Razavi A, Moein ST, SeyedAlinaghi S, JamaliMoghadamSiahkali S, Morassi M, Padovani A, Giunta M, Libri I, Beretta S, Ravaglia S, Foschi M, Calabresi P, Primiano G, Servidei S, Biagio Mercuri N, Liguori C, Pierantozzi M, Sarmati L, Boso F, Garazzino S, **Mariotto S**, Patrick KN, Costache O, Pincherle A, Klok FA, Meza R, Cabreira V, Valdoleiros SR, Oliveira V, Kaimovsky I, Guekht A, Koh J, Fernández Díaz E, Barrios-López JM, Guijarro-Castro C, Beltrán-Corbellini Á, Martínez-Poles J, Diezma-Martín AM, Morales-Casado MI, García García S, Breville G, Coen M, Uginet M, Bernard-Valnet R, Du Pasquier R, Kaya Y, Abdelnour LH, Rice C, Morrison H, Defres S, Huda S, Enright N, Hassell J, D'Anna L, Benger M, Sztriha L, Raith E, Chinthapalli K, Nortley R, Paterson R, Chandratheva A, Werring DJ, Dervisevic S, Harkness K, Pinto A, Jillella D, Beach S, Gunasekaran K, Rocha Ferreira Da Silva I, Nalleballe K, Santoro J, Scullen T, Kahn L, Kim CY, Thakur KT, Jain R, Umapathi T, Nicholson TR, Sejvar JJ, Hodel EM; Brain Infections Global COVID-Neuro Network Study Group, Tudur Smith C, Solomon T. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. PLoS One. 17(6):e0263595; 2022.

101. Orlandi R, **Mariotto S**, Gajofatto A. Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. Mult Scler Relat Disord. 2022 63:103884: 2022.
102. Dinoto A, Borin GU, Campana G, Carta S, Ferrari S, **Mariotto S**. Investigating paraneoplastic aquaporin-4 positive neuromyelitis optica spectrum disorder through a data-driven approach. Eur J Neurol. 2022 doi: 10.1111/ene.15479. Epub ahead of print. PMID: 35767391.
103. Sechi E, Cacciaguerra L, Chen JJ, **Mariotto S**, Fadda G, Dinoto A, Lopez-Chiriboga AS, Pittock SJ, Flanagan EP. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 17;13:885218, 2022.
104. Lambe J, McGinley MP, Moss BP, Mao-Draayer Y, Kassa R, Ciotti JR, **Mariotto S**, Kunchok A. Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series. J Neuroimmunol. 14;370:577933; 2022.
105. Matricardi S, Casciato S, Bozzetti S, **Mariotto S**, Stabile A, Freri E, Deleo F, Sartori S, Nosadini M, Pappalardo I, Meletti S, Giovannini G, Zucchi E, Di Bonaventura C, Di Gennaro G, Ferrari S, Zuliani L, Zoccarato M, Vogrig A, Lattanzi S, Michelucci R, Gambardella A, Ferlazzo E, Fusco L, Granata T, Villani F; Immune Epilepsies Study Group of the Italian League Against Epilepsy. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy. J Neurol Neurosurg Psychiatry; 2022 doi: 10.1136/jnnp-2022-329195. Epub ahead of print. PMID: 35879055.
106. Dinoto A, Ferrari S, **Mariotto S**. Treatment Options in Refractory Autoimmune Encephalitis. CNS Drugs. 2022. doi: 10.1007/s40263-022-00943-z. Epub ahead of print. PMID: 35917105.
107. Velasco R, Argyriou AA, Marco C, **Mariotto S**, Stradella A, Hernández J, Pernas S, Ferrari S, Bruna J. Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. J Neurol. 2022 doi: 10.1007/s00415-022-11377-4. Epub ahead of print. PMID: 36094631.
108. Dinoto A, Licciardi NM, Reindl M, Chiodega V, Schanda K, Carta S, Höftberger R, Ferrari S, **Mariotto S**. Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study. Mult Scler Relat Disord. 68:104214; 2022.
109. Ferrari S, **Mariotto S**, Cavallaro T, Fabrizi GM, Monaco S. Book Chapter in "Acquired neuromuscular disorders: pathogenesis, diagnosis, and treatment, Corrado Angelini Editor:

Infectious neuropathies", Springer ISBN 978-3-031-06730-3 ISBN 978-3-031-06731-0 (eBook).

110. Dinoto A, Mantovani E, Ferrari S, **Mariotto S (co-CA)**, Tamburin S. Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. Eur J Neurol. 2022. doi: 10.1111/ene.15624. Epub ahead of print. PMID: 36325694.
111. Dinoto A, Marcuzzo E, Chiodega V, Dall'Ora F, **Mariotto S (co-CA)**, Tinazzi M. Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders. J Neurol. 2022. doi: 10.1007/s00415-022-11480-6. Epub ahead of print. PMID: 36370187.
112. Lerch M, Schanda K, Lafon E, Würzner R, **Mariotto S**, Dinoto A, Wendel EM, Lechner C, Hegen H, Rostásy K, Berger T, Wilflingseder D, Höftberger R, Reindl M. More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies. Neurol Neuroimmunol Neuroinflamm. 10(1):e200059; 2022.
113. Bauer A, Rudzki D, Berek K, Dinoto A, Lechner C, Wendel EM, Hegen H, Deisenhammer F, Berger T, Höftberger R, Rostasy K, **Mariotto S**, Reindl M. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. 13:1037812. Front Immunol. 2022
114. Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Praticò AD, Annovazzi P, Cordani R, Cordelli DM, Crichiutti G, Di Rosa G, Dolcemascolo V, Fetta A, Freri E, Gallo P, Gastaldi M, Granata T, Grazian L, Iorio R, Lombardini M, Margoni M, **Mariotto S**, Matricardi S, Melani F, Nardocci N, Papetti L, Passarini A, Pisani F, Po' C, Puthenparampil M, Ragona F, Savasta S, Siliquini S, Toldo I, Tozzo A, Turco EC, Varone A, Vogrig A, Zuliani L, Bugin S, Rossato S, Orsini A, Cantalupo G, Mancardi MM, Ferilli MAN, Foiadelli T, Sartori S. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 10(1):e200065; 2022.
115. Gastaldi M, Foiadelli T, Greco G, Scaranzin S, Rigoni E, Masciocchi S, Ferrari S, Mancinelli C, Brambilla L, Mancardi M, Giacomini T, Ferraro D, Della Corte M, Gallo A, Di Filippo M, Benedetti L, Novi G, Versino M, Banfi P, Iorio R, Moiola L, Turco E, Sartori S, Nosadini M, Ruggieri M, Savasta S, Colombo E, Ballante E, Jarius S, **Mariotto S**, Franciotta D; NINA study group. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2:jnnp-2022-330237; 2022 doi: 10.1136/jnnp-2022-330237. Epub ahead of print. PMID: 36460438.

116. CartaÁlvaro Cobo Calvo S, Armangué T, Saiz A, Lechner C, Rostásy K, Breu M, Baumann M, Höftberger R, Ayzenberg I, Schwake C, Sepulveda M, Martínez-Hernández E, Olivé-Cirera G, Arrambide G, Tintoré M, Bernard-Valnet R, Du Pasquier RA, Brilot F, Ramanathan S, Schanda K, Gajofatto A, Ferrari S, Sechi E, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, **Mariotto S**. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. Neurology. 16:10.1212/WNL.0000000000201662.; 2022. doi: 10.1212/WNL.0000000000201662. Epub ahead of print. PMID: 36526426.

117. Cortese R, **Mariotto S**, Mancinelli CR, Tortorella C. Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know? Front Neurol. 13:1048502; 2022. doi: 10.3389/fneur.2022.1048502. PMID: 36601293; PMCID: PMC9806181.

118. Bosello F, Marastoni D, Pizzini FB, Zaffalon C, Zuliani A, Turri G, **Mariotto S**, Bonacci E, Pedrotti E, Calabrese M. Atypical myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: Case report and literature review. J Neuroimmunol. 375:578011; 2022 doi: 10.1016/j.jneuroim.2022.578011. PMID: 36621074; PMCID: PMC9779985.

119. Asseyer S, Asgari N, Bennett J, Bialer O, Blanco Y, Bosello F, Camos-Carreras A, Carnero Contentti E, Carta S, Chen J, Chien C, Chomba M, Dale RC, Dalmau J, Feldmann K, Flanagan EP, Froment Tilikete C, Garcia-Alfonso C, Havla J, Hellmann M, Kim HJ, Klyscz P, Konietschke F, La Morgia C, Lana-Peixoto M, Leite MI, Levin N, Levy M, Llufriu S, Lopez P, Lotan I, Lugaresi A, Marignier R, **Mariotto S**, Mollan SP, Ocampo C, Cosima Oertel F, Olszewska M, Palace J, Pandit L, Peralta Uribe JL, Pittock S, Ramanathan S, Rattanathamsakul N, Saiz A, Samadzadeh S, Sanchez-Dalmau B, Saylor D, Scheel M, Schmitz-Hübsch T, Shifa J, Siritho S, Sperber PS, Subramanian PS, Tiosano A, Vaknin-Dembinsky A, Mejia Vergara AJ, Wilf-Yarkoni A, Zarco LA, Zimmermann HG, Paul F, Stiebel-Kalish H. The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. Front Neurol. 14:1102353; 2023.

120. Dinoto A,* Zara P,* **Mariotto S**, Ferrari S, Flanagan EP, Budhram A, Orellana D, Turilli D, Solla P, Day GS, Sechi E, Lopez-Chiriboga AS. Autoimmune encephalitis misdiagnosis and mimics. J Neuroimmunol. 2023 Mar 16;378:578071. doi: 10.1016/j.jneuroim.2023.578071. Epub ahead of print. PMID: 36989703.

121. Brenner J,* **Mariotto S**,* Bastiaansen AEM,* Paunovic M, Ferrari S, Alberti D, de Bruijn MAAM, Crijnen YS, Schreurs MWJ, Neuteboom RF, Damoiseaux JGMC, de Vries JM, Titulaer MJ. Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis. Neurology. 100(21):e2204-e2213.

122. Spatola M, Nziza N, Jung W, Deng Y, Yuan D, Dinoto A, Bozzetti S, Chiodega V, Ferrari S, Lauffenburger DA, **Mariotto S**, Alter G. Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses. 146(10):4292-4305. Brain. 2023.

123. Campetella L, Papi C, Spagni G, Sabatelli E, **Mariotto S**, Gastaldi M, Masi G, Carta S, Ahmad L, Rossi F, Maniscalco GT, De Luca G, Iorio R. A score that predicts aquaporin-4-IgG positivity in patients with longitudinally extensive transverse myelitis. 30(8)2534-38. Eur J Neurol. 2023.

124. Zivelonghi C, Dinoto A, Irani SR, McKeon A, Pilotto A, Padovani A, Masciocchi S, Magni E, Mancinelli CR, Capra R, Maniscalco GT, Volonghi I, Easton A, Alberti D, Zanusso G, Monaco S, Salvagno GL, Lippi G, Ferrari S, **Mariotto S**. SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study. 71(5) 717-24 Immunol. Res. 2023

125. Trentinaglia M, Dinoto A, Carta S, Chiodega V, Ferrari S, Andreone V, Maniscalco GT, **Mariotto S**. Investigating the association between neoplasms and MOG antibody-associated disease. Front Neurol. 14:1193211; 2023 doi: 10.3389/fneur.2023.1193211. PMID: 37360349; PMCID: PMC10289293.

126. Lotan I, Chen JJ, Hacohen Y, Abdel-Mannan O, **Mariotto S**, Huda S, Gibbons E, Wilf-Yarkoni A, Hellmann MA, Stiebel-Kalish H, Pittock SJ, Flanagan EP, Molazadeh N, Anderson M, Salky R, Romanow G, Schindler P, Duchow AS, Paul F, Levy M. Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease. Mult Scler. 2023 Jul 10:13524585231184738. doi: 10.1177/13524585231184738. Epub ahead of print. PMID: 37431144.

127. Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A, Ferrari S, Milia S, Solla P, **Mariotto S**, Flanagan EP, Chiriboga ASL, Sechi E. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD, a literature review. Eur J Neurol. 2023 Jul 11. doi: 10.1111/ene.15983. Epub ahead of print. PMID: 37433584.

128. Berger-Sieczkowski E, Endmayr V, Haider C, Ricken G, Jauk P, Macher S, Pirker W, Högl B, Heidbreder A, Schnider P, Bradley-Zechmeister E, **Mariotto S**, Koneczny I, Reinecke R, Kasprian G, Weber C, Bergmann M, Milenkovic I, Berger T, Gaig C, Sabater L, Graus F, Gelpi E, Höftberger R. Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease. Acta Neuropathol. 2023 Aug 30. doi: 10.1007/s00401-023-02625-6. Epub ahead of print. PMID: 37646790.

129. Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, **Mariotto S**, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST,

Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N. Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects. Mult Scler. 2023 Oct 13:13524585231200720. doi: 10.1177/13524585231200720.

130. **Mariotto S**, de Gaspari P, Jäger D, Hahn S, Forni C, Saschenbrecker S, Lattwein E, Dinoto A, Ferrari S. A novel cell-based immunofluorescence assay for the detection of autoantibodies to myelin-associated glycoprotein. Front Neurol. 14:1289810; 2023.

131. Carta S, Dinoto A, Capobianco M, Valentino P, Montarolo F, Sala A, Reindl M, Lo Re M, Chiodega V, Branger P, Audoin B, Aboab J, Papeix C, Collongues N, Kerschen P, Zephir H, Créange A, Bourre B, Schanda K, Flanagan EP, Redenbaugh V, Villacieros-Álvarez J, Arrambide G, Cobo-Calvo A, Ferrari S, Marignier R, **Mariotto S**. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 11(1):e200188: 2024.

132. Dinoto A, Trentinaglia M, Carta S, Mantovani E, Ferrari S, Tamburin S, Tinazzi M, **Mariotto S**. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors. Mov Disord Clin Pract. 2024 Feb 23. doi: 10.1002/mdc3.14003. Epub ahead of print. PMID: 38400610.

133. Yogeshwar SM, Muñiz-Castrillo S, Sabater L, Peris-Sempere V, Mallajosyula V, Luo G, Yan H, Yu E, Zhang J, Lin L, Fagundes Bueno F, Ji X, Picard G, Rogemond V, Pinto AL, Heidbreder A, Höftberger R, Graus F, Dalmau J, Santamaria J, Iranzo A, Schreiner B, Giannoccaro MP, Liguori R, Shimohata T, Kimura A, Ono Y, Binks S, **Mariotto S**, Dinoto A, Bonello M, Hartmann CJ, Tambasco N, Nigro P, Prüss H, McKeon A, Davis MM, Irani SR, Honnorat J, Gaig C, Finke C, Mignot E. HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease. Brain. 2024 Mar 1:awae048. doi: 10.1093/brain/awae048. Epub ahead of print. PMID: 38425314.

134. **Mariotto S**, Carta S. Autologous hematopoietic stem cells transplantation in MOGAD. Mult Scler. 2024 Mar 25:13524585241239180. doi: 10.1177/13524585241239180. Epub ahead of print. PMID: 38525548.

135. Schanda K, **Mariotto S**, Rudzki D, Bauer A, Dinoto A, Rossi P, Ferrari S, Jarius S, Wildemann B, Boso F, Giometto B, Engels D, Kümpfel T, Wendel EM, Rostasy K, Reindl M. Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses? Brain Commun. 2024 Mar 25;6(2):fcae106. doi: 10.1093/braincomms/fcae106. PMID: 38576796; PMCID: PMC10994262.

136. Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG,

Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; **Guthy Jackson International Clinical Consortium*.** Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12452-8. Epub ahead of print. PMID: 38958756.

137. Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer SG, Levy M, Petzold A, Palace J, Flanagan EP, **Mariotto S**, Skou ST, Froelich A, Lotan I, Messina S, Geraldes R, Asseyer S, Stiebel-Kalish H, Oertel FC, Shaygannejad V, Sahraian MA, Kim HJ, Bennett JL, Böttcher C, Zimmermann HG, Weinshenker BG, Paul F, Asgari N. Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Front Immunol. 2024 Jul 2;15:1380025. doi: 10.3389/fimmu.2024.1380025. PMID: 39021565; PMCID: PMC11253107.

138. De Napoli G, Gastaldi M, Natali P, Bedin R, Simone AM, Santangelo M, **Mariotto S**, Vitetta F, Smolik K, Cardi M, Meletti S, Ferraro D. Kappa index in the diagnostic work-up of autoimmune encephalitis. J Neurol Sci. 2024 Jul 18;463:123146. doi: 10.1016/j.jns.2024.123146. Epub ahead of print. PMID: 39033735.

139. Klyscz P, Asseyer S, Alonso R, Bereuter C, Bialer O, Bick A, Carta S, Chen JJ, Cohen L, Cohen-Tayar Y, Contentti EC, Dale RC, Flanagan EP, Gernert JA, Haas J, Havla J, Heesen C, Hellmann M, Levin N, Lopez P, Lotan I, Luis MB, **Mariotto S**, Mayer C, Vergara AJM, Ocampo C, Ochoa S, Oertel FC, Olszewska M, Uribe JLP, Sastre-Garriga J, Scocco D, Ramanathan S, Rattanathamsakul N, Shi FD, Shifa J, Simantov I, Siritho S, Tiosano A, Tisavipat N, Torres I, Dembinsky AV, Vidal-Jordana A, Wilf-Yarkoni A, Wu T, Zamir S, Zarco LA, Zimmermann HG, Petzold A, Paul F, Stiebel-Kalish H. Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network. Ann Clin Transl Neurol. 2024 Aug 4. doi: 10.1002/acn3.52166. Epub ahead of print. PMID: 39099240.

140. Rossi S, Farina A, Malvaso A, Dinoto A, Fionda L, Cornacchini S, Florean I, Zuliani L, Garibaldi M, Lauletta A, Baccari F, Zenesini C, Rinaldi R, **Mariotto S**, Damato V, Diamanti L, Gastaldi M, Vogrig A, Marchioni E, Guarino M. Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200314. doi: 10.1212/NXI.0000000000200314. Epub 2024 Sep 19. PMID: 39298719; PMCID: PMC11413993.

141. Gandolfi M, Sandri A, **Mariotto S**, Tamburin S, Paolicelli A, Fiorio M, Pedrotti G, Barone P, Pellecchia MT, Erro R, Cuoco S, Carotenuto I, Vinciguerra C, Botto A, Zenere L, Canu E,

Sibilla E, Filippi M, Sarasso E, Agosta F, Tinazzi M; Group Collaborators Consortium. A window into the mind-brain-body interplay: Development of diagnostic, prognostic biomarkers, and rehabilitation strategies in functional motor disorders. PLoS One. 2024 Sep 26;19(9):e0309408. doi: 10.1371/journal.pone.0309408. PMID: 39325803; PMCID: PMC11426512.

142. Gelpi E, Reinecke R, Gaig C, Iranzo A, Sabater L, Molina-Porcel L, Aldecoa I, Endmayr V, Högl B, Schmutzhard E, Poewe W, Pfausler B, Popovic M, Pretnar-Oblak J, Leypoldt F, Matschke J, Glatzel M, Erro EM, Jerico I, Caballero MC, Zelaya MV, **Mariotto S**, Heidbreder A, Kalev O, Weis S, Macher S, Berger-Sieczkowski E, Ferrari J, Reisinger C, Klupp N, Tienari P, Rautila O, Niemelä M, Yilmazer-Hanke D, Guasp M, Bloem B, Van Gaalen J, Kusters B, Titulaer M, Fransen NL, Santamaria J, Dawson T, Holton JL, Ling H, Revesz T, Myllykangas L, Budka H, Kovacs GG, Lewerenz J, Dalmau J, Graus F, Koneczny I, Höftberger R. Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy. Acta Neuropathol. 2024;148(1):53. doi: 10.1007/s00401-024-02805-y. PMID: 39400557.

143. Mantovani E, Martini A, Dinoto A, Zucchella C, Ferrari S, **Mariotto S**, Tinazzi M, Tamburin S. Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses. NPJ Parkinsons Dis. 10(1):211; 2024.

144. Chuquisana O, Spatola M, Dinoto A, Sepúlveda M, **Mariotto S**, Tintore M, Montalban X, Comabella M, Lünemann JD. Soluble TREM2 distinguishes neuromyelitis optica spectrum disorder from MOG antibody disease. Brain. doi: 10.1093/brain/awae335. Epub ahead of print. PMID: 39530260; 2024.

145. Maniscalco GT, Dinoto A, Foglia MC, Di Battista ME, Moreggia O, Di Giulio Cesare D, Williams M, Rossi FW, Carta S, Chiodega V, Ferrari S, Viola A, de Paulis A, Andreone V, **Mariotto S**. Epstein-Barr virus infection in patients with MOGAD. Mult Scler. 13:13524585241298065. doi: 10.1177/13524585241298065. Epub ahead of print. PMID: 39668776; 2024.

146. Villacieros-Álvarez J, Lunemann JD, Sepulveda M, Valls-Carbó A, Dinoto A, Fernández V, Vilaseca A, Castillo M, Arrambide G, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, **Mariotto S**, Montalban X, Comabella M. Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 12(1):e200340; 2025.

147. Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto

P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Piñar Morales R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, **Mariotto S**, Cobo-Calvo A, Marignier R. Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025;12(2):e200362. doi: 10.1212/NXI.0000000000200362. PMID: 39752619.

148. Marignier R, Villacieros-Álvarez J, Espejo C, Arrambide G, Fissolo N, Gutiérrez L, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Martínez-Garcia P, Millán J, Bernard-Valnet R, González I, Orvíz García A, Tellez R, Navarro L, Presas-Rodríguez S, Romero-Pinel L, Martínez-Yélamos S, Cuello JP, Alonso Torres AM, Piñar R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafani V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira A, Auger C, Audoin B, Montalban X, Tintore M, **Mariotto S**, Cobo-Calvo A. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study. J Neurol Neurosurg Psychiatry. 2025 Feb 12:jnnp-2024-335137. doi: 10.1136/jnnp-2024-335137. Epub ahead of print. PMID: 39939136.

149. Dinoto A, Pacenti M, **Mariotto S**, Abate D, Lisi V, Satto S, Vogiatzis S, Chiodega V, Carta S, Ferrari S, Barzon L. Serum Levels of Neurofilament Light Chain and Glial Fibrillary Acidic Protein Correlate with Disease Severity in Patients with West Nile Virus Infection. Emerg Microbes Infect. 2025 Feb 13:2447606. doi: 10.1080/22221751.2024.2447606. Epub ahead of print. PMID: 39945666.

150. Lennol MP, García-Ayllón MS, Avilés-Granados C, Trasciatti C, Tolassi C, Quaresima V, Arici D, Cristillo V, Volonghi I, Caprioli F, De Giuli V, **Mariotto S**, Ferrari S, Zanusso G, Ashton NJ, Zetterberg H, Blennow K, Padovani A, Pilotto A, Sáez-Valero J. Increased cerebrospinal fluid ACE2 fragments as a read-out of brain infection in COVID-19 encephalopathy patients. J Infect Dis. 2025. doi: 10.1093/infdis/jiaf093. Epub ahead of print. PMID: 40036349.

151. Maniscalco GT, Ziello AR, Mantovani E, Dinoto A, Di Giulio Cesare D, Moreggia O, Di Battista ME, Carta S, Chiodega V, Stoppele E, Ferrari S, Andreone V, Tamburin S, **Mariotto S**. Cognitive Profile in Adult Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparative Study With Multiple Sclerosis. Eur J Neurol. 2025

Mar;32(3):e70115. doi: 10.1111/ene.70115. PMID: 40105307; PMCID: PMC11921136.

152. Orlandi R, **Mariotto** S, Gobbin F, Rossi F, Camera V, Calabrese M, Calabria F, Gajofatto A. Brain Volume Measures in Adults with MOG-Antibody-Associated Disease: A Longitudinal Multicenter Study. J Clin Med. 2025;14(7):2445. doi: 10.3390/jcm14072445. PMID: 40217895.

153. Abdelhak A, Bachhuber F, Ning K, Benkert P, John Boscardin W, Maleska Maceski A, Schaedelin S, Achtnichts L, Finkener S, Lalive PH, Uginet M, Pot C, Du Pasquier R, Hoepner R, Chan A, Gobbi C, Zecca C, Müller S, Roth P, Granziera C, Chitnis T, Madill E, Weiner HL, Green AJ, Hauser SL, Cree BA, Kümpfel T, Havla J, Skripuletz T, Gingele S, Senel M, Vardakas I, Taranu D, Ziemann U, Kowarik MC, Kleiter I, Hoshi MM, Zettl UK, Haarmann A, Thebault S, Freedman MS, Bergman HP, Iacobaeus E, Khademi M, Ferraro D, Cardi M, **Mariotto S**, Comabella M, Montalban X, Vilaseca-Jolonch A, Strijbis EM, Wessels MH, Killestein J, Hemmer B, Held F, Sellebjerg F, Højsgaard Chow H, Alvarez-Lafuente R, Domínguez-Mozo MI, Hegen H, Berek K, Deisenhammer F, Thouvenot E, Agherbi H, Rejdak K, Gąsior M, Tzanetakos D, Tzartos JS, Sormani MP, Dujmovic Basuroski I, Arrambide G, Khalil M, Piehl F, Teunissen CE, Kuhle J, Tumani H. Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. 2025 Jun 12:jnnp-2025-335831. doi: 10.1136/jnnp-2025-335831. Epub ahead of print. PMID: 40506119.

154. Villacieros-Álvarez J, Sepulveda M, Valls-Carbó A, Fissolo N, Dinoto A, Fernández V, Vilaseca A, Arrambide G, Gutierrez L, Castillo M, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Lünemann JD, Saiz A, **Mariotto S**, Montalban X, Comabella M. Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200432. doi: 10.1212/NXI.0000000000200432. Epub 2025 Jun 30. PMID: 40587836; PMCID: PMC12221159.

155. Milano C, Saylam E, Papi C, Marmolejo L, Sankovic A, Reinecke R, Kerstens J, Pizzanelli C, Simabukuro MM, Benaiteau M, Joubert B, Gastaldi M, Dutra LA, Leypoldt F, Jansen M, Kawachi I, Akiyama H, Boy N, Bozzetti S, Christensen PB, Businaro P, Dinoto A, Friedman-Korn T, Fujiwara U, Fukumoto T, Fuse K, Hooshmand SI, Hurst L, Iorio R, Korn-Lubetzki I, Rodrigues AFL, **Mariotto S**, Michael J, Morimoto Y, Neuteboom RF, Piquet AL, Rossetti AO, Rumpler-Kreiner S, Santoro JD, Schwendinger F, Shen B, Syrbe S, Troger J, Wagner I, Bien CG, Martinez-Hernandez E, Armangue T, Höftberger R, Iizuka T, Titulaer MJ, Honnorat J, Graus F, Dalmau JO, Magaña S, Spatola M. Clinical Characterization and Long-Term Outcome

in Children and Adults With Anti-AMPA Receptor Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200453. doi: 10.1212/NXI.0000000000200453. Epub 2025 Jul 18. PMID: 40680249; PMCID: PMC12275903.

156. Guso E, Volonghi I, **Mariotto S**, Arici D, Olivieri E, Pilotto A, Padovani A. Possible autoimmune encephalitis in a patient with Good's syndrome. Neurol Sci. 2025 Jul 21. doi: 10.1007/s10072-025-08374-6. Epub ahead of print. PMID: 40690068.

157. Carta S, Chiodega V, Tiberi R, Pasquali A, Ferrari S, Bozzetti S, Ranieri F, Marchioretto F, **Mariotto S**. GFAP as a marker of astrocytic damage correlated with medication overuse in migraine. Immunol Res. 2025 73(1):119; 2025. doi: 10.1007/s12026-025-09674-x. PMID: 40781571; PMCID: PMC12334492.

158. Carta S, Sechi E, Dinoto A, Mancinelli C, Greco G, Maniscalco GT, Cornacchini S, Giannoccaro MP, Calabria F, Marziali A, Masciocchi S, Risi M, Cossu A, Volonghi I, Cantalupo G, Zoccarato M, Orlandi R, Del Zotto E, Ferraro D, Trentinaglia M, De Biase S, Grazian L, Caleri F, Bianchi MR, Rossi P, Virgilio E, Capobianco M, Cortese R, Tortorella C, Rossi F, De Luca G, Perelli A, Bozzetti S, Zuliani L, Nosadini M, Sartori S, Brambilla L, Gajofatto A, Vogrig A, Massacesi L, Damato V, Gastaldi M, **Mariotto S**. Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200456. doi: 10.1212/NXI.0000000000200456. PMID: 40829090; PMCID: PMC12366032.

159. Furlan R, Schaedelin S, Frederiksen JL, Watanabe M, Piehl F, Fink K, Iacobaeus E, Evertsson B, Khademi M, Gastaldi M, Greco G, **Mariotto S**, Carta S, Di Sapio A, Bava CI, Giorgi L, Benkert P, Maceski AM, Oechtering J, Willemse E, Pröbstel AK, Pretzsch R, Finardi A, Mandelli A, Anthony D, Kuhle J, Leppert D. Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. Brain. 2025 Sep 24:awaf345. doi: 10.1093/brain/awaf345. Epub ahead of print. PMID: 40988129.

160. Shah S, **Mariotto S**, Flanagan EP, Pittock SJ, Sechi E, Bhatti MT, Chen JJ. Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies. Mult Scler Relat Disord. 2025 Sep 24;104:106771. doi: 10.1016/j.msard.2025.106771. Epub ahead of print. PMID: 41032997.

161. Zara P, Greco G, Masi F, Leoni S, Floris V, Othmani S, Sechi MM, Carta S, Caverzasi E, Pichiecchio A, Sotgiu S, Solla P, Colombo E, Cortese R, **Mariotto S**, Gastaldi M, Sechi E. Applying the Supporting Features for MOGAD Diagnosis to Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Nov;12(6):e200503. doi: 10.1212/NXI.0000000000200503. Epub 2025 Oct 8. PMID: 41061182.

162. Wendel EM, Chen JJ, Bertolini A, Blaschek A, Brilot F, Dale RC, Deiva K, Flanagan EP, Foiadelli T, Giorgi L, Huda S, Karenfort M, Kneen R, Lee V, Lim M, **Mariotto S**, Meirson H, Mohammed MZ, Nosadini M, Ramanathan S, Sartori S, Schimmel M, Shah VS, Thiels C, Tillema JM, Tomoum H, Wendel C, Schanda K, Reindl M, Rostasy K; BIOMARKER-Study group. Treatment response in children with relapsing MOG-antibody associated disease. Eur J Paediatr Neurol. 2025 Oct 10;59:45-51. doi: 10.1016/j.ejpn.2025.10.002. Epub ahead of print. PMID: 41092852.

163. Sechi E, Gastaldi M, Cortese R, Bisecco A, Vogrig A, Giannoccaro MP, Zuliani L, Zoccarato M, Casagrande S, Sartori S, Nosadini M, Iorio R, Spatola M, Damato V, **Mariotto S**. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management. J Neuroimmunol. 2025 Oct 17;410:578781. doi: 10.1016/j.jneuroim.2025.578781. Epub ahead of print. PMID: 41167090.

164. Lattanzi S, Matricardi S, Vogrig A, Pauletto G, Nosadini M, Sartori S, Massa F, Benedetti L, Meletti S, Bisulli F, Freri E, Operto FF, Bozzetti S, **Mariotto S**, Beretta S, Rosati E, Cesaroni E, Marini C, Granata T, Villani F; Immune Epilepsies Study Group of the Italian League Against Epilepsy. Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score. Epilepsia. 2025 Dec 30. doi: 10.1002/epi.70081. Epub ahead of print. PMID: 41467927.

165. Pakeerathan T, Davis J, Henderson AD, Sotirchos ES, Said Y, Havla J, Ringelstein M, Aktas O, Weise M, Gernert JA, Kornek B, Bsteh G, Rommer PS, Krajnc N, Pröbstel AK, Papadopoulou A, Kulsvehagen L, Pretzsch R, Schoenholzer K, Padungkiatsagul T, Moss HE, Villarreal Navarro SE, Herwerth M, Graure M, Kana V, Stiebel-Kalish H, Zlatkin R, Arnold AC, Bonelli L, Stellmann JP, Stolowy N, Schwake C, Schneider-Gold C, Kümpfel T, Albrecht P, Rattanathamsakul N, Pittock SJ, Flanagan EP, Carta S, **Mariotto S**, Gold R, Chen JJ, Ayzenberg I. OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD. Neurol Neuroimmunol Neuroinflamm. 2026 Mar;13(2):e200531. doi: 10.1212/NXI.0000000000200531. Epub 2026 Jan 7. PMID: 41499724.

166. De Gaspari P, Sartori S, Nosadini M, Sartori A, **Mariotto** S, Assandri R, Trabatti C, Cogo P, Simonato M. Cerebrospinal fluid metabolomic signatures in paediatric MOGAD and POMS. Front Immunol. 16:1650785; 2026 doi: 10.3389/fimmu.2025.1650785. PMID: 41550927; PMCID: PMC12808355.

167. Carta S, Tiberi R, De Rossi N, Maniscalco GT, Greco G, Lotti A, Marziali A, Sartori A, Favero A, Rossi F, Dinoto A, Trentinaglia M, Chiodega V, Boso F, Miante S, de Biase S, Caleri

F, Orlandi R, Guso E, Volonghi I, Nosadini M, Sartori S, Palmieri P, Cossu A, Calabria F, Zara P, Giannoccaro MP, Zuliani L, Vianello M, De Luca G, Zoccarato M, de Mauro A, Massacesi L, Cortese R, Gajofatto A, Rossi P, Sechi E, Vogrig A, Damato V, Gastaldi M, **Mariotto S**. Validation of the MOG-AR Score: A Retrospective Multicenter Study. Neurol Neuroimmunol Neuroinflamm. 2026 Mar;13(2):e200547. doi: 10.1212/NXI.0000000000200547. PMID: 41604616; PMCID: PMC12854483.

168. Takai Y, Hametner S, Riedl C, Misu T, Takahashi T, Suzuki H, Chihara N, Watanabe M, Miyahara H, Yoshida M, Iwasaki Y, Suzuki T, Di Pauli F, Bramow S, Laureys G, Banwell B, **Mariotto S**, Fujihara K, Aoki M, Bradl M, Lassmann H, Höftberger R. Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS. Acta Neuropathol. 2026 Feb 9;151(1):13. doi: 10.1007/s00401-026-02985-9. PMID: 41661329.

Platform presentations:

- *Sporadic CJD: focusing on the pathology of specific brainstem nuclei and cues for possible routes of infection*. At the "47th AINP and 37th AIRIC Congress", Genova, 05/2011.
- *Neurological complication of HCV infection*. At the "10th Mediterranean Neuroscience Congress, 15th Etnean Epilepsy Workshop", Catania, 06/2012.
- *Lysosomal storage diseases*. At the "Genetic laboratory in the clinical practice", Verona, 07/2012.
- *A demyelinating variant of anti-NMDA receptor encephalitis*. At the "49^0 AINPeNC and 39^0 AIRIC Congress", Pisa, 06/2013 and at the "XLIV SIN National Congress", Milano, 11/2013.
- *West Nile virus infection: neuropathological feature of an Italian case*. At the "49^0 AINPeNC and 39^0 AIRIC Congress", Pisa, 06/2013.
- *Autoimmune encephalitis*. At the "11th Mediterranean Neuroscience Congress and 16th Etnean Epilepsy Workshop", Catania, 11/2013.
- *A case of prion disorder.* At the "Update on parkinsonism and neurodegenerative disorders", Verona, 09/2013.
- *Atypical central and peripheral demyelinating disorders in chronic HCV infection*. At the "50^0 AINPeNC and 40^0 AIRIC Congress", Verbania, 06/2014.
- *Neurosyphilis manifesting with rapidly progressive dementia.* At the "New challenges in neuroinfectivology*:* comparison between clinical and research*",* Roma, 10/2014.
- *Demyelinating complications of chronic HCV infection*. At the, "17th Etnean Epilepsy

Workshop", Catania, 11/2014.

- *Brentuximab-Vedotin a microtubule Apollyon.* At the "5° ASNP Congress", Torino, 04/2015.
- *Anti-GAD encephalitis: an atypical clinical picture*. At the "51°AINPeNC and 41° AIRIC Congress", Verona, 06/2015.
- *Anti-MOG antibodies in inflammatory disorders*. Seminar of the Neurology Unit, University of Verona, 2016 and seminar at the Multiple Sclerosis Unit of Montichiari, Brescia, 07/2016.
- *Panel Discussion: significant clinical parameters and role of neuroimaging as new parameter of disease"*. At the "Multiple Sclerosis update course", Treviso, 09/2016.
- *Diagnosis of autoimmune encephalitis and discussion*. At the "National Congress AMCLI", Rimini, 11/2016.
- *Anti-MOG antibodies associated syndromes: report of 15 cases.* At the "3rd EAN Congress", Amsterdam, 06/2017.
- *Pediatric inflammatory demyelinating conditions: the role of laboratory.* At the "Periodic Neuropsychiatric Meeting", Verona, 01/2018 and at the "Autoimmune encephalitis and atypical demyelinating conditions", Verona, 02/2018.
- *Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in demyelinating disorders*. At the "Open Neuroscience Forum", Verona, 01/2018.
- *Antibody-mediated central nervous system disorders*. At the "54° AINP e NC and 44° AIRIC Congress", Milano, 05/2018.
- *NMO and MOG: diagnostic techniques and clinical update.* At the "N-LoGiSM", Milano, 06/2018.
- *Neurofilament light chain (NfL) serum concentration reflects disease severity in patients with MOG-Ab associated disorders.* At the "EAN congress", Lisbon, 06/2018.
- *Serum and CSF neurofilament light chain as possible biomarker in anti-neuropil antibody-associated encephalitis.* At the "EAN congress", Lisbon, 06/2018.
- *Plasma exchange in neurological disorders.* At the "Summer School of Apheresis and autoimmune conditions", Rif. Galassi, Calalzo di Cadore (BL), 07/2018.
- *Primary B-cell lymphoma of the CNS and anti-NMDAR encephalitis: a unique constellation.* At the "Rapidly progressive dementia and Limbic encephalitis meeting", Venice, 09/2018.
- *Non only Multiple Sclerosis.* At the "Theoretical and Practical Course on Multiple Sclerosis", Brescia, 10/2018.
- *AQP4-Ab and MOG-Ab: diagnosis and clinical update*. At the "24° ELAS annual symposium", Bologna, 11/2018.

- *Anti-MOG in encephalomyelitis.* At the "Current awareness and critical insights in clinical and experimental neuroimmunology", Pavia, 12/2018.
- *Autoimmune encephalitis: clinical aspects and diagnosis.* At the "Autoimmune encephalitis: aetiology, diagnosis and treatment", Como, 12/2018.
- *The Peculiarity of autoimmune diagnosis in Neurology.* At the "Pills of allergology and autoimmunity", Udine, 02/2019.
- *Antibody-associated CNS disorders: an introduction.* At the "Antibody-associated CNS disorders and their differential diagnosis", Verona, 02/2019.
- *Diagnosis of autoimmune encephalitis: serum and CSF biomarkers.* At the "Autoimmune encephalitis and atypical demyelinating conditions: aetiology, diagnosis and treatment", Reggio Emilia, 09/2019.
- *The problem of anti-MOG antibodies: laboratory and clinical aspects.* At the "Update on Multiple Sclerosis", Montichiari, Brescia, 10/2019.
- *Inflammatory demyelinating diseases: clinical aspects and diagnostic challenges.* At the "Euroimmun internal workshop on antibody-mediated disorders in Neurology", Lubeck, 10/2019.
- *Humoral immunity.* At the "Neurologist and immunology of inflammatory CNS disorders" congress, Brescia, 11/2019.
- *Neurofilament light chain in central and peripheral nervous system conditions: beyond multiple sclerosis.* At the "Oxford Roundtable", Oxford, 11/2019.
- *Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein.* At the "European NMO 2020 Meeting", Berlin, 02/2020.
- *CSF analysis in MOG-Abs positive cases.* At the "European NMO 2020 Meeting", Berlin, 02/2020.
- *Neurofilament light chain levels in patients with inflammatory demyelinating conditions associated with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs).* At the "European Academy of Neurology virtual congress", 05/2020.
- *Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelopathies.* At the "European Academy of Neurology virtual congress", 05/2020.
- *Nervous System: Subclinical Target of SARS-CoV-2 Infection*. At the "Simoa Success Webinar (online presentation)", 11/2020.
- *Treatment of atypical demyelinating syndrome (MOG e AQP4)*. At the "Neuroimmulogy: implications of the SARS-CoV-2 pandemic (online congress)", 12/2020.

- *Immuno-mediaded encephalitis and COVID-19.* At the "World week of the brain (online congress)", 03/2021.
- *NMOSD and MOGAD: clinical, diagnostic, and therapeutic aspect.* At the "Multiple sclerosis and infectious conditions: an update", Catania, 09/2021.
- *Limbic encephalitis.* At the "Diagnosis and treatment of neuroimmunological conditions", Lecco, 09/2021.
- *The significance of CSF antibody testing.* At the "The Neurologist and Immunology", Brescia, 11/2021.
- *SARS-CoV-2-related pandemic: how it influenced antibody-mediated CNS conditions and inflammatory peripheral neuropathies.* At the "Multiple Sclerosis and autoimmune CNS conditions", Trieste, 12/2021.
- *Autoimmune encephalitis.* At the "Clinical Neuroimmunology", Napoli, 02/2022.
- *SARS-CoV-2 and NMOSD/MOGAD.* At the European NMOSD/MOGAD meeting, Lyon, 06/2022.
- Guthy Jackson foundation round table (ask the doctors section) and patients' meeting, Los Angeles, CA, USA, 07/2022.
- *MOG antibodies and MOGAD.* At the Neuroimmunological disease congress, from symptoms to treatment, Lecco, 09/2022.
- *Diagnosis of MOG-Abs.* At the "3rd course for the diagnosis of demyelinating conditions", Alghero, 10/2022.
- *Clinical-laboratory discussion in the diagnosis of autoimmune neurological disorders: focus on the COVID-19 pandemic.* At the 7th National SIPmMeL congress (Italian society of clinical pathology and laboratory medicine), Riva del Garda, Trento, 10/2022.
- *Autoimmune encephalitis:* an update. At Neuromonday of the Neurology Brescia Unit, online, 10/2022.
- *Demyelinating conditions associated with anuto-antibodies: MOGAD.* At the Neurology Talk, online, 10/2022.
- *NMOSD and MOGAD: immunopathogenesis and diagnosis.* Scientific Seminar, Firenze, 11/2022.
- *PNS involvement in patients with central autoimmunity.* At the Specialised course on clinical and imaging neurophysiopathology of the peripheral nevous system, Verona, 11/2022.
- *NMOSD, MS, and MOGAD, similarities and differences.* Online patients' seminar promoted by the Sumaira Foundation, 12/2022.

- *Autoantibody profiles in Autoimmune encephalitis.* At the Clinical Neuroimmunology in Naples, II edition, Napoli, 02/2023.
- *Biosample collection: serum and CSF.* At the ACON Acute Optic Neuritis Network, Tel Aviv, 05/2023.
- *MAG-related neuropathy.* At the "Neurology Workshop", Padova, 05/2023.
- *GFAP and NfL in patients with NMOSD and MOGAD.* At the "" Fluid biomarkers and multiple sclerosis: the long road toward validation (online), 05/2023.
- *MOGAD: diagnosis and treatment.* At the "The requirement for neurological awareness in the future, young SIN event", Rimini, 05/2023.
- *Future perspective in laboratory research in MOGAD*. At the "FISM congress", Roma, 05-06/2023.
- *CSF MOG AQP4 antibody should be tested routinely with serum now.* At the MEDEN (Mogad Eugene Devic European Network) congress, Oxford, 06/2023.
- *Laboratory diagnosis in demyelinating CNS conditions*. At the Verona Multiple Sclerosis Day: MS, NMOSD, and MOGAD from diagnostic challenges to therapeutic implications, Verona, 06/2023.
- *NMOSD diagnosis and differential diagnosis.* At the Complement role in rare neurological disorders , Cagliari, 07/2023.
- *Antibody-mediated WM diseases across age* (NMO&MOGAD), Roma, 09/2023 (online)
- *NMOSD: aspetti diagnostici e terapeutici,* Pescara, 09/2023 (online)
- *NMOSD Workshop: describing the diagnostic moment.* At the "Change Direction in NMOSD, across new therapeutic Horizons", Roma, 09/2023.
- *MOGAD: diagnostic assays.* At the 9th Joint ECTRIMS ACTRIMS meeting, Milano, 10/2023.
- *Antibody-related diagnosis in NMOSD.* At the , "New Perspectived in NMOSD", Bologna, 11/2023.
- *Antibody-related diagnosis in NMOSD.* At the , "Corner, Expert Meeting-Focus on NMOSD", Porto San Giorgio (FM), 11/2023.
- *Neurological Complications of immune checkpoint inhibitors,* Expert Seminars for the University of Modena (online), 11/2023.
- *CSF MOG antibodies.* At the MOGAD Masterclass 2023, Oxford, UK, 12/2023.
- *NMOSD and MOGAD, CSF analysis.* At the "Update on MOGAD, NMOSD and Multiple Sclerosis", GDS Neuroophthalmology SIN meeting, Palermo, 12/2023.
- *Clinical utility of CSF MOG antibodies, NfL, and GFAP testing.* At the "UK-Childhood Neuro-Inflammatory Disorders Meeting", 01/2024 (online).

- Travel grant for the 34th ECTRIMS meeting, 2018
- Travel grant for the 35th ECTRIMS meeting, 2019

Participation to clinical trials:

- Principal investigator of a "Randomised, double-blind, placebo-controlled, multicenter, Phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of Rozanolixizumab to treat adult patients with MOGAD" (promoted by Paraxel international)
- Principal investigator of a "Phase III, randomised, double-blind, placebo-controlled multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Satralizumab as monotherapy or in addition to baseline therapy in patients with MOGAD" (promoted by Roche international)

Participation to research group:

- International clinical consortium for the study of NMOSD (Guthy-Jackson Foundation)
- The Sumaira Foundation scientific board
- Neuroimmunology Board of the European Academy of Neurology (EAN)
- NINA (Italian Network of Autoimmune Neurology) Scientific Board
- MEDEN (MOGAD Eugene Devic European Network) Scientific Board
- Neuro-COVID network
- EAN/ECTRIMS task force for the guideline on treatment in NMOSD
- EAN task force for Autoimmune Encephalitis guidelines

Membership/affiliations:

- AINI (Italian Association of Neuroimmunology)

- SIN (Italian Society of Neurology)
- EAN (European Academy of Neurology), also member of the Neuroimmunology Research Group
- Encephalitis Society
- GJF (Guthy Jackson Foundation)
- TSF (The Sumaira Foundation)

Contact: sara.mariotto@univr.it

Tutto quanto dichiarato nel presente Curriculum Vitae corrisponde a verità. Le dichiarazioni rese nel Curriculum Vitae sono rilasciate ai sensi degli articoli 46 e 47 del D.P.R. 445/2000.

Sara Mariotto

CURRICULUM VITAE

Name: **Luke A.J. O'Neill PhD MRIA MAE FRS**
Title: Professor (Chair of Biochemistry**)**
Affiliations: School of Biochemistry and Immunology
Trinity College Dublin, Ireland
Email: laoneill@tcd.ie

EDUCATION AND QUALIFICATIONS

1985: Awarded B.A. (Mod.) in Natural Sciences (Biochemistry)
Trinity College Dublin, Ireland. Class: I
1988: Awarded PhD in Pharmacology, University of London

EMPLOYMENT

1988 – 1991	Medical Research Council Post-doctoral fellow, Strangeways Research Laboratory, Cambridge, UK
1991 – 1999	Lecturer in Biochemistry, Trinity College Dublin
1996	Fellow, Trinity College Dublin
1999	Associate Professor of Biochemistry, Trinity College Dublin Visiting Professor, Millennium Pharmaceuticals, Cambridge MA
2004	Head of School of Biochemistry and Immunology, Trinity College Dublin
2007	Appointed to the Chair of Biochemistry, Trinity College Dublin
2011	Founder Director, Trinity Biomedical Sciences Institute
2016	Visiting Professor, GlaxoSmithKline Ltd
2023	Chief Scientific Officer, Senda Biosciences, Cambridge MA, USA

AWARDS AND HONOURS

2005	Elected member of European Molecular Biology Organisation
2009	Immunology 'Guru' National Institutes of Health Royal Dublin Society / Irish Times Boyle Medal for Scientific Excellence Science Foundation Ireland Researcher of the Year Award
2010	McGill University Dan Perry Award Lecture University of Oxford Jenner Institute Distinguished Lecturer Appointed Chair of the Programme Committee for Dublin European City of Science
2011	European Research Council Advanced Grant awardee President, International Cytokine Society
2012	Royal Irish Academy Gold Medal for Life Sciences
2014	European Federation of Immunology Societies Medal
2016	Visiting Professor, GlaxoSmithKline, Stevenage, UK Visiting Fellow, Christ's College Cambridge Elected Fellow of the Royal Society (FRS)
2018	Milstein Award, International Cytokine and Interferon Society Barcroft Medal for Medical Research, Queen's University Listed in Clarivates top 1% of scientists in Immunology based on citations
2019	Landsteiner Award for biomedical sciences, Austrian Academy of Sciences
2020	Science Foundation Ireland Science Communicator of the Year Award, for media work on COVID19.
2022	Honorary Doctor of Science, University of Bath Honorary Lifetime Membership, International Cytokine and Interferon Society
2023	Appointed to the governing body of the European Research Council Honorary Doctor of Science, University of Massachusetts
2024	Honorary Lifetime Membership, British Pharmacological Society

COMMERCIALISATION

Co-founder of 2 startup companies: **Inflazome Ltd** (with Matt Cooper) –acquired by Roche Ltd in 2020 for $410m up front with milestone payments of up to $2.1bn 3 clincial trials currently running in inflammatory diseases, targeting NLRP3. **Sitryx Ltd** (with Houman Ashrafian, Paul Peter Tak, Jeff Rathmell, Jonathan Powell and Mike Rosenberg), current finance: $70m, target: Immunometabolism, one clinical trial about to start in an inflammatory indication, and another in collaboration with Eli Lilly.

MENTORSHIP

I have supervised 54 PhD students to completion. 27 have gone on to academic posts, with 5 achieving Full Professorships. A further 54 postdoctoral scientists have worked in my lab, with 20 going on to academic posts, and 4 achieving Full Professorships. Many others who have trained in my lab are in science roles in industry or in public policy.

OUTREACH

-Weekly science slot on the Irish national radio station Newstalk.

-Extensive media work during the COVID19 Pandemic (including International media – Sky News, CNN, German, Canadian, French, Spanish and Australian TV) – awarded the Science Foundation Ireland Science Communicator of the Year Award in Ireland, 2021.

-In 2018, published *Humanology: A Scientist's Guide to our Amazing Existence* with Gill publishers. In 2019, published a science book for children, *The Great Irish Science Book* with Gill. In 2020 won the Irish Book of the Year Award for best popular non-fiction book for *Never Mind the B*ll*cks, Here's the Science*, published by Gill, which was a best seller. In 2021 published *Keep Calm and Trust the Science: A Remarkable Year in the Life of an Immunologist*. In 2023 published *To Boldly Go Where No Book had Gone Before* with Penguin/Random house.

CURRENT RESEARCH

Research Area: Molecular and Cellular basis to inflammation and innate immunity. Toll-like receptors. Pro-inflammatory cytokines. Signal transduction in the immune system. Molecular analysis of inflammatory and infectious diseases. Immunometabolism and Metabolic Reprogramming in immunity and inflammatory diseases.

PUBLICATIONS

-Ranked in the top 1% of Immunologists globally by Clarivates based on citations per paper since 2018.

-Ranked 85th in the world ranking for Immunology by ResearchGate

Peer-reviewed papers: 326	Reviews: 129	Book chapters: 5	h-Index: 160	Total citations: 112352

Notable recent publications

1. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, Jiang JK, Israelsen WJ, Keane J, Thomas C, Clish C, Vander Heiden M, Xavier RJ,

O'Neill LA. (2015) Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. **Cell Metab** Jan 6;21(1):65-80.

2. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA. (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. **Nature Medicine.** 21(3):248-55
3. Arbore G, West EE, Spolski R, Robertson AA, Klos A, Rheinheimer C, Dutow P, Woodruff TM, Yu ZX, O'Neill LA, Coll RC, Sher A, Leonard WJ, Köhl J, Monk P, Cooper MA, Arno M, Afzali B, Lachmann HJ, Cope AP, Mayer-Barber KD, Kemper C.T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in $CD4^+$ T cells. **Science**. 2016 Jun 17;352(6292):aad1210. doi: 10.1126/science.aad1210.
4. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. Trained immunity: A program of innate immune memory in health and disease. **Science**. 2016 Apr 22;352(6284):aaf1098. doi: 10.1126/science.aaf1098. Epub 2016 Apr 21.
5. Ní Cheallaigh C, Sheedy FJ, Harris J, Muñoz-Wolf N, Lee J, West K, McDermott EP, Smyth A, Gleeson LE, Coleman M, Martinez N, Hearnden CH, Tynan GA, Carroll EC, Jones SA, Corr SC, Bernard NJ, Hughes MM, Corcoran SE, O'Sullivan M, Fallon CM, Kornfeld H, Golenbock D, Gordon SV, O'Neill LA, Lavelle EC, Keane J. A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling. **Immunity**. 2016 Feb 16;44(2):368-79. doi: 10.1016/j.immuni.2016.01.019.
6. O'Neill LA. How Low Cholesterol Is Good for Anti-viral Immunity. **Cell**. 2015 Dec 17;163(7):1572-4. doi: 10.1016/j.cell.2015.12.004.
7. O'Neill LA, Kishton RJ, Rathmell J A guide to immunometabolism for immunologists. **Nature Reviews Immunol**. 2016 Sep;16(9):553-65. doi: 10.1038/nri.2016.70. Epub 2016 Jul 11.
8. McGettrick AF, Corcoran SE, Barry PJ, McFarland J, Crès C, Curtis AM, Franklin E, Corr SC, Mok KH, Cummins EP, Taylor CT, O'Neill LA, Nolan DP. Trypanosoma brucei metabolite indolepyruvate decreases HIF-1α and glycolysis in macrophages as a mechanism of innate immune evasion. **Proc Natl Acad Sci U S A**. 2016 Nov 29;113(48):E7778-E7787
9. Mills EL, Kelly B, Logan A, Costa AS, Varma M, Bryant CE, Tourlomousis P, Däbritz JH, Gottlieb E, Latorre I, Corr SC, McManus G, Ryan D, Jacobs HT, Szibor M, Xavier RJ, Braun T, Frezza C, Murphy MP, O'Neill LA. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. **Cell**. 2016 Oct 6;167(2):457-470.e13. doi: 10.1016/j.cell.2016.08.064.
10. O'Neill LA.The Hunger Games: Salmonella, Anorexia, and NLRP3. **Cell Metab.** 2017 Feb 7;25(2):225-226. doi: 10.1016/j.cmet.2017.01.015
11. Mills EL, Kelly B, O'Neill LAJ. Mitochondria are the powerhouses of immunity. **Nat Immunol.** 2017 Apr 18;18(5):488-498. doi: 10.1038/ni.3704. Review.
12. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA. A guiding map for inflammation. **Nat Immunol**. 2017 Jul 19;18(8):826-831. doi: 10.1038/ni.3790.
13. Hughes MM, Lavrencic P, Coll RC, Ve T, Ryan DG, Williams NC, Menon D, Mansell A, Board PG, Mobli M, Kobe B, O'Neill LAJ. Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. **Proc Natl Acad Sci U S A**. 2017 Aug

8;114(32):E6480-E6489. doi: 10.1073/pnas.1701868114. Epub 2017 Jul 24.

14. Chen W, Foo SS, Zaid A, Teng TS, Herrero LJ, Wolf S, Tharmarajah K, Vu LD, van Vreden C, Taylor A, Freitas JR, Li RW, Woodruff TM, Gordon R, Ojcius DM, Nakaya HI, Kanneganti TD, O'Neill LAJ, Robertson AAB, King NJ, Suhrbier A, Cooper MA, Ng LFP, Mahalingam S. Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. **Nat Microbiol.** 2017 Aug 28. doi: 10.1038/s41564-017-0015-
15. **O'Neill LA**, Cooper MA. Canakinumab for Atherosclerotic Disease. **N Engl J Med.** 2018 Jan 11;378(2):198-9. doi: 10.1056/NEJMc1714635
16. Mills, EL, Ryan, DG, Prag, HA, Dikovskaya, D, Menon, D, Zaslona, Z, 1, Jedrychowski, MP, Costa, ASG, Higgins, M, Hams, E, Szpyt, J, Runtsch, MC, King, M, McGouran, JF, Fischer, R, Kessler, BM, McGettrick, Hughes, MM, Carroll, RG, Booty, LM, Knatko, EV, Meakin, PJ, Ashford, MLJ, Modis, LK, Brunori, G, Sévin, DC, Fallon, PG, Caldwell, ST, Kunji, ERS, Chouchani, ET, Frezza, C, Dinkova-Kostova, AT, Hartley, RC, Murphy, MP and O'Neill1, LA. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. **Nature** 2018 April 6th doi: 10.1038/nature25986
17. Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, Robertson AAB, Butler MS, Rowe DB, **O'Neill LA**, Kanthasamy AG, Schroder K, Cooper MA, Woodruff TM.(2018) Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. **Sci Transl Med.** 2018 Oct 31;10(465). pii: eaah4066. doi: 10.1126/scitranslmed.aah4066.
18. Olagnier D, Brandtoft AM, Gunderstofte C, Villadsen NL, Krapp C, Thielke AL, Laustsen A, Peri S, Hansen AL, Bonefeld L, Thyrsted J, Bruun V, Iversen MB, Lin L, Artegoitia VM, Su C, Yang L, Lin R, Balachandran S, Luo Y, Nyegaard M, Marrero B, Goldbach-Mansky R, Motwani M, Ryan DG, Fitzgerald KA, **O'Neill LA**, Hollensen AK, Damgaard CK, de Paoli FV, Bertram HC, Jakobsen MR, Poulsen TB, Holm CK. (2018) Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming. **Nat Commun.** 2018 Aug 29;9(1):3506. doi: 10.1038/s41467-018-05861-7.
19. Murphy MP, O'Neill LAJ.(2018) Krebs Cycle Reimagined: The Emerging Roles of Succinate and Itaconate as Signal Transducers. **Cell**. 2018 Aug 9;174(4):780-784. doi: 10.1016/j.cell.2018.07.030
20. O'Neill LAJ, Artyomov MN (2019) Itaconate: the poster child of metabolic reprogramming in macrophage function. **Nat Rev Immunol**. 2019 Jan 31. doi: 10.1038/s41577-019-0128-5.
21. Galván-Peña S, Carroll RG, Newman C, Hinchy EC, Palsson-McDermott E, Robinson EK, Covarrubias S, Nadin A, James AM, Haneklaus M, Carpenter S, Kelly VP, Murphy MP, Modis LK, **O'Neill LA**.(2019) Malonylation of GAPDH is an inflammatory signal in macrophages. **Nat Commun**. 2019 Jan 18;10(1):338. doi: 10.1038/s41467-018-08187-6
22. Angiari S, Runtsch MC, Sutton CE, Palsson-McDermott EM, Kelly B, Rana N, Kane H, Papadopoulou G, Pearce EL, Mills KHG, (2020) Pharmacological Activation of Pyruvate Kinase M2 Inhibits $CD4_+$ T Cell Pathogenicity and Suppresses Autoimmunity. **Cell Metab.** 2020 Feb 4;31(2):391-405
23. Ryan DG, **O'Neill LAJ** Krebs Cycle Reborn in Macrophage Immunometabolism. **Annu Rev Immunol.** 2020 Jan 27. doi: 10.1146/annurev-immunol-081619-104850
24. Zasłona Z, Flis E, Wilk MM, Carroll RG, Palsson-McDermott EM, Hughes MM, Diskin C, Banahan K, Ryan DG, Hooftman A, Misiak A, Kearney J, Lochnit G, Bertrams W, Greulich T, Schmeck B, McElvaney OJ, Mills KHG, Lavelle EC, Wygrecka M, Creagh EM, **O'Neill LAJ.** Caspase-11 promotes allergic airway inflammation. **Nat Commun**. 2020 Feb 26;11(1):1055. doi: 10.1038/s41467-020-14945-2
25. **O'Neill LAJ**, Netea MG. BCG-induced trained immunity: can it offer

protection against COVID-19? **Nat Rev Immunol**. 2020 Jun;20(6):335-337. doi: 10.1038/s41577-020-0337-y.

26. Murphy MP, **O'Neill LAJ.** How should we talk about metabolism? **Nat Immunol**. 2020 Jul;21(7):713-715. doi: 10.1038/s41590-020-0691-8.PMID: 32409776
27. Runtsch MC, **O'Neill LAJ.** Pseudomonas Persists by Feeding off Itaconate. **Cell Metab.** 2020 Jun 2;31(6):1045-1047. doi: 10.1016/j.cmet.2020.05.005.PMID: 32492389
28. **O'Neill LAJ.** Targeting macrophage immunometabolism to prevent atherosclerosis. **Nat Metab.** 2019 Dec;1(12):1173-1174. doi: 10.1038/s42255-019-0154-4.PMID: 32694671
29. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan K, Hughes MM, Irvine AD, Fischer R, **O'Neill LAJ.** The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation. **Cell Metab**. 2020 Sep 1;32(3):468-478.e7. doi: 10.1016/j.cmet.2020.07.016.
30. Toller-Kawahisa JE, **O'Neill LAJ.** Creating ATP via creatine kinase B for NLRP3 activation. **Nat Immunol.** 2022 May;23(5):653-655. doi: 10.1038/s41590-022-01191-5.
31. Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, Spina JS, Ruzek MC, Argiriadi MA, McGettrick AF, Mendez RS, Zotta A, Peace CG, Walsh A, Chirillo R, Hams E, Fallon PG, Jayamaran R, Dua K, Brown AC, Kim RY, Horvat JC, Hansbro PM, Wang C, **O'Neill LAJ.**Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. **Cell Metab**. 2022 Mar 1;34(3):487-501.e8. doi: 10.1016/j.cmet.2022.02.002.
32. Hooftman A, **O'Neill LAJ.**Nanoparticle asymmetry shapes an immune response. **Nature**. 2022 Jan;601(7893):323-325. doi: 10.1038/d41586-021-03806-7.
33. Ryan TAJ, **O'Neill LAJ** Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities. **Eur J Immunol.** 2022 Jul;52(7):1024-1034. Doi: 10.1002/eji.202149410. Epub 2022 May 24
34. McGettrick AF, **O'Neill LA** Two for the price of one: itaconate and its derivatives as an anti-infective and anti-inflammatory immunometabolite. **Curr Opin Immunol.** 2023 Feb;80:102268. doi: 10.1016/j.coi.2022.102268. Epub 2022 Nov 26.
35. Day EA, **O'Neill LAJ.** Protein targeting by the itaconate family in immunity and inflammation. **Biochem J.** 2022 Dec 22;479(24):2499-2510. doi: 10.1042/BCJ20220364.
36. Ryan TAJ, Hooftman A, Rehill AM, Johansen MD, Brien ECO, Toller-Kawahisa JE, Wilk MM, Day EA, Weiss HJ, Sarvari P, Vozza EG, Schramm F, Peace CG, Zotta A, Miemczyk S, Nalkurthi C, Hansbro NG, McManus G, O'Doherty L, Gargan S, Long A, Dunne J, Cheallaigh CN, Conlon N, Carty M, Fallon PG, Mills KHG, Creagh EM, Donnell JSO, Hertzog PJ, Hansbro PM, McLoughlin RM, Wygrecka M, Preston RJS, Zasłona Z, **O'Neill LAJ.** Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon. **Nat Commun**. 2023 Jun 14;14(1):3513. doi: 10.1038/s41467-023-39174-1.
37. Hooftman, A, Peace C, Ryan DG, Day E, Yang M, McGettrick A, Yin M, Montano E, Huo L, Toller-Kawahisa J, Zecchini V, Ryan TAJ, Bolado-Carrancio A, Casey AM, Prag HA, Costa AS, De Los Santo G, Ishimori M, Walace DJ, Venuturupalli S, Nikitopoulou E, Frizzell N, Johansson C, Von Kriegsheim A, Murphy MP, Jefferies C, Frezza C and **O'Neill LAJ** Targeting fumarate hydratase promotes mitochondrial RNA-medicated interferon production. **Nature** (2023) 615(7952):490-498. doi: 10.1038/s41586-023-05720-6.
38. McGettrick AF, Bourner LA, Dorsey FC, **O'Neill LAJ.** Metabolic Messengers: itaconate. **Nat Metab**. 2024 Jul 26. doi: 10.1038/s42255-024-01092-x
39. Rebuffet L, Melsen JE, Escalière B, Basurto-Lozada D, Bhandoola A,

Björkström NK, Bryceson YT, Castriconi R, Cichocki F, Colonna M, Davis DM, Diefenbach A, Ding Y, Haniffa M, Horowitz A, Lanier LL, Malmberg KJ, Miller JS, Moretta L, Narni-Mancinelli E, **O'Neill LAJ**, Romagnani C, Ryan DG, Sivori S, Sun D, Vagne C, Vivier E. High-dimensional single-cell analysis of human natural killer cell heterogeneity. **Nat Immunol.** 2024 Aug;25(8):1474-1488. doi: 10.1038/s41590-024-01883-0

40. Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Bardoul A, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, **O'Neill LA**, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways. **Nat Commun.** 2024 May 15;15(1):4096. doi: 10.1038/s41467-024-48422-x
41. Carpenter S, **O'Neill LAJ.** From periphery to center stage: 50 years of advancements in innate immunity. **Cell**. 2024 Apr 25;187(9):2030-2051. doi: 10.1016/j.cell.2024.03.036.
42. Murphy MP, O'Neill LAJ.A break in mitochondrial endosymbiosis as a basis for inflammatory diseases. **Nature** (2024) Feb;626(7998):271-279. doi: 10.1038/s41586-023-06866-z. Epub 2024 Feb 7.
43. Douglas A, Stevens B, Rendas M, Kane H, Lynch E, Kunkemoeller B, Wessendorf-Rodriguez K, Day EA, Sutton C, Brennan M, O'Brien K, Kohlgruber AC, Prendeville H, Garza AE, **O'Neill LAJ**, Mills KHG, Metallo CM, Veiga-Fernandes H, Lynch L. (2024) Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis. **Nature**. 2024 Oct 30. doi: 10.1038/s41586-024-08131-3
44. O'Carroll SM, Peace CG, Toller-Kawahisa JE, Min Y, Hooftman A, Charki S, Kehoe L, O'Sullivan MJ, Zoller A, Mcgettrick AF, Day EA, Simarro M, Armstrong N, Annes JP, **O'Neill LAJ.**Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase. **Nat Metab**. 2024 Oct 15. doi: 10.1038/s42255-024-01145-1
45. Zotta A, Toller-Kawahisa J, Palsson-McDermott EM, O'Carroll SM, Henry ÓC, Day EA, McGettrick AF, Ward RW, Ryan DG, Watson MA, Brand MD, Runtsch MC, Maitz K, Lueger A, Kargl J, Miljkovic JL, Lavelle EC, **O'Neill LAJ** Mitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion.
Sci Adv. 2025 Jan 24;11(4):eadq7307. doi: 10.1126/sciadv.adq7307.

SELF-DECLARATION ON CONFLICT OF INTEREST – ECM

The undersigned, aware that an **E.C.M. conflict of interest** is any situation in which a secondary interest interferes or could interfere with the primary interest consisting of the objectivity, impartiality, and independence of professional education in the healthcare sector related to the **Continuing Medical Education (E.C.M.) Program**,

DECLARES

the absence of commercial interests in the healthcare sector in the last two years from the date of signing this curriculum.

Date and place of signature: _Dublin, Ireland 10.2.26_____



Signature: _____ _____

Note: *"Commercial interests" refers to situations such as ownership of shares in companies operating in the healthcare sector, employment relationships or other positions within the organization of such companies, or situations involving the receipt of royalties or commercial commissions from these companies.*



Sara Piccirillo

Data di nascita: 11/03/1980 | **Nazionalità:** Italiana | **Numero di telefono:** (+39) 3801730595 (Cellulare) | **Indirizzo e-mail:** piccirillo_sara@libero.it | **Sito web:** it.linkedin.com/in/sarapiccirillo |

Indirizzo: via moncenisio, 30, 00030, San cesareo, Italia (Abitazione)

ESPERIENZA LAVORATIVA

01/05/2019 – ATTUALE Roma, Italia

TECNOLOGO AGENZIA SPAZIALE ITALIANA

- Responsabile tecnico di fase istruttoria per la contrattualizzazione dei progetti: CardiCortEx, CASPR, REGOLIFE; MicrofunExpo;

- Project Manager dei progetti: CardiCortEx, CASPR, REGOLIFE; MicrofunExpo, 3D-Bronchial Mucosa, WAPS;

- Responsabile tecnico di fase istruttoria per le seguenti iniziative:

1. Bando ESA 2021 (approvazione della delibera per l'iniziativa strategica e successivo passaggio di consegne per congedo parentale);
2. Bando ESA 2020 (approvazione delibera per l'iniziativa strategica; pubblicazione del Bando; supporto alla contrattualizzazione dei 10 progetti selezionati);
3. Italian Pool of MELiSSA PhDs (approvazione della delibera per l'iniziativa strategica, Scientific Contact dell'Agreement con ESA).

- Componente della commissione di verifica di conformità per il contratto “Servizi industriali quadriennali nell’ambito dell’Accordo tra ASI e ESA relativo alla cooperazione per il funzionamento dell’European Astronaut Centre dell’ESA” e responsabile unico di verifica di conformità per i contratti: SAMY, IRIS, Drain brain 2.0;

- Componente delle seguenti commissioni di valutazione/aggiudicazione di offerte relative a bandi/gare:

1. Commissione di Valutazione delle candidature pervenute in risposta all'avviso di indagine di mercato VUS3: ISS4EXPLORATION;
2. Commissione di Valutazione delle candidature pervenute in risposta alla richiesta di offerta per VUS3: ISS4EXPLORATION;
3. Commissione di Gara relativa alla Procedura esperita ai sensi di quanto previsto dall’art. 158 e dall’art. 4 del D. Lgs. n. 50/2016 e ss.mm.ii., per l’affidamento dei Servizi di supporto alle attività di Utilizzazione della Stazione Spaziale Internazionale (UTISS 3);
4. Commissione per la Valutazione delle proposte in risposta al bando di finanziamento per l'individuazione dei Topical Teams finalizzati all'elaborazione di proposte di programmi di ricerca o di esperimenti scientifici spaziali di interesse nazionale e ad alto contenuto innovativo;
5. Commissione di Valutazione relativa al Bando di finanziamento per sviluppo di progetti/esperimenti scientifici nell'ambito dello studio degli effetti causati dall’esposizione a radiazioni e dalla gravità alterata sui sistemi biologici, e dello sviluppo di contromisure per la mitigazione del rischio in futuri scenari di esplorazione spaziale oltre leo.

- Componente della commissione di Valutazione delle candidature programmi formativi 2024 nell'ambito del Memorandum of Understading between Agenzia Spaziale Italiana (ASI) and International Space University (ISU) relating to higher Space Education;

- Rappresentante ASI (alternate) nel gruppo di lavoro International Space Life Science Working Group;

- Partecipazione ai gruppi di lavoro dell'International Space Exploration Coordination Working Group (ISECG): ISRU Technology Gap Assessment, LSS Technology Gap Assessment;

- Componente del Comitato Paritetico per l'Accordo Quadro ASI/Università degli Studi di Napoli "Federico II";

- Attività di divulgazione scientifica e di alta formazione.

Indirizzo via del politecnico snc, 00133, Roma, Italia

01/03/2014 – 30/04/2019 Roma, Italia

ASSEGNISTA DI RICERCA ASI (AGENZIA SPAZIALE ITALIANA)

Studio ed analisi della tematica oggetto dell'assegno di ricerca (Progetti di biologia/biotecnologia in ambiente microgr avitazionale) e supporto scientifico alle attività di ASI connesse:

- Attività di ricerca scientifica nell'ambito dell'accordo ASI/ENEA: "HORTSPACE";

- Supporto alla definizione del piano sperimentale della missione ASI dell'astronauta italiano Paolo Nespoli (exp52/53);

- Supporto scientifico al team di gestione ASI dei programmi di ricerca finanziati da ASI:

1. Bando ESA AO-2009 (3-D Ballistocardiography in microgravity; 3D-BCG; Aequabed; QT-Bed; Bice; Biomex-Cyano; BOSS-Cyano; Biomex-MCF; E-GEM; PSS; Dosis-3D; PASTA; Thermoprop; Oxytherm; Photosynchlamy; SFEF);
2. Bando per la selezione di proposte, nell'ambito del "Programma congiunto ASI/AM di Volo Umano Spaziale: Missione Shuttle 2010, per esperimenti scientifici e tecnologici eseguibili sulla Stazione Spaziale" – VUS1 (Check Saliva; S-Link);
3. Bando di Volo Umano Spaziale per Ricerche e Dimostrazioni Tecnologiche sulla Stazione Spaziale Internazionale - VUS2 (ARTE; In Situ; Cytospace; Wearable Monitoring; Drain Brain, NATO, SAMY, PERSEO, CORM, SERiSM, NANOROS, Myogravity, AUDIO, NutrISS);
4. Contratti scaturiti da RdO (Explotech);
5. Accordi (ALTEA-Brain RAD; ASI/MAECI per il finanziamento congiunto delle proposte selezionate tramite Bando pubblicato dal MAECI e concordato con ASI per esperimenti scientifici da condurre su piattaforme in microgravità a controllo remoto nel quadro del Laboratorio Congiunto Italia-Israele sulle attività spaziali per Usi Pacifici, HORTSPACE, MULTI-TROP).

- Supporto scientifico al team di gestione ASI del contratto ASI/Kayser Italia: "Servizi di supporto ad ASI per le attività di utilizzazione della Stazione Spaziale Internazionale - UTISS";

- Partecipazione a gruppi di lavoro nazionali e internazionali: IBIS (Italian Biorigenerative Systems), IMWG (International Microbial WG), ISLSWG (International Space life Science WG), Gruppo informale di lavoro "Biorigenerazione).

- Contributo all'organizzazione di Workshop;

- Contributo alla stesura di bandi di ricerca ("Missioni future di esplorazione umana dello spazio, Area tematica: Astrobiologia", "Missioni future di esplorazione umana dello spazio, Area tematica: Biomedicina", "Missioni future di esplorazione umana dello spazio, Area tematica: Sistemi Biorigenerativi"

Attività di divulgazione scientifica

- Realizzazione del progetto didattico associato alla Missione VITA dell'astronauta Paolo Nespol i "EXPLORA: Esplorazione umana e robotica dello spazio"

- Realizzazione del progetto didattico pilota associato alla Missione Futura dell'astronauta Samantha Cristoforetti "LISS: A lezione sulla Stazione Spaziale Internazionale" (http://www.asi.it/it/educational/liss-a-lezione-sulla-iss);

- Stesura di articoli per il sito istituzionale ASI;

- Interviste televisive e radiofoniche;

- Presentazioni orali nel corso di eventi di Education and Public Outreach e di Alta Formazione.

Indirizzo via del politecnico snc, 00133, Roma, Italia

01/02/2012 – 31/01/2014 Roma, Italia

BORSISTA CNR (CONSIGLIO NAZIONALE DELLE RICERCHE)

Gestione Tecnico Scientifica del Progetto di Ricerca:

"Studio sull'effetto differenziante dei campi magnetici ed elettromagnetici in cellule staminali umane di diversa derivazione e cellule specializzate con diverse capacità proliferative e a diversi stadi differenziativi cresciute in condizioni normali e di microgravità"

01/07/2010 – 30/06/2011 Roma, Italia
BORSISTA CNR (CONSIGLIO NAZIONALE DELLE RICERCHE)

Gestione Tecnico Scientifica del Progetto di Ricerca:
"Studio sull'effetto differenziante dei campi magnetici ed elettromagnetici in cellule staminali umane di diversa derivazione e cellule specializzate con diverse capacità proliferative e a diversi stadi differenziativi cresciute in condizioni normali e di microgravità"

01/09/2011 – 31/12/2011 Roma, Italia
STAGISTA NELL'AMBITO DEL MASTER UNIVERSITARIO DI II LIVELLO IN "ANALISI CHIMICHE E CONTROLLO DI QUALITÀ OMEGAFARM

Formulazione e preparazione di dispositivi medici

09/03/2009 – 31/12/2009 Roma, Italia
BORSISTA IRCCS SAN RAFFAELE PISANA

Attività di ricerca scientifica nell'ambito del progetto di ricerca dal titolo**:** "Role of recurrent herpetic infections in neuronal damage"

ISTRUZIONE E FORMAZIONE

12/01/2023 – 12/01/2024
MASTER ON LINE 24 Ore Business School in "Project Management"

01/11/2011 – 28/02/2012 Roma, Italia
MASTER UNIVERSITARIO DI II LIVELLO IN "ANALISI CHIMICHE E CONTROLLO DI QUALITÀ" Università degli studi di Roma "Sapienza"

- Definizione del concetto di qualità con opportuni approfondimenti relativi all'analisi chimica: chimica analitica quantitativa, metodi elettrochimici, metodi biochimici di analisi, tecniche cromatografiche, spettroscopia
- Normativa vigente nel campo della Qualità

Livello EQF Livello 8 EQF

01/11/2005 – 31/10/2008 Roma, Italia
DOTTORATO DI RICERCA IN BIOLOGIA CELLULARE E MOLECOLARE Università degli studi di Roma "Tor Vergata"

Titolo della tesi***:"Attivazione di Differenti Vie di Segnalazione Redox nella Risposta Cellulare allo Stress Ossidativo: Ruolo del Glutatione e dello Status Tiolico"***
1) Studio del ruolo dello stress ossidativo nei fenomeni di suscettibilità/resistenza al trattamento con chemioterapici in cellule di adenocarcinoma gastrico AGS:
- identificazione del ruolo di ERK1/2, del glutatione e dei tioli intracellulari nei fenomeni di resistenza allo stress ossidativo indotto da diverse tipologie di stimolo pro-ossidante
- studio della modulazione redox di membri della famiglia delle protein chinasi attivate dai mitogeni (MAPK)
- identificazione del ruolo del fattore di trascrizione Nrf2 nei processi di resistenza a stimoli pro-ossidanti
- studio dei meccanismi molecolari di innesco di morte indotta da agenti in grado di ossidare il pool tiolico intracellulare e identificazione della via di segnalazione fosforilativa mediata da ASK1/p38MAPK come diretta artefice dell'innesco della via mitocondriale
- identificazione del processo di ossidazione della tioredossina-1 e della modulazione dello stato redox del glutatione come sensori primari in grado di governare il destino di cellule AGS nella risposta a stimoli pro-ossidanti

2) Studio del ruolo dello stress ossidativo nell'induzione dei processi apoptotici in cellule di neuroblastoma umano SH-SY5Y:
- caratterizzazione del danno ossidativo a carico del DNA indotto da molecole innovative, potenzialmente impiegabili in chemioterapia (disolfuro di diallile e composti contenenti rame)
- produzione di prove a supporto dell'azione pro-ossidante e pro-apoptotica di questi composti per il possibile impiego delle molecole nella terapia antitumorale

3) Studio del ruolo dello stress ossidativo nei processi autofagici in cellule di carcinoma della cervice uterina HeLa:
- caratterizzazione della risposta cellulare al danno bio-energetico e allo stress ossidativo e identificazione dei processi autofagici e apoptotici

Livello EQF Livello 8 EQF

01/03/2007 – 31/08/2007 Francoforte, Germania
COLLABORAZIONE ESTERA NELL'AMBITO DEL DOTTORATO DI RICERCA Facoltà di Medicina, Johann Wolfgang Goethe-University

01/11/2003 – 19/07/2005 Roma, Italia
LAUREA SPECIALISTICA IN BIOLOGIA CELLULARE E MOLECOLARE Università degli Studi di Roma "Tor Vergata"

Votazione: 110/110 lode

Livello EQF Livello 7 EQF

01/09/2000 – 01/09/2003 Roma, Italia
LAUREA TRIENNALE IN BIOLOGIA CELLULARE E MOLECOLARE Università degli studi di Roma "Tor Vergata"

Votazione: 110/110 lode

Livello EQF Livello 6 EQF

COMPETENZE LINGUISTICHE

Lingua madre: **ITALIANO**

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	B2	C1	B2	B2	B2
FRANCESE	A2	B1	A2	A2	A2
TEDESCO	A2	A2	A2	A2	A2

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

COMPETENZE DIGITALI

Padronanza del Pacchetto Office (Word Excel PowerPoint ecc) | Gestione autonoma della posta e-mail | Social Network

PUBBLICAZIONI

Pubblicazioni

Pubblicazioni su riviste scientifiche:
- C. Schoenmaekers, A. van Ombergen, J. Mcphee, S. Bhattacharya, D. Chaput, V. Gil, S. Piccirillo, K. Stang, S. Baatout (2024) Reimagining the Horizons: Space agencies' goals for human space exploration. Frontiers in physiology *Submitted*
- 10.1007/s42496-020-00048-0
- 10.1007/s42496-020-00044-4
- 10.1007/s42496-020-00043-5
- 10.1007/s42496-020-00042-6
- 10.1007/s42496-020-00049-z
- 10.1038/s41598-019-44593-6
- 10.2217/nnm-2018-0316
- 10.4161/auto.6.2.10971
- 10.1074/jbc.M109.014837
- 10.1111/j.1471-4159.2006.04431.x

- Formazione interna: “PRIMO SOCCORSO GRUPPO B e C – Dlgs 81/08 art 37-DM 388/03” - 12 ore
- Formazione interna: “Competenze digitali per la PA" - 13 moduli
- Formazione interna: “La prevenzione della corruzione e la trasparenza negli appalti pubblici alla luce del Piano Nazionale Anticorruzione 2022” - 2 ore
- Formazione interna: “I doveri di comportamento dei dipendenti pubblici” - 1.5 ore
- Formazione interna: “Le competenze trasversali per il cambiamento organizzativo – Motivazione, autoefficacia e personal branding” - 14.5 ore
- Formazione interna: “Il trattamento di dati personali in ambito lavorativo” - 4 ore
- Formazione interna: “Accordi ex art. 15 della l. 241/90 e rendicontazione accordi e progetti” - 6 ore
- Formazione interna: “Prevenzione della corruzione nelle Pubbliche Amministrazioni” - 6 ore
- Formazione interna: “Be digital” - 8 ore
- Formazione interna: "Lingua inglese “EF Level 12 - Upper Intermediate - CEFR Level B2” - un semestre
- Formazione interna: “Il lavoro agile: opportunità, rischi e norme di comportamento con finalità preventive” - 6 ore
- Formazione interna in tema di “Gestione della gara: responsabilità, strumenti e obblighi della commissione” - 4 ore
- Corso di aggiornamento per lavoratori aziende basso rischio - 6 ore
- Formazione interna: “Protezione dei dati personali: il passaggio al nuovo Regolamento europeo n. 679/2016” - 4 ore
- Formazione interna: “D.L. 76/2020 - il regime eccezionale per gli appalti pubblici nel decreto semplificazioni: quadro delle novità” - 6 ore
- Formazione interna: “Il RUP e il DEC nel codice appalti” - 24 ore
- Formazione interna: “Programmazione Triennale dei Lavori Pubblici e su quella biennale degli acquisti di beni e servizi” - 4 ore
- Formazione interna: “Etica e legalità: Codice di comportamento e procedimenti disciplinari” - 7 ore
- Corso di Formazione: “Modelling radiation effects from initial physical events - Learning modelling approaches and techniques in radiation biophysics and radiobiology research, from basic mechanisms to applications” - 70 ore
- Corso di formazione: “Decision Making” - 28 ore
- Corso di Formazione on line: "Human Space Flight: an introduction" - 5 settimane
- Formazione interna: Lingua Inglese (C1.b Advanced) - 45 ore
- Corso di Lingua inglese presso il British Council - 45 ore
- Corso di formazione interna per lavoratori (Aziende Rischio Basso) - 8 ore

PRESENTAZIONI

Relatore per le seguenti presentazioni in eventi di Education and Public Outreach:

- "La Stazione Spaziale Internazionale nell’esplorazione umana dello spazio" - Docenza in: Progetto ROSITA
- “L’esplorazione umana dello spazio: dalla ISS al ritorno dell’uomo sulla luna” - Docenza in: Programma ZR-SAT dell'ASI
- "La sperimentazione italiana in biomedicina a bordo della ISS" - Docenza in: Master europeo in Medicina Aerospaziale
- “Coltivazioni e alimentazione nello Spazio, dalla ISS alla futura esplorazione planetaria” - Docenza in: Scuola Tutor ESERO Italia
- “L’esplorazione umana dello spazio: dalla ISS al ritorno dell’uomo sulla luna” - Docenza in: Spazio alla Conoscenza
- “La vita nello spazio: Le piante nell’esplorazione umana” - Docenza in: Scuola Tutor ESERO Italia
- “La vita nello Spazio” - Docenza in: Scuola Tutor ESERO Italia
- “La ricerca italiana a bordo della Stazione Spaziale internazionale” - Docenza in: Corso di Astrobiologia presso l'Università degli Studi di Torino
- “Le competenze ASI nel settore biorigenerativo: l’esperimento HORTEXTREME”. In: “Lo spazio e il futuro dell'uomo. I viaggi interspaziali, medicina e tecniche agronomiche, problemi e soluzioni”
- “Gli esperimenti di biomedicina della missione VITA”. In: “Lo spazio e il futuro dell'uomo. I viaggi interspaziali, medicina e tecniche agronomiche, problemi e soluzioni”
- “I Sistemi Biorigenerativi per la produzione di cibo nello Spazio”. In: Isola della Sostenibilità
- “Le competenze ASI nel Settore Biorigenerativo: stato e prospettive”. In: Biotecnologie Spaziali – Notte europea dei ricercatori
- “La missione scientifica VITA di Paolo Nespoli”. In: Festival dello Spazio di Busalla
- “Italian Space Agency: the Science and Research Directorate Initiatives for "Space Life Sciences”. In: Space Agencies Panel - 42 ISGP Conference
- Output Panel Life Sciences. In: Tavolo Tematico Strumentazione Scientifica
- “Biologia spaziale: cellule e animali sulla Stazione Spaziale Internazionale”. In: Progetto didattico dell'ASI associato alla missione VITA "EXPLORA"
- “La Stazione Spaziale Internazionale”. Docenza in: Corso Space Law presso la Facoltà di Scienze Politiche dell'Università Sapienza di Roma

- “I Sistemi Biorigenerativi per la produzione di cibo nello Spazio”. In: Zero Robotics presso IIS Pacinotti-Archimede
- "Italian Space Agency ISS Science Directory". In: 53esima Sessione Sottocomitato Scientifico e Tecnologico (Committee on the Peaceful Uses of Outer Space)

Co-relatore per le seguenti presentazioni in eventi di Education and Public Outreach:

- "Biomedical aspects of human space exploration". Docenza in: Corso di FISIOLOGIA DEGLI APPARATI – MODULO 1 presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Bologna
- “I Sistemi Biorigenerativi per la produzione di cibo nello Spazio”. In: Mission X 2016 – Allenati come un astronauta
- “Vita da astronauta”. In: “Basta poco… per apprendere”
- "Cellule e Spazio". In: Progetto didattico dell'ASI associato alla missione FUTURA "LISS-A Lezione sulla Stazione Spaziale Internazionale"
- "Spazio alle piante". In: Progetto didattico dell'ASI associato alla missione FUTURA "LISS-A Lezione sulla Stazione Spaziale Internazionale"
- "L'astrobiologia". In: Progetto didattico dell'ASI associato alla missione FUTURA "LISS-A Lezione sulla Stazione Spaziale Internazionale"
- "Le attività del gruppo IBIS e il workshop di Torino sui sistemi biorigenerativi". In: Agrispazio-Colonizzare Luna e Marte per nutrire la terra

INTERVISTE

Interviste a carattere divulgativo

- Video intervista per il documentario "lo Spazio italiano"
- “Nello Spazio l’astronauta non è solo. Lui è la punta, noi siamo la squadra” con Maurizio Iappini. In: La Stampa
- "Cibo nello Spazio“. In: 4rto Set - Case History, Professionisti, Punti per il nostro Tie Break” -
- “Nespoli: il ritorno dallo Spazio” - Intervista a due voci con Andrea Zanini. In: UnoMattina
- “Terapie extraterrestri: anche l'Italia sperimenta tra stelle e pianeti” con Alessio Chiodi. In: AboutPharma and Medical Device
- “Come sarà l'orto su Marte” con Giovanni Caprara. In: Corriere della Sera
- “ISS in fiore” con Sonia Filippazzi. In: GR RAI1
- Serie di interviste radiofoniche per "La missione FUTURA". In: Radio Popolare

ONORIFICENZE E RICONOSCIMENTI

Premio nazionale al progetto “LISS: a Lezione sulla Stazione Spaziale Internazionale” come miglior progetto di divulgazione scientifica in rete – Carnevale della Fisica - 48esima edizione

Link https://www.carnevaledellafisica.it/2015/02/i-vincitori-al-carnevale-della-fisica.html

DATI PERSONALI

Dati personali

Le informazioni contenute nel presente Curriculum vitae et studiorum sono rese sotto la personale responsabilità del sottoscritto ai sensi degli artt. 46 e 47 del D.P.R. 445/2000, consapevole della responsabilità penale prevista dall'art. 76 del medesimo D.P.R., per le ipotesi di falsità in atti e dichiarazioni mendaci.
Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dal D.LGS 196/2003 "Codice in materia di protezione dei dati personali".

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell’art. 13 d. lgs. 30 giugno 2003 n. 196 - “Codice in materia di protezione dei dati personali” e dell’art. 13 GDPR 679/16 - “Regolamento europeo sulla protezione dei dati personali”.

Il sottoscritto, consapevole che il “conflitto d’interessi E.C.M.” è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l’interesse primario consistente nell’obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA
l’assenza di interessi commerciali in ambito sanitario negli ultimi due anni dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: 13/04/2026 San Cesareo
Firma:

Sara Piccirillo
13.04.2026
09:23:25
GMT+01:00

BIOGRAPHICAL SKETCH

Name: [*Last, First, Middle Initial(s), Degree(s), place and date of birth*]	Position/Title:
Stefano Pluchino, MRCP, MD, PhD Ragusa (Italy, May 31st, 1971) Citizenships: Italian, British Marital status: married with Chiara, 2 children	*Clinical Professor of Regenerative Neuroimmunology and* *Honorary Consultant in Neurology* GMC registration no: 7060371 NHS employee no: 21863735

Education

Institution and Location	Degree	Year	Field of Study
University of Siena, Italy	MD	1995	Medicine
University of Siena, Italy	Residency in Neurology	1999	Neurology
Institute of Neurological Sciences, University of Siena, Italy and Neuroimmunology Unit, San Raffaele Scientific Institute, Milan, Italy	PhD	2004	Neuroscience

RESEARCH AND PROFESSIONAL EXPERIENCE

PREVIOUS EMPLOYMENT

1996-1998	Research Registrar, Brain Repair Centre (BRC), Institute of Neurology, Dept. of Neuroscience, Addenbrooke's Hospital, Cambridge (UK);
2000-2003	Research Registrar, Neuroimmunology Unit, Dept. Neuroscience, DIBIT-San Raffaele Scientific Institute (Milan, Italy);
2003-2004	Post Doctoral Fellow Italian Association for Multiple Sclerosis (AISM-FISM, Italy), Neuroimmunology Unit, Dept. Neuroscience, DiBiT-San Raffaele Scientific Institute (Milan, Italy);
2004-2005	Post Doctoral Fellow National Multiple Sclerosis Society (NMSS, USA), Neuroimmunology Unit, Dept. Neuroscience, DiBiT-San Raffaele Scientific Institute (Milan, Italy);
2005-2014	Non-tenured Professor of Regenerative Neuroscience, Medical School, University Vita e Salute, Milano, Italy;
2005-2008	Research Associate, Neuroimmunology Unit, Institute of Experimental Neurology (INSPE), Dept. Neuroscience, DIBIT-San Raffaele Scientific Institute (Milan, Italy) (*Tenure-track*);
2008-2015	Adjunct Associate Professor of Neurology, Department of Neurology, The University of Vermont College of Medicine, Burlington, VT, USA;
2008-2010	Group leader, CNS Repair Unit, INSPE, Division of Neuroscience, DIBIT2-San Raffaele Scientific Institute (*Tenure*) (Milan, Italy);
2010-2016	University Lecturer and Honorary Consultant in Neurology, Department of Clinical Neurosciences, Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Clifford Allbutt Building - Cambridge Biosciences Campus, Hills Road, CB2 0HA Cambridge, UK;
2019-2021	Co-Founder and Non-executive Director (NED), iSTEM Therapeutics Ltd (*part time*);
2016-2021	University Reader in Regenerative Neuroimmunology, Department of Clinical Neurosciences, University of Cambridge, Clifford Allbutt

	Building - Cambridge Biosciences Campus, Hills Road, CB2 0HA Cambridge, UK;
2018-present	Scientific Advisor, Altheia Science (Italy);
2019-2022	Co-Founder and NED, asitia Therapeutics Ltd.;
2021-2023	Chair of the Scientific Advisory Board, *ReNeuron Group plc*;
2014-present	Co-Founder and Director of Healthcare, Cambridge Innovation Technologies Consulting (CITC) Ltd. (*part time*);
2021-present	Founder and Director, Neurospace Ltd. (*part time*);
2021-2023	Professor of Regenerative Neuroimmunology, Department of Clinical Neurosciences, University of Cambridge, Clifford Allbutt;
2023-present	Clinical Professor of Regenerative Neuroimmunology, Department of Clinical Neurosciences, University of Cambridge, Clifford Allbutt;
2024-present	Affiliated Deputy Head Translational Medicine Program and Professor of Regenerative Neuroimmunology, Institute for Regenerative Medicine (ISbrEMIt), IRCCS Casa Sollievo della Sofferenza, Italy (*part time*);
2024-present	Scientific Advisor, Macomics Ltd. (UK);
2024-present	Scientific Advisor, Solute Guard Therapeutics Ltd. (UK);
2024-present	Elected Mentee, Neurology And NeuroSurgery Interest Group (NANSIG) Mentorship Program (UK);
2024-present	Scientific Consultant, Astex Pharmaceuticals Ltd. (UK);
2025-present	Board Member-at-Large, International Society for Extracellular Vesicles (ISEV);
2026-present	Elected Scientific Advisory Board Member, Romanian National Centre of Excellence of Neuroscience NeuRoX, Romania;

TEACHING RESPONSIBILITIES

TEACHING ACTIVITIES

2005-2007	Integrated course of Molecular and Cellular Neuroscience, Medical School, Degree program in Medical Biotechnology, University Vita e Salute, Milano, Italy (10 hours/course, problem-based learning);
2008-2014	Integrated course of Regenerative Neuroscience, Medical School, Degree program in Medical Biotechnology, University Vita e Salute, Milano, Italy (14 hours lectures/course);
2009	Co-chair (with SC Previtali), PhD Course in Neuroregeneration, International PhD Program in Molecular Medicine, Sections of Neuroscience, Neuroscience Technology and Experimental Neurology, University Vita-Salute San Raffaele, DIBIT-San Raffaele Scientific Institute, 9th-13th November, Milan, Italy;
2011	Wellcome Trust/Medical Research Council (MRC) PhD Programme in Stem Cell Research, University of Cambridge, UK (4 hours lectures/course, Lectures);
2012	Co-chair (with JW Fawcett), Spring School 2012 '*Stem Cells, Biomaterials and Nanotechnology*', Magdalene College, 27th-29th March, Cambridge, UK;
2014	Integrated course of Molecular medicine of nervous system degeneration, repair and regeneration - PON02_00563_3448479 Activating RINOVATIS "*Ingegneri Innovatori/Imprenditori specializzati in tecnologie e metodologie della Tissue Engineering*" at the University of Salento (Lecce, Italy) (40 hours lectures/course, Lectures);
2015	Co-chair (with JW Fawcett and RJ Franklin), Spring School 2015 '*Inflammation: its role in Degeneration and Regeneration'*, Magdalene College, 30th March – 1st April, Cambridge, UK;
2012-2018	Wellcome Trust/Medical Research Council (MRC) PhD Programme in Stem Cell Biology, Core Course, Module 'Stem Cell Transplantation Therapy', University of Cambridge, UK (8 hours lectures/course, Lectures);

2022 Organising Committee Member, 32nd Network for European CNS Transplantation and Restoration (NECTAR) Annual Congress, October 24 – 26, Athens, Greece;
2023 Organising Committee Member, 33rd Network for European CNS Transplantation and Restoration (NECTAR) Annual Congress, October 23 – 25, Naples, Italy;
2023 Organising Committee Member, UKEV Forum 2023, December 7-8, Cambridge, UK;
2025 Co-Director (with A Nadjar and RC Paolicelli), FENS/IBRO/Gatsby Foundation CAJAL Advanced Neuroscience Training Course in Neuroimmunology (http://cajal-training), November 24-December 6, Bordeaux Neurocampus, France;
2027 Elected Programme Committee 2027 Member, - 18th European Meeting on Glial Cells (EuroGlia) in Health and Disease, 7th-10th July 2027, Bologna, Italy;

MENTOR ACTIVITIES

Pre-Laurea student advisor

Lucia Zanotti; University of Milan, Bachelor in Pharmaceutical Biotechnology, training completed in March 03;
Marco Bacigaluppi; University Vita & Salute, Milan, Degree in Medicine and Surgery, training completed in July 04;
Sebastiano Bucello; University Vita & Salute, Milan, Degree in Medicine and Surgery, training completed in July 04;
Giulia Zotti; University Vita & Salute, Milan, Bachelor in Medical and Pharmaceutical Biotechnology, training completed in November 05;
Massimo Costanza; University Vita & Salute, Milan, Master Degree in Medical and Pharmaceutical Biotechnology, training completed in February 07;
Luca Peruzzotti Jametti; University Vita & Salute, Milan, Degree in Medicine and Surgery, training completed in September 07;
Giulia Zotti; University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 08;
Giulia Tyzack; University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 10;
Tommaso Leonardi; University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 12;
Edoardo Gaude; University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 12;
Matilde Stefanini, University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 13*;*
Silvia Basilico, University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in March 14*;*
Iacopo Bicci, University Vita & Salute, Milan, Master Degree in Cellular and Molecular Medical Biotechnology, training completed in June 16*;*
Giulia Manferrari, University of Bologna, Master Degree in Pharmaceutical Biotechnology, training completed in June 17*;*
Sara Bandiera, University of Trieste, Master Degree in Neurosciences, training completed in May 18*;*
Giuseppe D'Amico, University of Milano-Bicocca, Master Degree in Neurosciences, training completed in September 18*;*
Bryan Yu, University of Hong Kong, School of Medicine, training completed in July 19*;*
Veronica Testa, University of Milano-Bicocca, Master Degree in Neurosciences, training completed in March 21*;*
Andrea D'Angelo, University of Trieste, Master Degree in Neurosciences, training completed in October 21*;*
Larissa Roth, University of Wurzburg, Master Degree in Neurosciences, training completed in October 22*;*

Marlene Patterer, University of Wien (Austria), Master Degree in Neurosciences, training completed in August 23*;*
Madalena Abade, University of Groningen (The Netherlands), Master Degree in Neurosciences, training completed in December 24*;*
Ally Lyn, University of Hong Kong, School of Medicine, training completed in June 25*;*
Melika Karbalaee Mohammadhasan, MSc, University of Pavia (Italy), Master Degree in Neurosciences, training completed in June 25*;*

Post-Laurea student advisor
Michela Deleidi, MD; University Vita & Salute, Milan, Residency in Neurology, training completed in December 07;
Lucia Zanotti, BSc; PhD program in Molecular Medicine, Section of Experimental Neurology, San Raffaele Scientific Institute, February 06 – January 09;
Marco Bacigaluppi, MD; University Vita & Salute, Milan, Residency in Neurology, training completed in December 09;
Luca Peruzzotti-Jametti, MD; University Vita & Salute, Milan, Residency in Neurology, training completed in June 10;
Donatella Defeo, MD; University Vita & Salute, Milan, Residency in Neurology, training completed in June 10;
Adaoha Elizabeth C. Ihekwaba, PhD; European Research Council (ERC) post-doctoral fellow; Cambridge Centre for Brain Repair, University of Cambridge, UK, July 2010-August 2011;
Denise Drago, PhD, Ministry of Health post-doctoral fellow; CNS Repair Unit, INSPE and DIBIT2, San Raffaele Scientific Institute; January 2011-December 14;
Giulia Mallucci, MD, European Neurological Society (ENS) fellow; Cambridge Centre for Brain Repair, University of Cambridge, UK, September 2013-August 14;
Nunzio Iraci, PhD, Ministry of Health post-doctoral fellow; Cambridge Centre for Brain Repair, University of Cambridge, UK; February 2011-October 2016;
Giulio Volpe, MD, EC Lifelong Learning Programme awardee; Cambridge Centre for Brain Repair, University of Cambridge, UK, August 2014-October 2016;
Dai Matsuse, MD, PhD, The Great Britain SASAKAWA Foundation awardee; Cambridge Centre for Brain Repair, University of Cambridge, UK, October 2014-May 2017;
Almudena Fuster-Matanzo, PhD, Marie Curie IEF awardee; Clifford Allbutt Building - Cambridge Biosciences Campus, University of Cambridge, UK, January 2015-December 2016;
Inmaculada Conejos Sanchez, PhD; Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, March 2016-May 2017;
Jayden Aaron Smith, PhD, European Research Council (ERC) post-doctoral fellow; Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, November 2011-*present*;
Rebecca Rogal, PhD, Fritz Thyssen Foundation scholar; Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, September 2017-July 2018;
Grzegorz Krzak, PhD, Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, January 2024 - December 2024;\
Alexandra Nicaise, PhD, Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, March 2019 -*present*;
Cory Willis, PhD, Clifford Allbutt Building -Cambridge Biosciences Campus, University of Cambridge, UK, May 2019 -*present*;

Direct Supervisor in International MPhil/PhD Programs
Lucia Zanotti, BSc; University Vita-Salute San Raffaele, PhD Program in Molecular Medicine, Section of Experimental Neurology (Second Supervisor: Dr Gianvito Martino); 'Stem and precursor cell therapy of experimental multiple sclerosis', Milano, Italy, April 2009;
Melania Cusimano, BSc; University Vita-Salute San Raffaele, PhD Program in Molecular Medicine, Section of Experimental Neurology (Second Supervisor: Prof Antonio Malgaroli); 'The focal implantation of neural stem/precursor cells (NPCs) ameliorates a contusion spinal cord injury mouse model', Milano, Italy, April 2010;

- National Basic and Clinical Neuroimmunology Course and 3rd Clinical Neuroimmunology Symposium, Cesme, Izmir-Turkey, 1-4th April 2004;
- Route 28 student workshop: "Restoring Mobility: Stem Cells and Motor/Sensory Systems of the Spinal Cord, Semiahmoo, Washington, USA, 20th-26th August 2005;
- Berlin Brain Days 2005, Charitè, Berlin, 28th October- 1st November 2005;
- 8th Corso Residenziale di Neuroimmunologia (CRNI), Bergamo, Italy, 8th-11th March 2006;
- Neuroscience Seminar Series at the University of Vermont, Burlington, VM, USA, 22nd and 23rd February 2007;
- Neuroscience Seminar Series at the Oregon Health and Science University (OHSU), Portland, OR, USA, 20th and 21st January 2009;
- 9th European School of Neuroimmunology (ESNI) Course, Istanbul, Turkey, 1-4 September 2009;
- 10th Corso Residenziale di Neuroimmunologia (CRNI), Bergamo, Italy, 10th-13th March 2010;
- PhD course "Genetic programs of normal and cancer stem cells: from basic mechanisms to therapeutic approaches", Dept. of Biotechnologies and Biosciences, University of Milano-Bicocca, Milano, Italy, April 26th-28th 2010;

RESEARCH ACTIVITIES

MEMBERSHIPS

2004-2010	*Member*, Italian Society of Immunology and Clinical Allergology (SIICA, Italy);
2004-2010	*Member*, Italian Association of Cell Cultures (AICC, Italy);
2011-2013	*Advisory Board Member*, Brain (Oxford Journals, UK);
2005-2010	*Member*, International Society for Stem Cell Research (ISSCR, USA);
2008-2015	*Board Member*, Italian branch of The Myelin Project (CIPMT, Italy);
2009-2018	*Founder and Board Member*, Stem Cell Research (SCR, Italy);
2009-2015	*Member*, Italian Society for Neuroscience (SINS, Italy);
2009-2015	*Member*, Federation of European Neuroscience Societies (FENS);
2010-2015	*Member*, Italian Society of Biophysics and Molecular Biology (SIBBM);
2011-2015	*Scientific Advisory Board Member*, Fenexy foundation for Spinal Cord Injury cure (Spain);
2011-2018	*Jury committee member*, Royan International Research Award (Iran);
2012-2015	*Member*, International Society for Extracellular Vesicles (ISEV);
2012-2016	*Member*, Biomedical Research Scientific Committee, Italian Multiple Sclerosis Foundation (FISM);
2015-2017	*Advisory Board Member*, GIGA-Development, Stem Cells and Regenerative Medicine (Belgium);
2015-2018	*Science Advisor*, Life-to-young Institute of Biotechnology in Biomedical & Gene Therapy (China);
2017-2020	*Panel Member*, National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) (UK);
2018-2020	*Interview Panel Member*, The Wellcome Trust;
2018-2020	*Research Advisor*, Nan Yang Academy of Sciences (Singapore);
2020-2023	*Review Editor*, Frontiers in Molecular Biosciences;
2013-2024	*Editorial Board Member*, Brain Plasticity (IOS Press);
2023-to date	*Specialty Chief Editor*, Section of Neural Stem Cells, Frontiers in Stem Cell;
2011-present	*Editorial Board Member*, World Journal of Translational Medicine (WJTM; Baishideng Publishing Group);
2011-present	*Appointed Peer Referee*, European Research Council Executive Agency (ERCEA);
2011-present	*Honorary Life Member*, Stroke Society of Australasia (Australia);
2011-present	*Scientific Committee Member*, Associazione Ricerca Alzheimer (ARAL Onlus, Italy);
2011-present	*Scientific Advisory Committee Member*, Sam Schmidt Paralysis Foundation (USA);
2012-present	*Editorial Board Member*, International Scholarly Research Network Transplantation (ISRN);
1997-present	*Member*, Italian Neuroimmunology Society (AINI, Italy);
2006-present	*Founder and Honorary Member*, Brazilian Society of Cell Therapy (BSCT, Brasil);
2009-present	*Member*, Society for Experimental Stroke (S4ES, USA);

2012-present *Editorial Board Member*, Journal of Transplantation and Stem Cell Biology (Avens Press)
2009-present *Editorial Board Member*, World Journal of Stem Cells (WJSC; Baishideng Publishing Group);
2009-present *Honorary Member*, Tissue Engineering and Regenerative Medicine International Society (TERMIS);
2011-present *Key Opinion Leader* (KOL) Advisor on Stem Cell Clinical Trials, Fast Forward - National Multiple Sclerosis Society;
2013-present *Review Editor*, Frontiers in Cellular Neurosciences;
2014-present *Review Editor*, Frontiers in in Chemistry and Molecular Biosciences;
2015-present *Reviewer*, Conquer Paralysis Now (CPN) Grand Challenge;
2015-present *Member*, Royal College of Physicians (RCP);
2016-present *Editorial Board Member*, Matters, Journal for Single Observations (Switzerland);
2017-present *Member*, MS Society expert consortium on progressive MS trials (UK);
2019-present *Elected Board Member*, Network for European CNS Transplantation and Restoration (NECTAR);
2019-present *Elected Member*, European Science Foundation (ESF) College of Expert Reviewers;
2020-present *Section Editor*, 'Stem Cell Research', Multiple Sclerosis and Related Disorders (Elsevier);
2020-present *Section Editor*, 'Stem Cells', Cells (MDPI Press);
2020-present *Review Editor*, Frontiers in Bioengineering and Biotechnology, and Frontiers in Materials;
2020-present *Board Member*, PhD Program in Neuroscience and Education, University of Foggia (Italy);
2021-present *Editorial Board Member*, ExRNA (BioMed Central Press);
2021-present *Member*, EQA Network of Expert Evaluators (Spain);
2022 *Elected Board Member*, EUROMIT 2023;
2022-present *Associate Editor*, Exploration of Neuroscience (Open Exploration);
2022-2024 *Member*, Biomedical Research Scientific Committee, Italian Multiple Sclerosis Foundation (FISM);
2022-present *Panel Member*, 'Neuroscience and Neuropharmacology', National Committee for the Evaluation of Research (CNVR), Italian Ministry for Universities and Research (MUR);
2023-present *Elected Member*, Cambridge Mitochondrial Therapies Group (MTG; https://www.mitotherapy.co.uk);
2023-to date *Specialty Chief Editor*, Section of Neural Stem Cells, Frontiers in Stem Cells;
2024-to date *Advisory Board Member*, Solute Guard Therapeutics (SGTx),;
2024-to date *Core Member*, International Society for Extracellular Vesicles (ISEV) Committee on Translation, Regulation, and Advocacy;
2024-to date *Elected Member*, Academic Career Development Panel, Dept Clinical Neurosci, University of Cambridge (UK);
2025-to date *Scientific Advisory Board Member*, Progetto di Eccellenza "MyoHEALTH", University of Padua (Italy)
2025-to date *Associate Editor*, Frontiers in Cellular Neuroscience, Cellular Neuropathology section

FELLOWSHIPS

2003 Italian Multiple Sclerosis Foundation (FISM), Italy;
2004 National Multiple Sclerosis Society (NMSS), USA;
2004 Keystone Symposia Scholarship, Snowbird, Utah, USA;

AWARDS

2002 AINI Award, Moltrasio (CO), Italy;
2003 European Charcot Foundation (ECF) Award for young (under 35) European Investigators in the field of Multiple Sclerosis (Lisbon), Portugal;
2004 SIICA Award for Experimental Immunology, Ischia (Na), Italy;
2004 AICC Award, Naples (Na), Italy;

2006 Serono Foundation Multiple Sclerosis Award, Italy;
2007 Rita Levi-Montalcini Award, Italy;
2008 Regional Agency for Instruction, Formation and Work (ARIFL) Research and Internationalization Award, Italy;
2010 Young Investigator Award, Italian Ministry of Health, Italy;
2010 European Research Council (ERC) Starting Independent Researcher Grant;
2010 11th Royan International Research Award (Tehran), Iran;
2011 Elected Bye-Fellow, Sydney Sussex College, Cambridge, UK;
2014 Italian Ministry of Instruction, University and Research - National Scientific Qualification to the grade of Full Professor in Applied Biology (05/F1);
2014 Italian Ministry of Instruction, University and Research - National Scientific Qualification to the grade of Full Professor in Neurology (06/D6);
2025 UConn Health Petit Family Lecture and Distinguished Visiting Professorship in Multiple Sclerosis and Neuroimmunology, University of Connecticut, CT, USA;

CLINICAL ACTIVITIES

2014-present Clinical Lead, Progressive MS Clinic, Addenbrooke's CUH - Cambridge University Hospitals NHS Foundation Trust;
2017-present Senior and co-Principal Investigator, hNSC-SPMS phase I clinical trial (Leone, Profico, Gelati et al. *Cell Stem Cell* 2023);
2018-present Principal Investigator, MS-STAT2 phase III clinical trial (*The Lancet,* 2025);
2022-present Principal Investigator, study 'Interrogating Metabolic Processes Underlying The Evolution of Progressive Multiple Sclerosis (IMPUTE-PMS)';
2023-present Principal Investigator, OCTOPUS phase III clinical trial;
2024-present Senior and co-Principal Investigator, ClinicaL trial of intracerebrOventricular tranSplantation of allogeneic nEural stem cells in people with progressive multiple scleRosis (CLOSER) phase II study;
2026-present Elected Member, Data Monitoring Committee, NIHR167673 - REFINE-MS: A randomised, rater-blind, phase 3 trial to determine the optimal dose frequency of ocrelizumab for patients with relapsing remitting multiple sclerosis using a novel multi-arm multi-stage frequency-optimisation design.

PERSONAL STATEMENT

I have a strong interest in Regenerative Neuroimmunology, and my research over the last 20 years has recalibrated the classical view that neural grafts only function through structural cell replacement and opened a new therapeutic avenue by which to use exogenously delivered NSCs, or more recently, how to manipulate and interrogate patient stem cell lines to generate unique disease-in-a- dish models revealing new mechanisms of disease.

I have been first or senior author in seminal papers that have established the potential of somatic NSC-based experimental therapies for PMS (reviewed in *Trends Mol Med* 2020). My early studies identified a critical role around the route of cell injection (*Nature* 2003, *Nature* 2005, *Brain* 2009, *Ann Neurol* 2009, *Brain* 2012) and the mechanisms of NSC accumulation in the chronically inflamed CNS (*Nature* 2005, *Brain* 2009, *Ann Neurol* 2009, *Brain* 2012), as well as revealing an unexpected ability of NSC therapies to provide neurotrophic support (*Nature* 2003, *Nature* 2005, *PNAS* 2006, *Ann Neurol* 2009, *Brain* 2009, *Brain* 2012, *J Neuroinflamm* 2016, *Cell Stem Cell* 2018, *Stem Cells* 2018, *EBiomedicine* 2019, *Acta Neuropath Comms* 2019, *Mol Ther*, 2020) and inhibit detrimental host immune responses (*Nature* 2005, *Brain* 2009, *Ann Neurol* 2009, *Brain* 2012, *Cell Stem Cell* 2018) *in vivo*.

Our most recent work describes a delayed accumulation of the pro-inflammatory tricarboxylic acid (TCA) cycle intermediate succinate in the cerebrospinal fluid (CSF) of mice with experimental autoimmune encephalomyelitis (EAE), a model of chronic MS. We have identified a new complementary mechanism by which directly induced NSCs (iNSCs) respond to endogenous inflammatory metabolic signals to inhibit the activation of type-1 mononuclear phagocytes (MPs) *in vivo* after transplantation. Transplanted iNSCs respond to the succinate released by type-1 inflammatory macrophages and microglia in the CSF, which then signals to

Ivan Lombardi, MSc (Italy), visiting PhD student (University of Milano-Bicocca) 2024
Giulia Mallucci, MD (Italy), visiting graduate student, University of Pavia (Italy) from 2013 to 2014 (then Consultant Neurologist IRCCS Fondazione Istituto Neurologico Nazionale C Mondino)
Giulia Manferrari, BSc (Italy), visiting master student, University of Bologna (Italy) from 2015 to 2017
Hebe Manos, BSc (UK), MPhil student (Clin Neurosci) 2023
Dai Matsuse, MD, PhD (Japan), visiting PDRA from Tohoku University (Japan) from 2014 to 2017
Emanuele Mauri, MSc (Italy), visiting PhD student, Polytechnic University of Milan (Italy) from 2017 to 2018
Magdi Mekdad, BSc (Romania), MPhil studnet (Biological Sciences) 2023
Vasiliki Pappa, MSc, (Greece), Research Assistant from 2020 to 2022
Luca Peruzzotti Jametti, MD (Italy), PhD student (Clin Neurosci), then PRA and SRA from 2013 to 2024
Joan Pidgeon (USA), personal assistant from 2012 to 2016
Rebecca Rogal, MD, PhD (Germany), visiting post-doctoral research associate from 2017 to 2018
Larissa Roth, BSc (Germany), visiting master student, University of Wurzburg (Germany) from 2020 to 2022
Giuliana Salani, PhD (Italy), laboratory technician from 2005 to 2009
Silvia Snider, MD (Italy), PhD student (Experimental Neurology), University Vita & Salute San Raffaele (Italy) from 2009 to 2010 (then Consultant Neurosurgeon at San Raffaele Hospital)
Julia Schaeffer, MSc (France), MPhil student (Clinical Neuroscience), University of Cambridge from 2012 to 2013 (then PhD student at Cambridge University)
Jayden A. Smith, PhD (Australia), post-doctoral research associated from 2011 to 2022
Matilde Stefanini, BSc, visiting master student, University Vita & Salute San Raffaele (Italy) from 2011 to 2013 (then PhD student at Oxford University)
Gillian Tannahill, PhD (Northern Ireland), PDRA from 2013 to 2014 (then Research Scientist at GlaxoSmithKline)
Giulia Tyzack, BSc (Italy), master student and PhD student (Clinical Neurosciences), University of Cambridge from 2008 to 2011 (then PRA at UCL)
Daniel Trajkovski (Macedonia), Research Assistant, from 2018 to 2021
Alesandra Vaideanu, MSc (Hungary), visiting PhD student (Engineering), University of Cambridge from 2017 to 2018
Aletta van den Bosch, BSc (Netherlands), visiting master student, University of Amsterdam from 2018 to 2019
Beatriz Vega-Blanco, PhD (Spain), laboratory technician from 2013 to 2015 (then Senior Scientist at GlaxoSmithKline)
Nunzio Vicario, BSc (Italy), visiting PhD student (Pharmacology), University of Catania (Italy) from 2015 to 2017
Giulio Volpe, MD (Italy), MPhil student (Clinical Neurosciences), University of Cambridge from 2014 to 2016 (then Resident fellow in Ophtalmology at University of Rome – Tor Vergata)
Bryan Yu (Hong Kong), undergraduate student, University of Hong Kong from 2018 to 2019 (then School of Medicine intern at the University of Hong Kong)
Lucia Zanotti, BSc (Italy) master student and PhD student (Experimental Neurology) University Vita & Salute San Raffaele (Italy) from 2005 to 2009 (then PDRA at San Raffaele Institute)
Kay Zhou (China/Canada), MPhil studenti (Clin Neurosci) 2022
Giulia Zotti, BSc (Italy) master student from 2007 to 2008 (then CTM at PPD)
Mark Winterbone (UK), Senior Research Assistant and Lab Manager, from 2018 to 2019

DESCRIPTION OF THE RESEARCH ACTIVITIES *(http://www.pluchinolab.org)*

There are currently no approved therapies to slow down the accumulation of neurological disability that occurs independently of relapses in MS. International agencies are engaging to expedite the development of novel strategies capable of modifying disease progression, abrogating persistent CNS inflammation, and support degenerating axons in people with progressive MS. Understanding why regeneration fails in the progressive MS brain and

developing new regenerative approaches is a key priority for the Pluchino Lab.
My team aims to elucidate how the immune system, in particular its cells called myeloid cells, affects brain structure and function under normal healthy conditions and in disease.
Our objective is to find how myeloid cells communicate with the central nervous system and affect tissue healing and functional recovery by stimulating mechanisms of brain plasticity mechanisms such as the generation of new nerve cells and the reduction of scar formation. To this aim, we use state-of-the-art transcriptomics, proteomics, and molecular approaches to study murine and human disease models of inflammation and neurodegeneration.
Our main goal is to develop experimental molecular medicines, including those with stem cells and gene therapy vectors, to slow down the accumulation of irreversible disabilities and improve functional recovery after multiple sclerosis, stroke and traumatic injuries.
By understanding the mechanisms of intercellular (neuro-immune) signalling, diseases of the brain and spinal cord may be treated more effectively, and significant neuroprotection may be achieved with new tailored molecular therapeutics.

SCIENTIFIC INTERESTS

Ageing and cellular senescence
Somatic and pluripotent stem cells
Neural stem cells
Oligodendrocyte progenitors
Experimental cell therapies and cell transplantation
CNS regeneration
Mechanisms and molecules of neuroprotection
Extracellular membrane vesicles, including exosomes, and horizontal RNA transfer
Morphogens and morphogenesis
Multiple Sclerosis and experimental autoimmune encephalomyelitis
Nanotechnologies and Synthetic Biology
Experimental stroke
Experimental spinal cord injury
Mobile small ncRNAs
Tissue and cell engineering

SCIENTIFIC COLLABORATIONS

Italy
Bianca Marchetti, PhD, IRCCS Oasi Maria S.S., Troina;
Roberta Magliozzi, University of Verona, Italy;
Pasquina Marzola, PhD, Department of Morphological-Biomedical Sciences, University of Verona;

Europe
Mario Amendola, Genethon Paris, France;
Gabriel Balmus, Cambridge UKDRI, UK;
Catarina Brito, iBET - Instituto de Biologia Experimental e Tecnológica, Portugal;
Patrick Chinnery, University of Cambridge, UK;
Christian Frezza, University of Cologne;
Madeline Lancaster, MRC-LMB, Cambridge, UK;
Svetlana Khoronenkova, Dept of Biochemistry, University of Cambridge, UK;
Jose-Manuel Garcia-Verdugo, PhD, University of Valencia, Spain;
John Marioni, Cancer Research UK;
Mike Murphy, MRC Mitochondrial Biology Unit, University of Cambridge, UK;
Richard Nicholas, Imperial College of London, UK;
Alexander von Kriegsheim, University of Edinburgh, UK;

United States and Australia
Isabel Beerman and Myriam Gorospe, National Institute for Ageing, (NIA) USA;
Angelo D'Alessandro, University of Colorado at Denver, USA;

Valentina Fossati, NYSCF, USA;
Peixuan Guo, PhD, University of Kentucky College of Pharmacy, USA;
Francisco Quintana, Harvard University, USA;
Marco Tigano, Thomas Jefferson Medical School, USA;

AD-HOC REVIEWER FOR SCIENTIFIC JOURNALS

2005 (7)
American Journal of Pathology (1); Experimental Neurology (1); Brain (1); Stem Cells (1); Annals of Neurology (1); Expert Opinion on Biological Therapy (1); Neurobiology of Disease (1).
2006 (8)
Brain Research (1); Journal of Comparative Neurology (1); Brain (1); Neurobiology of Disease (2); Stem Cells (1); Journal of Neuroscience Research (1); BMC Neuroscience (1).
2007 (20)
Journal of Comparative Neurology (1); Neurobiology of Disease (5); Journal of Neurological Sciences (1); Journal of Neuroscience Research (1); Brain (3); Future Neurology (2); Annals of Neurology (1); Restorative Neurology and Neuroscience (1); Journal of Neurology (1); BMC Neuroscience (2); Stem Cells (1); Brain Research (1).
2008 (19)
Human Gene Therapy (1); Neurobiology of Disease (5); Nature Nanotechnology (1); BMC Neuroscience (1); Stem Cells (2); Stroke (1); Trends in Molecular Medicine (1); Annals of Neurology (1); Gene Therapy (1); Molecular and Cellular Neuroscience (1); Brain (2); Journal of Comparative Neurology (1); European Journal of Neuroscience (1).
2009 (33)
Laboratory Investigation (1); Brain (10); Brain Behaviour and Immunity (3); Brain Research (1); Cytotherapy (1); Annals of Neurology (2); Hormones and Behaviour (1); Journal of Neuroscience Research (3); Stem Cells (1); PLoS One (2); European Journal of Neuroscience (2); Neurobiology of Disease (1); GLIA (1); Experimental Neurology (2); Journal of Biological Chemistry (1); Cytotherapy (1).
2010 (22)
Acta Biomaterialia (1); Annals of Neurology (1); Brain (6); Brain Behaviour and Immunity (1); Cytotherapy (1); Experimental Neurology (4); Laboratory Investigation (2); Journal of Bioengineering and Rehabilitation (1); Molecular and Cellular Neuroscience (1); PLoS One (2); Regenerative Medicine (1); Tissue Engineering (1).
2011 (23)
Annals of Neurology (3); Brain (6); Cell Transplantation (1); Cytotherapy (1); European Journal of Cancer (1); GLIA (1); Laboratory Investigation (1); Journal of Cell Science (1); Journal of Cerebral Blood Flow and Metabolism (1); Journal of Neuroinflammation (1); Neurobiology of Disease (1); Molecular and Cellular Neuroscience (1); Neurotherapeutics (1); Organogenesis (1); Recent Patents on Regenerative Medicine (1); Tissue Engineering (1);
2012 (32)
Annals of Neurology (2); Biochimica and Biophysica Acta (1); Brain (7); Cellular and Molecular Life Sciences (1); European Journal of Cancer (1); Frontiers in Physiology (1); GLIA (9); Human Molecular Genetics (1); Laboratory Investigation (1); Journal of Clinical Investigation (1); Journal of Neurology (3); Journal of Proteomics (2); PLoS One (1); Stem Cells (1).
2013 (16)
Brain (5); Cell Mol Life Sci (1); Front Cell Neurosci (1); J Clin Invest (3); J Neurosci (1); J Neurosci res (1); Neurobiol Disease (1); Neuroscience (1); PLoS One (2).
2014 (13)
Brain (3); Exp Neurol (1); J Clin Invest (1); JoVE (1); Front Cell Neurosci (2); Neurobiol Disease (1); PLoS One (1); Sci Rep (1); Stem Cell Rev and Rep (1); Tissue Engineering (1);
2015 (7)
Brain (1); Exp Opin Drug Discovery (1); J Clin Invest (2); Science Advances (1); Sci Rep (1); Science Translational Medicine (1);
2016 (5)
Brain (2); J Clin Invest (2); J Neuroinfl (1).
2017 (6)

Adv Sci (1), Cell Reports (1), J Clin Invest (2), J Neuroinflamm (1), J Neurosci (1).
2018 (11)
Brain (2), Cell (1), Cell Death and Disease (1), Cell Reports (2), EBiomedicine (1), GLIA (1), Oncoimmunology (1), PLoS Biol (1), Stem Cell Transl Med (1).
2019 (3)
GLIA (1), Hematologica (1), J Clin Invest (1).
2020 (12)
Adv Health Mat (1); Brain (1); Cell Stem Cell (1); Clin and Transl Med (1); J Clin Invest (1); Mol Neurodegen (1); Mol Ther (1); MS and Rel Dis (1); Stem Cells (2); Stem Cell Reports (1); Stem Cell Transl Med (1).
2021 (8)
Adv Health Mat (1); Brain (1); iScience (1); J Neuroinflammation (1); MS and Rel Dis (1); Nat Neurosci (1); Nat Comms (1); Stem Cell Reports (1).
2022 (5)
Brain (1), Cell Stem Cell (1), J Exp Med (1), Nat Comms (1), Nat Rev Neurol (1).
2023 (9)
Cell Reports (1), Cell Stem Cell (1), EBiomedicine (1), Eur J Neurosci (1), Nat Comms (2), Nat Metab (1), Sci Advances (1), Stem Cell Reports (1),
2024 (6)
Cell (1), Nat Comms (1), Nat Immunol (1), Nat Metab (1), Science (1), Stem Cell reports (1)
2025 (…)

GRANT REVIEWER (NATIONAL AND INTERNATIONAL)
2003-present, Italian Multiple Sclerosis Association (AISM, Italy);
2003-present, The Myelin Project (TMP, USA);
2005-present, Dutch Foundation for the Support of MS Research (The Netherlands);
2005-present, National Multiple Sclerosis Society (NMSS, USA);
2005-present, Association pour la Recherche sur la Sclerose en Plaques (ARSEP, France);
2006-present, Fund for Scientific Research (FWO, Belgium);
2006-present, The Wellcome Trust (TWT, United Kingdom);
2006-present, Hasselt University Research Council, Belgium;
2008-present, Medical Research Council (MRC, United Kingdom);
2008-present, Mariani Foundation for Child Neurology (Italy);
2009-present, Agency for Science, Technology And Research's (A*STAR) BioMedical Research Council (BMRC, Singapore);
2009-present, Australian Government, Department of Innovation, Industry, Science and Research (Australia);
2009-present, Research Promotion Foundation (Cyprus);
2010-present, Association of British Neurologists (United Kingdom);
2010-present, Barts and The London Charity (United Kingdom);
2010-present, MS Research Australia (MSRA, Australia);
2010-present, MS Society of Canada (Canada);
2010-present, Wings for Life (Austria);
2011-present, Fast Forward, LLC (USA);
2011-present, Italian Ministry of Instruction, University and Research (MIUR);
2011-present, Greek Ministry of Education, Lifelong Learning and Religious Affairs (Greece);
2011-present, Agence Nationale de la Recherche (France);
2011-present, Telethon (Italy);
2011-present, European Research Council (ERC);
2011-present, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs, UK);
2011-present, Biotechnology and Biological Sciences Research Council (BBSRC, UK);
2012-present, Scleroseforeningen (MS Society, Denmark);
2012-present, Israeli Science Foundation (Israel);
2012-present, Research Grants Council (Hong Kong);
2012-present, Fundação para a Ciência e Tecnologia (FCT, Portugal);
2012-present, International Spinal Research Trust (ISRT, UK);

2014, External Evaluator, CRG ImPuLSe International Postdoctoral Programme (Spain);
2014-present, King's Health Partners R&D Challenge Fund (UK);
2014-present, Dutch Technology Foundation STW (The Nederland);
2016-present, Samsung Research Funding Center (South Korea);

GRANTING BODIES AS PRINCIPAL INVESTIGATOR (PI) or Co-PI

Approximate grant income last five years € 8M (£ 7.2M)

PAST

Agency: MS Italian Foundation (Code 2004/R/15)
Title of the Project: "*Pre-clinical assessment of three promising cell-based therapeutic approaches for multiple sclerosis: clinico-pathological, MRI and neurophysiological comparison between embryonic neural, adult neural and adult olfactory mucosal stem cells*"
Amount: € 70.000,00
PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from July 2005 to June 2007)

Agency: Ministry of Health, Programma Ricerca Finalizzata IRCCS
Title of the Project: "*A Multidisciplinary Approach to Test the Therapeutic Potential of Neural Stem Cell Transplantation in Preclinical Mouse Models of Parkinson's Disease*"
Amount: € 78.650,00
PI: Riccardo Brambilla, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from October 2007 to September 2009)

Agency: National Multiple Sclerosis Society (NMSS) USA (Code RG 4000-A-1) (*portable*)
Title of the Project: "Central vs peripheral immunomodulation in neural stem cell transplant for MS"
Amount: USD 278.452,00 (€ 201.937,776)
PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from October 2007 to September 2009)

Agency: MS Italian Foundation
Title of the Project: "Functional MRI to study brain plasticity in experimental MS"
Amount: € 25.000,00
PI: Pasquina Marzola, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from October 2007 to September 08)

Agency: Wings for Life (WfL) SE-013/09 (*portable*)
Title of the Project: "*REGENERATION OF THE INJURED SPINAL CORD WITH SOMATIC NEURAL STEM CELLS (NPCS) AND MICROENCAPSULATED GLIAL SCAR INHIBITORS (GSIS)*"
Amount: € 140.000,00 (£ 120.350,00)
PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from June 2009 to November 2011)

Agency: Banca Agricola Popolare di Ragusa (BAPR), Italy
Title of the Project: "Somatic neural stem cell transplantation as novel therapeutic approach for the treatment of multiple sclerosis"
Amount: € 200.000,00
PI: Stefano Pluchino, MD, PhD
Duration: 36 months (from June 2008 to November 2011)

Agency: FinLombarda SpA
Title of the Project: "*TRAPIANTO AUTOLOGO DI CELLULE DELLA MUCOSA OLFATTIVA IN PAZIENTI CON TRAUMI SPINALI: UNO STUDIO CLINICO DI FASE 2 INTERNAZIONALE MULTICENTRICO (AUTO-OEC)"*
Amount: € 175.000,00 (£ 150.500,00)
PI: Pietro Mortini, MD
Deputy PI: Stefano Pluchino, MD, PhD
Duration: 18 months (from March 2011 to September 2012)

Agency: Associazione Italiana Sclerosi Multipla/Fondazione Italiana Sclerosi Multipla (AISM/FISM; RG 2010/R/31 and 2010/R/31/B)

Title of the Project: "*Noncoding RNAs and therapeutic plasticity of neural stem cells*"
Amount: € 105.000,00 (£ 90.280,00)
PI: Stefano Pluchino, MD, PhD
Duration: 36 months (from March 2011 to February 2014)

Agency: Federation of the Societies of Biochemistry and Molecular Biology (FEBS; Long term fellowship)
Title of the Project: Mechanisms of mobile ncRNAs in stem cells
Amount: € 88.000,00 (£ 69.000,00)
PI: Nunzio Iraci, PhD
Sponsor: Stefano Pluchino MD, PhD
Duration: 24 (+ 12) months (from January 2012 to December 2014)

Agency: European Neurological Society training fellowship
Title of the Project: Transplantation of next-generation directly-induced neural stem cells (iNSCs) in mice with experimental multiple sclerosis
Amount: € 12.000,00 (£ 9.766,00)
PI: Giulia Mallucci, MD
Sponsor: Stefano Pluchino MD, PhD
Duration: 12 months (from September 2013 to August 2014)

Agency: Italian Ministry of Health – Young Investigator Award GR08-7 – (*portable*) (*March 09 call*)
Title of the Project: "*MICRORNAS AS NOVEL REGULATORS OF THE THERAPEUTIC PLASTICITY OF SOMATIC STEM CELLS (MIR-STEM)*"
Amount: € 586.000,00 (£ 503.800,00)
PI: Stefano Pluchino, MD, PhD
Co-PI: John S. Mattick, PhD
Duration: 36 months (from December 2010 to November 2014)

Agency: EU 7th Framework Programme (Small or medium-scale focused research project; RG 64462)
Title of the Project: Implantable Organic Nano-Electronics (iONE)
Amount: € 3.995.709,00 (£ 3.132.289,674)
PI: Fabio Biscarini, PhD
Co-PI: Stefano Pluchino MD, PhD
Duration: 36 months (from March 2012 to February 2015)

Agency: European Research Council (ERC) Starting Grant # FP7 260511 (RG 58508)
Title of the Project: *"SEcreted Membrane vesicles: role in the therapeutic plasticity of neural StEM cells"*
Amount: € 1.500.000,00 (£ 1.244.710,00)
PI: Stefano Pluchino, MD, PhD
Duration: 60 months (from December 2010 to November 2015)

Agency: International Foundation for Research in Paraplegia (November 12 call; RG 69318)
Title of the Project: "A nanomedicine approach with packaging RNA nanostructures to manipulate the glial scar in severe spinal cord injuries"
Amount: CHF 150.000,00 (£ 102.274,00)
PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from June 13 to December 15)

Agency: UK Multiple Sclerosis Society (RG 941/11)
Title of the Project: "*Cambridge Centre for Myelin Repair Renewal*"
Amount: £ 2.141.907,00 (€ 2.491.327,72)
Lead PI: Robin Franklin, PhD
Co-PI: Stefano Pluchino, MD, PhD (together with Drs Spillantini, Compston, Kotter, Coles and Zhao)

Duration: 60 months (from March 2011 to February 2016)

Agency: The Evelyn Trust (March 13 call) RG 69865
Title of the Project: "*Cell signalling through secreted extracellular RNAs in neuro-immune interactions*"
Amount: £ 247.169,00
PI: Stefano Pluchino, MD, PhD
Duration: 36 months (from December 13 to November 16)

Agency: EUROPEAN COMMISSION, Research Executive Agency – Marie Curie Intra-European Fellowship (RG 74074)
Title of the Project: "*WNT3A IN NEUROIMMUNE INTERACTIONS IN STROKE BRAIN*"
Amount: € 221.606,40 (£184.643,659)
Scientist in Charge: Stefano Pluchino, MD, PhD
Researcher: Almudena Fuster Matanzo
Duration: 24 months (from January 15 to December 16)

Agency: The Great Britain Sakakawa Foundation - Butterfield Awards UK-Japan collaboration in medical research and public health practice (RG 75426)
Title of the Project: *Human Muse cells for the treatment of Spinal Cord Injury*
Amount: £ 8,000.00
PI: Stefano Pluchino, MD, PhD
Co-PI: Mari Dezawa, PhD
Duration: 12 months (from October 15 to September 16)

Agency: International Progressive Multiple Sclerosis Alliance 2014/PMS/4 (RG 71303)
Title of the Project: "*Stably expandable induced neural stem cells (iNSCs) for the treatment of progressive multiple sclerosis (iNSC_MS)'*
Amount: € 61,000 (£ 43,214)
PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from October 15 to September 16)

Agency: Progressive Multiple Sclerosis Alliance: Collaborative Network Award (Phase 1 application)
Title of the Project: "*Stem cell-derived oligodendrocyte progenitor-based therapy of progressive MS'*
Amount: $ 50,000 (£ 32,400)
PI: Steve Goldman, MD, PhD
Co-PIs: S Pluchino, R Franklin, F Edenhofer, A Goodman, P Sorensen, T Ben-Hur, B Reubinoff
Duration: 12 months (from January 16 to December 16)

Agency: WELLCOME TRUST - Research Training Fellowship (RRZA/057 RG 79423)
Title of the Project: "Directly induced neural stem cells (iNSCs) for the treatment of progressive multiple sclerosis (PMS_iNSC)"
Amount: £189,702.00 (€ 264,271.88)
Scientist in Charge: Luca Peruzzotti-Jametti, MD
Supervisor: Stefano Pluchino, MD, PhD
Duration: 36 months (from February 15 to February 18)

Agency: UK Regenerative Medicine Platform - Acellular (smart material) approaches for therapeutic delivery (RG 69889)
Title of the Project: *Cell signalling through secreted extracellular RNAs in the interactions with host immune system*
Amount: £ 50,000.00
PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from March 15 to February 16)

Agency: UK Regenerative Medicine Platform - Acellular (smart material) approaches for therapeutic delivery (RG 69889)
Title of the Project: *Cell signalling through secreted extracellular RNAs in the interactions with host immune system*
Amount: £ 50,000.00
PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from March 15 to February 16)

Agency: Montreal Neurological Institute-University of Cambridge Initiative
Title: Derivation of respiratory motor neurons from human induced pluripotent stem cells for the study of motor neuron diseases
Amount: CND 20,000 (£ 9,600)
PI: Stefano Stifani, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from January 16 to December 16)

Agency: Wings for Life (WfL) (RG 82921)
Title of the Project: Induced neural stem cells and RNA nanotechnology: a combinatorial approach to spinal cord injury
Amount: € 200.000 (£ 155,666)
PI: Stefano Pluchino, MD, PhD
Duration: 24 months (from July 16 to June 18)

Agency: Montreal Neurological Institute-University of Cambridge Initiative
Title: Generation of human iPSC- derived motor neurons and microglia to model ALS pathophysiology in a dish
Amount: CND 30,000 (£7,279.41 going to Cambridge)
PI: Stefano Stifani, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from June 17 to May 18)

Agency: Montreal Neurological Institute-University of Cambridge Douglas Avrith Graduate Studentship
Title of the Project: Single-cell RNA analysis of astrocytes after spinal cord Injury
Amount: CND 25.000,00 (£ 14.000,00)
PI: Regan Hamel, BSc
Mentor: Stefano Pluchino, MD, PhD
Duration: 12 months (from April 18 to March 19)

Agency: Congressionally Directed Medical Research Program (CDMRP) MS Research Program – *Investigator Initiated Partnership Award* (RG 77094)
Title of the Project: "*Restorative Neuroimmunology in Experimental Models of Multiple Sclerosis via Directly Induced Neural Stem Cell Transplantation (MS_iNSC)'*
Amount: 1,488,845 USD (£ 900,527 with £ 420,000 going to Cambridge)
PI: Stefano Pluchino, MD, PhD
Co-PIs: Regina Amstrong, PhD and Frank Edenhofer, PhD
Duration: 36 months (from January 16 to December 19)

Agency: Addenbrooke's Cambridge Trust (RG 97519)
Title of the Project: Understanding the metabolic determinants of progressive MS
Amount: £ 24.184,00
PI: Luca Peruzzotti-Jametti, MD, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from January 19 to December 20)

Agency: Wings for Life (WfL)- 1y extension (RG 82921)
Title of the Project: Induced neural stem cells and RNA nanotechnology: a combinatorial approach to spinal cord injury

Amount: £ 95,000
PI: Stefano Pluchino, MD, PhD
Duration: 12 months (from September 18 to August 19)

Agency: The Isaac Newton Trust (RG 97440)
Title of the Project: In vivo characterisation and manipulation of succinate-dependent injury in chronic neuroinflammation
Amount: £ 25.000,00
PI: Stefano Pluchino, MD, PhD
Co-PI: Luca Peruzzotti-Jametti, MD, PhD
Duration: 24 months (from October 18 to September 20)

Agency: John and Lucille Van Geest Endowment
Title of the Project: start up grant at the CCBR (including one PhD student position and funding for consumables/equipment)
Amount: £ 360.000,00 (€ 418.000,00)
PI: Stefano Pluchino, MD, PhD
Duration: unrestricted

Agency: Fondazione Italiana Sclerosi Multipla – Senior Research Fellowship (RG 90820)
Title of the Project: In vivo characterization and manipulation of succinate-dependent brain injury in neuroinflammation
Amount: € 88.604(£ 79.119,00)
PI: Luca Peruzzotti-Jametti, MD, PhD
Mentor: Stefano Pluchino, MD, PhD
Duration: 24 months (from March 18 to February 20)

Agency: Cambridge International Scholarship
Title of the Project: PhD In Clinical Neurosciences
Amount: £ 129.000,00
PI: Regan Hamel, BSc
Mentor: Stefano Pluchino, MD, PhD
Duration: 36 months (from October 18 to September 21)

Agency: Rosetree Trust Studentship (RG 93740)
Title of the Project: Single-cell RNA analysis of astrocytes after spinal cord Injury
Amount: € 82.435 (£ 73.500,00)
PI: Regan Hamel, BSc
Mentor: Stefano Pluchino, MD, PhD
Duration: 36 months (from April 18 to March 21)

Agency: National MS Society (USA) (RG 92222)
Title of the Project: Characterisation and manipulation of the metabolic pathways driving neuroinflammation
Amount: USD 307.653,00 (£ 219.000,00)
PI: Stefano Pluchino, MD, PhD
Co-PI: Luca Peruzzotti-Jametti, MD, PhD
Duration: 36 months (from October 18 to September 21)

Agency: Italian MS Foundation (2018/R/14) (RG 96607)
Title of the Project: Characterisation and manipulation of the metabolic pathways driving chronic neuroinflammation
Amount: € (175.000) £ 158.000,00
PI: Stefano Pluchino, MD, PhD
Duration: 36 months (from October 18 to September 21)

Agency: ECTRIMS Multiple Sclerosis Postdoctoral Research Fellowship Exchange Program (G104956)

Title of the Project: Modelling Cellular Senescence in Progressive Multiple Sclerosis with Neural Stem Cells and Animal Disease Models
Amount: 110,000 euro (~ £99,500)
PI: Alexandra Nicaise
Duration: 24 months (January 2021 - December 2022)

Agency: Advanced Therapy Network (ATN) Collaborate-to-Innovate
Title of the Project: Investigate the expansion and quality control (QC) assessment of induced neural stem cells (iNSCs) under good manufacturing practice (GMP) conditions
Amount: £109,405.10
PI: Francesco Dazzi (King's College of London)
Co-PI: Stefano Pluchino and Jayden Smith (CITC Ltd.)
Duration: 12 months (from Nov 2019 to June 2021)

Agency: The Bascule Charitable Trust (RG 75149)
Title of the Project: '*Stem Cell Research and Brain Repair*'
Amount: £ 250.000,00
PI: Stefano Pluchino, MD, PhD
Duration: unrestricted (from April 14 to Febr 23)

Agency: Wings for Life - Spinal Cord Research Foundation (RG 104102)
Title of the Project: Defining the heterogeneity of non-neuronal (immune) CELLular responses following spinal cord injury using ex vivo single-cell RNA sequencing (CELL_seq)
Amount: € (300,000) £ 260,000
PI: Stefano Pluchino
Duration: 36 months (from January 21 to December 23)

Agency: Wellcome Trust Clinical Research Career Development Fellowship
Title of the Project: Exploring the Role of MITOchondrial ImmunoMETAbolism in Neuroinflammation: Mechanisms and New Targets for Progressive MS Treatment (MITO_META) (G105713)
Amount: £ 442,048.00
PI: Luca Peruzzotti-Jametti
Duration: 36 months (from Nov 2020 to Oct 2023)

Agency: National Multiple Sclerosis Society (US) (RRAG/249)
Title of the Project: Exploring the role of ASTROcytic succinate recepTOR in neuroinflammation
Amount: $1 66,512
PI: Cory Willis
Duration: 36 months (July 2021 to July 2024)

Agency: The Ferblanc Foundation (RRAG/267)
Title of the Project: Metabolic Control of Brain Ageing in Progressive Multiple Sclerosis (Meta_PMS)
Amount: £ 48,000
PI: Stefano Pluchino, MD, PhD
Co-PI: Alexandra Nicaise, PhD
Duration: 24 months (from Sept 21 to Aug 23)

Agency: Multiple Sclerosis Society (UK) (G11854)
Title of the Project: Exploring the role of the astrocytic succinate receptor 1 in people with MS
Amount: $ 58,079.00 (£ 47.139,00)
PI: Stefano Pluchino, MD, PhD
Co-PIs: Cory Willis, PhD and Alexandra Nicaise, PhD
Duration: 12 months (from February 23 to January 24)

Agency: The Bascule Charitable Trust (RG 98181)

Title of the Project: '*Directly induced neural STEM cells from people with progressive multiple sclerosis for applications in REGenerative Neuroimmunology (STEM_REG)*'
Amount: £ 260.000
PI: Stefano Pluchino, MD, PhD
Duration: unrestricted

Agency: UK MS Society
Title of the Project: Cambridge Centre for Myelin Repair (CCMR) – 4
Amount: £1.800.000
PIs: Alasdair Coles, Thora Karadottir and Stefano Pluchino
Co-PIs: David Rowitch, Joanne Jones, Mark Kotter
Duration: 60 months (from 1 April 2021 to 30 March 2027)

ACTIVE (3.5M£ 2018-2025)
Agency: National MS Society (USA) (G116428)
Title of the Project: METAbolic control of smoldering NEUROinflammation (META_NEURO)
Amount: $599,422.00 (£ 500.853)
PI: Luca Peruzzotti-Jametti, MD, PhD
Co-PIs: Zoltan Takats, PhD, and Stefano Pluchino, MD, PhD
Duration: 36 months (from March 23 to December 26)

Agency: ROSETREES TRUST (RRAG/436
Title of the Project: Metabolite Signalling in the Progression of Smouldering Neuroinflammation (MET_SIG_NEURO)
Amount: $ 182.644,96 (£ 151.516)
PI: Stefano Pluchino, MD, PhD
Co-PIs: Cory Willis, PhD; and Luca Peruzzotti-Jametti, MD, PhD
Duration: 36 months (from June 23 to May 26)

Agency: Italian Multiple Sclerosis Foundation (FISM) (G115839)
Title of the Project: The Epigenetic PrograM of BRAin Stem CEll Aging in Progressive Multiple Sclerosis (EMBRACE)
Amount: € 349.558 (£ 290.000)
PI: Stefano Pluchino, MD, PhD
Co-I: Alexandra Nicaise, PhD
Duration: 36 months (from March 23 to December 26)

Agency: Montreal Neurological Institute-University of Cambridge Douglas Avrith Graduate Collaboration
Title of the Project: Mechanisms and role of ASD-associated Chd8 gene in reactive gliosis and neurodegeneration
Amount: CAD 50,000.00 (£12.000 to the Cambridge team)
PI: Yang Zhou, PhD
Co-PI: Stefano Pluchino, MD, PhD
Co-I: Irina Mohorianou, PhD
Duration: unrestricted

Agency: International Progressive MS Alliance - 2024 Experimental Medicine Trials RFA
Title of the Project: neuRal stEm cell-baSed Therapy Of pRogressivE MS (RESTORE)
Amount: $ 99.000 (£ 72.000)
PI: Stefano Pluchino, MD, PhD
Co-Is: Angelo Vescovi, PhD, Olga Ciccarelli, MD, Mariapia Sormani, PhD, Fedrik Barkhof, MD, et al.
Duration: 18 months (May 25- Aug 26)

Agency: UK MS Society
Title of the Project: Cambridge Centre for Myelin Repair (CCMR) – 5

Amount: £2.000.000 (€ 2.300.000)
PIs: Alasdair Coles, Thora Karadottir and Stefano Pluchino
Duration: 60 months (from 1 April 2026 to 30 March 2031)

PENDING

Agency: La Caixa Foundation – Health Research 2026
Title of the Project: '*MEtabolic Nanomedicines for Disease-modifying therapy in Multiple Sclerosis'*
Amount: € 900.000 (£ 780.000)
PI: Giuseppe Battaglia, PhD
Co-I: Stefano Pluchino, MD, PhD
Duration: 36 months

Agency: Fast Forward Lcc (National MS Society)
Title of the Project: '*OPTImized malonate nanoparticles targeting smoldering inflammation in progressive MS (OPTI-MS)*'
Amount: $ 800.000 (£ 586.000)
PI: Luca Peruzzotti-Jametti, MD, PhD
Co-PI: Stefano Pluchino, MD, PhD
Co-I: Giuseppe Battaglia, PhD
Duration: 36 months

Agency: National MS Society
Title of the Project: '*Targeting CNS-Compartmentalised Neuroinflammation via σ1R and 5-HT2A Signalling to Stop MS Progression and Enable Repair*'
Amount: $ 600.000 (£ 439.000)
PI: Ola Rutkowska, PhD
Co-PI: Stefano Pluchino, MD, PhD
Duration: 36 months

Agency: HORIZON-WIDERA-2025-ACCESS-01 – Teaming for Excellence
Title of the Project: '*Institute for Integrated Social and Biological Assessment*'
Amount: € 15.000.000 (£ 13.000.000)
PI: Lino Ferreira, PhD
Co-Is: Stefano Pluchino, MD, PhD; Francisco Javier, PhD and Philipp Tsolakis, PhD
Duration: 84 months

Agency: The Wellcome Trust – Wellcome Trust Discovery Award
Title of the Project: '*Mitochondrial RNA sensing drives glial senescence in progRessive MS: decoding and targeting a newly discovered pAthway to neurodeGEneration (MIRAGE)*
Amount: £ 3,522,507.00 (€ 4.054.810,65)
PI: Stefano Pluchino, MD, PhD
Co-Is: Gabriel Balmus, PhD; Laura Morcom, PhD
Duration: 60 months

PATENTS

(1) '*Inflammation*' - UK patent application No. 0514300.3 filed on 12/07/2005;
- International patent application No. PCT/IB2006/002896 filed on 12/07/2006;
- International Publication Number WO2007015173;
- Australia - patent application No. 2006274653 filed on 12/07/2006;
- Europe - patent application No. 06809040.6 filed on 12/07/2006;
- Canada - patent application No. 2,614,666 filed on 12/07/2006;
- Japan - patent application No. 2008-520984 filed on 12/07/2006;
- US - patent application No. 11/995,598 filed on 12/07/2006.

Inventor(s): Gianvito Martino, Stefano Pluchino
Applicant(s): Gianvito Martino, Stefano Pluchino, Fondazione Centro San Raffaele del Monte Tabor

(2) '*Banking of stem cells and business methods related to the same*' - UK patent application No. GB1600597.7 filed on 12/01/2016
Inventor(s): **Stefano Pluchino**, Luigi G. Occhipinti
Applicant(s): Cambridge Innovation Technologies Consulting Limited
Status: *Ceased*

(3) '*Human asparaginase lacking glutaminase activity*' - European patent application No. 16189525.5 filed on 20/09/2016
Inventor(s): **Stefano Pluchino**, Christian Frezza, Nunzio Iraci, Edoardo Gaude, Tommaso Leonardi
Applicant(s): Cambridge Innovation Technologies Consulting Limited
Status: *Ceased*

(4) *'Active implantable multifunctional device on a biodegradable/bioresorbable scaffold and its manufacturing processes'* - European patent application No EP3375482A1 filed on 14/03/2017
Inventor(s): Fabio Biscarini, Giulia FOSCHI, Pierpaolo Greco, Mauro Murgia, Tobias CRAMER, Elena GIUSTO, Matteo DONEGA', **Stefano PLUCHINO**, Alessandra CAMPANA
Applicant(s): Cambridge Innovation Technologies Consulting Ltd, Consiglio Nazionale delle Ricerche CNR, Università di Bologna, Scriba Nanotecnologie Srl
Status: Withdrawn

(5) '*Paper-based in-vitro diagnostic device and method*' - UK patent application No. GB1706988.1 filed on 03/05/2017
Inventor(s): Luigi G. Occhipinti, **Stefano Pluchino**
Applicant(s): Cambridge Innovation Technologies Consulting Limited
Status: *Pending*

(6) '*Treatment or prevention of central nervous system (CNS) disorder'*
International application reference: PCT/GB2024/051730 and WO2026008955A1 filed on 03/07/2024
Inventors: Luca Peruzzotti Jametti, Michael Patrick Murphy, and **Stefano Pluchino**.
Applicant(s): Cambridge Enterprise Ltd
Status: *Pending*

INVITED LECTURES AND/OR SEMINARS
(selected; > 50 in the last 5 years)

Selected overall

- International Diabetes Society (IDS)/International Society of Neuroimmunology (ISNI) Satellite Symposium, Montreal, Canada, 18th July 2004;
- International Symposium on new approaches to understanding the basis of multiple sclerosis, Valencia, Spain, 26-28th June 2005;
- 2nd Annual Christopher Reeve "Hot Topics in Stem Cell Biology" Satellite Symposium at the Society for Neuroscience Meeting, Washington DC, USA, 14th November 2005;

- 16th Annual Meeting of the Network of European CNS Transplantation And Regeneration (NECTAR), Amsterdam, The Netherlands, 8-10th December 2005;
- Centennial Golgi Symposium: The node and the network. The fundamental contribution of Camillo Golgi to modern neuroscience, Pavia, Italy, 2-4th October 2006;
- 2006 European Charcot Foundation Symposium, Taormina, Italy, 16-18th November 2006;
- European MS Platform Conference, Brussels (Belgium), 29th- 30th May 2007;
- XXXVIII Congresso della Società Italiana di Neurologia, Firenze, Italy, 13th -17th October 2007;
- European Charcot Foundation Symposium, Fiuggi, Italy, 29th November – 1st December 2007;
- International Conference 'Adult Stem Cells – Biology and Clinical Applications', The Queensland Conservatorium of Music, Griffith University, Nathan, Queensland, Australia, 26th-28th November 2008;
- American Society of Neurochemistry (ASN) 40th annual meeting, Charleston, SC, USA, 7-11 March 2009;
- Neuroscience Seminar Series at the Tohoku University, Sendai, Japan, 12th-13th May 2009 (host: Mari Dezawa);
- The 7th Stem Cell Research Symposium, Keyo University School of Medicine, Tokyo, Japan, 17th-18th May 2009;
- Symposium: Regeneration and Rehabilitation in MS. Institut fur Neuroimmunologie un Klinische MS-Forschung (IniMS), Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany, 26th-27th June 2009;
- 2nd Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress (keynote lecture), Seoul, Republic of Korea, 31st August – 3rd September, 2009;
- 15th Annual meeting of Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)**,** Basic and Clinical Issues in Multiple Sclerosis Research **(***Keynote lecture*), San Antonio, TX, USA, June 5th, 2010;
- 11th Royan International Twin Congress, Tehran, Iran 15th-17th September 2010 (*Keynote lecture*);
- 1st Stem Cell Symposium, Samsun, Turkey, 29th September – 1st October 2010 (*Keynote lecture*);
- Dulbecco Telethon Institute (DTI) Annual Scientific Retreat, Terrasini, Italy, 22nd- 24th October 2010 (*Keynote lecture*);
- Seminar Series at the Inserm 975, Hospital de la Salpetriere, Paris, France, 10th January 2011 (host: Catherine Lubetzki);
- Annual 'Neuroscience days', Institute of Neurological Sciences and Psychiatry, Hacepette University, Ankara, Turkey, 4th-5th April 2011 (*Keynote lecture*);
- Seminar Series at the Dept of Biomedical Engineering, University of Cincinnati, OH, USA, 18th April 2011 (host: Peixuan Guo);
- 25th International Symposium on Cerebral Blood Flow, Metabolism and Function, Barcelona, Spain, 24th May, 2011 (*Keynote lecture*);
- 22nd Stroke Society of Australasia Annual Scientific Meeting, Adelaide, Australia, 14th-16th September 2011 (two *Keynote lectures*);
- Qatar Stem Cell Research and Policy Issues Conference, Doha, Qatar, 27th February-1st March 2012 (*Keynote lecture*);
- Seminar Series at the College of Pharmacy, University of Kentucky, KY, USA, 5th – 9th March 2012 (host: Peixuan Guo);
- 8th Asia Pacific Symposium on Neural Regeneration (APSNR) in conjunction with the 5th Pan Pacific Symposium on Stem Cells and Cancer Research (PPSSC) the 1st Cross-Strait Biotechnology Forum, Taipei, Taiwan on April 13th to 15th, 2012 (*Keynote lecture*);
- 1st International Society for Extracellular Vesicles (ISEV) Annual Congress, Gothenburg, Sweden, April 18th- 21th 2012 (oral presentation);
- 7th International Symposium on Neuroprotection and Neurorepair, Potsdam, Germany, 2nd-5th May 2012 (*Keynote lecture*);
- Seminar Series at the Dept of Ophtalmology, Third Military Medical University of China, Chongqing, China, 17th-22nd June 2012 (host: CongJan Zhao);
- Seminar Series at the Department of Physiology, Anatomy and Genetics, University of Oxford, UK, 24th September 2012 (host: Francis Szele);

- Seminar Series at the University of Virginia School of Medicine, Charlottesville, VA (USA), 1st November 2012 (host: Jonathan Kipnis);
- 11th International Society of Neuroimmunology (ISNI) Congress, Boston, USA, 4th-8th November 2012 (symposium chair and *Keynote lecture*);
- Seminar Series at the Massachusetts General Hospital, Harvard University, Boston, MA (USA) 9th November 2012 (host: Xandra Breakfield);
- Markey Cancer Centre Research Seminar at the University of Kentucky (USA) (host: Guo-Min Li);
- 2nd International Conference on RNA Nanotechnology and Therapeutics, 3rd-5th April 2013, Lexington, KY (USA) (*Keynote lecture*);
- Symposium on Cell-Based Therapies in Central Nervous System Pathology, 12th April 2013, Hasselt, Belgium (*Keynote lecture*);
- Frye-Halloran Educational Symposium of ISEV on Exosomes and the nervous system: molecular biology, diagnosis and therapeutic implications, 16th April 2013, Boston, USA (*Keynote lecture*);
- Seminar Series at the Centro de Investigación Príncipe Felipe, Valencia (Spain) 21st June 2013 (host: Maria Jesus Vicent);
- 11th European Meeting on Glial Cells (EuroGlia) in Health and Disease, 3rd – 6th July 2013, Berlin, Germany (*Keynote lecture*);
- 10th Annual Yale-Cambridge meeting, 7th-9th September 2013, New Haven (USA);
- 11th European Congress of Toxicologic Pathology, 10th-13rd September 2013, Ghent, Belgium;
- Medical Research Council (MRC) UK – China Stem Cell Workshop, 16th-19th October 2013, Shangai (China);
- 15th International Symposium on Neural Regeneration, 12th-15th December 2013, Pacific Grove (USA) (*Keynote lecture*);
- Seminar Series at the Cedars-Sinai Medical Centre, Los Angeles (USA) 16th December 2013 (host: Dolores Di Vizio);
- Seminar Series at the Sandford-Burnham Medical Research Institute, La Jolla (USA) 17th December 2013 (host: Pierlorenzo Puri);
- 20th Annual Meeting of the French Club of Glial Cells, 20th-22nd March 2014, Carry-Le-Rouet (France) (*Invited lecture*);
- EMBL conference "Microglia: Guardians of the Brain, 26th-29th March 2014, Heidelberg (Germany) (*Invited lecture*);
- Seminar Series at the Montreal Neurological Institute and Hospital, Montreal (Canada), 15th April 2014 (host: Jack Antel);
- Joint Congress of the European Federation of Neurological Societies (EFNS)/European Neurological Society (ENS) congress – Focused Symposium on Recent advances in multiple sclerosis research – 31st May 2014, Istanbul (Turkey) (*Invited lecture*);
- Seminar Series at the University of Michigan, MI (USA), 8th September 2014 (host: Yang Mao-Draayer);
- Joint Congress of the European and American Committees for Treatment in Multiple Sclerosis (ECTRIMS/ACTRIMS), 10th-13th September, Boston (USA) (*Invited lecture*);
- Seminar Series at Zhejiang University (China), 26th- 29th November 2014 (host: Jian-Qing Gao);
- Seminar Series at Peking University (China), 4th- 7th February 2015 (host: Yuchun Gu);
- 2015 Meeting of the International Society for Extracellular Vesicles (ISEV), 23rd-26th April 2015, Washington (USA) (*two Plenary Lectures*);
- Seminar Series at Nestle' Institute of Health Sciences, Lausanne (Switzerland) 18th June 2015 (host: Pascal Steiner);
- Seminar Series at The Francis Crick Institute (UK), 13th July 2015 (host: Dominique Bonnet);
- Biannual meeting of the International Society of Neurochemistry (ISN), 23rd-27th August 2015, Cairns (Australia) (*Invited lecture*);
- Drug Discovery '15 ELRIG meeting, 2nd-3rd September 2015, Telford (UK) (*Plenary lecture*);
- Joint European Neonatal Societies (jENS) Congress, 16th-20th September 2015, Budapest (Hungary) (*Invited lecture*);
- Plenary Lecture Series at the San Raffaele Scientific Institute, Milano (Italy), 24th September 2015 (host: Angela Gritti) (*Plenary lecture*);

- FENS Featured Regional Meeting, 7th-10th October 2015, Thessaloniki (Greece) (*Invited lecture*);
- International Conference on Cell-Based Therapies for Multiple Sclerosis, 19th-21th November 2015, Lisbon (Portugal);
- Hong Kong & Guangzhou International Conference on Stem Cell and Regenerative Medicine, 21st December 2015, Hong Kong Science Park (*Keynote lecture*);
- Advanced Drug Delivery in Cancer: intracellular targets and vesicular carriers, 4th-5th March 2016, Manchester (UK) (*Keynote lecture*);
- Advanced Cell Therapy Symposium, 14th-15th March 2016, London (UK) (*Invited lecture*);
- 3rd International Symposium – The therapeutic applications of extracellular vesicles, 29th-30th September 2016, San Sebastian (Spain) (*Keynote lecture*);
- Annual Montreal Neurological Institute (MNI)-Cambridge University Symposium, 3rd-4th November 2016, Montreal (Canada) (*Keynote lecture*);
- More than neurons: toward a less neuronocentric view of brain disorders, 1st-3rd December 2016, Turin (Italy) (*Keynote lecture*);
- Seminar Series at the Universitätsklinikum Essen, Germany, 24th January 2017 (host: Dirk Hermann/Bernd Giebel) (*Special Faculty Seminar*);
- First QMBL neuroscience symposium on demyelinating diseases, London, UK, 18th February 2017 (*Keynote lecture*);
- UNISTEM Day 2017 at NICO - Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy, 17th March 2017 (*Keynote Lecture*);
- UK Regenerative Medicine Platform Acellular Hub annual meeting, Cardiff, UK, 19th April 2017 (*Invited lecture*);
- Wings for Life Annual Scientific Meeting, Salzburg, Austria, 11th -12th May 2017 (*Invited lecture*);
- Italian MS Foundation Annual Scientific Congress, Rome, Italy, 29th-31st May 2017 (*Invited lecture*);
- Advances in Neuroimmunology (ANIS) – Seminar Series 2017 at the University of Zurich (Switzerland), 22nd June 2017 (*Invited lecture*);
- 22nd Congress of the European Hematology Association (EHA22) - Scientific Working Group session on "The immunology of tissue repair", Madrid (Spain), 24th June 2017 (*Keynote lecture*);
- XIII European Meeting on Glial Cells in Health and Disease, Edinburgh, UK, 8th-11th July 2017;
- 2017 Hong Kong & Guangzhou International Conference on Stem Cell and Regenerative Medicine, 9th November 2016, Hong Kong Science Park (*Keynote lecture*);
- Annual UK EV meeting, Birmingham, UK, 12th December 2017;
- Seminar Series at Genethon, Evry', France, 13th March 2018 (host: Mario Amendola) (*Special Faculty Lecture*);
- ISEV2018 Annual Meeting, 2nd-6th May, Barcelona, Spain (*Invited lecture*);
- The New York Stem Cell Foundation (NYSCF) Conference 2018, 23rd-24th October 2018, New York, USA (*Invited lecture*);
- 28th Annual Meeting of the Network for European CNS Transplantation & Restoration (NECTAR) and BrainMatTrain EU network, 6th – 7th December 2018, Paris, France (*Invited lecture)*;
- 2019 UIG Group Annual Symposium in Belfast - Immunology without borders: Protecting, nourishing, healing, 13th - 14th June 2019, Belfast, Northern Ireland (*Invited lecture*);
- XIV European Meeting on Glial Cells in Health and Disease, Porto, Portugal, 10th-12th July 2019;

Last 5 years

- Neurowebinars 2021 series, 20th April 2021 (virtual *Invited lecture*);
- Seminar Series at the PhD Program in Medical Sciences, University of Padua, 24th June 2021, Padua (Italy) (host: Carlo Viscomi) (virtual *Invited Lecture*);
- XV European Meeting on Glial Cells in Health and Disease, 7th-10th July 2021, Marseille (France) (virtual *Invited lecture*);

- EV symposium 2021 - EXTRACELLULAR VESICLES IN PATHOPHYSIOLOGY, 26th-27th August 2021, Tartu (Estonia) (virtual *Keynote lecture*);
- Italian MS Foundation Annual Scientific Congress, Rome, Italy, 26th-28th October 2021 (virtual *Invited lecture*);
- Seminar Series at the Cambridge Centre for Myelin Repair (CCMR)-4, University of Cambridge, 25th November 2021 (host: Thora Karadottir) (virtual *Invited Lecture*);

2022 (16)
- Seminar Series at the Neuroscience and Mental Health Research Institute and School of Biosciences (BIOSI) and Dementia Research Institute, Cardiff University, 22nd January 2022 (host: Yasir Syed) (*Invited lecture*);
- Seminar Series at the Institute for Bioengineering of Catalonia (IBEC), 4th March 2022 (host: Josep Samitier) (*Invited lecture*);
- 12th International Meeting of the Portuguese Society for Stem Cells and Cell Therapies (SPCE-TC), 10th-11th March 22, Mino (Portugal) (*Plenary lecture*);
- Gordon Research Conference (GRC) *Central Nervous System Injury and Repair*, March 20-25, 2022, Oxnard River Ridge (CA, USA) (hosts/organisers: Yimin Zou and Simone Di Giovanni) (*Invited lecture; declined because of CoVID*)
- EMBO workshop 'Long-distance cell-cell signalling in development and disease', 10th-13th April 2022, Exeter (UK) (*Invited lecture*);
- Wings for Life Annual Scientific Meeting, Salzburg, Austria, 17th-18th May 2022;
- British Society of Immunology Immunometabolism Meeting, May 24th-25th 2022, Newcastle, UK (*Invited lecture; declined because of conflict with Annual FISM Meeting in Rome*);
- Italian MS Foundation Annual Scientific Congress, Rome, Italy, 24th-26th May 2022 (*Rita Levi Montalcini Plenary lecture*);
- Seminar Series at the UCL Neuroscience Society, 28th May 2022, London, UK (*Invited lecture*);
- 30th International Symposium on Cerebral Blood Flow, Metabolism and Function & 15th International Conference on Quantification of Brain Function with PET, 29th May- 1st June 2022, Glasgow, UK (*Invited lecture*);
- CEMCAT INTERNATIONAL ROUNDS, Barcelona, Spain, 30th May 2022 (*invited lecture*);
- Seminar Series at the Manitoba Neuroscience Network, 13th June 2022 (host: Soheila Karimi) (*Invited lecture*);
- Seminar Series at the Humanitas Research Hospital, 23rd June 2022 (host: Simona Lodato and Michela Matteoli) (*Invited lecture*);
- MitoNice 2022, 15th-17th September 2022, Nice (France) (*invited lecture*);
- Human Brains. Preserving the Brain: Forum on Neurodegenerative Diseases. 6th-8th October 2022, Milan (Italy) (*invited lecture*);
- 32nd Annual Meeting of the Network for European CNS Transplantation & Restoration (NECTAR) and BrainMatTrain EU network, 24th – 26th October 2022, Athens, Greece (*Invited lecture)*;

2023 (8)
- FENS-Hertie Winter School on Neuroimmune interactions, 29th January – 4th February 2023, University Center Obergurgl, Austria (*Invited lecture*);
- Keystone 'Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions', 14th-19th May 2023, Whistler, BC, USA (*Invited lecture*);
- Italian MS Foundation Annual Scientific Congress, Rome, Italy, 30th May-1st June 2023 (*Invited lecture*);
- EUROMIT 2023, International Meeting on Mitochondrial Pathology, 11th-15th June 2023, Bologna, Italy (*Invited lecture*);
- Corso ECM Residenziale "NEURO NEXT BOOTCAMP 2023 - Le sfide e opportunità della ricerca nelle Neuroscienze", 10th-11th July 2023, Pavia, Italy (*Invited lecture*);
- Multiple Sclerosis Management Service for Children Research and Education Meeting, 20th July 2023, Cambridge, UK (*Invited lecture*);
- 31st Annual Meeting of the European Charcot Foundation (ECF), 9th-11th November 2023, Baveno, Italy (*Invited lecture*);

- 1st ISEV symposium 'Extracellular Vesicles in Nervous Systems', 6th-8th December 2023, Rome, Italy (*Keynote lecture*);

2024 (9)
- Spring Brain Conference 2024, 28th April-1st May 2024, Sedona (AZ) (*Keynote lecture*);
- Annual GIBB Meeting, Vieste (FG), June 6-8, 2024 (*Keynote lecture);*
- Stem Cell Research Italy XII meeting, 13th-15th June 2024, Palermo, Italy (*Keynote lecture*);
- Alberta MS Network Seminar Series, 20th June 2024 (virtual) (*Keynote lecture*) (host: Wee Yong);
- Conference 'Our Health, Our Planet, Our Future' on September 7th-8th 2024, Brighton, UK (*Keynote lecture*);
- 9th CMBI Meeting of the Center of Molecular Biosciences (CMBI), September 27th 2024, Innsbruck, Austria (*Keynote lecture*);
- 15th World Congress of the World Mitochondria Society, Targeting Mitochondria, Berlin, October 29-31 (*Keynote lecture*);
- 32nd Annual Meeting of the European Charcot Foundation (ECF), 21st-23rd November 2024, Baveno, Italy (*Invited lecture*);
- Conference 'Brain-computer interfaces: opportunities and issues: Towards a reasoned use of neurotechnologies', Accademia Nazionale dei Lincei, 20th December 2024, Rome, Italy (*Invited lecture*);

2025 (10)
- Novartis Microglia Seminar series (*online*), 29th January 2025, hosts: Martin Stangel and Bernd Kieiser (*Invited lecture*);
- 6th Translational Neuroimmunology Symposium (under the umbrella of the Brazilian Committee for Treatment and Research in MS, BCTRIMS; *online*), 15th March 2025, host: Jean Pierre Schatzmann Peron (*Invited lecture*);
- PhD Course & mini-symposium on Mitochondria in immunity and neurodegeneration, 12th-16th May 2025, Copenhagen (Denmark) (*Invited lecture*);
- European Society of Neurochemistry, 18th-21st May 2025, Naxos (Greece) (*Invited lecture*);
- XVII European Meeting on Glial Cells in Health and Disease, 8th-11th July 2025, Marselle (France);
- FEBS Workshop 'Immunology, Metabolism, Ageing', 8th-11th September 2025, Matrei in Brennero (Austria) (*Invited lecture*);
- EMBO conference 'Mitochondria in the nervous system', 28th September-2nd October 2025, Engelberg (Switzerland) (*Invited lecture*);
- 2nd International Conference of Neurology Specialty Hospital (ICNSH), 15th and 16th November 2025, Seoul (South Korea) (*Keynote lecture*);
- Society for Neuroscience (SfN) 2025, Mini Symposium '*Oligodendrocyte Pathophysiology and Repair Mechanisms in Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease*', 15th-19th November 2025, San Diego, CA (*Invited lecture*);
- Cajal course on Neuroimmunology, 24th November-6th December 2025, Bordeaux (France) (*co-director of the course*);

2026 (…)
- The Milner Institute Seminars. *Focus on neurodegeneration*, 27th January 2026, Cambridge (*Invited lecture*);
- MS 2026, 14th March 2026, Lodz (Poland) (*Invited lecture*);
- Francisco Cobos Foundation Symposium '*Decoding Neurodegeneration: From Molecular Mechanisms to Therapeutic Action'*, 18th March 2026, Madrid (Spain) (*Invited lecture*);
- 36th Cambridge Neuroscience Seminar, 1st April 2026, Queens' College, Cambridge (*Invited lecture*);
- XXXIV AINI Congress, 4th-6th May 2026, Rome (Italy) (*Invited lecture*);
- 16th International Conference on Brain Energy Metabolism 2026, 29th June-2nd July 2026, Barcelona (Spain) (*Invited lecture*);
- Pre-FENS event, *Understanding the Paths from Neuron Induction to Circuit Integration*, 6th July 2026, Barcelona (Spain) (*Invited lecture*);

- EVIta Bootcamp "*Drug Delivery Based on Extracellular Vesicles*", 26th-28th October 2026, Lake Como, Italy (*Invited lecture*);

PUBLICATIONS

Total publications *(Scopus)= 167; (Google Scholar)= 295*
Total impact factor*= 1541.59;* ***Average impact factor****: 9.52*
H index Scopus*: 58;* ***H index Google Scholar****: 68;* ***i10-index****: 127*
Tot cit Scopus*: >15000;* ***Tot cit Google Scholar****: >21000*

ORCID iD 0000-0002-6267-9472
Scopus author iD 6701668987

ORIGINAL RESEARCH ARTICLES

84. R Kollyfas, M Cagna, AM Nicaise**, S Pluchino**, L Vallier and I Mohorianu. Unveiling Gene Regulatory Network Dynamics using Fuzzy Clustering. ***BIORXV*** 2026, https://www.biorxiv.org/content/10.64898/2025.12.31.697266v1.abstract;

83. HA Vecchiarelli, K Bisht, K Sharma, S Weiser Novak, ME Traetta, ME Garcia-Segura, M-K St-Pierre, JC Savage, C Willis, K Picard, M Bordeleau, N Vernoux, R Garg, YY. Grinberg, J Faustino, SM Loewen, CJ Murray, M Khakpour, T Halvorson, V Lau, **S Pluchino**, ZS Vexler, MJ Carson, U Manor, L Peruzzotti-Jametti and ME Tremblay. TREM2-Dependent Dark Microglia Are Abundant in Normal Postnatal Hippocampus. ***BIORXV*** 2024, doi: https://doi.org/10.1101/2024.10.15.618087;

82. P Prasad, A Dugourd, AN Makar, JA Reisz, M Miclaus, L Barea Moya, AM Nicaise, CM Willis, D Maddison, S Gil-Perotin, D Stephenson, M Dzieciatkowska, RB Ionescu, S Khoronenkova, E Avezov, JM Garcia Verdugo, A Von Kriegsheim, A D'Alessandro, J Saez-Rodriguez, M Tigano, G Balmus and **S Pluchino**. Mitochondrial dsRNA drives senescence and antiviral immunity in a stem cell model of progressive multiple sclerosis. ***CELL STEM CELL***, *under revision* (IF: **20.400**);

81. ED Carvalho, MRG Morais, G Athanasopoulou, M Araújo, B Cavadas, SC Guimaraes, E Mendes, **S Pluchino**, CC Barrias, AP Pêgo. Orthogonal control of oligodendrocyte differentiation in viscoelastic hydrogels: high stiffness modulates metabolism while slow relaxation dictates immune state. ***BIORXV*** 2025 https://www.biorxiv.org/content/10.1101/2025.10.09.680975v1; ***BIOMATERIALS***, *under revision* (IF: **12.479**);

80. V Testa, J Montero-Muñoz, V Baruffi, M Alzeer, L Mularoni, I Fernandez-Carasa, G Simmini, N Comellas-Comaposada, F Arnold Ake, Y Richaud, C Weissleder, J Amengual, I Fabregat, M Deleidi, M Plass, **S Pluchino**, A Raya, A Consiglio. Astrocytic Ceruloplasmin Deficiency Triggers Iron Toxicity and Neurodegeneration in a LRRK2 Parkinson's Tri-Culture Model. ***BIORXV*** 2025 https://www.biorxiv.org/content/10.1101/2025.08.01.668099v1; ***CELL STEM CELL***, *under revision* (IF: **20.400**)*;*

79. G Krzak, CM Willis, L Pirvan, M Repollés-de-Dalmau, JA Reisz, RB Ionescu, G Jordan, ME Garcia-Segura, B Barlas, A Ghia, AM Nicaise, I Lombardi, D Rowitch, G Balmus, A D'Angelo, S Fernández-Veledo, I Mohorianu, **S Pluchino** and L Peruzzotti-Jametti. Succinate Receptor 1 (SUCNR1) Signaling in Microglia Supports Neuroinflammation. ***NAT IMMUNOL***, *under revision* (IF: **27.600**);

78. RB Ionescu, JA Reisz, M Dzieciatkowska, D Stephenson, AM Nicaise, P Prasad, CM Willis, M Suarez Cubero, L Peruzzotti-Jametti, F Edenhofer, C Frezza, **S Pluchino** and A D'Alessandro. Protocol for stable isotopic tracing to assess cellular lipogenic activity in induced neural stem cells. ***STAR PROT*** 2026; 7: 104309 **DOI: 10.1016/j.xpro.2025.104309** (IF: **1.300**);

77. B Park, AM Nicaise, D Tsitsipatis, L Pirvan, D Žucha, A Munteanu, P Prasad, M Larraz Lopez De Novales, J Whitten, CM Willis, L Culig, J Llewellyn, RB Ionescu, M Mekdad, MBC Simões-Abade, G Krzak, J Fan, S De, M Ellis, M Suarez Cubero, A Spathopoulou, L Peruzzotti-Jametti, T Leonardi, G Balmus, F Edenhofer, M Gorospe, L Valihrach, I Mohorianu, **S Pluchino**, and I Beerman. Integrated Omics Reveals Disease-Associated Radial Glia-like Cells with Epigenetically Dysregulated Interferon Response in Multiple Sclerosis. ***NEURON***

2025; 113: 4158-4177.e10 **DOI: 10.1016/j.neuron.2025.09.022** (IF: **16.268**; Altmetric Score: **139**);

- *This study uncovers radial glia-like cells in MS (DARGs) with epigenetically dysregulated interferon responses. These findings suggest a novel cellular target within the MS pathology, potentially paving the way for new therapeutic interventions focused on epigenetic modulation.*

76. J Chataway, T Williams, J Blackstone, N John, M Braisher, F de Angelis, A Bianchi, A Calvi, A Doshi, SA Mangion, C Wade, E Bordea, R Merry, G Barton, D Lyle, E Jarman, D Mahad, A Shehu, T Arun, G McDonnell, R Geraldes, M Craner, C Hillier, J Ganesalingam, L Fisniku, J Hobart, C Spilker, NP Robertson, S Kalra, **S Pluchino**, S Harikrishnan, M Mattoscio, T Harrower, C Young, M Lee, S Kumar Chhetri, F Ahmed, D Rog, E Silber, P Gallagher, M Duddy, A Straukiene, R Nicholas, C Rice, S Tebbs, A Hawton, R Hunter, G Giovannoni, O Ciccarelli, J Beveridge, S Nixon, AJ Thompson, J Greenwood, OR Pearson, N Evangelou, B Sharrack, I Galea, E Gray, S Pavitt, S Chandran, HL Ford, C Frost, JM Nicholas, on behalf of the MS-STAT2 Investigators*. Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. ***THE LANCET*** 2025; 406 (10512): 1611-1624 **DOI: 10.1016/S0140-6736(25)01039-6** (IF: **98.4**; times cited *Scopus***: 11;** Altmetric Score: **25**);

- *This phase 3 trial (MS-STAT2) found that simvastatin did not slow disability progression in secondary progressive multiple sclerosis (SPMS). The study highlights the challenges of translating promising phase 2 results into effective treatments for SPMS.*

*Comment in M Filippi and M Rocca. MS-STAT2: lessons from negative trials in multiple sclerosis. **THE LANCET** 2025; 406 (10512): 1540-1542.*

75. L Peruzzotti-Jametti, N Vicario, G Volpe, S Rizzi, C Kwok, A D'Angelo, I Lombardi, AM Nicaise, G D'Amico, G Krzak, CM Willis, A Braga, K Saeb-Parsy, C Zhao, RJM Franklin, F Edenhofer, **S Pluchino**. Remyelination of the chronic demyelinated lesions of the spinal cord with directly induced Neural Stem Cell (iNSC) grafts. ***BRAIN*** 2025; 148 (10): 3505–3513 **DOI: 10.1093/brain/awaf208** (IF: **11.9**; times cited *Scopus***: 47**; Views: **4542**; Altmetric Score: **153**);

- *This study identifies that iNSC grafts promote remyelination in spinal cord lesions in mice, even when natural remyelination is impaired. Human iNSCs are safe and produce myelin, suggesting their potential as a therapy for demyelinating diseases like progressive MS.*

74. RB Ionescu, AM Nicaise, JA Reisz, EC Williams, P Prasad, M Dzieciatkowska, D Stephenson, M Suarez Cubero, L Pirvan, CM Willis, L Peruzzotti-Jametti, V Fossati, F Edenhofer, T Leonardi, C Frezza, I Mohorianu, A D'Alessandro and **S Pluchino**. Increased Cholesterol Synthesis Drives Neurotoxicity in Patient Stem Cell-Derived Model of Multiple Sclerosis. ***CELL STEM CELL*** 2024; 31:1574-1590.e11 **DOI: 10.1016/j.stem.2024.09.014** (IF: **24.668**; times cited *Scopus***: 23**; Captures: **19**; Altmetric Score: **51**) *Journal **COVER IMAGE**;

- *This study identifies that cholesterol synthesis in neural stem cells from patients with multiple sclerosis drives neurotoxicity. Blocking this synthesis pharmacologically can reduce the neurotoxic effects and promote cell survival.*

*Comment in S Eichhorner, L Traxler, O Borgogno, and J Mertens. All roads lead to cholesterol: Modulating lipid biosynthesis in multiple sclerosis patient-derived models. **CELL STEM CELL** 2024; 31: 1551-1552.*

73. J Blackstone, T Williams, JM Nicholas, E Bordea, F De Angelis, A Bianchi, A Calvi, A Doshi, N John, S Apap Mangion, C Wade, R Merry, G Barton, D Lyle, E Jarman, D Mahad, A Shehu, T Arun, G McDonnell, R Geraldes, M Craner, C Hillier, J Ganesalingam, L Fisniku, J Hobart, C Spilker, N Robertson, S Kalra, **S Pluchino**, S Harikrishnan, M Mattoscio, T Harrower, C Young, M Lee, S Chhetri, F Ahmed, D Rog, E Silber, P Gallagher, M Duddy, A Straukiene, R Nicholas, C Rice, SJ Nixon, J Beveridge, A Hawton, S Tebbs, M Braisher, G Giovannoni, O Ciccarelli, J Greenwood, AJ Thompson, R Hunter, S Pavitt, O Pearson, N Evangelou, B Sharrack, I Galea , S Chandran, HL Ford, C Frost, J Chataway. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. ***BMJ OPEN*** 2024; 14: e086414 (IF: **2.900**);

72. L Peruzzotti-Jametti, CM Willis, G Krzak, R Hamel, L Pirvan, RB Ionescu, JA Reisz, HA Prag, ME Garcia-Segura, V Wu, Y Xiang, B Barlas, AM Casey, AMR van den Bosch, AM Nicaise, L Roth, GR Bates, H Huang, P Prasad, AE Vincent, C Frezza, C Viscomi, G Balmus, Z Takas, J Marioni, A D'Alessandro, MP Murphy, I Mohorianou and **S Pluchino**. Mitochondrial

complex I activity in microglia sustains neuroinflammation. ***NATURE*** 2024; 628, 195-203 **DOI: 10.1038/s41586-024-07167-9** (IF: **64.800**; times cited *Scopus***: 134**; Accesses: **53k**; Altmetric score**: 160**];

- *This study identifies mitochondrial complex I (CI) activity in microglia as key driver of neuroinflammation by driving reverse electron transport and the production of reactive oxygen species (ROS). Blocking CI in pro-inflammatory microglia protects the central nervous system against neurotoxic damage and improves functional outcomes.*
- *Comment in Sonner, J.K., Mayer, C. & Friese, M.A. Microglial complex I activity: a crucial factor for smoldering inflammation in the central nervous system. **SIG TRANSDUCT TARGET THER** 2024; 9: 185 https://doi.org/10.1038/s41392-024-01894-1*

71. MA Leone, M Gelati, DC Profico, C Gobbi, E Pravata', M Copetti, C Conti, A D'Alessandro, L Peruzzotti-Jametti, **S Pluchino** and AL Vescovi. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive Multiple Sclerosis. ***CELL STEM CELL*** 2023; 30, 1-13 **DOI: 10.1016/j.stem.2023.11.001** (IF: **19.800**; times cited *Scopus***: 23**; Captures: **73**; Altmetric score: **2420**) *Journal **COVER IMAGE**; [(*) Over 550 pieces of international media coverage, including *ITV National News, Guardian, New York Post, Independent, Daily Mail* and *Conversation*. This study has been featured as one of the 10 most widely read **CELL STEM CELL** papers in 2023].

- *This first-in-human phase I trial demonstrates the feasibility and safety of transplanting allogeneic neural stem cells into the brains of people with progressive multiple sclerosis. The study also suggests a potential link between the treatment and changes in brain volume and metabolic markers.*

70. F Shekari, FJ Alibhai, H Baharvand, V Börger, S Bruno, O Davies, B Giebel, M Gimona, GH Salekdeh, L Martin-Jaular, S Mathivanan, I Nelissen, E Nolte-'t Hoen, L O'Driscoll, F Perut, **S Pluchino**, G Pocsfalvi, C Salomon, C Soekmadji, S Staubach, AC Torrecilhas, G Vilas Shelke, T Tertel, D Zhu, C Théry, K Witwer, R Nieuwland. Cell culture-derived extracellular vesicles: considerations for reporting cell culturing parameters. ***J OF EXTRACELLULAR BIO*** 2023, *https://doi.org/10.1002/jex2.115* (times cited *Scopus***: 51**);

69. R Hamel, L Peruzzotti-Jametti, K Ridley, V Testa, B Yu, D Rowitch, J Marioni and **S Pluchino**. Time-resolved single-cell RNAseq profiling identifies a novel *Fabp5*-expressing subpopulation of inflammatory myeloid cells in chronic spinal cord injury. ***HELIYON*** 2023; 9: e18339 (IF: **3.776**);

68. T Williams, N John, A Calvi, A Bianchi, F De Angelis, A Doshi, S Wright, M Shatila, MC Yiannakas, F Chowdhury, J Stutters, A Ricciardi, F Prados, D MacManus, M Braisher, J Blackstone, O Ciccarelli, CAM Gandini Wheeler-Kingshott, F Barkhof, J Chataway, UCL MS-STAT2 Investigators (W Brownlee, M Wynne, L Hockey, J Parker, J Flight, C Frost, J Nicholas, S Nixon, J Beveridge, S Chandran, P Connick, D Lyle, I Galea, E Jarman, H Ford, L Fernandes, M Vinjam, S Pavitt, B Sharrack, D Paling, A Shehu, T Arun, M Belhag, O Pearson, G Ingram, C Rickards, G McDonnell, S Hughes, C Spilker, L Fisniku, J Aram, C Rise, **S Pluchino**, L Peruzzotti-Jametti, S Harikrishnan, P Gallagher, F Ahmed, C Young, H Arndt, E Silber, R Nicholas, M Duddy, M Lee, N Evangelou, C Allen, M Craner, R Geraldes, J Hobart, C Hillier, S Chhetri, M Mattoscio, A Chaudhuri, S Kalra, A Straukiene, D Rog). Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial. ***EUR J NEUROL*** 2023 Sep;30(9):2769-2780 (IF: **6.288**);

67. M Keshavarz-Fathi, N Yazdanpanah, S Kolahchi, H Ziaei, GL Darmstadt, T Dorigo, F Dochy, L Levin, V Thongboonkerd, S Ogino, WH Chen, M Perc, MS Tremblay, BO Olusanya, IM Rao, N Hatziargyriou, M Moradi-Lakeh, F Bella, L Rosivall, AH Gandomi, A Sorooshian, M Gupta, C Gal, AM Lozano, C Weaver, M Tanzer, A Poggi, SG Sepanlou, R Weiskirchen, AR Jambrak, PJ Torres, E Capanoglu, FJ Barba, CKJ Ernest, M Sigman, **S Pluchino**, GB Gharehpetian, SM Fereshtehnejad, MH Yang, S Thomas, W Cai, E Comini, NJ Scolding, PS Myles, JJ Nieto, G Perry, C Sedikides, and N Rezaei. Universal Research Index: An Inclusive Metric to Quantify Scientific Research Output. ***J ACAD LIBRARIANSH*** 2023; 49 (3): 102714 (IF: **1.533**);

66. Y Wang, H Sheng, M Cong, W Wang, Q He, H Li, S Li, Y Chen, S Guo, L Fang, **S Pluchin**o, E Biskup, F Chen, Y Li, J Chen, Yan Wo, Sijia Feng. Spatio-temporally Deciphering

Peripheral Nerve Regeneration in vivo after EVs Therapy under NIR-II Fluorescence Imaging. ***NANOSCALE*** 2023 May 4;15(17):7991-8005 (IF: **8.307**);

65. A Mottahedin, H Prag, A Dannhorn, C Schmidt, M Yang, A Sorby-Adams, J Lee, N Burger, D Mottahedin, M Huang, **S Pluchino**, L Peruzzotti-Jametti, R Goodwin, C Frezza, M Murphy and T Krieg. Targeting succinate metabolism to decrease brain injury upon mechanical thrombectomy treatment of ischemic stroke. ***REDOX BIOLOGY*** 2023; 59: 102600 (IF: **11.789**; times cited *Scopus***: 43**);

64. X Yao, J Chen, Z Yu, Z Huang, R Hamel, Y Zeng, Z Huang, K Tu, J Liu, Y Lu, Z Zhou, **S Pluchino**, Q Zhu, J Chen. Bioinformatics analysis identified apolipoprotein E as a hub gene regulating neuroinflammation in macrophages and microglia following spinal cord injury. ***FRONT IMMUNOL***, 2022; 13: 964138 (IF: **8.786**; times cited *Scopus***: 3**);

63. L Leggio, F L'Episcopo, A Magrì, MJ Ulloa-Navas, G Paternò, S Vivarelli, C Bastos, C Tirolo, N Testa, S Caniglia, P Risiglione, F Pappalardo, N Faria, L Peruzzotti-Jametti, **S Pluchino**, JM Garcia-Verdugo, A Messina, B Marchetti, N Iraci. Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease. ***ADV HEALTHCARE MAT*** 2022; 11 (20): e2201203 (IF: **9.599**; times cited *Scopus***: 40**);

62. LB Jarvis, D Rainbow, V Coppard, S Howlett, J Davies, H Kaur Mullay, J Heste, T Ashmore, A Van Den Bosch, J Grist, AJ Coles, H Mousa, **S Pluchino**, K Mahbubani, J Griffin, K Saeb-Parsy, F Issa, L Peruzzotti-Jametti, L Wicker, JL Jones. Therapeutically expanded human regulatory T-cells are super- suppressive due to HIF1A induced expression of CD73. ***COMMS BIOL*** 2021; 4: 1186 (IF: **6.268**; times cited *Scopus***: 10**);

61. Peruzzotti-Jametti, JD Bernstock, CM Willis, G Manferrari, R Rogall, E Fernandez-Vizarra, JC Williamson, A Braga, A van den Bosch, T Leonardi, G Krzak, A Kittel, C Benincá, N Vicario, S Tan, C Bastos, I Bicci, N Iraci, JA Smith, B Peacock, KH Muller, PJ Lehner, EI Buzas, N Faria, M Zeviani, C Frezza, A Brisson, NJ Matheson, C Viscomi and **S Pluchino**. Neural stem cells traffic functional mitochondria via extracellular vesicles. ***PLOS BIOL*** 2021; 19(4): e3001166 **DOI: 10.1371/journal.pbio.3001166** (IF: **7.076**; times cited *Scopus***: 186**: Views: **>18k**; Save: **229**; Shares: **164**; Altmetric scores: **105**) [The study was selected to appear in the **PLOS Showcase**];

- *This study finds that neural stem cells release functional mitochondria via extracellular vesicles, which can restore mitochondrial function in target cells and ameliorate clinical deficits in a mouse model of multiple sclerosis. This suggests a novel therapeutic avenue for treating mitochondrial dysfunction in CNS disorders.*

60. N Cunniffe, K Vuong, D Ainslie, D Baker, J Beveridge, S Bickley, P Camilleri. M Craner, D Fitzgerald, A de la Fuente, G Giovannoni, E Gray, L Hazlehurst, R Kapoor, R Kaur, D Kozlowski, D Mahad, B Neumann, L Peruzzotti-Jametti, **S Pluchino**, J Robertson, A Rothal, L Shellard, K Smith, A Wilkins, A Williams, A Coles. A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. ***J NEUROL NEUROSURG PSYCHIATRY*** 2021; 92: 295–30 (IF: **8.234**; times cited *Scopus***: 15**);

59. GM Sullivan, AK Knutsen, L Peruzzotti-Jametti, A Korotcov, JD Bernstock, A Bosomtwi, BJ Dardzinski, F Edenhofer, **S Pluchino**, RC Armstrong. Transplantation of induced neural stemcells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits. ***ACTA NEUROPATHOL COMMUN*** 2020; 8(1):84 (IF: **5.883**; times cited *Scopus***: 15**);

58. A Braga, S Bandiera, J Verheyen, R Hamel, C Rutigliani, F Edenhofer, JA Smith and **S Pluchino**. Combination of *in situ Lcn2* pRNA-RNAi nanotherapeutics and iNSC transplantation ameliorates experimental spinal cord injury in mice. ***MOL THER*** 2020; 28 (12): 2677-2690 (IF: **8.986**; times cited *Scopus***: 4**);

57. Thiry L, Hamel R, **Pluchino S**, Durcan T, Stifani S. Characterization of Human iPSC-derived Spinal Motor Neurons by Single-cell RNA Sequencing. ***NEUROSCIENCE*** 2020; 1: 450:57-70 (IF: **3.240**; times cited *Scopus***: 13**);

56. Conejos-Sánchez I, Gallon E, Niño-Pariente A, Smith JA, De la Fuente AG, Di Canio L, **Pluchino S**, Franklin RJM, Vicent MJ. Polyornithine-based polyplexes to boost effective gene silencing in CNS disorders. ***NANOSCALE*** 2020; 12(11): 6285-6299 (IF: **6.895**; times cited *Scopus***: 9**);

55. JD Bernstock, L Peruzzotti-Jametti, N Vicario, D Ye, T Leonardi, KR Johnson, D Maric, Y Mou, FA Gessler, B Balzarotti, Y Lee, RJ Franklin, JM Hallenbeck, **S Pluchino**. SUMOylation promotes survival and integration of neural stem cell grafts in ischemic stroke. ***EBIOMEDICINE*** 2019; 42: 214-224 (IF: **6.183**; times cited *Scopus***: 28**);

54. C Falcone, M Santo, G Liuzzi, N Cannizzaro, C Grudina, E Valencic, L Peruzzotti-Jametti, **S Pluchino** and A Mallamaci. Foxg1 antagonizes neocortical stem cell progression to astrogenesis. ***CEREB CORTEX*** 2019; 29(12):4903-4918 (IF: **6.308**; times cited *Scopus***: 8**);

53. F L'Episcopo, L Peruzzotti-Jametti, MF Serapide, C Tirolo, N Testa, B Balzarotti, S Caniglia, **S Pluchino**, B Marchetti. Neural Stem Cell Grafts Promote Astroglia-Driven Neurorestoration in the Aged Parkinsonian Brain via Wnt/β-Catenin Signaling. ***STEM CELLS*** 2018; 36(8): 1179-1197 (IF: **5.599**; times cited *Scopus***: 38**);

52. PP Amaral, T Leonardi, N Han, E Viré, DK Gascoigne, R Arias-Carrasco, M Buscher, A Zhang, **S Pluchino**, V Maracaja-Coutinho, HI Nakaya, Martin Hemberg, R Shiekhattar, AJ Enright, T Kouzarides. Genomic positional conservation identifies topological anchor point (tap)RNAs linked to developmental loci. ***GENOME BIOL*** 2018; 19(1): 32 (IF: **11.908**; times cited *Scopus***: 98**);

51. JA Smith, A Braga, J Verheyen, S Basilico, C Alfaro-Cervello, L Peruzzotti-Jametti, F Haque, P Guo, **S Pluchino**. RNA nanotherapeutics for the amelioration of astroglial reactivity. ***MOL THER NUCLEIC ACIDS*** 2018; 10: 103-121 (IF: **6.392**; times cited *Scopus***: 12**);

50. E Mauri, A Sacchetti, N Vicario, L Peruzzotti-Jametti, F Rossi and **S Pluchino**. Evaluation of RGD functionalization in hybrid hydrogels as 3D neural stem cell culture systems. ***BIOMATER SCI*** 2018; 6(3): 501-510 (IF: **4.210**; times cited *Scopus***: 33**);

49. L Peruzzotti-Jametti, JD Bernstock, N Vicario, ASH Costa, CK Kwok, T Leonardi, LM Booty, I Bicci, B Balzarotti, G Volpe, G Mallucci, G Manferrari, N Iraci, A Braga, JM Hallenbeck, MP Murphy, F Edenhofer, C Frezza and **S Pluchino**. Macrophage-Derived Extracellular Succinate Licenses Neural Stem Cells to Suppress Chronic Neuroinflammation. ***CELL STEM CELL*** 2018; 22(3): 355-368 **DOI: 10.1016/j.stem.2018.01.020** (IF: **23.394**; times cited *Scopus***: 230**; Captures: **335**; Altmetric score: **308**);

- *This study discovers that extracellular succinate, released by inflammatory macrophages, activates neural stem cells (NSCs) via the SUCNR1 receptor to suppress chronic neuroinflammation. Activated NSCs then secrete PGE2 and scavenge succinate, reprogramming macrophages towards an anti-inflammatory state.*

*Comment in Kokaia Z, Lindvall O. Sensors of Succinate: Neural Stem Cell Grafts Fight Neuroinflammation. **CELL STEM CELL** 2018; 22(3): 283-285.*

48. M Donegà, E Giusto, T Leonardi, C Alfaro-Cervello and **S Pluchino**. Group I metabotropic glutamate receptor signalling regulates the release of BDNF and LIF by neural stem cells. ***MATTERS***, *DOI: 10.19185/matters.201801000002*;

47. A Fuster-Matanzo, G Manferrari, B Marchetti and **S Pluchino**. Wnt3a promotes pro-angiogenic features in macrophages *in vitro*: implications for stroke pathology. ***EXP BIOL MED*** (Maywood) 2018; 243(1): 22-28 (IF: **2.680**; times cited *Scopus***: 8**);

46. Bernstock JD, Ye D, Smith JA, Lee YJ, Gessler FA, Yasgar A, Kouznetsova J, Jadhav A, Wang Z, **Pluchino S**, Zheng W, Simeonov A, Hallenbeck JM, Yang W. Quantitative high-throughput screening identifies cytoprotective molecules that enhance SUMO conjugation *via* the inhibition of SUMO-specific protease (SENP)2. ***FASEB J*** 2018; 32(3): 1677-1691 (IF: **5.498**; times cited *Scopus***: 28**) [The study has an **Altmetric score of 194**]*;*

45. JD Bernstock, D Ye, FA Gessler, L Peruzzotti-Jametti, MR Gilbert, Y Pommier, **S Pluchino**, I Nakano, JM Hallenbeck. Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma; Implications for Immunotherapy. ***MATTERS***, (https://www.sciencematters.io/articles/201709000008/info);

44. Huang B, Jiang XC, Zhang TY, Hu YL, Tabata Y, Chen Z, **Pluchino S**, Gao JQ. Peptide modified mesenchymal stem cells as targeting delivery system transfected with miR-133b for the treatment of cerebral ischemia. ***INT J PHARM*** 2017; 531(1): 90-100 (IF: **3.640**; times cited *Scopus***: 43**);

43. N Iraci, E Gaude, T Leonardi, ASH Costa, C Cossetti, HK Saini, AJ Enright, C Frezza and

S Pluchino. Extracellular vesicles are independent metabolic units delivering functional Asparaginase-like protein 1. ***NAT CHEM BIOL*** 2017; 13(9):951-955 **DOI: 10.1038/nchembio.2422** (IF: **12.709**; times cited *Scopus***: 115**; Accesses: **>5k**; Altimetric score: **26**) *Journal **COVER IMAGE**;

- *This study discovers that neural stem cell-derived extracellular vesicles (EVs) exhibit L-asparaginase activity, catalysed by Asrgl1, enabling them to function as independent metabolic units modifying nutrient concentrations in their microenvironment. This suggests EVs can deliver specific enzymatic activity with potential implications for cell physiology and acellular therapeutics.*

*Comment in Sullivan LB. Extracellular vesicles: Taking metabolism on the road. **NAT CHEM BIOL** 2017; 13(9): 924-925*;

42. Bernstock JD, Ye D, Gessler FA, Lee YJ, Peruzzotti-Jametti L, Baumgarten P, Johnson KR, Maric D, Yang W, Kögel D, **Pluchino S**, Hallenbeck JM. Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. ***SCI REP*** 2017; 7(1): 7425 (IF: **4.259**; times cited *Scopus***: 23**);

41. E Giusto, M Donegà, A Dumitru, G Foschi, M Bianchi, A Russo, S Casalini, T Leonardi, F Biscarini, R Garcia and **S Pluchino**. Interfacing Polymers and Tissues: Quantitative Local Assessment of the Foreign Body Reaction of Mononuclear Phagocytes to Polymeric Materials. ***ADV BIOSYS*** doi: 10.1002/adbi.201700021;

40. Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang CS, Askenase P, Batagov AO, Benito-Martin A, Camussi G, Clayton A, Collino F, Di Vizio D, Falcon-Perez JM, Fonseca P, Fonseka P, Fontana S, Gho YS, Hendrix A, Hoen EN, Iraci N, Kastaniegaard K, Kislinger T, Kowal J, Kurochkin IV, Leonardi T, Liang Y, Llorente A, Lunavat TR, Maji S, Monteleone F, Øverbye A, Panaretakis T, Patel T, Peinado H, **Pluchino S**, Principe S, Ronquist G, Royo F, Sahoo S, Spinelli C, Stensballe A, Théry C, van Herwijnen MJC, Wauben M, Welton JL, Zhao K, Mathivanan S. A novel community driven software for functional enrichment analysis of extracellular vesicles data. ***J EXTRACELL VESICLES*** 2017; 6(1): 1321455 (IF: **14.976**; times cited *Scopus***: 295**)

39. D Drago, V Basso, E Gaude, G Volpe, L Peruzzotti-Jametti, A Bachi, G Musco, A Andolfo, C Frezza, A Mondino and **S Pluchino**. Metabolic determinants of the immune modulatory function of neural stem cells**. *J NEUROINFLAMMATION*** 2016; 13(1): 232 (IF: **4.667**; times cited *Scopus***: 22**);

38. N Gagliano, G Celesti, L Tacchini, **S Pluchino**, M Rasile, V Valerio, L Laghi, V Conte, P Procacci. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma cells: characterization in a 3D-cell culture model. ***WORLD J GASTROENT*** 2016; 22(18): 4466-83 (IF: **2.787**; times cited *Scopus***: 24**);

37. S Stewart, F Gessler, **S Pluchino** and K Moreau. Inside out: unpredicted Annexin A2 localisation on the surface of extracellular vesicles. ***MATTERS*** (https://www.sciencematters.io/articles/201602000015);

36. B Ossola, C Zhao, M Goedert, A Compston, **S Pluchino**, RJM Franklin, MG Spillantini. Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation. ***GLIA.*** 2016; 64(3): 457-71 (IF: **6.031**; times cited *Scopus***: 15**);

35. JD Bernstock, Y Lee, L Peruzzotti-Jametti, N Southall, KR Johnson, D Maric, G Volpe, J Kouznetsova, W Zheng, **S Pluchino**, JM Hallenbeck. A Novel Quantitative High-throughput Screen Identifies Drugs that both Activate SUMO-conjugation via the Inhibition of MicroRNAs 182 and 183 and Facilitate Neuroprotection in a Model of Oxygen and Glucose Deprivation. ***J CEREB BLOOD FLOW METAB*** 2016; 36(2): 426-41 (IF: **5.407**; times cited *Scopus***: 28**) ***Journal COVER IMAGE**;

34. S Tambalo, L Peruzzotti-Jametti, R Rigolio, S Fiorini, P Bontempi, G Mallucci, A Sbarbati, P Marmiroli, G Cavaletti, **S Pluchino*** and P Marzola*. Functional magnetic resonance imaging reveal brain cortex remodelling in a rat model of chronic multiple sclerosis. ***J NEUROSCI*** 2015; 35(27): 10088 –10100 (IF: **6.908**; times cited *Scopus***: 53**) *co-corresponding authors;

33. T Lener, M Gimona, L Aigner, V Börger, G Camussi, N Chaput, FA Court, HA del Portillo, L O'Driscoll, S Fais, JM Falcon-Perez, U Felderhoff, L Fraile, YS Gho, RC Gupta, A Hendrix, DM Hermann, AF Hill, F Hochberg, PA Horn, D de Kleijn, L Kordelas, BW Kramer, EM

Krämer-Albers, S Laner-Plamberger, S Laitinen, T Leonardi, M Lorenowicz, S Kiang Lim, J Lötvall, CA Maguire, I Nazarenko, T Ochiya, T Patel, S Pederson, GK Pocsfalvi, **S Pluchino**, P Quesenberry, IG Reischl, FJ Rivera, R Sanzenbacher, K Schallmoser, I Slaper-Cortenbach, D Strunk, T Tonn, P Vader, BWM van Balkom, M Wauben, S EL Andaloussi, C Théry, E Rohde and B Giebel. Applying extracellular vesicle-based therapeutics in clinical trials an ISEV position paper. ***J EXTRACELL VESICLES*** 2015; 4: 30087 (IF: **14.976**; times cited *Scopus***: 1233**);

32. C Cossetti, N Iraci, TR Mercer, T Leonardi, E Alpi, D Drago, C Alfaro-Cervello, H Saini, M Davis, J Schaeffer, W Muller, JM Garcia-Verdugo, S Mathivanan, A Bachi, A Enright, JS Mattick, **S Pluchino**. Extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signalling in target cells. ***MOL CELL*** 2014; 56(2): 193-204 **DOI: 10.1016/j.molcel.2014.08.020** (IF: 1**4.464**; times cited *Scopus***: 270**; Altmetric score: **360**);

- *This study discovers that extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signalling in target cells, revealing a novel mechanism for cell communication. This process involves EV-associated IFN-γ/Ifngr1 complexes and is essential for the immune modulatory activities of stem cells.*

31. M Donegà, E Giusto, C Cossetti, J Schaeffer and **S Pluchino**. Systemic injection of neural stem/progenitor cells in mice with chronic EAE. ***J VIS EXP*** 2014; (86) (IF: **1.2**; times cited *Scopus***: 17**);

30. F L'Episcopo, C Tirolo, N Testa, S Caniglia, MC Morale, MF Serapide, **S Pluchino**, B Marchetti. Wnt/β-catenin signalling is required to rescue midbrain dopaminergic progenitors and restore nigrostriatal plasticity in ageing mouse model of Parkinson's disease. ***STEM CELLS*** 2014; 32(8): 2147-63 (IF: **7.701**; times cited *Scopus***: 85**);

29. Cerri F, Salvatore L, Memon D, Martinelli Boneschi F, Madaghiele M, Brambilla P, Del Carro U, Taveggia C, Riva N, Trimarco A, Lopez ID, Comi G, **Pluchino S**, Martino G, Sannino A, Quattrini A. Peripheral nerve morphogenesis induced by scaffold micropatterning**.** ***BIOMATERIALS*** 2014; 35(13): 4035-45 (IF: **7.604**; times cited *Scopus***: 35**);

28. F L'Episcopo, C Tirolo, S Caniglia, N Testa, MC Morale, MF Serapide, **S Pluchino**, B Marchetti. Targeting Wnt signaling at the neuroimmune interface in dopaminergic neuroreprotection/repair in Parkinson's disease. ***J MOL CELL BIOL*** 2014; 6(1): 13-26 (IF: **7.308**; times cited *Scopus***: 59**);

27. AF Hill, DM Pegtel, U Lambertz, T Leonardi, L O'Driscoll, **S Pluchino**, D Ter-Ovanesyan, ENM Nolte-'t Hoen. ISEV Position Paper: Extracellular Vesicle RNA analysis and bioinformatics. ***J EXTRACELL VESICLES*** 2013; 2. doi: 10.3402/jev.v2i0.22859 (IF: **14.976**; times cited *Google Scholar***: 164**);

26. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F, **Pluchino S**, Marchetti B. Aging-Induced Nrf2-ARE Pathway Disruption in the Subventricular Zone Drives Neurogenic Impairment in Parkinsonian Mice via PI3K-Wnt/β-Catenin Dysregulation. ***J NEUROSCI*** 2013; 33(4): 1462-148 (IF: **6.908**; times cited *Scopus***: 91**);

25. Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borràs FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, Gabrielsson S, Gho YS, Gupta D, Harsha HC, Hendrix A, Hill AF, Inal JM, Jenster G, Krämer-Albers EM, Lim SK, Llorente A, Lötvall J, Marcilla A, Mincheva-Nilsson L, Nazarenko I, Nieuwland R, Nolte-'t Hoen EN, Pandey A, Patel T, Piper MG, **Pluchino S**, Prasad TS, Rajendran L, Raposo G, Record M, Reid GE, Sánchez-Madrid F, Schiffelers RM, Siljander P, Stensballe A, Stoorvogel W, Taylor D, Thery C, Valadi H, van Balkom BW, Vázquez J, Vidal M, Wauben MH, Yáñez-Mó M, Zoeller M, Mathivanan S. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. ***PLOS BIOL*** 2012; 10(12): e1001450 (IF: **12.690**; times cited *Scopus***: 1099**);

24. Herz J, Reitmeir R, Hagen SI, Reinboth BS, Guo Z, Zechariah A, ElAli A, Doeppner TR, Bacigaluppi M, **Pluchino S**, Kilic U, Kilic E, Hermann DM. Intracerebroventricularly delivered VEGF promotes contralesional corticorubral plasticity after focal cerebral ischemia via mechanisms involving anti-inflammatory actions. ***NEUROBIOL DIS*** 2012; 45(3): 1077-85 (IF: **5.624**; times cited *Scopus***: 54**);

23. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Deleidi M, Serapide MF,

Pluchino S, Marchetti B. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuroprotection and repair. ***J NEUROSCI*** 2012; 32(6): 2062-85 (IF: **6.908**; times cited *Scopus***: 126**);

22. Cusimano M, Biziato D, Brambilla E, Donegà M, Alfaro-Cervello C, Snider S, Salani G, Pucci F, Comi G, Garcia-Verdugo JM, De Palma M, Martino G, **Pluchino S**. Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord. ***BRAIN*** 2012; 135(Pt 2): 447-60 (IF: **9.920**; times cited *Scopus***: 196**);

21. L'episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Morale MC, **Pluchino S**, Marchetti B. A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. ***MOL NEURODEGENER*** 2011; 6: 49 (IF: **4.278**; times cited *Scopus***: 182**);

20. Cimadamore F, Fishwick K, Giusto E, Gnedeva K, Cattarossi G, Miller A, **Pluchino S**, Brill LM, Bronner-Fraser M, Terskikh AV. Human ESC-derived neural crest model reveals a key role for SOX2 in sensory neurogenesis. ***CELL STEM CELL*** 2011; 8(5): 538-51 (IF: **25.421**; times cited *Scopus***: 85**);

19. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C, D'Adamo P, Zardini E, Andreoni L, Ihekwaba AE, Serra PA, Franciotta D, Martino G, **Pluchino S**, Marchetti B. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ***NEUROBIOL DIS*** 2011; 41(2): 508-27 (IF: **5.403**; times cited *Scopus***: 176**);

18. Reitmeir R, Kilic E, Kilic U, Bacigaluppi M, ElAli A, Salani G, **Pluchino S**, Gassmann M, Hermann DM. Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity. ***BRAIN*** 2011; 134(Pt 1): 84-99 (IF: **9.457**; times cited *Scopus***: 135**);

17. Melzi R, Antonioli B, Mercalli A, Battaglia M, Valle A, **Pluchino S**, Galli R, Sordi V, Bosi E, Martino G, Bonifacio E, Doglioni C, Piemonti L. Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice. ***PLOS ONE*** 2010; 5(4): e10357 (IF: **4.411**; times cited *Scopus***: 27**);

16. Gagliano N, Costa F, Cossetti C, Pettinari L, Bassi R, Chiriva-Internati M, Cobos E, Gioia M, **Pluchino S**. Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. ***ONCOL REP*** 2009; 22(6): 1349-56 (IF: **1.524**; times cited *Scopus***: 38**);

15. **Pluchino S**, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, Cossetti C, Del Carro U, Comi G, 't Hart B, Vescovi A, Martino G. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. ***ANN NEUROL*** 2009; 66(3): 343-54 (IF: **9.935**; times cited *Scopus***: 178**)

14. Bacigaluppi M, **Pluchino S**, Peruzzotti-Jametti L, Kilic E, Kilic U, Salani G, Brambilla E, West MJ, Comi G, Martino G, Hermann DM. Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. ***BRAIN*** 2009; 132(Pt 8): 2239-51 (IF: **9.490**; times cited *Scopus***: 328**);

13. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, Rolls A, Mack M, **Pluchino S**, Martino G, Jung S, Schwartz M. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. ***PLOS MED*** 2009; 6(7): e1000113 (IF: **13.050**; times cited *Scopus***: 646**);

12. **Pluchino S**, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, Salani G, Cossetti C, Borsellino G, Battistini L, Ponzoni M, Doglioni C, Garcia-Verdugo JM, Comi G, Manfredi AA, Martino G. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. ***PLOS ONE*** 2009; 4(6): e5959 (IF: **4.351**; times cited *Scopus***: 118**);

11. **Pluchino S**, Muzio L, Imitola J, Deleidi M, Alfaro-Cervello C, Salani G, Porcheri C, Brambilla E, Cavasinni F, Bergamaschi A, Garcia-Verdugo JM, Comi G, Khoury SJ, Martino G. Persistent inflammation alters the function of the endogenous brain stem cell compartment.

BRAIN 2008; 131(Pt 10): 2564-78 (IF: **9.603**; times cited *Scopus***: 210**);

10. Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S, Cattalini A, Esposito M, Stornaiuolo A, Comi G, **Pluchino S**, Mavilio F, Martino G, Furlan R. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. ***GENE THER*** 2008; 15(7): 504-15 (IF: **4.492**; times cited *Scopus***: 94**);

9. Serra PA, **Pluchino S**, Marchetti B, Desole MS, Miele E. The MPTP mouse model: cues on DA release and neural stem cell restorative role. ***PARKINSONISM RELAT DISORD*** 2008; 14 Suppl 2: S189-93 (IF: **1.907**; times cited *Scopus***: 28**);

8. Politi LS, Bacigaluppi M, Brambilla E, Cadioli M, Falini A, Comi G, Scotti G, Martino G, **Pluchino S**. Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. ***STEM CELLS*** 2007; 25(10): 2583-92 (IF: **7.531**; times cited *Scopus***: 104**);

7. Ziv Y, Avidan H, **Pluchino S**, Martino G, Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. ***PROC NATL ACAD SCI U S A*** 2006; 103(35): 13174-9 (IF: **9.643**; times cited *Scopus***: 262**);

6. Amadio S, **Pluchino S**, Brini E, Morana P, Guerriero R, Martinelli Boneschi F, Comi G, Zaratin P, Muzio V, del Carro U. Motor evoked potentials in a mouse model of chronic multiple sclerosis. ***MUSCLE NERVE*** 2006; 33(2): 265-73 (IF: **2.456**; times cited *Scopus***: 23**);

5. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, **Pluchino S**, Martino G, Schwartz M. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. ***MOL CELL NEUROSCI*** 2006; 31(1): 149-60 (IF: **4.607**; times cited *Scopus***: 808**);

4. **Pluchino S**, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, Martinello M, Cattalini A, Bergami A, Furlan R, Comi G, Constantin G, Martino G. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. ***NATURE*** 2005; 436(7048): 266-71 **DOI: 10.1038/nature03889** (IF: **29.273**; times cited *Scopus***: 699**; Accesses: **>3k**; Altimetric score: **30**);

- *This study demonstrates that transplanted neural precursor cells (NPCs) in a mouse model of CNS inflammation promote neuroprotection by modulating the immune response. The NPCs induce apoptosis of encephalitogenic T cells, reducing neural tissue loss and disease-related disability.*

3. **Pluchino S**, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A, Furlan R, Comi G, Vescovi AL, Martino G. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. ***NATURE*** 2003; 422(6933): 688-94 **DOI: 10.1038/nature01552** (IF: **30.979**; times cited *Scopus***: 999**; Accesses: **>5k**; Altimetric score: **41**);

- *This study finds that adult neural stem cells injected into mice with a multiple sclerosis model migrate to damaged areas, differentiate into brain cells, promote remyelination, and improve functional recovery. This suggests a potential therapeutic approach for demyelinating diseases.*

Comment in Steinman L. Medicine: Collateral damage repaired. ***NATURE*** *2003; 422(6933): 671-2*

2. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, **Pluchino S**, Uccelli A, Comi G, Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. ***BRAIN*** 2003; 126(Pt 2): 285-91 (IF: **7.967**; times cited *Scopus***: 118**);

1. Annunziata P, **Pluchino S**, Martino T, Guazzi G. High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis. ***J NEUROIMMUNOL*** 1997; 77(1): 128-33 (IF: **3.577**; times cited *Scopus***: 17**).

REVIEW ARTICLES

64. F Brilot, **S Pluchino**, A Cross, T Kuhlmann, N Isobe, S Pittock, A Prat, S Baranzini, B Bebo, O Ciccarelli, P de Jager, B Engelhardt, E Gray, I Huitinga, M Jagodic, J Morahan, Y Okada, D Reich, L Schirmer, FD Shi, MP Sormani, C Tur, S Zamvil, H Wiendl and A Bar-Or. A strategic roadmap for Human Clinical Translation in Neuroimmunology - Recommendations from the International Society for Neuroimmunology White Paper Task Force. *In preparation*

for ***NAT REV NEUROL*** (IF: **33.100**);

63. M Karbalaee, A Lin, L Peruzzotti-Jametti, S Mozafari and **S Pluchino**. From Insights to Innovations: Evaluating Preclinical Paradigms in Demyelinating Disease Therapeutics. ***LAB ANIMAL***, *in the press* (IF: **6.900**);

62. N Akbar, D Burger, B Bussolati, EI Buzás, RP Carney, YE Cho, TAP Driedonks, JM Falcon-Perez, Y Fujita, DCI Goberdhan, A Hendrix, Y Huang, S Mathivanan, MG Mahoney, S Mohanty, A Möller, N Noren Hooten, **S Pluchino**, C Salomon, AC Torrecilhas, SI Veiga, KW Witwer. Updating MISEV: When, What, How, and Why? ***J EXTRACELL VESICLES*** 2026; 15(2):e70230 **DOI: https://doi.org/10.1002/jev2.70230** (IF: **14.500**);

61. U Gurriaran-Rodriguez, B Bussolati, M Gimona, K Glebov, Y Fujita, A Marcilla, C Neri, QL Fu, S Das, **S Pluchino**, N Zarovni, C Salomon, K Witwer, JM Falcon-Perez. From Lab to Industry: Awareness of the translational potential of Extracellular Vesicles by the ISEV Translation, Regulation and Advocacy Committee (ISEV-TRA). ***J EXTRACELL VESICLES*** 2026; 15 (1): e70220 **DOI: https://doi.org/10.1101/2025.10.31.685739** (IF: **14.500**);

60. E Asimakidou, **S Pluchino**, BA Silva, and L Peruzzotti-Jametti. The Metabolic Engine of Cognition: Microglia-Neuronal Interactions in Brain Health, Aging and Disease. ***NAT METAB*** 2025; 7(12): 2395-2413. **DOI: 10.1038/s42255-025-01409-4** (IF: **20.800**; Altimetric score: **58**);

59. DM Hermann, M Bacigaluppi, CL Bassetti, G Bassotti, J Boltze, A Chan, T Dalkara, A Denes, E Diez-Tejedor, R Dodel, TR Doeppner, E Dzyubenko, A ElAli, T Fulop, A Gerhard, B Giebel, J Gronewold, M Gunzer, T Heinbockel, K Huang, M Iriti, H Karnath, D Kasteleijn-Nolst Trenite, E Kilic, G Lanza, A Liesz, T Ullrich Magnus, J Mandrioli, A Mohamud-Yusuf, T Müller, S Pan, L Peruzzotti-Jametti, **S Pluchino**, R Pluta, A Popa-Wagner, A Rezayof, ML Seghier, X Shu, V Singh, J Sipilä, M Slevin, Y Tang, G Tsivgoulis, G Varrassi, C Wang, B Yilmaz, MS Zaki, J Zhang. Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation. ***EXPLOR NEUROSCI***, 2025; 4: 1006106;

58. EH Moretti, ALY Lin, L Peruzzotti-Jametti, **S Pluchino** and Sabah Mozafari. Neural Stem Cell-Derived Extracellular Vesicles for Advanced Neural Repair. ***J NEUROCHEM*** 2025, 169 (8), e70170 (IF: **4.200**);

57. S Mozafari, L Peruzzotti-Jametti and **S Pluchino**. Mitochondria transfer for myelin repair. ***J CEREB BLOOD FLOW METAB*** 2025, https://doi.org/10.1177/0271678X251325805 (IF: **5.407**; times cited *Scopus***: 6**);

56. MBC Simões-Abade, M Patterer, AM Nicaise, **S Pluchino**. Brain Organoid Methodologies to Explore Mechanisms of Disease in Progressive Multiple Sclerosis. ***FRONT CELL NEUROSCI*** 2024, 18:1488691 (IF: **6.2**; times cited *Scopus***: 8**);

55. DH Hermann, L Peruzzotti-Jametti, B Giebel and **S Pluchino**. Extracellular vesicles set the stage for brain plasticity and recovery by multimodal neuroimmune signalling. ***BRAIN*** 2024; 147: 372-389 (IF: **18.500**; times cited *Scopus***: 47**);

54. CM Willis, AM Nicaise, G Krzak, B Ionescu, A D'Angelo, R Agarwal, **S Pluchino**. Soluble factors influencing the neural stem cell niche in brain physiology, inflammation, and aging. ***EXP NEUROL*** 2022; 355: 114124 (IF: **4.562**; times cited *Scopus***: 14**) ***invited review article**;

53. AM Nicaise, A D'Angelo, CM Willis, RB Ionescu, G Krzak and **S Pluchino**. The Role of Neural Stem Cells in Regulating Scar Formation and Repair. ***CELL TISSUE RES*** 2022; 387 (3): 399-414 (IF: **3.043**; times cited *Scopus***: 10**) ***invited review article**;

52. Smith JA, Nicaise AM, Ionescu RB, Hamel R, Peruzzotti-Jametti L, **Pluchino S**. Stem Cell Therapies for Progressive Multiple Sclerosis. ***FRONT CELL DEV BIOL*** 2021; 9: 696434 (IF: **5.180**; times cited *Scopus***: 43**);

51. Peruzzotti-Jametti L, Willis CM, Hamel R, Krzak G, **Pluchino S**. Metabolic control of smouldering neuroinflammation. ***FRONT IMMUNOL*** 2021; 12: 705920 (IF: **6.429**; times cited *Scopus***: 29**) [The study has an **Altmetric score of 107**];

50. Islam Y, Leach AG, Smith J, **Pluchino S**, Coxon CR, Sivakumaran M, Downing J, Fatokun AA, Teixidò M, Ehtezazi T. Physiological and Pathological Factors Affecting Drug Delivery to

the Brain by Nanoparticles. ***ADV SCI (Weinh)*** 2021; 8(11): e2002085 (IF: **15.840**; times cited *Scopus***: 19**);

49. Y Islam, P Ehtezazi, A Cashmore, E Marinsalda, AG Leach, CR Coxon, AA Fatokun, DW Sexton, I Khan, G Zouganelis, J Downing, **S Pluchino**, M Sivakumaran, M Teixido, T Ehtezazi. The Inclusion of a Matrix Metalloproteinase-9 Responsive Sequence in Self-assembled Peptide-based Brain-Targeting Nanoparticles Improves the Efficiency of Nanoparticles Crossing the Blood-Brain Barrier at Elevated MMP-9 Levels. ***JOURNAL OF PHARMACEUTICAL SCIENCES*** 2021; 110: 1349-1364 (IF: **2.590**; times cited *Scopus***: 2**);

48. G Krzak, CM Willis, JA Smith, **S Pluchino** and L Peruzzotti-Jametti. Succinate receptor SUCNR1 (GPR91) - an emerging regulator of myeloid cell function in neuroinflammation. ***TRENDS IMMUNOL*** 2021; 42(1): 45-58 (IF: **13.422**; times cited *Scopus***: 63**);

47. C Willis, AM Nicaise, JA Smith, L Peruzzotti-Jametti and **S Pluchino**. Harnessing the Neural Stem Cell Secretome for Regenerative Neuroimmunology. ***FRONT CELL NEUROSCI*** 2020; 14: 590960 (IF: **4.555**; times cited *Scopus***: 22**);

46. Marchetti B, Tirolo C, L'Episcopo F, Caniglia S, Testa N, Smith JA, **Pluchino S**, Serapide MF. Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair. ***AGING CELL*** 2020; 19(3):e13101 (IF: **7.080**; times cited *Scopus***: 74**);

45. Y Islam, A Khalid, **S Pluchino**, M Sivakumaran, M Teixidò, A Leach, A Fatokun, J Downing, C Coxon, T Ehtezazi. Development of Brain Targeting Peptide Based MMP-9 Inhibiting Nanoparticles for the Treatment of Brain Diseases with Elevated MMP-9 Activity. ***JOURNAL OF PHARMACEUTICAL SCIENCES*** 2020; 109 (10): 3134-3144 (IF: **2.590**; times cited *Scopus***: 6**);

44. Pluchino S, Smith JA, Peruzzotti-Jametti L. Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. ***TRENDS MOL MED*** 2020; 26(10): 898-912 (IF: **11.099**; times cited *Scopus***: 51**) [The study has an **Altmetric score of 96**];

43. Y Islam, AG Leach, JA Smith, **S Pluchino**, CR Coxon, M Sivakumaran, J Downing, AA Fatokun, M Teixidò, T Ehtezazi. Peptide based drug delivery systems to the Brain. ***NANO EXPRESS*** 2020; 1 (1), 012002 (IF: **1.438**; times cited *Scopus***: 19**);

42. Lilley E, Andrews MR, Bradbury EJ, Elliott H, Hawkins P, Ichiyama RM, Keeley J, Michael-Titus AT, Moon LDF, **Pluchino S**, Riddell J, Ryder K, Yip PK. Refining rodent models of spinal cord injury. ***EXP NEUROL*** 2020; 328: 113273 (IF: **4.483**; times cited *Scopus***: 23**);

41. Willis CM, Nicaise AM, Peruzzotti-Jametti L, **Pluchino S**. The neural stem cell secretome and its role in brain repair. ***BRAIN RES*** 2020; 1729: 146615 (IF: **2.733**; times cited *Scopus***: 58**) ***invited review article**;

40. AM Nicaise, CM Willis, S Crocker and **S Pluchino**. Stem Cells of the Aging Brain. ***FRONT AGING NEUROSCI*** 2020; 12: 247 (IF: **4.504**; times cited *Scopus***: 69**);

39. G Volpe, JD Bernstock, L Peruzzotti-Jametti and **S Pluchino**. Modulation of host immune responses following non-hematopoietic stem cell transplants: Prospects for therapy in Progressive Multiple Sclerosis. ***J NEUROIMMUNOL*** 2019; 331: 11-27 (IF: **3.033**; times cited *Scopus***: 18**) ***invited review article**;

38. L Peruzzotti-Jametti and **S Pluchino**. Targeting mitochondrial metabolism in neuroinflammation: towards a therapy for progressive multiple sclerosis? ***TRENDS MOL MED*** 2018; 24(10): 838-855 (IF: **10.732**; times cited *Scopus***: 60**) ***Journal COVER IMAGE**;

37. F L'Episcopo, S Caniglia, C Tirolo, MF Serapide, N Testa, L Leggio, S Vivarelli, N Iraci, **S Pluchino**, B Marchetti. Microglia Polarization, Gene-Environment Interactions and Wnt/β-catenin Signalling: Emerging Roles of Glia-Neuron and Glia-Stem/Neuroprogenitor Crosstalk for Dopaminergic Neurorestoration in Parkinsonian Brain. ***FRONT AGING NEUROSCI*** 2018; 10: 12 (IF: **4.504**; times cited *Scopus***: 59**);

36. JD Bernstock, W Yang, DG Ye, Y Shen, **S Pluchino**, Y Lee, JM Hallenbeck, W Paschen. SUMOylation in Brain Ischemia: Patterns, Targets, and Translational Implications. ***J CEREB BLOOD FLOW METAB*** 2018; 38(1): 5-16 (IF: **5.407**; times cited *Scopus***: 40**);

35. Scolding NJ, Pasquini M, Reingold SC, Cohen JA on behalf of attendees at the International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. ***BRAIN*** 2017; 140(11): 2776-2796 (IF: **10.292**; times cited *Scopus***: 117**);

34. JD Bernstock, L Peruzzotti-Jametti, D Ye, FA Gessler, Y Lee, JM Hallenbeck and **S Pluchino**. Neural Stem Cell transplantation in Ischemic Stroke: a Role for Preconditioning and Cellular Engineering. ***J CEREB BLOOD FLOW METAB*** 2017; 37(7): 2314-2319 (IF: **5.407**; times cited *Scopus***: 89**);

33. Ballini A, Scacco S, Coletti D, **Pluchino S**, Tatullo M. Mesenchymal Stem Cells as Promoters, Enhancers, and Playmakers of the Translational Regenerative Medicine. ***STEM CELLS INT*** 2017; 2017: 3292810 (IF: **2.806**; times cited *Scopus***: 67**);

32. N Iraci, T Leonardi, F Gessler, B Vega and **S Pluchino**. Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles. ***INT J MOL SCI*** 2016; 17(2) ***invited review article** (IF: **2.862**; times cited *Scopus***: 191**);

31. A Fuster-Matanzo, F Gessler, T Leonardi, N Iraci and **S Pluchino**. Acellular Approaches for Regenerative Medicine: on the Verge of Clinical Trials with Extracellular Membrane Vesicles? ***STEM CELL RES THER*** 2015; 6: 227 (IF: **3.370**; times cited *Scopus***: 48**) ***invited review article**;

30. Smith JA, Leonardi T, Huang B, Iraci N, Vega B, **Pluchino S**. Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases. ***BIOGERONTOLOGY*** 2015; 16(2): 147-85 (IF: **3.190**; times cited *Scopus***: 45**);

29. Mallucci G, Peruzzotti-Jametti L, Bernstock JD, **Pluchino S**. The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. ***PROG NEUROBIOL*** 2015; 127-128: 1-22 (IF: **10.301**; times cited *Scopus***: 124**) ***invited review article and Journal COVER IMAGE**;

28. Tannahill GM, Iraci N, Gaude E, Frezza C, **Pluchino S**. Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. ***FRONT IMMUNOL*** 2015; 6: 106 (IF: **6.429**; times cited *Scopus***: 38**);

27. Giusto E, Donegà M, Cossetti C and **Pluchino S**. Neuro-immune interactions of neural stem cell transplants: from animal disease models to human trials. ***EXP NEUROL*** 2014; 260: 19-32 ***invited review article** (IF: **4.645**; times cited *Scopus***: 68**);

26. DM Hermann, L Peruzzotti-Jametti, J Schlechter, JD Bernstock, TR Doeppner, **S Pluchino**. Neural precursor cells in the ischemic brain - integration, cellular crosstalk and consequences for stroke recovery. ***FRONT CELL NEUROSCI*** 2014; 8: 291 (IF: **4.171**; times cited *Scopus***: 73**);

25. Peruzzotti-Jametti L, Donegá M, Giusto E, Mallucci G, Marchetti B, **Pluchino S**. The role of the immune system in central nervous system plasticity after acute injury. ***NEUROSCIENCE*** 2014; 283: 210-21 (IF: **3.122**; times cited *Scopus***: 77**);

24. D Drago, C Cossetti, N Iraci, E Gaude, G Musco, A Bachi and **S Pluchino**. The stem cell secretome and its role in brain repair. ***BIOCHIMIE*** 2013; 95(12): 2271-85 (IF: **3.142**; times cited *Scopus***: 311**) ***invited review article**;

23. **Pluchino S** and Cossetti C. How stem cells speak with host immune cells in inflammatory brain diseases. ***GLIA*** 2013; 61(9): 1379-401 (IF: **5.406**; times cited *Scopus***: 106**) ***invited review article and Journal COVER IMAGE**;

22. Marchetti B, L'Episcopo F, Morale MC, Tirolo C, Testa N, Caniglia S, Serapide MF and **S Pluchino**. Uncovering Novel Actors in Astrocyte-Neuron Crosstalk in Parkinson's Disease: the Wnt/β-Catenin Signaling Cascade as Common Final Pathway for Neuroprotection and Self-Repair. ***EUR J NEUROSCI*** 2013; 37(10): 1550-63 (IF: **3.879**; times cited *Scopus***: 84**) ***invited review article**;

21. Marchetti B, **Pluchino S**. Wnt your brain be inflamed? Yes, it Wnt! ***TRENDS MOL MED*** 2013; 19(3): 144-56 (IF: **10.142**; times cited *Scopus***: 149**);

20. Cossetti C, Alfaro-Cervello C, Donegà M, Tyzack G, **Pluchino S**. New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies. ***CELL TISSUE RES***

2012; 349(1): 321-9 (IF: **3.677**; times cited *Scopus***: 56**);

19. S Bolton, D Hassall, D Hildebrand, W Bruck, JK Huang, **S Pluchino**, T McKevitt, J Parry, M McFarlane, R Fagg, A Rulois. Anti-inflammatory Disease Therapies: Challenges and Strategies in Drug Development. ***TOXICOL PATHOL*** 2012; 40: 122-125 (IF: **2.150**; times cited *Google Scholar***: 1**);

18. Cossetti C, Smith JA, Iraci N, Leonardi T, Alfaro-Cervello C, **Pluchino S**. Extracellular membrane vesicles and immune regulation in the brain. ***FRONT PHYSIOL*** 2012; 3: 117 (IF: **4.134**; times cited *Scopus***: 44**);

17. Martino G, **Pluchino S**, Bonfanti L, Schwartz M. Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. ***PHYSIOL REV*** 2011; 91(4): 1281-304 (IF: **26.066**; times cited *Scopus***: 213**);

16. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A; MSCT Study Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. ***MULT SCLER*** 2010; 16(4): 503-10 (IF: **3.312**; times cited *Scopus***: 183**);

15. **Pluchino S**, Cusimano M, Bacigaluppi M, Martino G. Remodelling the injured CNS through the establishment of atypical ectopic perivascular neural stem cell niches. ***ARCH ITAL BIOL*** 2010; 148(2): 173-83 (IF: **0.778**; times cited *Scopus***: 29**);

14. **Pluchino S**, Zanotti L, Brini E, Ferrari S, Martino G. Regeneration and repair in multiple sclerosis: the role of cell transplantation. ***NEUROSCI LETT*** 2009; 456(3): 101-6 (IF: **1.925**; times cited *Scopus***: 60**);

13. **Pluchino S**, Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. ***J NEUROL SCI*** 2008; 265(1-2): 105-10 (IF: **2.359**; times cited *Scopus***: 66**);

12. Bacigaluppi M, **Pluchino S**, Martino G, Kilic E, Hermann DM. Neural stem/precursor cells for the treatment of ischemic stroke. ***J NEUROL SCI*** 2008; 265(1-2): 73-7 (IF: **2.359**; times cited *Scopus***: 106**);

11. **Pluchino S**, Zanotti L, Martino G. Rationale for the use of neural stem/precursor cells in immune-mediated demyelinating disorders. ***J NEUROL*** 2007; 254 Suppl 1: I23-I28 (IF: **3.578**; times cited *Scopus***: 9**);

10. Martino G, **Pluchino S**. The therapeutic potential of neural stem cells. ***NAT REV NEUROSCI*** 2006; 7(5): 395-406 (IF: **23.054**; times cited *Scopus***: 679**);

9. **Pluchino S**, Martino G. The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders. ***J NEUROL SCI*** 2005; 233(1-2): 117-9 (IF: **2.080**; times cited *Scopus***: 48**);

8. **Pluchino S**, Zanotti L, Deleidi M, Martino G. Neural stem cells and their use as therapeutic tool in neurological disorders. ***BRAIN RES BRAIN RES REV*** 2005; 48(2): 211-9 (IF: **4.617**; times cited *Scopus***: 103**);

7. **Pluchino S**, Bacigaluppi M, Bucello S, Butti E, Deleidi M, Zanotti L, Martino G, Furlan R. Gene and stem cell therapy for autoimmune demyelination. ***ERNST SCHERING RES FOUND WORKSHOP*** 2005; (53): 133-46;

6. Furlan R, Butti E, **Pluchino S**, Martino G. Gene therapy for autoimmune diseases. ***CURR OPIN MOL THER*** 2004; 6(5): 525-36 (IF: **3.452**; times cited *Scopus***: 10**);

5. **Pluchino S**, Furlan R, Martino G. Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies. ***CURR OPIN NEUROL*** 2004; 17(3): 247-55 (IF: **4.017**; times cited *Scopus***: 59**);

4. **Pluchino S**, Zanotti L, Martino G. Antibodies and myelination: facts and misacts. ***NEUROL SCI.*** 2003; 24 Suppl 4: S231-3 (IF: **1.315**; times cited *Scopus***: 0**);

3. Furlan R, **Pluchino S**, Martino G. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. ***CURR OPIN NEUROL*** 2003; 16(3): 385-92 (IF: **4.107**; times cited *Scopus***: 13**);

2. Furlan R, **Pluchino S**, Martino G. Gene therapy-mediated modulation of immune processes in the central nervous system. ***CURR PHARM DES*** 2003; 9(24): 2002-8 (IF: **5.550**; times cited

*Scopus***: 17**);

1. Furlan R, **Pluchino S**, Marconi PC, Martino G. Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. ***METHODS MOL BIOL*** 2003; 215: 279-89 (IF: **13.920**; times cited *Scopus***: 23**);

INVITED NEWS & VIEWS OR COMMENTARIES

18. L Peruzzotti-Jametti and **S Pluchino**. Mitochondrial stress response drives microglial senescence. ***NAT NEUROSCI*** 2026, *in the press* (IF: **19.500**);

17. S Pluchino and Sabah Mozafari. Early human intrathecal MSC study in progressive MS faces delivery challenges. ***NEUROLOGY*** 2026, *in the press* (IF: **9.000**);

16. S Pluchino and Cory M. Willis. Targeting mitochondrial Kv1.3 enables precise autoreactive T cell therapy for multiple sclerosis. ***EMBO MOL MED*** 2025; 17(11): 2850–2852 **DOI 10.1038/s44321-025-00306-3** (IF: **8.300**);

15. S Pluchino and Cory M. Willis. Cholesterol fuels microglia in chronic stroke. ***NAT METAB*** 2025; 7, 1970–1971 **DOI: 10.1038/s42255-025-01362-2** (IF: **21.200**);

14. RC Paolicelli and **S Pluchino**. Complex roles for mitochondrial complexes in microglia. ***NAT METAB*** 2024*;* 6: 1426–1428 (IF: **20.800**);

13. S Pluchino and I Lombardi. Crossing species boundaries in Regenerative Neuroscience with rat-mouse brain chimeras. ***LAB ANIM*** 2024; 53: 179–180 (IF: **6.900**);

12. S Pluchino and P Prasad. Oligodendroglia-to-Neuron Material Transfer lights up the Mouse CNS. ***J EXP MED*** 2023; 220 (7): e20230489 (IF: **17.579**);

11. V Fossati, L Peruzzotti-Jametti, and **S Pluchino**. A neural stem cell treatment for progressive multiple sclerosis. ***NAT MED*** 2023; 29: 27–28 (IF: **87.241**);

10. L Peruzzotti-Jametti and **S Pluchino**. Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time. ***MS JOURNAL*** 2022; 9: 1328-1329 (IF: **5.412**);

9. S Pluchino and AM Nicaise. NSCs: sentinel cells of the brain. ***CELL STEM CELL*** 2021; 28 (2): 177-179 (IF: **20.860**);

8. **Pluchino S** and Willis C. Intrinsic antiviral immunity drives neurodegeneration in Alzheimer disease. ***J CLIN INVEST*** 2020; 130(4): 1622-1624 (IF: **12.282**);

7. **S Pluchino** and JA Smith. Explicating Exosomes: reclassifying the rising stars in intercellular communication. ***CELL*** 2019; 177(2): 225-227 (IF: **38.637**);

6. **S Pluchino** and L Peruzzotti-Jametti. Interleukin-four induced one (IL4I1) promotes central nervous system remyelination. ***BRAIN*** 2016; 139(Pt 12): 3052-3054 (IF: **10.103**);

5. **S Pluchino**, L Peruzzotti-Jametti and C Frezza. Astrocytes power fuel neurons during stroke. ***SWISS MED WKLY*** 2016; 146: w14374 (IF: **2.086**);

4. **S Pluchino** and L Peruzzotti-Jametti. Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons ***BRAIN*** 2013; 136: 3525-3527 (IF: **9.915**);

3. **Pluchino S** and Alfaro-Cervello C. Cyclooxygenase (COX)-1 takes control of adult hippocampal neurogenesis. ***CELL CYCLE***. 2011; 10(19): 3229 (IF: **5.359**);

2. **Pluchino S** and Martino G. Neural stem cell-mediated immunomodulation: repairing the haemorrhagic brain. ***BRAIN*** 2008; 131(Pt 3): 604-5 (IF: **9.603**);

1. Martino G and **Pluchino S**. Neural stem cells: guardians of the brain. ***NAT CELL BIOL*** 2007; 9(9): 1031-4 (IF: **17.623**).

BOOK CHAPTERS

18. ME Garcia-Segura, **S Pluchino**, L Peruzzotti-Jametti. *Metabolic Control of Microglia*. In: ***MICROGLIA: PHYSIOLOGY, PATHOPHYSIOLOGY AND THERAPEUTIC POTENTIAL***. (Eds) Marie-Ève Tremblay and Alexei Verkhratsky. Springer Link 2024, pp607-622;

17. N Yazdanpanah, […], **S Pluchino** et al. *Global Challenges after a Global Challenge: Lessons Learned from the COVID-19 Pandemic*. In: ***The COVID-19 Aftermath***. Advances in Experimental Medicine and Biology. N. Rezaei (ed.). Springer Nature Switzerland AG 2024, pp 1457;

16. P Prasad, L Roth, RB Ionescu, C Willis, A Nicaise, G Krzak, L Peruzzotti-Jametti, **S Pluchino**. *Neuroinflammation in Multiple Sclerosis*. In: ***ENCYCLOPEDIA OF CELL BIOLOGY*** (Second Edition). (Eds) Ralph A. Bradshaw, Gerald W. Hart and Philip D. Stahl. Science Direct publisher 2023, pp 666-686;

15. RB Ionescu, C Willis, AM Nicaise, G Krzak, R Hamel, L Peruzzotti-Jametti, **Stefano Pluchino**. *Multiple sclerosis and neuromyelitis optica spectrum disorders*. In: ***NEUROBIOLOGY OF BRAIN DISORDERS***. (Eds) Academic Press 2023/1/1, pp 575-608;

14. A Braga, G Manferrari, JA Smith and **S Pluchino**. *Extracellular Vesicles (EVs): Naturally Occurring Vehicles for RNA Nanotherapeutics*. In: ***RNA NANOTECHNOLOGY AND THERAPEUTICS*** (2nd edition). (Eds) Peixuan Guo, Kirill A. Afonin. CRC Press 2022, pp;

13. JA Smith, A Braga, R Hamel, C Rutigliani, B Yu, L Peruzzotti-Jametti and **S Pluchino**. *The therapeutic potential of exogenous adult stem cells for the injured central nervous system*. In: ***HANDBOOK OF INNOVATIONS IN CENTRAL NERVOUS SYSTEM REGENERATIVE MEDICINE***. (Ed)s Antonio Salgado. Academic Press 2020, pp 147-258;

12. G Volpe, JD Bernstock, L Peruzzotti-Jametti and **S Pluchino**. *Past, Present and Future of Cell-Based Therapy in Progressive Multiple Sclerosis*. In: ***STEM CELL GENETICS FOR BIOMEDICAL RESEARCH: PAST, PRESENT, AND FUTURE***. (Eds) Raul Delgado-Morales; Springer Nature publisher 2018, pp 87-132;

11. JA Smith, C Alfaro, C Cossetti, N Iraci, M Stefanini, **S Pluchino**. *Extracellular membrane vesicles (EMVs) and EMV-based therapeutics for brain diseases*. In: ***RNA NANOTECHNOLOGY AND THERAPEUTICS.*** (Eds) P Guo. Taylor & Francis publishers 2013, pp 409-428;

10. T Ben-Hur, **S Pluchino**, G Martino. *Immune Modulation and Repair Following Neural Stem Cell Transplantation*. In: ***MYELIN REPAIR AND NEUROPROTECTION IN MULTIPLE SCLerosis***. Springer US 2013, pp153-178;

9. N Iraci, GE Tyzack, C Cossetti, C Alfaro-Cervello and **S Pluchino**. *Viral Manipulation of neural stem/precursor cells*. In: ***VIRAL VECTOR APPROACHES IN NEUROBIOLOGY AND BRAIN DISEASES***. (Eds) R Brambilla. Humana Press publishers 2013, pp 269-288;

8. M Donegà, E Giusto, C Cossetti and **S Pluchino**. *Systemic Neural Stem Cell-Based Therapeutic Interventions for Inflammatory CNS Disorders*. In: ***NEURAL STEM CELLS - NEW PERSPECTIVES***. (Eds) L Bonfanti. InTech - Open Access Publisher 2013, pp 287-348;

7. C Alfaro-Cervello, C Cossetti, E Giusto, M Donegà and **S Pluchino**. *New prospects for neural stem cell therapies of nervous system diseases toward the establishment of atypical ectopic perivascular stem cell niches.* **In: *REGENERATIVE MEDICINE AND CELL THERAPY***. (Eds) H Baharvand. Springer, Heidelberg publishers 2013, pp 23-40;

6. S Pluchino, R Furlan, L Muzio, and G Martino. *Tissue regeneration and repair in multiple sclerosis: the role of neural stem cells*. In: ***MULTIPLE SCLEROSIS: RECOVERY OF FUNCTION AND NEUROREHABILITATION***. (Eds) J Kesselring, G Comi & A J Thompson. Cambridge University Press, Cambridge, UK, 2010, pp 60-66;

5. S Pluchino, L Zanotti and G Martino. *Stem Cells, Therapeutic Use for Myelin Repair in Autoimmune Demyelinating Disorders*. In: ***ENCYCLOPEDIA OF NEUROSCIENCE***. (Eds) M.D. Binder, N. Hirokawa, U. Windhorst, M.C. Hirsch. Springer, Heidelberg. 2009, pp. 234-241;

4. S Pluchino, M Bacigaluppi, S Bucello, E Butti, M Deleidi, L Zanotti, G Martino, R Furlan. *Gene and stem cell therapy for autoimmune demyelination*. ***ERNST SCHERING RES FOUND WORKSHOP***. 2005; (53): 133-46;

3. R Furlan, E Butti, **S Pluchino** and G Martino. *Gene therapy approaches for autoimmune diseases of central nervous system and other tissues*. In ***GENE THERAPY OF AUTOIMMUNE DISEASE***. (Eds) Gerald J. Prud'homme. Eurekah.com and Kluver Academic/Plenum publishers. 2005, pp 1-8;

2. S Pluchino, M Bacigaluppi, S Bucello, E Butti, M Deleidi, L Zanotti, G Martino, R Furlan. *Gene and Stem cell therapy for autoimmune demyelination*. In: ***OPPORTUNITIES AND CHALLENGES OF THE THERAPIES TARGETING CNS REGENERATION***. Springer. 2005, pp 133-146;

1. P Annunziata, **S Pluchino**. *Sclerosi laterale amiotrofica associata a IgA monoclonale con anticorpi anti-GM1 e anti-neurofilamenti*. ***LIBRO GIUBILARE DEDICATO A G.C. GUAZZI***. (Eds) A Rossi and P Annunziata. Tipografia Senese, Siena 1997, pp 71-78.

IN THE MEDIA (selected)

CAMBRIDGE NEUROSCIENCE https://neuroscience.cam.ac.uk/member/pluchino/
CAMBRIDGE IMMUNOLOGY NETWORK https://www.immunology.cam.ac.uk/Networkdirectory/spp24%40cam.ac.uk
NIHR CAMBRIDGE BIOMEDICAL RESEARCH CENTRE – NEUROSCIENCE THEME https://cambridgebrc.nihr.ac.uk/research/neuroscience/contact-details/
WIKIPEDIA https://en.wikipedia.org/wiki/Stefano_Pluchino)
TOP ITALIAN SCIENTISTS https://topitalianscientists.org/tis/40136/Stefano%20Pluchino%20-%20Top%20Italian%20Scientist%20in%20Neurosciences%20&%20Psychology

2016 NEWS MEDICAL LIFE SCIENCES *Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino* (https://www.news-medical.net/news/20160105/Using-stem-cells-to-tackle-CNS-disorders-an-interview-with-Dr-Stefano-Pluchino.aspx)
2017 TECHNOLOGY NETWORKS INTERVIEW
(https://www.technologynetworks.com/diagnostics/videos/the-immune-modulatory-functions-of-neural-stem-cells-279532)
2018 LA SICILIA *Lotta "personalizzata" con staminali alla sclerosi multipla: tre "cervelli" siciliani ci stanno lavorando* (https://www.lasicilia.it/sicilians/lotta-personalizzata-con-staminali-alla-sclerosi-multipla-tre-cervelli-siciliani-ci-stanno-lavorando-890815/)
2018 CAMBRIDGE INDEPENDENT *University of Cambridge researchers find reprogramming skin cells could help multiple sclerosis patients* (https://www.cambridgeindependent.co.uk/business/university-of-cambridge-researchers-find-reprogramming-skin-cells-could-help-multiple-sclerosis-patients-9053084/)
2021 CAMBRIDGE NEUROSCIENCE Interdisciplinary Seminar Series (https://www.youtube.com/watch?v=g86ZN-rE3qM)
2022 Rita Levi Montalcini Lecture at Annual Congress of the Italian MS Foundation (https://www.youtube.com/watch?v=B4x4-E3d5Rk)
2022 Preserving the Brain Forum (https://www.youtube.com/watch?v=CdLWj7CRsf4)
2023 University of Cambridge *Early-stage stem cell therapy trial shows promise for treating progressive MS* (https://www.cam.ac.uk/research/news/early-stage-stem-cell-therapy-trial-shows-promise-for-treating-progressive-ms)
2023 The Guardian *Doctors encouraged by early-stage trial of MS stem cell therapy* (https://www.theguardian.com/science/2023/nov/27/doctors-encouraged-by-early-stage-trial-of-ms-stem-cell-therapy)
2023 National MS Society *Early Stem Cell Trial Shows Safety in People with Secondary Progressive MS* (https://www.nationalmssociety.org/About-the-Society/News/Early-Stem-Cell-Trial-Shows-Safety-in-People-with)
2023 EuroNews *Stem cell therapy trial shows 'safe and promising' early results for MS treatment* (https://www.euronews.com/next/2023/11/29/ms-stem-cell-therapy-trial-shows-safe-and-promising-early-results-for-treatment)
2023 Medical News Today *Stem cell therapy could protect cognition in progressive MS* (https://www.medicalnewstoday.com/articles/stem-cell-therapy-could-protect-cognition-in-progressive-ms)

2023 European Pharmaceutical Review *Could stem cell therapy stabilise MS progression?* (https://www.europeanpharmaceuticalreview.com/news/189321/could-stem-cell-therapy-stabilise-ms-progression/)
2023 The Conversation *Stem cell therapy shows promise for treating multiple sclerosis – new study* (https://theconversation.com/stem-cell-therapy-shows-promise-for-treating-multiple-sclerosis-new-study-218528)
2023 European Scientist *Revolutionary new treatment for multiple sclerosis* (https://www.europeanscientist.com/en/public-health/revolutionary-new-treatment-for-multiple-sclerosis/)
2023 Multiple Sclerosis News Today *Stem cell therapy well tolerated in SPMS clinical trial* (https://multiplesclerosisnewstoday.com/news-posts/stem-cell-therapy-well-tolerated-secondary-progressive-ms-trial/)
2023 EurekAlert! *Early-stage stem cell therapy trial shows promise for treating progressive MS* (https://www.eurekalert.org/news-releases/1008883)
2023 ITV News *Multiple sclerosis breakthrough could lead to treatments that halt disease's progression*
(https://www.itv.com/news/2023-11-27/ms-breakthrough-could-lead-to-treatments-that-halt-diseases-progression)
2024 BeewellwithMS *New Treatment Horizons in MS - Regenerative Neuroimmunology with Cambridge Prof Stefano Pluchino* (https://www.beewellwithms.com and https://open.spotify.com/episode/7jc6JHbF6QghXxVSE9uM6i?si=1df0513657124786)
2024 Regenerative Medicine Global *A Successful and Safe Stem Cell Therapy for Progressive MS* (https://reachmd.com/programs/neurofrontiers/a-successful-and-safe-stem-cell-therapy-for-progressive-ms/17928/ and https://www.youtube.com/watch?v=sH0oR65nFZo)
2024 Overcoming MS *Advanced cell therapy for progressive MS with Dr Stefano Pluchino* (https://overcomingms.org/live-well/resources/podcast/s6e06-advanced-cell-therapy-for-progressive-ms-with-dr-stefano-pluchino/)
2024 The Empowering Neurologist *Inside the Study That Reveals Promise for Treating Multiple Sclerosis with Stem Cells | Dr. Pluchino*
(https://www.youtube.com/watch?v=tRkmKVZlOuo)
2025 ECTRIMS MS Spotlight - *Stem Cells: From Science Fiction to the Clinic* (https://ectrims.eu/stem-cells-from-science-fiction-to-the-clinic/?fbclid=IwY2xjawKSr9lleHRuA2FlbQIxMQBicmlkETFtZzh3czlxNDdvWURxRmhqAR7OGNinWfYcGqXgskq81OXEOADh_zJLuJLVSREuf7-w-zu8232Tc_sn-dxDEA_aem_QFk7WzN481J9XYFQmy1H_g)
2025 International Progressive MS Alliance *Putting people with MS at the centre of research* (https://www.youtube.com/watch?v=QjpldX1wo1s)
2025 MS Living Well podcast with Dr Barry Singer *Repair, Reset, Reimagine: Stem Cell Therapies for Multiple Sclerosis* (https://www.mslivingwell.org/2025/07/22/stem-cells/)
2025 EurekAlert! *International Progressive MS Alliance announces experimental medicine trial awardees for three development projects* (https://www.eurekalert.org/news-releases/1081948)
2025 EurekAlert! *Cambridge study shows stem cell grafts can restore myelin in MS lesions in mice* (https://www.eurekalert.org/news-releases/1089896)
2025 EurekAlert! *'Disease in a dish' study of progressive MS finds critical role for unusual type of brain cell'* (https://www.eurekalert.org/news-releases/1089896)
2025 LA SICILIA '*Stefano Pluchino, the doctor from Ragusa who can eradicate multiple sclerosis'* (https://www.lasicilia.it/news/attualita/3011721/stefano-pluchino-the-doctor-from-ragusa-who-can-eradicate-multiple-sclerosis.html)
2026 The National News '*Could stem cell treatments bring about MS breakthrough?'*
(https://www.thenationalnews.com/news/uae/2026/01/24/could-stem-cell-treatments-offer-breakthrough-in-treatment-of-ms/)

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),
DICHIARA
l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Cambridge 8th April 2026

Firma:

Peter Spaeth, PhD, FAMH Immunology, graduated in Biochemistry from the Swiss Federal Institute of Technology in Zurich. After his postdoctoral years he joined the plasma fractionation site of the Swiss Red Cross Blood Transfusion Service (BSD-SRC) in Bern, Switzerland. There were exciting times, as the first fully active intravenous immunoglobulin (IVIG) developed by BSD-SRC started clinical use (later known as Sandoglobulin). This IVIG became the one with which the immunomodulatory potential of IVIG was demonstrated by Paul Imbach working at the Pediatric Clinic of the University Hospital in Bern. Peter's duty was to build up and run as accredited head a clinical immunology diagnostic laboratory with a particular focus on primary immune deficiencies and diseases with a derailed complement system. The focus on complement primarily served to study the exciting beneficial and the known and unknow severe adverse effects of IVIG therapies. His work allowed Peter acquiring and combining knowledge in manufacturing, pathogen safety and clinical use of IVIG and other plasma products. Over the years Peter was involved in many IVIG studies, e.g. from scratch on the side of the manufacturer in the IVIG Guillain-Barré/plasma exchange study lead by Richard Hughes. Furthermore, Peter recalls lengthy discussions with several leading Italian neurologists.

In the 90's, for a few years, Peter was invited professor at the Scuola di Specializzazione, Medical Faculty, Università degli Study, Ancona. His teaching efforts for Italian medical students promoted him to the edge of becoming an Italian citizen: he received his 'Codice Fiscale'.

The expertise of the clinical immunology diagnostic laboratory allowed Peter to build up an international network of collaborations. Publications in various fields of medicine were the basis for a successful application for venia docendi in immunology at the Faculty of Medicine, University of Bern. After quitting employment, Peter joined the Institute of Pharmacology of his University. Autum 2025 he changed over to the club of emeriti of the university.

Bern, 14 April 2006

Personal details

Name: Marvin M. van Luijn, PhD
Birth date: 09/12/81
Gender: Male

Master's degree: University of Utrecht, Utrecht, NL
Main subject: Biomedical Sciences (Biology of Disease)

PhD degree: VU Amsterdam, Amsterdam, NL
Date: 15/02/12
Supervisors: Dr. van Ham, Dr. van de Loosdrecht and Prof. Ossenkoppele
Thesis title: Impaired antigen presentation as escape mechanism in AML

Work experience

Position	Period	Institution
Associate professor	2025 -	Department of Immunology, Erasmus MC, Rotterdam, NL
Assistant professor	2020 - 2024	Department of Immunology, Erasmus MC, Rotterdam, NL
Workgroup leader	2019 -	Department of Immunology, Erasmus MC, Rotterdam, NL
Management team member	2019 -	MS Center ErasMS, Erasmus MC, Rotterdam, NL
Senior Postdoc	2016 - 2019	Department of Immunology, Erasmus MC, Rotterdam, NL
Visiting scientist	2013 - 2014 (18 months)	Neefjes group, Netherlands Cancer Institute, Amsterdam NL
Junior postdoc	2012 - 2015	Department of Immunology, Erasmus MC, Rotterdam, NL
Visiting scientist	2010 (3 months)	van Hall & van Veelen group, LUMC, Leiden, NL
Visiting scientist	2006 (1 month)	Ostrand-Rosenberg group, University of Maryland, US

Research

I lead my own immunological research group (mostly funded by (inter)national grants on which I am [co-]PI, €7.1M) on how B and T cells interact to infiltrate the brain and instigate pathology in people with multiple sclerosis (MS). I learnt state-of-the-art technology and elucidated mechanisms of HLA class II-driven T-cell responses in leukemia (visiting one international and two national laboratories). Motivated by the findings during my PhD (10 publications as first author), I joined the department of Immunology as part of MS Center ErasMS at the Erasmus MC to understand these processes in MS. My group identified a type of B cells that not only forces T cells to enter the brain, but also gradually accumulates within the brain itself to mature into antibody producers as a disease hallmark. In the last years, we have developed disease-relevant human *in vitro* models and applied *ex vivo* single cell technologies to unique biomaterials from different MS cohorts to find triggers underlying these events. We uncovered intrinsic (genetic variants) and extrinsic (EBV, steroids) factors that selectively influence B- and T-cell interaction in MS. I was promoted to assistant professor in 2020 and became associate professor in 2025. I got a ZonMw-Vidi grant in 2020 and the Dutch MS-Fellowship award in 2022. I have 49 articles published in peer-reviewed journals (12 as first, 7 as second, 23 as last author). I am a PI in 3 worldwide MS consortia (e.g. WP leader in Europe Health-funded project), member of the Scientific Advisory Committee of Nationaal MS Fonds and frequently asked to give lectures at both national and international level. I am incoming board member of the Dutch Society of Immunology (DSI). Currently, I supervise 4 PhD students, 5 postdocs and 3 technicians. I successfully supervised 6 PhD students (5 as copromotor) and 2 postdocs.

Publications (Top-5)

van Langelaar J, van der Vuurst de Vries RM, Janssen M, Wierenga-Wolf AF, Spilt IM, Siepman TA, Dankers W, Verjans GM, de Vries HE, Lubberts E, Hintzen RQ, **van Luijn MM**. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain 2018; 141(5):1334-49

van Langelaar L, Rijvers L, Janssen M, Wierenga-Wolf AF, Melief MJ, Siepman TA, de Vries HE, Unger PA, van Ham SM, Hintzen RQ, **van Luijn MM**. Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis. Ann Neurol 2019; 86(2):264-78

van Langelaar J, Rijvers L, Smolders J, **van Luijn MM**. B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol 2020; 11:760

Bogers L, Engelenburg HJ, Janssen M, Unger PPA, Melief MJ, Wierenga-Wolf AF, Hsiao CC, Mason MRJ, Hamann J, van Langelaar J, Smolders J, **van Luijn MM**. Selective emergence of antibody-secreting cells in the multiple sclerosis brain. EBioMed 2023; 89:104465

Ingelfinger F, Kuiper KL, Ulutekin C, Rindlisbacher L, Mundt S, Gerdes LA, Smolders J, **van Luijn MM***, Becher B*. Twin Study dissects CXCR3+ memory B cells as non-heritable feature in multiple sclerosis. Med 2024; 5(4):368-73.e3

Total

Peer-reviewed publications (any position author)	51
Peer-reviewed publications (first author)	12
Peer-reviewed publications (second author)	7
Peer-reviewed publications (penultimate author)	0
Peer-reviewed publications (last author)	24
Other examples: books, patents, …	1

Grant allocation

Years	Funding source	Own share of grant (€)	Total grant (€)	Role on project
2026 – 2030	ZonMw Open Competition	1,050,000	1,050,000	Co-PI
2026 – 2029	Nationaal MS Fonds	433,330	433,330	PI
2026 – 2030	Nationaal MS Fonds	407,047	407,047	Co-PI
2026 – 2029	Nationaal MS Fonds	350,000	350,000	Co-PI
2025 – 2029	Stichting MoveS	352,565	352,565	PI
2025 – 2026	Stichting MS Research	5,000	10,000	PI
2024 – 2025	Stichting de Merel	60,000	60,000	PI
2024 – 2025	Stichting MoveS	250,000	250,000	Co-PI
2023 – 2028	Horizon Europe - Health	447,964	7,103,102	WP (co-)leader
2023 – 2026	Nationaal MS Fonds	347,953	347,953	PI
2022 – 2027	Health~Holland TKI-LSH	417,500	417,500	PI
2023 – 2025	Idorsia Pharmaceuticals Ltd	120,000	120,000	PI
2023 – 2025	Novartis	50,000	50,000	PI
2021 – 2025	Erasmus MC Foundation	500,000	500,000	PI
2021 – 2023	GlaxoSmithKline	254,180	254,180	PI
2021 – 2026	ZonMw - Vidi grant	800,000	800,000	PI
2021 – 2025	Stichting MS Research	284,102	284,102	PI
2020 – 2021	Stichting MS Research	17,000	17,000	PI
2020	Idorsia Pharmaceuticals Ltd	45,000	45,000	PI
2018 – 2020	EMD Serono	196,722	196,722	PI
2018 – 2022	Stichting MS Research	249,474	249,474	PI
2016 – 2020	Stichting MS Research	249,170	249,170	PI
2015 – 2016	Stichting Zabawas	30,000	30,000	PI
2014 – 2018	Erasmus MC, Mrace	150,000	150,000	PI

Institutional and non-institutional citizenship (Top-5)

PI in HORIZON Europe-funded program 'BEHIND-MS', which aims to uncover the role of EBV in MS (12 partners/6 countries)

PI in International MS Genetics Consortium (IMSGC), which aims to understand the genetics of MS (18 partners/12 countries)

Participant in strategic phase of Dutch Immunology program 'ImmuneHealthXL'

Member of Scientific Advisory Board of Nationaal MS Fonds

Co-organizer of the Erasmus MC Immunology Consortium (EIC) meetings, which aims to connect local immunological research

SELF-DECLARATION ON CONFLICT OF INTEREST – ECM

The undersigned, aware that an E.C.M. conflict of interest is any situation in which a secondary interest interferes or could interfere with the primary interest consisting of the objectivity, impartiality, and independence of professional education in the healthcare sector related to the Continuing Medical Education (E.C.M.) Program,

DECLARES

the absence of commercial interests in the healthcare sector in the last two years from the date of signing this curriculum.

Date and place of signature: April 16th 2026

Signature:

europass Curriculum vitae

FORMATO EUROPEO PER IL CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	**BATTISTINI LUCA**
Indirizzo	**VIA DEL FOSSO DI FIORANO 64**
Telefono	**06 50170 3073**
Fax	**06 50170 3326**
E-mail	**l.battistini@hsantalucia.it**
Nazionalità	**Italiana**
Data di nascita	**02/03/1964**

ESPERIENZA LAVORATIVA

• Date (da – a)	**2018-presente**
• Nome e indirizzo del datore di lavoro	***Fondazione Santa Lucia, Roma***
• Tipo di azienda o settore	***IRCCS***
• Tipo di impiego	***Dirigente Medico di Ricerca di struttura complessa (II Livello)***
• Principali mansioni e responsabilità	***Vice-Direttore Scientifico IRCCS Fondazione Santa Lucia***

• Date (da – a)	**2001-2018**
• Nome e indirizzo del datore di lavoro	***Fondazione Santa Lucia, Roma***
• Tipo di azienda o settore	***IRCCS***
• Tipo di impiego	***Dirigente Medico di Ricerca di struttura semplice (I Livello)***
• Principali mansioni e responsabilità	***Director of Neuroimmunology and Flow Cytometry Units***

• Date (da – a)	**1997 - 2001**
• Nome e indirizzo del datore di lavoro	***Fondazione Santa Lucia, Roma***
• Tipo di azienda o settore	***IRCCS***
• Tipo di impiego	***Dirigente Medico di Ricerca***
• Principali mansioni e responsabilità	***Directore of Neuroimmunology Unit***

• Date (da – a)	**1995 – 1997**
• Nome e indirizzo del datore di lavoro	***Harvard Medical School, Boston, USA.***
• Tipo di azienda o settore	***Academic***
• Tipo di impiego	***Junior Faculty - Instructor***
• Principali mansioni e responsabilità	***Principal Investigator- Lab Head***
• Date (da – a)	**1993 - 1995**
• Nome e indirizzo del datore di lavoro	***Albert Einstein College of Medicine, NY, USA***
• Tipo di azienda o settore	***Academic***
• Tipo di impiego • Principali mansioni	***Research Associate***
• Date (da – a)	***1990 - 1992***
• Nome e indirizzo del datore di lavoro	***Istituto di Neurobiologia Consiglio Nazionale delle Ricerche (CNR), Roma.***
• Tipo di azienda o settore	***Academic***
• Tipo di impiego	***Research fellow,***
• Principali mansioni e responsabilità	***Project leader***

ISTRUZIONE E FORMAZIONE

• Date (da – a)	***2003***
• Nome e tipo di istituto di istruzione o formazione	***SDA Bocconi, School of Management***
• Principali materie / abilità professionali oggetto dello studio	***Management for Health***
• Qualifica conseguita	***Management for Health***
• Date (da – a)	***2000***
• Nome e tipo di istituto di istruzione o formazione	***University of Florence, Florence,***
• Principali materie / abilità professionali oggetto dello studio	***Neuroscience***
• Qualifica conseguita	***Ph.D.***
• Livello nella classificazione nazionale (se pertinente)	***Livello 6***
• Date (da – a)	***1994***
• Nome e tipo di istituto di istruzione o formazione	***Università di Roma "La Sapienza", Roma***
• Principali materie / abilità professionali oggetto dello studio	***Neurology***

• Qualifica conseguita	***Specialist in Neurology***
• Livello nella classificazione nazionale (se pertinente)	***Livello 5B***
• Date (da – a)	***1989***
• Nome e tipo di istituto di istruzione o formazione	***University of Siena, Siena, Italy***
• Principali materie / abilità professionali oggetto dello studio	***Neurology***
• Qualifica conseguita	***Medical Doctor***
• Livello nella classificazione nazionale (se pertinente)	***Livello 5A***

CAPACITÀ E COMPETENZE PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA	***ITALIANO***
ALTRE LINGUA	
	INGLESE
• Capacità di lettura	**ECCELLENTE**
• Capacità di scrittura	**ECCELLENTE**
• Capacità di espressione orale	**ECCELLENTE**

ALTRE CAPACITÀ E COMPETENZE

Competenze non precedentemente indicate.

2001-present

Professore di Immunologia, Universita' di Roma "Tor Vergata", Roma.

Per ulteriori informazioni:
www.cedefop.eu.int/transparency
www.europa.eu.int/comm/education/index_it.html
www.eurescv-search.com

7 Aprile 2026

Premi e borse di studio:

1993	Fellowship from the Italian Government (M.U.R.S.T. Program for research training in USA)
1994	Recipient of a short-term Fellowship from the Italian Multiple Sclerosis Society (A.I.S.M.)
1995-1997	Recipient of a long-term Senior Fellowship from the National Multiple Sclerosis Society (N.M.S.S.)
2002	Rita Levi Montalcini Award for the “Best Young Scientist” in the Multiple Sclerosis field
2016	Roche prize for Neuroscience.

Progetti di ricerca multicentrici (Principal Investigator)

2005-2007	National coordinator of the Project “Malattie neurodegenerative. Meccanismi immunologici e sinaptici del danno neurodegenerativo in corso di Sclerosi Multipla e Sclerosi Multipla Sperimentale”. Italian Ministry of Health.
2014-2018	National coordinator of Project “Può la flora intestinale influenzare le risposte autoimmuni nella sclerosi multipla? Il ruolo delle cellule MAIT”. Italian Ministry of Health.
2019-2022	National coordinator of Project “"Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to a novel therapy in multiple sclerosis”

Attività didattica e titoli accademici:

2000-present	Contract as Professor of Immunology, University of Rome “Tor Vergata”, Italy.
2014	National Academic Qualification as Full Professor in Neurology (Italian Ministry of Research MIUR).
2014	National Academic Qualification as Full Professor in Applied Biology (Italian Ministry of Research MIUR).

Attività editoriale

Ad hoc reviewer for Immunity, Annals of Neurology, Brain, Blood, J. Immunol., Journal of Leukocyte Biology, Eur. J. Immunol., Plos Pathogens, Hepatology, Plos One, Multiple Sclerosis, J Neuroimmunology, Immunology, Clinical Immunology, Journal of Neurological Sciences, Neuroscience.

Revisore scientifico

Evaluator of grant applications for: Italian (AISM/FISM), UK-MS Society, Australian MS Society, Human Frontier Science Program (HFSP), Agence Nationale de la Recherche, (ANR), Italian Ministry of Education, University and Research (MIUR), Italian Institute of Health (ISS).

Commissoni scientifiche

2016-2021	Member of the Scientific Board of the International Society of Neuroimmunology (ISNI)
2023-present	Member of the Scientific Board of the Italian Multiple Sclerosis Foundation (FISM)
2018-present	Member of the Scientific Board of the European School of Neuroimmunology (ESNI)

Società scientifiche

1989-present	Member of the Italian Society of Neurology (SIN)
1993-present	Member of the American Academy of Neurology (AAN)
1993-present	Member of the International Society of Neuroimmunology (ISNI)
1997-present	Member of the Italian Society of Immunology (SII and SIICA from 2002)
1998-present	Founder of the Italian Society of Neuroimmunology (AINI)

2006-2008 Member of AINI Advisory Board

Brevetti

- Publication number: EP1501505 (A1) Publication date: 2005-02-02

Battistini L., Borsellino G., De santis R., Carminati P. **"** Use of 3-(2-ethylphenyl)-S-methoxy-1H-1,2,4-triazole for the treatment of autoimmune diseases **"**WO2818-101

- European Patent Application No. 04 745 177.8 – 2404

Battistini L. Borsellino G., Diamantini A. "Use of multiparametric flow cytometry for the diagnosis, prognosis and immunotherapy validation of autoimmune and oncohematologic disorders "

Convegni scientifici (Organizzatore):

- Chairman of the Scientific Committee, Workshop "Pathogenic and Regulatory Cells in Demyelinating Diseases". Rome, 12-15 September 1999.
- Chairman of the Organizing Committee, VII International Congress, International Society of Neuroimmunology (ISNI). Venice (Italy), September 2004.
- Chairman of the Organizing Committee, XVI National AINI Congress. Ostuni (I), 2006.

Research supervision:
42 undergraduate students
31 PhD students

Pubblicazioni: >160 scientific papers in peer reviewed international journals.

Official Scopus H index: 64

Scopus Author Id: 7004688360

RESEARCH ID: D-6920-2014

ORCID ID: 0000.0000-6488-4891

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: _____7 Aprile 2026, Roma_____

Firma: _____

"Autorizzo il trattamento dei miei dati personali per le finalità dell' Avviso Pubblico "Progetti gruppi di Ricerca 2020" ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

PERSONAL INFORMATION Giovanna Borsellino

European Centre for Brain Research
Fondazione Santa Lucia IRCCS
Neuroimmunology and Flow Cytometry Units
Via del Fosso di Fiorano 64
00149 Rome, Italy

+39 06 501703073 +39 3475229237

g.borsellino@hsantalucia.it

Gender F | *Date of birth* 29/10/1965 | *Nationality* Italian

Languages

Italian and English: Native
French: fluent

Official Scopus H index: 50

Scopus Author Id: 7004207740

RESEARCH ID: D-6920-2014

ORCID ID: 0000-0002-4227-6481

EMPLOYMENTS

From 2018 –present **Head, Neuroimmunology Unit**
Santa Lucia Foundation IRCCS, Rome, Italy
main activities and responsibilities: **Neuroimmunologist, Director of the Neuroimmunology Laboratory.**

1998-present **Head, Flow Cytometry Unit, Co-Head Neuroimmunology Unit**
Santa Lucia Foundation IRCCS, Rome, Italy

1995 – 1997 **Research Associate**
Harvard University, Cambridge, USA
Mentor: Prof. Jack L. Strominger

1992 – 1995 **Postsdoctoral Fellow**
Harvard University, Cambridge, USA
Mentor: Prof. Jack L. Strominger

EDUCATION AND ACADEMIC DEGREES

(1996-1999) Specialist in Neurophysiopathology
70/70

(1993-1996) PhD in Neuropsychology
University of Rome "La Sapienza"

(1984-1991) Medical Doctor
University of Rome "La Sapienza"
With honours

ACHIEVEMENTS AND AWARDS

Editorial activity

Ad hoc reviewer for Journal of Immunology, Frontiers in Immunology, Frontiers in Neuroscience, Science Immunology, Blood, Cell Reports Medicine.

Active Grants

PNRR-MAD-2022-12375634 - "Innate immune CElls in MUltiple SCLErosis - ICEMUSCLE", from 20.05.2023 to 18.11.2025, 250.000 euro; Principal Investigator Santa Lucia Foundation Unit.

PNRR-TR1-2023-12377980 - "Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention", from 31.08.2024 to 30.08.2026, 300.000 euro; Principal Investigator Santa Lucia Foundation Unit.

2023/R-Single/044 , Fondazione Italiana Sclerosi Multipla - "Antigen-specific and bystander immune responses to viruses in persons with multiple sclerosis", from 31.03.2024 to 31.03.2026. 200.000 euro; Principal Investigator.

ADDITIONAL INFORMATION

Teaching activities and Academic achievements:
2000-present: Contract as Professor of Immunology and Haematology, University of Rome "Tor Vergata", Italy.
2014- National Academic Qualification as Associate Professor in Neurology (Italian Ministry of Research MIUR).
2014- National Academic Qualification as Full Professor in Applied Biology (Italian Ministry of Research MIUR).

External Reviewer
Evaluator of grant applications for: Italian (AISM/FISM), UK-MS Society, Australian MS Society, Italian Ministry of Education, University and Research (MIUR), Italian Institute of Health (ISS).

Scientific Societies membership
1992-present Member of the Italian Society of Neurology (SIN)
1995-present Member of the American Academy of Neurology (AAN)
1995-present Member of the International Society of Neuroimmunology(ISNI)
1997-present Member of the Italian Society of Immunology (SIICA)
2006-2014: Advisory Board, Italian Association for Neuroimmunology
2014-2022: Secretary/Treasurer, Italian Society for Neuroimmunology
2016-present: Advisory Board, Federazione SPERA, Le ragioni della ricerca.
2018-2022: Advisory Board, Italian Society for Cytometric Cell Analysis (ISCCA)

Publications

109 publications in peer-review journals
Total Impact Factor (IF): 623,809 (average IF/paper = 6,447)
Total number of citations: 10,746
H index: 50 (Scopus ID: 7004207740)

1) Tomassini L, Pacifico T, Serra MA, Sommella EM, Sambucci M, Sica GS, Savino L, Vitale S, Ortenzi A, Biancone L, Battistini L, Borsellino G, Monteleone I, Barnaba V, Fiori ME, Monteleone G, Stolfi C, Laudisi F. Rafoxanide disrupts mitochondrial homeostasis through VDAC1 modulation in colorectal cancer cells. Cell Death Discov. 2026 Mar 5. doi: 10.1038/s41420-026-02986-3. Epub ahead of print. PMID: 41786695.

2) Ventura A, Libonati A, Marcozzi S, Ucci MA, Salvatore G, Galgani A, Pirrò S, Massimiani M, Picozza M, Russo R, Vumbaca S, Farini D, Chambery A, Borsellino G, De Felici M, Klinger FG, Campanella V, Camaioni A. Comparative analysis of human Mesenchymal Stromal Cells from Adipose Tissue and Dental Pulp: phenotypic characterization and secretome profiling. Biol Direct. 2025 Nov 13;20(1):111. doi: 10.1186/s13062-025-00697-w. PMID: 41233824; PMCID: PMC12616983.

3) La Barbera L, Krashia P, Loffredo G, Cauzzi E, De Paolis ML, Montanari M, Saba L, Spoleti E, Ficchì S, Zaccone C, De Bardi M, Palazzo C, Marino R, Latagliata EC, Puglisi-Allegra S, Borsellino G, Keller F, Lo Iacono L, Viscomi MT, Nobili A, D'Amelio M. Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer's Disease. Mol Neurodegener. 2025 Oct 13;20(1):105. doi: 10.1186/s13024-025-00893-2. PMID: 41077614; PMCID: PMC12516900.

4) Menculini G, Sperandei S, Gaetani L, Mancini A, Cinesi G, Di Sabatino E, Bellingacci L, Canonichesi J, Guerrera G, Battistini L, Tortorella A, Parnetti L, Borsellino G, Di Filippo M. Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis. Mult Scler Relat Disord. 2025 Mar;95:106309. doi: 10.1016/j.msard.2025.106309. Epub 2025 Feb 7. PMID: 39983519.

5) Guerrera G, Sambucci M, Timperi E, Picozza M, Misiti A, Placido R, Corbisiero S, D'Orso S, Termine A, Fabrizio C, Gargano F, Eleuteri S, Marchioni L, Bordoni V, Coppola L, Iannetta M, Agrati C, Borsellino G,

Battistini L. Identification of an immunological signature of long COVID syndrome. Front Immunol. 2025 Jan 8;15:1502937. doi: 10.3389/fimmu.2024.1502937. PMID: 39845978; PMCID: PMC11750999.

6) De Stefano S, Tiberi M, Salvatori I, De Bardi M, Gimenez J, Pirshayan M, Greco V, Borsellino G, Ferri A, Valle C, Mercuri NB, Chiurchiù V, Spalloni A, Longone P. Hydrogen Sulfide Modulates Astrocytic Toxicity in Mouse Spinal Cord Cultures: Implications for Amyotrophic Lateral Sclerosis. Antioxidants (Basel). 2024 Oct 15;13(10):1241. doi: 10.3390/antiox13101241. PMID: 39456494; PMCID: PMC11504967.

7) Catarinella G, Bracaglia A, Skafida E, Procopio P, Ruggieri V, Parisi C, De Bardi M, Borsellino G, Madaro L, Puri PL, Sacco A, Latella L. STAT3 inhibition recovers regeneration of aged muscles by restoring autophagy in muscle stem cells. Life Sci Alliance. 2024 Jun 6;7(8):e202302503. doi: 10.26508/lsa.202302503. PMID: 38843935; PMCID: PMC11157169.

8) Giannessi F, Percario Z, Lombardi V, Sabatini A, Sacchi A, Lisi V, Battistini L, Borsellino G, Affabris E, Angelini DF. Macrophages treated with interferons induce different responses in lymphocytes via extracellular vesicles. iScience. 2024 May 10;27(6):109960. doi: 10.1016/j.isci.2024.109960. PMID: 38832015; PMCID: PMC11144789.

9) Maple PA, Tanasescu R, Constantinescu CS, Valentino P, Capobianco M, D'Orso S, Borsellino G, Battistini L, Ristori G, Mechelli R, Salvetti M, Gran B. Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy. Pathogens. 2024 Jun 12;13(6):499. doi: 10.3390/pathogens13060499. PMID: 38921797; PMCID: PMC11206421.

10) Liguori F, Alberti F, Amadio S, Angelini DF, Pilesi E, Vitale G, Tesoriere G, Borsellino G, Vernì F, Volonté C. Pan-neuronal expression of human mutant SOD1 in Drosophila impairs survival and motor performance, induces early neuroinflammation and chromosome aberrations. Biochim Biophys Acta Mol Basis Dis. 2024 Jun;1870(5):167192. doi: 10.1016/j.bbadis.2024.167192. Epub 2024 Apr 22. PMID: 38657911.

11) Poletti S, Zanardi R, Mandelli A, Aggio V, Finardi A, Lorenzi C, Borsellino G, Carminati M, Manfredi E, Tomasi E, Spadini S, Colombo C, Drexhage HA, Furlan R, Benedetti F. Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers. Brain Behav Immun. 2024 May;118:52-68. doi: 10.1016/j.bbi.2024.02.019. Epub 2024 Feb 15. PMID: 38367846.

12) Cirotti C, Taddei I, Contadini C, Di Girolamo C, Pepe G, De Bardi M, Borsellino G, Helmer-Citterich M, Barilà D. NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. Life Sci Alliance. 2023 Oct 25;7(1):e202302205. doi: 10.26508/lsa.202302205. PMID: 37879937; PMCID: PMC10599979.

13) D'Orso S, Pirronello M, Verdiani A, Rossini A, Guerrera G, Picozza M, Sambucci M, Misiti A, De Marco L, Salvia A, Caltagirone C, Giardina E, Battistini L, Borsellino G. Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection. Vaccines (Basel). 2023 Nov 9;11(11):1705. doi: 10.3390/vaccines11111705. PMID: 38006037; PMCID: PMC10675240.

14) Morroni J, Benedetti A, Esposito L, De Bardi M, Borsellino G, Riera CS, Giordani L, Bouche M, Lozanoska-Ochser B. Injury-experienced satellite cells retain long-term enhanced regenerative capacity. Stem Cell Res Ther. 2023 Sep 12;14(1):246. doi: 10.1186/s13287-023-03492-4. PMID: 37697344; PMCID: PMC10496398.

15) Cappelli S, Spalloni A, Feiguin F, Visani G, Šušnjar U, Brown AL; NYGC ALS Consortium; De Bardi M, Borsellino G, Secrier M, Phatnani H, Romano M, Fratta P, Longone P, Buratti E. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology. Brain Commun. 2022 Sep23;4(5):fcac242. doi: 10.1093/braincomms/fcac242. PMID: 36267332; PMCID: PMC9576154.

16) Di Pietro L, Giacalone F, Ragozzino E, Saccone V, Tiberio F, De Bardi M, Picozza M, Borsellino G, Lattanzi W, Guadagni E, Bortolani S, Tasca G, Ricci E, Parolini O. Non-myogenic mesenchymal cells contribute to muscle degeneration in facioscapulohumeral muscular dystrophy patients.
Cell Death Dis. 2022 Sep 16;13(9):793. doi: 10.1038/s41419-022-05233-6. PMID: 36114172; PMCID:PMC9481542.

17) Gargano F, Guerrera G, Piras E, Serafini B, Di Paola M, Rizzetto L, Buscarinu MC, Annibali V, Vuotto C, De Bardi M, D'Orso S, Ruggieri S, Gasperini C, Pavarini L, Ristori G, Picozza M, Rosicarelli B, Ballerini C, Mechelli R, Vitali F, Cavalieri D, Salvetti M, Angelini DF, Borsellino G, De Filippo C, Battistini L. Proinflammatory mucosal-associated invariant CD8+ T cells react to gut flora yeasts and infiltrate multiple sclerosis brain. Front Immunol. 2022 Jul 28;13:890298. doi: 10.3389/fimmu.2022.890298. PMID: 35979352; PMCID: PMC9376942.

18) Lanna A, Vaz B, D'Ambra C, Valvo S, Vuotto C, Chiurchiù V, Devine O, Sanchez M, Borsellino G, Akbar AN, De Bardi M, Gilroy DW, Dustin ML, Blumer B, Karin M. An intercellular transfer of telomeres rescues T cells from senescence and promotes long-term immunological memory.
Nat Cell Biol (IF: 28.82; Q1). 2022 Oct;24(10):1461-1474. doi: 10.1038/s41556-022-00991-z. Epub 2022 Sep 15.

19) Picozza M, Cristofoletti C, Bresin A, Fioretti M, Sambucci M, Scala E, Monopoli A, Cantonetti M, Pilla MA, Accetturi MP, Borsellino G, D'Atri S, Caprini E, Russo G, Narducci MG. Genetically driven CD39 expression affects Sezary cell viability, IL-2 production and detects two patient subsets with distinct prognosis. J Invest Dermatol. 2022 May 6:S0022-202X(22)00372-4. doi: 10.1016/j.jid.2022.04.017. Online ahead of print.

20) Cappelli S, Spalloni A, Feiguin F, Visani G, Šušnjar U, Brown AL; NYGC ALS Consortium, De Bardi M, Borsellino G, Secrier M, Phatnani H, Romano M, Fratta P, Longone P, Buratti E. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology. Brain Commun. 2022 Sep 23;4(5):fcac242. doi: 10.1093/braincomms/fcac242. PMID: 36267332; PMCID: PMC9576154.

21) Riolo G, Ricci C, De Angelis N, Marzocchi C, Guerrera G, Borsellino G, Giannini F, Battistini S. BDNF and Pro-BDNF in Amyotrophic Lateral Sclerosis: A New Perspective for Biomarkers of Neurodegeneration. Brain Sci. 2022 May 9;12(5):617. doi: 10.3390/brainsci12050617. PMID: 35625004; PMCID: PMC9139087.

22) Guerrera G, Mandelli A, Finardi A, Orrico M, D'Orso S, Picozza M, Noviello M, Beretta V, Bonetti B, Calabrese M, Marastoni D, De Rossi N, Capra R, Salvetti M, Buscarinu MC, Inglese M, Uccelli A, Moiola L, Raposo C, Muros-Le Rouzic E, Pedotti R, Filippi M, Bonini C, Battistini L, Borsellino G, Furlan R. Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
Mult Scler (IF: 6.31; Q1). 2022 Oct;28(12):1937-1943. doi: 10.1177/13524585221102158. Epub 2022 Jun 20.

23) De Marco L., D'Orso S., Pirronello M., Verdiani A., Termine A., Fabrizio C., Capone A., Sabatini A., Guerrera G., Placido R., Sambucci M., Angelini D.F., Giannessi F., Picozza M., Caltagirone C., Salvia A., Volpe E., Balice M.P., Rossini E., Rotzschke O., Giardina E., Battistini L*. and Borsellino G*. Assessment of T cell reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals. Jama Network Open 2022; Apr 1;5(4):e2210871. doi: 10.1001/jamanetworkopen. 2022.10871.

24) Caputo V, Calvino G, Strafella C, Termine A, Fabrizio C, Trastulli G, Ingrascì A, Peconi C, Bardini S, Rossini A, Salvia A, Borsellino G, Battistini L, Caltagirone C, Cascella R, Giardina E. Tracking the Initial Diffusion of SARS-CoV-2

Omicron Variant in Italy by RT-PCR and Comparison with Alpha and Delta Variants Spreading. Diagnostics (Basel) 2022 Feb 11;12(2):467. doi: 10.3390/diagnostics12020467

25) Guerrera G, Picozza M, D'Orso S, Placido R, Pirronello M, Verdiani A, Termine A, Fabrizio C, Giannessi F, Sambucci M, Balice MP, Caltagirone C, Salvia A, Rossini A, Battistini L, Borsellino G. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci Immunol. 2021 Dec 24;6(66):eabl5344. doi: 10.1126/sciimmunol.abl5344. Epub 2021 Dec 24. PMID:34726470.

26) Buscarinu MC, Gargano F, Lionetto L, Capi M, Morena E, Fornasiero A, Reniè R, Landi AC, Pellicciari G, Romano C, Mechelli R, Romano S, Borsellino G, Battistini L, Simmaco M, Fagnani C, Salvetti M, Ristori G. Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis Treated With Dimethylfumarate. Front Neurol. 2021 Aug 26;12:683398. doi: 10.3389/fneur.2021.683398. PMID: 34512507; PMCID: PMC8426620.

27) Strafella C, Caputo V, Guerrera G, Termine A, Fabrizio C, Cascella R, Picozza M, Caltagirone C, Rossini A, Balice MP, Salvia A, Battistini L, Borsellino G, Giardina E. Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk. Front Immunol. 2021 Jun 23;12:708820. doi: 10.3389/fimmu.2021.708820. PMID: 34249017; PMCID: PMC8270685.

28) Proietti D, Giordani L, De Bardi M, D'Ercole C, Lozanoska-Ochser B, Amadio S, Volonté C, Marinelli S, Muchir A, Bouché M, Borsellino G, Sacco A, Puri PL, Madaro L. Activation of skeletal muscle-resident glial cells upon nerve injury. JCI Insight. 2021 Apr 8;6(7):e143469. doi: 10.1172/jci.insight.143469. PMID:33661767; PMCID: PMC8119188.

29) Candiloro F, Borioli V, Borsellino G, Picozza M, Pellini R, Cereda E, Gargano F, Caraccia M RD, Nardi MT, Bellu L, Tondulli L, Imarisio I, Pozzi E, Pedrazzoli P, Caccialanza R, Battistini L. Influence of different lipid emulsions on specific immune cell functions in head and neck cancer patients receiving supplemental parenteral nutrition: An exploratory analysis. Nutrition. 2021 Jun;86:111178. doi: 10.1016/j.nut.2021.111178. Epub 2021 Jan 30. PMID: 33631618.

30) Guerrera G, Ruggieri S, Picozza M, Piras E, Gargano F, Placido R, Gasperini C, Salvetti M, Buscarinu MC, Battistini L, Borsellino G, Angelini DF. EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 17;7(6):e876. doi:10.1212/NXI.0000000000000876. PMID: 32817203; PMCID: PMC7455312.

31) Vuotto C, Battistini L, Caltagirone C, Borsellino G. Gut Microbiota and Disorders of the Central Nervous System. Neuroscientist. 2020 Oct-Dec;26(5-6):487-502. doi: 10.1177/1073858420918826. Epub 2020 May 22. PMID:32441219.

32) Sambucci M, Gargano F, Guerrera G, Battistini L, Borsellino G. One, No One, and One Hundred Thousand: T Regulatory Cells' Multiple Identities in Neuroimmunity. Front Immunol. 2019 Dec 20;10:2947. doi: 10.3389/fimmu.2019.02947.

33) Cossarizza A, Chang HD, Radbruch A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 2019 Oct;49(10):1457-1973. doi: 10.1002/eji.201970107. PubMed PMID: 31633216.

34) Logozzi M, Angelini DF, Giuliani A, Mizzoni D, Di Raimo R, Maggi M, Gentilucci A, Marzio V, Salciccia S, Borsellino G, Battistini L, Sciarra A, Fais S. Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. Cancers (Basel). 2019 Sep 27;11(10). pii: E1449. doi: 10.3390/cancers11101449. PubMed PMID: 31569672.

35) Furlan R, Melloni E, Finardi A, Vai B, Di Toro S, Aggio V, Battistini L, Borsellino G, Manfredi E, Falini A, Colombo C, Poletti S, Benedetti F. Natural killer cells protect white matter integrity in bipolar disorder. Brain Behav Immun. 2019 Oct;81:410-421. doi: 10.1016/j.bbi.2019.06.037. Epub 2019 Jun 26. PubMed PMID: 31254622.

36) Becher J, Simula L, Volpe E, Procaccini C, La Rocca C, D'Acunzo P, Cianfanelli V, Strappazzon F, Caruana I, Nazio F, Weber G, Gigantino V, Botti G, Ciccosanti F, Borsellino G, Campello S, Mandolesi G, De Bardi M, Fimia GM, D'Amelio M, Ruffini F, Furlan R, Centonze D, Martino G, Braghetta P, Chrisam M, Bonaldo P, Matarese G, Locatelli F, Battistini L, Cecconi F. AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis. Dev Cell. 2018 Dec 3;47(5):592-607.e6. doi: 10.1016/j.devcel.2018.11.010. PubMed PMID: 30513302.

37) Annibali V, Umeton R, Palermo A, et. Al. Analysis of coding and non-coding transcriptome ofperipheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. J Neuroimmunol. 2018 Nov 15;324:165-171. doi: 10.1016/j.jneuroim. 2018.09.005. Epub 2018 Sep 15. PubMed PMID: 30270021.

38) Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, Ruggieri S, Capone A, Gasperini C, Matarese G, Battistini L, Borsellino G. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. Sci Rep. 2018 Feb 27;8(1):3674. doi: 10.1038/s41598-018-21861-5.

39) Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018 Jan 8;19(1). pii: E179. doi:10.3390/ijms19010179.

40) Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol. 2017 Oct;47(10):1584-1797.

41) Sbardella D, Tundo GR, Campagnolo L, Valacchi G, Orlandi A, Curatolo P, Borsellino G, D'Esposito M, Ciaccio C, Cesare SD, Pierro DD, Galasso C, Santarone ME, Hayek J, Coletta M, Marini S. Retention of Mitochondria in Mature Human Red Blood Cells as the Result of Autophagy Impairment in Rett Syndrome. Sci Rep. 2017 Sep 26;7(1):12297. doi: 10.1038/s41598-017-12069-0.

42) Cencioni MT, Magliozzi R, Nicholas R, Ali R, Malik O, Reynolds R, Borsellino G, Battistini L, Muraro P. Programmed death 1 is highly expressed on CD8+CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to EBV. Immunology. 2017 Dec;152(4):660-676. doi: 10.1111/imm.12808. Epub 2017 Sep 21.PMID: 28767147

43) Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. Cancer Lett. 2017 Sep 10;403:318-329.

44) Volpe E, Sambucci M, Battistini L, Borsellino G. Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis. Front Immunol. 2016 Sep 27;7:382.

45) Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016 Aug 26;13(1):207.

46) Volpe E, Battistini L, Borsellino G. Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis. Mediators Inflamm. 2015;2015:475158. doi: 10.1155/2015/475158.

47) Di Mitri D, Sambucci M, Loiarro M, De Bardi M, Volpe E, Cencioni MT, Gasperini C, Centonze D, Sette C, Akbar AN, Borsellino G, Battistini L. The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology. 2015 Oct;146(2):251-63

48) Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, Gasperini C, Centonze D, Barilá D, Battistini L, Volpe E. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Death Dis. 2015 Jun 11;6:e1785.

49) Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Clin Cancer Res. 2015 Sep 1;21(17):3977-85.

50) Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, Gasperini C, Furlan R, Centonze D, Battistini L, Volpe E. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. Clin Sci (Lond). 2015 Aug;129(4):291-303.

51) Saccone V, Consalvi S, Giordani L, Mozzetta C, Barozzi I, Sandoná M, Ryan T, Rojas-Muñoz A, Madaro L, Fasanaro P, Borsellino G, De Bardi M, Frigè G, Termanini A, Sun X, Rossant J, Bruneau BG, Mercola M, Minucci S, Puri PL. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev. 2014 Apr 15;28(8):841-57.

52) Picozza M, Battistini L, Borsellino G. Mononuclear phagocytes and marker modulation: when CD16 disappears, CD38 takes the stage. Blood. 2013 Jul 18;122(3):456-7.

53) Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220.

54) Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice.
EMBO Mol Med. 2013 Apr;5(4):626-39.

55) Chiurchiù V, Cencioni MT, Bisicchia E, De Bardi M, Gasperini C, Borsellino G, Centonze D, Battistini L, Maccarrone M. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol. 2013 May;73(5):626-36.

56) Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
J Alzheimers Dis. 2012;31(4):865-78.

57) Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
Oncogene. 2012 Jun 28;31(26):3148-63.

58) Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R. T regulatory cells are markers of disease activity in multiple sclerosis patients.
PLoS One. 2011;6(6):e21386.

59) Santini MP, Lexow J, Borsellino G, Slonimski E, Zarrinpashneh E, Poggioli T, Rosenthal N. IGF-1Ea induces vessel formation after injury and mediates bone marrow and heart cross-talk through the expression of specific cytokines.
Biochem Biophys Res Commun. 2011 Jul 1;410(2):201-7.

60) Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, Romano S, Paolillo A, Abderrahim H, Diamantini A, Borsellino G, Aloisi F, Battistini L, Salvetti M. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis.
Brain. 2011 Feb;134(Pt 2):542-54.

61) Esposito M, Ruffini F, Bergami A, Garzetti L, Borsellino G, Battistini L, Martino G, Furlan R. IL-17- and IFN-γ-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity.
J Immunol. 2010 Dec 15;185(12):7467-73.

62) Angelini DF, Zambello R, Galandrini R, Diamantini A, Placido R, Micucci F, Poccia F, Semenzato G, Borsellino G, Santoni A, Battistini L. NKG2A inhibits NKG2C effector functions of γδ T cells: implications in health and disease.
J Leukoc Biol. 2011 Jan;89(1):75-84.

63) De Santis G, Ferracin M, Biondani A, Caniatti L, Rosaria Tola M, Castellazzi M, Zagatti B, Battistini L, Borsellino G, Fainardi E, Gavioli R, Negrini M, Furlan R, Granieri E. Altered miRNA expression in T regulatory cells in course of multiple sclerosis.
J Neuroimmunol. 2010 Sep 14;226(1-2):165-71.

64) Vitiello L, Masci AM, Montella L, Perna F, Angelini DF, Borsellino G, Battistini L, Merola G, De Palma R, Spadaro G, Cosentini E, Palmieri G, Racioppi L. Thymoma-associated immunodeficiency: a syndrome characterized by severe alterations in NK, T and B-cells and progressive increase in naïve CD8+ T Cells.
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):307-16.

65) Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.
PLoS One. 2010 Jan 14;5(1):e8688.

66) Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, Cossetti C, Del Carro U, Comi G, 't Hart B, Vescovi A, Martino G. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates.
Ann Neurol. 2009 Sep;66(3):343-54.

67) Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, Salani G, Cossetti C, Borsellino G, Battistini L, Ponzoni M, Doglioni C, Garcia-Verdugo JM, Comi G, Manfredi AA, Martino G. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function.
PLoS One. 2009 Jun 19;4(6):e5959.

68) Chiacchio T, Casetti R, Butera O, Vanini V, Carrara S, Girardi E, Di Mitri D, Battistini L, Martini F, Borsellino G, Goletti D. Characterization of regulatory T cells identified as CD4(+)CD25(high)CD39(+) in patients with active tuberculosis.
Clin Exp Immunol. 2009 Jun;156(3):463-70.

69) Rötzschke O, Borsellino G, Battistini L, Falk K, Kleinewietfeld M. In vivo-activated CD103+ Foxp3+ Tregs: of men and mice.
Blood. 2009 Feb 26;113(9):2119-20;

70) Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rötzschke O, Falk K. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells.
Blood. 2009 Jan 22;113(4):827-36.

71) de Lalla C, Festuccia N, Albrecht I, Chang HD, Andolfi G, Benninghoff U, Bombelli F, Borsellino G, Aiuti A, Radbruch A, Dellabona P, Casorati G. Innate-like effector differentiation of human invariant NKT cells driven by IL-7.
J Immunol. 2008 Apr 1;180(7):4415-24.

72) Poggi A, Catellani S, Fenoglio D, Borsellino G, Battistini L, Zocchi MR. Adhesion molecules and kinases involved in gammadelta T cells migratory pathways: implications for viral and autoimmune diseases.
Curr Med Chem. 2007;14(30):3166-70.

73) Limana F, Zacheo A, Mocini D, Mangoni A, Borsellino G, Diamantini A, De Mori R, Battistini L, Vigna E, Santini M, Loiaconi V, Pompilio G, Germani A, Capogrossi MC. Identification of myocardial and vascular precursor cells in human and mouse epicardium.
Circ Res. 2007 Dec 7;101(12):1255-65.

74) Poggi A, Zancolli M, Catellani S, Borsellino G, Battistini L, Zocchi MR.
75) Migratory pathways of gammadelta T cells and response to CXCR3 and CXCR4 ligands: adhesion molecules involved and implications for multiple sclerosis pathogenesis.
Ann N Y Acad Sci. 2007 Jun;1107:68-78.

76) Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
Blood. 2007 Aug 15;110(4):1225-32.

77) Thedrez A, de Lalla C, Allain S, Zaccagnino L, Sidobre S, Garavaglia C, Borsellino G, Dellabona P, Bonneville M, Scotet E, Casorati G. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells.
Blood. 2007 Jul 1;110(1):251-8.

78) Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, Battistini L, Rosenthal N, Molinaro M, Musarò A. Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines.
FASEB J. 2007 May;21(7):1393-402

79) Somma P, Ristori G, Battistini L, Cannoni S, Borsellino G, Diamantini A, Salvetti M, Sorrentino R, Fiorillo MT. Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis.
J Leukoc Biol. 2007 Mar;81(3):696-710.

80) Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, Borsellino G, Kroczek RA, La Mendola C, Scotet E, Dieli F, Salerno A. CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production.
J Immunol. 2006 Oct 15;177(8):5290-5.

81) Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G, Leoni O, Palumbo R, Battistini L, Rastaldo R, Müller S, Pompilio G, Anversa P, Bianchi ME, Capogrossi MC. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation.
Circ Res. 2005 Oct 14;97(8):e73-83.

82) Lolli F, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, Mazzanti B, D'Ursi AM, Novellino E, Pazzagli M, Lovato L, Alcaro MC, Peroni E, Pozo-Carrero MC, Nuti F, Battistini L, Borsellino G, Chelli M, Rovero P, Papini AM. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10273-8.

83) Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, Battistini L, Dieli F, Salerno A. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets.
Eur J Immunol. 2005 Jun;35(6):1764-72.

84) Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF. Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphate-containing ligands.
J Immunol. 2005 May 15;174(10):6144-52.

85) Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
J Exp Med. 2005 Apr 18;201(8):1257-68.

86) Battistini L, Caccamo N, Borsellino G, Meraviglia S, Angelini DF, Dieli F, Cencioni MT, Salerno A. Homing and memory patterns of human gammadelta T cells in physiopathological situations.
Microbes Infect. 2005 Mar;7(3):510-7.

87) Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rötzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset.
Blood. 2005 Apr 1;105(7):2877-86.

88) De Toni L, Marconi S, Nardelli E, Alberti D, Borsellino G, Fracasso G, Bach S, Bertolasi L, Santo A, Bassi A, Tramonti D, Battistini L, Bonetti B. Gangliosides act as onconeural antigens in paraneoplastic neuropathies.
J Neuroimmunol. 2004 Nov;156(1-2):178-87

89) Bordoni V, Alonzi T, Agrati C, Poccia F, Borsellino G, Mancino G, Fimia GM, Piacentini M, Fantoni A, Tripodi M. Murine hepatocyte cell lines promote expansion and differentiation of NK cells from stem cell precursors.
Hepatology. 2004 Jun;39(6):1508-16.

90) Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, Poccia F, Fournié JJ, Battistini L. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004 Sep 15;104(6):1801-7

91) Musarò A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, Ottolenghi S, Cossu G, Bernardi G, Battistini L, Molinaro M, Rosenthal N. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1.
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1206-10.

92) Falciatori I, Borsellino G, Haliassos N, Boitani C, Corallini S, Battistini L, Bernardi G, Stefanini M, Vicini E. Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis.
FASEB J. 2004 Feb;18(2):376-8.

93) Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G, Mancardi GL, Battistini L, Uccelli A. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS.
J Leukoc Biol. 2003 May;73(5):584-90.

94) Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, Ottoboni L, Ciabini D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1.
Blood. 2003 Jun 15;101(12):4775-82.

95) Poggi A, Zocchi MR, Carosio R, Ferrero E, Angelini DF, Galgani S, Caramia MD, Bernardi G, Borsellino G, Battistini L. Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II.
J Immunol. 2002 Jun 15;168(12):6071-7.

96) Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, Poccia F. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis.
J Immunol. 2002 Feb 1;168(3):1484-9.

97) Cipriani B, Borsellino G, Knowles H, Tramonti D, Cavaliere F, Bernardi G, Battistini L, Brosnan CF. Curcumin inhibits activation of Vgamma9Vdelta2 T cells by phosphoantigens and induces apoptosis involving apoptosis-inducing factor and large scale DNA fragmentation.
J Immunol. 2001 Sep 15;167(6):3454-62.

98) Ristori G, Montesperelli C, Fiorillo MT, Battistini L, Chersi A, Sorrentino R, Borsellino G, Perna A, Tramonti D, Cannoni S, Perrone MP, Giubilei F, Riccio P, Salvetti M, Buttinelli C. T cell response to N-formylated peptides in humans.
Eur J Immunol. 2001 Sep;31(9):2762-70.

99) Ristori G, Montesperelli C, Perna A, Cannoni S, Battistini L, Borsellino G, Riccio P, Pesole G, Chersi A, Pozzilli C, Buttinelli C, Salvetti M. Global immune disregulation in multiple sclerosis: from the adaptive response to the innate immunity.
J Neuroimmunol. 2000 Jul 24;107(2):216-9. Review.

111) Aloisi F, Carè A, Borsellino G, Gallo P, Rosa S, Bassani A, Cabibbo A, Testa U, Levi G, Peschle C. Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha.
J Immunol. 1992 Oct 1;149(7):2358-66.

112) Aloisi F, Borsellino G, Samoggia P, Testa U, Chelucci C, Russo G, Peschle C, Levi G. Astrocyte cultures from human embryonic brain: characterization and modulation of surface molecules by inflammatory cytokines.
J Neurosci Res. 1992 Aug;32(4):494-506.

La sottoscritta, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Roma, 10 marzo 2026

Firma: 

CURRICULUM VITAE

Name: Chiurchiù Valerio
ORCID: 0000-0002-0316-7311
Research ID: G-6227-2011
Date of birth: 03/07/1983
Nationality: Italian
URL for web site:
https://www.researchgate.net/profile/Valerio_Chiurchiu



Head of the Laboratory of Resolution of Neuroinflammation

Istituto di Farmacologia Traslazionale (IFT),
CNR
Via del Fosso del Cavaliere 100 –
00133, Roma

&

European Center for Brain Research (CERC)
IRCCS Fondazione Santa Lucia
Via del Fosso di Fiorano 64 –
00143, Roma

Tel: +39 06501703210
Email: v.chiurchiu@hsantalucia.it

• EDUCATION

2011 PhD in Immunology and Applied Biotechnology
Department of Biology, Tor Vergata University of Rome, Italy
2007 Master Degree in Biology
Department of Biology, Tor Vergata University of Rome, Italy

• CURRENT POSITION(S)

2020 – Researcher in Pathophysiology at Institute of Translational Pharmacology, CNR, Rome, Italy
2020 – Head of the laboratory of Resolution of Neuroinflammation,
European Center for Brain Research, IRCCS Santa Lucia Foundation of Rome, Italy
2019 – Visiting Researcher
Brigham and Women's Hospital, Harvard Medical School, Boston, USA

• PREVIOUS POSITIONS

2016 – 2019 Assistant Professor in Biochemistry
Department of Medicine, Campus Bio-medico University of Rome, Italy
2016 – 2016 Post-doctoral Fellowship, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Sweden
2014 – 2015 Research Fellow

Department of Medicine, Campus Bio-medico University of Rome, Italy

2012 – 2014 Research Fellow
Department of Biomedical Sciences, University of Teramo, Italy

- **TEACHING ACTIVITIES**

2022 – Lecturer – General Pathology, Campus Bio-Medico University of Rome/Italy (CFU = 3)
2015 – Lecturer – Pharmacology, International College of Osteopathy and Manual Medicine/Italy (CFU = 2)
2015 – Lecturer – Microbiology, International College of Osteopathy and Manual Medicine/Italy (CFU = 2)
2014 – Lecturer – General Pathology and Immunology, International College of Osteopathy and Manual Medicine/Italy (CFU = 4)
2016 – 2020 Assistant Professor – Biochemistry, Campus Bio-medico University of Rome/Department of Medicine/Italy (CFU = 8)
2016 – 2020 Assistant Professor – Biochemistry of Nutrition, Campus Bio-medico University of Rome/Department of Medicine/Italy (CFU = 6)
2015 – 2017 Lecturer for the Corso di Perfezionamento sulla Sclerosi Multipla, Tor Vergata University of Rome
2014 – 2017 Lecturer – Histology, International College of Osteopathy and Manual Medicine/Italy (CFU = 5)

- **ORGANISATION OF SCIENTIFIC MEETINGS**

2022 Co-Organizer of 5th BraYn Conference
2015 Co-Chair and Organizer, Gordon Research Seminar in "Endocannabinoid signaling in Neurobiology: from Molecules to Networks"/Italy

- **COMMISSIONS OF TRUST**

2023 – Scientific Committee of the Italian Foundation of Multiple Sclerosis (FISM)
2020 – Member of "Collegio dei docenti della Scuola di Dottorato in Immunologia", University of Tor Vergata, Rome, Italy
2019 – Evaluator of the ERC 2019, Consolidator Grants
2019 – Evaluator of FISM Grants
2019 – Evaluator of the Brayn Starting Grants
2018 – ASN – II Fascia in General Pathology (MED/04)
2018 – ASN – II Fascia in Biochemistry (BIO/10)
2016 – Member of the Editorial Board (Review Editor) of Frontiers in Immunology
2009 – Reviewer for the following peer-reviewed journals: Nat Med, Nature Communications, Cell Reports, JCI, JCI Insight, Metabolism, Autophagy, FASEB J, Front Immunol, Sci Rep, J Transl Med, Cell Commun Signal, Molecular Neurobiol, JAD, Cell & Tissue Research, J Biol Regulators & Homeostatic Agents, Curr Med Chem, Int J Mol Sciences, Neuronal Regeneration Res
2017 Scientific Evaluation of a Grant Project for the Czech Science Foundation, Institute of Experimental Medicine, Czech Academy of Sciences/Czech Republic.
2017 Evaluator of the BelPD-Marie Curie COFUND, University of Liège/ Belgium
2015 Scientific Evaluation of a Grant Project for the Programm Klinische Forschung (KLIF), Department of Internal Medicine, Medical

University of Graz/Austria.

- **MEMBERSHIPS OF SCIENTIFIC SOCIETIES**

2019 – Member of "*Atlas Inflammation Resolution*" (AIR)
2008 – Member of "*Italian Association of Neuroimmunology*" (AINI)
2012 – Member of "*Italian Society of Immunology, Clinical Immunology and Allergology*" (SIICA)
2012 – 2016 Member of "*International Cannabinoid Society*" (IRCS)
2011 – 2013 Member of "*European Atherosclerosis Society*" (EAS)
2010 – 2012 Member of "*Italian Society for the Study of Atherosclerosis*" (SISA)

- **MAJOR COLLABORATIONS**
  - *Prof. Charles N Serhan, Brigham and Women's Hospital, Harvard Medical School, Boston/USA*
  - *Prof. Helga de Vries, MS Center Amsterdam, The Netherlands*
  - *Prof. Daniele Piomelli, Department of Anatomy and Neurobiology, University of California, Irvine/USA*
  - *Prof. Diego Centonze, UOC Neurologia, Istituto Neuromed, Pozzilli, Italy*
  - *Prof. Nicola Biagio Mercuri, UOC Neurologia, Policlinico Tor Vergata, Italy*
  - *Prof. Anders Jacobsson, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University/Sweden*

- **GRANTS/FUNDINGS**

2024/2026 – Full research grant from the Italian Foundation of Multiple sclerosis (Principal Investigator) **136.600,00 €**

2024/2024 – Metagenics Pharmaceutical grant (Principal Investigator) **20.000,00 €**

2023/2025 – PRIN (Ministry of University and Research) (Principal Investigator) **219.713,00 €**

2023/2025 – PRIN (Ministry of University and Research) (Main Collaborator; PI: Ingrid Reverte) **241.250,00 €**

2023/2025 – PNRR (Ministry of Health) (Co-PI; PI: Prof. Nicola Mercuri) **1.000.000,00 €**

2022 – Roche Grant (Principal Investigator) **50.000,00 €**

2021 – Mosaic of Autoimmunity (MAI) Grant (Principal Investigator) **10.000,00 €**

2020 – Full research grant from the Italian ministry of health, bando Finalizzata (RF-2018-12365509) (Main Collaborator; PI: Prof. Nicola Mercuri) **450.000,00 €**

2019 – Merck Pharmaceutical grant (External Collaborator; PI: Ass. Prof. Gijs Kooij) **750.000,00 €**

2019 – NWO/VIDI Research grant from the Netherland ministry of health (External Collaborator; PI: Ass. Prof. Gijs Kooij) **800.000,00 €**

2019 – Corbus Pharmaceutical grant (Principal Investigator) **40.000,00 €**

2018 – Full research grant from the Italian Foundation of Multiple sclerosis (Principal Investigator) **130.000,00 €**

2017 – Full research grant from the Italian Ministry of Health, bando Finalizzata - Giovani Ricercatori (GR-2016-02362380) (Principal Investigator) **411.150,00 €**

2016 - Full research grant from the Italian Foundation of Multiple sclerosis (Principal Investigator) **55.000,00 €**

2014 – Pilot research grant from the Italian Foundation of Multiple sclerosis (Principal Investigator) **30.000,00 €**

TOTAL FUNDINGS at IRCCS Santa Lucia Foundation (2014-2024) = **2.312.750,00 €**
TOTAL FUNDINGS at CNR-IFT (2022-2024) = **480.963,00 €**

- **PRICES/AWARDS/ACADEMIC MEMBERSHIPS:**

2024 – Rita Levi Montalcini Prize

2022 – AINI Award, Career Award in Neuroimmunology

2022 – Elsevier, Progress in Lipid Research, Young Investigator Award

2020 – MAI Award, Best Young Investigator

2019 – Young Investigator Award, Eicosanoid Research Foundation

2018 – Galeno Award, Best Young Italian Researcher

2014-2016 – Best scientific contribution at Human & Translational Immunology Conference (Rhodes, Greece 2016) and at 24th Symposium of the international Cannabinoid Society Conference (Baveno, Italy 2014)

2014 – Menzione Speciale at Galeno Award for Best Young Italian Researcher

2013 - "Marco Vergelli" Award for Best Scientific Contribution

2009-2016 – Winner of several travel grants from the following national and international conferences: ISNI (Jerusalem, 2016); Aegean Conferences (Rhodes, 2016); ECTRIMS (London, 2016); SIICA (Abano Terme, 2016; Bari, 2017); ICRS (Baveno, 2014); Gordon Conference (Waterville Valley, USA, 2013); AINI (2014, Sorrento - 2013, Milano - 2010, Stresa); Keystone Symposia (2010, Kyoto, Japan); European Society of Neuroimmunology (2009, Istanbul, Turkey).

CLINICAL TRIALS

- Lipid Mediators in Multiple Sclerosis (LipidMediators) - ClinicalTrials.gov Identifier:NCT03492606

- RiSolviMi - Reinstatement of resolution of inflammation mediators in patients with relapsing Multiple Sclerosis: a pilot study – *under approval*

CONGRESSES

Invited Speaker at the following national and international conferences/seminars:
-XXXIII AINI Congress, Torino, 5-8th May 2025
-9th European Workshop on Lipid Mediators (EWLM), Edinburg, 26-28th June 2024
-L'impatto della citofluorimetria sulla salute pubblica, ISS, Roma 21st March 2024
-Resolution of Inflammation Symposium, Boston 1-4th February 2024
-BraYn conference, Palermo 27-29th September 2023
-SIN, Rimini 12-19th May 2023
-Seminario Sclerosi Multipla, San Raffaele, Milano, 5th April 2023
-Workshop Advances in Flow Cytometry, Rome 2nd March 2023
-BraYn conference, 28-30th September 2022
-Ambiotis Resolution of Inflammation Symposium, 16th September 2022
-BraYn conference, 20-22th October 2021
-Lipid Mediator in Brain diseases Symposium, 9-10th September 2021
-Miltenyi Biotec, Neuroscience Roadshow Seminar, April 7th 2021
-Miltenyi Biotec Flow-Fix Seminar, March 12th 2021
-Neurowebinar, Rome, February 10th 2021
-Webinar Johns Hopkins Hospital, January 15th 2020
-Webinar Beckman Coulter, New Perspectives in Immunology, December 16th 2020
-Webinar at Wayne State University, Lipids@Wayne Seminars, November 4th 2020
-Conferenza Nazionale CNR, October 24th 2020
-Seminar at Humanitas University, June 23rd Milan, 2020
-Miltenyi Biotec, Advanced technologies for neuroscience research workshop, Rome, February 20th 2020
-Keystone Symposia on Lipidomics and functional metabolic pathways (Steamboat Springs, Colorado, USA, 31st March-5th April, 2019)
-7th Mediterrean Society of Neuroscience Conference (Marrakech, 23-27 June, 2019)
-73th Sisvet Conference (Olbia, Italy June 19-22nd 2019)
-Immunology 2018 (Paris, September 17-19th 2018)
-Mass Workshop (Stockholm, August 29th 2016)
-Workshop Giornata Italiana Immunologia (Roma, November 20th 2015)
-Innate Immunity Summit (London, November 17-19th 2015)
-VII European Workshop on Cannabinoids (Sestri Levante, September 17-19th 2015)
-Workshop "Biochemistry, Physiology and Pharmacology of Oxidative Stress" (Roma, July 2-4th 2015)

Organizer or chair/moderator of national and international conferences:
- Assistant Chairman at the "Gordon Research Seminar - Endocannabinoid Signaling in Neurobiology: From Molecules to Networks" (Lucca, May 23-24th 2015)
- Moderator at Gordon Conference Seminar "Cannabinoid Function in the CNS (Waterville Valley, USA 2013)

Presentation (oral or poster) in the following national and international conferences:
- Fondazione Italiana Sclerosi Multipla (FISM 2012-2024) – **13** congresses
- Associazione Italiana Neuroimmunologia (AINI 2010, 2013, 2014, 2016, 2017, 2018, 2019, 2022, 2023, 2024) - **10** congresses
- Keystone Symposia (2010, 2014, 2015, 2018, 2019) - **5** congresses
- Cell Symposia (2016, 2017, 2019, 2020) - **4** congresses
- International Cannabinoid Research Society (ICRS 2012, 2014, 2016, 2019) - **4** congresses
- BraYn Conference (Genova, 2018; Milan 2019; Virtual 2020; Pisa 2021, Rome 2022; Napoli 2023; Verona 2024) – **7** congresses

- Gordon Conferences (2013, 2015, 2018, 2019) - **4** congresses
- Società Italiana per lo studio dell'Aterosclerosi (SISA 2010-2012) - **3** congresses
- European Immunology Congress (ECI 2012, 2015) - **2** congresses
- European Atherosclerosis Society (EAS 2011, 2013) - **2** congresses
- Società Italiana Immunologia e Allergologia Clinica (SIICA 2016-2017) - **2** congresses
- Human & Translational Immunology Conference (Rhodes, Greece 2016; Kos, Greece 2019) - **2** congress
- International Society of Neuroimmunology (ISNI, Jersualem, Israel 2016) - **1** congress
- 7th Mediterrean Society of Neuroscience Conference (Marrakech, 23-27 June, 2019) – **1** congress
- 15th International Conference on Innate Immunity (Chania, Greece 2018) – **1** congress
- 11th Congresso internazionale di autoimmunità (Lisbona, 2018) – **1** congress
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS, Londra, UK 2016) - **1** congress
- Miami Winter Symposium (MIAM, Miami, USA 2016) - **1** congress
- International Immunology Congress (ICI, Milano, Italia 2013) - **1** congress
- World Immune Regulating Meeting (WIRM, Davos, Svizzera 2012) - **1** congress

LANGUAGES

- Mother tongue: Italian
- Excellent knowledge of English, both spoken and written (C2, native speaker diploma)
- Very good knowledge of French, both spoken and written (B2)
- Basic Hebrew (A2)

PREVIOUS RESEARCH ACTIVITY

Dr. Chiurchiù has centered his research activity of the past 17 years on studying the immunomodulatory role and mechanism of action of several bioactive lipids and peptides (phospholipids, endomorphins, natriuretic peptides, endocannabinoids and specialized pro-resolving lipid mediators) on distinct immune cell populations of both innate and adaptive immunity in health and disease, with a particular focus on the recent field of "Resolution of inflammation" and on Multiple sclerosis. His studies have contributed to the discovery of the physiological role of endogenous lipids such as endocannabinoids, resolvins and maresins in the modulation of T lymphocytes and their impairment in several chronic inflammatory and neurodegenerative diseases.

PROGRAMS FOR THE FUTURE

In my lab we are aiming at unraveling the complex molecular, biochemical and immunological mechanisms at the basis of the failure in timely resolving inflammation at a tissue- and cell-specific level. On the therapeutic "frontline", our future goal is not only to develop innovative and non-invasive diagnostic and prognostic tests for several neurodegenerative diseases but also to develop novel and safe therapies based on boosting endogenous mechanisms that curtail excessive inflammation and prompt its timely resolution to keep neuroinflammation within physiologic boundaries, to prevent its chronicity and to ultimately slow down progression of neurodegeneration.

natural variant of human NDP52 and its functional consequences on mitophagy. Cell Death Differ. 2021, 28(8):2499-2516.
36. Klionsky DJ et al., Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021 Jan;17(1):1-382.
37. Serhan CN, Gupta SK, Perretti M, Godson C, Brennan E, Li Y, Soehnlein O, Shimizu T, Werz O, **Chiurchiù V**, Azzi A, Dubourdeau M, Gupta SS, Schopoh P, Hoch M, Gjorgevikj D, Khan FM, Brauer D, Tripathi A, Cesnulevicius K, Lescheid D, Schultz M, Särndah E, Repsilber D, Kruse R, Sala A, Haeggström JZ, Levy BD, Filep JG, Wolkenhauer O. The Atlas of Inflammation Resolution (AIR). Mol Aspects Med 2020 Sep 3:100894.
38. Kooij G, Derada Troletti C, Leuti A, Norris PC, Riley I, Albanese M, Ruggieri S, Libreros S, van der Pol SMA, van Het Hof B, Schell Y, Guerrera G, Buttari F, Mercuri NB, Centonze D, Gasperini C, Battistini L, de Vries HE, Serhan CN, **Chiurchiù V**. Specialized Pro-Resolving Lipid Mediators Are Differentially Altered in Peripheral Blood of Patients With Multiple Sclerosis and Attenuate Monocyte and Blood-Brain Barrier Dysfunction. Haematologica. 2020;105:2056-2070. *IF = 8,2*
39. Talamonti E, Sasso V, To H, Haslam RP, Napier JA, Ulfhake B, Pernold K, Asadi A, Hessa T, Jacobsson A, **Chiurchiù V**[*], Viscomi MT[*]. Impairment of DHA Synthesis Alters the Expression of Neuronal Plasticity Markers and the Brain Inflammatory Status in Mice. FASEB J. 2020 Feb;34(2):2024-2040. [*]*co-senior and corresponding author IF = 4,4*
40. Gentile A, De Vito F, Fresegna D, Rizzo FR, Bullitta S, Guadalupi L, Vanni V, Buttari F, Stampanoni Bassi M, Leuti A, **Chiurchiù V**, Marfia GA, Mandolesi G, Centonze D, Musella A. Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons. Neuropathol Appl Neurobiol. 2020; 46:160-170.
41. Krashia P, Cordella A Nobili A, La Barbera L, Federici A, Leuti A, Campanelli F, Natale G, Marino G, Calabrese V, Ghiglieri V, Picconi B, Di Lazzaro G, Schirinzi T, San Cesario G, Casadei N, Riess O, Bernardini S, Pisani A, Viscomi MT, Calabresi P, Serhan CN, **Chiurchiù V**[*], D'Amelio M[*], Mercuri NB[*]. Blunting Neuroinflammation with resolvin D1 prevents early signs of Parkinson's disease in a rat model. Nat Commun, 2019 Sep 2;10(1):3945. [*]*co-senior*
42. Leuti A, Maccarrone M, **Chiurchiù V**. Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress. Oxid Med Cell Longev 2019; 1759464.
43. **Chiurchiù V**, Leuti A, Saracini S, Fontana D, Panaiotis F, Giua R, Padovini L, Antonelli Incalzi R, Maccarrone M. Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes. FASEB J. 2019;33(1):909-916.
44. Battista N, Di Tommaso M, Norfini A, Passerai M, **Chiurchiù V**, Mauro Maccarrone M, Monica Bari. Altered Anandamide Metabolism in Microgravity: the "RESLEM" experiment. Front Physiol, 2018. DOI: 10.3389/conf.fphys.2018.26.00013
45. Lo Iacono L, Catale C[*], Martini A[*], Valzania A, Viscomi MT, **Chiurchiù V**, Guatteo E, Bussone S, Perrone F, Di Sabato P, Aricò E, D'Argenio A, Troisi A, Mercuri NB, Maccarrone M, Puglisi-Allegra S, Casella P, Carola V. From traumatic childhood to cocaine abuse: the critical function of the immune system. Biol Psychiatry. 2018; 84:905-916. [*]*Equally contributing*
46. **Chiurchiù V**, Leuti A, Smoum R, Mechoulam R, Maccarrone M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J. 2018; 32: 5716-5723
47. **Chiurchiù V**, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018 Jan 29;9:38.
48. Bisicchia E, Sasso V, Catanzaro G, Leuti A, Besharat ZM, Chiacchiarini M, Molinari M, Ferretti E, Viscomi MT, **Chiurchiù V**. Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via

79. Cencioni MT*, **Chiurchiù V***, Catanzaro G, Borsellino G, Bernardi G, Battistini L and Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One, 2010 Jan 14;5(1):e8688. **Equally contributing*
80. Izzi V, **Chiurchiù V**, D'Aquilio F, Palumbo C, Tresoldi I, Modesti A and Baldini PM. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. International Journal of Oncology, 2009 Feb;34(2):543-50 Feb;34(2):543-50.
81. Izzi V, **Chiurchiù V**, D'Aquilio F, Martino A, Tresoldi I, Modesti A and Baldini PM. "Endomorphin-1 (EM-1) inhibits the activation and the development of a hyporesponsive-like phenotype in lipopolysaccharide (LPS)-stimulated THP-1 monocytes. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):833-43.
82. **Chiurchiù V**, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regulatory Peptides, 2008. Jun 5;148(1-3):26-32.
83. Izzi V*, **Chiurchiù V***, and Baldini PM*. Pharmacological and clinical applications of natriuretic peptides: accepted knowledges or changing views? Current Pharmaceutical Analysis, 2007 3(3):195-204. **Equally contributing*
84. Auricchio G, D'Aquilio F, **Chiurchiù V**, Mancino G, Baldini PM. Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme. Current Enzyme Inhibition, 2007 3(4):309-333. (2,618).
85. D'Aquilio F, Procaccini M, Izzi V, **Chiurchiù V**, Giambra V, Carotenuto F, Di Nardo P, Baldini PM. Activatory properties of lysophosphatidic acid on human THP-1 cells. Inflammation 2007 Oct;30(5):167-77.

BOOKS AND BOOK CHAPTERS

- **Chiurchiù Valerio** and Maccarrone Mauro. I Radicali liberi e la loro rilevanza in biomedicine: dai meccanismi molecolari alle prospettive terapeutiche. Piccin, Aprile 2016. ISBN: 978-88-299-2748-7.
- **Chiurchiù Valerio** and Mauro Maccarrone. Capitolo 25. Citofluorimetria. Metodologie biochimiche e biomolecolari (strumenti e tecniche per il laboratorio del nuovo millennio). I edizione, Giugno 2019, Zanichelli editore S.p.A., Bologna.
- **Chiurchiù Valerio**. Capitolo 26. Analisi al Citofluorimetro. Metodologie biochimiche e biomolecolari (strumenti e tecniche per il laboratorio del nuovo millennio). I edizione, Giugno 2019, Zanichelli editore S.p.A., Bologna.

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),
DICHIARA
l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Roma, 15 Aprile 2026

Firma: 

CURRICULUM VITAE

PROF.SSA GABRIELA CONSTANTIN

DIPARTIMENTO DI MEDICINA

UNIVERSITÀ DEGLI STUDI DI VERONA

Lab website: dp.univr.it/~constantin/LONI
https://twitter.com/G_ConstantinLab

TITOLI DI STUDIO

1. **Laurea in Medicina e Chirurgia** (110/110 e lode) ottenuta il 6 Novembre 1991 presso l'Università degli Studi di Milano.

2. **Specializzazione in Neurologia** ottenuta presso la Scuola di Specializzazione in Neurologia dell'Universita' di Milano (1991 - 1995) con una tesi dal titolo "La migrazione dei linfociti nel sistema nervoso centrale: uno studio sui meccanismi".

3. **Dottorato in Biologia e Patologia Molecolare e Cellulare** (2000 - 2004) presso L'Università degli Studi di Verona, con una tesi dal titolo: "Molecular mechanisms controlling lymphocyte recruitment in inflamed brain venules: a critical role for P-selectin glycoprotein ligand-1".

ATTIVITÀ PROFESSIONALE

- 1991 - 1994, Attività di ricerca presso l'Istituto di Patologia Generale, della Facoltà di Medicina e Chirurgia, Università di Verona, nel periodo compreso fra aprile 1991 e giugno 1994 e ha lavorato nell'ambito di un progetto collaborativo fra l'Università degli Studi di Milano e l'Università degli Studi di Verona teso a caratterizzare i meccanismi coinvolti nelle malattie autoimmuni del sistema nervoso. In particolare, sono state studiate le funzioni proinfiammatorie indotte nei fagociti umani da parte di componenti della mielina.
- 1997 - presente, Attività di ricerca presso il Dipartimento di Patologia e Diagnostica e successivamente presso il Dipartimento di Medicina dell'Università degli Studi di Verona. Dirige un gruppo di ricerca che studia i meccanismi molecolari coinvolti nel traffico dei leucociti e altri meccanismi che controllano i processi infiammatori e autoimmuni.
- 2000 - 2006, Assegnista di ricerca presso il Dipartimento di Patologiae Diagnostica, Sezione di Patologia Generale, Università di Verona.
- 2006 - 2014, Ricercatrice presso il Dipartimento di Patologia e Diagnostica, Università degli Studi di Verona
- 2012, Ha ricevuto esito positivo da parte del CUN per chiamata diretta come professore di seconda fascia in quanto vincitrice di un progetto dell'European Research Council (starting grant) ai sensi dall'art. 1, comma 9, della legge n. 230 del 2005, e successive modifiche, e dall'art. 29, comma 7, della legge n. 240 del 2010 e del D.M. attuativo n. 276 del 1° luglio 2011.
- 2014 - 2016, Professore Associato di Patologia Generale ed Immunologia (SSD MED04), Università di Verona
- 2016 - 2022, **Coordinatore del Corso di Dottorato in Infiammazione, Immunità e Cancro, Scuola di dottorato in Life and Health Sciences, Università degli Studi di Verona**.
- 2017 - presente, **Professore prima fascia di Patologia Generale ed Immunologia (SSD MED04), Università degli Studi di Verona**.
- 2018, **Direttore della Scuola di Dottorato in Life and Health Sciences**
- 2019 - 2021, **Co-deputato del Rettore per la Ricerca e lo Sviluppo**, membro della governance team, Università di Verona.
- 2021- 2024, Vice-direttore, Dipartimento di Medicina, Università di Verona

SOGGIORNI DI RICERCA ALL'ESTERO

Dal 1 Luglio 1994 al 30 Settembre 1997, ha svolto attività di ricerca come Postdoctoral Fellow, presso il laboratorio del prof. Eugene C. Butcher, Dipartimento di Patologia, dell'Università di Stanford, CA, USA. In questa sede ha condotto studi sui meccanismi molecolari coinvolti nel reclutamento dei linfociti nel sistema nervoso durante l'encefalomielite sperimentale autoimmune, il modello animale della sclerosi multipla. Ha inoltre studiato meccanismi di homing linfocitario negli organi linfoidi secondari in vivo in condizioni fisiologiche.

FINANZIAMENTI OTTENUTI

- Nel periodo 1996 - 2004 la dott.ssa Constantin (assegnista di ricerca) è stata titolare dei seguenti **finaziamenti per un valore totale di 610.000 Euro**: 1 Progetto Sclerosi Multipla dell'Istituto Superiore di Sanità e successivo rinnovo; 1 Progetto Strategico CNR; 3 progetti binennali Ricerca finalizzata, Ministero della Sanità; PI Unità operativa in 2 progetti della Fondazione Italiana Sclerosi Multipla; 2 progetti finanziati dalla Fondazione Cariverona; 1 progetto triennale, FIRB-MIUR postgenoma; subcontractor in 1 progetto della National Multiple Sclerosis Society, New York, USA.

- Nel periodo 2004 - 2010 ho ottenuto come PI i seguenti **finaziamenti per un valore totale di 3.230.859 Euro**:
- **1 European Research Council (ERC) Starting grant, Acronimo NEUROTRAFFICKING, n. 261079, nell'area biomedica che ha come scopo studiare meccanismi infiammatori e identificare nuovi approcci terapeutici in malattie del sistema nervoso: la sclerosi multipla e l'epilessia**; Durata del progetto: 4 anni; **Totale finanziamento: 1.200.000 Euro.**
- 3 progetti finanziati dalla National Multiple Sclerosis Society, New York, USA;
- 3 progetti finanziati della Fondazione Italiana Sclerosi Multipla;
- 1 progetto finanziato della Multiple Sclerosis International Federation; London UK;
- E' stata coordinatrice di un progetto finanziato dalla Fondazione Cariverona;
- PI unità operativa in 2 progetti finanziati della Fondazione Cariverona;
- PI Unità operativa in progetto PRIN;
- Ha ottenuto un Joint Project dall'Università degli Studi di Verona in collaborazione con la ditta Nikem Reserach, Milano.

- Nel 2009 è stato valutato positivamente il progetto europeo "In and out blood-brain barrier endothelia" Programma "Cooperation", Acronimo 3B PASSPORT (triennale), Programma Cooperation, Call FP7-HEALTH-2009-2.2.1-4 nel quale la dott.ssa Constantin era coordinatrice. Il progetto non è stato finanziato per "mancanza di fondi".

- Nel 2010 la dott.ssa Constantin ha ottenuto (come presentatrice del progetto e responsabile scientifico) **un finanziamento MIUR di 988.000 Euro per fondare la prima spinoff della Facoltà di Medicina dell'Università degli Studi di Verona.**

- Nel 2015 la Prof.ssa Constantin ha ottenuto un finanziamento dell'European Research Council (ERC) tipologia "Proof of Concept" per il periodo 2016-2017, acronimo IMPEDE grant n. 69256.
Titolo progetto: Immunomodulatory effects of sustained pantethine release in inflammatory diseases
Entità: 150.000 Euro.

- Nel 2015 la Prof.ssa Constantin ha ottenuto un finanziamento dalla National Multiple Sclerosis Society, New York, USA con un progetto dal titolo: "The role of neutrophil trafficking mechanisms in the pathogenesis of animal models of multiple sclerosis". Ruolo nel progetto: PI.
Entità: 148.000 $ USA.

- Nel 2015 la Prof.ssa Constantin (co-PI) ha ottenuto un finanziamento dall'Alzheimer Drug Discovery Foundation (ADDF), USA, con un progetto dal titolo "Inhibiting Neutrophil Extracellular Trap (NET) formation as a novel therapeutic approach to Alzheimer's disease". Ruolo nel progetto: Co-PI.
Entità: 150.000 $ USA.

- Nel 2016 la Prof.ssa Constantin ha ottenuto il progetto ERC advanced 2016-2021, grant n. 695714, acronimo IMMUNOALZHEIMER. Grant Agreement firmato in data 12.07.2016.
Titolo: The role of immune cells in Alzheimer's disease.
Entità: 2.500.000 Euro.

- ERC Proof of Concept grant Giugno 2022-Maggio 2024, intitolato "Targeting neutrophil-dependent neurotoxicity for the treatment of Alzheimer's disease", Acronym NeutrAD (GA 101069397).

- 2023-2027, PI e beneficiary in Horizon Europe Marie Curie doctoral networks; Progetto #101072895 "*Targeting Circadian Clock Dysfunction in Alzheimer's Disease*" (TClock4AD).

- Piano Nazionale di Ripresa e Resilienza (PNRR), #NEXTGENERATIONEU (NGEU), project MNESYS (PE0000006) – A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). La Prof.ssa Constantin è coordinatrice nazionale dello Spoke 7 "Neuroimmunology and neuroinflammation" e referente nazionale UNIVR.
Euro: 1.658.394 (spoke 7 coordinato dalla Prof. Constantin); Euro 4.273.600 (finanziamento UNIVR; coordinatore a livello di Ateneo: Prof. Constantin).

- Progetto PNRR - #NextGenerationEU – nell'ambito del National Biodiversity Future Center (NBFC), Centro Nazionale 5. (M4C2I1) (DM n. 3138 del 16/12/2021). Euro: 400.000 Euro (PI Prof. Constantin).

BREVETTI

- **Inhibition of Autoimmune Inflammatory Disease by a Kinase Inhibitor**
1998, Stanford University, USA
Stanford Docket Number = S97-181
G. Constantin: Inventor
Present status: expired

- **Indole and azaindole for the treatment of inflammatory and autoimmune diseases**
Application No./Patent No.: 06819177.4 – 1216 PCT/EP2006067889
Filing date: 27.10.2006
PRIORITY: EP/28.10.05/EPA 05110149
G. Constantin: Inventor
Present status: full application

- **V-ATP-ase inhibitors for use in the treatment of septic shock**
Application No./Patent No.: 06819178.2 – 1216 PCT/EP2006067890
Filing date: 27.10.2006
PRIORITY: EP/28.10.05/EPA 05110163
G. Constantin: Inventor
Status: full application

- **Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy**
Application No./Patent No.: 07809438.0 – 1222 PCT/US2007013624
Filing date: 06.06.2007
PRIORITY: US/07.06.06/ USP 811873G. Constantin: Inventor
Status: full application/licensed

- **Modulation of leukocyte activity in treatment of neuroinflammatory degenerative diseases**
Application No./Patent USA: 61886562
Filing date: 03.10.2014
G. Constantin: Inventor
Status: full application

- **Blockade of Tim-1 Pathways and P-Selectin Pathways in Treatment of Neuroinflammatory Degenerative Disease**
U.S. Application Serial No. 62/334,986
Filing date: 21.06.2016
G. Constantin: Inventor
Status: full application

BORSE DI STUDIO ED ONORIFICENZE

1993 - Premio di studio "De Vizart" 1993 conferito dall'Universita' degli Studi di Milano ai neolaureati per attività di ricerca

1995 - Borsa di Studio conferita dalla National Multiple Sclerosis Society, New York, USA

1997 - Borsa di Studio conferita dalla Fondazione Italiana Sclerosi Multipla

2000 - Primo premio dell'European Charcot Foundation, Lausanne (CH), assegnato a la giovani ricercatori (sotto 35 anni) per la ricerca europea sulla sclerosi multipla.

2003 - **Premio Rita Levi Montalcini** assegnato a giovani ricercatori per "l'importante contributo alla ricerca scientifica internazionale sulla sclerosi multipla".

2004 - Nomination, " International Health Professional 2005", International Biographical Centre, Cambridge, UK.

2006 - Nomination, Multiple Sclerosis International Federation, Londra, Regno Unito.

2012 - **Nomination, "Outstanding female scientist" dall'European Research Council (ERC)**.

AFFILIAZIONI A SOCIETA' SCIENTIFICHE

- 2000 - presente, memebro dell'Associazione Italiana di Neuroimmunologia
- 2000 - presente, meembro della Societa' Italiana di Immunologia e Allergologia Clinica (SIICA)
- 2002 - presente, memebro dell'American Association of Immunologists (AAI), USA
- 2006 - presente, emmbro della Henry Kunkel Society, Rockefeller University, New York, USA
- 2014 - presente, membro dell'Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)

"COMMISSIONS OF TRUST" (selezione)

- 2006 - 2009, Membro del Consiglio Direttivo dell'Associazione Italiana di Neuroimmunologia (AINI).
- 2011 -2016, 2018-presente, Membro del Comitato Scientifico della Fondazione Italiana Sclerosi Multipla.
- 2010 - 2014, Membro del Scientific Advisory Board della ditta Micromet AG, Munich, Germany e dell'Amgen Corporation, Thousand Oaks, CA, USA.
- 2010 - presente, Membro dell'Organismo Preposto per il Benessere Animale (OPBA) (Comitato tecnico-scientifico) dell'Università di Verona.
- 2014 - presente, Membro del editorial board di Scientific Reports (Nature group) e PeerJ journal.
- 2018 – 2022 Membro del Scientific Board dell'International Society of Neuroimmunology (ISNI).
- 2018 - presente, Membro del Comitato Scientifico della Fondazione Italiana Sclerosi Multipla.
- 2019, Member of the evaluation panel for Germany's Excellence Strategy, German Council of Science and Humanities.

- 2019 - presente, Membro del Consiglio Direttivo dell'Associazione Italiana di Neuroimmunologia (AINI).
- 2017 - 2021, Member of the Neuroscience Panel, Research Council of Norway
- 2021 - 2024, Representante del Dipartimento per la Ricerca e assicurazione della qualità (AQ)
- 2024 - 2026, Chair del Consiglio Direttivo dell'Associazione Italiana di Neuroimmunologia (AINI).
- 2025 - 2026, Panel member per la valutazione dei progetti europei tipologia ERC avanzato, settore LS5 Neuroscienze e malattie neurologiche.

La Prof.ssa Constantin ha collborato/collabora attualmente con le seguenti ditte: GlycoMimetics Inc, Gaithersburg, MD USA, Astrazeneca R&D, Mölndal, Sweeden, ONO Pharmaceutical Japan, Nikem Research Milan, Italy, Biogen Idec USA, Vifor/OM Pharma, Switzerland, CLS Therapeutics, UK, Carthera, Francia.

ATTIVITA' DIDATTICA

- Docente di Fisiopatologia generale, AA 2000 - 2001, Laurea Triennale in infermieristica, Sede Legnago
- Docente di Fisiopatologia medica, AA 2001 - 2002, Laurea Triennale in Infermieristica, Sede Legnago
- Docente di Fisiopatologia generale, AA 2002 - 2003, Laurea Triennale in Infermieristica, Sede Legnago
- Docente di Patologia Generale ed Immunologia, 2003 - 2018, Laurea triennale in Infermieristica, Sede Verona (30 ore/anno)
- Docente di Patologia Generale ed Immunologia, 2005 - 2018, Laurea triennale in Tecniche della Prevenzione nell'Ambiente e nei Luoghi di Lavoro (TPALL), Sede Rovereto (20 ore/anno)
- Docente presso la Laurea Magistrale in Bioinformatica e Biotecnologie mediche (LM9), 2010-presente, Corso Avanzato di Biologia dei Sistemi (32 ore/anno)
- Docente presso la Laurea Magistrale in Informatica (Bioinformatica medica, LM18), 2016-presente, Corso Avanzato di Biologia dei Sistemi (32 ore/anno)
- Attività didattica presso il Corso di Dottorato in Infiammazione, Immunità e Cancro presso il quale svolge anche attività di Coordinatore dal 2016.
- 2017 - presente, Docente presso la Laurea Magistrale in Molecular and Medical Biotechnology (LM9), Corso in Molecular and Cell Pathology (48 ore/anno)
- 2024 - presente, Docente presso il Corso di Laurea in Scienze nutraceutiche e della salute alimentare

RELATORE A CORSI DI AGGGIORNAMENTO

- Relatore presso la Royal Society of Medicine, Corso intitolato "Signal transduction pathways in chronic inflammation", Londra, UK, 11 Dicembre 2000.
- Relatore presso il Corso Residenziale di Neuroimmunologia (CRNI), programma ECM del Ministero della Sanita', Bergamo, 20-23 Marzo 2002.

- Relatore presso il Corso Biennale Patogenesi e Clinica delle Malattie Demielinizzanti, programma ECM del Ministero della Sanita', Milano, 2-5 Marzo 2004.
- Relatore presso l'International PhD Program of Molecular Medicine, and International PhD Program in Cell and Molecular Biology della Vita Salute San Raffaele University, Corso intitolato "Spatial And Temporal Dynamics Of Immune Responses", Dibit-Scientific Institute San Raffaele, Milano, IT, Aula Aristotele, 21-25 giugno 2004.
- Relatore presso il Corso Residenziale di Neuroimmunologia (CRNI), programma ECM del Ministero della Sanita', programma ECM del Ministero della Sanita'Bergamo, 6-9 Aprile 2016.

ATTIVITA' DI REVIEWER e EDITORIALE

- Dal 2009 fa parte dell'Editorial Board di Experimental and Therapeutic Medicine (www.spandidos-publications.com)
- Dal 2014 – presente fa parte dell'Editorial board di PeerJ (http://peerj.com)
- Dal 2015 – presente fa parte dell'Editorial board di Scientific Reports (gruppo Nature) (nature.com/scientificreports)
- Reviewer di progetti di ricerca sottoposti a richiesta di finanziamento alle seguenti agenzie: Fondazione Italiana Sclerosi Multipla, Genova, Italia; National Multiple Sclerosis Society, New York, USA; Wellcome Trust, London UK; UK Multiple Sclerosis Society.
- Reviewer per le seguenti riviste: Nature, Nat. Communic., Immunity, Proc. Natl. Acad. Sci.; J. Immunol.; J. Exp. Med.; Trends in Mol. Med.; Blood; Br. J. Pharmacol.; J. Neuroimmunol., etc

CONGRESSI E SEMINARI (selezione)

1. Organizatrice del International meeting "New insights into immunosuppression and treatment of autoimmune diseases", Verona, November 3, 2006; sponsor Miltenyi Biotec.
2. Organizatrice del 17th meeting of the Italian Neuroimmunology Association (AINI), Verona Sept. 30-Oct 3, 2007.
3. Organizatrice, del 29th meeting of the Italian Neuroimmunology Association (AINI), Verona Sept. 16-19, 2021.
4. Organizatrice, del 31st meeting of the Italian Neuroimmunology Association (AINI), Palermo, May 3-6, 2023.
5. Organizzatrice del 33st meeting of the Italian Neuroimmunology Association (AINI), Torino, May 6-8, 2025.
6. Membero del comitato organizzatore dell'International Congress of Neuroimmunology, Venice, October 2027.

INVITED SPEAKER (selezione):

- Chairman della sezione di "Leukocyte recruitment", del 7TH International Congress of Neuroimmunology, Venice, September 27 - October 02, 2004.
- Dal 2004 - 2016, Chairman, congressi annuali dell'Associazione Italiana Neuroimmunologia

PUBBLICAZIONI

1) Baron P., **G. Constantin**, A. D'Andrea, D. Ponzin, E. Scarpini, G. Scarlato, G. Trinchieri, F. Rossi and M. Cassatella.
Production of tumor necrosis factor and other proinflammatory cytokines in human mononuclear phagocytes stimulated with myelin P2 protein.
Proc. Natl. Acad. Sci. USA, 90:4414-4418, 1993.

2) Cassatella M.A., M. Aste, F. Calzzetti, **G. Constantin**, M. Ceska and F. Rossi. Studies on the regulatory mechanisms of Inteleukin-8 gene expression in resting and IFN-gamma-treated neutrophils: evidence on the capability of staurosporine of inducing the production of Interleukin-8 by human neutrophils
Biochem. Biophys. Res. Communic. 190:660-667, 1993.

1) Cassatella M.A., L. Meda, S. Bonora, M. Ceska, and **Constantin G.**
Interleukin 10 inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of TNF and IL-10 in mediating the production of IL-8 triggered by lipopolysaccaride.
J. Exp.Med. 178:170-175, 1993.

4) Laudanna C., **Constantin G.**, P. Baron, E. Scarpini, G. Scarlato, G. Cabrini, M.A. Cassatella F. Rossi and G. Berton.
Sulfatides trigger increase of cytosolic free calcium, and enhanced expression of tumor necrosis factor-alfa, and interleukin-8 mRNAs in human neutrophils. Evidence for a role of L-selectin as a signaling molecule.
J. Biol Chem. 269:4021-4026, 1994.

5) **Constantin G.**, C. Laudanna, P. Baron, and G. Berton.
Sulfatides trigger cytokine genes expression and protein secretion in human monocytes
FEBS letters 350:66-70, 1994.

6) P. Baron, **Constantin G.**, L. Meda, E. Scarpini, G. Scarlato, G. Trinchieri, G. Monastra, F. Rossi. and M.A. Cassatella.
Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein
Neurosci. Letters, 252:151, 1998.

7) **Constantin G.**, C. Laudanna and E. Butcher.
Novel method for following lymphocyte traffic in mice using [3H]-glycerol labelling
J. Immunol. Meth., 203:35, 1997.

8) **Constantin G.**, S. Brocke, A. Izikson, C. Laudanna, E. Butcher.
Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively-induced experimental allergic encephalomyelitis.
Eur. J. Immunol., 28:3523-3529, 1998.

9) **Constantin G.**, C. Laudanna, S. Brocke, E. Butcher.
Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor.
J. Immunol., 162:1144-1149, 1999.

10) C. Laudanna, D. Mochly-Rosen, T. Lion, **G. Constantin**, E. Butcher.
Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil in integrin-dependent adhesion and chemotaxis.
J. Biol. Chem., 273:30306-30315, 1998.

11) **Constantin G.**, L Piccio, Bussini S, Pizzuti A., E. Scarpini, P. Baron, G. Conti, S. Pizzul, G. Scarlato.
Induction of adhesion molecules on human Schwann cells, an immunofluorescence study.
J. Neurol. Sci., 170:124-130, 1999.

12) **Constantin G.,** M. Majeed, C. Giagulli, L. Piccio, J. Y. Kim, and C. Laudanna.
Chemokines trigger immediate beta2 Integrin affinity and mobility Changes: differential regulation and roles in lymphocyte arrest under flow
Immunity, 16:759-769, 2000.

13) Y. Torrente, J.P. Tremblay, F. Pisati, M. Belicchi, B. Rossi, M. Sironi, **G. Constantin**, M. El Fhaime, M.G. D'Angelo, N. Caron, D. Paulin, G. Scarlato and N. Bresolin.
Intraarterial injection of muscle-derived CD34+ SCA-1+ stem cells restore dystrophin in *mdx* mouse.
J. Cell Biology, 152(2):335-48, 2001.

14) Molecular mechanisms involved in lymphocyte recruitment in brain microcirculation: critical roles for PSGL-1 and trimeric Galphai linked receptors
Piccio L., Rossi B., Scarpini E., Giagulli C, Laudanna C., Issekutz A., Vestweber D., Butcher E., **Constantin G.**
J. Immunol., 168(4):1940-1949, 2002.

15) Laudanna C., Kim Y., **Constantin G.,** Butcher E.
Rapid integrin activation by chemokines.
Immunol. Rev. 186: 37-46, 2002.

16) Laudanna C. and **Constantin G**.
New models of intravital microscopy for analysis of chemokine receptor-mediated leukocyte vascular recognition.
J. Immunol. Methods, 273(1-2):115-123, 2003.

17) Battistini L., Piccio L., Rossi B., Bach S., Galgani S., Gasperini C., Ottoboni L., Ciabini D., Caramia D., Bernardi G., Laudanna C., Scarpini E., Borsellino G. and **Constantin G**.
CD8+ lymphocytes from acute multiple sclerosis patients display selective increase of adesiveness in brain venules: a critical role for P-selectin-glycoprotein ligand-1.
Blood, 101(12):4775-82, 2003.

Nat Med. 2008 Dec;14(12):1377-83.

35) Bolomini-Vittori M, Montresor A, Giagulli C, Staunton D, Rossi B, Martinello M, **Constantin G**, Laudanna C.
Regulation of conformer-specific activation of the integrin LFA-1 by a chemokine-triggered Rho signaling module.
Nat. Immunol. 2009 Feb;10(2):185-94.

36) **Constantin G**, Marconi S, Rossi B, Angari S, Calderan L, Anghileri E, Gini B, Bach S, Martinella M, Bifari F, Galiè M, Turano E, Budui S, Sbarbati A, Krampera M, Bonetti B.
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis.
Stem Cells. 2009 Oct;27(10):2624-35.

37) Deban L, Russo CL, Sironi M, Moalli F, Scanziani M, Zimbelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, Evangelista V, Rossi B, Zenaro E, **Constantin G**, Laudanna C, Bottazzi B and Mantovani A. Binding to P-selectin and regulation of leukocyte recruitment by the long pentraxin PTX3, a key component of humoral innate immunity.
Nat. Immunol. 2010 Apr;11(4):328-34.

38) **Constantin G** and Laudanna C. A deadly migration.
Immunity, 2010 Feb; 32(2): 147-149.

39) **Constantin G**, Laudanna C. Leukocyte chemotaxis: from lysosomes to motility.
Nat. Immunol., 2010 Jun;11(6):463-4.

40) Fabene PF, Bramanti P, **Constantin G**. The emerging role for chemokines in epilepsy.
J Neuroimmunol. 2010 Jul 27;224(1-2):22-7.

41) Sotgiu S, Murrighile MR, **Constantin G**.
Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.
BMC Neurol. 2010 Sep 23;10:84.

42) Lapilla M, Gallo B, Martinello M, Procaccini C, Costanza M, Musio S, Rossi B, Angiari S, Farina C, Steinman L, Matarese G, **Constantin G**, and Pedotti R. Histamine regulates autoreactive T cell activation and adhesiveness in inflamed brain microcirculation.
J Leukoc Biol. 2011 Feb;89(2):259-67.

43) Rossi B, Angiari S, Zenaro E, Budui SL, **Constantin G**.
Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions.
J Leuk Biol. 2011 Apr;89(4):539-56.

44) Rossi B, Zenaro E, Angiari S, Ottoboni L, Bach S, Piccio L, Pietronigro EC, Scarpini E, Fusco M, Leon A, **Constantin G**.
Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism.
J Neuroimmunol. 2011 Apr;233(1-2):97-105.

45) **Constantin G**, Laudanna C.
Transmigration of effector T lymphocytes: changing the rules.
Nat Immunol. 2011 Dec 16;13(1):15-6.

46) Marconi S, Castiglione G, Turano E, Bissolotti G, Angiari S, Farinazzo A, **Constantin G**, Bedogni G, Bedogni A, Bonetti B.
Human adipose-derived mesenchymal stem cells systemically injected promote peripheral nerve regeneration in the mouse model of sciatic crush.
Tissue Eng Part A. 2012 Jun;18(11-12):1264-72.

47) Montresor A, Toffali L, **Constantin G**, Laudanna C.
Chemokines and the signaling modules regulating integrin affinity.
Front Immunol. 2012 May 25;3:127.

48) Fabene P, Laudanna C, **Constantin G**.
Leukocyte trafficking mechanisms in epilepsy
Mol. Immunol., 2013 Jan 23. 013 Apr;91(4):271-80.

49) Use of imaging to study leukocyte trafficking in the central nervous system.
Zenaro E, Rossi B, Angiari S, **Constantin G**.
Immunol Cell Biol. 2013 Apr;91(4):271-80.

50) M tuberculosis in the Adjuvant Modulates Time of Appearance of CNS-Specific Effector T Cells in the Spleen through a Polymorphic Site of TLR2.
Nicolò C, Di Sante G, Procoli A, Migliara G, Piermattei A, Valentini M, Delogu G, Cittadini A, **Constantin G**, Ria F.
PLoS One. 2013;8(2):e55819.

51) Rougerie P, Largeteau Q, Megrelis L, Carrette F, Lejeune T, Toffali L, Rossi B, Zeghouf M, Cherfils J, **Constantin G**, Laudanna C, Bismuth G, Mangeney M, Delon J. Fam65b is a new transcriptional target of FOXO1 that regulates RhoA signaling for T lymphocyte migration.
J Immunol. 2013 Jan 15;190(2):748-55.

52) Marconi S, Bonaconsa M, Scambi I, Squintani GM, Rui W, Turano E, Ungaro D, D'Agostino S, Barbieri F, MD, Angiari S, Farinazzo A, **Constantin G**, Del Carro U, Bonetti B, Mariotti R.
Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model.
Neuroscience, 2013 May 28;248C:333-343.

disease
Front Immunol. 2016 Feb 15;7:33. doi: 10.3389/fimmu.2016.00033.

62) Piermattei A, Migliara G, Di Sante G, Foti M, Hayrabedyan SB, Papagna A, Geloso MC, Corbi M, Valentini M, Sgambato A, Delogu G, **Constantin G**, Ria F.
Toll-Like Receptor 2 Mediates In Vivo Pro- and Anti-inflammatory Effects of Mycobacterium Tuberculosis and Modulates Autoimmune Encephalomyelitis
Front Immunol. 2016 May 24;7:191. doi: 10.3389/fimmu.2016.00191.

63) Rossi B, **Constantin G**. Live Imaging of Immune Responses in Experimental Models of Multiple Sclerosis.
Front Immunol. 2016 Nov 21;7:506.

64) Zenaro E, Piacentino G, **Constantin G**. The blood-brain barrier in Alzheimer's disease.
Neurobiol Dis. 2016 Jul 15. pii: S0969-9961(16)30165-6.

65) Pietronigro E, Della Bianca V, Zenaro E, **Constantin G**. NETosis in Alzheimer's disease
Front Immunol. 2017 Mar 2;8:211. doi: 10.3389/fimmu.2017.00211.

66) Zenaro E, **Constantin G**. Targeting neuroinflammation in the treatment and prevention of Alzheimer's disease. *Drugs of the future, 2017; 42(1), pp. 21-42.*

67) Farinazzo A, Angiari S, Turano E, Bistaffa E, Dusi S, Ruggieri S, Bonafede R, Mariotti R, **Constantin G**, Bonetti B.
Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis.
Sci Rep. 2018 May 10;8(1):7473. doi: 10.1038/s41598-018-25676-2.

68) Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D and **Constantin G.**
Functional morphology of the blood-brain barrier in health and disease.
Acta Neuropathol. 2018 Mar;135(3):311-336.

69) Zhang X, Wang Y, Yuan J, Li N, Pei S, Xu J, Luo X, Mao C, Liu J, Yu T, Gan S, Zheng Q, Liang Y, Guo W, Qiu J, **Constantin G**, Jin J, Qin J, Xiao Y.
Macrophage/microglial EXh2 facilitates autoimmune inflammation through inhibition of Socs 3.
J Exp Med. 2018 May 7;215(5):1365-1382. doi: 10.1084/jem.20171417. Epub 2018 Apr 6.

70) Pietronigro E, Zenaro E, Bianca VD, Dusi S, Terrabuio E, Iannoto G, Slanzi A, Ghasemi S, Nagarajan R, Piacentino G, Tosadori G, Rossi B, **Constantin G**.
Blockade of α4 integrins reduces leukocyte-endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer's disease.
Sci Rep. 2019 Aug 19;9(1):12055. doi: 10.1038/s41598-019-48538-x.

71) Rossi B , **Constantin G** , Zenaro E. The Emerging Role of Neutrophils in Neurodegeneration
Immunobiology. 2019 Nov 9[Online ahead of print]. PMID: 31740077.
DOI: 10.1016/j.imbio.2019.10.014

72) Dusi S, Angiari S, Pietronigro EC, Lopez N, Angelini G, Zenaro E, Della Bianca V, Tosadori G, Paris F , Amoruso A , Carlucci T, **Constantin G**, Rossi B. LFA-1 Controls Th1 and Th17 Motility Behavior in the Inflamed Central Nervous System
Front Immunol., 10, 2436 2019 Oct 18 eCollection 2019.

73) Mantile F, Capasso A, Villacampa N, Donnini M, Liguori GL, Constantin G, De Berardinis P, Heneka MT, Prisco A. Vaccination With (1-11)E2 in Alum Efficiently Induces an Antibody Response to β-Amyloid Without Affecting Brain β-Amyloid Load and Microglia Activation in 3xTg Mice.
Aging Clin Exp Res 2019 Nov 22 [Online ahead of print]. PMID 31758499.

74) Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G.
In vitro Models of Neurodegenerative Diseases.
Front Cell Dev Biol. 2020 May 13;8:328. doi: 10.3389/fcell.2020.00328. eCollection 2020.

75) Xu J, Yu T, Pietronigro EC, Yuan J, Arioli J, Pei Y, Luo X, Ye J, **Constantin G**, Mao C, Xiao Y.
Peli1 impairs microglial Aβ phagocytosis through promoting C/EBPβ degradation.
PLoS Biol. 2020 Oct 5;18(10):e3000837. doi: 10.1371/journal.pbio.3000837. eCollection 2020 Oct.

76) Rossi B, Santos-Lima B, Terrabuio E, Zenaro E, Constantin G.
Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease.
Front Immunol. 2021 Feb 19;12:639369. doi: 10.3389/fimmu.2021.639369. eCollection 2021.

77) Peikert K, Federti E, Matte' A, **Constantin G**, Pietronigro EC, Fabene PF, Defilippi P,… Hermann A, De Franceschi L.
Therapeutic Targeting of Lyn Kinase to Treat Chorea-Acanthocytosis.
Acta Neuropathol Commun. 2021 May 3;9(1):81. doi: 10.1186/s40478-021-01181-y.

78) Caligola S, Carlucci T, Fummi F, Laudanna C, **Constantin G**, Bombieri N e Giugno R.
Automatic Parameterization of the Purine Metabolism Pathway through Discrete Event-based Simulation
16th IEEE International Conference on Computational Intelligence in Bioinformatics and Computational Biology (IEEE CIBCB 2019).

79) Montresor A, Toffali A, Fumagalli L, **Constantin G**, Vinante F, Rigo A, Ferrarini I, Laudanna C. Activation of protein tyrosine phosphatase receptor type γ (PTPRG) suppresses mechanisms of adhesion and survival in CLL cells.
J Immunol. 2021 Jul 15;207(2):671-684. doi: 10.4049/jimmunol.2001462.

80) Tredicine M, Camponeschi C, Pirolli D, Lucchini M, Valentini M, Geloso MC, Mirabella M, Fidaleo M, Righino B, Moliterni C, Giorda E, Rende M, De Rosa MC, Foti M, **Constantin G**, Ria F, Di Sante G.
A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis.
iScience. 2022 Jan 11;25(2):103763. doi: 10.1016/j.isci.2022.103763.

81) The role of neutrophils in the dysfunction of central nervous system barriers.
Santos-Lima B, Pietronigro EC, Terrabuio E, Zenaro E, **Constantin G**.
Front Aging Neurosci. 2022 Aug 11;14:965169. doi: 10.3389/fnagi.2022.965169. eCollection 2022.

82) Costa S, Bevilacqua D, Caveggion E, Gasperini S, Zenaro E, Pettinella F, Donini M, Dusi S, **Constantin G**, Lonardi S, Vermi W, De Sanctis F, Ugel S, Cestari T, Abram CL, Lowell CA, Rodegher P, Tagliaro F, Girolomoni G, Cassatella MA, Scapini P.
Neutrophils inhibit γδ T cell functions in the imiquimod-induced mouse model of psoriasis.
Front Immunol. 2022 Nov 15;13:1049079. doi: 10.3389/fimmu.2022.1049079. eCollection 2022.

83) Toffali L, D'Ulivo B, Giagulli C, Montresor A, Zenaro E, Delledonne M, Rossato M, Iadarola B, Sbarbati A, Bernardi P, Angelini G, Rossi B, Lopez N, Linke WA, Unger A, Di Silvestre D, Benazzi L, De Palma A, Motta S, **Constantin G**, Mauri P, Laudanna C.
An isoform of the giant protein titin is a master regulator of human T lymphocyte trafficking.
Cell Rep. 2023 May 30;42(5):112516. doi: 10.1016/j.celrep.2023.112516. Epub 2023 May 18.

84) Angelini G, Bani A, **Constantin G**, Rossi B.
The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis.
Front Cell Neurosci. 2023 Feb 15;17:1101379. doi: 10.3389/fncel.2023.1101379. eCollection 2023.

85) Rossi B, Dusi S, Angelini G, Bani A, Lopez N, Della Bianca V, Pietronigro EC, Zenaro E, Zocco C, **Constantin G**.
Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis.
Front Immunol. 2023 Apr 18;14:1071553. doi: 10.3389/fimmu.2023.1071553. eCollection 2023.

86) Expression of the ether-a-gò-gò-related gene 1 channel during B and T lymphocyte development: role in BCR and TCR signaling.
Sala C, Staderini M, Lottini T, Duranti C, Angelini G, **Constantin G**, Arcangeli A.
Front Immunol. 2023 Sep 8;14:1111471. doi: 10.3389/fimmu.2023.1111471. eCollection 2023.

87) slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.
Finotti G, Pietronigro E, Balanzin C, Lonardi S, **Constantin G**, Chao MP, Tecchio C, Vermi W, Cassatella MA.
Cancer Immunol Res. 2023 Nov 1;11(11):1538-1552. doi: 10.1158/2326-6066.CIR-23-0239.

88) Terrabuio E, Zenaro E, Constantin G.
The role of the CD8+ T cell compartment in ageing and neurodegenerative disorders.
Front Immunol. 2023 Jul 28;14:1233870. doi: 10.3389/fimmu.2023.1233870.

89) Rigo A, Vaisitti T, Laudanna C, Terrabuio E, Micillo M, Frusteri C, D'Ulivo B, Merigo F, Sbarbati A, Mellert K, Möeller P, Montresor A, Di Napoli A, Cirombella R, Butturini E, Massaia M, **Constantin G**, Vinante F, Deaglio S, Ferrarini I.
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome.
Cell Death Dis. 2024 May 9;15(5):323. doi: 10.1038/s41419-024-06707-5.

90) Bontempi P, Piccolantonio G, Busato A, Conti A, Angelini G, Lopez N, Bani A, **Constantin G**, Marzola P.
Resting-state functional magnetic resonance imaging reveals functional connectivity alteration in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
NMR Biomed. 2024 Jun;37(6):e5127. doi: 10.1002/nbm.5127.

91) Turano E, Scambi I, Bonafede R, Dusi S, Angelini G, Lopez N, Marostica G, Rossi B, Furlan R, **Constantin G**, Mariotti R, Bonetti B.

Extracellular vesicles from adipose mesenchymal stem cells target inflamed lymph nodes in experimental autoimmune encephalomyelitis.
Cytotherapy. 2024 Mar;26(3):276-285. doi: 10.1016/j.jcyt.2023.12.007. Epub 2024 Jan 16.

92) De Sanctis F, Dusi S, Caligola S, Anselmi C, Petrova V, Rossi B, Angelini G, Erdeljan M, Wöll S, Schlitter AM, Metzler T, Steiger K, Borok Z, Bailey P, Bauer A, Halin C, Boschi F, Giugno R, Canè S, Lawlor R, Corbo V, Scarpa A, **Constantin G**, Ugel S, Vascotto F, Sahin U, Türeci Ö, Bronte V.
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer.
Immunity. 2024 Jun 11;57(6):1378-1393.e14. doi: 10.1016/j.immuni.2024.04.021. Epub 2024 May 14.

93) Terrabui E and **Constantin G**.
APOE4 affects neutrophil–microglia crosstalk in Alzheimer's disease.
Trends in Immunology, October 2024, Vol. 45, No. 10, 726-727.

94) Angiari S, Carlucci T, Budui SL, Bach SD, Dusi S, Walter J, Ellmeier E, Schnabl A, Stracke A, Bordag N, Tafrali C, Demjaha R, Khalil M, Angelini G, Terrabuio E, Pietronigro EC, Zenaro E, Laudanna C, Rossi B, Constantin G.
Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation.
J Neuroinflammation. 2024 Nov 5;21(1):287. doi: 10.1186/s12974-024-03270-w.

95) Heneka MT, …. **Constantin G**, …Riechers SP. Neuroinflammation in Alzheimer's disease.
Nat Revs Immunol, 2024 Dec 9. doi: 10.1038/s41577-024-01104-7.

CAPITOLI DI LIBRI

1) Carnini C., **Constantin G**., Rossi B., De Curtis M., Folco G.
Firm adhesion of neutrophils to cerebral vascular endothelium "in vivo": a role for cys-leukotrienes.
Source: Advances in prostaglandin, leukotriene, and other bioactive lipid research: basic science and clinical applications. Book Series:
Adv Exp Med Biol. 525:35-8, 2003.

2) **Constantin G**.
Visualization and analysis of adhesive events in brain venules by using intravital microscopy.
In *Cell migration in inflammation: Methods and Protocols.* F. Sinigaglia and D. D'Ambrosio eds., The Humana Press Inc, Totowa, NJ.
Methods Mol Biol. 2004;239:189-98.

3) **Constantin G** & Laudanna C.
Mechanisms of leukocyte integrin activation.
In *Leukocyte trafficking***,** Hamann and Engelhardt editors, Wiley-VCH, 2005, *pp 68-81.*

4) **Constantin G** & Laudanna C.
Lymphocyte-endothelial cell interaction
In *Lymphocyte trafficking in Health and Disease,* Badolato and Sozzani editors, Birkhauser Verlag, Basel Switzerland 2006, *pp39-54.*

5) **Constantin G.**
Analysis of leukocyte recruitment in synovial microcirculation by intravital microscopy.
In *Arthritis Research: Methods and Protocols. vol.1, pp 333-341.* Andrew P. Cope ed., The Humana Press Inc, Totowa, NJ. Methods Mol Med. 2007;135:333-41.

6) Fabene PF, **Constantin G**, Bentivoglio M and Sbarbati A. Modulation of neuronal excitability: vascular changes and inflammation. *In: Encyclopedia of basic epilepsy research, 2009,* vol. 2, p. 593-599, P.A. Schwartzkroin editor.

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),
DICHIARA
l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Verona, 16/04/2024

Firma: _____

Prof.ssa Gabriela Constantin

ANTONELLA CONTE
Curriculum Vitae

Part I – General Information

Full Name	Antonella Conte
Date of Birth	30/03/1972
Place of Birth	Rome
Citizenship	Italian
E-mail	antonella.conte@uniroma1.it

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,…)
Corso Alta Formazione	2021	Politecnico di Milano-	Formazione su controllo di gestione e performance di processo in neurologia.
PhD	2009	Sapienza, University of Rome	PhD in Clinical and Experimental Neurology
Specialty training/Residency	2005	Sapienza, University of Rome	Neurology
University graduation	1999	Sapienza, University of Rome	Medical Doctor Degree
Licensure 01	2000	Ordine dei Medici chirurghi e odontoiatria di Rome	n° 50094

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
30/10/2024	**To date**	**Department of Human Neuroscience, "Sapienza", University of Rome, Rome, Italy**	**Full Professor of Neurology**
2022	To date	Research labs "Human neurosciences, movement disorders and epilepsy"	Head

09/01/2020	To date	Scientific Board certified Full Professor in Neurology (Abilitazione Scientifica Nazionale a Professore I Fascia; MED26- SD 06/D6).	
02/05/2019	29/10/2024	Department of Human Neuroscience, "Sapienza", University of Rome, Rome, Italy	Associate Professor in Neurology
02/05/2016	01/05/2019	"Sapienza", University of Rome/ Department of Neurology and Psychiatry	Researcher -Ricercatore TD-B (art. 24 c.3-b L. 240/10);
1/11/2012	31/10/2015	"Sapienza", University of Rome/ Department of Neurology and Psychiatry	Researcher -Ricercatore a t.d. A-t. defin. (art. 24 c.3-a L. 240/10)
3/11/2008	02/11/2011	"Sapienza", University of Rome/ Department of Neurology and Psychiatry	Researcher- Ricercatore a t.d. (art.1 comma 14 L. 230/05);

IIIB – Clinical appointments

Start	End	Institution	Position
2026	To date	Policlinico Umberto I Hospital – Neurology Unit- DAI Neuroscience and Mental Health	Director of the Program Unit for High-Complexity Neurological Disorders
02/02/2023	To date	Policlinico Umberto I Hospital-Hospital drugs & therapeutics committee	Member
01/01/2020	To date	Multiple Sclerosis Center- Policlinico Umberto I Hospital – Neurology Unit-DAI Neuroscience and Mental Health	Head/Coordinator
01/01/2019	To date	Policlinico Umberto I Hospital – Neurology Unit- DAI Neuroscience and Mental Health	Neurologist Consultant

IIIC – Clinical trials

Principal Investigator of the following clinical trials:

- "A phase IIIB multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with relapsing multiple sclerosis" Codice Protocollo: BN42082 Sponsor: F. Hoffmann-La Roche Ltd

- "A PHASE III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in adult patients with relapsing multiple sclerosis" Codice Protocollo: GN41851 Sponsor: F. Hoffmann-La Roche Ltd

- "Natalizumab da Endovenoso A Sottocutaneo: Indagine su Efficienza e Risparmi – lo studio EASIER" Sponsor: Biogen

- "Prospective Observational Study Aimed at Evaluating Treatment Satisfaction and Effectiveness in Patients with Relapsing Multiple Sclerosis Starting CLADRibinE TAbLets (CLADREAL)
  Codice Protocollo: MS700568_0199 Sponsor: Merck

- "Oral CLADribine in patients that Change from first-line Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety study (CLAD CROSS)" Codice Protocollo: MS700568_0070 Sponsor: Merck

- "TOP Tysabri Observational Program" Codice Protocollo: IMA-06-02. Sponsor: Biogen

- "Studio osservazionale multicentrico, globale per raccogliere informazioni sulla sicurezza e per documentare l'utilizzo farmacologico di Tecfidera TM (dimetilfumarato), quando usato nella pratica medica di routine nel trattamento della sclerosi multipla (ESTEEM)" 109MS401 Sponsor: Biogen

- "Registro Italiano Sclerosi Multipla" SM001 prot. N. 50/17 Rif. CE 4350 e per SM002 prot. N. 51/17 Rif. CE 4351, per Emendamento SM001 Prot. n. 1022/18 Rif. 4350, per Emendamento SM002 Prot. n. 1023/18 Rif. 4351) PI per il centro sclerosi multipla Policlinico Umberto I, Roma. Sponsor: Fondazione Italiana Sclerosi Multipla (FISM)

Part IV – Teaching experience

Year	Institution	Position held/ Lecture/Course
2025-to date	"Sapienza", University of Rome	Director – Specialty training program in Neurology – Residency in Neurology
2022-to date	"Sapienza", University of Rome	President - Bachelor of Occupational Therapy.
2022-to date	"Sapienza", University of Rome	Vice-Director – Specialty training program in Neurology – Residency in Neurology
2022-to date	"Sapienza", University of Rome	Director- Master I livello "Muscoskeletal and rheumatological physiotherapy" Identification number: 31522
2022-to date	"Sapienza", University of Rome	CLMMC-A School of Medicine and Odontoiatry- Course: Disease of the nervous system- Lecturer- 1 CFU
2022	Master "Non-invasive Neuromodulation" University of Tor Vergata, Rome, IRCCS Neuromed	Faculty-Lecturer
2022	Master "Assistive Technology" Sapienza, University of Rome	Faculty-Lecturer
2022	CIVIS Domain 15 "Neurophysiology, Neurosciences, and Neurodegenerative Diseases"	Faculty-Lecturer-Board Member CIVIS
2022-2023	European Board Neurology EAN	Examiner for the European board of neurology-EAN 2022
2020-to date	"Sapienza", University of Rome	Specialty training program in Neurology – Residency in Neurology (Secretary and lecturer)
2017-to date	"Sapienza", University of Rome	Scientific Board Member PhD "Neuroscienze clinico-sperimentali e Psichiatria - DOT1326K3G"/ Clinical and Experimental Neurosciences and Psychiatry.
2020-2022	"Sapienza", University of Rome	Vicepresident - Bachelor of Occupational Therapy.
2017-to date	"Sapienza", University of Rome	Director of Studies - Bachelor of Physiotherapy

2017/2018	"Sapienza", University of Rome	Faculty "Corso Alta Formazione in Elettromiografia Clinica/ Master in Clinical Electromyography"
2013/2014	"Sapienza", University of Rome	Bachelor of Physiotherapy, "Sapienza", University of Rome

Part V - Society memberships, Awards and Honors

Year	Title
2023-present	Coordinatore del Centro Studi Fondazione SIN, Referente per il Censimento Attività di Ricerca nell'ambito del Centro Studi Fondazione SIN Membro della Consulta Neurologia e Sanità SIN Referente SIN per il progetto pro4all Membro della Consulta di Genere SIN per il Gender Equality Plan.
2023-2025	Consigliere della Società Italiana di Neurologia- Scientific Board Member- Italian Society of Neurology
2021-2023	Consigliere della Società Italiana di Neurologia- Scientific Board Member- Italian Society of Neurology
2021	Co-winner Premio ARD- Dystonia
2008-present	Accademia Limpe-Dismov Membership
2017-present	Società Italiana Neurologia (SIN) Membership
2020	Associate Editor - Frontiers in Neurology

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2023	Vibro-tactile stimulation as a non-invasive treatment method for cervical dystonia	Progetto Ateneo Medio	€9550
2022	Digital Driven Diagnostics, prognostics and therapeutics for sustainable Health care" D3-4 Health- Spoke 3- Investigator	PNRR PNC Salute	€ 126.500.000
2021	"Investigating non-invasive biomarkers of cortical network disruption underlying motor impairment in Parkinson's disease and Multiple Sclerosis"	Progetto Ateneo Medio	€ 10000
2020	"proNGF/NGF interaction and microRNA expression in people with multiple sclerosis treated with disease-modifying drugs"	Bando Gruppi di Ricerca 2020 Regione Lazio	€ 150000
2020	"House and Garden"	"Roche per i servizi. A supporto di soluzioni innovative per la Sclerosi Multipla"	€ 25000

2020	“New clinical and neurophysiological measures of fatigue in Multiple Sclerosis: their evaluation in patients treated with Natalizumab”	Biogen research sponsor	€ 180000
2019	In vivo Advanced Systems for qualitative and quantitative Magnetic Resonance Imaging of the brain and heart. GA11916BD1141EF0.	Progetto Ateneo Acquisizione di grandi attrezzature scientifiche (Co–Investigator)	€ 420000
2019	La riabilitazione cognitiva come possibile approccio terapeutico aggiuntivo in pazienti affetti da blefarospasmo: studio pilota clinico e neurofisiologico. RP11916B6E5DA6DF	Progetto Ateneo	€ 3000
2019	"Un trifoglio per la Sclerosi Multipla"	Bando "Roche a fianco delle Persone con Sclerosi Multipla"	€ 25000
2018	Subtyping Parkinson’s disease: a clinical and neurophysiological study. RM118164264AEFB2.	Progetto Ateneo-Coinvestigator	€ 10000
2017		MIUR-fondo per la ricerca di base	€ 3000
2017	Meccanismi di alterata integrazione sensorimotoria nei pazienti con distonia focale ed effetto della tossina botulinica: studio neurofisiologico e neuroradiologico - n. protocollo RP11715C5369FAAD	Progetto Ateneo	€ 4000
2017	“Longitudinal analysis of clinical and neurophysiological variables in idiopathic (benign essential) blepharospasm”	Benign Blepharospasm Foundation	
2016	“Integrazione sensoriale e movimento volontario nei soggetti normali ed in pazienti con disordini del movimento- Numero protocollo: RP116154CD53D382”	Progetto Ateneo	€ 5000
2014	"Somatosensory temporal discrimination threshold in patients with essential tremor and focal tremor of unknown origin" prot. C26A14XFXP”	Progetto Ateneo	€ 5000
2013	"Plasticità corticale nell'uomo: meccanismi fisiologici e fisiopatologici. Strumentazione per la stimolazione magnetica transcranica ripetitiva delle aree cerebrali e sistema di registrazione dei segnali bioelettrici. Prot. C26G13BY5K”	Progetto Ateneo Acquisizione di grandi attrezzature scientifiche (Co–Investigator)	
2007	"La discriminazione temporale somatosensoriale nella distonia" prot. 2007K2EMES_001 -06 - 24 mesi	PRIN	

Part VII – Research Activities

Keywords

Multiple Sclerosis
Movement Disorders
Clinical Neurophysiology
Transcranial magnetic stimulation
Cortical Plasticity

Head of the research laboratories of "Human Neurosciences, movement disorders and epilepsy" at the Department of Human Neurosciences, Sapienza, University of Rome.
Research activity has been focused over the years on clinical neurophysiology and the use of neurophysiological techniques, including transcranial magnetic stimulation, and electrophysiological approaches investigating brainstem and spinal reflexes. Areas of specific interest have been the mechanisms of synaptic plasticity in primary motor cortex, cortico-cortical connectivity, motor learning and somatosensory temporal discrimination in healthy humans, in patients with multiple sclerosis and in patients with movement disorders.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	**284**	(Database: Pubmed, Scopus)	2000	2026
Books [scientific]	**3**			
Books [teaching]	1			
Total Citations	**6826 (Scopus)**			
Hirsch (H) index	**43 (Scopus)**			

Part IX- Invited speaker at International and National congresses

- 24-28 October 2025 - **Congresso Società Italiana Neurologia** speaker and chair
- **2025- 11° Congresso della Società Italiana Parkinson e Disordini del Movimento/LIMPE-DISMOV**, chiar session
- 10-12 November 2024 - **Congresso Società Italiana Neurologia -Rome** speaker and chair
- 1st – 3rd June 2023- **Samuel Belzberg 6th International Dystonia Symposium** Dublin, Ireland, speaker: title "Abnormal sensory processes are a non-specific consequence of the disorder"
- 4-6 Maggio 2023, **9° Congresso della Società Italiana Parkinson e Disordini del Movimento/LIMPE-DISMOV**, chiar session "Comunicazioni Libere 3 "
- 2-3 Marzo 2023 – **Bologna Parkinson**, speaker title "Fisiopatologia della distonia"
- 23-24 febbraio 2023 **X Congresso Nazionale La rete delle Neurocardiologie**, chair session "Problemi clinici emergenti in neurocardiologia: la sclerosi multipla e le sindromi da intolleranza all'ortostatismo"
- 3-6 Dicembre 2022 – **52° Congresso Società Italiana Neurologia**, speaker and chair title "Fragilità Biologica nelle Malattie Neurodegenerative e Neuroinfiammatorie: fragilità nelle malattie neuroinfiammatorie"
- 16-18 Novembre 2022- **8° Congresso Accademia LIMPE-DISMOV**: Napoli, speaker title "Biomarcatori di diagnosi e progressione nella malattia di Parkinson: Ruolo dei markers neurofisiologici"
- 18-21 July 2022- **Summer School CIVIS Domain 15 Neuroscience**s "Advancements in experimental and clinical neuroscience of motor and cognitive systems in neurodegenerative diseases", speaker: title "Sensory system and movement disorders"
- 12-13 maggio 2022 - **IX Congresso Nazionale La rete delle Neurocardiologie,** speaker e chiar "Sclerosi multipla recidivante remittente: predittori clinici per la personalizzazione della terapia"
- 6-7 Maggio 2022, Cagliari- **Scuola Superiore dei Disturbi del Movimento** "Corea, tic, mioclono"

	10.1177/13524585221102918.	
100	Bergamaschi R, Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Mosconi P; Italian Multiple Sclerosis and Related Disorders Register Centers Group and the Scientific Committee of Italian SM and Related Disorders Register, Aguglia U, Amato MP, Ancona AL, Ardito B, Avolio C, Balgera R, Banfi P, Barcella V, Barone P, Bellantonio P, Berardinelli A, Bergamaschi R, Bertora P, Bianchi M, Bramanti P, Morra VB, Brichetto G, Brioschi AM, Buccafusca M, Bucello S, Busillo V, Calchetti B, Cantello R, Capobianco M, Capone F, Capone L, Cargnelutti D, Carrozzi M, Cartechini E, Cavaletti G, Cavalla P, Celani MG, Clerici R, ClericoM, Cocco E, Confalonieri P, Coniglio MG, Conte A, Corea F, Cottone S, Crociani P, D'Andrea F, Danni MC, De Luca G, de Pascalis D, De Riz M, De Robertis F, De Rosa G, De Stefano N, Corte MD, Di Sapio A, Docimo R, Falcini M, Falcone N, Fermi S, Ferraro E, Ferrò MT, Fortunato M, Foschi M, Gajofatto A, Gallo A, Gallo P, Gatto M, Gazzola P, Giordano A, Granella F, Grasso MF, Grasso MG, Grimaldi LME, Iaffaldano P, Imperiale D, Inglese M, Iodice R, Leva S, Luezzi V, Lugaresi A, Lus G, Maimone D, Mancinelli L, Maniscalco GT, Marfia GA, Marini B, Marson A, Mascoli N, Massacesi L, Melani F, Merello M, Meucci G, Mirabella M, Montepietra S, Nasuelli D, Nicolao P, Passantino F, Patti F, Peresson M, Pesci I, Piantadosi C, Piras ML, Pizzorno M, Plewnia K, Pozzilli C, Protti A, Quatrale R, Realmuto S, Ribizzi G, Rinalduzzi S, Rini A, Romano S, Romeo M, Ronzoni M, Rossi P, Rovaris M, Salemi G, Santangelo G, Santangelo M, Santuccio G, Sarchielli P, Sinisi L, Sola P, Solaro C, Spitaleri D, Strumia S, Tassinari T, Tonietti S, Tortorella C, Totaro R, Tozzo A, Trivelli G, Ulivelli M, Valentino P, Venturi S, Vianello M, Zaffaroni M, Zarbo R, Trojano M, Battaglia MA, Capobianco M, Pugliatti M, Ulivelli M, Mosconi P, Gasperini C, Patti F, Amato MP, Bergamaschi R, Comi G. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurol Sci. 2022 Jun 7. doi: 10.1007/s10072-022-06169-7.	3.3
101	Belvisi D, Pellicciari R, Fabbrini A, Costanzo M, Ressa G, Pietracupa S, De Lucia M, Modugno N, Magrinelli F, Dallocchio C, Ercoli T, Nicoletti A, Zappia M, Solla P, Bologna M, Fabbrini G, Tinazzi M, Conte A, Berardelli A, Defazio G. Relationship between risk and protective factors and clinical features of Parkinson's disease. Parkinsonism Relat Disord. 2022 Apr 29;98:80-85. doi:10.1016/j.parkreldis.2022.04.017.	4.1
102.	Tofani M, Santecchia L, Conte A, Berardi A, Galeoto G, Sogos C, Petrarca M, Panuccio F, Castelli E. Effects of Mirror Neurons-Based Rehabilitation Techniques in Hand Injuries: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 May 2;19(9):5526. doi: 10.3390/ijerph19095526.	4.614
103.	Ferrazzano G, Zingaropoli MA, Costanzo M, Belvisi D, Dominelli F, Pasculli P, Ciardi MR, Fabbrini G, Defazio G, Berardelli A, Conte A. Neurofilament assessment in patients with cervical dystonia. Parkinsonism Relat Disord. 2022 Apr 23;98:70-71. doi: 10.1016/j.parkreldis.2022.04.013.	4.1
104.	Ruotolo I, Sellitto G, Ianniello A, Petsas N, Castelli L, Galeoto G, Berardi A, Barletta V, Conte A, Pozzilli C. Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS). Neurol Sci. 2022 Apr 22. doi: 10.1007/s10072-022-06080-1.	3.3
105.	Berardi A, Conte A, Cimmino L, Cimmino C, Baione V, Crisafulli SG, Tofani M, Tartaglia M, Fabbrini G, Galeoto G. Evaluation of the Psychometric Properties of the Health Assessment Questionnaire (HAQ) in a Population of Individuals With Multiple Sclerosis. Front Neurol. 2022 Mar 28;13:847786. doi: 10.3389/fneur.2022.847786.	3.4
106.	Berardi A, Galeoto G, Pasquali F, Baione V, Crisafulli SG, Tofani M, Tartaglia M, Fabbrini G, Conte A. Evaluation of the Psychometric Properties of Jebsen Taylor Hand Function Test (JTHFT) in Italian	3.4

129.	Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744.	5.430
130.	Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. J Neurol. 2021 Jun 28. doi: 10.1007/s00415-021-10676-6.	6.682
131.	Ferrazzano G, Frantellizzi V, De Bartolo MI, De Feo MS, Conte A, Fabbrini G, De Vincentis G, Berardelli A. Response to "Response to isolated head tremor: A DAT-SPECT and somatosensory temporal discrimination study". Parkinsonism Relat Disord. 2021 May 27:S1353-8020(21)00196-6. doi: 10.1016/j.parkreldis.2021.05.025.	4.40
132.	Iaffaldano P, Lucisano G, Caputo F, Paolicelli D, Patti F, Zaffaroni M, Brescia Morra V, Pozzilli C, De Luca G, Inglese M, Salemi G, Maniscalco GT, Cocco E, Sola P, Lus G, Conte A, Amato MP, Granella F, Gasperini C, Bellantonio P, Totaro R, Rovaris M, Salvetti M, Torri Clerici VLA, Bergamaschi R, Maimone D, Scarpini E, Capobianco M, Comi G, Filippi M, Trojano M; Italian MS Register. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021 May 31;14:17562864211019574. doi: 0.1177/17562864211019574.	6.430
133.	Leodori G, De Bartolo MI, Belvisi D, Ciogli A, Fabbrini A, Costanzo M, Manetto S, Conte A, Villani C, Fabbrini G, Berardelli A. Salivary caffeine in Parkinson's disease. Sci Rep. 2021 May 10;11(1):9823. doi:10.1038/s41598-021-89168-6.	4.997
134.	Baione V, Ferrazzano G, Celletti C, De Rosa M, Belvisi D, Fabbrini G, Galli M, Camerota F, Conte A. Attention-Demanding Cognitive Tasks Worsen Postural Control in Patients With Cervical Dystonia: A Case-Control Study. Front Neurol. 2021 Apr 6;12:666438. doi: 10.3389/fneur.2021.666438.	4.086
135.	Belvisi D, Giannì C, Tartaglia M, Petsas N, Baione V, Crisafulli SG, Pantano P, Berardelli A, Conte A. Abnormal motor surround inhibition associated with cortical and deep grey matter involvement in multiple sclerosis. Clin Neurophysiol. 2021 May;132(5):1151-1156. doi: 10.1016/j.clinph.2021.01.029.	4.86
136.	Sulli S, Scala L, Berardi A, Conte A, Baione V, Belvisi D, Leodori G, Galeoto G. The efficacy of rehabilitation in people with Guillain-Barrè syndrome: a systematic review of randomized controlled trials. Expert Rev Neurother. 2021 Apr;21(4):455-461. doi:10.1080/14737175.2021.1890034.	4.287
137.	Belvisi D, Canevelli M, Baione V, Buscarinu MC, Pellicciari G, Fantozzi R, Creta A, Cecchi G, Cola G, Nicoletti CG, Cortese A, De Giglio L, Tartaglia M, Crisafulli SG, Bruno G, Ferraro E, Marfia GA, Centonze D, Salvetti M, Conte A. Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.	5.855

138.	Sellitto G, Morelli A, Bassano S, Conte A, Baione V, Galeoto G, Berardi A. Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021 Jan 28. doi: 10.1080/14737167.2021.1883430.	2.039
139.	Lucchini M, Prosperini L, Buscarinu MC, Centonze D, Conte A, Cortese A, Elia G, Fantozzi R, Ferraro E, Gasperini C, Ianniello A, Landi D, Marfia GA, Nociti V, Pozzilli C, Salvetti M, Tortorella C, Mirabella M. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. J Neurol. 2021 Jan 26. doi: 10.1007/s00415-021-10412-0.	6.682
140.	Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.	11.274
141.	Fabbrini G, Conte A, Ferrazzano G, Esposito M, Albanese A, Pellicciari R, Di Biasio F, Bono F, Eleopra R, Ercoli T, Altavista MC, Berardelli A, Defazio G; Italian Dystonia Registry participants. Neuroimaging in idiopathic adult-onset focal dystonia. Neurol Sci. 2021 Jan 3. doi: 10.1007/s10072-020-05025-w.	3.83
142.	Latorre A, Cocco A, Bhatia KP, Erro R, Antelmi E, Conte A, Rothwell JC, Rocchi L. Defective Somatosensory Inhibition and Plasticity Are Not Required to Develop Dystonia. Mov Disord. 2021 Apr;36(4):1015-1021. doi: 10.1002/mds.28427.	9.69
143.	Iaffaldano P, Lucisano G, Patti F, Brescia Morra V, De Luca G, Lugaresi A, Zaffaroni M, Inglese M, Salemi G, Cocco E, Conte A, Ferraro D, Galgani S, Bergamaschi R, Pozzilli C, Salvetti M, Lus G, Rovaris M, Maniscalco GT, Logullo FO, Paolicelli D, Achille M, Marrazzo G, Lovato V, Comi G, Filippi M, Amato MP, Trojano M; Italian MS Register. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Mult Scler. 2021 Mar;27(3):430-438. doi: 10.1177/1352458520974366.	5.855
144.	Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group, the Scientific Committee of Italian SM Register. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. Eur J Neurol. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589.	6.288
145.	Ferrazzano G, Crisafulli SG, Baione V, Tartaglia M, Cortese A, Frontoni M, Altieri M, Pauri F, Millefiorini E, Conte A. Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. J Neurol. 2021 Jun 5. doi: 10.1007/s00415-020-09964-4.	6.682
146.	Belvisi D, Fabbrini A, De Bartolo MI, Costanzo M, Manzo N, Fabbrini G, Defazio G, Conte A, Berardelli A. The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes. Mov Disord. 2021 Feb;36(2):370-379. doi: 10.1002/mds.28321.	9.69
147.	Baione V, Belvisi D, Crisafulli SG, Tartaglia M, Leodori G, Ferrazzano G, Conte A. Is somatosensory temporal discrimination threshold a biomarker of disease progression in multiple sclerosis? Clin Neurophysiol. 2020 Dec;131(12):2935-2936.	3.708
148.	Ferrazzano G, Frantellizzi V, De Bartolo MI, De Feo MS, Conte A, Fabbrini G, De Vincentis G, Berardelli A. Isolated head tremor: A DAT-SPECT and somatosensory temporal discrimination study. Parkinsonism Relat Disord. 2020 Oct 9;81:56-59. doi: 10.1016/j.parkreldis.2020.10.015.	4.891

163.	Berardelli A, Conte A. Dystonias. Handb Exp Pharmacol. 2019 Dec 10. doi: 10.1007/164_2019_339.	-
164.	Conte A, Rocchi L, Latorre A, Belvisi D, Rothwell JC, Berardelli A. Ten-Year Reflections on the Neurophysiological Abnormalities of Focal Dystonias in Humans. Mov Disord. 2019 Nov;34(11):1616-1628.	8.679
165.	Tofani M, Massai P, Fabbrini G, Berardi A, Pelosin E, Conte A, De Bartolo I, Valente D. Psychometric properties of the Italian version of the Barthel Index in patients with Parkinson's disease: a reliability and validity study. Funct Neurol. 2019 Jul/Sep;34(3):145-150.	-
166.	Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. J Neurol. 2019 Dec;266(12):3098-3107.	3.956
167.	Conte A, Defazio G, Hallett M, Fabbrini G, Berardelli A. The role of sensory information in the pathophysiology of focal dystonias. Nat Rev Neurol. 2019 Apr;15(4):224-233.	27.0
168.	Cortese A, Lucchetti R, Altobelli A, Conte A, Primavera M, Valesini G, Millefiorini E, Scrivo R. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: report of two clinical cases. Multiple Sclerosis and Related Disorders. 2019; 35: 193-195.	2.889
169.	Ferrazzano G, Berardelli I, Conte A, Baione V, Concolato C, Belvisi D, Fabbrini G, Defazio G, Berardelli A. Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications. J Neurol. 2019; 266: 2780-2785; doi: 10.1007/s00415-019-09484-w.	3.956
170.	Baione V, Ferrazzano G, Berardelli I, Belvisi D, Berardelli A, Conte A. Unravelling mechanisms of altered modulation of trigemino-facial circuits in blepharospasm. Clin Neurophysiol. 2019 Sep;130(9):1642-1643.	3.214
171.	Ferrazzano G, Conte A, Belvisi D, Fabbrini A, Baione V, Berardelli A, Fabbrini G. Writing, reading, and speaking in blepharospasm. J Neurol. 2019 May;266(5):1136-1140.	3.956
172.	Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease: A pilot study. Ther Adv Neurol Disord. 2019 May 8;12:1756286419843458. doi: 10.1177/1756286419843458.	5.00
173.	D'Antonio F, De Bartolo MI, Ferrazzano G, Trebbastoni A, Amicarelli S, Campanelli A, de Lena C, Berardelli A, Conte A. Somatosensory Temporal Discrimination Threshold in Patients with Cognitive Disorders. J Alzheimers Dis. 2019;70(2):425-432. doi: 10.3233/JAD-190385.	3.909
174.	Berardelli I, Pasquini M, Conte A, Bologna M, Berardelli A, Fabbrini G. Treatment of psychiatric disturbances in common hyperkinetic movement disorders. Expert Rev Neurother 2019 Jan;19(1):55-65.	3.743
175.	Ferrazzano G, Conte A, Gigante A, Defazio G, Berardelli A, Fabbrini G. Disease progression in blepharospasm: a 5-year longitudinal study. Eur J Neurol. 2019 Feb;26(2):268-273.	4.516
176.	Conte A, Belvisi D, De Bartolo MI, Manzo N, Cortese FN, Tartaglia M, Ferrazzano G, Fabbrini G, Berardelli A. Abnormal sensory gating in patients with different types of focal dystonias. Mov Disord. 2018 Dec;33(12):1910-1917	8.22

177.	Belvisi D, Conte A, Cortese FN, Tartaglia M, Manzo N, Li Voti P, Suppa A, Berardelli A. Voluntary movement takes shape: the link between movement focusing and sensory input gating. Frontiers in Human Neuroscience. 17 August 2018, doi.org/10.3389/fnhum.2018.00330.	2.870
178.	Avanzino L, Fiorio M, Conte A. Actual and Illusory Perception in Parkinson's Disease and Dystonia: A Narrative Review. Frontiers in Neurology. 20 July 2018. doi.org/10.3389/fneur.2018.00584	2.635
179.	Conte A, Ferrazzano G, Belvisi D, Manzo N, Battista E, Li Voti P, Nardella A, Fabbrini G, Berardelli A. Somatosensory temporal discrimination in Parkinson's disease, dystonia and essential tremor: Pathophysiological and clinical implications. Clin Neurophysiol. 2018;129:1849-1853.	3.675
180.	Di Stasio F, Suppa A, Fabbrini A, Marsili L, Asci F, Conte A, Trebbastoni A, De Lena C, Berardelli A. Parkinsonism is associated with altered primary motor cortex plasticity in frontotemporal dementia-primary progressive aphasia variant. Neurobiol Aging. 2018;69:230-238.	4.398
181.	Fabbrini G, Conte A, Berardelli A. Language use at Italian medical congresses. Neurol Sci. 2018 May 24. doi: 10.1007/s10072-018-3452-9.	2.48
182.	Belvisi D, Conte A, Cutrona C, Costanzo M, Ferrazzano G, Fabbrini G, Berardelli A. Re-emergent tremor in Parkinson's disease: the effect of dopaminergic treatment. Eur J Neurol. 2018;25:799-804.	4.387
183.	Berardelli I, Bloise MC, Bologna M, Conte A, Pompili M, Lamis DA, Pasquini M, Fabbrini G. Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson's disease. Neuropsychiatr Dis Treat. 2018;14:399-405.	2.228
184.	Cortese A, Conte A, Ferrazzano G, Sgarlata E, Millefiorini E, Frontoni M, Berardelli A. Photophobia in multiple sclerosis. Mult Scler Relat Disord. 2018 Nov;26:55-57.	2.725
185.	Lee MS, Lee MJ, Conte A, Berardelli A. Abnormal somatosensory temporal discrimination in Parkinson's disease: Pathophysiological correlates and role in motor control deficits. Clin Neurophysiol. 2017;129:442-447.	3.614
186.	Conte A, McGovern EM, Narasimham S, Beck R, Killian O, O'Riordan S, Reilly RB, Hutchinson M. Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia. Front Neurol. 2017;8:625.	3.508
187.	Conte A, Ferrazzano G, Defazio G, Fabbrini G, Hallett M, Berardelli A. Increased blinking may be a precursor of blepharospasm: a longitudinal study. Mov Disord Clin Pract. 2017;4:733-736.	-
188.	Conte A, Ferrazzano G, Belvisi D, Manzo N, Suppa A, Fabbrini G, Berardelli A. Does the Somatosensory Temporal Discrimination Threshold Change over Time in Focal Dystonia? Neural Plast. 2017: 9848070.	3.161
189.	Conte A, Ferrazzano G, Berardelli A. Viewpoints on the Clinical Heterogeneity of Blepharospasm. Curr Adv Neurol Neurol Disord 2017;1:1-4.	-
190.	Ferrazzano G, Berardelli I, Conte A, Suppa A, Fabbrini G, Berardelli A. Interoceptive sensitivity in patients with cervical dystonia. Parkinsonism Relat Disord. 2017;44:129-132.	4.721
191.	Leodori G, Formica A, Zhu X, Conte A, Belvisi D, Cruccu G, Hallett M, Berardelli A. The third-stimulus temporal discrimination threshold: focusing on the temporal processing of sensory input within primary somatosensory cortex. J Neurophysiol. 2017;118:2311-2317.	2.502
192.	Bologna M, Suppa A, Di Stasio F, Conte A, Fabbrini G, Berardelli A. Neurophysiological studies on atypical parkinsonian syndromes. Parkinsonism Relat Disord. 2017;42:12-21.	4.721
193.	Conte A, Belvisi D, Tartaglia M, Cortese FN, Baione V, Battista E, Zhu XY, Fabbrini G, Berardelli A. Abnormal Temporal Coupling of Tactile	3.508

	Perception and Motor Action in Parkinson's Disease. Front Neurol. 2017;8:249.	
194.	Defazio G, Conte A, Gigante AF, Ferrazzano G, Pellicciari R, Dagostino S, Fabbrini G, Berardelli A. Clinical heterogeneity in patients with idiopathic blepharospasm: A cluster analysis. Parkinsonism Relat Disord. 2017;40:64-68.	4.721
195.	Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A. Blepharospasm 40 years later. Mov Disord. 2017;32:498-509.	6.32
196.	Belvisi D, Conte A, Bologna M, Bloise MC, Suppa A, Formica A, Costanzo M, Cardone P, Fabbrini G, Berardelli A. Re-emergent tremor in Parkinson's disease. Parkinsonism Relat Disord. 2017;36:41-46.	4.721
197.	Suppa A, Bologna M, Conte A, Berardelli A, Fabbrini G. The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions. Expert Rev Neurother. 2017;17:181-192.	3.696
198.	Bologna M, Bertram K, Paparella G, Papi C, Belvisi D, Conte A, Suppa A, Williams DR, Berardelli A. Reversal of long term potentiation-like plasticity in primary motor cortex in patients with progressive supranuclear palsy. Clin Neurophysiol. 2017 Sep;128(9):1547-1552.	3.614
199.	Bologna M, Latorre A, Di Biasio F, Conte A, Belvisi D, Modugno N, Suppa A, Berardelli A, Fabbrini G. The Effect of L-Dopa/Carbidopa Intestinal Gel in Parkinson Disease Assessed Using Neurophysiologic Techniques. Clin Neuropharmacol. 2016;39:302-305.	1.451
200.	Conte A, Leodori G, Ferrazzano G, De Bartolo MI, Manzo N, Fabbrini G, Berardelli A. Somatosensory temporal discrimination threshold in Parkinson's disease parallels disease severity and duration. Clin Neurophysiol. 2016;127:2985-2989	3.866
201.	Conte A, Li Voti P, Pontecorvo S, Quartuccio ME, Baione V, Rocchi L, Cortese A, Bologna M, Francia A, Berardelli A. Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis. Mult Scler. 2016;22:1359-1366.	4.840
202.	Conte A, Belvisi D, Manzo N, Bologna M, Barone F, Tartaglia M, Upadhyay N, Berardelli A. Understanding the link between somatosensory temporal discrimination and movement execution in healthy subjects. Physiol Rep. 2016;4:18.	-
203.	Rocchi L, Conte A, Bologna M, Li Voti P, Millefiorini E, Cortese A, Pontecorvo S, Berardelli A. Somatosensory temporal discrimination threshold is impaired in patients with multiple sclerosis. Clin Neurophysiol. 2016;127:1940-1941.	3.866
204.	Suppa A, Di Stasio F, Marsili L, Upadhyay N, Belvisi D, Conte A, Modugno N, Colosimo C, Berardelli A. Primary motor cortex LTP/LTD-like plasticity in probable corticobasal syndrome. J Neurophysiol. 2016;115:717-727.	2.396
205.	Bologna M, Suppa A, Conte A, Latorre A, Rothwell JC, Berardelli A. Are studies of motor cortex plasticity relevant in human patients with Parkinson's disease? Clin Neurophysiol. 2016;127:50-59.	3.866
206.	Bologna M, Piattella MC, Upadhyay N, Formica A, Conte A, Colosimo C, Pantano P, Berardelli A. Neuroimaging correlates of blinking abnormalities in patients with progressive supranuclear palsy. Mov Disord. 2016;31:138-143.	7.07
207.	Conte A, Berardelli I, Ferrazzano G, Pasquini M, Berardelli A, Fabbrini G. Non-motor symptoms in patients with adult-onset focal dystonia: Sensory and psychiatric disturbances. Parkinsonism Relat Disord. 2016;22 Suppl 1:S111-4.	4.484
208.	Giannantoni A, Proietti S, Giusti G, Gubbiotti M, Millefiorini E, Costantini E, Berardelli A, Conte A. OnabotulinumtoxinA intradetrusorial injections	2.397

239.	Iezzi E, Suppa A, Conte A, Li Voti P, Bologna M, Berardelli A. Short-term and long-term plasticity interaction in human primary motor cortex. Eur J Neurosci. 2011;33:1908-1915.	3.631
240.	Suppa A, Marsili L, Belvisi D, Conte A, Iezzi E, Modugno N, Fabbrini G, Berardelli A. Lack of LTP-like plasticity in primary motor cortex in Parkinson's disease. Exp Neurol. 2011;227:296-301.	4.699
241.	Conte A, Modugno N, Lena F, Dispenza S, Gandolfi B, Iezzi E, Fabbrini G, Berardelli A. Subthalamic nucleus stimulation and somatosensory temporal discrimination in Parkinson's disease. Brain. 2010;133:2656-2663.	9.232
242.	Iezzi E, Suppa A, Conte A, Agostino R, Nardella A, Berardelli A. Theta-burst stimulation over primary motor cortex degrades early motor learning. Eur J Neurosci. 2010;31:585-592.	3.658
243.	Suppa A, Iezzi E, Conte A, Belvisi D, Marsili L, Modugno N, Fabbrini G, Berardelli A. Dopamine influences primary motor cortex plasticity and dorsal premotor-to-motor connectivity in Parkinson's disease. Cereb Cortex. 2010;20:2224-2233.	6.844
244.	Conte A, Fabbrini G, Belvisi D, Marsili L, Di Stasio F, Berardelli A. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm. Eur J Neurol. 2010;17:449-455.	3.765
245.	Scontrini A, Conte A, Defazio G, Fiorio M, Fabbrini G, Suppa A, Tinazzi M, Berardelli A. Somatosensory temporal discrimination in patients with primary focal dystonia. J Neurol Neurosurg Psychiatry. 2009;80:1315-1319.	4.869
246.	Iezzi E, Conte A, Suppa A, Agostino R, Dinapoli L, Scontrini A, Berardelli A. Phasic voluntary movements reverse the aftereffects of subsequent theta-burst stimulation in humans. J Neurophysiol. 2008;100:2070-2076.	3.648
247.	Agostino R, Iezzi E, Dinapoli L, Suppa A, Conte A, Berardelli A. Effects of intermittent theta-burst stimulation on practice-related changes in fast finger movements in healthy subjects. Eur J Neurosci. 2008;28:822-828.	3.385
248.	Agostino R, Iezzi E, Dinapoli L, Gilio F, Conte A, Mari F, Berardelli A. Effects of 5 Hz subthreshold magnetic stimulation of primary motor cortex on fast finger movements in normal subjects. Exp Brain Res. 2007;180:105-111.	2.027
249.	Conte A, Barbanti P, Frasca V, Iacovelli E, Gabriele M, Giacomelli E, Aurilia C, Pichiorri F, Gilio F, Inghilleri M. Differences in short-term primary motor cortex synaptic potentiation as assessed by repetitive transcranial magnetic stimulation in migraine patients with and without aura. Pain. 2010;148:43-48.	6.0
250.	Conte A, Lenzi D, Frasca V, Gilio F, Giacomelli E, Gabriele M, Bettolo CM, Iacovelli E, Pantano P, Pozzilli C, Inghilleri M. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis. J Neurol. 2009;256:933-938.	2.903
251.	Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32:41-47.	2.349
252.	Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain. 2009;13:472-477.	3.612
253.	Gilio F, Iacovelli E, Conte A, Frasca V, Gabriele M, Giacomelli E, Bettolo CM, Scaldaferri N, Trebbastoni A, Prencipe M, Inghilleri M. Asymmetric	2.2

	responses to repetitive transcranial magnetic stimulation (rTMS) over the left and right primary motor cortex in a patient with lateralized progressive limb-kinetic apraxia. Neurosci Lett. 2008;437:125-129.	
254.	Gilio F, Bettolo CM, Conte A, Iacovelli E, Frasca V, Serrao M, Giacomelli E, Gabriele M, Prencipe M, Inghilleri M. Influence of the corticospinal tract on the cutaneous silent period: a study in patients with pyramidal syndrome. Neurosci Lett. 2008;433:109-113.	2.2
255.	Gilio F, Di Rezze S, Conte A, Frasca V, Iacovelli E, Marini Bettolo C, Gabriele M, Giacomelli E, Pizzuti A, Pirro C, Fattapposta F, Habib FI, Prencipe M, Inghilleri M. Case report of adult-onset Allgrove syndrome. Neurol Sci. 2007;28:331-335.	1.006
256.	Cantello R, Rossi S, Varrasi C, Ulivelli M, Civardi C, Bartalini S, Vatti G, Cincotta M, Borgheresi A, Zaccara G, Quartarone A, Crupi D, Laganà A, Inghilleri M, Giallonardo AT, Berardelli A, Pacifici L, Ferreri F, Tombini M, Gilio F, Quarato P, Conte A, Manganotti P, Bongiovanni LG, Monaco F, Ferrante D, Rossini PM. Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. Epilepsia. 2007;48:366-374.	3.569
257.	Conte A, Gilio F, Iacovelli E, Bettolo CM, Di Bonaventura C, Frasca V, Carbone A, Prencipe M, Berardelli A, Inghilleri M. Effects of repetitive transcranial magnetic stimulation on spike-and-wave discharges. Neurosci Res. 2007;57:140-142.	2.121
258.	Lenzi D, Conte A, Mainero C, Frasca V, Fubelli F, Totaro P, Caramia F, Inghilleri M, Pozzilli C, Pantano P. Effect of corpus callosum damage onipsilateral motor activation in patients with multiple sclerosis: a functional and anatomical study. Hum Brain Mapp. 2007;28:636-644.	6.151
259.	Gilio F, Conte A, Vanacore N, Frasca V, Inghilleri M, Berardelli A. Excitatory and inhibitory after-effects after repetitive magnetic transcranial stimulation (rTMS) in normal subjects. Exp Brain Res. 2007;176:588-593.	2.027
260.	Conte A, Gilio F, Iezzi E, Frasca V, Inghilleri M, Berardelli A. Attention influences the excitability of cortical motor areas in healthy humans. Exp Brain Res. 2007;182:109-117.	2.027
261.	Conte A, Attilia ML, Gilio F, Iacovelli E, Frasca V, Bettolo CM, Gabriele M, Giacomelli E, Prencipe M, Berardelli A, Ceccanti M, Inghilleri M. Acute and chronic effects of ethanol on cortical excitability. Clin Neurophysiol. 2008;119:667-674.	2.972
262.	Conte A, Belvisi D, Iezzi E, Mari F, Inghilleri M, Berardelli A. Effects of attention on inhibitory and facilitatory phenomena elicited by paired-pulse transcranial magnetic stimulation in healthy subjects. Exp Brain Res. 2008;186:393-399.	2.195
263.	Inghilleri M, Gilio F, Conte A, Frasca V, Marini Bettolo C, Iacovelli E, Gregori B, Prencipe M, Berardelli A. Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation. Exp Brain Res. 2006;174:667-672.	1.959
264.	Carbone A, Palleschi G, Conte A, Bova G, Iacovelli E, Bettolo CM, Pastore A, Inghilleri M. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol. 2006;29:206-214.	2.323
265.	Mecarelli O, Gregori B, Gilio F, Conte A, Frasca V, Accornero N, Inghilleri M. Effects of repetitive transcranial magnetic stimulation in a patient with fixation-off sensitivity. Exp Brain Res. 2006 ;173:180-184.	1.959
266.	Inghilleri M, Conte A, Frasca V, Scaldaferri N, Gilio F, Santini M, Fabbrini G, Prencipe M, Berardelli A. Altered response to rTMS in patients with Alzheimer's disease. Clin Neurophysiol. 2006;117:103-109.	2.718
267.	Inghilleri M, Conte A, Frasca V, Bettolo CM, Iacovelli E, Aragona M, Carbone A, Prencipe M. Venlafaxine and bladder function. Clin Neuropharmacol. 2005;28:270-273.	1.890

268.	Inghilleri M, Conte A, Frasca V, Vaudano AE, Meco G. Belly dance syndrome due to spinal myoclonus. Mov Disord. 2006;21:394-396.	3.323
269.	Inghilleri M, Conte A, Frasca V, Gilio F, Lorenzano C, Berardelli A. Synaptic potentiation induced by rTMS: effect of lidocaine infusion. Exp Brain Res. 2005;163:114-117.	2.118
270.	Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain. 2005;9:33-38.	2.460
271.	Mainero C, Inghilleri M, Pantano P, Conte A, Lenzi D, Frasca V, Bozzao L, Pozzilli C. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology. 2004;62:2044-2050.	5.973
272.	Inghilleri M, Conte A, Currà A, Frasca V, Lorenzano C, Berardelli A. Ovarian hormones and cortical excitability. An rTMS study in humans. Clin Neurophysiol. 2004;115:1063-1068.	2.538
273.	Modugno N, Currà A, Conte A, Inghilleri M, Fofi L, Agostino R, Manfredi M, Berardelli A. Depressed intracortical inhibition after long trains of subthreshold repetitive magnetic stimuli at low frequency. Clin Neurophysiol. 2003;114:2416-2422.	2.485
274.	Inghilleri M, Conte A, Frasca V, Curra' A, Gilio F, Manfredi M, Berardelli A. Antiepileptic drugs and cortical excitability: a study with repetitive transcranial stimulation. Exp Brain Res. 2004;154:488-493.	2.304
275.	Inghilleri M, Lorenzano C, Conte A, Frasca V, Manfredi M, Berardelli A. Effects of transcranial magnetic stimulation on the H reflex and F wave in the hand muscles. Clin Neurophysiol. 2003;114:1096-1101.	2.485
276.	Inghilleri M, Clemenzi A, Conte A, Frasca V, Manfredi M. Bilateral spike-and-wave discharges in a hemi-deafferented cortex. Clin Neurophysiol. 2002;113:1970-1972.	2.120
277.	Lorenzano C, Gilio F, Inghilleri M, Conte A, Fofi L, Manfredi M, Berardelli A. Spread of electrical activity at cortical level after repetitive magnetic stimulation in normal subjects. Exp Brain Res. 2002;147:186-192.	2.3
278.	Carbone A, Palleschi G, Parascani R, Morello P, Conte A, Inghilleri M. Modulation of viscero-somatic H-reflex during bladder filling: a possible tool in the differential diagnosis of neurogenic voiding dysfunctions. Eur Urol. 2002;42:281-288.	1.798
279.	Inghilleri M, Conte A, Frasca V, Berardelli A, Manfredi M, Cruccu G. Is the cutaneous silent period an opiate-sensitive nociceptive reflex? Muscle Nerve. 2002;25:695-699.	2.450
280.	Inghilleri M, Carbone A, Pedace F, Conte A, Frasca V, Berardelli A, Cruccu G, Manfredi M. Bladder filling inhibits somatic spinal motoneurones. Clin Neurophysiol. 2001;112:2255-2260.	1.922
281.	Aragona, M., Perinelli, D., Bancheri, L., ...Conte, A., Inghilleri, M. Clinical features of the DSM-IV Pain disorder | Caratteristiche cliniche delle sindromi da dolore non spiegabile esclusivamente su base somatica (DSM-IV Pain disorder). Rivista di Psichiatria, 2001, 36(5), pp. 286–291	
282.	Lorenzano, C., Modugno, N., Gilio, F., ...Inghilleri, M., Berardelli, A. Effects of repetitive transcranial magnetic stimulation on human cortical excitability Neurological Sciences, 2000, 21(4 SUPPL.)	-
283.	Perinelli, D., Conte, A., Lorenzano, C., ...Berardelli, A., Inghilleri, M. Differential synaptic effect on cervical motoneurons from aδ fiber activation. Neurological Sciences, 2000, 21(4 SUPPL.)	-
284.	Fabri, P., Conte, A., Libertucci, V., ...Antonini, G., Inghilleri, M. A clinical and electrophysiological open study of 3,4 diaminopyridine in CIDP patients Neurological Sciences, 2000, 21(4 SUPPL.)	-

285.	Inghilleri, M., Carbone, A., Perinelli, D., ...Berardelli, A., Manfredi, M. Changes in spinal motoneuron excitability during bladder filling. Neurological Sciences, 2000, 21(4 SUPPL.)	-
286.	Inghilleri, M., Conte, A., Gilio, F., ...Perinelli, D., Berardelli, A. Effects of carbamazepine on motor cortex excitability in humans: A study with repetitive transcranial magnetic stimulation. Neurological Sciences, 2000, 21(4 SUPPL.)	-

Si autorizza il trattamento dei dati personali ai sensi della vigente normativa sulla privacy – D.lgs. n. 196/2003 e ss.mm.ii. ed ex articolo 13 del Regolamento Europeo 2016/679 (GDPR).

La sottoscritta, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA
l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Roma, 07/04/2026

Prof.ssa Antonella Conte

Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i)	**Farina Cinthia**
Indirizzo(i)	Istituto di Neurologia Sperimentale INSpe e Divisione di Neuroscienze, IRCCS Ospedale S. Raffaele
Telefono(i)	02-26436180
E-mail	farina.cinthia@hsr.it
Cittadinanza	Italiana

Esperienza professionale

Date	Dal 2018
Principali attività e responsabilità	Referente Medicina di Genere
Nome e indirizzo del datore di lavoro	IRCCS Ospedale San Raffaele
Date	Dal 2010
Principali attività e responsabilità	Group Leader
Nome e indirizzo del datore di lavoro	IRCCS Ospedale San Raffaele
Date	2005-2010
Principali attività e responsabilità	Group leader, Rientro dei Cervelli
Nome e indirizzo del datore di lavoro	IRCCS Istituto Neurologico Carlo Besta, Milano
Date	1998-2005
Principali attività e responsabilità	1998-2001 borsista, 2001-2005 assistente di ricerca
Nome e indirizzo del datore di lavoro	Max-Planck-Institute di Neurobiologia, Martinsried, Germania
Date	1992-1997
Principali attività e responsabilità	1992-1994 Tesista, 1994-1997 borsista
Nome e indirizzo del datore di lavoro	Istituto Nazionale Tumori, Milano

Istruzione e formazione

Date	Dicembre 2006
Titolo della qualifica rilasciata	PhD in Biologia Umana, Facoltà di Medicina, Ludwig-Maximilians-University, Monaco, Germania.
Date	Luglio 1994
Titolo della qualifica rilasciata	Laurea in scienze biologiche, Facoltà di Biologia, Università degli Studi di Milano.

Capacità e competenze personali

Madrelingua(e)	**Italiano**
Altra(e) lingua(e)	**Inglese, Tedesco**

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010

Capacità e competenze organizzative	Esperienza nell'istruire e coordinare il lavoro di tecnici, studenti, giovani scienziati. Esperienza nel coordinare le attività di un laboratorio di ricerca biomedica. Capacità di attrazione di finanziamenti per progetti di ricerca.
Capacità e competenze professionali	Attività di ricerca traslazionale nell'ambito delle malattie infiammatorie e neurodegenerative del sistema nervoso mediante approcci in vitro (test su cellule immunitarie, gliali e neuronali), ex vivo (analisi di tessuti da pazienti), in vivo (utilizzo di modelli animali) ed in silico (analisi bioinformatiche, di biologia dei sistemi e machine learning).
Altre capacità e competenze	Expert Evaluator per la Commissione Europea e per il Ministero della Salute Spagnolo. Revisore di progetti per numerose agenzie, quali Agence Nationale de la recherché, National Institute for Social Care and Health Research (NISCHR)/Welsh Assembly Government, UK multiple sclerosis society, DFG Deutsche Forschungsgesellschaft, Foundation ARSEP-French MS research Society, SAO-FRMA Stichting voor Alzheimer Onderzoek Fondation pour la Recherche sur la Maladie d'Alzheimer, AFMTéléthon, FISM Fondazione Italiana Sclerosi Multipla. Revisore per numerose riviste scientifiche internazionali, quali PNAS, Journal of Experimental Medicine, Science Translational Medicine, Lancet Neurology, Acta Neuropathologica, EMBO J, Journal of Immunology, Journal of Leukocyte Biology, Glia, PLoSONE, Brain Behaviour and Immunity, Journal of Neuroinflammation, Pharmacogenomics. Membro della Associazione italiana di Neuroimmunologia e della Società Internazionale di Neuroimmunologia. Dal 2012 al 2019 Membro eletto del Direttivo dell'Associazione italiana di Neuroimmunologia. Dal 2014 al 2018 Membro eletto del Direttivo della Società internazionale di Neuroimmunologia. Dal 2015 Membro selezionato del comitato scientifico della UK Multiple Sclerosis Society. Dal 2018 Referente di Ospedale San Raffaele per la medicina di genere presso il Ministero della Salute. 2019- Membro del gruppo redazionale del Piano Nazionale per la Medicina di Genere recepito con Decreto Ministeriale in data 13 giugno 2019. 2020 e 2021- Membro del gruppo redazionale del documento "Bussole IRCCS-Medicina di Genere e COVID-19" emesso dal Ministero della Salute. Dal 2024- Membro del Gruppo di Approfondimento tecnico sulla Medicina di Genere di Regione Lombardia Nov 2005: Primo premio come miglior giovane scienziato per la ricerca sulla sclerosi multipla attribuito dalla European Charcot Foundation. Giugno 2008: Miglior Tesi di Dottorato presso la Ludwig-Maximilians University di Monaco, Germania. Novembre 2012: Premio Internazionale Trotula attribuito dal Centro Studi Civitas Hippocratica, Salerno. Gennaio 2014: Abilitazione Nazionale come Professore di II fascia per 06/A2 Patologia Generale e Patologia Clinica, 05/H2 Istologia, 05/F1 Biologia Applicata, 05/E2 Biologia Molecolare

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010

Ulteriori informazioni

(Co-)Autrice di più di 70 pubblicazioni sottoposte a revisione su riviste scientifiche internazionali ad alto impact factor (5945 citazioni in Scopus, 7.2 impact factor medio, Scopus h-index 33, Google scholar h-index 35) e di più di 100 contributi presentati a congressi nazionali ed internazionali.

Pubblicazioni selezionate:

1. Maryam Omrani, Rosaria Rita Chiarelli, Massimo Acquaviva, Claudia Bassani, Gloria Dalla Costa, Federico Montini, Paolo Preziosa, Francesca Grassivaro, Simone Guerrieri, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Mauro Zaffaroni, Anna Pietroboni, Alessandra Protti, Marco Puthenparampil, Roberto Bergamaschi, Giancarlo Comi, Maria A. Rocca, Vittorio Martinelli, Massimo Filippi, Cinthia Farina. Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics. **Brain Behavior Immunity** 121, 2024.
2. Emanuela Colombo, Marco Di Dario, Ramesh Menon, Valente Maria Maddalena, Claudia Bassani, Nicole Sarno, Davide Mazza, Federico Montini, Lucia Moiola, Giancarlo Comi, Vittorio Martinelli and Cinthia Farina. *HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity*. **Journal of Autoimmunity** 138, 2023.
3. Emanuela Colombo, Daniela Triolo, Bassani Claudia, Francesco Bedogni, Marco Di Dario, Giorgia Dina, Evelien Fredrickx, Isabella Fermo, Vittorio Martinelli, Jia Newcombe, Carla Taveggia, Angelo Quattrini, Giancarlo Comi and Cinthia Farina. *Dysregulated copper transport in multiple sclerosis may cause demyelination via astrocytes.* **P.N.A.S.** 118, 2021.
4. Massimo Acquaviva, Ramesh Menon, Marco Di Dario, Gloria Dalla Costa, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Cinthia Farina. *Inferring Multiple Sclerosis stages from blood transcriptome via machine learning*. **Cell Rep. Med.** 1, 2020.
5. Emanuela Colombo, Claudia Bassani, Anthea De Angelis, Francesca Ruffini, Linda Ottoboni, Giancarlo Comi, Gianvito Martino and Cinthia Farina. *Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced neurodegeneration.* **Front. Immunol**. 2020.
6. Sundararajan Srinivasan, Marco Di Dario, Alessandra Russo, Ramesh Menon, Elena Brini, Marzia Romeo, Francesca Sangalli, Gloria Dalla Costa, Mariaemma Rodegher, Marta Radaelli, Lucia Moiola, Daniela Cantarella, Enzo Medico, Gianvito Martino, Roberto Furlan, Vittorio Martinelli, Giancarlo Comi, Cinthia Farina. *Dysregulation of multiple sclerosis risk genes and pathways at distinct stages of disease.* **Neurol. Neuroimmunol. Neuroinflamm**. 4 (3): e337, 2017.
7. Colombo Emanuela, Farina Cinthia. *Astrocytes: key regulators of Neuroinflammation*. **Trends in Immunology** 37, 2016.
8. Emanuela Colombo, Marco Di Dario, Eleonora Capitolo, Linda Chaabane, Jia Newcombe, Gianvito Martino and Cinthia Farina. *Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide*. **Annals Neurol.** 76 2014.
9. Emanuela Colombo, Chiara Cordiglieri, Giorgia Melli, Jia Newcombe, Markus Krumbholz, Luis Parada, Enzo Medico, Reinhard Hohlfeld, Edgar Meinl and Cinthia Farina. *Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration*. **J. Exp. Med**. 209, 2012.
10. Ramesh Menon, Marco Di Dario, Chiara Cordiglieri, Silvia Musio, Loredana La Mantia, Clara Milanese, Anna Luisa Di Stefano, Massimo Crabbio, Diego Franciotta, Roberto Bergamaschi, Rosetta Pedotti, Enzo Medico and Cinthia Farina. *Gender-based blood transcriptomes and interactomes in multiple sclerosis: Involvement of SP1 dependent gene transcription*. **J. Autoimmunity** 38, 2012.

Firma

Data 01-04-2026

"Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 D. Lgs. 30 giugno 2003 n°196 – "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali".

Data __01/04/2026

Firma _____

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "conflitto d'interessi E.C.M." è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),
DICHIARA
l'assenza di interessi commerciali in ambito sanitario negli ultimi due anni dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: _Milano 01-04-2026__

Firma: __ **_____**

Nb : Si precisa che per "interessi commerciali" si intendono situazioni di possesso di quote azionarie di società che operano in ambito sanitario, rapporto di lavoro dipendente o comunque incarichi che lo collochino nell'organizzazione delle medesime società, oppure situazioni di percepimento di royalties o provvigioni commerciali dalle stesse società.

Per maggiori informazioni su Europass: http://europass.cedefop.europa.eu
© Unione europea, 2002-2010 24082010

INFORMAZIONI PERSONALI

Diana Ferraro

Indirizzo lavoro

Ospedale Civile di Baggiovara

Via P. Giardini, 1355, Modena

tel lavoro 059/3961678

mail lavoro ferra-ro.diana@aou.mo,it

CF: FRRDNI78C58Z133C

ESPERIENZA PROFESSIONALE

01/03/2022-Presente: Dirigente Medico di Neurologia presso Ospedale Civile di Baggiovara dell'Azienda Ospedaliero-Universitaria di Modena

01/03/2022-Presente: Responsabile Centro Sclerosi Multipla dell'Ospedale Civile di Baggiovara dell'Azienda Ospedaliero-Universitaria di Modena

ATTIVITA' PREGRESSA

Dal 16/11/2020 - 28/02/2022 ricercatore in Neurologia presso Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze (Università di Modena e Reggio Emilia, Modena) con integrazione per attività assistenziale presso 'Unità Operativa di Neurologia dell'Ospedale Civile, Azienda Ospedaliero-Universitaria di Modena

2/3/2020-15/11/2020 Dirigente Medico di Neurologia presso Azienda Ospedaliero-Universitaria di Modena

Dal 2/3/2015 al 1/3/2020 ricercatore in Neurologia presso Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze (Università di Modena e Reggio Emilia, Modena) con integrazione per attività assistenziale presso 'Unità Operativa di Neurologia dell'Ospedale Civile, Azienda Ospedaliero-Universitaria di Modena

Dal 1/02/2009 al 31/12/2013 e dal 16/8/2014 al 1/3/2015 titolare di contratto libero professionale per lo svolgimento di attività assistenziale, in qualità di neurologo, presso l'Unità Operativa di Neurologia del Nuovo Ospedale Civile Sant'Agostino Estense in Baggiovara (AUSL di Modena

ISTRUZIONE E FORMAZIONE

Dal 1/1/2011 al 31/12/2013: Dottorato di Ricerca in Neuroscienze presso il Dipartimento di Neuroscienze dell'Università di Modena e Reggio Emilia, Modena

Dal 16/01/2009 al 15/01/2011: Titolare di assegno di ricerca presso il Dipartimento di Neuroscienze dell'Università di Modena

e Reggio Emilia, Modena

10/11/2008: Specializzazione in Neurologia con votazione di 50/50 e lode presso l'Università Cattolica del Sacro Cuore (Roma).

24/07/2003: Laurea in Medicina e Chirurgia con votazione di 110/110 e lode presso l'Università Cattolica del Sacro Cuore (Roma)

COMPETENZE PERSONALI

Lingua madre: Italiano

INGLESE: superamento dell'APIEL (Advanced Placement International English Language) con il massimo dei voti nel 1997.

Capacità di lettura	Eccellente
Capacità di scrittura	Eccellente
Capacità di espressione orale	Eccellente

TEDESCO

Capacità di lettura	Eccellente
Capacità di scrittura	Eccellente
Capacità di espressione orale	Eccellente

ALTRE CAPACITA' O COMPETENZE

Partecipazione al Corso di perfezionamento in "Statistica applicata ai quesiti clinici"(durata: 10 mesi; impegno: 400 ore; CFU: 16) diretto dal Prof. Roberto D'Amico, presso l'Università degli Studi di Modena e Reggio Emilia con superamento dell'esame in data 26/04/2011 con voto di 110/110.

Partecipazione al Corso di Perfezionamento in "Revisioni Sistematiche e Meta-analisi Cochrane" (impegno: 84 ore; CFU: 16) diretto dal Prof. Roberto D'Amico, presso l'Università degli Studi di Modena e Reggio Emilia

Associate Editor della rivista BMC Neurology (2018-2022)

Membro del Consiglio Direttivo dell'Associazione Italiana di Neuroimmunologia (AINI) dal 2022

Membro della Commissione di Esperti di Studi Osservazionali del Registro Italiano della Sclerosi Multipla da giugno 2024.

Partecipazione in qualità di principal investigator, sub-investigator o study coordinator a sperimentazioni cliniche nazionali ed internazionali di fase II-IV.

-

ULTERIORI INFORMAZIONI Autore di 167 articoli in extenso su riviste nazionali e internazionali; citazioni: 4000; H-index: 36 (fonte: Scopus)

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data 10/04/2026 Firma



CURRICULUM VITAE

Name: **Roberto Furlan**
Date of birth: 5th april 1964
Birthplace: Frankfurt-M (Germany)
Citizenship: Italian
Home address: Via Campo dei Fiori 32, 20026 Novate Milanese, Milano, Italy
Office address: Clinical Neuroimmunology Unit
Division of Neuroscience – Institute of Experimental Neurology
San Raffaele Scientific Institute,
Via Olgettina 60, 20132 Milano, Italy
(Tel. +39-02-26434867, Fax +39-02-26434855)
Email: furlan.roberto@hsr.it

EDUCATION AND DEGREES

1983	Matriculation, High School "S.Allende", Milano, Italy, (58/60)
1991	Medical Degree, University of Milano, Italy, (110/110 and honours)
2001	PhD, Open University, London, UK
2007	Residency in Neurology, Vita e Salute University, Milan, Italy

CERTIFICATIONS

1992	Board Certified Medical Licensure, University of Milano, Italy
2014	Abilitation for Full Professorship, Medicine section 06/A2, General and Clinical Pathology
2014	Abilitation for Full Professorship, Biology section 05/F1, Applied Biology

TRAINING AND PROFESSIONAL APPOINTMENTS

1984-85	Research Fellow, "M. Negri" Institute for Pharmacology Research, Milano, Italy
1988	Internship, Institute of Pharmacology, University of Milano, San Raffaele Scientific Institute, Italy
1990-91	Internship, Laboratory of Neurophysiology and Cellular Neurobiology, Department of Neurology, University of Milan, San Raffaele Scientific Institute, Italy
1991-94	Post-doctoral fellow, Neuroimmunology Unit - DIBIT, San Raffaele Scientific Institute, Milan, Italy
1992	Visiting Scientist, Department of Neurology, University of Chicago, U.S.A..
1993	Visiting Scientist, Clinical Laboratories, Sao Rafael Hospital, Salvador-Bahia, Brazil.
1994-95	Post-doctoral fellow, Dept. of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, U.S.A.

1996-99	Post-doctoral fellow, Neuroimmunology Unit, Dept. of Neuroscience, DIBIT-San Raffaele Scientific Institute, Milano, Italy.
1999-2001	Non-tenured Research Assistant, University of Milan, Milan, Italy
2002-2008	Research assistant, Neuroimmunology Unit, Dept. of Neuroscience, DIBIT-San Raffaele Scientific Institute, Milano, Italy.
2009-2015	Group Leader of the Clinical Neuroimmunology Unit - San Raffaele Scientific Institute, Milano, Italy.
2004-2023	Non-tenured professor, Vita e Salute San Raffaele University, Milano, Italy
2015-present	Head of the Clinical Neuroimmunology Unit - San Raffaele Scientific Institute, Milano, Italy.
2017-2021	Vice-Director of the Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy
2022-2024	Director of the Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy
2023-present	Associate Professor of General Pathology, Vita e Salute San Raffaele University, Milano, Italy

HONORS, AWARDS AND FELLOWSHIPS

1992	Fellowship, "Associazione Italiana Sclerosi Multipla", Genova, Italy
1994	Fellowship, "Istituto Superiore di Sanità", Roma, Italy
1995	De Visart" Award for Neurological Research, University of Milano, Italy
1999	Teva and Marion Hoechst Award on MultipleSclerosis, European Charcot Found.
2002	European Neurological Society award for the scientific paper " Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57BL/6 mice.", Berlin 22-26 June.
2009	Rita Levi Montalcini Award, AISM, Roma, Italy
2009	Board member of the Italian Neuroimunology Association – AINI
2009-2010	EC evaluator for the Sixth Framework Programme Project "Neuropromise"
2010-2014	Scientific Board member of the Italian Multiple Sclerosis Association
2010-	Secretary of the Residential Courses of Neuroimmunology – CRNI
2010-2018	Secretary-Treasurer of the International Neuroimmunology Society – ISNI
2011	SIICA Best Abstract Awards for the paper "Microvesicles in the cerebrospinal fluid reflect microglia/macrophage activation in rodent and human neuro-inflammation". Riccione 28 sept.-1 oct.
2012-	Board Member of the Europan School of Neuroimmunology
2014	Abilitation as Full Professor in General Pathology and in Applied Biology
2014- 2016	Secretary of the Italian Higher School of Neurology
2019-	President of the Italian Neuroimmunology Association – AINI
2021-2023	Vice President of the International Society of Neuroimmunology– ISNI
2023-2025	President of the International Society of Neuroimmunology – ISNI

2025-2027 Past President – ISNI
2025- Associate Editor of African Brain Journal

Reviewer for the following journals: Annals of Neurology, Brain, Neurology, European Journal of Neurology, Human Gene Therapy, Journal of Immunology, Human Immunology, European Journal of Immunology, Journal of Neuroimmunology, Multiple Sclerosis, Neuroscience Letters, Journal of Gene Medicine, Molecular and Cellular Neurological Sciences, PlosOne, PNAS, Science Translational Medicine.
Academic Editor for PlosOne.
Reviewer for the following granting agencies: European Community, Fondazione Italiana Sclerosi Multipla – FISM, Association pour la Recherche de la Sclerose en Plaque – Arsep, Sheffield Hospitals Charitable Trust, UK MS Society, Australian MS Society, Portuguese Science Foundation.

P.I. or co-P.I: in the following grants:

- Ex Art. 56 – "Cognitive, neurophysiological, immunological and biomolecular studies of Multiple Sclerosis patients and of experimental models of the disease: correlation with cognitive impairment".
- TEVA Contract 14/06 "Serial study of PBMC phenotype and relactivity to glatiramer acetate (copaxone TM) in patients with relapsing remitting MS trated with Copaxone TM"
- FISM2007/R/2 "Ruolo dei Linfociti T regolatori CD39+ nella SM"
- The Myelin Project "Terapia genica e cellulare per la cura della Sclerosi Multipla, sviluppo e validazione di un nuovo terapeutico approccio combinato"
- NICOX "Valutazione clinica ed immunopatologica dell'efficacia preventiva e terapeutica del NO-flurbiprofen (HCT-1026) nell'encefalite autoimmune sperimentale (EAE)"
- NMS401SA2 "The role of endogenous neural stem/precursors cells in MS"
- AVENTIS "Ancillare immunological study of the ICARO protocol"
- Programma strategico CONTRABASS - COgnitive Neuroendophenotypes for Treatment and RehAbilitation of psychoses: Brain imaging, inflAmmation and StresS
- Teva Contract 2010 "Effects of laquinimod on synaptic neurodegenerative damage in experimental multiple sclerosis: involvement of microglia and t regulatory cells".
- Telormedix Contract 2010 "M1/M2 shift in microglia cells upon TLR7 partial agonist TMX-302 administration in vitro and in chronic progressive EAE mice"
- FISM 2010 (2011-2013) "IL-27 and IL-35 in experimental autoimmune encephalomyelitis: a family affair",
- Merck-Serono unrestricted grant (2011-2013) "Special project Microglia"
- FIRB Functional Genomics of Neurodegenerative Diseases 2012-2015
- GR-2010-2316745 SPES–***S***ervice for detection of Pre-psychosES: from genomics to phenomenology in a human/animal perspective
- Fondazione Veronesi "Nuovi meccanismi per la cura delle malattie da prioni." (2013-2015)
- Merck-Serono unrestricted grant (2014-2016) "Detrimental vs. protective microglia"
- PON Rinovatis 2007-2013 (delayed to 2015)

- FISM 2014 (2015-2017) “Microglia microvesicles as therapeutic vector in neuroinflammation”
- Ivascomar, Cluster Alisei, 2012-2017
- ERANET NEURON 2014 (2015-2018) “MS_NANOMED Advancing an antigen-specific nanomedicine for the treatment of central nervous system autoimmunity”
- FISM 2017/R/12 (2018-2020))Microglial microvesicles as therapeutic vector for neuroinflammation.
- FRRB (2020-2022) New frontiers of engineered nanovectors to improve treatment efficacy and safety in neurological disorders.
- FISM 2020/R-single/023 (2021-2024) Immuneregulatory neutrophils in neuroinflammation.
- Ministry of Health PNRR PNRR-MAD-2022-12375634 (2023-2025) Innate immune CElls in MUltiple SCLErosis – ICEMUSCLE.
- Ministry of Health PNRR-MCNT2-2023-12378040 (2024-2026) Measuring Immunological Self-Tolerance Reservoir to Validate Innovative Therapies in Patients with Relapsing-Remitting Multiple Sclerosis
- Ministry of University and Research PE00000006 “A multiscale integrated approach to the study of the nervous system in health and disease” MNESYS, Spoke 7, (2024-2025) REGNNI – REGulatory Neutrophils in NeuroInflammation
- FISM Special Project (2025-2027) Hematopoietic stem cells engineered to release therapeutic extracellular vesicles in the central nervous system: a novel treatment platform for multiple sclerosis. HERCULES

Inventor in patent no. WO 2011107962 A1 “Increase of myeloid microvesicles in the cerebrospinal fluid as biomarker of microglia/macrophage activation in neurological disorders”

Supervisor of over 20 undergraduate students, 9 PhD students, 4 residents in neurology.

Currently supervising 1 PhD candidate.

M, Clerici M, Comi G, Rovaris M, Furlan R. Oxidative stress is differentially present in multiple sclerosis courses, early evident and unrelated to treatment. J Immunol Res. 2014:961863. doi: 10.1155/2014/961863. (I.F. 3.064)

108. Rossi S, Studer V, Motta C, Germani G, Macchiarulo G, Buttari F, Mancino R, Castelli M, De Chiara V, Weiss S, Martino G, Furlan R, Centonze D. Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in Multiple Sclerosis. J Neuroinflamm. 2014 11:32. doi: 10.1186/1742-2094-11-32. (I.F. 4.350)

109. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N, Rambaldelli G, Tansella M, Finardi AM, Martino G, Perlini C, Furlan R. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry. 2014 Jul 1,4:e406. doi: 10.1038/tp.2014.46. (I.F. 5.538)

110. Sardi C, Zambusi L, Finardi A, Ruffini F, Tolun AA, Dickerson IM, Righi M, Zacchetti D, Grohovaz F, Provini L, Furlan R, Morara S. Involvement of Calcitonin Gene-Related Peptide and Receptor Component Protein in experimental autoimmune encephalomyelitis. J Neurimmunol. 2014 Jun 15,271(1-2):18-29. doi: 10.1016/j.jneuroim.2014.03.008 (I.F. 3.014)

111. Mori F, Nicoletti CG, Rossi S, Motta C, Kusayanagi H, Bergami A, Studer V, Buttari F, Barbieri F, Weiss S, Nisticò R, Martino G, Furlan R, Centonze D. Growth Factors and Synaptic Plasticity in relapsing-remitting Multiple Sclerosis. Neur Mol Med. 2014 Jun,16(2):490-8. doi: 10.1007/s12017-014-8297-7 (I.F. 4.492)

112. Cianciaruso C, Pagani A, Martelli C, Bacigaluppi M, Squadrito ML, Dico AL, De Palma M, Furlan R, Lucignani G, Falini A, Biffi A, Ottobrini L, Politi LS. Cellular magnetic resonance with iron oxide nanoparticles: long-term persistence of SPIO signal in the CNS after transplanted cell death. Nanomedicine (Lond). 2014 May 13:1-18. (I.F. 5.260)

113. Rossi S, Motta C, Studer V, Rocchi C, Macchiarulo G, Barbieri F, Marfia GA, Furlan R, Martino G, Mancino R, Centonze D. Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. Mult Scler. 2014 May 29. pii: 1352458514537365. (I.F. 4.255)

114. Agosta F, Dalla Libera D, Gioele Spinelli E, Finardi A, Canu E, Bergami A, Bocchio Chiavetto L, Baronio M, Comi G, Martino G, Matteoli M, Magnani G, Verderio C, Furlan R. Myeloid microvesicles in CSF are associated with myelin damage and neuronal loss in mild cognitive impairment and alzheimer disease. Ann. Neurol. 2014 doi: 10.1002/ana.24235. (I.F. 11.193)

115. Montarolo F, Raffaele C, Perga S, Martire S, Finardi A, Furlan R, Hintermann S, Bertolotto A. Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mouse. PloS One. 2014 9(9):e108791. doi: 10.1371/journal.pone.0108791. (I.F. 3.534)

116. Arnò B, Grassivaro F, Rossi C, Bergamaschi A, Castiglioni V, Furlan R, Greter M, Favaro R, Comi G, Becher B, Martino G, Muzio L. Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun. 2014 Nov 26,5:5611. doi: 10.1038/ncomms6611. (I.F. 10.742)

117. Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F, Ruocco G, Buttari F, Finardi A, Mancino R, Weiss S, Battistini L, Martino G, Furlan R, Drulovic J,

Centonze D. Interleukin-1beta causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol. Neurodeg. 2014 12,9:56. doi: 10.1186/1750-1326-9-56 (I.F. 5.290)

118. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier U, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Zborníková P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson HB, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martinez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Colombo E, Franciotta D, Derfuss T, Lindberg RLP, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar L, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan S, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. MSJ. 2015 Feb 13. pii: 1352458514568827. (I.F. 4.863)

119. Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, Furlan R, Martino G, Centonze D. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler. 2015 Jan 12. pii: 1352458514564482. (I.F. 4.255)

120. Joshi P, Benussi L, Furlan R, Ghidoni R, Verderio C. Extracellular Vesicles in Alzheimer's Disease: Friends or Foes? Focus on Aβ-Vesicle Interaction. Int. J. Mol. Sci. 2015 16 4800-4813. (I.F. 2.721).

121. Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, Gasperini C, Furlan R, Centonze D, Battistini L, Volpe E. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. Clin. Sci. 2015 29:291-303. doi: 10.1042/CS20140608 (I.F. 5.629)

122. Carandini T, Colombo F, Finardi A, Casella G, Garzetti L, Verderio C, Furlan R. Microvesicles: what is the role in multiple sclerosis? Front. Neurol. 2015 26,6:111. doi: 10.3389/fneur.2015.00111.

123. Graziano F, Desdouits M, Garzetti L, Podini P, Alfano M, Rubartelli A, Furlan R, Benaroch P, Poli G. Extracellular ATP induces the rapid release of HIV-1from virus containing compartments of human macrophages. PNAS. 2015 112(25):E3265-73. doi: 10.1073/pnas.1500656112 (I.F. 9.809)

124. Prada I, Amin L, Furlan R, Legname G, Verderio C, Cojoc D. A new approach to follow single extracellular vesicle-cell interaction using optical tweezers. Biotechniques. 2016 60:35-41 (I.F. 2.754)

125. Penton-Rol G, Lagumersindez-Denis N, Muzio L, Bergami A, Furlan R, Fernández-Masso JR, Nazabal-Galvez M, Llópiz-Arzuaga A, Herrera-Rolo T, Veliz-Rodriguez T, Polentarutti N, Marín-Prida J, Raíces-Cruz I, Valenzuela-Silva C, Martins Teixeira M, Pentón-Arias E. Comparative neuroregenerative effects of c-phycocyanin and IFN-beta in a model of multiple sclerosis in mice. J Neuroimmune Pharmacology. 2016 11:153-67 (I.F. 4.110)

13. Furlan R, Butti E, Pluchino S, Martino G. Gene therapy approaches for autoimmune diseases of the central nervous system and other tissues. In Gene Therapy of Autoimmune Diseases. Geràld J. Prud'homme (Ed). Kluwer Academic/Plenum Publisher. 2005, pp 1-16.

14. Pluchino S, Bacigaluppi M, Bucello S, Butti E, Deleidi M, Zanotti L, Martino G, Furlan R. Gene and stem cell therapy for autoimmune demyelination. Ernst Schering Res Found Workshop. 2005,(53):133-46.

15. Butti E, Martino G, Furlan R. The ependymal route for central nervous system gene therapy. In Handbook of Experimental Neurology: Methods and Techniques in Animal Research. Fisher M, Tatlisumak T. (Eds). Cambridge Press. 2006, pp.257-268.

16. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. In Methods in Molecular Medicine: Neural transplantation. Scolding N and Gordon D. (Eds). Humana Press. 2009, 549, pp. 157-173.

17. Pluchino S, Furlan R, Muzio L, Martino G. Tissue regeneration and repair in multiple sclerosis, the role of neural stem cells. In: Textbook of Neurorehabilitation in Multiple Sclerosis. J. Kesselring, G. Comi, A. Thompson (Eds.). Cambridge University Press, Cambridge. 2010 pp. 60-66.

18. Furlan R, Maiorino C, Gatta A, Ruffini F, Martino G. Gene therapy of multiple sclerosis. In Gene Therapy for Autoimmune and Inflammatory Diseases. Chernajovsky Y, Robbins PD (Eds.). Springer Basel. 2010 pp. 65-68

19. Franciotta D, Alessio M, Garzetti L, Furlan R. Methods for Biomarker analysis. In Cerebrospinal Fluid in Clinical Neurology. Deisenhammer, F., Sellebjerg, F., Teunissen, C.E., Tumani, H. (Eds.). Springer. 2015 pp. 159-171

20. Furlan R. Cladribina e il suo meccanismo d'azione. In: Sclerosi multipla recidivante: immunopatogenesi e azione di cladribina. A cura di: Diego Centonze, Roberto Furlan. Therapy Perspectives for rational drug use & disease management. Springer. Anno XXIII, N.5, Ottobre 2020

21. Pratesi ML, Sfondrini G, Finardi A, Brambilla P, Benedetti F, Furlan R. Immunopsichiatria. In: Neuroscienze Psichiatriche e Computazionali. A cura di Paolo Brambilla. Edizioni Minerva Medica 2020.

22. Furlan R. Indagini strumentali e di laboratorio. Laboratorio. In: Sclerosi Multipla e malattie demielinizzanti del sistema nervoso centrale. Giancarlo Comi Editor. Edizioni Minerva Medica 2022.

Invited lectures (since 2010):

1. FISM Scientific Meeting May 26-27 2010, Rome, Italy
2. Advances in Clinical Neuroimmunology, May 31-June 1 2010, Gdansk, Poland
3. University of Southern Denmark, June 21-22 2010, Odense, Denmark
4. AISM Sondrio, July 24 2010, Sondrio, Italy
5. Neuroimmunology Satellite to ICI, August 18-21 2010, Kyoto, Japan
6. International Society of Neuroimmunology, October 26-29 2010, Barcelona, Spain
7. Al Fayoum University Neuroimmunology Course, November 7-9 2010, Al Fayoum, Egypt
8. Fast Forward Meeting on Progressive MS, December 1-2 2010, Boston, USA
9. Advances in Clinical Neuroimmunology, March 25-26 2011, Pécs, Hungary
10. SISSA, May 27th 2011, Trieste, Italy
11. Top Seminars, June 15-17 2011, Milan, Italy
12. Internship MS Excellence, June 27-30 2011, Milan, Italy
13. University of Mainz, November 18th 2011, Mainz, Germany
14. C. Besta Neurological Institute, March 6 2012, Milan, Italy
15. Neuroscience Institute Cavalieri Ottolenghi, April 11 2012, Orbassano (To), Italy
16. Advances in Clinical Neuroimmunology, May 31-June 1 2012, Wien, Austria
17. Italian Association of Neuroimmunology, September 26-29 2012, Catania, Italy
18. International Society of Neuroimmunology, November 4-7 2012, Boston, USA
19. Young AISM meeting, November 30- December 2 2012, Roma, Italy
20. MS Workshop, December 4-7 2012, Athens, Greece
21. Prion Meeting SISSA, January 10-11 2012, Trieste, Italy
22. Gallarate Multiple Sclerosis Center, February 28 2013, Gallarate (Va), Italy
23. IRCCS Humanitas, March 8 2013, Rozzano (Mi), Italy
24. SISSA, March 20 2013, Trieste, Italy
25. AISM Como, April 20 2013, Como, Italy
26. MS Symposium, May 10 2013, Roma, Italy
27. Top Seminars, May 25 2013, Baveno (No), Italy
28. MS Talent, June 17 2013, Milan, Italy
29. European School of Neuroimmunology, July 2-5 2013, Porto, Portugal
30. International Congress in Immunology – ICI, August 23-27 2013, Milan, Italy
31. Italian Neuroscience Society – SINS, September 3-5 2013, Rome, Italy
32. Cognitive Disfunction in MS, October 17-18 2013, Taormina (Ct), Italy

153. Accademia Medica di Roma, April 13th 2023, Rome Italy
154. Giovani oltre la SM Sud. April 28-29 2023, Pizzo Calabro, Italy
155. Associazione Italiana Neuroimmunologia – AINI. May 3rd 2023, Palermo, Italy
156. Insight – Insieme. June 19th 2023, Milan, Italy
157. Criteri per una cura personalizzata della sclerosi multipla. June 28th 2023, Milan, Italy
158. Neurology Talks, May 22nd 2023, virtual
159. Society of Neuroscience Africa – SONA, July 12th 2023, Johannesburg, South Africa
160. Translational Research on Neuroimmunology, Neuroinflammation and Infections of the Nervous System. October 26-29 2023, Rabat, Morrocco
161. Young AISM meeting, December 2nd 2023, Roma, Italy
162. Greek Society of Neuroimmunology, December 15th 2023, Tessaloniki, Greece
163. Le cellule B come miglior target per il trattamento del paziente con SM. December 16th 2023, Turin, Italy
164. SM tra presente e futuro. January 26th 2024, Parma, Italy
165. Dalla diagnosi alla presa in carico riabilitativa nella sclerosi multipla. February 21st 2024. Webinar
166. Sclerosi multipla: una singola malattia o uno spettro di patologie. April 5th 2024, Milan, Italy
167. Space of care as one for patients. April 5th 2024, Milan, Italy
168. La gestione delle terapie ad alta efficacia nel paziente con SM: esperienze a confronto. April 10th 2024, Milan, Italy
169. AISM leadership. April 13th 2024, Rome, Italy
170. Pathogenesis of MS for SISSA. May 22nd 2024, Webinar
171. Family planning, gravidanza e post-partum: l'approccio multidisciplinare nella Sclerosi Multipla. June 5th 2024, Milan, Italy
172. I disturbi affettivi nell'era delle Neuroscienze: attualità e prospettive. June 14-15 2024, Genova, Italy
173. Summer school Immunità. August 28th-September 1st 2024, Pozzilli (Is), Italy
174. JAMS 2024. 3-4 October 2024. Genova, Italy
175. Il neurologo e l'immunologia. 17-18 October 2024, Desenzano del Garda (Bs), Italy
176. AISM Arezzo. October 26th 2024, Arezzo, Italy

177. Meet the expert. November 6th 2024, Como, Italy
178. AISM Ravenna. November 23rd 2024, Ravenna, Italy
179. Apertis Verbis: Early treatment strategies. November 29th 2024. Merano, Italy
180. Young AISM meeting, December 1st 2024, Roma, Italy
181. Grandangolo, January 7-8 2025, Milan, Italy
182. SIN Sud, March 14-15 2025, Villa San Giovanni, Italy
183. Disability Progression in MS, NMO and MOGAD: from bench to bedside, March 20-21 2025, Verona, Italy
184. IRCCS Burlo-Gorofolo, March 24th 2025
185. Approfondimenti monotematici nella Sclerosi Multipla. March 28th 2025, Gallarate, Italy
186. Improve 2025, April 4th 2025, Modena, Italy
187. IBRO and AFSNI School, April 9-16 2025, Rabat, Morocco
188. SONA meeting, April 17-20 2025, Marrakesh, Morocco
189. AINI, May 5-8, Turin, Italy
190. Rethinking MS, May 9-10 2025, Giardini Naxos, Italy
191. Nobel Symposia, June 2-5 2025, Stockholm, Sweden

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.), **DICHIARA**
l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: _Milano 7 Aprile 2026
Firma: _____

Curriculum vitae of: Andrea Fuso **Date:** April, 2026

Andrea fuso, PhD

Associate Professor of Clinical Biochemistry and Clinical Molecular Biology
Member of the board of the directors of the Center for Research in Neurobiology (CRiN)
Sapienza University of Rome

Member of the Board of the Directors of the Epigenetics Society (ES)

Member of the Scientific Committee of the "Space Biomedicine and Biotechnology Laboratory"
Sapienza University – Thales Alenia Space

Education and Employment:

1991-1997: Degree (MS) in Biological Sciences (Cum Laude), Sapienza University of Rome, Rome, Italy
1997-2001: Ph.D. in Enzymology, University of L'Aquila, L'Aquila, Italy
2002-2010: Postdoctoral Fellow (Assegno di Ricerca) in Neuroscience, Dept. of Surgery "P. Valdoni" and Dept. of Psychology, Sapienza University of Rome, Rome, Italy
2010-2013: Lecturer in Clinical Pathology, Post-graduation School of Clinical Pathology, Sapienza University of Rome, Rome, Italy
2012-2015: Assistant Professor (RTD), Dept. of Psychology, Sect. Neuroscience, Sapienza University of Rome (RTDa; 1/10/2012 - 30/9/2015)
2013-2017: Scientist, S. Lucia Foundation, Rome, Italy - Lab. of Lipid Neurochemistry (Lab. Head prof. M. Maccarrone)
2013: National Qualification (Abilitazione Scientifica Nazionale, ASN) as Associate Professor in Applied Biology (SSD 05/F1 – Bio/13; until 22/01/2020); National Qualification as Associate Professor in Biochemistry (SSD 05/E1 – Bio/10; until 16/06/2020).
2015-2018: Scientific Consultant to Lo.Li.Pharma S.r.l., Rome, Italy
2015-2018: Guest researcher, Dept. of Surgery, Sapienza University of Rome, Italy
2018-2021: Assistant Professor (RTD), Dept. of Experimental Medicine, Sapienza University of Rome (RTDb; 1/11/2018 - 31/10/2021)
2021-pres.: Associate Professor (PA) in Clinical Biochemistry and Clinical Molecular Biology, Dept. of Experimental Medicine, Sapienza University of Rome

Other professional experiences:

1991-1997: **Undergraduate student, Dept. of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy**
Study of the methylation status of 5′-flanking and exon I of the regulatory gene *myogenin*, during muscular differentiation *in vitro.* Study on the effects of hypomethylating drugs during muscle differentiation.

1997-2001: **Ph.D. student, Dept. of Cellular Biotechnology and Hematology, Sapienza University of Rome, and University of L'Aquila, Italy.**
Further studies on the effect and mechanism of action of hypomethylating drugs on DNA methylation during muscle differentiation.

2002-2010: **Postdoctoral Fellow in Neuroscience, Dept. of Surgery "P. Valdoni" and Dept. of Psychology, Sapienza University of Rome, Rome, Italy.**
Studies on One-carbon metabolism alterations *in vitro* and *in vivo* by modulation of B vitamins supplementation and use of hypomethylating and hypermethylating drugs. Alzheimer's Disease: study of the molecular mechanisms of homocysteine toxicity; role of DNA and protein methylation in amyloidogenesis and fibrillogenesis.

2010-2012.: **Contract Researcher and Lecturer in Clinical Pathology, Dept. of Surgery "P. Valdoni", Sapienza University of Rome, Rome, Italy.**

Studies on the modulation of non-CpG methylation in *in vitro* and *in vivo* models. Studies on the role of One-carbon metabolism in Alzheimer's Disease in *in vitro* and *in vivo* models and in human samples. Studies on the DNA methylation of PSEN1 gene in relation to alterations of One-carbon metabolism. Studies on the effect of B vitamins on PARP activity and on RAGE and LRP1 regulation. Role of One-carbon metabolism on animal models of autism and Rett syndrome.

Main research interest

General Areas:

- ●Epigenetics
- ●One-Carbon Metabolism
- ●Neurodegeneration
- ●Nutrition and disease

Applicative fields:

- ●Alzheimer's disease
- ●Space Biomedicine
- ●Cystic Fibrosis
- ●Rett Syndrome
- ●Autism
- ●Muscle differentiation

Current and past research support

Active research projects:

2026-2028: INAIL, BRIC grant 2025, XENOMICS - U n Toolkit Innovativo di Valutazione del Rischio Basato su Metodologie Omiche e Intelligenza Artificiale per la Sicurezza Occupazionale: € 84.000. **Role: Unit PI.**

2024-2026: Aurora Biosearch, grant for studies on fish egg extract (Stamisome) in neuroinflammation: € 16.000 per year. **Role: PI**

2024-2026: Gnosis by Lesaffre, grant for studies on S-adenosylmethionine and S-acetylglutathione in neurodegeneration and neuroinflammation; € 10.000 per year. **Role: PI**

2023-2026: PRIN 2022: Theratipyng of Cystic Fibrosis. € 120.000. **Role: Participant.**

2023: Sapienza University, Finanziamento per Medie Apparecchiature #(000055_24_RS_FUSO_MedieAttrezzature2023) ; € 60.000. **Role: PI**

2022: ASI, Agenzia Spaziale Italiana. Progetto OvoSpace. € 320.000. **Role: Co-PI**.

Completed research projects:

2022: Gnosis by Lesaffre, grant for studies on Vitamin K in neurodegeneration and neuroinflammation; € 19.000. **Role: PI**

2022: Sapienza University, Progetto di Ricerca Medio #RM11916B88D5E704. € 10.000. Role: participant.

2022: Sapienza University, Finanziamento per convegni, seminari, workshop 2022 #CC1221814E60CADF. € 3.500. **Role: PI**

2021: Sapienza University, Progetto di Ricerca Medio. € 20.000. Precision therapy of Cystic Fibrosis. Role: participant

2020: Sapienza University, Progetto di Ricerca Medio. € 20.000. The personalized therapy of Cystic Fibrosis by theratyping and gene targeting

2019: Progetto di Ricerca Medio. € 20.000. Application of gene targeting by Small Fragment Homologous Replacement (SFHR) to human Cystic Fibrosis stem-like and differentiated cellular systems. Role: participant

2018: Progetto di Ricerca Medio. € 20.000. Application of a gene targeting strategy to a mouse reporter system and to stem-induced human primary Cystic Fibrosis epithelial cells. Role: participant.

2013 – 2016: Sapienza University Grant, title: Aggregazione di fibrille amiloidi nella malattia di Alzheimer: processi rapidi e processi lenti; Total budget: € 11.000/year. Role: Unit PI.

2013 – 2015: FP7 Grant, title: DEVELAGE; Total budget: € 4.000.000. Role: Co-investigator.

2007 – 2011: Research project financed by Gnosis s.p.a. for the development of researches on "Molecular mechanisms and possible clinical applications of S-adenosylmethionine". About 100.000 € per year. Role: Co-Investigator (PI: Scarpa S.)

2002 – 2003: Young researchers grant of the Sapienza University of Rome; study of the DNA methylation mechanisms in Alzheimer's Disease models. Role: PI

Committee responsibilities

Referee for the Grant Programs of the:
Alzheimer's Association, Swiss National Science Foundation, Parkinson's UK, Lise Meitner-Program, Austrian Science Fund, UK Medical Research Council, MIUR, Università di Modena e Reggio Emilia, Unicampania, Università di Verona, PRIN

Editorial responsibilities (Reviewer)

Neurobiology of Aging, Journal of Alzheimer's Disease, Journal of Neurochemistry, Current Alzheimer Research, PlosOne, Current Pharmaceutical Design, AGE, Epigenetics, International Journal of Developmental Neuroscience, Archives of Medical Research, Amino Acids, Frontiers in Aging Neuroscience, Frontiers in Genetics, WIRE, European Journal of Neuroscience, Cancer Biomarkers, Expert Review of Molecular Diagnostics, Epigenetics, Epigenomics, Longevity & Healthspan.

Editorial responsibilities (Editorial boards)

Associate editor for: Clinical Epigenetics, Epigenomes, Frontiers in Molecular Biosciences, Frontiers in Environmental Science, Frontiers in Ecology and Evolution, Frontiers in Nutrition, Annals of Nutritional Disorders & Therapy

Teaching

1998-2001: Guest lecturer at "Chemistry and Introductory Biochemistry" course at Nurse Training College "San Giovanni di Dio".

2002-2008: Guest lecturer at post-graduation courses (Scuola di Specializzazione) of Hematology and of Clinical Pathology, Sapienza University of Rome

2010-pres.: Guest lecturer at Sapienza University of Rome School of Medicine; seminars on "Molecular mechanisms of Alzheimer's Disease"

2011-2012: **Techniques of Cellular and Molecular Biology**, post-graduation course of "Clinical Pathology", Sapienza University of Rome.

2012-pres.: **Epigenetics**, Master in "Stress, sport, nutrition: new diagnostic and therapeutic approaches for fitness, wellness, prevention and rehabilitation", Medical and Pharmaceutical School, Sapienza University of Rome.

2013-2015: **Molecular basis of the Life** (classes of Biology and Genetics, Bio/13), School of Therapists of Child Neuropsychomotricity, Sapienza University of Rome

2015-2016: **Molecular basis of the Life** (classes of Biochemistry, Bio/10, and Biology, Bio/13), Schools of Nursing (S. Andrea, Pomezia, Frosinone), Sapienza University of Rome

2015-2016: **Epigenetics**, Master in Methodology for Therapeutic Intervention in Neurology, Sapienza University of Rome

2016-2019: **Epigenetics and Dementia**, Master in Diagnosi e terapia integrata della malattia di Alzheimer e delle altre demenze, Tor Vergata University, Rome

2019-pres: **Laboratory Medicine**, School of Medicine, Sapienza University of Rome

2019-pres: **Biochemistry**, School of Nursing Sciences, Sapienza University of Rome.

2020-pres: **Molecular Biology**, School of Biomedical Laboratory Technicians, Sapienza University of Rome.

2024-pres.: **Clinical Biochemistry and Molecular Biology**, School of Molecular Biology, Medicinal Chemistry and Computer Science for Pharmaceutical Applications, Sapienza University of Rome.

Mentoring

2001-pres: more than 15 undergraduate students (Biological Sciences, Biotechnology) and PhD students (Human Biology)

Membership to scientific societies:

2007-2018.: International Society to Advance Alzheimer Research and Treatment (ISTAART)
2008-2018: Society for Neuroscience (SfN)
2008-pres.: Italian Society for Neuroscience (SINS)
2010-pres.: Epigenetics Society (ES); **Board of Directors member since 2015**
2014-pres.: Associazione Italiana per la Ricerca sull'Invecchiamento Cerebrale (AIRIC)
2019-pres.: Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBIOC)
2019-pres.: Società Italiana di Biochimica (SIB)
2024-pres.: The International Society for Molecular and Clinical Epigenetics (*isMOCLEP*)

Honors:

2009: Invited Chair at the symposium "Epigenetics of Alzheimer's Disease", 9th International Conference on Alzheimer's Disease (ICAD) (Wien, Austria)
2009: Organizer of the Symposium "Homocysteine in Alzheimer's Disease", National Congress of the Italian Society for Neuroscience (Milan, IT)
2010: Travel Fellowship to attend the 10th International Conference on Alzheimer's Disease (ICAD) (Honolulu, HA, USA)
2011: Invited Plenary Speaker, 8th International Conference on Homocysteine Metabolism (Lisbon, Portugal)
2011: Travel Fellowship to attend the 11th International Conference on Alzheimer's Disease (ICAD) (Paris, France)
2012: Invited Plenary Speaker, conference on Advances and Controversies in B-Vitamins and Choline (Leipzig, Germany)
2012: Fellowship from Unipharma to perform studies on a schizophrenia animal model
2013: Invited Plenary Speaker, Keystone Symposia on "Nutrition, Epigenetic and Human Disease" (Santa Fe, NM, USA)
2013: Organizer and chair of the Symposium "Environment, epigenetics and neurodegeneration", National Conference of the Italian Society for Neuroscience (Rome, IT)
2013: Chair of the Symposium "Neuroepigenetics: Environmental determinants of brain and behavior", Joint Italian-Israeli symposium at National ISFN Conference (Eilat, IL)
2014: Invited Plenary Speaker, 20th Symposium on Neurobiology and Neuroendocrinology of Aging (Bregenz, AT)
2015: Board of Directors, Epigenetic Society (ES)
2015: Member of the Scientific/Organizing Committee, "Nanoscience and Nanotechnology" International Conference (Frascati, IT)
2016: Member of the Scientific/Organizing Committee, "52° Congresso della Società Italiana di Neuropatologia e Neurobiologia Clinica" (Rome, IT)
2023: Chair and head of the Organizing Committee of the 1st Epigenetics Society International Meeting (Rome, IT)
2023: Invited plenary speaker, 16th ITU Conference (Istanbul, Turkey)
2025: Invited Institutional lecture, 2nd Epigenetics Society International Meeting (Chicago, USA)

Invited lectures:

- "Epigenetic mechanisms in AD", RepEat Project - University of Teramo, November 13 2017; host Dr. Claudio D'Addario

- “CpG and non-CpG methylation in Alzheimers’ Disease”; The Hebrew University of Jerusalem, May 19 2016; host Dr. Aron Troen.
- “CpG and non-CpG methylation patterns of PSEN1 during neurodevelopment and neurodegeneration in mice and humans”; CIBIO, University of Trento, February 27 2015; host Dr. Margherita Grasso.
- “DNA methylation and mRNA expression patterns of PSEN1 during neurodevelopment and neurodegeneration in mice and humans”; Dept. of Cellular Biology and Neurosciences, Istituto Superiore di Sanità, Rome, February 2 2015; host Dr. Bianca De Filippis
- “Presenilin1 CpG and non-CpG methylation in Alzheimer’s Disease”; Dept. of Biochemical Sciences, Sapienza University of Rome - January 16 2015; host Dr. Maria D’Erme
- “Looking for Alzheimer's Disease mechanisms: one-carbon metabolism and methylation reactions”; Dept. of Scienze e Biotecnologie Medico-Chirurgiche, Sapienza University of Rome - Latina, February 8 2011; host Dr. Rita Businaro.
- “Role of methylation metabolism in Alzheimer’s Disease”; Mario Negri Institute for Pharmacological Research, February 23 2010; host Dr. Ugo Lucca.
- “Methylation imbalance as a pathway to disease: the Alzheimer's Disease model”; Dept. Of Histology and Medical Embryology, Sapienza University of Rome, November 25, 2009; host Dr. Carla Boitani.
- “DNA methylation and Alzheimer’s Disease”; Center for Research in Neurobiology “Daniel Bovet”, Sapienza University of Rome, June 8, 2009; host Dr. Antonella De Jaco.
- “Homocysteine cycle, methylation and Alzheimer’s Disease"; Dept. of Pharmacology, Chemiotherapy and Medical Toxicology, CNR Center, University of Milan, September 27, 2006; host Dr. Carlo Sala.

Patents:
- S-Adenosylmethionine and derivatives thereof for the treatment and prevention of Alzheimer’s Disease. Patent n° WO2001IT00528.
- Use of S-adenosylmethionine (SAM) e Superoxidedismutase (SOD) for the preparation of drugs for the treatment of Alzheimer’s Disease. Application n° 08425123.0

Scientific Collaborations:
- I. Ferrer, Institute of Neuropathology, Bellvitge University Hospital, Hospitalet de Llobregat (Barcelona), Spain
- E. Aronica, Amsterdam University, Netherland
- G. Kovacs, Medical University Wien, Austria
- A. Troen, Yuval Dor, Benjamin Glaser, Institute of Biochemistry, Food Science and Nutrition, Hebrew University of Jerusalem
- F. Gosselet, Université d’Artois, Lens, France
- E. Rodrigues, *i*Med.UL - Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Portugal
- M. D’Erme, L. Mosca, Dept. Biochemistry, Sapienza University of Rome
- Stefano Gustincich, SISSA, Trieste
- L. Ricceri, G. Laviola, B. De Filippis, Dept. Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome
- R. Businaro, Dept. Scienze e Biotecnologie Medico-Chirurgiche, Sapienza University of Rome

Languages:
Italian: mother tongue
English: fluent, written and spoken.
French: fluent, spoken; good, written

38. Nicolia V, Cavallaro RA, López-González I, Maccarrone M, Scarpa S, Ferrer I, Fuso A. DNA methylation profiles of selected pro-inflammatory cytokines in Alzheimer's Disease. J Neuropathol Exp Neurol. 2017; 76:27-31. IF 3.43
39. Nicolia V, Ciraci V, Cavallaro RA, Ferrer I, Scarpa S, Fuso A. GSK3β 5'-flanking DNA methylation and expression in Alzheimer's Disease patients. Curr Alz Res. 2017; 14:753-759. IF 3.15
40. Palladino G, Nicolia V, Kovacs GG, Canterini S, Ciraci V , Fuso A, Mangia F, Scarpa S, Fiorenza MT. Sexually dimorphic expression of reelin in the brain of a mouse model of Alzheimer disease. J Alz Dis. 2017; 61:359-367. IF 3.92
41. Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12:1181-96. IF 2.83
42. Martire S, Fuso A, Mosca L, Forte E, Correani V, Fontana M, Scarpa S, Maras B, d'Erme M Bioenergetic impairment in animal and cellular models of Alzheimer's disease: PARP-1 inhibition rescues metabolic dysfunctions. J Alz Dis. 2016;54:3017-24. IF 4.15
43. Fuso A, Iyer AM, van Scheppingen J, Maccarrone M, Scholl T, Hainfellner JA, Feucht M, Jansen FE, Spliet WG, Krsek P, Zamecnik J, Mühlebner A, Aronica E. Promoter-specific hypomethylation correlates with IL-1β overexpression in Tuberous Sclerosis Complex (TSC). J Mol Neurosci. 2016;59:464-70. IF 2.34
44. Businaro R, Corsi M, Azzara G, Di Raimo T, Laviola G, Romano E, Ricci L, Maccarrone M, Aronica E, Fuso A, Ricci S. Interleukin-18 modulation in autism spectrum disorders. J Neuroinflammation. 2016;13(1):2. IF 5.4
45. De Filippis B, Chiodi V, Adriani W, Lacivita E, Mallozzi C, Leopoldo M, Domenici MR, Fuso A, Laviola G. Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome. Frontiers in Behavioral Neuroscience 2015. *In Press*. IF 4.16
46. Fuso A., Ferraguti G., Scarpa S., Ferrer I., Lucarelli M. Disclosing bias in bisulfite assay: MethPrimers underestimate high DNA methylation. PLoS One 2015. 10(2):e0118318. *IF 3.53*
47. López-González I, Schlüter A, Aso E, Garcia-Esparcia P, Ansoleaga B, LLorens F, Carmona M, Moreno J, Fuso A, Portero-Otin M, Pamplona R, Pujol A, Ferrer I. Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species. J Neuropathol Exp Neurol. 2015;74(4):319-44. *IF 4.37*
48. Persichilli S, Gervasoni J, Di Napoli A, Fuso A, Nicolia V, Giardina B, Scarpa S, Desiderio C, Cavallaro RA. Plasma Thiols Levels in Alzheimer's Disease Mice under Diet-Induced Hyperhomocysteinemia: Effect of S-Adenosylmethionine and Superoxide-Dismutase Supplementation. J Alzheimers Dis. 2015;44(4):1323-31. *IF 3.61*

Book Chapters:

1. Tarashi S., Omrani MD, Siadat SD, **Fuso A.** The Correlation of Microbiota and Host Epigenome in Tuberculosis. 2023. In "Tubercolosis", Springer.
2. **Fuso A.** Aging and Disease: the epigenetic bridge. 2023. In: Tollefsbol, T. (ed), Epigenetics in Human Disease - III edition. Academic Press/Elsevier
3. **Fuso A.** Aging and Disease: the epigenetic bridge. 2017. In: Tollefsbol, T. (ed), Epigenetics in Human Disease - II edition. Academic Press/Elsevier
4. **Fuso A.** Epigenetica e demenza. In: Sancesario, G. And Caltagirone, C. (eds), Malattia di Alzheimer e Altre Demenze: Diagnosi e Terapia Integrata. 2017 In press. Società Editrice Universo
5. **Fuso A** and Domenichelli C. Diet, epigenetics and Alzheimer's Disease. In: Patel, V. and Preedy, V.R. (eds), Handbook of nutrition, diets and epigenetics. Springer, In Press

6. Cavallaro R.A. and **Fuso A.** Next Generation Drugs in Alzheimer's Disease Treatment: From Benchtop to Bedside. 2013; 109-146. In: Atta-Ur-Rahman (ed), Frontiers in Clinical Drug Research – Alzheimer Disorders (vol. # 1), 465 pp. September 2013. Bentham Science Publications
7. **Fuso A.** Aging and Disease: the epigenetic bridge. 2012; 519-544. In: Tollefsbol, T. (ed), Epigenetics in Human Disease. 592 pp. June 2012. Academic Press/Elsevier.

Roma, 3/4/2026

Andrea Fuso

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Roma, 3/4/2026

Firma:

CURRICULUM VITAE

PERSONAL INFORMATION

Name	**MATTEO GASTALDI**
Address	**VIALE DELLA RIMEMBRANZA 109, NOVI LIGURE (AL), ITALY**
E-mail	**matteo.gastaldi@mondino.it**
Medical Licence (Italy)	8734 (Ordine dei medici di Pavia)
Nationality	Italian
Date of birth	29/07/1985

LATEST POSITION

• Date	**January 2021- present**
Department	Neuroimmunology laboratory/Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation
Address	Neuroimmunology laboratory, IRCCS Mondino Foundation, Via Mondino 2, 27100, Pavia(PV), Italy
Position	Head of the Neuroimmunology Research Section
Occupation (laboratory)	Coordination of Neuroimmunology diagnostic and Research activity for the Mondino Neuroimmunology laboratory, a referral centre for second level diagnostic collecting samples from all Italian regions
Occupation (clinic)	Inpatient care; autoimmune neurology specialized outpatients care (myasthenia gravis, autoimmune encephalitis, paraneoplastic disorders, stiff person syndrome, neuromyelitis optica spectrum disorders, MOGAD and multiple sclerosis).

• Date	**December 2025-present**
University	University of Pavia
Role	Tenure Track researcher
Course	MED26, Medicine and Surgery

EDUCATION

• Date	**November 2015- November 2018**
University	University of Pavia, Pavia (PV), Italy
Department	Nervous system and behavioural sciences department
Position	PhD in Biomedical sciences
Tutor	Dr. Diego Franciotta (IRCCS C. Mondino, Pavia, Italy)
Co-Tutor	Prof. Angela Vincent (University of Oxford, Oxford, UK)
Thesis	Title:"Autoantibodies against neuroglial surface antigens: laboratory strategies for their detection and roles in acquired demyelinating syndromes, autoimmune encephalitis and acquired neuromyotonia"
Main topics	Diagnostic techniques in antibody mediated disorders of the nervous system; role of MOG antibodies in demyelinating disorders.

• Date	**July 2011- July 2016**
University	University of Pavia, specialization school in neurology, Pavia (PV), Italy

Title	Specialization in neurology (50/50 cum laude). Title: "*Antibody detection in anti-NMDAR encephalitis*"
• Date	**September 2003- July 2010**
University	University of Pavia, faculty of Medicine, Pavia (PV), Italy
Title	Medical degree (110/110 cum laude). Title: "Poliomavirus *DNA in patients with MS treated with natalizumab*"
• Date	**August 2007- February 2008**
University	University of Tampere, Tampere, Finland
Position	*Visiting Student* (Erasmus program)
• Date	**August 2007- February 2008**
School	High school (liceo classico) E. Amaldi, Novi Ligure (AL), Italy
Title	Diploma di maturita' (100/100)

PAST RESEARCH EXPERIENCE

• Date	**October 2017- December 2017**
University	University di Barcelona, Barcelona, Spain
Hospital	Hospital Clinic, Barcelona
Position	Visiting research fellow
Tutor	Prof. Francesc Graus/Prof. Josep Dalmau
Field	Diagnostic techniques in neuroimmunology
• Date	**January 2015- December 2015**
University	University of Oxford, Oxford (UK)
Hospital	John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences, Neuroimmunology Laboratory
Position	Visiting research fellow
Tutor	Prof. Angela Vincent
Field	Antibody mediated disorders of the central nervous system

MEDICAL EXPERIENCE

• Date	**From July 2016 to February 2019**
Hospital	IRCCS Mondino foundation, Pavia (PV), Italy
Department	Department of General neurology, Neuro-oncology and neuroinflammation unit
Position	Contract neurologist
Occupation	Outpatient clinic (clinical neuroimmunology, peripheral nervous system disorders, multiple sclerosis); neuroncology ward.
• Date	**January 2015- December 2015**
Hospital	John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences,
Department	Nuffield department of clinical neurosciences, Oxford (UK)
Position	Observer
Occupation	Outpatient clinic (Neuromyelitis Otpica, Myasthenia Gravis, Autoimmune Encephalitis)
• Date	**July 2011- July 2016**
University	University of Pavia, specialization school in Neurology, Pavia (PV), Italy
Position	Registrar
Hospital	Circolo Hospital / Macchi Foundation, Varese (VA), Italy, Neurology and Stroke Unit IRCCS Mondino Foundation, Pavia (PV), Italy, general neurology

Field	Neuroimmunology, Neuro-oncology, CNS infections, epilepsy, Multiple Sclerosis;
Technical skills	EEG, 24-hour EEG monitoring and video-EEG intepretation.
• Date	**August 2009- September 2009**
Hospital	Johannes Gutenberg University of Mainz, Department of neurology and neurosurgery
Position	Formulanterinn (Internship)
• Date	**June 2009- July 2009**
Hospital	Hospital St. Antonio e Arrigo, Alessandria (AL), Italy, Neurosurgery Unit
Position	Internship

TEACHING

• Date	**October 2013- December 2014**
University	AIMO (Italian academy of Ostheopathy), Saronno (VA), Italy
Position	Neurology course teaching
• Date	**September 2008- July 2010**
University	University of Pavia
Position	Tutor in “practical skills laboratory”
Role	Teaching basic practical skills to medicine students

CLINICAL TRIAL EXPERIENCE

In the past 5 years Principal Investigator for 6 trials in Myasthenia Gravis, 2 trials in MOGAD, 2 trials in NMOSD, 2 trials in Autoimmune Encephalitis

ROLE IN SCIENTIFIC SOCIETIES

• Date	**June 2019- Present**
Scientif Society	Italian Association of Neuroimmunology
Role	Member of the Board and Founder of the Italian group for the study of Autoimmune Neurology (NINA, www.nina.aini.it)
• Date	**December 2022- Present**
Scientif Society	Encephalitis society
Role	Member of the scientific advisory group
• Date	**April 2021- Present**
Scientif Society	Italian Association of Neuroimmunology
Role	Coordinator and Founder of the Italian Network for Autoimmune Neurology (NINA group)
• Date	**January 2020- Present**
Scientif Society	European Academy of Neurology
Role	Neuroimmunology Panel member (managing group)

FUNDING

• Date	**February 2025-Present**
Project	Clinical, prognostic and pathogenic relevance of conformational antibodies to proteolipid protein 1 in MOGAD, seronegative NMOSD, MS and other autoimmune demyelinating diseases of the central nervous system
Duration	2 years
Funding	Fondazione Italiana Sclerosi Multipla (FISM)

Topic	Characterization of the clinical relevance of PLP1 antibodies
Role	Principal Investigator,

• Date	**January 2025-Present**
Project	Natural history of chemotherapy related peripheral neuropathies
Duration	3 years
Funding	PNRR/PNC
Topic	Biomarkers in chemotherapy induced neuropathies
Role	Principal Investigator,

• Date	**December 2024-Present**
Project	iDOT study
Duration	2 years
Funding	Guthy Jackson Charitable Foundation (GJCF)
Topic	Worldwide validation of a novel iDOT test for AQP4 abs
Role	Principal Investigator,

• Date	**January 2022-Present**
Project	Conformational Antibodies and Neuromuscolar disorders: LABoratory diagnostics and novel targets (CANLAB)
Duration	3 years
Funding	Fondo Regionale per la Ricerca Biomedica (FRRB)
Topic	Standardization of antibody diagnostic in neuropathies, novel antibody targets, pathogenic mechanisms in nodo/paranodopathies
Role	Principal Investigator

• Date	**August 2024-Present**
Project	Autoantibodies against known and novel glial surface targets in demyelinating disorders: developing and validating high-thoughput in-vitro systems to assess effector functions (TARGET)
Duration	1 year
Funding	Bando a cascata per PNRR MNESYS
Topic	Functional characterization of autoantibodies in demyelinating disorders
Role	Co-Principal Investigator

• Date	**November 2024-Present**
Project	Implementation of a national network to promote diagnosis, care and research in autoimmune encephalitis and paraneoplastic neurological syndromes
Duration	2 years
Funding	Ministero della salute (PNRR)
Topic	Implementation of the italian registry for Autoimmune Encephalitis
Role	Co-Principal Investigator

• Date	**January 2022-Present**
Project	NINA-Flow project
Duration	2 years
Funding	Alexion/Astrazeneca farmaceutical
Topic	Implementation of a second level diagnostic system for AQP4, MOG, ACHR and MUSK abs
Role	Design and planning of the study; Hub laboratory

• Date	**June 2022-Present**
Project	Cognitive rehabilitation in patients with Autoimmune Encephalitis: the Core Aim Study”
Duration	2 years
Funding	Autoimmune Encephalitis Alliance SEED funding
Role	Principal Investigator

• Date	**January 2021-present**
Project	“antibody mediated disorders of the CNS and PNS”
Duration	3 years
Funding	IRCCS C. Mondino, Pavia- fondi ricerca corrente
Role	Principal Investigator

• Data	**January 2021-June 2025**

Project	Neuronal synaptic autoantibodies and PsycHosis: evaLuation of A systematic approach to increase autoiMmune Encephalitis diagnosis in acute adult and pediatric patients and relevance of the autoantibodies in chronic forms. The PHLAMES Study
Duration	3 years
Funding	Ministero della Salute, Progetti di ricerca finalizzata giovani ricercatori
Role	Principal Investigator

• Data	**March 2020-present**
Project	Conformational antibodies in patients with multiple sclerosis: re-evaluation of old targets
Duration	1 year
Funding	Fondazione Italiana Sclerosi Multipla (FISM), progetto pilota
Role	Principal Investigator

• Data	**January 2018-Jun 2020**
Project	Autoantibodies in psychosis
Funding	IRCCS C. Mondino, Pavia- fondi 5X1000
Role	Principal Investigator

SPECIAL AWARDS

2023 “Rita Levi Montalicini” prize for young researchers in the field of multiple sclerosis and associated disorders, Associazione Italiana Sclerosi Multipla (AISM)

Mondino best clinical paper of the year 2022 for “Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study”

AINI prize 2021 for relevant scientific contribution to the field. XXIX Italian Association of Neuroimmunology conference, Verona.

“Marco Vergelli” prize for the best scientifc contribution (title: *Thymoma-associated myasthenia gravis and neuromyotonia comorbidity: a clinical and serological study)*
XXVII Italian Association of Neuroimmunology Trieste, 7-10 Maggio 2018

Prize from Lions Club “Montù Beccaria Le Vigne”, for the best thesis on Musltiple Sclerosis of the year 2011

BIBLIOMETRIC SCORES

(Scopus) H-Index: 27; number of publications: 138; number of citations: 2569.

PUBLICATIONS (FIRST/LAST NAME)

In bold are highlighted the most relevant publications

Businaro, P., Masciocchi, S., Barnabei, R., Scaranzin, S., Morandi, C., Scucchi, M., Bernini, S., Bottiroli, S., Barone, P., Toriello, A., Arbasino, C., Padiglioni, C., Cenciarelli, S., Benedetti, L., Cerne, D., Risi, M., Paoletti, M., Pichiecchio, A., Diamanti, L., Bini, P., … Gastaldi, M. (2025). Serum Autoantibody Titers and Neurofilament Light Chain Levels in CASPR2/LGI1 Encephalitis: A Longitudinal Study. *Neurology(R) neuroimmunology & neuroinflammation,* 12(5), e200431. https://doi.org/10.1212/NXI.0000000000200431

Masciocchi, S., Businaro, P., Greco, G., Scaranzin, S., Malvaso, A., Morandi, C., Zardini, E., Risi, M., Vegezzi, E., Diamanti, L., Bini, P., Siquilini, S., Giannoccaro, M. P., Morelli, L., Liguori, R., Patti, F., De Giuli, V., Portaccio, E., Zanetta, C., Bergamoni, S., … Neuroimmunology

platform study group (PNI) (2025). Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders. *Neurology(R) neuroimmunology & neuroinflammation*, *12*(2), e200359. https://doi.org/10.1212/NXI.0000000000200359

Malvaso, A., Cerne, D., Sara, B., Sara, B., Enrico, M., Pietro, B., Stefano, M., Chiara, M., Silvia, S., Mobilia, E. M., Cappa, S. F., Luana, B., Diego, F., & Gastaldi, M. (2025). Retrograde Amnesia in LGI1 and CASPR2 Limbic Encephalitis: Two Case Reports and a Systematic Literature Review. *European journal of neurology*, *32*(3), e70113. https://doi.org/10.1111/ene.70113

Greco, G., Risi, M., Masciocchi, S., Businaro, P., Rigoni, E., Zardini, E., Scaranzin, S., Morandi, C., Diamanti, L., Foiadelli, T., Giannoccaro, M. P., Morelli, L., Liguori, R., Barone, P., Tozzo, A., Passarini, A., Gelibter, S., Patti, F., Banfi, P., Simone, A. M., … Neuroimmunology Platform (PNI) study group (2024). Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis. *Journal of neurology, neurosurgery, and psychiatry*, *95*(12), 1176–1186. https://doi.org/10.1136/jnnp-2024-333554

Risi, M., Greco, G., Masciocchi, S., Rigoni, E., Colombo, E., Businaro, P., Scaranzin, S., Morandi, C., Bisecco, A., Bini, P., Diamanti, L., Gallo, A., Franciotta, D., & Gastaldi, M. (2024). MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment. *Journal of neurology*, *271*(5), 2840–2843. https://doi.org/10.1007/s00415-024-12180-z

Masciocchi, S., Businaro, P., Scaranzin, S., Morandi, C., Franciotta, D., & Gastaldi, M. (2024). General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis. *Critical reviews in clinical laboratory sciences*, *61*(1), 45–69. https://doi.org/10.1080/10408363.2023.2247482

Greco, G., Masciocchi, S., Diamanti, L., Bini, P., Vegezzi, E., Marchioni, E., Colombo, E., Rigoni, E., Businaro, P., Ferraro, O. E., Bianchi Marzoli, S., Bergamaschi, R., Franciotta, D., & Gastaldi, M. (2023). Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy: Two Case Reports and a Systematic Literature Review. *Neurology(R) neuroimmunology & neuroinflammation*, *10*(5), e200146. https://doi.org/10.1212/NXI.0000000000200146

Gastaldi, M., & Franciotta, D. (2023). Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary. *Multiple sclerosis (Houndmills, Basingstoke, England)*, *29*(8), 930–931. https://doi.org/10.1177/13524585231172960

Gastaldi, M., Foiadelli, T., Greco, G., Scaranzin, S., Rigoni, E., Masciocchi, S., Ferrari, S., Mancinelli, C., Brambilla, L., Mancardi, M., Giacomini, T., Ferraro, D., Della Corte, M., Gallo, A., Di Filippo, M., Benedetti, L., Novi, G., Versino, M., Banfi, P., Iorio, R., … NINA study group (2023). Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. *Journal of neurology, neurosurgery, and psychiatry*, *94*(3), 201–210. https://doi.org/10.1136/jnnp-2022-330237

Gastaldi, M., Scaranzin, S., Pietro, B., Lechiara, A., Pesce, G., Franciotta, D., & Lorusso, L. (2022). Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New. *Current oncology reports*, *24*(10), 1237–1249. https://doi.org/10.1007/s11912-022-01279-z

Gastaldi, M., Scaranzin, S., Businaro, P., Mobilia, E., Benedetti, L., Pesce, G., & Franciotta, D. (2021). Improving laboratory diagnostics in myasthenia gravis. *Expert review of molecular diagnostics*, *21*(6), 579–590.

***(Houndmills, Basingstoke, England)*, *24*(13), 1743–1752. https://doi.org/10.1177/1352458517731911**

Gastaldi, M., Zardini, E., & Franciotta, D. (2017). An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. *Expert review of molecular diagnostics*, *17*(1), 31–46. https://doi.org/10.1080/14737159.2017.1262260

Gastaldi, M., Thouin, A., Franciotta, D., & Vincent, A. (2017). Pitfalls in the detection of N-methyl-d-aspartate-receptor (NMDA-R) antibodies. *Clinical biochemistry*, *50*(6), 354–355. https://doi.org/10.1016/j.clinbiochem.2016.11.023

Gastaldi, M., Thouin, A., & Vincent, A. (2016). Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, *13*(1), 147–162. https://doi.org/10.1007/s13311-015-0410-6

Gastaldi, M., Ferrario, A., Basilico, C., Merli, M., Mauri, M., Tibiletti, M. G., Passamonti, F., Franciotta, D., & Bono, G. (2014). Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy. *Journal of the neurological sciences*, *344*(1-2), 234–235. https://doi.org/10.1016/j.jns.2014.06.036

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: Pavia, 8/4/2026

Firma: 

Nb : Si precisa che per "interessi commerciali" si intendono situazioni di possesso di quote azionarie di società che operano in ambito sanitario, rapporto di lavoro dipendente o comunque incarichi che lo collochino nell'organizzazione delle medesime società, oppure situazioni di percepimento di royalties o provvigioni commerciali dalle stesse società.

Curriculum vitae

INFORMAZIONI PERSONALI

Alice Laroni
Researcher unique identifier(s): ORCID ID 0000-0001-5599-9788; Scopus ID: 14013173700; ResearcherID: K-4714-2016
Data di nascita: 22/04/1978
Nazionalità: Italiana
URL: https://rubrica.unige.it/personale/U0NOXFph

FORMAZIONE E TITOLI DI STUDIO

2024	Abilitazione Scientifica Nazionale al ruolo di Professore di Prima Fascia, settore scientifico disciplinare: Neurologia
2016	Abilitazione Scientifica Nazionale al ruolo di Professore di Seconda Fascia, settore scientifico disciplinare: Neurologia
2015	Dottorato in Neuroscienze, Dip di Neuroscienze, Riabilitazione, Oftalmologia, Genetica, e Scienze Materno Infantili, (DINOGMI), Università di Genova, Italia Nome del supervisore PhD: Prof. A. Uccelli
2009	Specializzazione in Neurologia, 70/70 e lode Dip. Di Neuroscienze, Università di Padova, Italia. Supervisore: Prof. P. Gallo
2003	Laurea in Medicina e Chirurgia 110/110 e lode Dipartimento di Neuroscienze, Università di Padova, Italia, Supervisori: Prof. Leontino Battistin, Prof. Paolo Gallo

RUOLO LAVORATIVO

2022	Professore Associato di Neurologia DINOGMI, Università di Genova, Genova, Italia
2016	Dall'1/2/2016 convenzione con l'IRCCS AOU San Martino IST con equiparazione alla qualifica di Dirigente Medico, nell'ambito della U.O.C. Clinica Neurologica, con rapporto di lavoro esclusivo. Dal 15/7/2021 riconoscimento di incarico di media professionalità. Dall'1 marzo 2025 titolare di incarico di rilevante professionalità. IRCCS Ospedale Policlinico San Martino, Genova, Italia

RUOLI LAVORATIVI PRECEDENTI

2019-2022	Ricercatore Universitario di tipo B DINOGMI, Università di Genova, Genova Italia
2014 – 2019	Ricercatore universitario di tipo A DINOGMI, Università di Genova, Genova Italia
2011 – 2013	Collaboratore di Ricerca DINOGMI, Università di Genova, Genova Italia

FELLOWSHIPS E PREMI

2016	**Premio di ricerca Rita Levi Montalcini, Fondazione Italiana Sclerosi Multipla.**
2016	Premio Speciale della Giuria-Premio Aldo Fasolo 2016, Università di Torino
2015	Premio per miglior Poster, Conferenza Annuale della Società Italiana di Neurologia.
2009-2011	Borsista della Società Italiana Sclerosi Multipla, DINOGMI, Università di Genova, Italia.
2008-2009	Research Fellow, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.

RESPONSABILITÀ ISTITUZIONALI

- 2024- presente. Membro eletto della Giunta del Dipartimento di Neuroscienze, Riabilitazione Oftalmologia, Genetica e Scienze Materno infantili, Università di Genova
- 2024- presente. Membro della Commissione Didattica, DINOGMI, Università di Genova, Italia.
- 2019-presente Membro del Consiglio dei Docenti, Specializzazione in Oftalmologia, Università di Genova, Italia
- 2019-2021 Membro della Commissione Ricerca, DINOGMI, Università di Genova, Italia.
- 2018-presente Membro del Consiglio dei Docenti, Specializzazione in Neurologia, Università di Genova, Italia.
- 2016-presente Membro del Consiglio dei Docenti, Dottorato in Neuroscienze, Università di Genova.

.

APPARTENENZA A SOCIETÀ SCIENTIFICHE

- 2016-presente Membro della Società Internazionale di Neuroimmunologia (ISNI).
- 2012-presente Membro della Società Italiana di Neurologia (SIN).
- 2007-presente Membro della Società Italiana di Neuroimmunologia (AINI).

PERSONAL STATEMENT

Neurologa, esperta riconosciuta a livello nazionale ed internazionale di neuroimmunologia, ricerca scientifica sulle basi delle malattie immuno-mediate del sistema nervoso centrale e di cura delle persone con immuno-mediate del sistema nervoso centrale.

Attività di ricerca neuroimmunologica

Esperta riconosciuta internazionalmente nel campo neuroimmunologico e in particolare della regolazione della risposta immunitaria da parte del sistema immunitario innato, con studio specifico della funzione delle cellule natural killer (NK). La mia ricerca ha contribuito in modo sostanziale a definire il ruolo regolatorio delle cellule NK nelle persone sane (Laroni et al 2011, Laroni et al 2016), la sua disfunzione nella SM (Laroni et al 2016, Gross et al 2016) e il suo ruolo come biomarcatore dell'efficacia dei trattamenti (Laroni et al 2020, Palmeri et al 2021). Ho avviato questo campo di ricerca autonomamente nel laboratorio di Howard Weiner presso la Harvard Medical School/Brigham and Women's Hospital, durante la mia fellowship di ricerca nel 2008-2009. Grazie alla mia esperienza in questo settore, sono stata invitata a contribuire come autore unico alla serie "Controversie nella SM", pubblicata sul "Multiple Sclerosis Journal" (Laroni 2019).
La ricerca attuale del mio laboratorio si concentra sulla signature immuno-metabolica-microbica della SM (Principal Investigator, finanziata dal Ministero della Salute, 50.183,72 euro), sull'interazione tra catecolamine e funzionalità immunitaria nella SM (Co-Principal Investigator, finanziato dal Ministero della Salute, finanziamento complessivo 1.000.000 euro), sugli effetti immunologici dell'invecchiamento nella SM (finanziata dal Ministero della Salute), sugli effetti della vaccinazione anti-SARS-CoV2 sulle risposte immunitarie innate nella SM (finanziata dall'IRCCS Ospedale Policlinico San Martino), sul ruolo dei metaboliti derivati dal microbioma nella regolazione delle cellule NK (finanziata dalla Fondazione Italiana Sclerosi Multipla nel 2018), e sulla regolazione immuno-metabolica del sistema immunitario (finanziata dal Ministero dell'Università, 115.264,00 euro a UO Laroni).

Specialista in Neurologia; lunga esperienza clinica nell'ambito della Neurologia generale; dal febbraio 2016, come neurologa in convenzione con l'IRCCS Ospedale Policlinico San Martino; in questo contesto attività assistenziale in ambito elettivo, di ricovero e ambulatoriale, neurologia d'urgenza ed emergenza, consulenza per tutti i reparti dell'Ospedale Policlinico San Martino. Membro dello Stroke Team dell'Ospedale Policlinico San Martino. Lunga esperienza nella cura e nella gestione autonome delle persone con sclerosi multipla e altre malattie immuno-mediate del sistema nervoso centrale; titolare di un ambulatorio sclerosi multipla presso l'IRCCS Ospedale Policlinico San Martino (ca. 400 visite specialistiche effettuate in prima persona all'anno, numerose altre visite effettuate in supervisione di medici in formazione specialistica). Per la mia esperienza sono coinvolta in numerosi Advisory Board internazionali e nazionali.
Supervisiono personalmente l'attività di numerosi Medici in Formazione Specialistica Neurologica.

Attività di ricerca clinica

Esperta di ricerca clinica sulla sclerosi multipla, iniziata con la tesi di laurea in Medicina e Chirurgia (Laroni A et al J Neurology 2006). Coautrice di un editoriale su "The Lancet Neurology" (Sormani e Laroni, 2017) e di un articolo di ricerca sulle comorbidità nella SM (Laroni et al Neurology 2017), che ha ricevuto un editoriale e commenti su NEJM Journal Watch. Ho contribuito in modo significativo all'ideazione e alla conduzione del primo studio clinico internazionale multicentrico con cellule staminali mesenchimali per la SM, insieme ai PI Antonio Uccelli e Mark Freedman (Uccelli, Laroni et al Lancet Neurology 2021; Uccelli, Laroni et al 2019; Laroni et al 2015; Laroni et al 2013; Uccelli, Laroni e Freedman 2013; Uccelli, Laroni e Freedman Lancet Neurol 2011). Vincitrice, nel 2016, del premio di ricerca "Rita Levi Montalcini" della Fondazione Italiana Sclerosi Multipla, con la motivazione: "Dr Laroni is providing a significant added value to the research on multiple sclerosis by translating her research findings into clinical practice." Parte di diversi board internazionali. Ho contribuito a realizzare risorse destinate alle persone con SM, per una medicina centrata sulla persona.

Attività didattica

Docente in numerosi corsi dell'Università di Genova, incentrati sulla neurologia clinica e sulle basi neurobiologiche delle patologie del sistema nervoso centrale e periferico, con ottimo feedback da parte degli studenti, come documentato dalla valutazione annuale della didattica (Anno Accademico 2023/2024: valutazioni positive: mediana 96.97%, IQR 7.34). Relatrice/Correlatrice di numerose tesi di laurea in Medicina e Chirurgia, Infermieristica, Biotecnologie, Biologia, Dietistica, e di tesi di Specializzazione in Neurologia.

Pubblicazioni

Autrice/coautrice di 89 pubblicazioni indicizzate su Scopus, 28 come autore principale (primo/ultimo/corrispondente). Autrice/coautrice di 196 pubblicazioni indicizzate su Web of Science. H-index 34 (Web of science); i-10 index: 61. La mia produzione scientifica si caratterizza per alto impatto citazionale (5282 citazioni – Author impact beamplot summary: 75^ percentile - Web of Science).

Convegni e Terza Missione.

Organizzatrice di convegni e workshop e relatrice su invito a numerosi convegni. Ho una passione per la divulgazione scientifica; ho vinto il Premio Speciale della Giuria al Premio Aldo Fasolo per la divulgazione scientifica, per un breve video che descrive la mia ricerca (https://www.youtube.com/watch?v=m6K3XL7WiU0). Ho vinto il premio per il miglior poster alla Società Italiana di Neurologia nel 2015 e il premio del pubblico locale alla competizione Famelab di Torino nel 2016. Ho partecipato a due podcast internazionali diretti a persone con SM.

Tra le attività 2023-2026 segnalo:

Nel 2023 e 2024 esperta su invito per call in due stadi dell'agenzia della Commissione Europea HADEA HORIZON-HLTH-2024-DISEASE-03-13 two stage (primo stadio da remoto e secondo stadio presso la sede HADEA a Bruxelles).

Nel 2025 esperta su invito per revisione del progetto europeo COMMUTE.

Nel 2025 esperta su invito per primo stadio di una call di Agenzia HADEA della Commissione Europea (*dati riservati*).

Nel 2024 ho tenuto un corso su invito di 10 ore di Neuroimmunologia a tutto il personale della Business Unit Neuroscienze di Novartis Italia, incluse le leadership della Direzione Medica, delle Vendite e del Marketing.

Il 23 maggio 2024 sono stata relatrice su invito di un seminario dal titolo "Per una leadership europea nell'innovazione sanitaria" al workshop: "Unige Università Europea- Progetto Europa" promosso dall'Università di Genova.

Genova, 13/4/2026



AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo di sottoscrizione: __Genova, 13/4/2026_____

Firma: _____



Sara Mariotto, M.D. PhD

CURRICULUM VITAE ET STUDIORUM

Personal statement:

Sara Mariotto was born in Verona on 13-03-1985. She got her high school diploma at the "Scipione Maffei Institute" (classical studies) in 2004 with a score of 100/100 cum laude and graduated in Medicine and Surgery in July 2010 at the University of Verona, with a thesis entitled "Study of the Cingolate Anterior Cortex in Frontotemporal Dementia" obtaining a score of 110/110 cum laude. In July 2016 she specialised in Neurology with a thesis entitled "Diagnostic role of serum anti-myelin oligodendrocyte glycoprotein antibodies in patients with suspected neuromyelitis optica seronegative for anti-aquaporin-4 antibodies" obtaining a score of 70/70 cum laude. She then completed a 3-year PhD in the Graduate School of Life and Health Sciences, Doctoral program in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences at the Department of Neurosciences, Biomedicine, and Movement Sciences, University Hospital of Verona, Italy, defending her doctoral thesis entitled "Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs)" in May, 2020 with a positive result. She also obtained the certificate of Doctor Europaeus. During her 3-years PhD she performed clinical activity with night-shift as a neurologist at the Neurology Unit, University of Verona (5 *per* months). Her research areas include neuroimmunology, neuroinfectivology, neuropathology, and peripheral nerve diseases. Her principal field of interest is the study of autoimmune/inflammatory encephalitis, encephalomyelitis, and peripheral inflammatory neuropathies. In relation to these topics, she studied antibody-mediated disorders of the CNS under the supervision of Prof. Markus Reindl, learning anti-MOG antibodies detection/IgG subclass analysis with cell-based assay, peripheral blood mononuclear cells isolation, and the detection of cytokines in serum and CSF with ELISA during her fellowship at the Clinical Department of Neurology, Medical University of Innsbruck (March-October 2017). She also spent a period (October 2017) at the Institute of Neurology, Medical University of Vienna learning new techniques for the diagnosis of autoimmune encephalitis, under the supervision of Prof. Romana Höftberger. During her residency and PhD she actively participated to the clinical and research activities and study design on central and peripheral nervous system inflammatory and autoimmune conditions. In particular, she introduced novel diagnostic and prognostic assays in the diagnostic workup of the Laboratory of

Neuropathology, designed scientific collaborative studies, and she presented research results at national and international meetings on these topics. After her PhD she was awarded an 8-month scholarship (October-May 2020) on the study of diagnostic and prognostic test in antibody-mediated encephalitis and neuromyelitis optica. From December, 2020 to October 2021 she worked as a Junior Researcher at the Neurology Unit, University and AOUI of Verona, Italy. Since then, we works as a Neurologist at the AOUI Verona, Italy.
She obtained the National associated professor qualification (Neurology) on 28/01/2022.

H index: 33

Skills:

- Immunohistochemistry and immunofluorescence techniques, cell-based assay, ELISA, PBMC isolation
- Optic and fluorescence microscopy
- Nerve and skin biopsy
- Clinical neurology
- Neurophysiology and EEG

Publications:

1. Monaco S, **Mariotto S**, Ferrari S. Peripheral neuropathy and central nervous system involvement in Cryoglobulinemia. In F. Dammacco (ed.), HCV Infection and Cryoglobulinemia, Springer-Verlag; 2011.
2. Monaco S, Ferrari S, Gajofatto A, Zanusso G, **Mariotto S**. HCV-related nervous system disorders. Clin Dev Immunol. 2012: 236148; 2012.
3. **Mariotto S**, Bianchi MR, Ferrari S, Zanusso G, Ghimenton C, Testoni M, Faccioli F, Frisoni GB, Monaco S. Cauda equina syndrome caused by lumbosacral epidural lipomatosis. A case report. Clin Neurol Neurosurg. 115: 1549-51; 2013.
4. Stefani A, Riello M, Rossini F, **Mariotto S**, Fenzi F, Gambina A, Zanusso G, Monaco S. Neurosyphilis manifesting with rapidly progressive dementia: report of three cases. Neurol Sci. 34: 2027-30; 2013.
5. **Mariotto S**, Tamburin S, Salviati A, Ferrari S, Zoccarato M, Giometto B, Bertolasi L, Alessandrini F, Benedetti MD, Monaco S. Anti-N-methyl-d-aspartate receptor encephalitis

dysimmune peripheral neuropathies. Neurol Sci. 38(Suppl 2):243-7; 2017.

28. Franciotta D, Gastaldi M, Benedetti L, Garnero M, Biagioli T, Brogi M, Costa G, Fadda E, Andreetta F, Simoncini O, Giannotta C, Bazzigaluppi E, Fazio R, Bedin R, Ferraro D, **Mariotto S**, Ferrari S, Galloni E, De Riva V, Zardini E, Cortese A, Nobile-Orazio E. Diagnostics of anti-MAG antibody polyneuropathy. Neurol Sci. 38(Suppl 2):249-52; 2017.
29. **Mariotto S**, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol. 264: 2420-30; 2017.
30. Arru G, Sechi E, **Mariotto S**, Farinazzo A, Mancinelli C, Alberti D. Ferrari S, Gajofatto A, Capra R, Monaco S. Deiana G, Caggiu E, Mameli G, Sechi L, Sechi GP. Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler J Exp Transl Clin. 3: 2055217317742425; 2017.
31. **Mariotto S**, Farinazzo A, Monaco S. Gajofatto A, Zanusso G, Schanda K, Capra R, Mancinelli C, Bonora A, Bombardi R, Reindl M, Ferrari S. Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. Mult Scler J Exp Transl Clin 3: 2055217317743098; 2017.
32. **Mariotto S**, Bentivoglio M, Cotrufo T, Berzero A, Monaco S, Mazzarello P, Ferrari S. Clinical Neuropathology image 1-2018: Golgi silver staining, the black reaction. Clin Neuropathol. 37: 4-5; 2017.
33. Russi S, Sansonno D, Monaco S, **Mariotto S**, Ferrari S, Pavone F, Lauletta G, Dammacco F. HCV RNA genomic sequences and HCV-E2 glycoprotein in sural nerve biopsies from HCV-infected patients with peripheral neuropathy. Neuropathol Appl Neurobiol. 44: 427-38; 2018.
34. Sechi E, Addis A, Batzu L, **Mariotto S**, Ferrari S, Conti M, Sechi G. Late presentation of NMOSD as rapidly progressive leuokencephalopathy with atypical clinical and radiological findings. Mult Scler. 24: 685-8; 2018.
35. **Mariotto S**, Ferrari S, Monaco S. Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. Journal of Neuro-Oncology. 137: 665-6; 2018.
36. Bo M, Arru G, Sechi E, Niegowska M, **Mariotto S**, Mancinelli C, Farinazzo A, Alberti D, Gajofatto A, Ferrari S, Capra R, Monaco S, Sechi GP, Sechi LA. Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by

disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Mult Scler Relat Disord. 2022;58:103424.

91. **Mariotto S**, Carta S, Dinoto A, Lippi G, Salvagno GL, Masin L, Alberti D, Marignier R, Ferrari S. Is there a correlation between MOGAD and SARS-CoV-2 infection? Eur J Neurol; 2022 doi: 10.1111/ene.15304. Epub ahead of print. PMID: 35224824.
92. Trentinaglia M, Lippi G, Salvagno GL, Rispoli MG, De Angelis MV, Castellani F, Alberti D, Maniscalco GT, Rossi F, Turri M, Rossi P, Del Zotto E, Fusina S, Cardellini D, Zivelonghi C, Volonghi I, Monaco S, Briani C, Ferrari S, **Mariotto S**. Peripheral neuropathies during the COVID-19 pandemic: is there a relation? Immunol Res. 2020; doi: 10.1007/s12026-022-09272-1. Epub ahead of print. PMID: 35237933; PMCID: PMC8890815.
93. Chen JJ, Huda S, Hacohen Y, Levy M, Lotan I, Wilf-Yarkoni A, Stiebel-Kalish H, Hellmann MA, Sotirchos ES, Henderson AD, Pittock SJ, Bhatti MT, Eggenberger ER, Di Nome M, Kim HJ, Kim SH, Saiz A, Paul F, Dale RC, Ramanathan S, Palace J, Camera V, Leite MI, Lam BL, Bennett JL, **Mariotto S**, Hodge D, Audoin B, Maillart E, Deschamps R, Pique J, Flanagan EP, Marignier R. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2022 doi: 10.1001/jamaneurol.2022.0489. Epub ahead of print. PMID: 35377395.
94. Karteri S, Bruna J, Argyriou AA, **Mariotto S**, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP. Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients. J Peripher Nerv Syst. 2022 doi: 10.1111/jns.12493. Epub ahead of print. PMID: 35384143.
95. Dinoto A, Sechi E, Flanagan EP, Ferrari S, Solla P, **Mariotto S**, Chen JJ. Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Front Neurol. 2022;13:866824.
96. Dinoto A, Gastaldi M, Iorio R, Marini S, Damato V, Farina A, Zoccarato M, Sechi E, Pinna F, Maniscalco GT, Barnabei R, Zuliani L, Ferrari S, **Mariotto S**. Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders. Mult Scler Relat Disord. 63:103827; 2022.
97. Wieczorek M, **Mariotto S**, Ferrari S, Mosna F, Micò MC, Borghero C, Dubbini MV, Malagola M, Skert C, Andreini A, De Marco B, Polo D, Tfaily A, Krampera M, Grassi A, Candoni A, Ranzato F, Volonghi I, Quatrale R, Benedetti F, Tecchio C. Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term

Infectious neuropathies", Springer ISBN 978-3-031-06730-3 ISBN 978-3-031-06731-0 (eBook).

110. Dinoto A, Mantovani E, Ferrari S, **Mariotto S (co-CA)**, Tamburin S. Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. Eur J Neurol. 2022. doi: 10.1111/ene.15624. Epub ahead of print. PMID: 36325694.
111. Dinoto A, Marcuzzo E, Chiodega V, Dall'Ora F, **Mariotto S (co-CA)**, Tinazzi M. Neurofilament light chain: a promising diagnostic biomarker for functional motor disorders. J Neurol. 2022. doi: 10.1007/s00415-022-11480-6. Epub ahead of print. PMID: 36370187.
112. Lerch M, Schanda K, Lafon E, Würzner R, **Mariotto S**, Dinoto A, Wendel EM, Lechner C, Hegen H, Rostásy K, Berger T, Wilflingseder D, Höftberger R, Reindl M. More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies. Neurol Neuroimmunol Neuroinflamm. 10(1):e200059; 2022.
113. Bauer A, Rudzki D, Berek K, Dinoto A, Lechner C, Wendel EM, Hegen H, Deisenhammer F, Berger T, Höftberger R, Rostasy K, **Mariotto S**, Reindl M. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. 13:1037812. Front Immunol. 2022
114. Nosadini M, Eyre M, Giacomini T, Valeriani M, Della Corte M, Praticò AD, Annovazzi P, Cordani R, Cordelli DM, Crichiutti G, Di Rosa G, Dolcemascolo V, Fetta A, Freri E, Gallo P, Gastaldi M, Granata T, Grazian L, Iorio R, Lombardini M, Margoni M, **Mariotto S**, Matricardi S, Melani F, Nardocci N, Papetti L, Passarini A, Pisani F, Po' C, Puthenparampil M, Ragona F, Savasta S, Siliquini S, Toldo I, Tozzo A, Turco EC, Varone A, Vogrig A, Zuliani L, Bugin S, Rossato S, Orsini A, Cantalupo G, Mancardi MM, Ferilli MAN, Foiadelli T, Sartori S. Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurol Neuroimmunol Neuroinflamm. 10(1):e200065; 2022.
115. Gastaldi M, Foiadelli T, Greco G, Scaranzin S, Rigoni E, Masciocchi S, Ferrari S, Mancinelli C, Brambilla L, Mancardi M, Giacomini T, Ferraro D, Della Corte M, Gallo A, Di Filippo M, Benedetti L, Novi G, Versino M, Banfi P, Iorio R, Moiola L, Turco E, Sartori S, Nosadini M, Ruggieri M, Savasta S, Colombo E, Ballante E, Jarius S, **Mariotto S**, Franciotta D; NINA study group. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. J Neurol Neurosurg Psychiatry. 2:jnnp-2022-330237; 2022 doi: 10.1136/jnnp-2022-330237. Epub ahead of print. PMID: 36460438.

116. CartaÁlvaro Cobo Calvo S, Armangué T, Saiz A, Lechner C, Rostásy K, Breu M, Baumann M, Höftberger R, Ayzenberg I, Schwake C, Sepulveda M, Martínez-Hernández E, Olivé-Cirera G, Arrambide G, Tintoré M, Bernard-Valnet R, Du Pasquier RA, Brilot F, Ramanathan S, Schanda K, Gajofatto A, Ferrari S, Sechi E, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, **Mariotto S**. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. Neurology. 16:10.1212/WNL.0000000000201662.; 2022. doi: 10.1212/WNL.0000000000201662. Epub ahead of print. PMID: 36526426.

117. Cortese R, **Mariotto S**, Mancinelli CR, Tortorella C. Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know? Front Neurol. 13:1048502; 2022. doi: 10.3389/fneur.2022.1048502. PMID: 36601293; PMCID: PMC9806181.

118. Bosello F, Marastoni D, Pizzini FB, Zaffalon C, Zuliani A, Turri G, **Mariotto S**, Bonacci E, Pedrotti E, Calabrese M. Atypical myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: Case report and literature review. J Neuroimmunol. 375:578011; 2022 doi: 10.1016/j.jneuroim.2022.578011. PMID: 36621074; PMCID: PMC9779985.

119. Asseyer S, Asgari N, Bennett J, Bialer O, Blanco Y, Bosello F, Camos-Carreras A, Carnero Contentti E, Carta S, Chen J, Chien C, Chomba M, Dale RC, Dalmau J, Feldmann K, Flanagan EP, Froment Tilikete C, Garcia-Alfonso C, Havla J, Hellmann M, Kim HJ, Klyscz P, Konietschke F, La Morgia C, Lana-Peixoto M, Leite MI, Levin N, Levy M, Llufriu S, Lopez P, Lotan I, Lugaresi A, Marignier R, **Mariotto S**, Mollan SP, Ocampo C, Cosima Oertel F, Olszewska M, Palace J, Pandit L, Peralta Uribe JL, Pittock S, Ramanathan S, Rattanathamsakul N, Saiz A, Samadzadeh S, Sanchez-Dalmau B, Saylor D, Scheel M, Schmitz-Hübsch T, Shifa J, Siritho S, Sperber PS, Subramanian PS, Tiosano A, Vaknin-Dembinsky A, Mejia Vergara AJ, Wilf-Yarkoni A, Zarco LA, Zimmermann HG, Paul F, Stiebel-Kalish H. The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. Front Neurol. 14:1102353; 2023.

120. Dinoto A,* Zara P,* **Mariotto S**, Ferrari S, Flanagan EP, Budhram A, Orellana D, Turilli D, Solla P, Day GS, Sechi E, Lopez-Chiriboga AS. Autoimmune encephalitis misdiagnosis and mimics. J Neuroimmunol. 2023 Mar 16;378:578071. doi: 10.1016/j.jneuroim.2023.578071. Epub ahead of print. PMID: 36989703.

121. Brenner J,* **Mariotto S**,* Bastiaansen AEM,* Paunovic M, Ferrari S, Alberti D, de Bruijn MAAM, Crijnen YS, Schreurs MWJ, Neuteboom RF, Damoiseaux JGMC, de Vries JM, Titulaer MJ. Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis. Neurology. 100(21):e2204-e2213.

Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; **Guthy Jackson International Clinical Consortium*.** Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12452-8. Epub ahead of print. PMID: 38958756.

137. Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer SG, Levy M, Petzold A, Palace J, Flanagan EP, **Mariotto S**, Skou ST, Froelich A, Lotan I, Messina S, Geraldes R, Asseyer S, Stiebel-Kalish H, Oertel FC, Shaygannejad V, Sahraian MA, Kim HJ, Bennett JL, Böttcher C, Zimmermann HG, Weinshenker BG, Paul F, Asgari N. Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Front Immunol. 2024 Jul 2;15:1380025. doi: 10.3389/fimmu.2024.1380025. PMID: 39021565; PMCID: PMC11253107.

138. De Napoli G, Gastaldi M, Natali P, Bedin R, Simone AM, Santangelo M, **Mariotto S**, Vitetta F, Smolik K, Cardi M, Meletti S, Ferraro D. Kappa index in the diagnostic work-up of autoimmune encephalitis. J Neurol Sci. 2024 Jul 18;463:123146. doi: 10.1016/j.jns.2024.123146. Epub ahead of print. PMID: 39033735.

139. Klyscz P, Asseyer S, Alonso R, Bereuter C, Bialer O, Bick A, Carta S, Chen JJ, Cohen L, Cohen-Tayar Y, Contentti EC, Dale RC, Flanagan EP, Gernert JA, Haas J, Havla J, Heesen C, Hellmann M, Levin N, Lopez P, Lotan I, Luis MB, **Mariotto S**, Mayer C, Vergara AJM, Ocampo C, Ochoa S, Oertel FC, Olszewska M, Uribe JLP, Sastre-Garriga J, Scocco D, Ramanathan S, Rattanathamsakul N, Shi FD, Shifa J, Simantov I, Siritho S, Tiosano A, Tisavipat N, Torres I, Dembinsky AV, Vidal-Jordana A, Wilf-Yarkoni A, Wu T, Zamir S, Zarco LA, Zimmermann HG, Petzold A, Paul F, Stiebel-Kalish H. Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network. Ann Clin Transl Neurol. 2024 Aug 4. doi: 10.1002/acn3.52166. Epub ahead of print. PMID: 39099240.

140. Rossi S, Farina A, Malvaso A, Dinoto A, Fionda L, Cornacchini S, Florean I, Zuliani L, Garibaldi M, Lauletta A, Baccari F, Zenesini C, Rinaldi R, **Mariotto S**, Damato V, Diamanti L, Gastaldi M, Vogrig A, Marchioni E, Guarino M. Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200314. doi: 10.1212/NXI.0000000000200314. Epub 2024 Sep 19. PMID: 39298719; PMCID: PMC11413993.

141. Gandolfi M, Sandri A, **Mariotto S**, Tamburin S, Paolicelli A, Fiorio M, Pedrotti G, Barone P, Pellecchia MT, Erro R, Cuoco S, Carotenuto I, Vinciguerra C, Botto A, Zenere L, Canu E,

F, Orlandi R, Guso E, Volonghi I, Nosadini M, Sartori S, Palmieri P, Cossu A, Calabria F, Zara P, Giannoccaro MP, Zuliani L, Vianello M, De Luca G, Zoccarato M, de Mauro A, Massacesi L, Cortese R, Gajofatto A, Rossi P, Sechi E, Vogrig A, Damato V, Gastaldi M, **Mariotto S**. Validation of the MOG-AR Score: A Retrospective Multicenter Study. Neurol Neuroimmunol Neuroinflamm. 2026 Mar;13(2):e200547. doi: 10.1212/NXI.0000000000200547. PMID: 41604616; PMCID: PMC12854483.

168. Takai Y, Hametner S, Riedl C, Misu T, Takahashi T, Suzuki H, Chihara N, Watanabe M, Miyahara H, Yoshida M, Iwasaki Y, Suzuki T, Di Pauli F, Bramow S, Laureys G, Banwell B, **Mariotto S**, Fujihara K, Aoki M, Bradl M, Lassmann H, Höftberger R. Characteristic patterns of complement deposition in NMOSD, MOGAD, and MS. Acta Neuropathol. 2026 Feb 9;151(1):13. doi: 10.1007/s00401-026-02985-9. PMID: 41661329.

Platform presentations:

- *Sporadic CJD: focusing on the pathology of specific brainstem nuclei and cues for possible routes of infection*. At the "47th AINP and 37th AIRIC Congress", Genova, 05/2011.
- *Neurological complication of HCV infection*. At the "10th Mediterranean Neuroscience Congress, 15th Etnean Epilepsy Workshop", Catania, 06/2012.
- *Lysosomal storage diseases*. At the "Genetic laboratory in the clinical practice", Verona, 07/2012.
- *A demyelinating variant of anti-NMDA receptor encephalitis*. At the "49^0 AINPeNC and 39^0 AIRIC Congress", Pisa, 06/2013 and at the "XLIV SIN National Congress", Milano, 11/2013.
- *West Nile virus infection: neuropathological feature of an Italian case*. At the "49^0 AINPeNC and 39^0 AIRIC Congress", Pisa, 06/2013.
- *Autoimmune encephalitis*. At the "11th Mediterranean Neuroscience Congress and 16th Etnean Epilepsy Workshop", Catania, 11/2013.
- *A case of prion disorder.* At the "Update on parkinsonism and neurodegenerative disorders", Verona, 09/2013.
- *Atypical central and peripheral demyelinating disorders in chronic HCV infection*. At the "50^0 AINPeNC and 40^0 AIRIC Congress", Verbania, 06/2014.
- *Neurosyphilis manifesting with rapidly progressive dementia.* At the "New challenges in neuroinfectivology*:* comparison between clinical and research*",* Roma, 10/2014.
- *Demyelinating complications of chronic HCV infection*. At the, "17th Etnean Epilepsy

Workshop", Catania, 11/2014.

- *Brentuximab-Vedotin a microtubule Apollyon.* At the "5° ASNP Congress", Torino, 04/2015.
- *Anti-GAD encephalitis: an atypical clinical picture*. At the "51°AINPeNC and 41° AIRIC Congress", Verona, 06/2015.
- *Anti-MOG antibodies in inflammatory disorders*. Seminar of the Neurology Unit, University of Verona, 2016 and seminar at the Multiple Sclerosis Unit of Montichiari, Brescia, 07/2016.
- *Panel Discussion: significant clinical parameters and role of neuroimaging as new parameter of disease"*. At the "Multiple Sclerosis update course", Treviso, 09/2016.
- *Diagnosis of autoimmune encephalitis and discussion*. At the "National Congress AMCLI", Rimini, 11/2016.
- *Anti-MOG antibodies associated syndromes: report of 15 cases.* At the "3rd EAN Congress", Amsterdam, 06/2017.
- *Pediatric inflammatory demyelinating conditions: the role of laboratory.* At the "Periodic Neuropsychiatric Meeting", Verona, 01/2018 and at the "Autoimmune encephalitis and atypical demyelinating conditions", Verona, 02/2018.
- *Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in demyelinating disorders*. At the "Open Neuroscience Forum", Verona, 01/2018.
- *Antibody-mediated central nervous system disorders*. At the "54° AINP e NC and 44° AIRIC Congress", Milano, 05/2018.
- *NMO and MOG: diagnostic techniques and clinical update.* At the "N-LoGiSM", Milano, 06/2018.
- *Neurofilament light chain (NfL) serum concentration reflects disease severity in patients with MOG-Ab associated disorders.* At the "EAN congress", Lisbon, 06/2018.
- *Serum and CSF neurofilament light chain as possible biomarker in anti-neuropil antibody-associated encephalitis.* At the "EAN congress", Lisbon, 06/2018.
- *Plasma exchange in neurological disorders.* At the "Summer School of Apheresis and autoimmune conditions", Rif. Galassi, Calalzo di Cadore (BL), 07/2018.
- *Primary B-cell lymphoma of the CNS and anti-NMDAR encephalitis: a unique constellation.* At the "Rapidly progressive dementia and Limbic encephalitis meeting", Venice, 09/2018.
- *Non only Multiple Sclerosis.* At the "Theoretical and Practical Course on Multiple Sclerosis", Brescia, 10/2018.
- *AQP4-Ab and MOG-Ab: diagnosis and clinical update*. At the "24° ELAS annual symposium", Bologna, 11/2018.

- *Anti-MOG in encephalomyelitis.* At the "Current awareness and critical insights in clinical and experimental neuroimmunology", Pavia, 12/2018.
- *Autoimmune encephalitis: clinical aspects and diagnosis.* At the "Autoimmune encephalitis: aetiology, diagnosis and treatment", Como, 12/2018.
- *The Peculiarity of autoimmune diagnosis in Neurology.* At the "Pills of allergology and autoimmunity", Udine, 02/2019.
- *Antibody-associated CNS disorders: an introduction.* At the "Antibody-associated CNS disorders and their differential diagnosis", Verona, 02/2019.
- *Diagnosis of autoimmune encephalitis: serum and CSF biomarkers.* At the "Autoimmune encephalitis and atypical demyelinating conditions: aetiology, diagnosis and treatment", Reggio Emilia, 09/2019.
- *The problem of anti-MOG antibodies: laboratory and clinical aspects.* At the "Update on Multiple Sclerosis", Montichiari, Brescia, 10/2019.
- *Inflammatory demyelinating diseases: clinical aspects and diagnostic challenges.* At the "Euroimmun internal workshop on antibody-mediated disorders in Neurology", Lubeck, 10/2019.
- *Humoral immunity.* At the "Neurologist and immunology of inflammatory CNS disorders" congress, Brescia, 11/2019.
- *Neurofilament light chain in central and peripheral nervous system conditions: beyond multiple sclerosis.* At the "Oxford Roundtable", Oxford, 11/2019.
- *Neurofilament light chain levels in patients with antibodies to myelin oligodendrocyte glycoprotein.* At the "European NMO 2020 Meeting", Berlin, 02/2020.
- *CSF analysis in MOG-Abs positive cases.* At the "European NMO 2020 Meeting", Berlin, 02/2020.
- *Neurofilament light chain levels in patients with inflammatory demyelinating conditions associated with antibodies to myelin oligodendrocyte glycoprotein (MOG-Abs).* At the "European Academy of Neurology virtual congress", 05/2020.
- *Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelopathies.* At the "European Academy of Neurology virtual congress", 05/2020.
- *Nervous System: Subclinical Target of SARS-CoV-2 Infection*. At the "Simoa Success Webinar (online presentation)", 11/2020.
- *Treatment of atypical demyelinating syndrome (MOG e AQP4)*. At the "Neuroimmulogy: implications of the SARS-CoV-2 pandemic (online congress)", 12/2020.

- *Immuno-mediaded encephalitis and COVID-19.* At the "World week of the brain (online congress)", 03/2021.
- *NMOSD and MOGAD: clinical, diagnostic, and therapeutic aspect.* At the "Multiple sclerosis and infectious conditions: an update", Catania, 09/2021.
- *Limbic encephalitis.* At the "Diagnosis and treatment of neuroimmunological conditions", Lecco, 09/2021.
- *The significance of CSF antibody testing.* At the "The Neurologist and Immunology", Brescia, 11/2021.
- *SARS-CoV-2-related pandemic: how it influenced antibody-mediated CNS conditions and inflammatory peripheral neuropathies.* At the "Multiple Sclerosis and autoimmune CNS conditions", Trieste, 12/2021.
- *Autoimmune encephalitis.* At the "Clinical Neuroimmunology", Napoli, 02/2022.
- *SARS-CoV-2 and NMOSD/MOGAD.* At the European NMOSD/MOGAD meeting, Lyon, 06/2022.
- Guthy Jackson foundation round table (ask the doctors section) and patients' meeting, Los Angeles, CA, USA, 07/2022.
- *MOG antibodies and MOGAD.* At the Neuroimmunological disease congress, from symptoms to treatment, Lecco, 09/2022.
- *Diagnosis of MOG-Abs.* At the "3rd course for the diagnosis of demyelinating conditions", Alghero, 10/2022.
- *Clinical-laboratory discussion in the diagnosis of autoimmune neurological disorders: focus on the COVID-19 pandemic.* At the 7th National SIPmMeL congress (Italian society of clinical pathology and laboratory medicine), Riva del Garda, Trento, 10/2022.
- *Autoimmune encephalitis:* an update. At Neuromonday of the Neurology Brescia Unit, online, 10/2022.
- *Demyelinating conditions associated with anuto-antibodies: MOGAD.* At the Neurology Talk, online, 10/2022.
- *NMOSD and MOGAD: immunopathogenesis and diagnosis.* Scientific Seminar, Firenze, 11/2022.
- *PNS involvement in patients with central autoimmunity.* At the Specialised course on clinical and imaging neurophysiopathology of the peripheral nevous system, Verona, 11/2022.
- *NMOSD, MS, and MOGAD, similarities and differences.* Online patients' seminar promoted by the Sumaira Foundation, 12/2022.

- *Autoantibody profiles in Autoimmune encephalitis.* At the Clinical Neuroimmunology in Naples, II edition, Napoli, 02/2023.
- *Biosample collection: serum and CSF.* At the ACON Acute Optic Neuritis Network, Tel Aviv, 05/2023.
- *MAG-related neuropathy.* At the "Neurology Workshop", Padova, 05/2023.
- *GFAP and NfL in patients with NMOSD and MOGAD.* At the "" Fluid biomarkers and multiple sclerosis: the long road toward validation (online), 05/2023.
- *MOGAD: diagnosis and treatment.* At the "The requirement for neurological awareness in the future, young SIN event", Rimini, 05/2023.
- *Future perspective in laboratory research in MOGAD*. At the "FISM congress", Roma, 05-06/2023.
- *CSF MOG AQP4 antibody should be tested routinely with serum now.* At the MEDEN (Mogad Eugene Devic European Network) congress, Oxford, 06/2023.
- *Laboratory diagnosis in demyelinating CNS conditions*. At the Verona Multiple Sclerosis Day: MS, NMOSD, and MOGAD from diagnostic challenges to therapeutic implications, Verona, 06/2023.
- *NMOSD diagnosis and differential diagnosis.* At the Complement role in rare neurological disorders , Cagliari, 07/2023.
- *Antibody-mediated WM diseases across age* (NMO&MOGAD), Roma, 09/2023 (online)
- *NMOSD: aspetti diagnostici e terapeutici,* Pescara, 09/2023 (online)
- *NMOSD Workshop: describing the diagnostic moment.* At the "Change Direction in NMOSD, across new therapeutic Horizons", Roma, 09/2023.
- *MOGAD: diagnostic assays.* At the 9th Joint ECTRIMS ACTRIMS meeting, Milano, 10/2023.
- *Antibody-related diagnosis in NMOSD.* At the , "New Perspectived in NMOSD", Bologna, 11/2023.
- *Antibody-related diagnosis in NMOSD.* At the , "Corner, Expert Meeting-Focus on NMOSD", Porto San Giorgio (FM), 11/2023.
- *Neurological Complications of immune checkpoint inhibitors,* Expert Seminars for the University of Modena (online), 11/2023.
- *CSF MOG antibodies.* At the MOGAD Masterclass 2023, Oxford, UK, 12/2023.
- *NMOSD and MOGAD, CSF analysis.* At the "Update on MOGAD, NMOSD and Multiple Sclerosis", GDS Neuroophthalmology SIN meeting, Palermo, 12/2023.
- *Clinical utility of CSF MOG antibodies, NfL, and GFAP testing.* At the "UK-Childhood Neuro-Inflammatory Disorders Meeting", 01/2024 (online).

- *MOGAD: how it differs from other neuroinflammatory disorders.* At the Clinical Neuroimmunology in Naples, Napoli, 02/2024.
- *MOG associated syndromed in adults.* At the Neuroimmunological disorders in adults and pediatrics, Lecco, 02/2024.
- *Glial and neuronal damage biomarkers in autoimmune neurology.* At the "AAN datablitz", online, 02/2024.
- *Expert seminar at the University of Berlin: Differential diagnosis of MS: focus on NMOSD and MOGAD antibody testing and biomarker analysis.* Berlin, 02/2024.
- "Autoimmune encephalitis""At the "2° INCONTRO CUNEESE DI NEUROIMMUNOLOGIA", online, 03/2024.
- *Laboratory diagnosis and MRI in the differential diagnosis of demyelinating conditions*. At the "Demyelinating conditions: differential diagnosis between MS, NMOSD, and MOGAD and their treatment", Bolzano, 03/2024.
- *NMOSD and MOGAD, autoantibody testing and serostatus fluctuations.* At the "Diagnosis and treatment of autoimmune demyelinating CNS disorders and Myasthenia Gravis", Alghero, 04/2024.
- *GFAP/NfL are useful to monitor disease activity in NMOSD and MOGAD and Working Group on Seronegative NMOSD activity presentation.* At the MEDEN 2024 meeting, Berlino, 05/2024
- *Monitoring GFAP/NfL are useful to monitor disease activity in NMOSD and MOGAD* and presentation of WG2", MEDEN 2024 meeting, Berlino, 05/2024.
- *Treatment options in refractory autoimmune encephalitis*, seminar at the "Neurology Pils", online, 06/2024.
- *"MOGAD patients should be treated with chronic immunosuppressants after first presentation: No" in the EAN/ISNI section: Controversy in management of patients with MOGAD.* At the 10th EAN Congress, Helsinki, 07/2024.
- *"Pitfolls in serological diagnosis and biomarkers of glial and neuronal damage in NMOSD and MOGAD ".* At the AAN Summer Coference, Atlanta, USA, 07/2024.
- *Rountable discussion on the utility of biomarkers in NMOSD/MOGAD.* At the GJF pre-ECTRIMS meeting, Copenhagen, Denmark, 09/2024
- *How to use MOG antibody testing: whatm where, and when.* At the ECTRIMS meeting (40th congress of the European Committee for Treatment and Research in Multiple Sclerosis), Copenhagen, Denmark, 09/2024.

- *Can you recognize it? Challenges in diagnosis and management of MOGAD.* At the ECTRIMS meeting (40th congress of the European Committee for Treatment and Research in Multiple Sclerosis), Copenhagen, Denmark, 09/2024.
- *NMOSD and AQP4-Abs testing: opportunities to improve.* At the 54° meeting of the Italian Society of Neurology (SIN), Roma, 11/2024.
- *When and Why do not test for MOG-Abs.* At the X NapleSMeeting, Napoli, 11/2024.
- *Live cell-based assays,* at the "AINI Winter School, Laboratory Diagnostic in Neuroimmunology", Trento, 12/2024.
- *CSF MOG antibodies and emerging biomarkers in blood and CSF*. At the "MOGAD Masterclass", Lyon, 12/2024
- *Serum and CSF biomarkers in NMOSD and MOGAD*. At the "Clinical Neuroimmunology in Naples, IV edition, 02/2025".
- *Autoimmune myelitis*. At the "5 Congresso Nazionale SIMEGEN Neurologia di Genere. Prevenzione e terapie per la salute del cervello e una longevità sana, Palermo, 04/2025".
- *The evolving concept of "seronegative" NMOSD and risk of misdiagnosis*. At the "Autoimmune Neurology update", Alghero, 05/2025.
- *Autoimmune encephalitis in adults.* At the 19° International Congress of Neurology, Cyprus Neurological Society, Cyprus, 05/2025
- *Experimental models and epilettogenic rules of antibodies in autoimmune encephalitis.* At the "Innovations and challenges in rare and complex epilepsy", Chieti, 05/2025
- *NMO therapy and progression*, at the "New insights on disease progression in MS and NMOSD", Napoli, 06/2025
- *MOGAD case presentation,* at the "Aini Summer School Neuroimaging in Neuroimmunology" Siena, 07/2025
- *The relevance of live CBA.* At the Case-Based workshop, Prague, 09/2025
- *Molecular characterization of double seronegative disease.* At ECTRIMS (the 41st Congress of the European Committee for treatment and research in Multiple Sclerosis and 30th Conference of Rehabilitation in Multiple Sclerosis), Barcelona, 09/2025
- *NMOSD and MOGAD, what's age got to do with this?* At ECTRIMS (the 41st Congress of the European Committee for treatment and research in Multiple Sclerosis and 30th Conference of Rehabilitation in Multiple Sclerosis), Barcelona, 09/2025
- *Interactive discussion on laboratory diagnosis of autoimmune CNS disorders.* At the Juniors in Neuroimmunology Meet the Expert meeting, Napoli, 10/2025

- "Antibody-associated CNS disorders and their differential diagnosis", Verona, 03/2019.
- "2020 World Encephalitis day, Verona, 02/2020.
- "2021 World Encephalitis day, Online, 02/2021.
- "Autoantibodies in central and peripheral nervous system disorders", Verona, 03/2022.
- "Autoimmune and Paraneoplastic disorders of the Central Nervous System" Verona, 17/11/2023
- "An update on Neuroimmunological disorders" + Verona Patients day, Verona, 6-7/12/2024
- "The evolving spectrum of Neuroimmunological disorders", Verona, 10/11/2025

Congress attendance:

- "Clinical, diagnostic and therapeutics meetings in neurology", Verona, 16/09/2011.
- "47th AINP and 37th AIRIC Congress", Genova, 19-21/05/2011.
- "Clinical, diagnostic and therapeutics meetings in neurology", Verona, 16/12/2011.
- "10th Mediterranean Neuroscience Congress, 15th Etnean Epilepsy Workshop", Catania, 06/2012.
- "Multiple Sclerosis: a different perspective; Meeting of the Italian association of Neuroepidemiology", Verona, 02/05/2012.
- "Clinical, diagnostic and therapeutics meetings in neurology", Verona, 14/09/2012.
- "Update on Parkinson disease and monogenic parkinsonisms", Verona, 20/09/2012.
- "Genetic laboratory in the clinical practice", Verona, 9 and16/10/2012.
- "49^0 AINPeNC and 37^0 AIRIC Congress", Pisa, 30/05 and 01/06/2013.
- "XLIV Congress of the Italian Society of Neurology", Milano, 02-05/11/2013.
- "11th Mediterranean Neuroscience Congress and 16th Etnean Epilepsy Workshop", Catania, 11/2013.
- "Update on Parkinsonism and neurodegenerative disorders", Verona, 19/09/2013.
- "High specialized course for the staff of stroke unit in Veneto region", Verona, 15/11/2013.
- "Cerebral hemorrhage: when blood reaches the brain", Verona, 06/12/2013.
- "50^0 AINPeNC and 40^0 AIRIC Congress", Verbania, 05-07/06/2014.
- "XLV Congress of the Italian Society of Neurology", Cagliari, 11-13/10/2014.
- "New challenges in neuroinfectious disorders: comparison between clinical and research", Roma, 23/10/2014.
- "17th Etnean Epilepsy Workshop", Catania, 11/2014.

- "Autoimmune encephalitis: characterisation and differential diagnosis", Verona, 30/01/2015.
- "Ist Meeting of Neuroautoimmunity", Prato, 20-21/02/2015.
- "The Lancet Neurology Autoimmune Disorders Conference", Barcelona, 26-27/03/2015.
- "Vth Meeting of the Italian Society for the Peripheral Nervous System Study", Torino, 09-11/04/2015.
- "Neuropathology and autoimmunity", Verona, 04/06/2015.
- "51° Congress of the Italian society of Neuropathology and Clinical Neurobiology; 41° Congress of the Italian Society for the research in brain aging", Verona, 4-6/06/2015.
- "91st Annual Meeting of the American Association of Neuropathologists", Denver, USA, 11-14/06/2015.
- "Clinical and therapeutic approach to acute neuromuscular disorders", Modena, 13/11/2015.
- "Recent advantages in virus-induced and autoimmune liver damage", Bari, 04/12/2015.
- "Change of perspective about placebo, pregnancy and Devic", Orbassano, 05/02/2016.
- "Encephalomyelitis: an overview", Verona, 19/02/2016.
- "VI Meeting of the Italian Society for the Peripheral Nervous System Study", Mondello, 14-16/04/2016.
- "XXV AINI Congress", Lecce, 11-14/05/2016.
- "Extrahepatic complications of HCV: new therapeutic perspectives", Bologna, 26/05/2016.
- "32nd Congress of the european committee for treatment and research in multiple sclerosis and 21st annual conference of rehabilitation in MS", London, 14-17/09/2016.
- "XLVII SIN national congress", Venezia, 22-25/10/2016.
- "National Congress AMCLI", Rimini, 6-9/11/2016.
- "3rd Congress of the European Academy of Neurology", Amsterdam 24-27/06/2017.
- "XXVI AINI Congress, 16th ESNI Course", Venezia, 26-30/06/2017.
- "7th Joint Ectrims-Actrims meeting", Paris, 25-28/09/2017.
- "Autoimmune encephalitis and atypical demyelinating conditions", Verona, 16/02/2018.
- "10 th Internation NMO meeting Roundtable Conference", Los Angeles, 21/04/2018.
- "2018 American Academy of Neurology annual meeting", Los Angeles, 21-27/04/2018.
- "54° AINP e NC and 44° AIRIC Congress", Milano, 17-19/05/2018.
- "N-LoGiSM", Milano, 6/06/2018.
- "European Academy of Neurology (EAN)" annual meeting, Lisbon, 16-19/06/2018.
- "Summer School of Apheresis and autoimmune conditions", Rif. Galassi, Calalzo di Cadore (BL), 6-8/07/2018.

- "Rapidly progressive dementia and Limbic encephalitis", Venice, 14-15 September 2018.
- "2018 NMO Symposium", Berlin, 9/10/2018.
- "34th Congress of the european committee for treatment and research in multiple sclerosis", Berlin, 10-12/10/2018.
- „The Lancet Summit: inflammation and immunity in disorders of the brain and mind", Barcelona, 15-17/11/2018.
- "24° ELAS annual symposium", Bologna, 18-21/11/2018.
- "Current awareness and critical insights in clinical and experimental neuroimmunology", Pavia, 12/12/2018.
- "Autoimmune encephalitis: aetiology, diagnosis and treatment", Como, 13/12/2018.
- "Pills of allergology and autoimmunity", Udine, 8/02/2019.
- "71st Annual Meeting of the American Academy of Neurology", Philadelphia, PA, 4-10/05/19.
- "5th European Academy of Neurology (EAN) Congress", Oslo, Norway 29/06/19-02/07/19.
- "GJF Round Table", Stoccolma, Svezia 10/09/2019.
- "35th ECTRIMS meeting", Stoccolma, Svezia 11-13/09/2019.
- "Autoimmune encephalitis and atypical demyelinating conditions: aetiology, diagnosis and treatment", Reggio Emilia, 19/09/2019.
- "Neurologist and immunology of inflammatory CNS disorders", Brescia, 14/11/2019.
- "Measurement of treatment efficacy: a comparison of prospectives" at the Multiple Sclerosis Day, Verona, 15/11/2019.
- "Powering precision health summit", Barcelona, 19/11/2019.
- "Cerebrospinal fluid in neuroinflammation and neurodegeneration: updates on diagnostic and prognostic opportunities", Ferrara, 22/11/2019.
- "Encephalitis conference 2019", London, 02/12/2019.
- "MS Academy SM", Bolzano, 07/02/2020.
- "European NMO 2020 Meeting", Berlin, 13-14/02/2020.
- "GJF Round Table", online meeting (as a panelist), 14/11/2020.
- "Encephalitis Conference", online meeting, 07/12/2020.
- "Joint meeting AIM-ASNP Digital Edition 2020" 9-12/12/2020, chairmen on poster session 1, "Biomarkers and outcome measures in neuromuscular disorders"
- "Annual Meeting of the American Academy of Neurology", virtual 17-22/04/2021
- "Neurological disorders associated with COVID-19" (neurowebinar), 01/05/2020

- Member of the Editorial Board as a Review Editor of Frontiers in Neurology -Multiple Sclerosis and Neuroimmunology- (since October, 2021) and of Frontiers in Neurology - Neuromuscular disorders and peripheral neuropathies (since July, 2022)-
- Member of the Scientific Board of DyNAMICS Academy (since October, 2021)
- Member of the Scientific Panel of the Sumaira Foundation (since September, 2022)

Awards:

- Bando FISM 2024, codice 2024/R-Multi/015, "A multicenter longitudinal prospective study to assess determinants of residual disability in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
- "Bando Ricerca Finalizzata 2021", Young Researcher on a project entitled "Multiparametric biomarkers to predict the response to different protocols of motor-cognitive rehabilitation in Parkinson's disease subjects with postural instability and gait disorders"
- The Sumaira Foundation 2022 Spark Grant for a project entitled "Myelin basic Protein as a potential biomarker in MOGAD"
- "Best presentation at the V Meeting of the Italian Society for the Peripheral Nervous System Study and subsequent publication" received at the VI Meeting of the Italian Society for the Peripheral Nervous System Study, Mondello, 16/04/2016
- "EAN research fellowship" for 2017
- "Best scientific publication" received at the 54° AINP e NC and 44° AIRIC Congress, Milano, 19/05/2018
- Travel grant award for the 3rd Congress of the European Academy of Neurology (EAN), 2017
- Travel grant award for the 4th Congress of the European Academy of Neurology (EAN), 2018
- Travel grant award for the 5th Congress of the European Academy of Neurology (EAN), 2019
- Travel grant award for the 2018 American Academy of Neurology (AAN) annual meeting, 2018
- Travel grant award for the 2019 American Academy of Neurology (AAN) annual meeting, 2019
- Travel grant for the 7th Joint ECTRIMS-ACTRIMS meeting, 2017

- Travel grant for the 34th ECTRIMS meeting, 2018
- Travel grant for the 35th ECTRIMS meeting, 2019

Participation to clinical trials:

- Principal investigator of a "Randomised, double-blind, placebo-controlled, multicenter, Phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of Rozanolixizumab to treat adult patients with MOGAD" (promoted by Paraxel international)
- Principal investigator of a "Phase III, randomised, double-blind, placebo-controlled multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Satralizumab as monotherapy or in addition to baseline therapy in patients with MOGAD" (promoted by Roche international)

Participation to research group:

- International clinical consortium for the study of NMOSD (Guthy-Jackson Foundation)
- The Sumaira Foundation scientific board
- Neuroimmunology Board of the European Academy of Neurology (EAN)
- NINA (Italian Network of Autoimmune Neurology) Scientific Board
- MEDEN (MOGAD Eugene Devic European Network) Scientific Board
- Neuro-COVID network
- EAN/ECTRIMS task force for the guideline on treatment in NMOSD
- EAN task force for Autoimmune Encephalitis guidelines

Membership/affiliations:

- AINI (Italian Association of Neuroimmunology)

PERSONAL INFORMATION

Clara Ballerini

Via di San Romano, 46 50135 Firenze, ITALY

+39 3396638216

clara.ballerini@unifi.it

Sex female | Date of birth 24/03/1961 | Nationality Italiana

Married, one daughter (Virginia) 32 years old

Life sketch

Clara Ballerini graduated (Natural Sciences) at the University of Florence, she was PhD in Neurosciences, University of Florence, with a research work on genetic aspects of susceptibility to multiple sclerosis that leads to the identification of several associated alleles. On the other hand CB have been also investigating the immunological aspects of multiple sclerosis studying the T cell phenotype in cerebral spinal fluid (CSF) cell populations, utilizing MoAb and cytofluorimetry methods and investigating the main characteristics of T cells as proliferation properties, cytokine production, antigen specificity and cytotoxicity. CB research activity involved also the study of the animal model of multiple sclerosis: experimental autoimmune encephalomyelitis (EAE). Recently CB has been investigating the functional status of T cell together with the molecular analysis of the T cell receptor repertoire. During her post doc at the E209 INSERM (Paris, France) under the direction of prof. Pierre Aucutourier and the supervision of Claude Carnaud focused her research on prion disease and immune system. During her work at INSERM, she has investigated the role of prion protein at the immunological synapse between T cell and dendritic cell, the role in CNS during EAE and she has investigated the possibility to brake immune tolerance to prion protein in mouse developing a protocol to immunize mice with dendritic cells as a tool for prion disease therapy. In all the projects where CB participates she achieves expected scientific results. Back at the Neuroimmunology Unit of University of Florence, she starts working on the possibility to modulate dendritic cell (DC) function from immunogenic to tolerogenic as possible therapy in CNS autoimmune diseases. She is group leader coordinating three persons on different projects and collaborating with several units.

Recent studies reveal striking parallels between cellular signaling mechanisms in the immune (IS) and nervous systems (CNS) that may provide unexpected insights into the development, function, and diseases of both systems. Therefore, CB focused her experience, knowledge and skills into project concerning biological and physical properties shared between CNS cells and IS with particular interest on dual role of inflammation, view as a cross talk between the two systems, in CNS during neurological diseases. In this perspective, CB collaborations permit her to investigate the role of histamine and histamine receptors on EAE and a more recently on DCs, cell cytoskeleton and T lymphocytes polarization. Furthermore, CB collaboration with Laura Ballerini (SISSA, Trieste) widened her research field into nanotechnology, with several recent publications on carbon nanotubes, graphene oxide and nanoparticles. Finally, CB collaboration with Cosima Baldari, University of Siena, and Duccio Cavalieri, University of Florence, permitted her to investigate the signal adaptor of T cell receptor signaling (SchA, Rai) role in astrocytes during EAE and new treatment based on miR isolated from vegetables, able to shift dendritic cell activation into tolerogenic one, as therapy during EAE.

orcid.org/0000-0002-7812-9029

From 21/01/ 2021 to date

Associate Professor of General Pathology (MED 04)
University of Florence, Department of Experimental and Clinical Medicine (DMSC)
Research activity: group leader and coordinator laboratory of Neuroimmunology
Didactic: 103 hours/year frontal lessons, tutor of graduating/resident/PhD students

from 1/04/2018- to 2020

Researcher RTD b (MED 04)
University of Florence, Department of Experimental and Clinical Medicine (DMSC)
Research activity: group leader and coordinator laboratory of Neuroimmunology
Didactic: 95 hours/year frontal lessons, tutor of graduating/resident/PhD students

WORK EXPERIENCE in Italy and Abroad

from 2/12/2012- to 02/12/2017

Researcher RTD a (MED 26)
University of Florence, Florence Italy

- Research activity: group leader, laboratory of Neuroimmunology, Department of Neuroscience, Psychology, Drug and Child Health (NEUROFARBA). This activity comprises writing and submission of research projects, writing and submission of original manuscripts and abstracts, coordination of post docs and students and research work organization, participation in scientific societies and scientific committees
- Didactics: 95 hours/year frontal lessons, tutor for graduating/resident/PhD students, revision of thesis

from1 /04/1999 to 1/12/2012

Assistant researcher (technician)
University of Florence

- Research activity as principal investigator, Laboratory of Neuroimmunology (testified by publications between 1999-2012, see complete list of publications); tutor for students (graduating, resident and PhD), Department of NEUROFARBA
- Diagnostic activity as coordinator of the cerebrospinal fluid laboratory, I Neurological Clinic, Careggi Hospital, University of Florence (from 01/01/2006 to 01/12/2012)

from 1 /05/2002 to 30/5/2003

Post Doc INSERM (place posted and assigned through Nature Jobs)
INSERM E209 "Maladie a Prion et Système Immunitaire", Hôpital Necker, rue du Sèvres, 75007, Paris, France

- Research activity: principal investigator of the following project: "Mécanismes physiopathologiques des étapes précliniques des infections à prions: étude du rôle des cellules dendritiques dans la tremblante expérimentale murine" (Meccanismi fisiopatologici delle fasi precliniche delle infezioni a prioni: studio del ruolo delle cellule dendritiche nel modello murino"

from 1/06/2003- to 30/06/2004

Post Doc UPMC (Univ. Pierre et Marie Curie), Paris VI INSERM
INSERM E209 "Maladie a Prion et Système Immunitaire", Hôpital St Antoine, rue du Faubourg St Antoine 75012 Paris, France

- Research activity: principal investigator of the project "Rôle de la protéine prion (PrPc) dans la synapse immunologique" (Ruolo della proteina prionica nella sinapsi immunologica)

EDUCATION AND TRAINING

December 2007

Master II level in Biomedical Journalism
University of Florence, Florence, Italy

aa 1995-1999

Ph.D in Neuroscience
University of Florence, Florence, Italy

title of the thesis: "Study of Multiple Sclerosis genetic susceptibility by candidate gene approach"

1992-1995

AISM fellowship
Italian Association of Multiple Sclerosis (AISM), winner of a 3 years fellowship, grant concerning the study of Multiple Sclerosis, focus on gene determined disease susceptibility. University of Florence, Florence, Italy

CITFI (national pharmacological consortium) fellowship

© European Union, 2002-2015 | europass.cedefop.europa.eu

1990-1991 University of Florence, Florence, Italy; during the fellowship training period at the Neuroimmunology Unit, Harvard, Boston (MA). Director Stephen Hauser

Doctor in Natural Sciences

April 1990 University of Florence, Florence, Italy

PERSONAL SKILLS

Mother tongue: Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	good	good	fluent	fluent	good
French	good	good	good	good	basic

ADDITIONAL INFORMATION

Publications

- see complete list of publications at the end of this document

Scientific Collaborations (1998-today)

. Collaboration with Roberto Tosi, Institute of Cell Biology CNR Rome from 01-01-1998 to 01-01-2000
. Collaboration with Patricia Momigliano-Richiardi, Laboratorio di Genetica Umana, Università del Piemonte Orientale, Novara from 01-01-2000 to 01-01-2004
. Collaboration with Steven Jacobson, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda from 01-01-2000 to 01-01-2002
. Collaboration with Claude Carnaud, INSERM UMR S 938, UPMC Univ Paris 06, Hôpital St-Antoine, F-75012 Paris, France from 01-01-2008 to 01-01-2012
. Collaboration with Armaud Nicot INSERM, UMR S 1064, CHU Hôtel-Dieu, 30 Bd Jean Monnet, 44093 Nantes cedex, France from 01-01-2010 to 01-01-2012
. Collaborator in the project: The Rai adaptor protein in Th17 cell differentiation, effector function and chemotaxis and in the pathogenesis of multiple sclerosis (Dept Evolutionary Biology, University of Siena, project leader Cosima Tatiana Baldari) from 01-01-2010 to 31-12-2012
. Collaborator in the project: The histaminergic H4 receptor as a novel therapeutic target for the treatment of autoimmune neuropathologies (Dept of Preclinical and Clinical Pharmacology,University of Florence, project leader Beatrice Passani) from 01-06-2010 to 31-05-2011
. Collaborator in the pilot project: Analysis of Epstein-Barr virus infection and immune response in the cerebrospinal fluid and blood of patients with multiple sclerosis using highly sensitive PCR techniques (multicenter study, coordinator Francesca Aloisi, Istituto Superiore di Sanità (ISS) Rome, Francesca Aloisi) from 01-01-2011 to 31-12-2011
. Collaboration with Roberto Viola, Research and Innovation Centre, Fondazione Edmund Mach, via E. Mach 1, 38010 San Michele all'Adige (TN) from 01-01-2013 to date
. Collaborator in the project NEUROSCAFFOLD #604263 FP7 with CNRS Strasburg France from 01-06-2013 to 01-07-2016
. Collaborator in the project: "Astrocyte deficiency of the Shc family member Rai attenuates myelin-reactive Th17 cell-dependent neurodegeneration in EAE: a mechanistic study of astrocyte-T cell interactions", coordinator of the project Cosima Baldari, University of Siena from 01-01-2015 to date

Projects (from qualified private and public institutions)

CITFI (national pharmacological consortium) fellowship and funds for training period at the Neuroimmunology Unit, Harvard, Boston (MA). Director Stephen Hauser from 01-10-1990 to 31-10-1991
Biogen, Group leader in the project: Pilot evaluation of infection containment in patients with relapsing-

remitting multiple sclerosis under natalizumab treatment. from 01-01-2012 to 31-12-2014
Merck-Serono funds (assigned to Clara Ballerini) for the project: Biological marker research in CSF isolated from Multiple Sclerosis patients and other inflammatory/autoimmune diseases, from 01-01-2013 to 31-12-2014
Università degli Studi Firenze, Fondi Ateneo (ex 60%) assigned to Clara Ballerini, from 01-01-2013 to 2-12-2017
Istituto Mach, S Michele all'Adige, Trento, Italy funds (assigned to Clara Ballerini) to coordinate the project: Evaluation of treatment with vegetal miR during active and passive induced experimental autoimmune encephalomyelitis (EAE), animal model of multiple sclerosis (MS): decrypting a possible mechanism of immune modulation, from 01-01-2013 to 31-12-2013
2015 Regione Toscana: finanziamento per progetto INSIDE – "SvIluppo di targeting diagNostici e teranoStici basati su nano sIstemi e/o linfociti ingegnerizzati per l'indiviDuazione precoce e il trattamento del mElanoma e della sclerosi multipla" "Development of diagnostic and theranostic targeting based on nano system and/or engineered lymphocytes for melanoma and multiple sclerosis treatment"; a valere sul PROGRAMMA OPERATIVO REGIONALE FESR 2014 – 2020, BANDI RSI Bando 1: Progetti Strategici di ricerca e sviluppo from 01-01-2015 to date
Angelini, funds (assigned to Clara Ballerini) for the project: Evaluation of immunological biomarkers in peripheral blood cells of patients with major depressive episode (MDE) diagnosis, from 01-01-2015 to 31-12-2015

Projects (from calls for funding and peer reviews evaluations)

- Italian Foundation for Multiple Sclerosis (FISM); Principal Investigator 2005 FISM project: Immunological evaluation of bone marrow in severe Multiple Sclerosis patients undergoing autologous hematopoietic stem cell transplantation, from 01-01-2005 to 30-01-2005
- Italian Foundation for Multiple Sclerosis (FISM) multicenter project (local principal investigator Clara Ballerini) Immunological evaluation of bone marrow in severe Multiple Sclerosis patients undergoing autologous hematopoietic stem cell transplantation, from 01-01-2010 to 31-12-2012
- Responsible of Centre 3, (University of Florence) in the 2015 FISM multicenter project "Combined analysis of EBV and cellular gene expression in clinically isolated syndrome, relapsing-remitting and primary progressive multiple sclerosis for the identification of prognostic biomarkers", from 01-01-2015 to date
- FISM (Italian Foundation for Multiple Sclerosis) coordinator multicenter two years project " Impact of successful immunomodulatory therapies in RRMS on human TCR repertoire by next generation sequencing", from 01-01-2016 to 2019
- FISM (Italian Foundation for Multiple Sclerosis) collaborator of the two years project "Herpesvirus infections in KIR2DL2 positive Multiple Sclerosis patients: mechanisms triggering autoimmunity". PI Roberta Rizzo, University of Ferrara; from 2020-2022
- FISM (Italian Foundation for Multiple Sclerosis) collaborator of the two years project "New insights for remyelinating therapies: oligodendrogenic role of adenosine A2B receptors and their putative interplay with sphingosine-1-phosphate axis". PI AnnaMaria Pugliese, University of Florence; from 2020-2022
- FISM (Italian Foundation for Multiple Sclerosis) PI of the Florence University Unit in the multicentre project "SARS-CoV-2 and Multiple Sclerosis: Has the Interplay Started? A Study on the Impact of Infection and Vaccine on the Development of Multiple Sclerosis" coordinator Marco Salvetti 2021-2024

Conferences (Organization and participation as presenting author)

- Presenting author, platform presentation "Implication of cellular prion protein at the immune synapse", and invited chair session "Gene and gene-expression in autoimmune diseases of the Nervous System", XV Congress AINI, 13-15 October 2005, Abbazia di Praglia, Teolo Padova. from 13-10-2005 to 15-10-2005
- Presenting author, platform presentation, "Impairment of dendritic cell function is involved in protection afforded by PARP-1 inhibitors in experimental models of multiple sclerosis", XVIII congress AINI, 8-11 October (Napoli). from 08-10-2008 to 11-10-2008
- Presenting author, platform presentation, "MSCs-DCs interaction: a cell-cell contact mechanism inducing tolerance". International congress of European bone marrow transplantation" EBMT 2009 Goteborg, Sweden from 21-03-2009 to 25-03-2009
- Invited Chair, Session "Regulatory B Cells in Healthy and in Patients with Autoimmunity" XXIII AINI Congress as a workshop in the International Congress of Immunology Milan from 22-08-2013 to 22-08-2013
- American Society for Nanomedicine, invited lecture "Nano-materials at the neuro-immune interface" March 28-30 Rockville, Washington DC, USA from 28-03-2014 to 30-03-2014
- Invited Chair Session: Molecular Mechanisms in T Cell Activation and Migration: Role in

Autoimmunity, XXIV AINI Congress Sorrento, Naples from 01-10-2014 to 04-10-2014
- First Congress Neuro-autoimmune Diseases, Prato 20-21 February, invited lecture " The laboratory in the diagnosis of neuro-autoimmune diseases" from 20-02-2015 to 21-02-2015
- Invited Chair, session: Environment and Neuroimmunology, XXV Italian Association Neuroimmunology (AINI) Congress 2016 Lecce, from 11-05-2016 to 14-05-2016
- 2017 Workshop: Focus on the key roles of histaminergic receptors in inflammation and lung and brain diseases, Firenze 19 March, Auditorium Fondazione Cassa di Risparmio di Firenze; invited lecture "Immunological synapse and neuroinflammation: possible role of histaminergic receptors".
- Organizing Committee, chair for the 27th Meeting of the Italian Neuroimmunology Society, 7-10 May 2018, venue: Stazione Marittima Trieste ITALY
- Comitato Scientifico e Faculty, Corsi Residenziali Neuroimmunologia, CRNI, 18a edizione, Centro Congressi Giovanni XXIII, Bergamo 11-13 aprile 2019, “The Basis of Neuroimmunology”
- Organizing Committee, chair for the 28th Meeting of the Italian Neuroimmunology Society, 6-9 May 2019, venue: Camogli (GE), Italy
- SIICA 2021 XII National Congress, 26-28 May; invited lecture “ TCR repertoire dynamics in multiple sclerosis: comparing one shot and continuous immunosuppressive therapies”
- Comitato Scientifico e Faculty, Corsi Residenziali Neuroimmunologia, CRNI, 19a edizione, Centro Congressi Giovanni XXIII, Bergamo 2-4 aprile 2020, “The B side of Neuroimmunology” delayed to July 2021 for Coronavirus emergence
- Comitato Scientifico e Faculty, Corsi Residenziali Neuroimmunologia, CRNI, 20a edizione, Centro Congressi Giovanni XXIII, Bergamo 20-22 aprile 2023, “The use of AI in Neuroinflammation”

Seminars and invited lessons

- 2023 PhD School in Pharmacology, University of Florence. ”The gut-brain axis in neurological diseases”.
- 2022 March 23rd Neuroimmunology and MS research, NIMS seminar series, University Hospital Zurich; invited seminar “T-cell receptor (TCR) repertoire dynamics and diversity in multiple sclerosis”
- 2021 June 15th National Institute for Health and Medical Research (INSERM)/University of Nantes, invited seminar “TCR repertoire dynamics in multiple sclerosis and immunosuppressive therapies”
- 2020 MASTER DI II LIVELLO IN RICERCA TRASLAZIONALE IN REUMATOLOGIA Firenze, Dicembre 2019 – Settembre 2020, 14 February 2020, lesson (3h) “T cell receptor structure and study”
- 2019 PhD School in Pharmacology, University of Florence – “Experimental autoimmune encephalomyelitis: from side effect to animal model”.
- 2017 International Brain Research Organization IBRO, invited teacher (three lessons: "Physiology in Neuroscience", “Introduction to immunology” and "Multiple Sclerosis"), course of Neuroimmunology and Infections, November 21st-29th Rabat, Marocco
- 2013 COST Action BM0806, invited instructor, Training School “Pharmacological Models of Inflammatory and Immunological Disorders” Trinity College Dublin, Dublin Ireland 30TH January-1st February from 29-01-2013 to 30-01-2013
- 2011 Università di Siena, PhD school in Evolutionary Biology, lesson on the following topic: “The experimental autoimmune encephalomyelitis: animal model for Multiple Sclerosis and possible model of nervous system-immune system interactions”
- 2011 University of Florence, lesson for residents in Neurology: “Mesenchymal stem cells in autoimmune diseases: the example of Multiple Sclerosis”
- 2008 Serono, Ivrea. Invited seminar titled: “Modulation of dendritic cells: from immunogenic to tolerogenic responses”

Editorial board and ad hoc referee activities

- From October 2020 Associate Editor for Frontiers in Neurology and Frontiers in Immunology, section Multiple Sclerosis and Neuroimmunology
- From April 2017 CB joined the Editorial Board of Frontiers in Immunology and Neurology as Review Editor for the section Multiple Sclerosis and Neuroimmunology (associated editor Jens Geginat, INGM Milan, Italy)
- Ad hoc referee for Cancer Immunology and Immunotherapy
- Ad hoc referee for Cellular and Molecular Life Sciences
- Ad hoc referee for Cytotherapy
- Ad hoc referee for Israel Science Foundation

© European Union, 2002-2015 | europass.cedefop.europa.eu

- Ad hoc referee for Nanomedicine
- Ad hoc referee for National Medical Research Council Singapore
- Ad hoc referee for Journal of the Neurological Sciences
- Ad hoc referee for Journal of Neurology
- Ad hoc referee of Scientific Committee FISM
- Ad hoc referee for Stem Cells
- Ad hoc referee for Scientific Reports
- Ad hoc referee for PlosOne
- ....

Scientific board

- 2014- 2018 and 2023 to date FISM (Fondazione Italiana Sclerosi Multipla), Membro del Consiglio Scentifico
- 2016- 2022 AINI (Associazione Italiana Neuroimmunologia) Advisor Steering Committee
- 2018-2023 Member of the International Advisor Board, International Society of Neuroimmunology (ISNI)
- 2022-2023 Research Foundation Flanders, panel member TMB call 2022 and 2023

Memberships

- Member of Italian Neuroimmunology Society (AINI)
- Member of International Society of Neuroimmunology (ISNI)
- Member of Italian Multiple Sclerosis Society (AISM)
- Member of American Association of Immunologists (AAI, expired in 2016)
- Member of Italian Society of Immunology and Clinical Allergology (SIICA)
-

Courses at the School of Human Health, University of Florence, Italy

- -B020486 - coordinatore, NEUROFISIOPATOLOGIA DEL SISTEMA NERVOSO PERIFERICO 24 hours (Neurophysiopathology of SNC) from 2012 to 2018
- -B020426 - FONDAMENTI ANATOMO-FISIOLOGICI DELL'ATTIVITA' PSICHICA 50 hours (Bases of anatomy and physiology of CNS) from 2012 to date
- B030219 Propedeutica clinica – coordinator, docente del modulo B030221 Patologia Generale, Immunologia e medicina trasfusionale 45 hours from 2018 to date
- Scuola di specializzazione in Patologia Clinica e Biochimica Clinica, 8 hours from 2021 to date
- Scuola di Specializzazione in Immunologia ed Allergologia Clinica, 4 hours from 2022- to date

PhD School

- A.A. 2020- to date Membro Collegio dei docenti del Dottorato TOSCANO DI NEUROSCIENZE Università degli Studi di FIRENZE
- Tutor at "PhD school of Neuroscience, Regione Toscana" Coordinator prof. Felicita Pedata, Department NEUROFARBA University of Florence; from 2006
- Steering Committee UCLouvain , Commission doctorale du domain sciences médicales Bruxelles (2021-2026)

Abilitazione Scientifica Nazionale (prima fascia) dal 31/05/2021 AL 31/05/2032

- Settore Concorsuale 06/A2 Patologia Generale e Patologia Clinica

Complete Publication List
(doi added from 2007)

1. Lolli F, Liuzzi GM, Vergelli M, Massacesi L, **Ballerini C**, Amaducci L, Riccio P *Antibodies specific for the lipid bound form of myelin basic protein during experimental autoimmune encephalomyelitis* J Neuroimmunol 1993 44:69-75

2. Massacesi L, Vergelli M, Zehetbauer B, Liuzzi GM, Olivotto J, **Ballerini C**, Uccelli A, Mancardi L, Riccio P, Amaducci L *Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid bound form* J Neurol Sci 1993 119:91-8

3. Vergelli M, Mazzanti B, **Ballerini C**, Gran B, Amaducci L, Massacesi L *Transforming growth factor-beta 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors* J Neurosci Res 1995 40:127-33

4. Cascino I, **Ballerini C**, Audino S, Rombolà G, Massacesi L, Colombo G, Scorza Smeraldi R, D'Alfonso S, Momigliano Richiardi P, Tosi R, Ruberti G *Fas gene polymorphisms are not associated with systemic lupus erythematosus, multiple sclerosis and HIV infection* Dis Markers 1998 13:221-5

5. Gran B, Gestri D, Sottini A, Quiros Roldan E, Bettinardi A, Signorini S, Primi D, **Ballerini C**, Taiuti R, Amaducci L, Massacesi L *Detection of skewed T-cell receptor V-beta gene usage in the peripheric blood of patients with multiple sclerosis* J Neuroimmunol 1998 85:22-32

6. **Ballerini C**, Nacmias B, Rombolà G, Marcon G, Massacesi L, Sorbi S *HLA A2 allele is associated with age of onset of Alzheimer's disease* Ann Neurol 1999 45:397-400

7. D'Alfonso S, Nistico L, Zavattari P, Marrosu MG, Murru R, Lai M, Massacesi L, Repice A, **Ballerini C**, Gestri D, Salvetti M, Ristori G, Bomprezzi R, Trojano M, Liguori M, Gambi D, Quattrone A, Fruci D, Cucca F, Richiardi PM, Tosi R *Linkage analysis of multiple sclerosis with candidate region markers Sardinian and Continental Italian families* Eur J Hum Genet 1999 7:377-85

8. Mazzanti B, Hemmer B, Traggiai E, **Ballerini C**, McFarland HF, Massacesi L, Martin R, Vergelli M *Decrypting the spectrum of antigen-specific T-cell responses: the avidity repertoire of MBP-specific T-cells* J Neurosci Res 2000 59:86-93

9. D'Alfonso S, Nistico L, Bocchio D, Bomprezzi R, Marrosu MG, Murru MR, Lai M, Massacesi L, **Ballerini C**, Repice A, Salvetti M, Montesperelli C, Ristori G, Trojano M, Liguori M, Gambi D, Quattrone A, Tosi R, Momigliano-Richiardi P *An attempt to identifying MS-associated loci as follow-up of a genomic linkage study in the Italian population* J Neurovirol 2000 2: S18-22

10. **Ballerini C**, Campani D, Rombolà G, Gran B, Nacmias B, Amato MP, Siracusa G, Bartolozzi L, Sorbi S, Massacesi L *Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis* Neurosci Lett 2000 296:174-6

11. Chiarugi A, Cozzi A, **Ballerini C**, Massacesi L, Moroni F *Kinureine 3-mono-oxygenase activity and neurotoxic kynureine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelithis* Neuroscience 2001 102:687-95

12. Soldan SS, Fodgell-Hahan A, Brennan MB, Mittleman BB, **Ballerini C**, Massacesi L, Seya T, McFarland HF, Jacobson S *Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis* Ann Neurol 2001 50:486-93

13. Papini AM, Mazzanti B, Nardi E, Traggiai E, **Ballerini C**, Biagioli T, Kalbacher H, Beck H, Deeg M,

Chelli M, Ginanneschi M, Massacesi L, Vergelli M *Palmitoyl derivatives of GpMBP epitopes: T-cell response and peptidases susceptibility* J Med Chem 2001 44:3504-10

14. Vergelli M, Mazzanti B, Traggiai E, Biagioli T, **Ballerini C**, Parigi A, Konse A, Pellicano G, Massacesi L *Short-term evolution of autoreactive T cell repertoire in multiple sclerosis* J Neurosci Res 2001 66:517-24

15. Traggiai E, Biagioli T, Rosati E, **Ballerini C**, Mazzanti B, Ben Nun A, Massacesi L, Vergelli M

IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis J Neuroimmunol 2001 121:119-9

16. **Ballerini C**, Rosati E, Salvetti M, Ristori G, Cannoni S, Biagioli T, Massacesi L, Sorbi S, Vergelli M *Protein tyrosine phophatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population* Neurosci Lett 2002 328:325-7

17. Buzzetti R, Pozzilli P, Di Mario U, **Ballerini C**, Massacesi L *Multiple Sclerosis and Type I diabetes* Diabetologia 2002 45:1735-6

18. Mellai M, Giordano M, D'Alfonso S, Marchini M, Scorza R, Danieli GM, Leone M, Ferro I, Liguori M, Trojano M, **Ballerini C**, Massacesi L, Cannoni S, Bomprezzi R, Momigliano-Richiardi P *Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus* Hum Immunol 2003 64:274-84

19. **Ballerini C**., Guerini F.R., Rombolà G., Rosati E., Massacesi L., Ferrante P., Caputo D., Figà Talamanca L., Naldi P., Liguori M., Alizadeh M., Momigliano-Richiardi P., D'Alfonso S. *HLA-Multiple Sclerosis association in Continental Italy and correlation with disease prevalence in Europe* J Neuroimm, 2004 150(1-2):178-85

20. Bruley Rosset M., **Ballerini C**., Gregoire S., Metharom P., Carnaud C., and Pierre Aucouturier. *Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice* J Immunol, 2004 172(9):5168-74.

21. Mazzanti B., Biagioli T., Aldinucci A., Cavaletti G., Cavaletti E., Oggiorni N., Frigo M., Rota S., Tagliabue E., **Ballerini C**., Massacesi L., Riccio P., Lolli F. *Effects of pixantrone on immune-cell function in the curse of acute rat experimental allergic encephalomyelitis* J Neuroimm, 2005;168(1-2):111-7.

22. **Ballerini C**., Gourdain P, Bachy V., Blanchard N., Levavasseur E., Gregoire S., Aucouturier P, Hivroz C., Carnaud C. *Functional implication of cellular prion protein (PrPC) in antigen-driven interactions between T cells and dendritic cells* J Immunol, 2006, 176: 7254–7262.

23. Alessandra Aldinucci, Gianni Gerlini, Silvia Fossati, Giulia Cipriani, **Clara Ballerini**, Tiziana Biagioli, Nicola Pimpinelli, Lorenzo Borgognoni, Luca Massacesi, Flavio Moroni, and Alberto Chiarugi *A Key Role for Poly(ADP-Ribose) Polymerase-1 Activity during Human Dendritic Cell Maturation* J. Immunol., Jul 2007; 179: 305 - 312.

24. Sandra D'Alfonso, Elisabetta Bolognesi, Franca R Guerini, Nadia Barizzone, Sara Bocca, Daniela Ferrante, Luca Castelli, Laura Bergamaschi, Cristina Agliardi, Pasquale Ferrante, Paola Naldi, Maurizio Leone, Domenico Caputo, **Clara Ballerini**, Marco Salvetti, Daniela Galimberti, Luca Massacesi, Maria Trojano, Patricia Momigliano-Richiardi, *A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy* . Genes Immun. 2007 Jan;9(1):7-15 doi:10.1038/sj.gene.6364437

25. Francesco Liotta, MD, Francesca Frosali, BSc, Valentina Querci, BSc, Andrej Mantei, BSc, Lucia Filı`, BSc, Laura Maggi, BSc, Benedetta Mazzinghi, BSc, Roberta Angeli, BSc, Elisa Ronconi, BSc, Veronica Santarlasci, PhD, Tiziana Biagioli, PhD, Laura Lasagni, PhD, **Clara Ballerini, PhD**, Paola Parronchi, MD, Alexander Scheffold, PhD, Lorenzo Cosmi, MD, Enrico Maggi, MD, Sergio Romagnani, MD, and Francesco Annunziato, PhD, *Human immature myeloid dendritic cells trigger a TH2-polarizing program via Jagged-1/Notch interaction* J Allergy Clin Immunol 2008 Apr;121(4):1000-5 doi: 10.1016/j.jaci.2008.01.004.

26. Ilaria Luccarini, **Clara Ballerini**, Tiziana Biagioli, Filippo Biamonte, Arianna Bellucci, Maria Cristina Rosi, Cristina Grossi, Luca Massacesi, Fiorella Casamenti, *Combined treatment with atorvastatin and minocycline suppresses severity of EAE* Experimental Neurology 211, 2008 214–226 doi: 10.1016/j.expneurol.2008.01.022.

27. Benedetta Mazzanti b,1, Alessandra Aldinucci a,1, Tiziana Biagioli a, Alessandro Barilaro a, Serena Urbani b, Simone Dal Pozzo b, Maria Pia Amato a, Gianfranco Siracusa a, Clara Crescioli d, Cinzia Manuelli c, A. Bosi b, Riccardo Saccardi b, Luca Massacesi a, **Clara Ballerini** a, *Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment* J Neuroimm 2008, Aug 13;199(1-2):142-50 doi: 10.1016/j.jneuroim.2008.05.006

28. Véronique Bachy, **Clara Ballerini**, Pauline Gourdain, Aurélie Prignon, Saci Iken, Nadine Antoine, Martine Bruley-Rosset, Claude Carnaud, *Breaking T- and B-cell tolerance against the prion protein (PrP) with peptidi-loaded dendritic cells*, *overcomes tolerance and delays scrapie* J Gen Virol, 2009, Nov 18, (Epub ahead printing) doi: 10.1099/vir.0.013417-0

29. Alessandra Aldinucci, Tiziana Biagioli, Cinzia Manuelli, Luca Massacesi, **Clara Ballerini** *Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP* J Neuroimm 2009, Nov 25 (Epub ahead printing) doi: 10.1016/j.jneuroim.2009.11.001

30. Aldinucci A, Rizzetto L, Pieri L, Nosi D, Romagnoli P, Biagioli T, Mazzanti B, Saccardi R, Beltrame L, Massacesi L, Cavalieri D, **Ballerini C**. *Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation.* J Immunol. 2010 Nov 1;185(9):5 102-10. Epub 2010 Oct 1 doi: 10.4049/jimmunol.1001332.

31. Franciotta D, Di Stefano AL, Jarius S, Zardini E, Tavazzi E, **Ballerini C**, Marchioni E, Bergamaschi R, Ceroni M *Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases* . J Neuroimmunol. *2011 Jan;230(1-2):160-3*. doi: 10.1016/j.jneuroim.2010.10.027. Epub 2010 Nov 24.

32. Bonetti MI, Pieri L, Domenici L, Urbani S, Romano G, Aldinucci A, **Ballerini C**, Monici M, Saccardi R, Basile V, Bosi A, Romagnoli P *Dendritic cells with lymphocyte stimulating activity differentiate from human*

CD133 positive precursors. Blood. 2011 Feb 8. [Epub ahead of print] doi: 10.1182/blood-2010-08-299735

33. Cavone L, Aldinucci A, **Ballerini C**, Biagioli T, Moroni F, Chiarugi A. *PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.* Mult Scler. 2011 Feb 22. [Epub ahead of print] doi: 10.1177/1352458511399113

34. Gourdain P, **Ballerini C**, Nicot AB and Carnaud C. *Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: evidence for a critical role of the central nervous system*. Journal of Neuroinflammation 2012, 9:25 Pub date 26 Jan 2012 doi: 10.1186/1742-2094-9-25.

35. Passani M. B. and **Ballerini C**. *Histamine and neuroinflammation: insights from mouse experimental autoimmune encephalomyelitis*. Front. Syst. Neurosci. 2012 6:32. doi:10.3389/fnsys.2012.00032

36. **C. Ballerini**, A. Aldinucci, I. Luccarini, A. Galante, C. Manuelli, P. Blandina, M. Katebe, P.L. Chazot, E. Masini and M.B. Passani. 2013 *Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis* Br J Pharmacol. 2013 Sep;170(1):67-77. doi:10.3389/fnsys.2012.00032.

37. Bonetti MI, Bacci S, SantuossoM, Mazzanti B, Aldinucci A, **Ballerini C**, Guasti D, Calosi L, Bosi A, Romagnoli P. 2013 *Rosiglitazone promotes the differentiation of Langerhans cells and inhibits that of other dendritic cell types from CD133 positive hematopoietic precursors.* Histol. Histopathol. 2013 Jul 24. [Epub ahead of print] doi: 0.14670/HH-29.323

38. Amedei A, Codolo G, Ozolins D, **Ballerini C**, Biagioli T, Jaunalksne I, Zilevica A, D Elios S, De Bernard M, D' Elios MM. 2013 *Cerebrospinal fluid T-regulatory cells recognize Borrelia burgdorferi NAPA in chronic Lyme borreliosis.* Int J Immunopathol Pharmacol Oct-Dec; 26 (4): 907-15 doi:10.1177/039463201302600409

39. Alessandra Aldinucci,† Antonio Turco,‡ Tiziana Biagioli,† Francesca Maria Toma,‡ Daniele Bani,§ Daniele Guasti,§ Cinzia Manuelli,§ Lisa Rizzetto,†,‡,§,‖ Duccio Cavalieri,†,‡,§,‖ Luca Massacesi,† Tommaso Mello,⊥ Denis Scaini,□ Alberto Bianco,¶ Laura Ballerini,*,□ Maurizio Prato,*, and **Clara Ballerini***,† *Carbon Nanotube Scaffolds Instruct Human Dendritic Cells: Modulating Immune Responses by Contacts at the Nanoscale;* Nano Letters 2013 doi: 10.1021/nl403396e.

40. Renato Ribeiro-Viana‡, Elena Bonechi‡, Javier Rojo, **Clara Ballerini**, Giuseppina Comito, Barbara Richichi* and Cristina Nativi. *Human dendritic cell activation induced by a permannosylated dendron containing an antigenic GM3-lactone mimetic* Beilstein J. Org. Chem. 2014, 10, 1317–1324. doi: 10.3762/bjoc.10.133

41. Elena Bonechi, Alessandra Aldinucci, Benedetta Mazzanti, Massimo di Gioia, Anna Maria Repice, Cinzia Manuelli, Riccardo Saccardi, Luca Massacesi and **Clara Ballerini***. *Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT,* Ann Clin Transl Neurol, 2014 DOI: 10.1002/acn3.92

42. **Clara Ballerini***, Giovanni Baldi, Alessandra Aldinucci, Pietro Maggi *Nanomaterial Applications in Multiple Sclerosis Inflamed Brain*, Journal of Neuroimmune Pharmacology 2015 doi: 10.1007/s11481-015-9588-y

43. Fibbi B, Benvenuti S, Giuliani C, Deledda C, Luciani P, Monici M, Mazzanti B, **Ballerini C**, Peri A. *Low*

Curriculum Vitae

Prof. Massimiliano Di Filippo

INFORMAZIONI PERSONALI

Via Pompili 30, 06122 – Perugia (PG)

0755783830 3471222201

massimiliano.difilippo@unipg.it

Data e Luogo di Nascita: 15/01/1980, Perugia - Cittadinanza: Italiana

Indirizzo lavorativo: Clinica Neurologica, Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, Ospedale S Maria della Misericordia, Loc. S Andrea delle Fratte, 06156, Perugia, Italy

Researcher unique identifier(s):

ORCID ID: https://orcid.org/0000-0002-2645-7477

RESEARCH ID: K-8070-2016

Lingue straniere: ottima conoscenza di Inglese scritto e parlato e buona conoscenza di Francese scritto.

Conoscenze informatiche. Ottima conoscenza di Word, Excel, PowerPoint e del programma di analisi statistica STATA.

Istruzione e formazione

Luglio 2004	**Laurea in Medicina e Chirurgia (votazione 110/110 e lode)** presso **l'Università di Perugia**.
Febbraio 2005	**Abilitazione all'esercizio della professione medica**.
Giugno-Luglio 2005	**Attività medica volontaria** presso il "Pirimiti Health Center", in Malawi, Africa.
2005-2009	**Specializzando in Neurologia** presso la Clinica Neurologica, Università di Perugia (Direttore, Professor Paolo Calabresi). Durante tale periodo ha svolto attività assistenziale di reparto ed ambulatoriale con particolare riguardo alla cura dei pazienti affetti da sclerosi multipla ed ha svolto attività di ricerca nel campo dell'elettrofisiologia sperimentale applicata allo studio di modelli sperimentali di malattie neurologiche.
Ottobre 2009.	**Specializzazione in Neurologia (votazione di 50/50 e lode)** presso **l'Università degli Studi di Perugia** (Scuola di Specializzazione in Neurologia, Direttore Professor Paolo Calabresi) con discussione di tesi di Specializzazione dal titolo "Il coinvolgimento sinaptico e neuronale in corso di sclerosi multipla: dati di elettrofisiologia sperimentale e risonanza magnetica".
Dicembre 2012	**Titolo di Dottore di Ricerca in Neuroscienze presso l'Università di Perugia** con discussione di Tesi di Laurea dal titolo "Studio della plasticità sinaptica ippocampale in un modello sperimentale di sclerosi multipla".
Giugno-Ottobre 2021	Presso il Politecnico di Milano, Graduate School of Buisness, ha completato il percorso di **"Formazione su controllo di gestione e performance di processo in Neurologia".**
2020	Acquisizione dei certificati attestanti l'avvenuta formazione per ricoprire il **ruolo di responsabile del benessere animale** di cui all'art. 3, comma 1, lettera h, e di membro scientifico di cui all'art. 3, comma 1, lettera i, del D.Lgs 26/14, a seguito della partecipazione agli eventi formativi, riconosciuti idonei dal Ministero della Salute, erogati dall'Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna (IZSLER).

Attività formative all'estero

2007- 2008	**Visiting Research Fellow (durata 10 mesi) presso l'"Institute of Neurology", Queen Square, London**. Durante questo periodo ha lavorato presso la "NMR Research Unit" del Dipartimento di Neuroinfiammazione sotto la guida del Professor David Miller, svolgendo un progetto di ricerca nel campo della **risonanza magnetica applicata alla sclerosi multipla**, con particolare riguardo allo studio dell'atrofia cerebrale come marker predittivo. I risultati di tale studio sono stati presentati al primo congresso mondiale sulla sclerosi multipla (Montreal, Canada, 17-20 settembre 2008) e sono stati pubblicati dalla rivista internazionale "Journal of Neurology, Neurosurgery and Psychiatry". Durante l'intero periodo di permanenza presso l'"Institute of Neurology" ha anche frequentato l'"**Outpatient Multiple Sclerosis Clinic" del "National Hospital for Neurology and Neurosurgery**", Queen Square, London, dove ha approfondito le nozioni cliniche riguardo a diagnosi e trattamento delle malattie demielinizzanti del sistema nervoso centrale.

Aprile- Maggio 2008 **Frequenza presso l'"Institute of Cell and Molecular Science", Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom**, sotto la guida del Professor David Baker. Durante questo periodo ha appreso le **tecniche di induzione di un modello sperimentale di sclerosi multipla**, l'encefalomielite autoimmune sperimentale ed ha intrapreso un'attiva collaborazione con il gruppo del Professor Baker per lo studio delle alterazioni sinaptiche in corso di tale modello sperimentale.

Abilitazioni scientifiche Nazionali

Febbraio 2014 Consegue l'**abilitazione scientifica nazionale a Professore Associato**, settore scientifico-disciplinare Neurologia 06/D6 (Bando 2012, DD n 222/2012)

Luglio 2018 Consegue l'**abilitazione scientifica nazionale a Professore Ordinario**, settore scientifico-disciplinare Neurologia 06/D6 (Bando 2016, DD n 1532/2016)

Posizioni universitarie

Gennaio 2011 – Gennaio 2014 **Ricercatore Universitario a tempo determinato**, settore scientifico-disciplinare **Neurologia**, MED26, Università di Perugia, per l'espletamento del progetto "Studio delle patologie neurodegenerative e della Sclerosi Multipla".

Gennaio 2014-Dicembre 2014 **Ricercatore Universitario a tempo determinato**, settore scientifico-disciplinare **Neurologia** 06/D6, Università di Perugia, per l'espletamento del progetto "Ruolo dei meccanismi sinaptici e dell'infiammazione in modelli di malattia di Parkinson (MP) e di altre malattie neurodegenerative".

Dicembre 2014-oggi **Vincitore di concorso per Ricercatore Universitario a tempo determinato ai senso dell' art. 24 – comma 3 – lettera b)** della Legge 30.12.2010 n 240, settore scientifico-disciplinare Neurologia 06/D6, Università di Perugia, per l'espletamento del progetto "Studio dei meccanismi di danno neuronale e sinaptico nelle malattie del sistema nervoso centrale".

Ottobre 2017 **Nomina a Professore di ruolo di II fascia nel settore scientifico-disciplinare MED/26, Neurologia** – Art 24, comma 5, Legge 240/2010, con entrata in ruolo a dicembre 2017

Ruoli ed incarichi universitari

2020-oggi Nomina a **Direttore Vicario della Scuola di Specializzazione in Neurologia**, Università di Perugia

2023-oggi Nomina a **Direttore Vicario della Scuola di Specializzazione in Neurologia**, Università di Perugia

2021-2024 Nomina dal Senato Accademico quale **coordinatore della linea d'azione "Salute"** nell'ambito del "**Piano delle azioni collaborative di Ateneo" per l'Università di Perugia**

2023-oggi **Vice-coordinatore del Dottorato di Ricerca in Medicina Clinica e Molecolare**, Università di Perugia

2023-oggi	**Membro della Commissione Paritetica Docenti-Studenti del Corso di Laurea Magistrale in Medicina e Chirurgia**, Università di Perugia.
2025-oggi	Membro della **Commissione Ricerca del Dipartimento di Medicina e Chirurgia, Università di Perugia**

Dal 2020 è membro dell'**Organismo Preposto al Benessere degli Animali (OPBA)**, dell'Università degli Studi di Perugia. Marzo 2023 –

Ruoli ed incarichi clinico-assistenziali

2011 – oggi	Attività assistenziale in qualità di **Dirigente Medico di I livello presso la S.C. Clinica Neurologica**, Azienda Ospedaliera di Perugia
2013 – oggi	Conferimento dell'**incarico professionale "Gestione dei pazienti con malattie demielinizzanti**" da parte dell'Azienda Ospedaliera di Perugia
2017-oggi	**Ruolo di responsabile del Centro Malattie Demielinizzanti della S.C. di Clinica Neurologica**
2017-oggi	Membro del **gruppo tecnico Regionale per la stesura del Percorso Diagnostico Terapeutico Assistenziale Regionale per la Sclerosi Multipla nella Regione Umbria**
2022-2024	**Incarico di sostituto del Direttore Responsabile di Struttura Complessa, presso la Clinica Neurologica, Azienda Ospedaliera ed Università di Perugia**
2024-oggi	**Conferimento dell'incarico di "Coordinatore gruppo Professionale" Coordinatore dell'attività di diagnostica e cura delle malattie infiammatorio-disimmuni del sistema nervoso centrale (Art. 22 c. 1 Par II Lett b) CCNL 2019 - 2021**

Attività clinica e di coordinamento

*Sin dai primi anni di formazione ha svolto **attività clinico-assistenziale presso il reparto di degenza e presso il Centro Malattie Demielinizzanti della Clinica Neurologica** dell'Azienda Ospedaliera di Perugia, di cui è divenuto responsabile nel 2017. Ha in questo ambito contributo alla **creazione di una rete inter-disciplinare ed inter-dipartimentale per la cura della persona con sclerosi multipla**, coninvolgente tra le altre le Strutture di Neuroradiologia, Oftalmologia, Urologia/Unità Spinale, Pscihiatria, Ginecologia, Cardiologia e Dermatologia. Ha negli anni contribuito in prima persona ad un processo di standardizzazione delle procedure diagnostiche e di monitoraggio per le persone con sclerosi multipla, implementando l'utilizzo di nuovi marcatori e di terapie innovative presso il Day-Hospital della Clinica Neuurologica. In tale ambito ha coordinato e coordina un gruppo di neurologi, specialisti in formazione ed infermieri. Grazie a specfica **esperienza in ambito neuro-immunologico** ed a collaborazioni inambito Nazionale in tal senso, ha contribuito altresì all'implementazione dei processi di diagnosi e cura per le patologie neuro-immuni del sistema nervoso centrale, con particolare riguardo alla **neuromielite ottica con Ab anti anti AQ4 ed anti MOG ed alle encefaliti autoimmuni**. Sempre in ambito neuro-immunologico è anche (i) **parte del gruppo "CAR-Team"** (in collaborazione con la S.C. Ematologia) per la **valutazione delle possibili complicanze della terapia con cellule CAR-T** (chimeric antigen receptor) nelle neoplasie meatologiche e (ii) consulente per la S.C. Ematologia **per i pazienti trapiantati o che devono sottoporsi a trapianto autologo o allogenico. E' inoltre** consulente su chiamata per la S.C. Oncologia per la **diagnosi e gestione delle complicanze neurologiche disimmuni della***

terapia con inibitori dei check points immuni *nella terapia anti-tumorale. Nel 2024, in relazione a tali attività gli è stato conferito dall'Azienda Ospedaliera di Perugia ruolo di* ***coordinatore dell'attività di diagnostica e cura delle malattie infiammatorie-disimmuni del sistema nervoso centrale****.*

Attività di ricerca

Attività di ricerca pre-clinica.

Sotto la guida del Professor Paolo Calabresi ha svolto sin dai primi anni di formazione (2005) attività di ricerca presso i Laboratori di Neurologia Sperimentale della Clinica Neurologica, Università di Perugia. I ***principali ambiti di ricerca*** *sono stati in tale periodo rappresentati dallo* ***studio dei meccanismi di neuroprotezione, trasmissione e plasticità sinaptica mediante metodiche di elettrofisiologia sperimentale*** *(tecniche di registrazione intracellulare, di campo e patch-clamp) in modelli sperimentali di malattie neurologiche, con particolare riguardo alle* ***neuroimmunologia sperimentale*** *ed allo studio dei* ***meccanismi di memoria sinaptica in modelli sperimentali di neuroinfiammazione e sclerosi multipla****.*

Attività di ricerca clinica*.*

Sin dai primi anni di formazione ha svolto ***attività di ricerca presso il Centro Malattie Demielinizzanti della Clinica Neurologica*** *dell'Azienda Ospedaliera di Perugia. Ha coordinato e coordina nell'ambito della* ***ricerca sulla sclerosi multipla e sulla neuro-immunologia*** *clinica e traslazionale* ***studi di risonanza magnetica e mediante biomarcatori fludi.***

h-index

H-index calcolato a **gennaio 2026** (fonte Scopus): **48.** Numero citazioni totali: **8697.**

Premi e menzioni

Premio **Rita Levi Montalcini 2019 da parte della Fondazione Italiana Sclerosi Multipla**, premio attribuito ogni anno per la **ricerca di eccellenza con rilevante impatto clinico**, per aver "portato alla luce i meccanismi che modulano la neuroplasticità e in particolare la capacità delle sinapsi di subire cambiamenti a lungo termine nell'efficacia della trasmissione sinaptica".

Premio per la migliore pubblicazione Anno 2018, per l'articolo "**Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis**", ***Sci Rep***. 2016 Feb 18;6:20926.

Partecipazioni a società scientifiche

Dal 2006 è socio della **Società Italiana di Neurologia** . Nell'ambito della stessa membro dei grippi di studio in "sclerosi multipla", "neuroimmuniologia" e "biomarcatori".

Dal 2018 è socio dell'**Associazione Italiana di Neuro-Immunologia**.

Dal 2021 **membro del gruppo di studio "Immunopsichiatria e Immunopsicologia"** dell'**Associazione Italiana di Neuro-Immunologia**.

Ruoli istituzionali e riconoscimenti

Dal 2018 è parte del **registro REPRISE** (registro degli esperti scientifici del **Ministero dell'Istruzione, Università e Ricerca**), sezione Fundamental Research.

Dal 2018 al 2023 è stato parte del Comitato Scientifico della Fondazione Italiana Sclerosi Multipla (**Biomedical Research FISM Scientific Committee**).

Nel 2025 membro ad hoc del Comitato Scientifico della Fondazione Italiana Sclerosi Multipla (**Biomedical Research FISM Scientific Committee**).

Dal 2022, su invito, parte dell'Accademia Nazionale di Medicina, in qualità di socio aggregato in rappresentanza delle Università per la Sezione "Neurologia".

Dal 2023 inserito tra i "**Best Scientists in Neuroscience**" dal sito Research.com (https://research.com/u/massimiliano-di-filippo)

Partecipazioni a gruppi di ricerca multicentrici Nazionali ed Internazionali

Dal 2014 membro del **gruppo di ricerca multicentrico Italiano sulla sclerosi multipla "RIREMS (Raising Italian Researchers in Multiple Sclerosis)"**: http://www.rirems.it/

Dal 2021 membro del **gruppo di ricerca multicentrico Internazionale "Move the Science"**

Collaborazioni Internazionali

Co-autore di lavori scientifici editi su riviste internazionali derivati da collaborazioni con neuroscienziati negli Stati Uniti ed Europa, come il Professor Paul Greengard (The Rockefeller University, New York, U.S., premio Nobel per la Fisiologia o la Medicina), il **Professor David Baker** (Queen Mary University of London, UK) ed il **Professor James Bibb** (The University of Texas Southwestern Medical Center, Dallas, Texas, U.S.).

Nel 2024 **coordintaore, per la rivista The Lancet (Regional Health Europe) degli esperti Europei in materia di sclerosi multipla**, per la stesura di una serie (*Series*) di articoli di revisione sui principali aspetti della patologia, inclusi revisione dei fenotipi clinici, risonanza magnetica e biomarcatori fluidi.

Attività Editoriale

Dal 2012 al 2014 è stato parte dell'**Editorial Board della rivista "ISRN Neuroscience**".

Dal 2014 al 2017 è stato parte dell'**Editorial Board della rivista "Behavioural Neurology**".

Dal 2020 è parte dell'Editorial Board della rivista "**International Journal of Molecular Science**", Section "Molecular Pathology, Diagnostics, and Therapeutics"

Nel 2020-2021 **Guest Editor** per la rivista Internazionale "**Biomolecules**", research topic "**Molecular Events in Neurodegenerative and Neuroinflammatory Diseases in Italy: Implications for Treatments**"

Nel 2020-2021 **Guest Editor** per la rivista Internazionale "**Frontiers in Neurology**", research topic "**Cognition in multiple sclerosis**".

Dal 2020 Review Editor per le riviste “Frontiers in Neurology (Section Multiple Sclerosis and Neuroimmunology)” e “Frontiers in Molecular Neuroscience”.

Nel 2023 **Guest Editor** (assieme al Prof. Masismiliano Calabrese, Università di Verona) per la Special Issue **"Recent Progress and Perspectives in Multiple Sclerosis"** della rivista internazionale “**International Journal of Molecular Science**”

Dal 2026 **membro del comitato scientifico della rivista LaNeurologia Italiana**
https://neurologiaitaliana.it/

Attività di Referee

Ha svolto e svolge **attività di Referee ad hoc per le riviste internazionali**:

“The Journal of Neuroscience”
“European Journal of Neurology”
“Journal of Neuroinflammation”
“Journal of Alzheimer Disease”
“Journal of Inflammation”
“Neurochemistry International”
“BioMed Research International”
“European Neurology”
“BMC Neurology”
“Behavioural Brain Research”
“Journal of the Neurological Sciences”
“Neuroscience Letters”
“Journal of Neurology Neurosurgery and Psychiatry”
“Neuropharmacology”
“Journal of Neurology”
“Neurobiology of Disease”
“European Journal of Neuroscience”
“European Journal of Pharmacology”
“Mediators of Inflammation”
“Neurourology and Urodynamics”
“Scientific Reports”
“Neural Plasticity”
“Neurological Sciences”
“Multiple Sclerosis Journal: experimental, translational and clinical”
“Genes, Brain, and Behavior”
“Frontiers in Neurology”
“Frontiers in Immunology”
“Neuro-psychopharmacology and biological psychiatry”
“Patient Related Outcome Measures”
“Journal of Neuroimmunology”
“Brain, behavior and immunity”
“Neuroimmunology and neuroinflammation”
“Journal of affective disorders”
“Multiple Sclerosis and Related Disorders”
“BMC Infectious Diseases”
“Multiple Sclerosis Journal”
“Lancet’s EBioMedicine”
“Molecular Neurobiology”
“Neurology”
“i-Science”

"Neurology and Therapy"
"Annals of Clinical and Translational Neurology"
"British Journal of Pharmacology"
"Biological Psychiatry"
"Psychiatry Research"
"The Lancet Neurology"
"Expert Review of Molecular Diagnostics"
"Neurology ®: Neuroimmunology and Neuroinflammation"
"Brain Research"
"Cell reports Medicine"
"Annals of Neurology"
"Receptors"
"Molecular Psychiatry"
.

Attività di revisore esterno nella valutazione di progetti di ricerca per:

Fondazione Italiana Sclerosi Multipla (2014-2025)
Università di Milano (2011)
Università degli Studi di Firenze-Fondazione Cassa di Risparmio di Firenze, bando congiunto (2021)
Università di Siena, progetti "curiosity driven", F-CUR, , macro-settore ERC Life Sciences (2022)
German Research Foundation (Deutsche Forschungsgemeinschaft) (2023)

Ha svolto attività di **revisore esterno delle Tesi di Dottorato di Ricerca (prevalentemente nel capo delle in Neuroscienze) per i seguenti Atenei:**

Università di Parma (2018)
Università di Genova (2019)
Università di Firenze (2019)
Università di Tor Vergata (2020, 2023)
Università del Piemonte Orientale (2023)
Università di Pavia (2023)
Università della Campania Luigi Vanvitelli (2023)

Attività di **revisore esterno dei contributi scientifici presentati per il Congresso Nazionale della Società Italiana di Neurologia**, in ambito di sclerosi multipla (2025).

Attività didattica e di supervisione

Corso di Laurea in Medicina e Chirurgia

Presso il **Corso di Laurea in Medicina e Chirurgia**, Università di Perugia (Sede di Terni), dall'anno accademico 2015/2016 in poi **titolare dell'insegnamento di Neurologia (comprensivo dei moduli di Neurologia,** SSD MED/26 **Neuroradiologia,** SSD MED/37 **Neurochirurgia,** SSD MED/27 **e tirocini professionalizzanti nelle stesse discipline)** (**8 CFU**). Negli stessi anni costante partecipazione agli esami di profitto.

Presso il **Corso di Laurea in Medicina e Chirurgia**, Università di Perugia (Sede di Terni), dall'anno accademico 2014/2015 in poi, **titolare dei tirocini professionalizzanti in Neurologia, Neuroradiologia e Neurochirurgia** nell'ambito **dell'insegnamento di Neurologia**.

Presso il **Corso di Laurea in Medicina e Chirurgia**, Università di Perugia (Sede di Terni), dall'anno accademico 2012/2013 in poi, **titolare del modulo di Neuroradiologia** nell'ambito **dell'insegnamento di Neurologia**.

Nell'ambito del corso di Laurea in Medicina, dall'anno 2013/2014, ha svolto attività di **tutor/relatore per la predisposizione di Tesi di Laurea in Medicina (disciplina Neurologia)** ed attività di **tutor/relatore nell'ambito della Scuola di Specializzazione in Neurologia**.

Dal 2014 svolge funzioni di **tutor-valutatore per la prova di Tirocinio in Medicina per gli esami di Stato di abilitazione all'esercizio della Professione di Medico-Chirurgo**.

Corso di Laurea in Scienze Riabilitative delle Professioni Sanitarie

Presso il **Corso di Laurea in Scienze Riabilitative delle Professioni Sanitarie**, Università di Perugia (Sede di Perugia), dall'anno accademico 2020/2021 in poi, **titolare dell'isegnamento di "Scienze riabilitative in area neurologica".**

Scuole di Specializzazione

Dall'anno accademico 2016/2017 in poi nell'ambito degli insegnamenti della **Scuola di Specializzazione in Neurologia (SSD/MED26)** titolare del Modulo "**Gestione ictus in fase acuta ed altre emergenze neurologiche"**

Dall'anno accademico 2015/2016 in poi nell'ambito degli insegnamenti della **Scuola di Specializzazione in Neurologia (SSD/MED26)** titolare del Modulo "**Neuroimmunologia"**

Nell'anno accademico 2013/2014 e 2015/2016 nell'ambito degli insegnamenti della **Scuola di Specializzazione in Neurologia (SSD/MED26)** titolare del Modulo "**Neurologia: basi fisiologiche del sistema nervoso Mod.3"**

Dall'anno accademico 2020/2021 in poi nell'ambito degli insegnamenti della **Scuola di Specializzazione in Neurologia (SSD/MED26)** titolare del Modulo "Malattie Demielinizzanti e potenziali evocati"

Dall'anno accademico 2021/2022 in poi nell'ambito degli insegnamenti della **Scuola di Specializzazione in Reumatologia** titolare dell'insegnamento di "**Neurologia" (SSD/MED26)**

Dal 2025 membro del Consiglio della **Scuola di Specializzazione in Medicina Interna e** titolare nello stesso dell'insegnamento di "**Neurologia" (SSD/MED26)** a partire dall'anno 2027.

Dottorati di Ricerca

Dall'anno 2013/2014 è nel Collegio Docenti del **Dottorato in Medicina Clinica e Molecolare dell'Università di Perugia, curriculum Neuroscienze**.

Dal 2022 al 2024 ruolo di **"second supervisor" per l'Istituto Scientifico San Raffaele**, **International PhD Course in Molecular Medicine,** curriculum neuroscienze e neurologia sperimentale.

Membro della commissione giudicatrice per il conseguimento del titolo di dottore di ricerca in "Neuroscienze" dell'Università degli Studi di Cagliari, a.a. 2021/2022 - XXXV ciclo

Membro della commissione giudicatrice per il conseguimento del titolo di dottore di ricerca in "Neuroscienze, scienze psicologiche e psichiatriche e scienze del movimento" dell'Università degli Studi di Verona, discussione del 31 ottobre 2024

Membro della commissione giudicatrice per il conseguimento del titolo di dottore di ricerca in "Neuroscienze", Dottorato Toscano di Neuroscienze, Università degli Studi di Firenze, XXXVI ciclo (2025)

Master

Anno accademico 2025/2026. Docente alla terza edizione del Master di I livello in Fisioterapia in ambito muscoloscheletrico e reumatologico, Università degli Studi di Perugia.

Ulteriore attività didattica

2009-oggi: **organizzazione di attività di tutorato, lezioni teorico-pratiche ed organizzazione di cicli di seminari per studenti e specializzandi in Neurologia**.

2011 **Attività di docenza per l'ASL2**, nell'ambito del corso "Attualità nella riabilitazione della persona con disabilità ortopedica e neurologica". Titolo delle relazioni "Sclerosi Multipla, inquadramento clinico e neurofisiopatologia" e "Sclerosi Multipla, la terapia farmacologica".

Anno 2010. **Attività di supporto alla didattica** nell'ambito dell'insegnamento di Neurologia, Corso di Laurea in "Scienze e Tecniche Psicologiche dei Processi Mentali", Facoltà di Scienze della Formazione, Università di Perugia.

2010 – Vincitore di un bando per "**Attività di tutorato, didattiche integrative, propedeutiche e di recupero**" per l'Anno Accademico 2009/2010, riservato ai dottorandi in Scienze Mediche e Scienze Biologiche, Università di Perugia.

Ruolo di supervisore/tutor/relatore di studenti presso Corsi di Laurea, Scuole di Specializzazione e Dottorati

2012 – present **Relatore di Tesi di Laurea in Neurologia per più di 60 studenti in Medicina e Chirurgia, Università di Perugia**

Tutor e Relatore di Tesi di Specializzazione di 9 specialisti in formazione, Scuola di Specializzazione in Neurologia, Università di Perugia.

Tutor e Relarore di tesi di Dottorato di 5 Dottorandi in Medicina Clinica e Molecolare, Curriculum di Neuroscienze, **Università di Perugia**

Ruolo di Principal Investigator, co-PI o responsabile di Unità in Progetti di Ricerca Nazionali ed Internazionali:

Vincitore del Bando Progetti di Ricerca Giovani Ricercatori – Ricerca Finalizzata 2010 Ministero della Salute, in qualità di **Principal Investigator** per il progetto "**Neuroinflammation and synaptic function: an electrophysiological analysis in experimental multiple sclerosis**", Codice Progetto **GR-2010-2312924**

Vincitore di un finanziamento della Fondazione Italiana Sclerosi Multipla (FISM) 2013, in qualità di **Principal Investigator** per il progetto "**Mitochondrial inhibition and experimental autoimmune encephalomyelitis: possible neuroprotective strategies" Codice Progetto 2013/R/12**

Co-Principal Investigator (PI Lucilla Parnetti) **del progetto "Toward molecular profiling of Parkinson's disease in easily accessible biological matrices"** European Union—Next Generation EU – PNRR M6C2 - Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN (PNRR-MAD-**2022**-12376035).

Responsabile di Unità Operativa nel progetto "Identification of diagnostic and prognostic markers of silent disease progression idependent of relapse (PIRA) in multiple sclerosis" vincitore del bando competitivo del Ministero della Salute – **Bando ricerca Finalizzata 2021** - (RF-2021-123733319)

Principal Investigator del progetto **"Quantifying synaptic dysfunction in multiple sclerosis by means of a cerebrospinal fluid biomarker panel: a pilot study", vinctore del bando 2023 della Fondazione Italiana Sclerosi Multipla (2023/PRSingle017).**

Partecipazione a Progetti di Ricerca Nazionali ed Internazionali:

2013. **Ricerca Finalizzata Ministero della Salute, progetti ordinari. Coordinatore di Unità** nell'ambito del progetto "Cell-type and subunit specific alterations of NMDA receptors in striatum at early stages of Parkinson's disease". (Principal Investigator Paolo Calabresi). RF-2013-02356215

2005-2008. **Progetto Europeo SYNSCAFF.** Synaptic scaffolding proteins orchestrating cortical synapse organisation during development. SIXTH FRAMEWORK PROGRAMME - PRIORITY (LSH-2003-2.1.3-5) (Cortical development) (Coordinator Professoressa Monica Di Luca, Università di Milano).

2010. **Progetto Fondazione Cassa di Risparmio di Perugia**. Titolo: "Dai meccanismi patogenetici ai biomarkers nella Malattia di Parkinson" (Principal Investigator Paolo Calabresi)

2010. **Progetto di Ricerca Fondazione Italiana Sclerosi Multipla**, dal titolo "**An electrophysiological study of synaptic plasticity in experimental models of multiple sclerosis**" (Principal Investigator Paolo Calabresi)

2011. **Progetto di Ricerca Fondazione Italiana Sclerosi Multipla**, dal titolo "**An electrophysiological study of the mechanisms of synaptic plasticity impairment in experimental multiple sclerosis**" (Principal Investigator Paolo Calabresi)

Ruolo di responsabile locale della sperimentazione in studi clinici multicentrici nazionali ed internazionali

2021. Studio clinico **CLAD CROSS MS700568_0070.** Oral Cladribine in patients that change from first-line disease modifying treatments for Multiple Sclerosis: a prospective effectiveness and safety study.

2023. **Studio clinico SWITCH ITA**: a multicentre, single country, prospective non interventional observational study to describe the switching from a first or second line DMT to ozanimod, in RRMS pateints treated according to clinical practice.

Ruolo disub-investigators o investigator in studi clinici multicentrici nazionali ed internazionali

2011. Studio clinico CFTY720DIT03, **An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists (Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica).**

2011. Studio Excellent. "Studio osservazionale prospettico di valutazione del trattamento con Extavia somministrato mediante l'utilizzo dell'autoiniettore extaviject 30G in pazienti con sclerosi multipla."

2012. Studio clinico "Implementation of the "Sapere Migliora" information aid for newly diagnosed MS patients in routine clinical practice (SIMS-Practice)", volto a verificare l'utilità di un supplemento informativo strutturato in persone che hanno ricevuto la diagnosi di Sclerosi Multipla (SM).

2012-2013. Studio OAK *(Off-Adherence keeping)* – Studio osservazionale in pazienti affetti da Sclerosi Multipla Recidivante Remittente trattati con immunomodulanti volontariamente non complianti.

2014 Studio CFTY720DIT08 (BEAT), Observational single-arm multicenter one-day trial in relapsing-remitting multiple sclerosis patients to characterize (in terms of demographic, clinical and neurovegetative aspects) the population for whom extended monitoring after the first dose of fingolimod was necessary.

2014 - 2015. Studio clinico **PROTEC 109MS408**. A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World Setting.

2016. Studio clinico **ESTEEM 109MS401.** A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis.

2016. Studio clinico **SWITCH DIREGL07914.** A cross-sectional survey of the occurrence and clinical factors of modifying therapy in relapsing-remitting multiple sclerosis patients.

2016. Studio clinico **CASTING MA30005.** An open-label study to evaluate the efficacy and safety of Ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

2016. Studio clinico **TASTE-M/SATIVX/05**. Sativex palatability and oral cavity tolerability possible improvement measures in multiple sclerosis patients with resistant spasticity: an open-label, prospective, multicenter, non-pharmacological, minor-interventional pilot study.

2018. Studio clinico **MA30130.** Protocol for ocrelizumab Compassionate Use Program in Patients with Primary Progressive Multiple Sclerosis. **2021.**

Organizzazione e responsabilità di eventi scientifici

Referente scientifco per l'evento "**Demyelinating disorders academy**", L'Aquila, 21 giugno 2024

Organizzatore e responsabile scientifico ed del webinar "**Fluid biomarkers and multiple sclerosis: the long road towards validation**" (virtual event), 16 maggio 2023

Responsabile scientifico degli incontri "**SPMS Umbria Patient Journey**", Perugia 14 settembre (virtual) e 28 ottobre 2021

Organizzazione e segreteria scientifica del convegno "**L'attuale scenario nel trattamento della sclerosi multipla**", Perugia, 24 gennaio 2020

Nel comitato organizzatore del 18esimo "**Congresso Nazionale della Società Italiana di Neuroscienze (SINS)**", Perugia, 26-29 settembre 2019

Responsabile Scientifico della conferenza Web interattiva "**CREW: connecting real life experience in the Web**", Perugia, 29 Maggio 2018

Organizzatore e coordinatore scientifico del convegno "**Multiple sclerosis: from bench to bedside**", Perugia, 1 Aprile 2016

Responsabile scientifico ed organizzatore del convegno "**Sclerosi Multipla: pratica clinica ed orizzonti terapeutici**", Perugia, 28-29 Novembre 2014

In qualità di membro della segreteria scientifica, organizzazione dell'incontro scientifico "**Sclerosi Multipla: stato dell'arte e nuove evidenze nell'approccio multidisciplinare**", Perugia, 10.12.2013

Partecipazione a corsi formativi nazionali/internazionali:

MS Preceptorship, Updating knowledge in Multiple Sclerosis, June 7-9 2011, Barcelona, Spain

Multiple Sclerosis in children and adolescents: emerging issues. Florence, 16th September 2009

Neuroscience for Clinicians & Cambridge Centre for Brain Repair Spring School 2008, University of Cambridge, Corpus Christi College, 1-3 April 2008

MRI Course for Clinicians. Institute of Neurology, Queen Square, London, UK (2007-2008)

Relazioni su invito a congressi, corsi e simposi internazionali in Italia ed all'estero:

Titolo della relazione. "**The role of biomarkers in inflammatory disease in the CNS (kappaFLC & sNFL)**" durante il webinar "Plasma protein science day", 7th Novembre 2024, evento virtuale internazionale organizzato da Siemens H.

Titolo della relazione: "**Rethinking the MS brain**", **35th National Conference of the Hellenic Neurological Society**, 30 maggio-2 giugno 2024, Rodi, Grecia

Titolo della relazione: "**Pathogenesis of PIRA**", **XII Congreso Latinoamericano de Escleroris Múltiple**, 15-18 novembre 2023, Quito, Ecuador.

Titolo della relazione: "**Early treatment to reduce brain volume loss and cognitive impairment**", in the satellite symposium "*It's time to look at the whole picture—from brain atrophy & cognitive impairment to disease progression",* **31st Annual Meeting of the European** Charcot Foundation, 9-11 novembre 2023, Baveno, Italy

Titolo della relazione: "**Astrocytic damage exists before and between demyelination and could be clinically relevant**" (vitual talk), 17th world congress on controversies in neurology, Dubrovnik, Croatia.

Titolo della relazione: "**Inflammation and synaptopathies**", 3rd International Workshop on "Biomarkers in the early diagnosis of neurodegenerative disorders". 21-23 Maggio, 2015, Assisi, Italy

Titolo della relazione: **"Role of IFNβ-1a in neuroprotection: modulation of STAT 1 signaling".** 2nd Scientific Forum, From Philadelphia to Port Heli, Review of American Academy Neurology Meeting 2014 for Multiple Sclerosis", 13 Giugno 2014, Port Heli, Grecia.

Titolo della relazione: "**How to design a correct animal model**" 17th Annual ESO Stroke Summer School. 8-14 September 2013, Perugia, Italy

Titolo della relazione: "**Role of hippocampal dyfunctions in Parkinson's disease**." 2nd International Workshop on "Biomarkers in the early diagnosis of neurodegenerative disorders". 7-9 Giugno, 2012, Assisi, Italy

Titolo della relazione "**Now is the time: l'appropriatezza terapeutica ed il trattamento precoce**". International MS Physician Summit Data-driven decision making in MS: Addressing MS patients needs today and tomorrow. 24-25 Marzo 2012, Londra, UK

Titolo della relazione: **"Learning, memory and striatal synaptic plasticity in physiological and pathological conditions**." International Behavioural Neuroscience Society meeting. 8-13 Giugno, 2010, Villasimius, Italia.

Titolo della relazione: "**Synaptic plasticity and neurodegenerative diseases**." International Workshop on "Biomarkers in the early diagnosis of neurodegenerative disorders". 3-4 Giugno, 2010, Assisi, Italy.

Titolo della relazione: "**Plasticity in experimental models of multiple sclerosis**." 1st International Workshop on "Synaptic plasticity: from bench to bedside." 28 Aprile- 1 Maggio, 2010, Taormina, Italia.

Titolo della relazione: "**Synaptic plasticity at corticostriatal synapses**." tenuta durante il XXIII Sandbjerg Symposium, Danish Society for Neuroscience, Neuroplasticity and Neurorehabilitation. May 3-5, 2009 a Sandbjerg Manor, Danimarca.

Relazioni su invito a congressi corsi e simposi nazionali:

Titolo della relazione "**Il neurofilamento come guida al monitoraggio e alla prevenzione (confront con il K-index)** ", durante il convegno "Neurofilamenti nella sclerosi multipla: dalla ricercar alla pratica clinica, focus su progression e monitoraggio terapeutico", Univesità Tor Vergata, Roma, 31 marzo 2026

Titolo della relazione "**From BOIgG to k index and other B cell biomarkers in clinical prospective**", durante il convegno "From active to smoldering demyelinating CNS diseases: bridging peripheral and compartimentalized inflammation", Verona, 26-27 marzo 2026

Titolo della relazione (opinion leader lecture) "**Substrati immunopatologici dell aprogressione nella sclerosi multipla**", durante la II masterclass esperienzale di Neurologia, Ospedale San Raffaele", Milano, 26 dicembre 2025

Titolo della relazione "**Biomarcatori e progression in pratica clinica**", durante il congresso "Ocrevity: the power of shared commitment in MS", Stazione Leopolda, Firenze, 2-3 dicembre 2025

Titolo della relazione "**Riconoscere la sclerosi multipla prima dell'esordio clinico: i marcatori umorali**", corso di aggiornamento al 55° Congresso della Società Italiana di Neurologia, Padova, 24-28 ottobre 2025

Titolo della relazione "**Oltre il modello focale: il ruolo dell'infiammazione smoldering nella progressione di malattia**", al 55° Congresso della Società Italiana di Neurologia, Padova, 24-28 ottobre 2025

Titolo della relazione "**Fisologia e patologia dell'interazione neuro-immune: il paradigma della sclerosi multipla**", lettura plenaria, al 54° Congresso della Società Italiana di Neurologia, Roma, 9-12 novembre 2024

Titolo della relazione "**Biomarcatori fluid e sclerosi multipla: una finestra sulla patogenesi**", durante il congresso "Precisione diagnostica nella sclerosi multipla: nuovi criteri e diagnosi differenziali", Ravenna, 28 novembre 2025

Titolo della relazione "**Quello che non si vede: memoria, sonno e psiche in SM**", durante il congresso "Rethink MS debate: storie di cambiamento nell'apporccio terapeutico", Torino, 25 novembre 2025

Moderatore della sessione "Le sfide diagnostiche e terapeutiche", live webinar "**We challenge multiple sclerosis**", evento in modalità virtuale, 29 settembre 2020

Moderatore della sessione "Misure di efficacia cliniche, strumentali e biologiche" al convegno "**Giornata veronese per la sclerosi multipla**", Verona, 15 Novembre 2019 Settembre 2021

Moderatore della sessione Poster Sclerosi Multipla 1, **50° congresso Nazionale della Società Italiana di Neurologia,** Bologna, 13 ottobre 2019

Moderatore della sessione "Neurodegeneration: molecular biology of the neuron" al "**XXVIII congresso della società dell'Associazione Italiana di Neuroimmunologia**", Camogli, 6-9 maggio 2019

Moderatore della sessione "**Linee di ricerca presenti e future"** al congresso "**JAMS: junior academy of multiple sclerosis**", Anacapri, 23-25 maggio 2019

Attività di divulgazione scientifica e terza missione

Partecipazione quale componente di tavola rotonda all'evento di politica sanitaria "**Sclerosi multipla: partecipazione, abilitazione e co-progettazione**. L'agenda strategica di AISM per una Sanità centrata sulla persona", organizzato da AISM presso il **Forum Leopolda Salute, Firenze, 21 ottobre 2025**

Evento divultagtivo per la popolazione e le persone con sclerosi multipla**, "La riforma della disabilità e l'impatto sulle persone con sclerosi multipla e patologie correlate L.62/2024"**, evento patrocinato da INPS e Regione Umbria ed organizzato da Associazione Italiana Sclerosi Multipla, presso Hotel Best Western Quattrotorri, Perugia, 28 giugno 2025

Partecipazione al progetto di divulgazione scientifica per la popolazione **"Videoscience", con il video "Passato e Memoria", 2025.** Piazza IV Novembre, Perugia: **https://www.youtube.com/watch?v=qp-Ej5UNNXo**

Evento divultagtivo per la popolazione**,** "**Lo stigma umano nel tempo dell'intelligenza artificiale**", conversazione con il Prof. **Giorgio Vallortigara**, ordinario di Neuropsicologia e Neuroscienze cognitive - Centre for Mind/Brain Science dell'Università di Trento, Assisi, **16 novembre 2024**

Intervista alla rivista "Aboutpharma" (Titolo dell'articolo "Sclerosi multipla: diagnosi e follow-up, il futuro passa (anche) dai biomarcatori nel sangue), pubblicata il 16.12.2024 https://www.aboutpharma.com/scienza-ricerca/sclerosi-multipla-diagnosi-e-follow-up-il-futuro-passa-anche-dai-biomarcatori-nel-sangue/

Contributo all'organizzazione di "**Open Days" informativi per la popolazione generale** presso l'Ospedale S Maria della Misericordia di Perugia (19 giugno 2024)

Partecipazione al **programma televisivo "L'agenda della salute" (Retesole)** con un'intervista a tema "**sclerosi multipla**", venerdì 24 maggio 2024 https://www.youtube.com/watch?v=ft_xWI_ltMo

Intervista per la rivista ***smitalia*** (Numero 3/2023), dedicata alle persone con sclerosi multipla a tema "**Il disturbi dell'umore e la SM**"

Partecipazione al **programma radiofonico di divulgazione scientifica "L'Uovo di Colombo"** (Umbria Radio InBlu) circa la **ricerca sulla sclerosi multipla**, 16 giugno 2022
https://www.youtube.com/watch?v=pPoBgNQte6E&t=21s

Seminario divulgativo "Neurobiologia della memoria, il fenomeno Pat Martino", tenuto presso la "**Science and Art House Farm**", Solomeo, Perugia, 25 aprile 2022

Conferenza divulgativa online (2021) su invito dal titolo "**Tracce di memoria: persistenza e caducità**", conferenza **TEDx Perugia Studio**: https://www.youtube.com/watch?v=xvqCvFxjz88&t=65s

Seminario divulgativo dal titolo "**Ricordi perduti**" nelll'ambito dell'iniziativa "**Apericerca**" dell' Università degli Studi di Perugia, Piazza Birago, 22 settembre 2021

Incontro online **"Sumoscience, Neurologia vs Ingegneria**" per gli studenti delle scuole secondarie di secondo grado**, nell'ambito della Notte Europea dei Ricercatori 2020, 24 novembre 2020**

2010- oggi: relatore nel corso di **eventi divulgativi ed informativi per persone con sclerosi multipla,** organizzati dalla sede locale dell'Associazione Italiana Sclerosi Multipla

Pubblicazioni scientifiche:

Riviste internazionali.

1. Zupo L, Adinolfi A, Pieraccioli M, Guerra M, Corvino V, Ria F, Ceci V, Chiurchiù V, Gaetani L, Sperandei S, **Di Filippo M**, Di Sante G, Geloso MC, Sette C. Transcriptome analysis of the prefrontal cortex identifies inflammatory genes associated with cognitive impairment in a model of multiple sclerosis. ***Cell Death Discov***. 2026 Mar 25;12(1):177.

2. Gaetani L, Bellingacci L, Sperandei S, **Di Filippo M**. Multiple sclerosis synaptic connectome: Insights from fluid biomarkers. ***Neural Regen Res***. 2026 Mar 14.

3. Sperandei S, Gaetani L, Manni G, Gargaro M, De Socio GV, Gallina MC, Fiacca A, Costa C, Mancini A, Parnetti L, Fallarino F, **Di Filippo M**. Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs***). J Neuroimmunol***. 2026 Mar;412:578834.

4. Costa C, Bellingacci L, Canonichesi J, Imperatore V, Taddei AA, Zafra-Puerta L, Iglesias-Cabeza N, Prontera P, Mancini A, **Di Filippo M**, Tozzi A, Martinello K, Barzasi M, Gardoni F, Sánchez MP, Serratosa JM, Parnetti L, Sciaccaluga M. Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease. ***Epilepsia***. 2025 Dec 17.

5. Schmidauer M, Berek K, Auer M, Bsteh G, Cavalla P, Di Pauli F, **Di Filippo M**, Deisenhammer F, Emeršič A, Föttinger F, Gaetani L, Hassler M, Krajnc N, Milosavljevic D, Ponleitner M, Petersen T, Presslauer S, Rosenstein I, Rot U, Tørring CW, Vecchio D, Vercellino M, Zrzavy T, Zinganell A, Walde J, Hegen H. Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosis. ***Front Immunol***. 2025 Nov 7;16:1658182.

6. Karlsson L, Janelidze S, Barthélemy NR, Horie K, Therriault J, Gaetani L, Bellomo G, Schindler SE, Vogel J, Arvidsson I, Åström K, Gordon BA, Raji CA, Benzinger TLS, Morris JC, Nilsson J, Brinkmalm A, Palmqvist S, Stomrud E, Salvadó G, Pichet Binette A, **Di Filippo M**, Parnetti L, Rosa-Neto P, Blennow K, Bateman RJ, Mattsson-Carlgren N, Hansson O. Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers. ***Brain***. 2025 Oct 6.

7. Bellingacci L, Sciaccaluga M, Megaro A, Cardinale A, Canonichesi J, De Carluccio M, Mastrantonio R, Costa C, **Di Filippo M**, Usiello A, Viscomi MT, Calabresi P, Tozzi A. Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms. ***NPJ Parkinsons Dis***. 2025 Jul 29;11(1):220.

8. Mancini A, Bellingacci L, Canonichesi J, Sciaccaluga M, Megaro A, Zianni E, De Carluccio M, Pariano M, Emiliano E, Tozzi A, Costa C, Zelante T, Romani L, Viscomi MT, Gardoni F, Calabresi P, Parnetti L, **Di Filippo M**. Immune control of the basal ganglia network: Interleukin-17 as a key modulator of striatal synaptic plasticity. ***Neurobiol Dis***. 2025 Jun 8;213:106994.

9. Menculini G, Sperandei S, Gaetani L, Mancini A, Cinesi G, Di Sabatino E, Bellingacci L, Canonichesi J, Guerrera G, Battistini L, Tortorella A, Parnetti L, Borsellino G, **Di Filippo M**. Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis. ***Mult Scler Relat Disord.*** 2025 Mar;95:106309.

10. Di Sabatino E, Ferraro D, Gaetani L, Emiliano E, Parnetti L, **Di Filippo M**. CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective. ***J Neurol***. 2025 Feb 17;272(3):211.

11. Masciocchi S, Businaro P, Greco G, Scaranzin S, Malvaso A, Morandi C, Zardini E, Risi M, Vegezzi E, Diamanti L, Bini P, Siquilini S, Giannoccaro MP, Morelli L, Liguori R, Patti F, De Giuli V, Portaccio E, Zanetta C, Bergamoni S, Simone AM, Lanzillo R, Bruno G, Gallo A, Bisecco A, **Di Filippo M**, Pauri F, Toriello A, Barone P, Tazza F, Bucello S, Banfi P, Fabris M, Volonghi I, Raciti L, Vigliani MC, Bocci T, Paoletti M, Colombo E, Filippi M, Pichiecchio A, Marchioni E, Franciotta D, Gastaldi M; Neuroimmunology platform study group (PNI). Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders. ***Neurol Neuroimmunol Neuroinflamm***. 2025 Mar;12(2):e200359.

12. Nociti V, Romozzi M, Annovazzi P, Fantozzi R, Tortorella C, Vercellino M, Iannone LF, De Luca G, Tomassini V, **Di Filippo M**, Lorefice L, Maniscalco GT, Paolicelli D, Pinardi F, Ronzoni M, Solaro CM, Gasperini C, Calabresi P, Vollono C, Cocco E. Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies. ***J Neurol Sci***. 2025 Jan 8;469:123392.

13. Nociti V, Romozzi M, Prosperini L, Clerici VT, Ragonese P, Gallo A, Maniscalco GT, **Di Filippo M**, Buscarinu MC, Lorefice L, Pinardi F, Gajofatto A, Cavalla P, Buttari F, Ferraro D, De Luca G, Solaro C, Gasperini C, Cocco E; RIREMS Study Group. Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study. ***Eur J Neurol***. 2025 Jan;32(1):e70019.

14. Barba L, Gaetani L, Sperandei S, Di Sabatino E, Abu-Rumeileh S, Halbgebauer S, Oeckl P, Steinacker P, Parnetti L, **Di Filippo M**, Otto M. CSF synaptic biomarkers and cognitive impairment in multiple sclerosis. ***J Neurol***. 2024 Dec 21;272(1):85.

15. Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, **Di Filippo M**, Tur C, Montalban X, Amato MP. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. ***Lancet Reg Health Eur***. 2024 Aug 22;44:100977.

16. Rocca MA, Preziosa P, Barkhof F, Brownlee W, Calabrese M, De Stefano N, Granziera C, Ropele S, Toosy AT, Vidal-Jordana À, **Di Filippo M**, Filippi M. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. ***Lancet Reg Health Eur***. 2024 Aug 22;44:100978.

17. **Di Filippo M**, Gaetani L, Centonze D, Hegen H, Kuhle J, Teunissen CE, Tintoré M, Villar LM, Willemse EAJ, Zetterberg H, Parnetti L. Fluid biomarkers in multiple sclerosis: from current to future applications. ***Lancet Reg Health Eur***. 2024 Aug 22;44:101009.

18. Prosperini L, Arrambide G, Celius EG, Goletti D, Killestein J, Kos D, Lavorgna L, Louapre C, Sormani MP, Stastna D, Ziemssen T, **Di Filippo M**. COVID-19 and multiple sclerosis: challenges and lessons for patient care. ***Lancet Reg Health Eur***. 2024 Aug 22;44:100979.

19. Landi D, Bartolomeo S, Bovis F, Amato MP, Bonavita S, Borriello G, Buccafusca M, Bucello S, Cavalla P, Cellerino M, Centonze D, Cocco E, Conte A, Cortese A, D'Amico E, **Di Filippo M**, Docimo R, Fantozzi R, Ferraro E, Filippi M, Foschi M, Gallo A, Granella F, Ianniello A, Lanzillo R, Lorefice L, Lucchini M, Lus G, Mataluni G, Mirabella M, Moiola L, Napoli F, Nicoletti CG, Patti F, Ragonese P, Realmuto S, Schirò G, Signoriello E, Sinisi L, Stromillo ML, Tomassini V, Vecchio D, Sormani MP, Marfia GA. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. ***Mult Scler***. 2024 Sep

20. Greco G, Risi M, Masciocchi S, Businaro P, Rigoni E, Zardini E, Scaranzin S, Morandi C, Diamanti L, Foiadelli T, Giannoccaro MP, Morelli L, Liguori R, Barone P, Tozzo A, Passarini A, Gelibter S, Patti F, Banfi P, Simone AM, Bisecco A, Ruggieri M, Maimone D, Bruno G, Siliquini S, Bova S, **Di Filippo M**, Lanzillo R, Gallo A, Colombo E, Franciotta D, Gastaldi M; Neuroimmunology Platform (PNI) study group. Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis. ***J Neurol Neurosurg Psychiatry***. 2024 Jun 6

21. Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M, Battaglini M, De Stefano N, **Di Filippo M**, Hametner S, Howell OW, Inglese M, Lassmann H, Martin R, Nicholas R, Reynolds R, Rocca MA, Tamanti A, Vercellino M, Villar LM, Filippi M, Magliozzi R. Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis. ***Ann Neurol***. 2024 Apr 3.

22. Gaetani L, Salvadori N, Brachelente G, Sperandei S, Di Sabatino E, Fiacca A, Mancini A, Villa A, De Stefano N, Parnetti L, **Di Filippo M**. Intrathecal B cell activation and memory impairment in multiple sclerosis. ***Mult Scler Relat Disord***. 2024 Mar 8;85:105548.

23. Zelante T, Paolicelli G, Fallarino F, Gargaro M, Vascelli G, De Zuani M, Fric J, Laznickova P, Kohoutkova MH, Macchiarulo A, Dolciami D, Pieraccini G, Gaetani L, Scalisi G, Trevisan C, Frossi B, Pucillo C, De Luca A, Nunzi E, Spaccapelo R, Pariano M, Borghi M, Boscaro F, Romoli R, Mancini A, Gentili L, Renga G, Costantini C, Puccetti M, Giovagnoli S, Ricci M, Antonini M, Calabresi P, Puccetti P, **Di Filippo M**, Romani L. A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis. ***Sci Rep***. 2024 Mar 20;14(1):6651.

24. Pozzilli V, Haggiag S, **Di Filippo M**, Capone F, Di Lazzaro V, Tortorella C, Gasperini C, Prosperini L. Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials. ***J Neurol Neurosurg Psychiatry***. 2024 Feb 21:jnnp-2023-332996.

25. Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, **Di Filippo M**, Zaffaroni M, Annovazzi P, Bertolotto A, Gasperini C, Quartuccio E, Centonze D, Fantozzi R, Gajofatto A, Gobbin F, Landi D, Granella F, Buccafusca M, Marfia GA, Chisari C, Naldi P, Bergamaschi R, Greco G, Zarbo IR, Rizzo V, Ulivelli M, Bezzini D, Florio L, Turazzini M, Di Gregorio M, Pugliatti M, Salemi G, Ragonese P; the MS-MigIT Study Group. The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT). ***J Neurol***. 2024 Feb 16.

26. Bellingacci L, Canonichesi J, Sciaccaluga M, Megaro A, Mazzocchetti P, Di Mauro M, Costa C, **Di Filippo M**, Pettorossi VE, Tozzi A. Locally Synthetized 17-β-Estradiol Reverses Amyloid-β-42-Induced Hippocampal Long-Term Potentiation Deficits. ***Int J Mol Sci***. 2024 Jan 23;25(3):1377.

27. Gaetani L, Bellomo G, Di Sabatino E, Sperandei S, Mancini A, Blennow K, Zetterberg H, Parnetti L, **Di Filippo M**. The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis. ***Int J Mol Sci***. 2023 Dec 21;25(1):139.

47. Natali P, Bedin R, Bernardi G, Corsini E, Cocco E, Schirru L, Crespi I, Lamonaca M, Sala A, Nicolò C, **Di Filippo M**, Villa A, Nociti V, De Michele T, Cavalla P, Caropreso P, Vitetta F, Cucinelli MR, Gastaldi M, Trenti T, Sola P, Ferraro D, On Behalf Of Rirems Rising Researchers In Ms. Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. ***Biomolecules***. 2022 May 7;12(5):677.

48. Giovannetti AM, Pakenham KI, Presti G, Quartuccio ME, Confalonieri P, Bergamaschi R, Grobberio M, **Di Filippo M**, Micheli M, Brichetto G, Patti F, Copetti M, Kruger P, Solari A. A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS). ***PLoS One***. 2022 May 2;17(5):e0267245

49. Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, **Di Filippo M**, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia A, Petruzzo M, De Angeli M, Brescia Morra V, Solaro C, Gasperini C, Cocco E, Moccia M, Lanzillo R; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. ***J Neurol.*** 2022 Feb 14.

50. **Di Filippo M**, Mancini A, Bellingacci L, Gaetani L, Mazzocchetti P, Zelante T, La Barbera L, De Luca A, Tantucci M, Tozzi A, Durante V, Sciaccaluga M, Megaro A, Chiasserini D, Salvadori N, Lisetti V, Portaccio E, Costa C, Sarchielli P, Amato MP, Parnetti L, Viscomi MT, Romani L, Calabresi P. Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. ***Cell Rep***. 2021 Dec 7;37(10):110094

51. Romozzi M, Bellavia S, Caldarola G, De Simone C, Luigetti M, Calabresi P, **Di Filippo M**, Masullo C, Lucchini M. Ixekizumab exposure associated with myelitis: A case report and a literature review. ***J Neuroimmunol***. 2021 Sep 29;361:577726.

52. Di Sabatino E, Gaetani L, Sperandei S, Fiacca A, Guercini G, Parnetti L, **Di Filippo M**. The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. ***J Neurol***. 2021 Nov 24.

53. Bellingacci L, Mancini A, Gaetani L, Tozzi A, Parnetti L, **Di Filippo M**. Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. ***Int J Mol Sci***. 2021 Sep 9;22(18):9753.

54. Cortese R, Carotenuto A, **Di Filippo M**, Lanzillo R. Editorial: Cognition in Multiple Sclerosis. ***Front Neurol***. 2021 Aug 30;12:751687

55. **Di Filippo M**, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, Ragonese P, Nociti V, Radaelli M, Laroni A, Buttari F, Lorefice L, Ferraro D, Gajofatto A, Prosperini L, Fantozzi R, Boffa L, Lanzillo R, Moccia M, Clerico M, De Luca G, Tomassini V, Calabrese M, Borrelli A, Paolicelli D, Maniscalco GT, Gazzola P, Gallo A, Solaro C, Cocco E, Gasperini C, Tortorella C; RIREMS (Rising Researchers in MS) group. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. ***J Neurol Neurosurg Psychiatry***. 2021 Aug 18:jnnp-2021-327200.

56. Gaetani L, Bellomo G, Parnetti L, Blennow K, Zetterberg H, **Di Filippo M**. Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. ***Cells***. 2021 Jul 29;10(8):1930.

57. Gaetani L, Parnetti L, Calabresi P, **Di Filippo M**. Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. ***Front Neurosci***. 2021 May 24;15:672954.

58. Menculini G, Chipi E, Paolini Paoletti F, Gaetani L, Nigro P, Simoni S, Mancini A, Tambasco N, **Di Filippo M**, Tortorella A, Parnetti L. Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. ***Int J Mol Sci***. 2021 Apr 23;22(9):4440.

59. Mancini A, Ghiglieri V, Parnetti L, Calabresi P, **Di Filippo M**. Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. ***Front Immunol***. 2021 Apr 19;12:644294.

60. Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, **Di Filippo M**, Dattola V, Fantozzi R, Ferraro E, Filippi MM, Gasperini C, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, Marfia GA, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. ***J Neurol***. 2021 Feb 22. doi: 10.1007/s00415-021-10455-3. Epub ahead of print. PMID: 33616742.

61. Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, Ragonese P, Annovazzi P, Gajofatto A, Prosperini L, Landi D, Nicoletti CG, Di Carmine C, Totaro R, Nociti V, De Fino C, Ferraro D, Tomassini V, Tortorella C, Righini I, Amato MP, Manni A, Paolicelli D, Iaffaldano P, Lanzillo R, Moccia M, Buttari F, Fantozzi R, Cerqua R, Zagaglia S, Farina D, De Luca G, Buscarinu MC, Pinardi F, Cocco E, Gasperini C, Solaro C, **Di Filippo M**. Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study. ***Eur J Neurol***. 2020 Dec 10. doi: 10.1111/ene.14672.

62. Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, **Di Filippo M**, Parnetti L. CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. ***Trends Pharmacol Sci***. 2020 Dec;41(12):1023-1037.

63. Mancini A, Mazzocchetti P, Sciaccaluga M, Megaro A, Bellingacci L, Beccano-Kelly DA, **Di Filippo M**, Tozzi A, Calabresi P. From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2. ***Front Cell Neurosci***. 2020 Jul 28;14:158.

64. Gaetani L, Salvadori N, Chipi E, Gentili L, Borrelli A, Parnetti L, **Di Filippo M**. Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. ***Neural Regen Res***. 2021 Jan;16(1):36-42.

65. Moccia M, Annovazzi P, Buscarinu MC, Calabrese M, Cavalla P, Cordioli C, **Di Filippo M**, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Lorefice L, Mallucchi S, Nociti V, Paolicelli D, Pinardi F, Prosperini L, Radaelli M, Ragonese P, Tomassini V, Tortorella C, Cocco E, Gasperini C, Solaro C. Harmonization of real-world studies in multiple sclerosis: retrospective analysis from the rirems group. ***Mult Scler Relat Disord***. 2020 Jul 12;45:102394.

66. Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu MC, Buttari F, Calabrese M, Cavalla P, Cocco E, Cordioli C, De Luca G, **Di Filippo M**, Fantozzi R, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Fermo SL, Malucchi S, Maniscalco GT, Moccia M, Nociti V, Paolicelli D, Pesci I, Prosperini L, Ragonese P, Tomassini V, Clerici VLAT, Rodegher M, Gherardi M, Gasperini C; RIReMS Group. Informing MS patients on treatment options: a consensus on the process of consent taking. ***Neurol Sci***. 2020 Apr 2.

67. Mazzocchetti P, Mancini A, Sciaccaluga M, Megaro A, Bellingacci L, **Di Filippo M**, Cesarini EN, Romoli M, Carrano N, Gardoni F, Tozzi A, Calabresi P, Costa C. Low doses of Perampanel protect

striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. ***Neurobiol Dis***. 2020 Mar 25:104848.

68. Gaetani L, Boscaro F, Pieraccini G, Calabresi P, Romani L, **Di Filippo M**, Zelante T. Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. ***Front Immunol***. 2020 Feb 18;11:157.

69. Mondanelli G, Coletti A, Greco FA, Pallotta MT, Orabona C, Iacono A, Belladonna ML, Albini E, Panfili E, Fallarino F, Gargaro M, Manni G, Matino D, Carvalho A, Cunha C, Maciel P, **Di Filippo M**, Gaetani L, Bianchi R, Vacca C, Iamandii IM, Proietti E, Boscia F, Annunziato L, Peppelenbosch M, Puccetti P, Calabresi P, Macchiarulo A, Santambrogio L, Volpi C, Grohmann U. Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. ***Proc Natl Acad Sci U S A.*** 2020 Feb 18;117(7):3848-3857.

70. Salvetti M, Battaglia MA, **Di Filippo M**, Mancardi GL, Mancuso M, Patti F, Sormani MP, Zaratin P. An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases. ***Neurol Sci***. 2019 Dec 19.

71. Gastaldi M, Mariotto S, Giannoccaro MP, Iorio R, Zoccarato M, Nosadini M, Benedetti L, Casagrande S, **Di Filippo M**, Valeriani M, Ricci S, Bova S, Arbasino C, Mauri M, Versino M, Vigevano F, Papetti L, Romoli M, Lapucci C, Massa F, Sartori S, Zuliani L, Barilaro A, De Gaspari P, Spagni G, Evoli A, Liguori R, Ferrari S, Marchioni E, Giometto B, Massacesi L, Franciotta D. Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. ***Eur J Neurol***. 2019 Dec 8. doi: 10.1111/ene.14139.

72. Gaetani L, Di Carlo M, Brachelente G, Valletta F, Eusebi P, Mancini A, Gentili L, Borrelli A, Calabresi P, Sarchielli P, Ferri C, Villa A, **Di Filippo M**. Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. ***J Neuroimmunol***. 2019 Nov 7;339:577108.

73. Parnetti L, Gaetani L, **Di Filippo M**. Serum neurofilament light chain as a preclinical marker of neurodegeneration. ***Lancet Neurol***. 2019 Dec;18(12):1070-1071.

74. Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, Fantozzi R, Paolicelli D, Ragonese P, Gajofatto A, Boffa L, Cavalla P, Lo Fermo S, Buscarinu MC, Lorefice L, Cordioli C, Calabrese M, Gallo A, Pinardi F, Tortorella C, **Di Filippo M**, Camera V, Maniscalco GT, Radaelli M, Buttari F, Tomassini V, Cocco E, Gasperini C, Solaro C. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. ***Mult Scler Relat Disord***. 2019 Oct 19;37:101461.

75. Romoli M, Krashia P, Sen A, Franciotta D, Gastaldi M, Nobili A, Mancini A, Nardi Cesarini E, Nigro P, Tambasco N, Mercuri NB, Parnetti L, **Di Filippo M**, D'Amelio M, Irani SR, Costa C, Calabresi P. Hippocampal epileptogenesis in autoimmune encephalitis. ***Ann Clin Transl Neurol***. 2019 Oct 15.

76. Prosperini L, **Di Filippo M**. Beyond clinical changes: Rehabilitation-induced neuroplasticity in MS. ***Mult Scler***. 2019 Sep;25(10):1348-1362.

77. Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, **Di Filippo M**. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. ***J Neurol***. 2019 Sep;266(9):2157-2163.

78. Gaetani L, Eusebi P, Mancini A, Gentili L, Borrelli A, Parnetti L, Calabresi P, Sarchielli P, Blennow K, Zetterberg H, **Di Filippo M**. Cerebrospinal fluid neurofilament light chain predicts disease

activity after the first demyelinating event suggestive of multiple sclerosis. ***Mult Scler Relat Disord***. 2019 Jul 27;35:228-232.

79. Calabrese M, Gasperini C, Tortorella C, Schiavi G, Frisullo G, Ragonese P, Fantozzi R, Prosperini L, Annovazzi P, Cordioli C, **Di Filippo M**, Ferraro D, Gajofatto A, Malucchi S, Lo Fermo S, De Luca G, Stromillo ML, Cocco E, Gallo A, Paolicelli D, Lanzillo R, Tomassini V, Pesci I, Rodegher ME, Solaro C; RIREMS group (Rising Italian Researchers in Multiple Sclerosis). "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. ***Neurology***. 2019 May 1.

80. Gaetani L, Blennow K, Calabresi P, **Di Filippo M**, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. ***J Neurol Neurosurg Psychiatry***. 2019 Apr 9. pii: jnnp-2018-320106.

81. Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, Quiroga-Varela A, Chiasserini D, Mellone M, Mazzocchetti P, Calabrese V, Campanelli F, Mechelli A, **Di Filippo M**, Ghiglieri V, Picconi B, El-Agnaf OM, De Leonibus E, Gardoni F, Tozzi A, Calabresi P. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. ***Brain***. 2019 Mar 29.

82. Mancini A, Gaetani L, Gentili L, **Di Filippo M**. Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. ***Neural Regen Res***. 2019 Jan;14(1):77-78.

83. Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, **Di Filippo M**. 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. ***J Neurol***. 2018 265(11):2684-2687.

84. **Di Filippo M**, Portaccio E, Mancini A, Calabresi P. Multiple sclerosis and cognition: synaptic failure and network dysfunction. ***Nat Rev Neurosci***. 2018 19(10):599-609.

85. Tozzi A, Durante V, Bastioli G, Mazzocchetti P, Novello S, Mechelli A, Morari M, Costa C, Mancini A, **Di Filippo M**, Calabresi P. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. ***Neurobiol Dis***. 2018 Jun 13.

86. Mazzocchetti P, Tantucci M, Bastioli G, Calabrese V, **Di Filippo M**, Tozzi A, Calabresi P, Costa C. Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity. ***Neuropharmacology***. 2018 Mar 31;135:424-430.

87. Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, **Di Filippo M**, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. ***J Neurol***. 2018 Mar 16.

88. Gaetani L, Höglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, Sarchielli P, Calabresi P, **Di Filippo M**, Zetterberg H, Blennow K. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. ***Alzheimers Res Ther***. 2018 Jan 23;10(1):8.

89. Di Gregorio M, Gaetani L, Eusebi P, Floridi P, Picchioni A, Rosi G, Mancini A, Floridi C, Baschieri F, Gentili L, Sarchielli P, Calabresi P, **Di Filippo M**. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. ***J Neurol***. 2018 Jan 11.

157. **Di Filippo M**, Tozzi A, Picconi B, Ghiglieri V, Calabresi P. Plastic abnormalities in experimental Huntington's disease. ***Curr Opin Pharmacol***. 2007 Feb;7(1):106-11.

158. Calabresi P, Picconi B, Parnetti L, **Di Filippo M**. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. ***Lancet Neurol.*** 2006 Nov;5(11):974-83..

159. **Di Filippo M**, Picconi B, Costa C, Bagetta V, Tantucci M, Parnetti L, Calabresi P. Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition**.** ***Eur J Pharmacol.*** 2006 Sep 1;545(1):65-72.

160. Costa C, Martella G, Picconi B, Prosperetti C, Pisani A, **Di Filippo M**, Pisani F, Bernardi G, Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. ***Stroke.*** 2006 May;37(5):1319-26.

Riviste in lingua italiana.

1. Calabresi P, **Di Filippo M**, Costa C. Ruolo delle neurotrofine nella corea di Huntington e nella malattia di Parkinson. ***Neurol Sci***. 2005 26:S371-S373.

2. Calabresi P, Picconi B, Tozzi A, **Di Filippo M**. Il controllo dopaminergico della plasticità sinaptica corticostriatale. ***It J Addict*** 2007 Dec; 57:21-30.

Capitoli di libri internazionali ed in lingua italiana.

Volume "Translational NeuroImmunology" (Volume 7). Capitolo "Immunity and Cognition in Multiple Sclerosis" (Autori Mancini A., Bellingacci L., Canonichesi J and Di Filippo M). (2023, Academic Press, Elsevier Inc.)

Volume "Handbook of Basal Ganglia Structure and Function" Capitolo "Regulation of Corticostriatal Synaptic Plasticity in Physiological and Pathological Conditions" (Autori: Di Filippo M and Calabresi P) (2010, Academic Press. Inc. Elsevier).

Volume "Malattia di Parkinson e parkinsonismi" Capitolo "Basi neurobiologiche dei deficit cognitivi nella malattia di Parkinson" (Autori: Di Filippo M and Calabresi P) (2009, Springer-Verlag Italia)

Volume "Parkinson e parkinsonismi: epidemiologia, diagnosi differenziale e ottimizzazione delle cure." Capitolo 1, Epidemiologia, patogenesi e genetica. (Autori: Calabresi P, Cilia R, Di Filippo M, Ferraris A, Goldwurm S, Morgante L, Siliquini S, Valente EM) (2008) GPAnet Editore.

Monografia "La terapia della sclerosi multipla con anticorpi anti-CD20: focus su ublituximab". (Autori: Di Filippo M e Centonze D) (2025, Il Pensiero Scientifico Editore)

AUTODICHIARAZIONE SUL CONFLITTO DI INTERESSI ECM

Il sottoscritto, consapevole che il "**conflitto d'interessi E.C.M.**" è ogni situazione nella quale un interesse secondario interferisce o potrebbe interferire con l'interesse primario consistente nell'obiettività, imparzialità e indipendenza della formazione professionale nel settore della salute connessa al Programma di Educazione Continua in Medicina (E.C.M.),

DICHIARA

l'assenza di interessi commerciali in ambito sanitario **negli ultimi due anni** dalla data di sottoscrizione del presente curriculum.

Data e luogo: Perugia, 20.4.2026

Firma:



00168, Rome, Italy | raffaele.iorio@policlinicogemelli.it

RAFFAELE IORIO

PROFESSIONAL EXPERIENCE

ASSOCIATE PROFESSOR OF NEUROLOGY 02/2025 to Current
Università Cattolica del Sacro Cuore, Rome, Italy

STAFF NEUROLOGIST 07/2015 to Current
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome

POST-DOCTORAL FELLOW- INSTITUTE OF NEUROLOGY 04/2014 to 06/2015
Università Cattolica del Sacro Cuore, Rome

RESEARCH FELLOW IN NEUROIMMUNOLOGY 04/2010 to 11/2011
Mayo Clinic, Rochester, Minnesota, USA

EDUCATION

Università Cattolica del Sacro Cuore, Rome
Ph.D., Neuroscience, 2014

Università Cattolica del Sacro Cuore, Rome
Residence in Neurology, 2010

Università Cattolica del Sacro Cuore, Rome
Medical Degree, 2005

TECHNICAL SKILLS

Tissue culture (lymphocytes, HEK293 cells, astrocytes, neurons, neural stem cells), immunohistochemistry, immunocytochemistry, flow cytometry with surface and intracellular staining, ELISA, cells sorting, SDS-PAGE, BN-PAGE, immunoprecipitation, transfection and culture of transfected cell lines (HEK293 cells, MDCK cells, CHO-K1 cells), confocal microscopy, animal surgery and immunization, molecular cloning, Real-time PCR.

SCIENTIFIC SOCIETIES

Member of the Italian association of Neuroimmunology
Member of the American Academy of Neurology
Member of the Italian Society of Neurology
Member of the European Academy of Neurology

BOARD CERTIFICATIONS

02/2006 Italian board of medical doctors and surgeons 11/2012 USMLE step 1 07/2013 USMLE step 2 CK 12/2016 ECFMG certificate (Philadelphia, USA) 28/03/2017 National Scientific habilitation for Associate Professor of Neurology (D.D. 1532/2016)

ADMINISTRATIVE POSTS

Member of the Neuromyelitis Optica International Clinical Consortium and Biorepository (funded by Guthy-Jackson Charitable Foundation)
Member of the Steering Committee of the Italian Neuromyelitis Optica Database
Member of Autoimmune Neurology Committee of the Italian association of Neuroimmunology

AWARDS AND HONORS

2013- American Academy of Neurology International Scholarship award
2013- "Anna Paola Batocchi" Award in Clinical Neuroimmunology
2015- Best PhD of 2014 at the Catholic University of Rome.

MEETING ABSTRACTS AND PUBLICATIONS

Abstracts presented at national and international meetings: 77.
Invited Lectures: 45
Publications on peer-reviewed journals: 159.

GRANTS

Italian Minister of Health GR-2019-12368727
Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with myasthenia gravis
Amount: 447000 Euro
EudraCT number: 2020-005619-35
Role: PI
MGNet Pilot Award 22-M34-INT
Single-cell deep phenotyping of B cells to predict treatment response in patients with Myasthenia gravis
Amount: 75000 USD
Role: PI
MGNet Pilot Award 23-M34-INT
Single-cell deep phenotyping of B cells to predict treatment response in patients with Myasthenia gravis
Amount: 75000 USD
Role: PI
PNRR-MR1-2023-12377506
Implementation of a national network to promote diagnosis, care, and research in autoimmune encephalitis and paraneoplastic neurological syndromes
Amount: 171500
Role: Head of Research Unit
Grant Pilota FISM 2024/R-Single/036
Investigating the effect of AQP4-IgG on Retinal Astrocytes Using Recombinant Human Monoclonal Antibodies and Retinal Organoids
Amount: 30000
Role: PI

CLINICAL TRIALS

- ARGX-113-1602- Myasthenia Gravis Study PHASE II role: sub-investigator
- ECU-MG-301. Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) (NCT01997229) PHASE III role: Investigator DATE: December 2013-2018
- ECU-MG-302. Open label trial of Eculizumab in Refractory Myasthenia gravis (REGAIN

study extension). DATE: 2015-2019. ROle: subinvestigator
-MSK-003_002-A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients. Role: sub-investigator
-ALXN1210_MG-306. Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis. Role: sub-investigator. Date: 2019- 2020
- MG0003. A phase 3, randomized, double-blind, pacebo controlled study evaluating efficacy and safety of Rozanolixizumab in adult patients with generalized myasthenia gravis. Role: Principal Investigator.: Date: 2020- 2021.
- MG0004. Open-label trial of Rozanolixizumab in adult patients with generalized myasthenia gravis. Role: Principal Investigator. Date:2020- 2021
- MG0007. Open-label trial of Rozanolixizumab in adult patients with generalized myasthenia gravis. Role: Principal Investigator. Date:2020-in corso
-REFINE. Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with Myasthenia Gravis: clinical trial to evaluate the efficacy and safety of Rituximab in generalized AChR-antibody positive Myasthenia Gravis. Role: Principal Investigator. Date: 2021-ongoing.
- INE301- MINT. VIELA BIO A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS. Role: Principal Investigator. Date 2021- ongoing.
-AIE001 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH LEUCINE-RICH GLIOMA INACTIVATED 1 AUTOIMMUNE ENCEPHALITIS. Role: Principal Investigator. Date: 2021-ongoing.
- EFC17262: A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis. Role: Principal Investigator. Date: 2022-terminated.
- ALXN2050-MG-201 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis. Role: Principal investigator. Date: 2022-ongoing.
- ALXN1720-MG-301 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Role: Principal Investigator. Date:2022-ongoing
- ARGNX-113-2003. A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis. Role: Principal Investigator. Date: 2022-ongoing.
- MOM-M281-011. Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis. Role: Principal Investigator. Date: 2022-ongoing.
- MOG001- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3, PIVOTAL STUDY WITH AN OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) ANTIBODY-ASSOCIATED DISEASE (MOG-AD**)**

SELECTED PUBLICATIONS

1. Falso S, Gessi M, Marini S, Benvenuto R, Sabatelli E, D'Amati A, Marini M, Evoli A, Iorio R. Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology. Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033. Epub ahead of print. PMID: 39007444.

paraneoplastic manifestation of prostate adenocarcinoma. Journal of Neuroimmunology 263, 155–158 (2013).
69. Quek, A. M. L. et al. Effects of age and sex on aquaporin-4 autoimmunity. Archives of Neurology 69, 1039–1043 (2012).
70. Iorio, R. & Lennon, V. A. Neural antigen-specific autoimmune disorders. Immunological Reviews 248, 104–121 (2012).
71. Iorio, R., Evoli, A., Lauriola, L. & Batocchi, A. P. A B3 type-thymoma in a 7-year-old child with myasthenia gravis. Journal of Thoracic Oncology 7, 937–938 (2012).

Rome, 10-Sep-2025

Univ.-Prof. Dr. med. Anne-Katrin Pröbstel

Name:	Anne-Katrin Pröbstel
Date of birth:	04.05.1986
Nationality;	German
Position:	Prof. Dr. med.
Institution:	Director, Center for Neurology & Clinic for Neuroimmunology, University Hospital Bonn Research Group Leader, German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen or DZNE) & University of Basel
Address:	Venusberg-Campus 1, 53127 Bonn
Phone:	+49 (0) 228 287-31430; +49 (0) 151 16858477
E-Mail:	anne-katrin.proebstel@ukbonn.de
Website:	https://www.ukbonn.de/neurologie/ https://biomedizin.unibas.ch
Position:	SNF Eccellenza Professor Senior Consultant and Research Group Leader Member of the clinic management team

Education and key qualifications (*clinical training periods)

2023 – 2025	*Certificate for Advanced Studies* (CAS) Leadership - Healthcare Management, degree program offered by the University of Applied Sciences Northwestern Switzerland and the University Hospital Basel
2021	Board certification in Neurology, Fédération des médecins suisses (FMH)
2019	Venia legendi/Habilitation in Neurology, University of Basel, Switzerland
2005 - 2012	Medical school, Ludwig-Maximilian-University Munich (LMU), Munich (Grade: excellent) Semester abroad: Université Paris-Diderot, Harvard Medical School
2007 - 2011	Doctoral degree in Neuroimmunology, Max-Planck-Institute for Neurobiology & Institute for Clinical Neuroimmunology, LMU ("Autoantibodies in children with demyelinating CNS disease") (16.01.2024; Grade: summa cum laude)

Current position(s)

02/2025-	Full Professor & Director, Center of Neurology & Clinic for Neuroimmunology, University Hospital of Bonn & University of Bonn Research Group Leader, German Center for Neurodegenerative Diseases (DZNE)
07/2021-	Swiss National Science Foundation (SNF) Eccellenza Professor & Research Group Leader, University Hospital and University of Basel

Previous position(s)

2021 - 2024	Senior Consultant, Department of Neurology, University Hospital of Basel
2020 - 2021*	Resident / Deputy Attending, Department of Immunology, University Hospital of Basel
2019 - 2020*	Resident, Department of Neurology, University Hospital of Basel
2016 - 2019	Postdoctoral Fellow, Weill Institute for Neurosciences, Division of Neuroimmunology and Glial Biology, Department of Neurology, University of California, San Francisco, US
01 - 02/2018	Visiting Scientist, Department of Immunology, University of Toronto, Canada
2012 - 2016*	Resident, Department of Neurology, University Hospital of Basel

Prizes and Awards (selection)

2025	International Society of Neuroimmunology (ISNI) "We are Neuroimmunology" Mid-Career Award (Prestigious international award for translation neuroimmunology research)
2023	Swiss Immunology Early Career Award, Swiss Society for Allergology and Immunology (Prestigious Swiss award for early career immunology researcher)
2022	Starting Grant, Swiss National Science Foundation (SNF) (ERC Back-up Funding)
2022	Sobek Junior Investigator Award, German Multiple Sclerosis Society (Most highly ranked award for junior investigators in neuroimmunology in Europe)
2022	Alumni Prize, Medical Faculty University of Basel

2021	Ingrid-zu-Solms-Prize in Medicine, Ingrid-zu-Solms Foundation
2021	Fritz-und-Ursula-Melchers-Postdoctoral Prize, German Society for Immunology
2021	Eccellenza Professorial Fellowship, Swiss National Science Foundation
2021	Bed-to-Bench for Top Clinicians Fellowship, Goldschmidt-Jacobson-Foundation
2020	Ellermann-Preis, Swiss Neurological Society
2017 - 2019	Postdoctoral Fellowship, National Multiple Sclerosis Society (NMSS)
2016 - 2019	Postdoctoral Fellowship, Swiss National Science Foundation
2016	Travel Scholarship "International Scholarship Award", American Academy of Neurology
2015	Best oral presentation Award, Annual Meeting of the Swiss Society of Neurology
2011	Munich-Harvard-Alliance Stipendium
2007 - 2009	Doctoral Fellowship, Förderung Forschung und Lehre, LMU
2011	Delegation Elitenetzwerk Bayern, Attendance Lindauer Nobelpreistagung
2007 - 2012	Stipend, Max-Weber-Program, Elite Network of Bavaria
2006 - 2012	Stipend, German National Academic Foundation (Germany's most prestigious scholarship for academic excellence and societal commitment)
2005	Karl-Frisch-Prize, Germany Society of Biology (Award for highest scoring biology exam)

Major conferences (selection)

2025	Invited Speaker, Paul-Martini-Foundation Symposium, Immune-based therapies in neurological diseases, Berlin (DE)
2025	Invited Speaker, 7th International Congress of Neuroimmunology (ISNI), Chiba (Greater Tokyo) (JA)
2025	Invited Faculty, Translational School of Immunology (TIS), German Society of Immunology, Potsdam (DE)
2025	Invited Speaker, 11th EAN Congress. Helsinki (FI)
2025	Invited Speaker, XXXIII AINI, the Italian Neuroimmunology Society, Congress. Turin (IT)
2024	European MEDEN Meeting, Berlin (DE)
2024	Invited Speaker, European Association of Neurooncology Annual Conference, Glasgow (UK)
2023	Harvard Medical School, MOGAD Symposium (US)
2023	Invited Speaker, European Network for Neuroscience, Bratislava (SK)
2021	Keynote Speaker, Turkish Congress of Neurology (TR)
2021	Keynote Speaker, Hungarian Conference of Neuroimmunology (HU)
2021	Invited Speaker, ECTRIMS, Vienna (AT)
2021	Invited Speaker, Swiss Neurology Society, Interlaken (CH)

Invited lecture at academic institutions

2024	CEMCAT Multiple Sclerosis Centre, International Grand Rounds, Barcelona (ES)
2023	Columbia University, Neuroimmunology Seminar Series, NYC (US)
2023	Neuroimmunology Seminar Series, Biomedical Center, LMU, Munich (DE)
2023	Immunology Grand Rounds, University Hospital Zurich, Zurich (CH)
2022	Neurology Grand Rounds, Koc University School of Medicine, Istanbul (TR)
2022	Immunology Grand Rounds, University of Geneva (CH)
2021	Max Planck Institute of Colloids and Interfaces, Potsdam (DE)
2021	Neuroscience Seminar Series, University of Lausanne (CH)
2021	Neuroscience Seminar Series, University of Cambridge (UK)

Board memberships (selection)

Since 2026	Member of the scientific board of the European Charcot Foundation
Since 2025	Member of the international board of ISNI (International Society of Neuroimmunology)
2023-2025	President, University of Basel Immunology Community (uBICo)
2023-	Medico-scientific steering committee, Herrmann und Lilly Schilling Foundation for medical research
2022-	Medico-scientific steering committee, Foundation ARSEP (French MS Society)
2022-	Steering committee, Germany Society of Neurology, Guidelines "Multiple Sclerosis, NMOSD und MOGAD"
2019-	Steering committee, International Women in Multiple Sclerosis (iWiMS)

Since 2017 Member, International Clinical Consortium, Guthy-Jackson Charitable Foundation (GJCF) for Neuromyelitis optica research

Memberships of scientific societies

American Academy of Neurology (AAN), European Academy of Neurology (EAN), International Society for Neuroimmunology (ISNI), Deutsche Gesellschaft für Neurologie (DGN), Deutsche Gesellschaft für Klinische Neurophysiologie (DGKN), Deutsche Gesellschaft für Immunologie (DGfI), Schweizerische Neurologische Gesellschaft (SNG), Schweizerische Gesellschaft für Klinische Neurophysiologie (SGKN), Swiss Society for Allergology and Immunology (SSAI)

Editorial Board Memberships

Neurology Neuroimmunology & Neuroinflammation (Deputy Editor), Frontiers in Immunology (Section Editor)

Reviewing activities (selection)

JAMA Neurology, Science Translational Medicine, Science Immunology, Nature Cardiovascular Research, Annals of Clinical and Translational Neurology, Neurology, Neurology Neuroimmunology & Neuroinflammation, Frontiers Immunology/Neurology, Journal of Immunology, JNNP, European Journal of Immunology, MS Journal, MS and Related Disorders, PLOS ONE, Gut Microbes

Organization of scientific meetings (selection)

2024-5 Organizer: Hertie Stiftung Multiple Sclerosis Symposium, Berlin (DE)
2024 Meeting President: Swiss Neurology Congress 2024, Basel (CH)
2024 Meeting President: Upper Rhine Immunology Network Meeting 2024, Basel (CH)
2022 Scientific Reviewing Committee ACTRIMS Forum Meeting, US,
2022 UBICO, Day of Immunology Public Science Event, Basel (CH)
2021 Scientific Organization Committee: Swiss Neurology Congress 2021 Interlaken (CH)
2021 Autoimmune Neurological Disorders Session Chair: ISNI Meeting, (FR)
2021 Microbiome Session Chair: ECTRIMS Annual Meeting
2018 Microbiome Session Chair: International Society of Neuroimmunology Annual Meeting, Brisbane (AU)

Mentorship, career development and teaching

Since 2012 Universities of Basel and Bonn: Teaching activities included teaching in the Human Medicine / Molecular Medicine degree programmes: Compulsory courses: Seminars; Tutorials; OSCE examiner; State examination; Main lecture in Human Medicine: Paraneoplastic syndromes, multiple sclerosis, immune tolerance and immune regulation; Main lecture in Molecular Medicine: Multiple sclerosis, immune diseases and therapies; Other courses: International EDSS training for clinical study participants; Supervision of numerous young scientists and clinicians at MSc, PhD and MD level, fostering their academic and clinical development. Among them, Dr. Tradite Neziraj, Dr. Patrick Lipps, Dr. Julia Flammer and Dr. Roxanne Pretzsch received highly competitive national and international fellowships and/or prizes, and many others, obtained prestigious awards, scholarships and early-career grants from institutions such as the Swiss National Science Foundation, the Hertie Foundation, and the Goldschmidt-Jacobson Foundation. Several students were able to publish their data in prestigious scientific journals, completing their PhD or MD theses with summa cum laude distinction and successfully continued into postdoctoral or independent academic careers in Switzerland and abroad. Former trainees and postdoctoral fellows have secured academic and industry positions at leading research centers and universities across Europe, and many remain active collaborators. Overall, the mentoring and supervision of young researchers has been a central aspect of my academic work, reflected in the numerous awards, fellowships, and academic achievements of my mentees, and in their continued success as the next generation of clinician scientists and researchers.

2005 - 2011 Ludwig Maximilian University of Munich: Research assistant at the Department of Anatomy, tutor for the histological microscopy course. Development of a medical curriculum for the pre-clinical phase at LMU as part of the Harvard Fellowship in close collaboration with colleagues in medical didactics at Harvard Medical School and LMU. The peer teaching programme ‘LMUlink’ aims to establish an early link between basic principles and clinical application and has been integrated into the LMU teaching concept.